Clinical.Annotation.ID,REF,ALT,Annotation.Text
981755803,A,A,"Patients with the rs75527207 AA genotype (two copies of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence response to ivacaftor."
981755803,A,G,"Patients with the rs75527207 AG genotype (one copy of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence response to ivacaftor."
981755803,G,G,"Patients with the rs75527207 GG genotype (do not have a copy of the CFTR G551D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence response to ivacaftor."
1449311190,C,C,"Patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma."
1449311190,C,T,"Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma."
1449311190,T,T,"Patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need an increased dose of mercaptopurine, or methotrexate, as compared to children with the CC or CT genotypes. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma."
981204774,A,A,"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AG and GG genotype. However, contradictory findings reporting the opposite association for this genotype with decreased likelihood of smoking cessation have been published. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
981204774,A,G,"Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings reporting the opposite association for this genotype with increased likelihood of smoking cessation have been published. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
981204774,G,G,"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings reporting the opposite association for this genotype with increased likelihood of smoking cessation have been published. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
1449191690,C,C,"Patients with the CC genotype (do not have a copy of the CFTR S977F variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence response to ivacaftor."
1449191690,C,T,"Patients with the CT genotype (one copy of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence response to ivacaftor."
1449191690,T,T,"Patients with the TT genotype (two copies of the CFTR S977F variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S977F. Other genetic and clinical factors may also influence response to ivacaftor."
1449191746,A,A,"Patients with the AA genotype (two copies of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence response to ivacaftor."
1449191746,A,G,"Patients with the AG genotype (one copy of the CFTR R1070Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence response to ivacaftor."
1449191746,G,G,"Patients with the GG genotype (do not have a copy of the CFTR R1070Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070Q. Other genetic and clinical factors may also influence response to ivacaftor."
981419532,C,C,Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity.
981419532,C,G,Patients with the CG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
981419532,G,G,Patients with the GG genotype may have increased risk of statin-related muscle symptoms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1449566379,A,A,"Patients with the AA genotype and hypertension may have an increased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1449566379,A,G,"Patients with the AG genotype and hypertension may have an increased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the GG genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1449566379,G,G,"Patients with the GG genotype and hypertension may have a decreased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451226160,A,A,"Infants who have been exposed to methadone in utero and who have the rs4680 AA genotype may have an increased severity of neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226160,A,G,"Infants who have been exposed to methadone in utero and who have the rs4680 AG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226160,G,G,"Infants who have been exposed to methadone in utero and who have the rs4680 GG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226166,A,A,"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AG or GG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226166,A,G,"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226166,G,G,"Infants who have been exposed to methadone in utero and who are born to women with the GG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226200,A,A,"Infants who have been exposed to buprenorphine in utero and who have the AA genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226200,A,C,"Infants who have been exposed to buprenorphine in utero and who have the AC genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226200,C,C,"Infants who have been exposed to buprenorphine in utero and who have the CC genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants with the AA or AC genotypes. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226206,A,A,"Infants who have been exposed to methadone in utero and who have the AA genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226206,A,C,"Infants who have been exposed to methadone in utero and who have the AC genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226206,C,C,"Infants who have been exposed to methadone in utero and who have the CC genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants with the AA or AC genotypes. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226212,A,A,"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226212,A,G,"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226212,G,G,"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 GG genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the AA or AG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226220,A,A,"Infants who have been exposed to methadone in utero and who are born to women with the AA genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226220,A,G,"Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451226220,G,G,"Infants who have been exposed to methadone in utero and who are born to women with the GG genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the AA or AG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451340320,C,C,Patients with the CC genotype may have increased concentrations of telmisartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.
1451340320,C,G,Patients with the CG genotype may have increased concentrations of telmisartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.
1451340320,G,G,Patients with the GG genotype may have decreased concentrations of telmisartan as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.
1450930839,A,A,"Patients with the AA genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450930839,A,G,"Patients with the AG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450930839,G,G,"Patients with the GG genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of nicotine dependence."
1451356840,C,C,Patients with the rs696 CC genotype may require decreased doses of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sufentanil dosage requirements.
1451356840,C,T,Patients with the rs696 CT genotype may require decreased doses of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sufentanil dosage requirements.
1451356840,T,T,Patients with the rs696 TT genotype may require increased doses of sufentanil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence sufentanil dosage requirements.
1451225360,A,A,Infants who have been exposed to buprenorphine in utero and who have the rs4680 AA genotype may have an increased severity of neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.
1451225360,A,G,Infants who have been exposed to buprenorphine in utero and who have the rs4680 AG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.
1451225360,G,G,Infants who have been exposed to buprenorphine in utero and who have the rs4680 GG genotype may have a decreased severity of neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.
1450930464,C,C,Patients with the CC genotype may begin using heroin at a later age as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.
1450930464,C,T,Patients with the CT genotype may begin using heroin at a later age as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.
1450930464,T,T,Patients with the TT genotype may begin using heroin at an earlier age as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's age at first use of heroin.
1451290960,C,C,Patients with diabetes mellitus and the CC genotype who are taking gliclazide may have decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.
1451290960,C,T,Patients with diabetes mellitus and the CT genotype who are taking gliclazide may have improved response as compared to patients with the CC genotype and decreased response compared to the TT genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.
1451290960,T,T,Patients with diabetes mellitus and the TT genotype who are taking gliclazide may have improved response as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.
1451356520,C,C,"Patients with the CC genotype may have decreased lipid-lowering response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin."
1451356520,C,T,"Patients with the CT genotype may have decreased lipid-lowering response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin."
1451356520,T,T,"Patients with the TT genotype may have increased lipid-lowering response to simvastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin."
1451356180,C,C,Patients with schizophrenia and the rs28379954 CC genotype may have increased serum concentrations of clozapine as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs28379954 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence serum concentrations of clozapine.
1451356180,C,T,Patients with schizophrenia and the rs28379954 CT genotype may have decreased serum concentrations of clozapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs28379954 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence serum concentrations of clozapine.
1451356180,T,T,"There is currently no available evidence regarding the association between the rs28379954 TT genotype and clozapine concentrations. However, patients with schizophrenia and the CT genotype may have decreased serum concentrations of clozapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs28379954 and clozapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence serum concentrations of clozapine."
1451151506,C,C,Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151506,C,T,Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151506,T,T,Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451356356,A,A,Patients with opioid dependence and the rs11265549 AA genotype may be more likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.
1451356356,A,G,Patients with opioid dependence and the rs11265549 AG genotype may be less likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.
1451356356,G,G,Patients with opioid dependence and the rs11265549 GG genotype may be less likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.
1451356386,A,A,Patients with opioid dependence and the rs11265549 AA genotype may have decreased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.
1451356386,A,G,Patients with opioid dependence and the rs11265549 AG genotype may have increased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.
1451356386,G,G,Patients with opioid dependence and the rs11265549 GG genotype may have increased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.
1451225320,A,A,"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs4680 AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AG or GG genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451225320,A,G,"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs4680 AG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451225320,G,G,"Infants who have been exposed to buprenorphine in utero and who are born to women with the rs4680 GG genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451356380,A,A,Patients with opioid dependence and the rs11265549 AA genotype may require decreased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence methadone dosage requirements.
1451356380,A,G,Patients with opioid dependence and the rs11265549 AG genotype may require increased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1451356380,G,G,Patients with opioid dependence and the rs11265549 GG genotype may require increased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1451240740,G,G,Patients with bladder cancer and the GG genotype may be at an increased risk of developing neutropenia when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.
1451240740,G,T,Patients with bladder cancer and the GT genotype may be at an increased risk of developing neutropenia when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.
1451240740,T,T,Patients with bladder cancer and the TT genotype may be at a decreased risk of developing neutropenia when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.
1451240746,G,G,Patients with bladder cancer and the GG genotype may be at an increased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.
1451240746,G,T,Patients with bladder cancer and the GT genotype may be at an increased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.
1451240746,T,T,Patients with bladder cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.
1450815092,A,A,Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815092,A,G,Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the AA genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815092,G,G,Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1451351160,A,A,Patients with the rs1799971 AA genotype and chronic pain may experience increased quality of sleep when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sleep quality when treated with opioids.
1451351160,A,G,Patients with the rs1799971 AG genotype and chronic pain may experience increased quality of sleep when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sleep quality when treated with opioids.
1451351160,G,G,Patients with the rs1799971 GG genotype and chronic pain may experience decreased quality of sleep when treated with opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence sleep quality when treated with opioids.
1451277440,C,C,Patients with two X-chromosomes and the CC genotype who are treated with risperidone may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.
1451277440,C,G,Patients with two X-chromosomes and the CG genotype who are treated with risperidone may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.
1451277440,G,G,"Patients with two X-chromosomes and the GG genotype who are treated with risperidone may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele."
1451244680,C,C,Patients with the CC genotype may have increased concentrations of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.
1451244680,C,T,Patients with the CT genotype may have increased concentrations of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.
1451244680,T,T,Patients with the TT genotype may have decreased concentrations of lovastatin acid as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.
1451351240,C,C,Patients with the rs79910351 CC genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect response to fentanyl.
1451351240,C,T,"There is currently no available evidence regarding the association between the rs79910351 CT genotype and response to fentanyl. However, patients with the rs79910351 TT genotype may have a decreased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to fentanyl."
1451351240,T,T,Patients with the rs79910351 TT genotype may have a decreased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to fentanyl.
1451121880,A,A,"Patients with the AA genotype may have an increased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the GG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
1451121880,A,G,"Patients with the AG genotype may have an increased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the GG genotype. However, some studies find no association with drug toxicity or one study reported reduced risk in heterozygotes. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
1451121880,G,G,"Patients with the GG genotype may have a decreased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the AA or AG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
1451351260,C,C,Patients with the rs79910351 CC genotype may have an increased response to remifentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect response to remifentanil.
1451351260,C,T,"There is currently no available evidence regarding the association between the rs79910351 CT genotype and response to remifentanil. However, patients with the rs79910351 TT genotype may have a decreased response to remifentanil as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to remifentanil."
1451351260,T,T,Patients with the rs79910351 TT genotype may have a decreased response to remifentanil as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to remifentanil.
1451350944,A,A,Patients with the rs1799971 AA genotype may have increased severity of sleep apnea when treated with morphine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence severity of sleep apnea when treated with morphine.
1451350944,A,G,Patients with the rs1799971 AG genotype may have decreased severity of sleep apnea when treated with morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of sleep apnea when treated with morphine.
1451350944,G,G,"There is currently no available evidence regarding the association between the rs1799971 GG genotype and severity of sleep apnea when treated with morphine. However, patients with the rs1799971 AG genotype may have decreased severity of sleep apnea when treated with morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of sleep apnea when treated with morphine."
1451325840,A,A,"There is currently no available evidence regarding the association between the rs671 AA genotype and acetaldehyde concentrations. However, patients with the rs671 AG genotype may have increased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and acetaldehyde and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of acetaldehyde."
1451325840,A,G,"Patients with the rs671 AG genotype may have increased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and acetaldehyde and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of acetaldehyde."
1451325840,G,G,"Patients with the rs671 GG genotype may have decreased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and acetaldehyde and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of acetaldehyde."
1450375701,A,A,"Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375701,A,C,"Patients with the AC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375701,A,T,"Patients with the AT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375701,C,C,"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375701,C,T,"Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375701,T,T,"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the AC, CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1451357200,C,C,"Patients with the rs4149056 CC genotype may have increased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin."
1451357200,C,T,"Patients with the rs4149056 CT genotype may have increased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin."
1451357200,T,T,"Patients with the rs4149056 TT genotype may have decreased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype CT or CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin."
1451244720,C,C,"Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy."
1451244720,C,T,"Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy."
1451244720,T,T,"Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy."
1450810357,A,A,Patients with the rs3778156 AA genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1450810357,A,G,Patients with the rs3778156 AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1450810357,G,G,Patients with the rs3778156 GG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451244700,C,C,"Patients with the rs4149056 CC genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes."
1451244700,C,T,"Patients with the rs4149056 CT genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes."
1451244700,T,T,"Patients with the rs4149056 TT genotype may have decreased concentrations of fluvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes."
1450375047,C,C,"Patients with testicular cancer and the CC genotype may have an increased risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide."
1450375047,C,T,"Patients with testicular cancer and the CT genotype may have a decreased risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide."
1450375047,T,T,"Patients with testicular cancer and the TT genotype may have a decreased risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia or pain as a result of treatment with bleomycin, cisplatin and etoposide."
1451357763,A,A,Patients with breast cancer and the rs6990851 AA genotype may have a decreased response to anastrozole as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to anastrozole.
1451357763,A,G,Patients with breast cancer and the rs6990851 AG genotype may have an increased response to anastrozole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anastrozole.
1451357763,G,G,Patients with breast cancer and the rs6990851 GG genotype may have an increased response to anastrozole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anastrozole.
1451357759,G,G,Patients with breast cancer and the rs1437153 GG genotype may have an increased response to anastrozole as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.
1451357759,G,T,Patients with breast cancer and the rs1437153 GT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.
1451357759,T,T,Patients with breast cancer and the rs1437153 TT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.
1451357783,G,G,Patients with breast cancer and the rs2449598 GG genotype may have an increased response to anastrozole as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.
1451357783,G,T,Patients with breast cancer and the rs2449598 GT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.
1451357783,T,T,Patients with breast cancer and the rs2449598 TT genotype may have a decreased response to anastrozole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anastrozole.
1451357790,C,C,Patients with breast cancer and the rs6981827 CC genotype may have an increased response to anastrozole as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.
1451357790,C,T,Patients with breast cancer and the rs6981827 CT genotype may have a decreased response to anastrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anastrozole.
1451357790,T,T,Patients with breast cancer and the rs6981827 TT genotype may have a decreased response to anastrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anastrozole.
1451238460,A,A,"Patients with the rs4680 AA genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more skin redness as compared to patients with the AG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence."
1451238460,A,G,"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report less skin redness as compared to patients with the AA or GG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence."
1451238460,G,G,"Patients with the rs4680 GG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more skin redness as compared to patients with the AG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. However, the direction of this association was reversed after the deprescription programme had ended. Other genetic and clinical factors may also affect the incidence of skin redness during treatment for opioid dependence."
1451123780,A,A,Patients with the A/A genotype who are treated with clopidogrel may have an average catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1448256712,A,A,"Patients with the AA genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1448256712,A,G,"Patients with the AG genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1448256712,G,G,"Patients with the GG genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1451328325,A,A,Patients with the rs10455872 AA genotype may have a decreased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AG or GG. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.
1451328325,A,G,Patients with the rs10455872 AG genotype may have an increased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AA. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.
1451328325,G,G,Patients with the rs10455872 GG genotype may have an increased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AA. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.
1451344820,G,G,Patients with the GG genotype may have increased risk of peripheral neuropathy when treated with taxanes in cancer patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence toxicity to taxanes.
1451344820,G,T,Patients with the GT genotype may have increased risk of peripheral neuropathy when treated with taxanes in cancer patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence toxicity to taxanes.
1451344820,T,T,Patients with the TT genotype may have decreased risk of peripheral neuropathy when treated with taxanes in cancer patients as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence toxicity to taxanes.
1451353040,C,C,Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the TT or CT genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.
1451353040,C,T,Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.
1451353040,T,T,Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.
1451238365,A,A,Patients with the AA genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451238365,A,G,Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451238365,G,G,Patients with the GG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451328500,A,A,Patients with the rs1800629 AA genotype may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to Tumor necrosis factor alpha (TNF-alpha) inhibitors.
1451328500,A,G,"Patients with the rs1800629 AG genotype may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to Tumor necrosis factor alpha (TNF-alpha) inhibitors."
1451328500,G,G,Patients with the rs1800629 GG genotype may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to Tumor necrosis factor alpha (TNF-alpha) inhibitors.
1451237983,G,G,Patients with depression and the GG genotype may have an increased response to antidepressants as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to antidepressants.
1451237983,G,T,Patients with depression and the GT genotype may have an increased response to antidepressants as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to antidepressants.
1451237983,T,T,Patients with depression and the TT genotype may have a decreased response to antidepressants as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to antidepressants.
1451238020,G,G,Patients with bipolar disorder and the GG genotype may have an increased response to paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to paroxetine.
1451238020,G,T,Patients with bipolar disorder and the GT genotype may have an increased response to paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to paroxetine.
1451238020,T,T,Patients with bipolar disorder and the TT genotype may have a decreased response to paroxetine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to paroxetine.
1451238040,G,G,Patients with depression and the GG genotype may have an increased response to escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to escitalopram.
1451238040,G,T,Patients with depression and the GT genotype may have an increased response to escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to escitalopram.
1451238040,T,T,Patients with depression and the TT genotype may have a decreased response to escitalopram as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to escitalopram.
1451336020,A,A,"There is currently no available evidence regarding the association between the rs34059508 AA genotype and exposure to olanzapine. However, patients with the AG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine."
1451336020,A,G,Patients with the rs34059508 AG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.
1451336020,G,G,Patients with the rs34059508 GG genotype may have decreased exposure to olanzapine as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs34059508 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect exposure to olanzapine.
1451336026,C,C,Patients with the rs3842 CC genotype may have decreased clearance of olanzapine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.
1451336026,C,T,Patients with the rs3842 CT genotype may have increased clearance of olanzapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.
1451336026,T,T,Patients with the rs3842 TT genotype may have increased clearance of olanzapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.
1451336041,A,A,Patients with the rs10248420 AA genotype may have a decreased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.
1451336041,A,G,Patients with the rs10248420 AG genotype may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.
1451336041,G,G,Patients with the rs10248420 GG genotype may have an increased likelihood of developing somnolence when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.
1451336060,C,C,"There is currently no available evidence regarding the association between the rs5128 CC genotype and exposure to olanzapine. However, patients with the rs5128 CG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine."
1451336060,C,G,Patients with the rs5128 CG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.
1451336060,G,G,Patients with the rs5128 GG genotype may have decreased exposure to olanzapine as compared to patients with the CG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.
1451245960,A,A,Patients with the AA genotype may have an increased response to rosuvastatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.
1451245960,A,G,Patients with the AG genotype may have a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.
1451245960,G,G,Patients with the GG genotype may have a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.
1451336074,A,A,Patients with the rs4728709 AA genotype may have a decreased likelihood of developing asthenia when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.
1451336074,A,G,Patients with the rs4728709 AG genotype may have a decreased likelihood of developing asthenia when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.
1451336074,G,G,Patients with the rs4728709 GG genotype may have an increased likelihood of developing asthenia when treated with olanzapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced asthenia.
1451336100,C,C,Patients with the rs3842 CC genotype may have an increased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.
1451336100,C,T,Patients with the rs3842 CT genotype may have a decreased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.
1451336100,T,T,Patients with the rs3842 TT genotype may have a decreased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.
1451246040,A,A,Patients with the AA genotype may experience a decreased severity of nicotine withdrawal as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of nicotine withdrawal.
1451246040,A,G,Patients with the AG genotype may experience a decreased severity of nicotine withdrawal as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of nicotine withdrawal.
1451246040,G,G,Patients with the GG genotype may experience an increased severity of nicotine withdrawal as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect the severity of nicotine withdrawal.
1450377208,A,A,Patients with the AA genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377208,A,G,Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377208,G,G,Patients with the GG genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1451352140,C,C,Patients with the rs6517442 CC genotype may have increased opioid dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect opioid dose requirements.
1451352140,C,T,Patients with the rs6517442 CT genotype may have decreased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect opioid dose requirements.
1451352140,T,T,Patients with the rs6517442 TT genotype may have decreased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect opioid dose requirements.
1451352146,A,A,Patients with the rs1045642 AA genotype may be less likely to experience nausea when treated with opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.
1451352146,A,G,Patients with the rs1045642 AG genotype may be more likely to experience nausea when treated with opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.
1451352146,G,G,Patients with the rs1045642 GG genotype may be more likely to experience nausea when treated with opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.
1451253880,C,C,"Patients with the CC genotype and Epilepsy may require an increased dose of carbamazepine as compared to patients with the the CT or TT genotypes. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine."
1451253880,C,T,"Patients with the CT genotype and Epilepsy may require a decreased dose of carbamazepine as compared to patients with the the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine."
1451253880,T,T,"Patients with the TT genotype and Epilepsy may require a decreased dose of carbamazepine as compared to patients with the the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine."
1450934061,C,C,Patients with the CC genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.
1450934061,C,T,Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.
1450934061,T,T,Patients with the TT genotype may be less likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.
1450934169,A,A,Patients with the AA genotype may have an increased response to mexiletine as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934169,A,T,Patients with the AT genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934169,T,T,Patients with the TT genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934181,G,G,Patients with the GG genotype may have an increased response to mexiletine as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934181,G,T,Patients with the GT genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934181,T,T,Patients with the TT genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1451359886,A,A,"Patients with temporomandibular disorder (TMD) and the rs4680 AA genotype may have an increased response to propranolol as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol."
1451359886,A,G,"Patients with temporomandibular disorder (TMD) and the rs4680 AG genotype may have a decreased response to propranolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol."
1451359886,G,G,"Patients with temporomandibular disorder (TMD) and the rs4680 GG genotype may have a decreased response to propranolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to propranolol."
1451351302,G,G,Patients with the rs368234815 GG genotype and chronic hepatitis C may have decreased response to sofosbuvir and ribavirin as compared to patients with the TT/TT genotype. Other genetic and clinical factors may also influence the response to sofosbuvir and ribavirin.
1451244869,A,A,"Patients with the rs4680 AA genotype may have a decreased analgesic response to fentanyl as compared to patients with the AG or GG genotypes, However, this association was not found to be statistically significant. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect analgesic response to fentanyl."
1451244869,A,G,"Patients with the rs4680 AG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes, However, this association was not found to be statistically significant. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect analgesic response to fentanyl."
1451244869,G,G,"Patients with the rs4680 GG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes, However, this association was not found to be statistically significant. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect analgesic response to fentanyl."
1451244900,A,A,"Patients with the rs4680 AA genotype may have an increased analgesic response to remifentanil as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to remifentanil."
1451244900,A,G,"Patients with the rs4680 AG genotype may have an increased analgesic response to remifentanil as compared to patients with the GG genotype, but a decreased response as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to remifentanil."
1451244900,G,G,"Patients with the rs4680 GG genotype may have a decreased analgesic response to remifentanil as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to remifentanil."
1451359601,C,C,Patients with the rs1611114 CC genotype and heroin dependence may be at an increased risk of experiencing memory impairment when taking heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of experiencing memory impairment when taking heroin.
1451359601,C,T,Patients with the rs1611114 CT genotype and heroin dependence may be at an increased risk of experiencing memory impairment when taking heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of experiencing memory impairment when taking heroin.
1451359601,T,T,Patients with the rs1611114 TT genotype and heroin dependence may be at a decreased risk of experiencing memory impairment when taking heroin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of experiencing memory impairment when taking heroin.
1451244980,A,A,"Patients with the rs4680 AA genotype may have an increased subjective response to oxycodone as compared to patients with the GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect subjective response to oxycodone."
1451244980,A,G,"Patients with the rs4680 AG genotype may have an increased subjective response to oxycodone as compared to patients with the GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect subjective response to oxycodone."
1451244980,G,G,"Patients with the rs4680 GG genotype may have a decreased subjective response to oxycodone as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect subjective response to oxycodone."
1451245004,A,A,"Patients with the rs4680 AA genotype may have decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect opioid dose requirements."
1451245004,A,G,"Patients with the rs4680 AG genotype may have decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect opioid dose requirements."
1451245004,G,G,"Patients with the rs4680 GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect opioid dose requirements."
981204995,C,C,Patients with the CC genotype and cancer who are treated with platinum-based chemotherapy may have shorter survival times as compared to patients with the CT or TT genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
981204995,C,T,Patients with the CT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
981204995,T,T,Patients with the TT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1451121940,A,A,"Patients with the rs11615 AA genotype may have a decreased response to cisplatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin."
1451121940,A,G,"Patients with the rs11615 AG genotype may have a decreased response to cisplatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin."
1451121940,G,G,"Patients with the rs11615 GG genotype may have an increased response to cisplatin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin."
1451245081,A,A,"Patients with the rs4680 AA genotype may have an increased analgesic response to morphine as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to morphine."
1451245081,A,G,"Patients with the rs4680 AG genotype may have an increased analgesic response to morphine as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to morphine."
1451245081,G,G,"Patients with the rs4680 GG genotype may have a decreased analgesic response to morphine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to morphine."
1451244920,A,A,"Patients with the rs4680 AA genotype may require decreased doses of sufentanil as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements."
1451244920,A,G,"Patients with the rs4680 AG genotype may require increased doses of sufentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements."
1451244920,G,G,"Patients with the rs4680 GG genotype may require increased doses of sufentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements."
1451254580,C,C,"Patients with the CC genotype and neoplasms who are treated with methotrexate may have a decreased clearance of methotrexate as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes."
1451254580,C,T,"Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes."
1451254580,T,T,"Patients with the TT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes."
1451245925,A,A,Patients with asthma and the AA genotype may have a decreased response to salbutamol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to salbutamol.
1451245925,A,G,There is currently no available evidence regarding an association between the AG genotype and response to salbutamol.
1451245925,G,G,Patients with asthma and the GG genotype may have an increased response to salbutamol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to salbutamol.
981237878,A,A,Patients with the AA genotype and Epilepsy who are treated with valproic acid may require a decreased dose as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.
981237878,A,C,Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.
981237878,C,C,Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.
827848785,C,C,Patients with the CC genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.
827848785,C,G,Patients with the CG genotype may have increased antidepressant response to escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to escitalopram.
827848785,G,G,Patients with the GG genotype may have decreased antidepressant response to escitalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to escitalopram.
981238234,C,C,"Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone."
981238234,C,T,"Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone."
981238234,T,T,"Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone."
981239568,A,A,Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence warfarin dose.
981239568,A,C,"Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose."
981239568,C,C,"Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose."
1449718265,C,C,"Patients with the CC genotype and breast cancer may have an increased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy."
1449718265,C,T,"Patients with the CT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy."
1449718265,T,T,"Patients with the TT genotype and breast cancer may have a decreased risk for leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with CC genotype. Other genetic and clinical factors may also influence risk for leukopenia in patients taking FAC chemotherapy."
1451245040,A,A,"Patients with the rs4680 AA genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to opioids."
1451245040,A,G,"Patients with the rs4680 AG genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to opioids."
1451245040,G,G,"Patients with the rs4680 GG genotype may have a decreased analgesic response to opioids as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to opioids."
1451289620,C,C,"Patients with the CC genotype may be at decreased, but not absent, risk of over-anticoagulation, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of over-anticoagulation."
1451289620,C,T,"Patients with the CT genotype may also be at increased risk of over-anticoagulation as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of over-anticoagulation."
1451289620,T,T,Patients with the TT genotype may be at increased risk of over-anticoagulation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of over-anticoagulation.
1451257000,C,C,"Patients with the CC (POR *1/*1) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3 (rs776746) may have decreased metabolism of tacrolimus as compared to patients with the CT and TT (*1/*28 and *28/*28) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes."
1451257000,C,T,"Patients with the CT (POR *1/*28) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3 (rs776746) may have increased metabolism of tacrolimus as compared to patients with the CC (*1/*1) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes."
1451257000,T,T,"Patients with the TT (POR *28/*28) genotype and transplantation who are treated with tacrolimus in combination with the CYP3A5 expressors genotype *1/*1 or *1/*3 (rs776746) may have increased metabolism of tacrolimus as compared to patients with the CC (*1/*1) genotype, however this has been contradicted in a number of studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1057868 and tacrolimus and does not include evidence about clinical outcomes."
1451354640,A,A,"There is currently no available evidence regarding the association between the rs1386493 AA genotype and dosage of methadone. However, patients with heroin dependence and the AG genotype may require decreased doses of methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dosage requirements."
1451354640,A,G,Patients with heroin dependence and the rs1386493 AG genotype may require decreased doses of methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1451354640,G,G,Patients with heroin dependence and the rs1386493 GG genotype may require increased doses of methadone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1449716213,A,A,Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716213,A,G,Patients with the AG genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716213,G,G,Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1451354647,C,C,Patients with heroin dependence and the rs2229205 CC genotype may require decreased doses of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1451354647,C,T,Patients with heroin dependence and the rs2229205 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1451354647,T,T,"There is currently no available evidence regarding the association between the rs2229205 TT genotype and methadone dosage. However, patients with heroin dependence and the CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements."
1451354700,C,C,Patients with heroin dependence and the rs16974799 CC genotype may require decreased doses of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1451354700,C,T,Patients with heroin dependence and the rs16974799 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1451354700,T,T,"There is currently no available evidence regarding the association between the rs16974799 TT genotype and methadone dosage. However, patients with heroin dependence and the CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements."
1450813849,C,C,Patients with the CC genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.
1450813849,C,T,Patients with the CT genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.
1450813849,T,T,Patients with the TT genotype may be more likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.
1451150004,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150004,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150004,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451338440,G,G,"Patients with the rs11322783 GG genotype and chronic hepatitis C may have decreased response when treated with direct acting antivirals, including sofosbuvir and ribavirin as compared to patients with genotype TT/TT or G/TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to direct acting antivirals."
1451150066,C,C,Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150066,C,T,Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150066,T,T,Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451354560,C,C,Patients with heroin dependence and the rs806368 CC genotype may require decreased doses of methadone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methadone dosage requirements.
1451354560,C,T,Patients with heroin dependence and the rs806368 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1451354560,T,T,Patients with heroin dependence and the rs806368 TT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.
1451346385,C,C,Patients with ADHD and the rs71647871 CC genotype may require an increased dose of methylphenidate as compared to patients with the CT genotype. Other genetic and clinical factors may also influence methylphenidate dosage requirements.
1451346385,C,T,Patients with ADHD and the rs71647871 CT genotype may require a decreased dose of methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methylphenidate dosage requirements.
1451346385,T,T,"There is currently no available evidence regarding the association between the rs71647871 TT genotype and methylphenidate dosage requirements. However, patients with ADHD and the CT genotype may require a decreased dose of methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methylphenidate dosage requirements."
981201387,A,A,"Patients with the rs2236225 AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
981201387,A,G,"Patients with the rs2236225 AG genotype may have decreased event free survival when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
981201387,G,G,"Patients with the rs2236225 GG genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
827836551,C,C,Patients with the CC genotype may have decreased pain relief to ibuprofen as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.
827836551,C,G,Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.
827836551,G,G,Patients with the GG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.
1449576301,C,C,"Patients with the CC genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide."
1449576301,C,T,"Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide."
1449576301,T,T,"Patients with the TT genotype may have an increased response to treatment with atenolol and hydrochlorothiazide, resulting in a decreased risk of having uncontrolled blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide."
1451337885,C,C,"Patients with the rs1041983 CC genotype and tuberculosis may have a decreased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin."
1451337885,C,T,"Patients with the rs1041983 CT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin."
1451337885,T,T,"Patients with the rs1041983 TT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin."
1450936284,A,A,Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936284,A,T,Patients with the AT genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936284,T,T,Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450935813,C,C,Patients with the CC genotype may have increased clearance of tolbutamide as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C9 protein as compared to the CT or TT genotypes. Other genetic and clinical factors may also affect tolbutamide clearance.
1450935813,C,T,Patients with the CT genotype may have decreased clearance of tolbutamide as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the CC genotype. Other genetic and clinical factors may also affect tolbutamide clearance.
1450935813,T,T,Patients with the TT genotype may have decreased clearance of tolbutamide as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the CC genotype. Other genetic and clinical factors may also affect tolbutamide clearance.
1450935826,C,C,Patients with the CC genotype may have decreased clearance of tolbutamide as compared to patients with the TT genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the TT genotype. Other genetic and clinical factors may also affect tolbutamide clearance.
1450935826,C,T,Patients with the CT genotype may have decreased clearance of tolbutamide as compared to patients with the TT genotype. This may be at least partly due to decreased expression of CYP2C9 protein as compared to the TT genotype. Other genetic and clinical factors may also affect tolbutamide clearance.
1450935826,T,T,Patients with the TT genotype may have increased clearance of tolbutamide as compared to patients with the CC or CT genotypes. This may be at least partly due to increased expression of CYP2C9 protein as compared to the CC or CT genotypes. Other genetic and clinical factors may also affect tolbutamide clearance.
1451223506,A,A,"Patients with the rs1801133 AA genotype may have a decreased response to methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1451223506,A,G,"Patients with the rs1801133 AG genotype may have a decreased response to methotrexate as compared to patients with the GG genotype but an increased response compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1451223506,G,G,"Patients with the rs1801133 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
655384558,C,C,Patients with the CC genotype may have reduced response to daunorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment.
655384558,C,G,Patients with the CG genotype may have reduced response to daunorubicin compared to patients with the GG genotype or may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.
655384558,G,G,Patients with the GG genotype may have increased response to daunorubicin compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment.
827847725,C,C,Patients with the CC genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.
827847725,C,T,Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.
827847725,T,T,Patients with the TT genotype may have decreased survival when treated with carboplatin and paclitaxel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence survival.
827847759,A,A,Patients with the AA genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.
827847759,A,G,Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.
827847759,G,G,Patients with the GG genotype may have decreased response to duloxetine as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.
827848740,A,A,"Patients with the AA genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693."
827848740,A,G,"Patients with the AG genotype may experience greater response to leflunomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693."
827848740,G,G,"Patients with the GG genotype may experience decreased response to leflunomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to leflunomide, particularly rs2234693."
827848751,A,A,"Patients with the AA genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density."
827848751,A,G,"Patients with the AG genotype may experience 1) smaller increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) larger decreases in spine bone mineral density when untreated, as compared to patient with the GG genotype. Other genetic and clinical factors may also influence spine bone mineral density."
827848751,G,G,"Patients with the GG genotype may experience 1) greater increases in spine bone mineral density when treated with conjugated estrogens and medroxyprogesterone or 2) smaller decreases in spine bone mineral density when untreated, as compared to patient with the AA genotype. Other genetic and clinical factors may also influence spine bone mineral density."
981201549,C,C,Patients with the CC genotype may have increased anxiety when exposed to caffeine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patients response to caffeine.
981201549,C,T,Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.
981201549,T,T,Patients with the TT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.
827848762,C,C,Patients with the CC genotype may have increased metabolism of tolbutamide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence tolbutamide metabolism.
827848762,C,T,Patients with the CT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.
827848762,T,T,Patients with the TT genotype may have decreased metabolism of tolbutamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolbutamide metabolism.
827848365,A,A,"Patients with the rs1801133 AA genotype and cancer who are treated with methotrexate may be at increased risk of toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
827848365,A,G,"Patients with the rs1801133 AG genotype and cancer who are treated with methotrexate may be at increased risk of toxicity as compared to patients with the GG genotype, and may be at decreased risk of toxicity compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
827848365,G,G,"Patients with the rs1801133 GG genotype and cancer who are treated with methotrexate may be at decreased risk of toxicity as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1450935819,A,A,Patients with the rs771237265 AA genotype may have increased clearance of tolbutamide as compared to patients with the AC or CC genotypes. This may be at least partly due to changes in CYP2C9 protein expression. This annotation only covers the pharmacokinetic relationship between rs771237265 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.
1450935819,A,C,Patients with the rs771237265 AC genotype may have decreased clearance of tolbutamide as compared to patients with the AA genotype. This may be at least partly due to changes in CYP2C9 protein expression. This annotation only covers the pharmacokinetic relationship between rs771237265 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.
1450935819,C,C,Patients with the rs771237265 CC genotype may have decreased clearance of tolbutamide as compared to patients with the AA genotype. This may be at least partly due to changes in CYP2C9 protein expression. This annotation only covers the pharmacokinetic relationship between rs771237265 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.
827863928,A,A,"Patients with the AA genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with verapamil compared to treatment with atenolol. Other genetic and clinical factors may also influence a patient's response to treatment."
827863928,A,G,"Patients with the AG genotype, hypertension and stable coronary artery disease, may respond similarily to treatment with atenolol or verapamil. Other genetic and clinical factors may also influence a patient's response to treatment."
827863928,G,G,"Patients with the GG genotype, hypertension and stable coronary artery disease, are more likely to benefit from treatment with atenolol compared to treatment with verapamil. Other genetic and clinical factors may also influence a patient's response to treatment."
981201408,C,C,"Patients with the CC genotype may have increased risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the TT or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events."
981201408,C,T,"Patients with the CT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events."
981201408,T,T,"Patients with the TT genotype may have decreased but not absent risk of acute kidney transplant rejection when treated with mycophenolate mofetil as compared to those with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's risk for adverse events."
981201424,C,C,Patients with the CC genotype may have decreased but not absent risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
981201424,C,T,Patients with the CT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
981201424,T,T,Patients with the TT genotype may have increased risk of leukopenia when treated with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
981201443,C,C,Patients with the CC genotype may have increased risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.
981201443,C,T,Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.
981201443,T,T,Patients with the TT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.
981201455,C,C,Patients with the CC genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
981201455,C,T,Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
981201455,T,T,Patients with the TT genotype may have decreased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
981201571,C,C,"Patients with the CC genotype who are treated with cytarabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity."
981201584,C,C,Patients with the CC genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.
981201770,G,G,Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.
981201770,G,T,"Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid."
981201770,T,T,Patients with the TT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.
981201788,C,C,Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201788,C,T,Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201788,T,T,Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201797,A,A,Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201797,A,C,Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201797,C,C,Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201805,A,A,Patients with the AA genotype may have increased metabolism of coumarin as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201805,A,C,Patients with the AC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201805,C,C,Patients with the CC genotype may have decreased metabolism of coumarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
981201827,A,A,"Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked."
981201827,A,C,"Patients with the AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked."
981201827,C,C,"Patients with the CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular other tag SNPs for alleles of CYP2A6 should be cross checked."
981201881,C,C,"Patients with the CC genotype may have Increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotypes. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events."
981201881,C,T,"Patients with the CT genotype may have increased risk of hypersensitivity when treated with abacavir as compared to patients with the TT genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events."
981201881,T,T,"Patients with the TT genotype may have decreased but not absent risk of hypersensitivity when treated with abacavir as compared to patients with the CC genotype. This variant is a tagging SNP for HLA-B*5701, for which there is greater evidence of association with abacavir-induced hypersensitivity. Other genetic and clinical factors may also influence a patient's risk for adverse events."
981201854,C,C,Patients with the CC genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism. This annotation only covers the pharmacokinetic relationship between rs28399499 and nevirapine and does not include evidence about clinical outcomes.
981201854,C,T,Patients with the CT genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism. This annotation only covers the pharmacokinetic relationship between rs28399499 and nevirapine and does not include evidence about clinical outcomes.
981201854,T,T,Patients with the TT genotype may have decreased plasma drug exposure when treated with nevirapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism. This annotation only covers the pharmacokinetic relationship between rs28399499 and nevirapine and does not include evidence about clinical outcomes.
1450935838,C,C,Patients with the rs183701923 CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935838,C,T,Patients with the rs183701923 CT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935838,T,T,Patients with the rs183701923 TT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein. This annotation only covers the pharmacokinetic relationship between rs183701923 and mephenytoin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect mephenytoin clearance.
827848732,A,A,"Patients with the rs9344 AA genotype may be at a decreased but not absent risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate."
827848732,A,G,"Patients with the rs9344 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate."
827848732,G,G,"Patients with the rs9344 GG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate."
827864513,A,A,"The current evidence base suggests that there is no significant association between the rs2230345 AA genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers."
827864513,A,T,"The current evidence base suggests that there is no significant association between the rs2230345 AT genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers."
827864513,T,T,"The current evidence base suggests that there is no significant association between the rs2230345 TT genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers."
981201888,A,A,Schizophrenia patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AA is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.
981201888,A,G,Schizophrenia patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.
981201888,G,G,Schizophrenia patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the AA or AG genotype. Genotype GG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype AA. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.
981202090,C,C,Patients with the rs71647871 CC genotype may have increased metabolism of methylphenidate as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs71647871 and methylphenidate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methylphenidate metabolism.
981202090,C,T,Patients with the rs71647871 CT genotype may have decreased metabolism of methylphenidate as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and methylphenidate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methylphenidate metabolism.
981202090,T,T,Patients with the rs71647871 TT genotype may have decreased metabolism of methylphenidate as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and methylphenidate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methylphenidate metabolism.
981202103,C,C,Patients with the rs7297610 CC genotype and hypertension who are treated with hydrochlorothiazide may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
981202103,C,T,Patients with the rs7297610 CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
981202103,T,T,Patients with the rs7297610 TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
981202334,G,G,Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GG genotype may have an increased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.
981202334,G,T,Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.
981202334,T,T,Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the TT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.
981202356,G,G,Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose requirements.
981202356,G,T,"Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements."
981202356,T,T,Patients with the TT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.
981202366,A,A,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have decreased conversion of the drug to active polyglutamates 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.
981202366,A,G,Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates as compared to the AA genotype 2) may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.
981202366,G,G,Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate 1) may have increased conversion of the drug to active polyglutamates 2) may have increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methotrexate metabolism and response.
981202440,A,A,"Patients with the AA genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy."
981202440,A,C,"Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy."
981202440,C,C,"Patients with the CC genotype with cancer who are treated with cetuximab may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy."
981202520,A,A,Asian patients with the AA genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
981202520,A,G,Asian patients with the AG genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
981202520,G,G,Asian patients with the GG genotype and Hypertension who are treated with hydrochlorothiazide may have a poorer response to treatment as compared to patients with the AA or AG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
981202551,A,A,Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
981202551,A,G,Patients with the AG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
981202551,G,G,Patients with the GG genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have a decreased risk of poorer outcome as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
981202562,A,A,"Patients with the AA genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity."
981202562,A,G,"Patients with the AG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite, and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity."
981202562,G,G,"Patients with the GG genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have increased metabolism of cyclophosphamide, leading to higher concentrations of the active metabolite and an increased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity."
981237704,A,A,"The current evidence base suggests that there is no significant association between the rs1805087 AA genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate."
981237704,A,G,"The current evidence base suggests that there is no significant association between the rs1805087 AG genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate."
981237704,G,G,"The current evidence base suggests that there is no significant association between the rs1805087 GG genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate."
981202646,A,A,Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.
981202646,A,G,Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.
981202646,G,G,Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have an increased risk of tardive dyskinesia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.
981202674,A,A,Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype. Metabolic syndrome was also associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.
981202674,A,G,Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype or decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AG genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.
981202674,G,G,Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. Patients with the GG genotype who are treated with antipsychotics and have metabolic syndrome may have similar levels of methylation at sites within the COMT gene promoter to those seen in patients with the AA genotype without metabolic syndrome. Other genetic and clinical factors may also influence methylation of the COMT gene promoter. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.
981204525,G,G,"Genotype GG may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed."
981204525,G,T,"Genotype GT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed."
981204525,T,T,"Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed."
981204864,G,G,"Patients with the GG genotype who have cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to patients with the TT genotype. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
981204864,G,T,"Patients with the GT genotype who have cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to patients with the TT genotype. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
981204864,T,T,"Patients with the TT genotype who have cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to patients with the GG or GT genotypes. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
981204874,A,A,"Patients with the AA genotype may more likely to respond to drugs to treat nicotine dependence as compared to patients with the GG genotype. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factors may influence a patient's response to treatment for nicotine dependence."
981204874,A,G,"Patients with the AG genotype may more likely to respond to drugs to treat nicotine dependence as compared to patients with the GG genotype. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factors may influence a patient's response to treatment for nicotine dependence."
981204874,G,G,"Patients with the GG genotype may less likely to respond to drugs to treat nicotine dependence as compared to patients with the AA or AG genotypes. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factors may influence a patient's response to treatment for nicotine dependence."
981238057,A,A,Patients with the AA genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.
981238057,A,C,Patients with the AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.
981238057,C,C,Patients with the CC genotype may have increased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of doxorubicin.
981238092,A,A,"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
981238092,A,C,"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
981238092,C,C,"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
981238108,A,A,Patients with genotype AA may have decreased metabolism of digoxin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of digoxin.
981238108,A,C,Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.
981238108,C,C,Patients with genotype CC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.
981238562,C,C,"The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
981238562,C,T,"The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
981238562,T,T,"The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
981238910,C,C,"Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment."
981238910,C,T,"Patients with the CT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype or may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment."
981238910,T,T,"Patients with the TT genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have an increased likelihood of treatment failure as compared to patients with the CC genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment."
981345277,C,C,"Patients with the CC genotype and cancer may have increased response to fluorouracil-containing chemotherapy regimens, as well as a decreased risk for and a later onset of sensory neuropathy, as compared to patients with the CT or TT genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
981345277,C,T,"Patients with the CT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
981345277,T,T,"Patients with the TT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
981202046,A,A,"Patients with the rs5031016 AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotypes. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. This annotation only covers the pharmacokinetic relationship between rs5031016 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nicotine."
981202046,A,G,"Patients with the rs5031016 AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. This annotation only covers the pharmacokinetic relationship between rs5031016 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nicotine."
981202046,G,G,"Patients with the rs5031016 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. Other variants within the CYP2A6 gene should be considered - allele G of this SNP is part of the *7, *10, *19, *36, *37 CYP2A6 alleles. This annotation only covers the pharmacokinetic relationship between rs5031016 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of nicotine."
981345285,C,C,"Patients with the CC genotype may have 1) increased survival and 2) increased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CT or TT genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
981345285,C,T,"Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
981345285,T,T,"Patients with the TT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment."
1448256098,C,C,Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 CC genotype may have decreased risk of adverse events when treated with mercaptopurine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine.
1448256098,C,T,Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 CT genotype may have decreased risk of adverse events when treated with mercaptopurine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine.
1448256098,T,T,Patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma and the rs2413739 TT genotype may have increased risk of adverse events when treated with mercaptopurine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with mercaptopurine.
981345311,C,C,Patients with the CC genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.
981345311,C,T,Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.
981345311,T,T,Patients with the TT genotype may have increased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.
1447814482,A,A,Patients with genotype AA and urticaria may have increased response to desloratadine and mizolastine compared to patients with genotypes AG or GG. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.
1447814482,A,G,Patients with genotype AG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.
1447814482,G,G,Patients with genotype GG and urticaria may have decreased response to desloratadine and mizolastine compared to patients with genotype AA. Other clinical and genetic factors also may affect response to desloratadine and mizolastine.
1447943646,A,A,Patients with the AA genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine .
1447943646,A,G,Patients with the AG genotype and Alzheimer's disease may have increased response to galantamine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.
1447943646,G,G,Patients with the GG genotype and Alzheimer's disease may have decreased response to galantamine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.
1448100370,A,A,"No patients with the AA genotype were available for analysis, but patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity."
1448100370,A,G,Patients with the AG genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100370,G,G,Patients with the GG genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100382,A,A,Patients with the AA genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100382,A,T,Patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100382,T,T,"No patients with the TT genotype were available for analysis, but patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity."
1448100389,C,C,"Patients with the CC genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CT and TT genotypes. Other factors may affect response to these drugs."
1448100389,C,T,"Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs."
1448100389,T,T,"Patients with the TT genotype and schizophrenia may have decreased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the CC and CT genotypes. Other factors may affect response to these drugs."
1448100396,A,A,Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.
1448100396,A,G,"Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared with patients with genotype GG, or more likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response."
1448100396,G,G,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.
1448100404,A,A,Patients with the AA genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the AG and GG genotypes. Other factors may affect response to adalimumab.
1448100404,A,G,Patients with the AG genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the GG genotype. Other factors may affect response to adalimumab.
1448100404,G,G,Patients with the GG genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the AA and AG genotypes. Other factors may affect response to adalimumab.
1448100426,C,C,Patients with the CC genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.
1448100426,C,T,Patients with the CT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
1448100426,T,T,Patients with the TT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
1448104131,A,A,"Patients with the AA genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response."
1448104131,A,G,"Patients with the AG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response."
1448104131,G,G,"Patients with the GG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have an increased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response."
1448264442,G,G,Patients with genotype GG may have decreased sustained virological response (svr) when treated with simeprevir/peginterferon/ribavirin therapy in people with genotype 1 Hepatitis C as compared to patients with genotype TT/TT. Other genetic and clinical factors may also influence the response to simeprevir/peginterferon/ribavirin therapy.
1448616845,A,A,"Patients with cancer and the AA genotype who are treated with capecitabine may have an increased incidence of adverse events, including hand-foot syndrome, as compared to patients with the AC or CC genotypes, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine."
1448616845,A,C,"Patients with cancer and the AC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine."
1448616845,C,C,"Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine."
1448616870,C,C,Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) risk of nausea and vomiting as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.
1448616870,C,T,Patients with cancer and the CT genotype who are treated with capecitabine may have a decreased (but not absent) risk of nausea and vomiting as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.
1448616870,T,T,Patients with cancer and the TT genotype who are treated with capecitabine may have an increased risk of nausea and vomiting as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.
1448616910,C,C,Patients with the CC genotype and Cancer who are treated with Capecitabine may have an increased risk of of Diarrhea as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine
1448616910,C,T,"Patients with the CT genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of Diarrhea as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine"
1448616910,T,T,"Patients with the TT genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of Diarrhea as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in patients with Cancer who are treated with Capecitabine"
1448624459,A,A,"Patients with the AA genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine)."
1448624459,A,G,"Patients with the AG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the AA genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the GG genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine)."
1448624459,G,G,"Patients with the GG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have Increased likelihood of neutropenia or leukopenia as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine)."
1449144358,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144358,A,C,"Patients with the AC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CC genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144358,C,C,Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144370,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144370,A,G,"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144370,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144376,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144376,A,G,"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144376,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144382,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144382,G,T,"Patients with the GT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144382,T,T,Patients with the TT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144396,A,A,"Patients with the AA genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer."
1449144396,A,C,"Patients with the AC genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the CC genotype and and worse response as compared to the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer."
1449144396,C,C,"Patients with the CC genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer."
1449155607,C,C,Patients with the CC genotype and psoriasis may have a poorer response when treated with ustekinumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155607,C,T,Patients with the CT genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155607,T,T,Patients with the TT genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155614,C,C,Patients with the CC genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155614,C,G,Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155614,G,G,Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155625,A,A,Patients with the AA genotype and psoriasis may have a poorer response when treated with ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155625,A,G,Patients with the AG genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155625,G,G,Patients with the GG genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ustekinumab response.
1449155631,A,A,Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
1449155631,A,G,Patients with the AG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
1449155631,G,G,Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
1449155637,C,C,Patients with the CC genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
1449155637,C,G,Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
1449155637,G,G,Patients with the GG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors or ustekinumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.
1449155643,C,C,Patients with the CC genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155643,C,T,Patients with the CT genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155643,T,T,Patients with the TT genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155649,A,A,Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155649,A,T,Patients with the AT genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449155649,T,T,Patients with the TT genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.
1449164603,A,A,Patients with the AA genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1449164603,A,G,"Patients with the AG genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the GG genotype, or less likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of complete remission."
1449164603,G,G,Patients with the GG genotype and acute myeloid leukemia may be less likely to have complete remission when treated with idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1449566691,C,C,"Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds."
1449566691,C,T,"Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds."
1449566691,T,T,"Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds."
1449575745,A,A,"Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose."
1449575745,A,G,"Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose as compared to the AA genotype, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose."
1449575745,G,G,"Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG or AA genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose."
1449576622,A,A,Patients with cardiovascular disease and the AA genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.
1449576622,A,G,Patients with cardiovascular disease and the AG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the GG genotype and decreased likelihood as compared to the AA genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.
1449576622,G,G,Patients with cardiovascular disease and the GG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of rhabdomyolysis as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients who are taking statins.
1449713649,A,A,"Patients with the AA genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713649,A,C,"Patients with the AC genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713649,C,C,"Patients with the CC genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713660,A,A,"Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713660,A,G,"Patients with the AG genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713660,G,G,"Patients with the GG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713666,C,C,"Patients with the CC genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713666,C,T,"Patients with the CT genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713666,T,T,"Patients with the TT genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713676,A,A,"Patients with the AA genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713676,A,T,"Patients with the AT genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713676,T,T,"Patients with the TT genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
981238437,A,A,"Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac."
981238437,A,C,"Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac."
981238437,C,C,"Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac."
1449191740,C,C,"Patients with the CC genotype (do not have a copy of the CFTR R1070W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence response to ivacaftor."
1449191740,C,T,"Patients with the CT genotype (one copy of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence response to ivacaftor."
1449191740,T,T,"Patients with the TT genotype (two copies of the CFTR R1070W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R1070W. Other genetic and clinical factors may also influence response to ivacaftor."
1449713682,A,A,"Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713682,A,G,"Patients with the AG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1449713682,G,G,"Patients with the GG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab."
1450373589,A,A,"Patients with the AA genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib."
1450373589,A,G,"Patients with the AG genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib."
1450373589,G,G,"Patients with the GG genotype and cancer may have decreased clearance of imatinib, as well as an increased response and an increased risk for toxicity when treated with imatinib as compared to patients with the AA or AG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib."
1450373595,A,A,Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.
1450373595,A,G,Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.
1450373595,G,G,Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.
1450373604,A,A,Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.
1450373604,A,G,Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.
1450373604,G,G,Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival times when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.
1450814557,A,A,Patients with cocaine dependence and the AA genotype may have increased cocaine cue-reactivity as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.
1450814557,A,C,Patients with cocaine dependence and the AC genotype may have decreased cocaine cue-reactivity as compared to patients with the AA genotype. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.
1450814557,C,C,Patients with cocaine dependence and the CC genotype may have decreased cocaine cue-reactivity as compared to patients with the AA genotype. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.
1450814659,C,C,"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814659,C,T,"Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814659,T,T,"Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814665,C,C,"Patients with the CC genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814665,C,G,"Patients with the CG genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814665,G,G,"Patients with the GG genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814822,C,C,Patients with the CC genotype may have increased exposure to pitavastatin as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.
1450814822,C,T,"Patients with the CT genotype may have increased exposure to pitavastatin as compared to patients with the TT genotype, but decreased exposure as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin."
1450814822,T,T,Patients with the TT genotype may have decreased exposure to pitavastatin as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's exposure to pitavastatin.
1450814923,C,C,"Patients with Type II diabetes and the CC genotype may have a decreased response to pioglitazone as compared to patients with the CG genotype. However, another study found no association between this variant and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone."
1450814923,C,G,"Patients with Type II diabetes and the CG genotype may have an increased response to pioglitazone as compared to patients with the CC genotype. However, another study found no association between this variant and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone."
1450814923,G,G,There is currently no available evidence supporting an association between the GG genotype and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone.
1450815142,A,A,Patients with schizophrenia and the AA genotype may have a decreased response to quetiapine as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.
1450815142,A,G,Patients with schizophrenia and the AG genotype may have an increased response to quetiapine as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to quetiapine.
1450815142,G,G,Patients with schizophrenia and the GG genotype may have an increased response to quetiapine as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.
1450815166,C,C,Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the CG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815166,C,G,Patients with schizophrenia and the CG genotype may have a decreased response to risperidone as compared to patients with the CC genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815166,G,G,Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the CC or CG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1449004733,A,A,Patients with mesothelioma and the AA genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.
1449004733,A,G,Patients with mesothelioma and the AG genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.
1449004733,G,G,Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.
1449004739,G,G,Patients with mesothelioma and the GG genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.
1449004739,G,T,Patients with mesothelioma and the GT genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.
1449004739,T,T,Patients with mesothelioma and the TT genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the GG and GT genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine.
1449004745,A,A,Patients with Mesothelioma and the AA genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.
1449004745,A,G,Patients with Mesothelioma and the AC genotype may have worse overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.
1449004745,C,C,Patients with Mesothelioma and the CC genotype may have improved overall and progression-free survival when treated with cisplatin and gemcitabine as compared to patients with the AA and AC genotype. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with mesothelioma.
1449005041,C,C,Pregnant patients infected with malaria and the CC genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.
1449005041,C,T,"Pregnant patients infected with malaria and the CT genotype may have elevated concentrations of lumefantrine as compared to patients with the TT genotype, and lower concentrations as compared to patients with the CC genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine."
1449005041,T,T,Pregnant patients infected with malaria and the TT genotype may have lower concentrations of lumefantrine as compared to patients with the CT or CC genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.
1449005047,C,C,Pregnant patients with malaria and the CC genotype may have increased concentrations and an improved response to lumefantrine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.
1449005047,C,T,Pregnant patients with malaria and the CT genotype may have increased concentrations and an improved response to lumefantrine as compared to patients with the TT genotypes and lower concentrations and worse response to lumefantrine as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.
1449005047,T,T,Pregnant patients with malaria and the TT genotype may have lower concentrations and worse response to lumefantrine as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.
1449645432,C,C,Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645432,C,T,Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645432,T,T,Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645438,C,C,Patients with the CC genotype may have an increased rate of sulfation of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645438,C,T,Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645438,T,T,Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645444,C,C,Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645444,C,T,Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645444,T,T,Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645450,C,C,"Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645450,C,T,"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645450,T,T,"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645456,A,A,Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645456,A,G,Patients with the AG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645456,G,G,Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645462,A,A,Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645462,A,G,Patients with the AG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645462,G,G,Patients with the GG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645468,A,A,"Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645468,A,G,"Patients with the AG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645468,G,G,"Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645474,G,G,Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645474,G,T,Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645474,T,T,Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645480,G,G,Patients with the GG genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645480,G,T,Patients with the GT genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645480,T,T,Patients with the TT genotype may have an increased rate of sulfation of morphine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645486,G,G,Patients with the GG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645486,G,T,Patients with the GT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645486,T,T,Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645492,G,G,"Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645492,G,T,"Patients with the GT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645492,T,T,"Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645498,A,A,"Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients."
1449645498,A,C,"Patients with the AC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients."
1449645498,A,T,There is currently no published evidence to suggest how the AT genotype may affect acetaminophen sulfation in patients.
1449645498,C,C,"Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes, but a decreased rate of acetaminophen sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients."
1449645498,C,T,"Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients."
1449645498,T,T,"Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients."
1449645507,A,A,Patients with the AA genotype may have an increased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645507,A,C,Patients with the AC genotype may have an increased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645507,C,C,Patients with the CC genotype may have a decreased rate of sulfation of morphine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645513,A,A,"Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients."
1449645513,A,C,"Patients with the AC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients."
1449645513,A,T,There is currently no published evidence to suggest how the AT genotype may affect tapentadol sulfation in patients.
1449645513,C,C,"Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes, but a decreased rate of tapentadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients."
1449645513,C,T,"Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients."
1449645513,T,T,"Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients."
1449645522,A,A,"Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645522,A,C,"Patients with the AC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CC, CT, or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645522,A,T,There is currently no published evidence to suggest how the AT genotype may affect O-desmethyl-tramadol sulfation in patients.
1449645522,C,C,"Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CT or TT genotypes, but a decreased rate of O-desmethyl-tramadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645522,C,T,"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645522,T,T,"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol as compared to patients with the AA, AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645531,C,C,Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645531,C,T,Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645531,T,T,Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645537,C,C,Patients with the CC genotype may have an increased rate of sulfation of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645537,C,T,Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645537,T,T,Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449718242,C,C,"Patients with the CC genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy."
1449718242,C,G,"Patients with the CG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy."
1449718242,G,G,"Patients with the GG genotype and breast cancer may have an decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy."
1449718248,G,G,"Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy."
1449718248,G,T,"Patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy."
1449718248,T,T,"No patients with the TT genotype were included in the analysis, but patients with the GT genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy."
1449718259,C,C,"Patients with the CC genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil."
1449718259,C,T,"Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil."
1449718259,T,T,"Patients with the TT genotype may have decreased risk for nausea, but an increased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil."
1451352420,A,A,"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and likelihood of experiencing adverse events when treated with sufentanil. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of experiencing adverse events when treated with sufentanil."
1451352420,A,G,"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and likelihood of experiencing adverse events when treated with sufentanil. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of experiencing adverse events when treated with sufentanil."
1451352420,G,G,"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and likelihood of experiencing adverse events when treated with sufentanil. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of experiencing adverse events when treated with sufentanil."
1451358900,C,C,"The current evidence base suggests that there is no association between the rs4149056 CC genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin."
1451358900,C,T,"The current evidence base suggests that there is no association between the rs4149056 CT genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin."
1451358900,T,T,"The current evidence base suggests that there is no association between the rs4149056 TT genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin."
1451244740,C,C,"Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy."
1451244740,C,T,"Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy."
1451244740,T,T,"Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with pravastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy."
1451350580,A,A,"The current evidence base suggests that there is no significant association between the rs8187710 AA genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir."
1451350580,A,G,"The current evidence base suggests that there is no significant association between the rs8187710 AG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir."
1451350580,G,G,"The current evidence base suggests that there is no significant association between the rs8187710 GG genotype and risk of toxicity when treated with tenofovir. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with tenofovir."
1451254826,C,C,"The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1451254826,C,T,"The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1451254826,T,T,"The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1451254820,C,C,"The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1451254820,C,T,"The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1451254820,T,T,"The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1449167568,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167568,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167568,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449005195,A,A,Patients with the AA genotype may require a decreased dose of warfarin as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence dose of warfarin.
1449005195,A,G,Patients with the AG genotype may require an increased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence dose of warfarin.
1449005195,G,G,Patients with the GG genotype may require an increased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence dose of warfarin.
1449167086,A,A,Caucasian patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to Caucasian patients with the AG or GG genotypes. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449167086,A,G,Caucasian patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449167086,G,G,Caucasian patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449167093,C,C,Caucasian patients with the CC genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449167093,C,T,Caucasian patients with the CT genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449167093,T,T,Caucasian patients with the TT genotype may have a decreased risk of developing opioid dependence as compared to Caucasian patients with the CC or CT genotypes. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449168307,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168307,A,C,Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168307,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168314,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168314,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168314,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168621,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168621,A,T,Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168621,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1450375674,A,A,Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375674,A,G,Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375674,G,G,Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375680,A,A,Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375680,A,G,Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375680,G,G,Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375686,A,A,Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375686,A,G,Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375686,G,G,Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450376133,C,C,Patients with the CC genotype may require a decreased dose of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450376133,C,T,Patients with the CT genotype may require a decreased dose of morphine as compared to patients with the TT genotype but an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450376133,T,T,Patients with the TT genotype may require an increased dose of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450810451,A,A,Patients with the rs671 AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of developing alcoholism.
1450810451,A,G,Patients with the rs671 AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of developing alcoholism.
1450810451,G,G,Patients with the rs671 GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect risk of developing alcoholism.
1450044809,A,A,Patients with central nervous system infections and the AA genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.
1450044809,A,G,Patients with central nervous system infections and the AG genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.
1450044809,G,G,Patients with central nervous system infections and the GG genotype may have decreased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.
1450112772,G,G,Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112772,G,T,Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112772,T,T,Patients with osteosarcoma and the TT genotype may have increased clearance of methotrexate as compared to patients with the GG or GT genotypes. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112778,G,G,Patients with osteosarcoma and the GG genotype may have increased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112778,G,T,Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112778,T,T,Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112789,C,C,Patients with osteosarcoma and the CC genotype may have increased clearance of methotrexate as compared to patients with the CT or TT genotypes. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112789,C,T,Patients with osteosarcoma and the CT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112789,T,T,Patients with osteosarcoma and the TT genotype may have decreased clearance of methotrexate as compared to patients with the CC genotype. This variant was highly correlated with rs13137622 and rs12505410 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450820971,A,A,"Patients with the AA genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms."
1450820971,A,G,"Patients with the AG genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms."
1450820971,G,G,"Patients with the GG genotype may have an increased severity of nicotine withdrawal, as indicated by a higher Minnesota Nicotine Withdrawal Scale score, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms."
1450928829,A,A,Female patients with the AA genotype may be more likely to respond to bupropion treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to bupropion.
1450928829,A,G,Female patients with the AG genotype may be more likely to respond to bupropion treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to bupropion.
1450928829,G,G,Female patients with the GG genotype may be less likely to respond to bupropion treatment for smoking cessation as compared to female patients with the AA or AG genotypes. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to bupropion.
1451397762,A,A,"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with gabapentin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin."
1451397762,A,G,Patients with the rs4240803 AG genotype may be at an increased risk of experiencing adverse events when treated with gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.
1451397762,G,G,Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with gabapentin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with gabapentin.
1449753234,C,C,Patients with the CC genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1449753234,C,T,Patients with the CT genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1451397780,A,A,"There is currently no available evidence regarding the association between the rs4240803 AA genotype and risk of adverse events when treated with pregabalin. However, patients with the AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin."
1451397780,A,G,Patients with the rs4240803 AG genotype may be at an increased risk of experiencing adverse events when treated with pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.
1451397780,G,G,Patients with the rs4240803 GG genotype may be at a decreased risk of experiencing adverse events when treated with pregabalin as compared to patients with the AG genotype. Other genetic and clinical factors may also affect risk of experiencing adverse events when treated with pregabalin.
981237959,G,G,"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin."
981237959,G,T,"Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genotype. However, a trend of an association is found for the GT genotype with increased progression free survival compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin."
981237959,T,T,"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) a decreased, but not absent, risk of Drug Toxicity 2) a decreased, but not absent, risk of early relapse and 3) increased progression free survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, leucovorin and oxaliplatin."
981478131,C,C,Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
981478131,C,T,Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
981478131,T,T,Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
1449715584,G,G,Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715584,G,T,Patients with the GT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715584,T,T,Patients with the TT genotype may have a decreased response to fentanyl as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1450376188,C,C,Patients with the CC genotype who are undergoing kidney or heart transplants may have a decreased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.
1450376188,C,T,Patients with the CT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.
1450376188,T,T,Patients with the TT genotype who are undergoing kidney or heart transplants may have an increased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.
1450932697,C,C,Patients with the CC genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.
1450932697,C,T,Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.
1450932697,T,T,Patients with the TT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.
1450934506,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934506,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934506,T,T,Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat
1450934515,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934515,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934515,T,T,Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934525,A,A,Patients with the AA genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934525,A,G,Patients with the AG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934525,G,G,"Patients with the GG genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934678,A,A,"Patients with the AA genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934678,A,G,Patients with the AG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934678,G,G,Patients with the GG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450935844,A,A,Patients with the AA genotype may have decreased clearance of mephenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935844,A,G,Patients with the AG genotype may have decreased clearance of mephenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935844,G,G,Patients with the GG genotype may have increased clearance of mephenytoin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.
1450936242,A,A,Patients with the AA genotype may have decreased sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936242,A,G,Patients with the AG genotype may have decreased sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936242,G,G,Patients with the GG genotype may have increased sulfation of tapentadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936747,C,C,"There is currently no available evidence concerning an association between the CC genotype and blood concentrations of acetaldehyde, a metabolite of ethanol. Other genetic and clinical factors may also affect acetaldehyde blood concentrations."
1450936747,C,T,"Patients with the CT genotype may have increased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaldehyde blood concentrations."
1450936747,T,T,"Patients with the TT genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect acetaldehyde blood concentrations."
1451397860,A,A,"There is currently no available evidence regarding the association between the rs4240803 AA genotype and response to gabapentin. However, patients with the AG genotype may have a decreased response to gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to gabapentin."
1451397860,A,G,Patients with the rs4240803 AG genotype may have a decreased response to gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to gabapentin.
1451397860,G,G,Patients with the rs4240803 GG genotype may have a decreased response to gabapentin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to gabapentin.
981204641,A,A,"Patients with the rs1799971 AA genotype may have a decreased, but not absent, severity of intoxication and a decreased response to ethanol as compared to patients with the AG and GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol."
981204641,A,G,"Patients with the rs1799971 AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol."
981204641,G,G,"Patients with the rs1799971 GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol."
981204941,C,C,Patients with CC genotype and cancer may have an increased risk for toxicity when treated with tegafur as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence tegafur toxicity.
981204941,C,G,Patients with CG genotype and cancer may have a decreased risk for toxicity when treated with tegafur as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tegafur toxicity.
981204941,G,G,Patients with GG genotype and cancer may have a decreased risk for toxicity when treated with tegafur as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tegafur toxicity.
1450935832,C,C,Patients with the CC genotype may have increased clearance of mephenytoin as compared to patients with the CT or TT genotypes. This may be at least partly due to increased expression of CYP2C19 protein as compared to the CT or TT genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935832,C,T,Patients with the CT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein as compared to the CC genotype. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935832,T,T,Patients with the TT genotype may have decreased clearance of mephenytoin as compared to patients with the CC genotype. This may be at least partly due to decreased expression of CYP2C19 protein as compared to the CC genotype. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935850,A,A,Patients with the AA genotype may have increased clearance of mephenytoin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935850,A,G,Patients with the AG genotype may have decreased clearance of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935850,G,G,Patients with the GG genotype may have decreased clearance of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935917,A,A,Patients with the AA genotype may be at an increased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AG or GG genotypes. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.
1450935917,A,G,Patients with the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AA genotype. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.
1450935917,G,G,Patients with the GG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AA genotype. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.
1450936195,C,C,Patients with the CC genotype may have increased sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936195,C,T,Patients with the CT genotype may have decreased sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936195,T,T,Patients with the TT genotype may have decreased sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936260,A,A,Patients with the AA genotype may have increased sulfation of tapentadol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936260,A,C,Patients with the AC genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936260,C,C,Patients with the CC genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936296,A,A,Patients with the AA genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936296,A,G,Patients with the AG genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936296,G,G,Patients with the GG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936563,C,C,Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.
1450936563,C,G,Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.
1450936563,G,G,Patients with malignant mesothelioma and the GG genotype may be at a decreased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.
1451397880,A,A,"There is currently no available evidence regarding the association between the rs4240803 AA genotype and response to pregabalin. However, patients with the AG genotype may have a decreased response to pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pregabalin."
1451397880,A,G,Patients with the rs4240803 AG genotype may have a decreased response to pregabalin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pregabalin.
1451397880,G,G,Patients with the rs4240803 GG genotype may have an increased response to pregabalin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to pregabalin.
982031741,C,C,"The current evidence base suggests that there is no significant association between the rs7439366 CC genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations."
982031741,C,T,"The current evidence base suggests that there is no significant association between the rs7439366 CT genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations."
982031741,T,T,"The current evidence base suggests that there is no significant association between the rs7439366 TT genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations."
982030998,A,A,Patients with the AA genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype AC. Other genetic and clinical factors may also influence a patient's response to treatment.
982030998,A,C,Patients with the AC genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or AA. Other genetic and clinical factors may also influence a patient's response to treatment.
982030998,C,C,Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.
982040494,C,C,"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine."
982040494,C,T,"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine."
982040494,T,T,"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine as compared to patients with the CT or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine."
1043880476,A,A,Patients with the AA genotype and Coronary Artery Disease may have a decreased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.
1043880476,C,A,Patients with the CA genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.
1043880476,C,C,Patients with the CC genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.
982032756,A,A,"Patients with the AA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium."
982032756,G,A,"Patients with the GA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium."
982032756,G,G,Patients with the GG genotype and Bipolar Disorder may have an increased risk for sleep disturbances when treated with lithium as compared to patients with the AA genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to lithium.
982034111,C,C,"Patients with the CC genotype may need increased dose of warfarin as compared to patients with the GG or CG genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin."
982034111,C,G,"Patients with the CG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin."
982034111,G,G,"Patients with the GG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin."
982037571,C,C,"Patients with the CC (CYP3A4 *1/*1) genotype may be less likely to respond to clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
982037571,C,T,"Patients with the CT (CYP3A4 *1/*1G) genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
982037571,T,T,"Patients with the TT (CYP3A4 *1G/*1G genotype may be more likely to respond to clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
1451397872,A,A,"There is currently no available evidence regarding the association between the rs4240803 AA genotype and gabapentin dosage requirements. However, patients with the AG genotype may require an increased dose of gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gabapentin dosage requirements."
1451397872,A,G,Patients with the rs4240803 AG genotype may require an increased dose of gabapentin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gabapentin dosage requirements.
1451397872,G,G,Patients with the rs4240803 GG genotype may require a decreased dose of gabapentin as compared to patients with the aG genotype. Other genetic and clinical factors may also influence gabapentin dosage requirements.
1043858980,C,C,Patients with the rs6065 CC genotype may have a decreased response and an increased risk for aspirin resistance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858980,C,T,"Patients with the rs6065 CT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1043858980,T,T,"Patients with the rs6065 TT genotype may have an increased response and a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1043880659,A,A,Patients with the AA genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.
1043880659,A,G,Patients with the AG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment.
1043880659,G,G,"Patients with the GG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have a decreased, but not absent, risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment."
1043880680,A,A,"Patients with the AA genotype who are treated with antipsychotics may have a decreased, but not absent, risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the DEL/A or DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics."
1127092670,A,A,Patients with the AA genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1127092670,A,G,Patients with the AG genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1127092670,G,G,Patients with the GG genotype and major depressive disorder who are treated with nortriptyline may have increased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1153928101,C,C,Patients with the CC genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.
1153928101,C,T,Patients with the CT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have worse prognosis (overall survival and progression-free survival) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.
1153928101,T,T,Patients with the TT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have better prognosis (overall survival and progression-free survival) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.
1183491157,C,C,Patients with the CC genotype and Arteriosclerosis who are treated with lovastatin may have a better response to treatment (measured by higher reductions in total cholesterol) as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183491157,C,T,Patients with the CT genotype and Arteriosclerosis who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183491157,T,T,"Patients with the TT genotype and Arteriosclerosis were not examined in the study, however; patients with the CT genotype who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment."
1183491380,A,A,Patients with the AA genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in LDL-cholesterol levels) as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491380,A,T,Patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491380,T,T,"Patients with the TT genotype were not studied, however patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment."
1183681866,A,A,Patients with the AA genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.
1183681866,A,G,Patients with the AG genotype may have increased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.
1183681866,G,G,Patients with the GG genotype may have decreased risk of myocardial infarction (MI) when treated with aspirin as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk for toxicity to aspirin.
1183614605,A,A,Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.
1183614605,A,G,Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.
1183614605,G,G,Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the AA or AG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.
1183630286,A,A,"Patients with the AA genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment."
1183630286,A,G,"Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment."
1183630286,G,G,"Patients with the GG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment."
1183631480,A,A,Patients with the AA genotype may have increased clearance of talinolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of talinolol.
1183631480,A,G,Patients with the AG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.
1183631480,G,G,Patients with the GG genotype may have decreased clearance of talinolol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of talinolol.
1183697747,C,C,Patients with the CC genotype may have increased clearance of metformin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of metformin.
1183697747,C,T,Patients with the CT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.
1183697747,T,T,Patients with the TT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin.
1183697752,A,A,"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin."
1183697752,A,C,"Patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin."
1183697752,C,C,"Patients with the CC genotype may have increased clearance of metformin as compared to patients with the AC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin."
1183698846,C,C,"Patients with the CC genotype and gastrointestinal stromal tumours may have a shorter time to progression when treated with imatinib, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression."
1183698846,C,G,"Patients with the CG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression."
1183698846,G,G,"Patients with the GG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression."
1183700503,A,A,Patients with the AA genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.
1183700503,A,C,Patients with the AC genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.
1183700503,C,C,Patients with the CC genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.
1183700536,A,A,"Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs."
1183700536,A,G,"Patients with the AG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs."
1183700536,G,G,"Patients with the GG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs."
1183700383,A,A,"Patients with the AA genotype and asthma may have a decreased response to corticosteroids as compared to patients with the GG genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's response to corticosteroids."
1183700383,A,G,"Patients with the AG genotype and asthma may have a decreased response to corticosteroids as compared to patients with the GG genotype or may have an increased response as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic and clinical factors may also influence a patient's response to corticosteroids."
1183700383,G,G,Patients with the GG genotype and asthma may have an increased response to corticosteroids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1183700522,C,C,Patients with the CC genotype may have increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1183700522,T,C,Patients with the TC genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1183700522,T,T,Patients with the TT genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1183700891,C,C,"Patients with the CC genotype may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin."
1183700891,C,T,"Patients with the CT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype or may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin."
1183700891,T,T,"Patients with the TT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin."
1451401800,A,A,"Patients with the rs4140981 AA genotype may have decreased clearance of methotrexate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance."
1451401800,A,G,"Patients with the rs4140981 AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype but decreased clearance of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance."
1451401800,G,G,"Patients with the rs4140981 GG genotype may have increased clearance of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance."
982030732,A,A,"Patients with the AA genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel."
982030732,A,C,"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel."
982030732,C,C,"Patients with the CC genotype may have increased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AC + CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel."
982030873,C,C,Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030873,C,T,Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030873,T,T,Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982031855,C,C,Patients with the CC genotype may have decreased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the TT genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.
982031855,C,T,Patients with the CT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies.Other clinical and genetic factors may also influence response to smoking cessation therapies.
982031855,T,T,Patients with the TT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies. Other clinical and genetic factors may also influence response to smoking cessation therapies.
982032763,G,G,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032763,G,T,Patients with the GT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032763,T,T,Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1123915607,C,C,Patients with the CC genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1123915607,C,T,Patients with the CT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1123915607,T,T,Patients with the TT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1451397981,A,A,Patients with the rs1801252 AA genotype may have a decreased response to carvedilol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to carvedilol.
1451397981,A,G,Patients with the rs1801252 AG genotype may have an increased response to carvedilol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to carvedilol.
1451397981,G,G,Patients with the rs1801252 GG genotype may have an increased response to carvedilol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to carvedilol.
1451398000,C,C,Patients with heart failure and the rs1801253 CC genotype may require decreased doses of carvedilol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.
1451398000,C,G,"There is currently no available evidence regarding the association between the rs1801253 CG genotype and carvedilol dosage requirements. However, patients with heart failure and the CC genotype may require decreased doses of carvedilol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements."
1451398000,G,G,Patients with heart failure and the rs1801253 GG genotype may require increased doses of carvedilol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.
1043880098,A,A,"Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
1043880098,A,G,"Patients with the AG genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
1043880098,G,G,"Patients with the GG genotype and Kidney Transplantation may have an increased clearance of mycophenolate mofetil as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
1043880293,C,C,Patients withe the CC genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the TT or TC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.
1043880293,T,C,Patients withe the TC genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.
1043880293,T,T,Patients withe the TT genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.
1043880323,A,A,Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880323,A,G,Patients with the AG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880323,G,G,Patients with the GG genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880402,A,A,Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880402,A,G,Patients with the AG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880402,G,G,Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880454,A,A,Patients with AA genotype and Coronary Artery Disease who are treated with pravastatin may have a higher risk of cardiovascular events as compared to patients with the AG or GG genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880454,A,G,Patients with AG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880454,G,G,Patients with the GG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880644,G,G,"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough."
1043880644,T,G,Patients with the TG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
1043880644,T,T,Patients with the TT genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.
1140655380,A,A,Patients with the AA genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.
1140655380,A,G,"Patients with the AG genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype, or may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia."
1140655380,G,G,Patients with the GG genotype and Coronary Artery Disease who are treated with atorvastatin may have a lower likelihood of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.
1152661500,A,A,Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1152661500,A,C,Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1152661500,A,T,Patients with the AT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1152661500,C,C,Patients with the CC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1152661500,T,T,Patients with the TT genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.
1183490952,G,G,"Patients with the GG genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding."
1183490952,G,T,"Patients with the GT genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding."
1183490952,T,T,Patients with the TT genotype and Atrial Fibrillation may have an increased risk for bleeding when treated with dabigatran as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.
1183491359,A,A,Patients with the AA genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491359,A,G,Patients with the AG genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491359,G,G,Patients with the GG genotype and Hypercholesterolemia may have a better response to fluvastatin treatment (determined by higher change in HDL-C levels) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491403,C,C,Patients with the CC genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491403,C,G,Patients with the CG genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491403,G,G,Patients with the GG genotype may benefit more from pravastatin treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183631470,A,A,Patients with the AA genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183631470,A,G,Patients with the AG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183631470,G,G,Patients with the GG genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183630246,A,A,Patients with the AA genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.
1183630246,A,G,Patients with the AG genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.
1183630246,G,G,Patients with the GG genotype and breast cancer who are treated with gemcitabine may have an increased risk of side effects including neutropenia as compared to patients with the AA or AG genotype combined with the G allele at rs9937. This association was not seen in a seperate study in patients with pancreatic cancer.Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.
1183632170,A,A,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines."
1183632170,A,C,"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines."
1183632170,C,C,"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines."
1451398106,A,A,Patients with mood disorders and the rs4713916 AA genotype may have an increased response to fluoxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluoxetine.
1451398106,A,G,Patients with mood disorders and the rs4713916 AG genotype may have an increased response to fluoxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluoxetine.
1451398106,G,G,Patients with mood disorders and the rs4713916 GG genotype may have a decreased response to fluoxetine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to fluoxetine.
1183617832,C,C,"Patients with the rs6295 CC genotype may have decreased response when treated with paroxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
1183617832,C,G,"Patients with the rs6295 CG genotype may have decreased response when treated with paroxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
1183617832,G,G,"Patients with the rs6295 GG genotype may have increased response when treated with paroxetine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
1183684162,C,C,"Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684162,C,T,"Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684162,T,T,"Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183689987,C,C,"Transplant recipients with the CC (CYP3A4 *1B/*1B) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
1183689987,C,T,"Transplant recipients with the CT (CYP3A4 *1B/*1) genotype may require an increased dose of sirolimus as compared to patients with the TT (*1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
1183689987,T,T,"Transplant recipients with the TT (CYP3A4 *1/*1) genotype may require a decreased dose of sirolimus as compared to patients with the CC (*1B/*1B) or CT (*1B/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements."
1183693433,A,A,Patients with the AA genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693433,A,C,Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693433,C,C,Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183689409,C,C,"Patients with the CC genotype and inflammatory diseases may have decreased response to anti-TNFalpha treatment as compared to patients with the CT or TT genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors."
1183689409,C,T,"Patients with the CT genotype and inflammatory diseases may have increased response to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors."
1183689409,T,T,"Patients with the TT genotype and inflammatory diseases may have increased response to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors."
1451398120,A,A,Patients with mood disorders and the rs4713916 AA genotype may have an increased response to mirtazapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1451398120,A,G,Patients with mood disorders and the rs4713916 AG genotype may have an increased response to mirtazapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to mirtazapine.
1451398120,G,G,Patients with mood disorders and the rs4713916 GG genotype may have a decreased response to mirtazapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to mirtazapine.
982047840,A,A,Patients with the AA genotype and HIV may have a decreased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.
982047840,A,C,Patients with the AC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.
982047840,C,C,Patients with the CC genotype and HIV may have an increased risk for a drug hypersensitivity reaction when treated with sulfamethoxazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of a drug hypersensitivity reaction.
1183491026,A,A,Patients with the AA genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
1183491026,A,G,Patients with the AG genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
1183491026,G,G,Patients with the GG genotype who are treated with lopinavir may have a lower accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.
1183533945,C,C,Patients with the CC genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183533945,C,T,Patients with the CT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183533945,T,T,Patients with the TT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183533950,C,C,Patients with the CC genotype and macular degeneration may have a poorer response when treated with bevacizumab or ranibizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.
1183533950,C,T,Patients with the CT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.
1183533950,T,T,Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.
1183533966,C,C,Patients with the CC genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.
1183533966,C,T,Patients with the CT genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.
1183533966,T,T,Patients with the TT genotype and asthma may have a better response when treated with flunisolide as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to flunisolide.
1183556309,A,A,Patients with the AA genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1183556309,A,G,Patients with the AG genotype and schizophrenia may have an increased response when treated with clozapine as compared to patients with the GG genotype or a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1183556309,G,G,Patients with the GG genotype and schizophrenia may have a decreased response when treated with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1183604793,C,C,Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183604793,C,T,"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects."
1183604793,T,T,Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183612432,C,C,"Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence overall survival time."
1183612432,C,G,"Patients with the CG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time."
1183612432,G,G,"Patients with the GG genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time."
1183612731,A,A,Women with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1183612731,A,G,Women with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with captopril as compared to women with the GG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1183612731,G,G,Women with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with captopril as compared to women with the AA or AG genotype. No significant differences were seen when considering systolic blood pressure. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1183614499,A,A,Patients with the AA genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.
1183614499,A,G,Patients with the AG genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.
1183614499,G,G,Patients with the GG genotype and cocaine dependence may have a decreased response when treated with disulfiram as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to disulfiram.
1183614855,C,C,Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614855,C,G,Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614855,G,G,Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183615135,C,C,Women with the CC genotype and mental disorders (excluding schizophrenia) may have smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain.
1183615135,C,G,"Women with the CG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype, or smaller weight gain when treated with olanzapine as compared to women with the GG genotype. Other genetic and clinical factors may also influence weight gain."
1183615135,G,G,Women with the GG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype. Other genetic and clinical factors may also influence weight gain.
1183615621,G,G,Patients with the GG genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.
1183615621,G,T,Patients with the GT genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.
1183615621,T,T,Patients with the TT genotype and hypertension may have an increased response when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to benazepril.
1183619864,C,C,"Children with the CC genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an reduced risk of requiring a blood transfusion as compared to children with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis."
1183619864,C,T,"Children with the CT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis."
1183619864,T,T,"Children with the TT genotype and malaria who are treated with amodiaquine, pyrimethamine and sulfadoxine may have an increased risk of requiring a blood transfusion as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of severe hemolysis."
1183631404,C,C,Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.
1183631404,C,T,Patients with the CT genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.
1183631404,T,T,Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to olanzapine.
1183697592,A,A,"Patients with the rs2306283 AA genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
1183697592,A,G,"Patients with the rs2306283 AG genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
1183697592,G,G,"Patients with the rs2306283 GG genotype may have decreased exposure to methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
1183679828,A,A,Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
1183679828,A,G,Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
1183679828,G,G,Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.
1183679848,C,C,Patients with the CC genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1183679848,C,T,Patients with the CT genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1183679848,T,T,Patients with the TT genotype may have decreased response to nortriptyline in people with Depression as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1183680570,C,C,Patients with the CC genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.
1183680570,C,T,Patients with the CT genotype may have decreased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.
1183680570,T,T,Patients with the TT genotype may have increased SVR (sustained virological response) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to peg-interferons.
1183697557,A,A,Cancer patients with the AA genotype may have a decreased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.
1183697557,A,G,Cancer patients with the AG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.
1183697557,G,G,Cancer patients with the GG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.
1451398140,A,A,"Patients with breast cancer as the rs1695 AA genotype may have an increased response to treatment with cyclophosphamide and epirubicin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin."
1451398140,A,G,"Patients with breast cancer as the rs1695 AG genotype may have an increased response to treatment with cyclophosphamide and epirubicin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin."
1451398140,G,G,"Patients with breast cancer as the rs1695 GG genotype may have a decreased response to treatment with cyclophosphamide and epirubicin as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide and epirubicin."
1183679122,C,C,Patients with the CC genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1183679122,C,T,"Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC genotype, and more likely to experience myopathy when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins."
1183679122,T,T,Patients with the TT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1183681861,A,A,"Patients with the AA genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel."
1183681861,A,G,"Patients with the AG genotype may have 1) increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) decreased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel."
1183681861,G,G,"Patients with the GG genotype may have 1) decreased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI) when treated with aspirin and clopidogrel, 2) increased collagen induced platelet aggregation after Aspirin or dual antiplatelet therapy (DAPT) administration as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response and risk for toxicity to aspirin and clopidogrel."
1183689585,C,C,Patients with the CC genotype and major depressive disorder may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.
1183689585,C,T,Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype or may be less likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.
1183689585,T,T,Patients with the TT genotype and major depressive disorder may be more likely to respond to treatment with selective serotonin-reuptake inhibitors (SSRIs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to SSRI treatment.
1183693443,C,C,Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693443,C,G,Patients with the CG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693443,G,G,Patients with the GG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183699226,A,A,Patients with the AA genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.
1183699226,A,G,Patients with the AG genotype who are treated with carboplatin or cisplatin may have increased risk of progression of disease as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.
1183699226,G,G,Patients with the GG genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.
1183700243,A,A,Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to first remission induction therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700243,A,G,Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700243,G,G,Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to first remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700279,G,G,Patients with the GG genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.
1183700279,G,T,Patients with the GT genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.
1183700279,T,T,Patients with the TT genotype and cancer who are treated with fluorouracil may have an reduced risk of leukopenia as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.
1183700396,A,A,"Children with the AA genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to treatment."
1183700396,A,G,"Children with the AG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have an increased risk of exacerbations as compared to children with the GG genotype or may have a reduced risk of exacerbations as compared to children with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to treatment."
1183700396,G,G,"Children with the GG genotype and asthma who are treated with corticosteroids and long acting beta-2-agonists may have a reduced risk of exacerbations as compared to children with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to treatment."
1183700527,A,A,"Patients with the AA genotype may have decreased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics."
1183700527,A,G,"Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics."
1183700527,G,G,"Patients with the GG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics."
1183698531,A,A,Patients with the rs2304016 AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased risk of drug resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antiepileptic drugs.
1183698531,A,G,Patients with the rs2304016 AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased risk of drug resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antiepileptic drugs.
1183698531,G,G,"Patients with the rs2304016 GG genotype and epilepsy who are treated with antiepileptic drugs may have a decreased, but not absent, risk of drug resistance as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence response to antiepileptic drugs."
1451398160,A,A,Patients with breast cancer and the rs1695 AA genotype may experience a decreased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.
1451398160,A,G,Patients with breast cancer and the rs1695 AG genotype may experience a decreased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.
1451398160,G,G,Patients with breast cancer and the rs1695 GG genotype may experience an increased severity of toxicity when treated with cyclophosphamide and epirubicin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence severity of toxicity when treated with cyclophosphamide and epirubicin.
1183698868,G,G,"The current evidence base suggests that there is no significant association between the rs4124874 GG genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan."
1183698868,G,T,"The current evidence base suggests that there is no significant association between the rs4124874 GT genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan."
1183698868,T,T,"The current evidence base suggests that there is no significant association between the rs4124874 TT genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan."
982031026,A,A,"Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission."
982031026,A,G,"Patients with the AG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance for remission."
982031026,G,G,"Patients with the GG genotype and depression who are treated with amitryptiline, citalopram, paroxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance for remission."
982032567,A,A,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032567,A,G,Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032567,G,G,Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032727,C,C,"Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium."
982032727,C,T,"Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium."
982032727,T,T,"Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium."
982037796,A,A,Patients with the AA genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982037796,A,G,Patients with the AG genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype or may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982037796,G,G,Patients with the GG genotype and coronary heart disease may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1043859380,A,A,Patients with the AA genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043859380,A,G,Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043859380,G,G,Patients with the GG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043880205,A,A,Patients with the AA genotype may have an increased response to lovastatin as compared to patients with the GG genotype or may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.
1043880205,A,G,Patients with the AG genotype may have an increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.
1043880205,G,G,Patients with the GG genotype may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.
1043880308,A,A,Patients with AA genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880308,A,G,Patients with AG genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880308,G,G,Patients with GG genotype may have decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880318,A,A,Patients with the AA genotype may have decreased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the CC or AC genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880318,A,C,Patients with the AC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880318,C,C,Patients with the CC genotype may have increased overall survival when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880328,A,A,Patients with the AA genotype may have increased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AG genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880328,A,G,Patients with the AG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880328,G,G,Patients with the GG genotype may have decreased likelihood of Neurotoxicity when treated with thalidomide in people with Multiple Myeloma as compared to patients with the AA genotype. Other clinical or genetic factors may also influence a patient's response to thalidomide.
1043880841,A,A,"Patients with the AA genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin."
1043880841,A,G,"Patients with the AG genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin."
1043880841,G,G,"Patients with the GG genotype and Colorectal Neoplasms may have 1) decreased response, 2) decreased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab, fluorouracil, irinotecan and leucovorin."
1043880433,C,C,Patients with the CC genotype who are treated with atorvastatin may have higher expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1043880433,C,T,Patients with the CT genotype who are treated with atorvastatin may have higher expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1043880433,T,T,Patients with the TT genotype who are treated with atorvastatin may have reduced expression of SCAP as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491162,C,C,Patients with the CC genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.
1183491162,C,T,"Patients with the CT genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype, or may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment."
1183491162,T,T,Patients with the TT genotype may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.
1451398180,A,A,Patients with breast cancer and the rs1695 AA genotype may be at an increased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.
1451398180,A,G,"There is currently no available evidence regarding the association between the rs1695 AG genotype and risk of developing neutropenia when treated with cyclophosphamide and epirubicin. However, patients with breast cancer and the AA genotype may be at an increased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin."
1451398180,G,G,Patients with breast cancer and the rs1695 GG genotype may be at a decreased risk of developing neutropenia when treated with cyclophosphamide and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing neutropenia when treated with cyclophosphamide and epirubicin.
1183492035,A,A,"Patients with the rs662799 AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to statin treatment."
1183492035,A,G,"Patients with the rs662799 AG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment."
1183492035,G,G,"Patients with the rs662799 GG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment."
982030805,C,C,Patients with the rs71647871 CC genotype who are treated with clopidogrel may have decreased exposure to clopidogrel as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.
982030805,C,T,Patients with the rs71647871 CT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.
982030805,T,T,Patients with the rs71647871 TT genotype who are treated with clopidogrel may have increased exposure to clopidogrel as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and clopidogrel and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clopidogrel pharmacokinetics.
1043880802,C,C,"Patients with the rs4149056 CC genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
1043880802,C,T,"Patients with the rs4149056 CT genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
1043880802,T,T,"Patients with the rs4149056 TT genotype who are treated with pravastatin may have a larger reduction in LDL and total cholesterol as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
1043858965,A,A,Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with captopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to captopril.
1043858965,A,C,Patients with the AC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.
1043858965,C,C,Patients with the CC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.
1183562698,C,C,Healthy males with the CC genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.
1183562698,C,T,Healthy males with the CT genotype may have an increased response when given dobutamine as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to dobutamine.
1183562698,T,T,Healthy males with the TT genotype may have a decreased response when given dobutamine as compared to healthy males with the CC or CT genotype. Other genetic and clinical factors may also influence response to dobutamine.
1183603764,A,A,"Patients with two X-chromosomes, the AA genotype, and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele."
1183603764,A,C,"Patients with two X-chromosomes, the AC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype, or decreased weight gain when treated with olanzapine as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele."
1183603764,C,C,"Patients with two X-chromosomes, the CC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele."
1183607901,C,C,Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183607901,C,T,Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183607901,T,T,Patients with the TT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183614761,A,A,Patients with the AA genotype who underwent kidney transplantation may have increased triglyceride levels when treated with sirolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence triglyceride levels.
1183614761,A,G,Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.
1183614761,G,G,Patients with the GG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.
1183615261,A,A,Patients with the AA genotype and schizophrenia may may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1183615261,A,G,"Patients with the AG genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype, or more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine."
1183615261,G,G,Patients with the GG genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1183615359,C,C,"No patients with the CC genotype were present in this study. However, patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab."
1183615359,C,G,Patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.
1183615359,G,G,Patients with the GG genotype and rheumatoid arthritis may be less likely to respond to rituximab treatment as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to rituximab.
1183615367,A,A,Patients with the AA genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1183615367,A,G,Patients with the AG genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1183615367,G,G,Patients with the GG genotype and lung cancer may have a poorer response when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1183615424,C,C,"Patients with the CC genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab."
1183615424,C,T,"Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab."
1183615424,T,T,"Patients with the TT genotype and psoriatic arthritis may have an increased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the CC or CT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab."
1183618924,A,A,Patients with the AA genotype and major depressive disorder who are treated with antidepressants and other treatments may have a reduced response and reduced likelihood of remission as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.
1183618924,A,G,Patients with the AG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.
1183618924,G,G,Patients with the GG genotype and major depressive disorder who are treated with antidepressants and other treatments may have a better response and an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment for major depressive disorder and likelihood of remission.
1183629315,C,C,"Patients with the CC genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183629315,C,T,"Patients with the CT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype and a decreased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183629315,T,T,"Patients with the TT genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183632145,C,C,Patients with the CC genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1183632145,C,T,Patients with the CT genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1183632145,T,T,Patients with the TT genotype may have decreased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1183632165,A,A,Patients with the AA genotype may have increased plasma insulin levels and increased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1183632165,A,T,"Patients with the AT genotype may have decreased plasma insulin levels when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. However, patients with the AT genotype may have increased severity of weight gain as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine."
1183632165,T,T,Patients with the TT genotype may have decreased plasma insulin levels and decreased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1451398187,A,A,"Patients with colorectal cancer and the rs1695 AA genotype may have a decreased response to treatment with capecitabine, epirubicin and platinum as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with capecitabine, epirubicin and platinum."
1451398187,A,G,"Patients with colorectal cancer and the rs1695 AG genotype may have a decreased response to treatment with capecitabine, epirubicin and platinum as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with capecitabine, epirubicin and platinum."
1451398187,G,G,"Patients with colorectal cancer and the rs1695 GG genotype may have an increased response to treatment with capecitabine, epirubicin and platinum as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to treatment with capecitabine, epirubicin and platinum."
1183679135,C,C,Patients with the CC genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1183679135,C,T,"Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the TT genotype, and more likely to experience myopathy when treated with statins as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins."
1183679135,T,T,Patients with the TT genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1183533955,A,A,Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183533955,A,G,Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183533955,G,G,Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183601914,A,A,"Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate."
1183601914,A,G,Patients with the AG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183601914,A,T,"Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the AG, GG or GT genotype. Other genetic and clinical factors may also influence response to fenofibrate."
1183601914,G,G,Patients with the GG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183601914,G,T,Patients with the GT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183602560,A,A,Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602560,A,G,"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects."
1183602560,G,G,Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183614466,A,A,Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.
1183614466,A,G,Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.
1183614466,G,G,Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in change in systolic blood pressure were seen. Other genetic and clinical factors may also influence decrease in diastolic blood pressure.
1183614600,A,A,Patients with the AA genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.
1183614600,A,G,Patients with the AG genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.
1183614600,G,G,Patients with the GG genotype and hypertension may be more likely to respond to treatment with candesartan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to candesartan.
1183615587,C,C,Patients with the CC genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.
1183615587,C,T,Patients with the CT genotype who have had a stroke may be at decreased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.
1183615587,T,T,Patients with the TT genotype who have had a stroke may be at increased risk for hemorrhagic transformation when treated with tissue plasminogen activator as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for hemorrhagic transformation.
1183617618,C,C,Patients with the CC genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.
1183617618,C,T,Patients with the CT genotype and major depressive disorder who are treated with antidepressants may have a reduced risk of adverse effects as compared to patients with the TT genotype or may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.
1183617618,T,T,Patients with the TT genotype and major depressive disorder who are treated with antidepressants may have an increased risk of adverse effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of adverse effects.
1183617644,A,A,Patients with the AA genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183617644,A,G,Patients with the AG genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype or may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183617644,G,G,Patients with the GG genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183622527,A,A,Patients with the AA genotype and major depressive disorder who are treated with escitalopram may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183622527,A,G,Patients with the AG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype or may 1) have increased metabolism of escitalopram at week 2 of treatment 2) experience more severe side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183622527,G,G,Patients with the GG genotype and major depressive disorder who are treated with escitalopram may 1) have reduced metabolism of escitalopram at week 2 of treatment 2) experience less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183622622,C,C,Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183622622,T,C,Patients with the TC genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the TT genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects
1183622622,T,T,Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183629310,A,A,"Patients with the AA genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183629310,A,G,"Patients with the AG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype and a decreased likelihood of remission as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183629310,G,G,"Patients with the GG genotype and Depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183684153,C,C,"Patients with the CC genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684153,C,T,"Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of fever as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684153,T,T,"Patients with the TT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183697540,A,A,"Patients with the AA genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment."
1183697540,A,G,"Patients with the AG genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment."
1183697540,G,G,"Patients with the GG genotype and metastatic colorectal cancer may have 1) decreased rapid response to treatment containing irinotecan, 2) shorter progression free survival, and 3) lower irinotecan-related time to treatment failure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment."
1183698808,C,C,"Patients with the CC genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype. Other genetic and clinical factors may also influence response to these drugs."
1183698808,C,T,"Patients with the CT genotype may have a better response to bumetanide, furosemide or torasemide, as compared to those with the TT genotype, or a poorer response as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs."
1183698808,T,T,"Patients with the TT genotype may have a poorer response to bumetanide, furosemide or torasemide, as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to these drugs."
1183698831,C,C,Patients with the CC genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.
1183698831,C,G,Patients with the CG genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.
1183698831,G,G,Patients with the GG genotype who have a high risk of cardiovascular disease may have a poorer anti-inflammatory response when treated with fenofibrate as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.
1451398240,A,A,"Patients with metastatic stomach cancer and the rs1695 AA genotype may have a decreased response to treatment with epirubicin, fluorouracil and oxaliplatin as compare to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with epirubicin, fluorouracil and oxaliplatin."
1451398240,A,G,"Patients with metastatic stomach cancer and the rs1695 AG genotype may have a decreased response to treatment with epirubicin, fluorouracil and oxaliplatin as compare to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with epirubicin, fluorouracil and oxaliplatin."
1451398240,G,G,"Patients with metastatic stomach cancer and the rs1695 GG genotype may have an increased response to treatment with epirubicin, fluorouracil and oxaliplatin as compare to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to treatment with epirubicin, fluorouracil and oxaliplatin."
1183617724,A,A,Patients with the AA genotype may have a better response to antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.
1183617724,A,G,Patients with the AG genotype may have a better response to antidepressants as compared to patients with the GG genotype or may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.
1183617724,G,G,Patients with the GG genotype may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.
1183698786,A,A,Patients with the AA genotype (CYP3A4 *1/*1) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.
1183698786,A,G,Patients with the AG genotype (CYP3A4 *1/*1B) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.
1183698786,G,G,Patients with the GG genotype (CYP3A4 *18B/*18B) who underwent kidney transplantation may have increased metabolism of cyclosporine as compared to patients with the AA or AG genotype (*1/*1 or *1/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.
1183698818,A,A,"No patients with this genotype were present in the study. However, patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk."
1183698818,A,G,"Patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk."
1183698818,G,G,"Patients with the GG genotype and HIV may have a decreased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk."
1183700230,G,G,Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better overall survival as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700230,G,T,Patients with the GT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700230,T,T,Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700238,C,C,Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better overall survival as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700238,C,G,Patients with the CG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700238,G,G,Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer overall survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700248,A,A,Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be less likely to have a complete response to the first course of remission induction therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700248,A,C,Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700248,C,C,Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700253,A,A,Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700253,A,G,Patients with the AG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700253,G,G,Patients with the GG genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a poorer response to treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700258,A,A,Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have better event-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700258,A,T,Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700258,T,T,Patients with the TT genotype were not studied. Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.
1183700512,C,C,Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183700512,T,C,Patients with the TC genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183700512,T,T,Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183700812,C,C,Patients with the CC genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.
1183700812,C,G,Patients with the CG genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype or may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.
1183700812,G,G,Patients with the GG genotype may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.
1183701068,C,C,Patients with the CC genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.
1183701068,C,G,Patients with the CG genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.
1183701068,G,G,Patients with the GG genotype may have a higher thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.
1451398300,A,A,"Patients with breast cancer and the rs1800566 AA genotype may have a decreased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil."
1451398300,A,G,"Patients with breast cancer and the rs1800566 AG genotype may have an increased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil."
1451398300,G,G,"Patients with breast cancer and the rs1800566 GG genotype may have an increased response to treatment with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil."
1451398340,C,C,Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.
1451398340,C,T,Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.
1451398340,T,T,Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.
1183700488,A,A,Patients with the AA genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1183700488,A,C,Patients with the AC genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1183700488,C,C,Patients with the CC genotype may have increased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
982030907,C,C,Patients with the CC genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030907,C,T,Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030907,T,T,Patients with the TT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030990,C,C,Patients with the CC genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.
982030990,C,T,Patients with the CT genotype and Thalassemia may be less likely to respond to hydroxyurea treatment as compared to genotype CC or TT. Other genetic and clinical factors may also influence a patient's response to treatment.
982030990,T,T,Patients with the TT genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.
982031767,A,A,Patients with AA genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.
982031767,A,C,Patients with AT genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.
982031767,C,C,Patients with CC genotype may require a decreased dose of paroxetine and may have an decreased risk of fatigue when treated with paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.
982031864,A,A,"Patients with the AA genotype may have increased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to NRT. Other clinical and genetic factors may also influence response to smoking cessation therapies."
982031864,A,G,"Patients with the AG genotype may have increased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to NRT. Other clinical and genetic factors may also influence response to smoking cessation therapies."
982031864,G,G,"Patients with the GG genotype may have decreased chance of achieving 6 month abstinence from smoking when treated with NRT (nicotine replacement therapy) as compared to patients with the AA or AG genotypes. However, another study failed to find an association between this variant and response to NRT. Other clinical and genetic factors may also influence response to smoking cessation therapies."
982032257,A,A,Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032257,A,G,Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032257,G,G,Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032396,C,C,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032396,C,T,Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032396,T,T,Patients with the TT genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982036556,C,C,"Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response."
982036556,C,T,"Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
982036556,T,T,"Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and clinical factors may also influence a patient's response."
982037368,C,C,Patients with the CC genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
982037368,C,T,Patients with the CT genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
982037368,T,T,Patients with the TT genotype may have an increased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with CC or CT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1148480056,C,C,"Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis."
1148480056,C,G,"Female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis."
1148480056,G,G,"Patients with the GG genotype were not studied but female patients with the CG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk for severe emesis as compared to patients with the CC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis."
982040423,A,A,"Patients with the AA genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
982040423,A,G,"Patients with the AG genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
982040423,G,G,"Patients with the GG genotype who are treated with clopidogrel may have a decreased, but not absent, risk of neurological events as compared to patients with the AA genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
1451398281,C,C,Patients with heart failure and the rs1801253 CC genotype may have an increased response to bucindolol as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence response to bucindolol.
1451398281,C,G,Patients with heart failure and the rs1801253 CG genotype may have a decreased response to bucindolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bucindolol.
1451398281,G,G,Patients with heart failure and the rs1801253 GG genotype may have a decreased response to bucindolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bucindolol.
1451398293,C,C,Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.
1451398293,C,T,Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.
1451398293,T,T,Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.
1183607419,C,C,Patients with the CC genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183607419,C,T,Patients with the CT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183607419,T,T,Patients with the TT genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No significant associations were seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.
1183607656,C,C,Patients with the CC genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183607656,C,T,"Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype, or a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate."
1183607656,T,T,Patients with the TT genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183574175,C,C,Patients with the rs2952768 CC genotype may have a decreased analgesic response to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to opioids.
1183574175,C,T,Patients with the rs2952768 CT genotype may have an increased analgesic response to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to opioids.
1183574175,T,T,Patients with the rs2952768 TT genotype may have an increased analgesic response to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to opioids.
1156738774,G,G,"Patients with the rs2231142 GG genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin."
1156738774,G,T,"Patients with the rs2231142 GT genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin."
1156738774,T,T,"Patients with the rs2231142 TT genotype may have increased exposure to simvastatin as compared to patients with the GT or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin."
1183614504,A,A,Patients with the AA genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.
1183614504,A,G,Patients with the AG genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.
1183614504,G,G,Patients with the GG genotype who have had a stroke may have an increased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.
1183614802,A,A,Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183614802,A,G,Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183614802,G,G,Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1043858656,C,C,Patients with the CC genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858656,C,T,Patients with the CT genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858656,T,T,Patients with the TT genotype and asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043859297,A,A,"Patients with the AA genotype may have a decreased, but not absent, risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
1043859297,A,G,Patients with the AG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1043859297,G,G,Patients with the GG genotype may have an increased risk for cardiovascular events (cardiac death and recurrent myocardial infarction) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1043859386,C,C,Patients with the CC genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.
1043859386,C,T,Patients with the CT genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.
1043859386,T,T,"Patients with the TT genotype and Kidney Transplantation may have a decreased, but not absent, risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the CC genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection."
1043880303,A,A,Patients with AA genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880303,A,C,Patients with AC genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880303,C,C,Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880367,A,A,Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880367,A,G,Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880367,G,G,Patients with the GG genotype may require an decreased dose of warfarin as compared to patients with the AG or AA genotypes. Other clinical or genetic factors may also influence warfarin dose.
1143176298,A,A,Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.
1143176298,A,G,Patients with the AG genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype or may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.
1143176298,G,G,Patients with the GG genotype and Hypercholesterolemia who are treated with simvastatin may have a higher risk of developing myalgia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.
1146391450,A,A,Patients with the AA genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1146391450,A,G,Patients with the AG genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1146391450,G,G,Patients with the GG genotype and Crohn Disease who are treated with corticosteroids may have a decreased likelihood of responsiveness as compared to patients with AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1148995043,A,A,"Patients with the rs2032582 AA genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment."
1148995043,A,C,"Patients with the rs2032582 AC genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype or may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment."
1148995043,A,T,"Patients with the rs2032582 AT genotype who are treated with atorvastatin may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment."
1148995043,C,C,"Patients with the rs2032582 CC genotype who are treated with atorvastatin may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment."
1148995043,T,T,"Patients with the rs2032582 TT genotype who are treated with atorvastatin may have a increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment."
1183491021,A,A,Patients with the AA genotype may have higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir as compared to the patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.
1183491021,A,G,The AG genotype was not studied.
1183491021,G,G,Patients with the GG genotype may have lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir as compared to the patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein.
1183532599,A,A,Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183532599,A,G,Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183532599,G,G,Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183619312,C,C,"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619312,C,T,"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the TT genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619312,T,T,"Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183564259,G,G,"Men with the GG genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GT genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan."
1183564259,G,T,"Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan."
1183564259,T,T,"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan."
1183623069,A,A,"Children with the AA genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
1183623069,A,G,"Children with the AG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype or may have a lower, but not absent, risk for hearing loss as compared to children with the GG genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
1183623069,G,G,"Children with the GG genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the AA genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
1183629480,A,A,Patients with the AA genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.
1183629480,A,G,Patients with the AG genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.
1183629480,G,G,Patients with the GG genotype who are treated with risperidone may have an increased likelihood of adverse reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.
1183631536,G,G,"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631536,G,T,"Patients with the GT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631536,T,T,"Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631564,G,G,"Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone."
1183631564,G,T,"Patients with the GT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone."
1183631564,T,T,"Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GT or GG genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone."
1183631782,C,C,Patients with the CC genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.
1183631782,C,T,Patients with the CT genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the TT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.
1183631782,T,T,Patients with the TT genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the CC or CT genotype. Other genetic or clinical factors may also influence a patient's response to salbutamol.
1183679813,C,C,Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1183679813,C,T,Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1183679813,T,T,Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1451398307,A,A,"Patients with the rs489693 AA genotype may have an increased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol."
1451398307,A,C,"Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol."
1451398307,C,C,"Patients with the rs489693 CC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol."
1451398314,A,A,"Patients with the rs489693 AA genotype may have an increased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol."
1451398314,A,C,"Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol."
1451398314,C,C,"Patients with the rs489693 CC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol."
1183492249,C,C,Patients with the rs7412 CC genotype may have decreased response to atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.
1183492249,C,T,Patients with the rs7412 CT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.
1183492249,T,T,Patients with the rs7412 TT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.
1183679833,A,A,"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1183679833,A,G,"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1183679833,G,G,"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1183617701,C,C,Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183617701,C,T,Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183617701,T,T,Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a slower response time as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183622263,C,C,Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622263,C,T,Patients with the CT genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622263,T,T,Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183680531,C,C,"Patients with the CC genotype may have decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide."
1183680531,C,T,"Patients with the CT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide."
1183680531,T,T,"Patients with the TT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide."
1451398287,A,A,Patients with the rs489693 AA genotype may be at an increased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.
1451398287,A,C,Patients with the rs489693 AC genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.
1451398287,C,C,Patients with the rs489693 CC genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.
1183632108,A,A,Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632108,A,G,Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the GG genotype and decreased reduction of diastolic blood pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632108,G,G,Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have a decreased reduction of diastolic blood pressure as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183693532,A,A,"Patients with schizophrenia and the rs11872992 AA genotype may have a decreased, but not absent, risk for weight gain when treated with clozapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk for weight gain when treated with clozapine."
1183693532,A,G,"Patients with schizophrenia and the rs11872992 AG genotype may have an increased risk for weight gain when treated with clozapine as compared to patients with the AA genotype and a decreased, but not absent, risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for weight gain when treated with clozapine."
1183693532,G,G,Patients with schizophrenia and the rs11872992 GG genotype may have an increased risk for weight gain when treated with clozapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk for weight gain when treated with clozapine.
1183679853,A,A,Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1183679853,A,G,Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1183679853,G,G,Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity.
1183679858,C,C,Patients with the CC genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CT. Other genetic and clinical factors may also influence a patient's response.
1183679858,C,T,Patients with the CT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.
1183679858,T,T,Patients with the TT genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Small Cell Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response.
1183684144,A,A,"Patients with the AA genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684144,A,T,"Patients with the AT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype and an increased likelihood of toxic liver disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684144,T,T,"Patients with the TT genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684167,C,C,"Patients with the CC genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.gemtuzumab ozogamicin and idarubicin."
1183684167,C,T,"Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684167,T,T,"Patients with the TT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183693438,A,A,Patients with the AA genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693438,A,C,Patients with the AC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693438,C,C,Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693448,C,C,Patients with the CC genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693448,C,T,Patients with the CT genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183693448,T,T,Patients with the TT genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.
1183679823,A,A,"Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1183679823,A,C,"Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1183679823,C,C,"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1451398347,A,A,"Patients with the rs489693 AA genotype may be at an increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone."
1451398347,A,C,"Patients with the rs489693 AC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone."
1451398347,C,C,"Patients with the rs489693 CC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone."
1451403400,C,C,Patients with the rs11030096 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403400,C,T,Patients with the rs11030096 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403400,T,T,Patients with the rs11030096 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403420,A,A,Patients with the rs4906902 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403420,A,G,Patients with the rs4906902 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403420,G,G,Patients with the rs4906902 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1183690892,A,A,"Patients with the rs1045642 AA genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART."
1183690892,A,G,"Patients with the rs1045642 AG genotype and HIV may have an increased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART."
1183690892,G,G,"Patients with the rs1045642 GG genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of virological failure on HAART."
1183697278,A,A,"Patients with the AA genotype may have increased metabolism of losartan as compared to patients with the AT or TT genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism."
1183697278,A,T,"Patients with the AT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism."
1183697278,T,T,"Patients with the TT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a separate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism."
1183680546,C,C,"Patients with the rs12979860 CC genotype and hepatitis C infection may have increased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy."
1183680546,C,T,"Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy."
1183680546,T,T,"Patients with the rs12979860 TT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy."
982031330,C,C,Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031330,G,C,Patients with the GC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031330,G,G,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032721,C,C,Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium or valproic acid as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032721,C,T,Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032721,T,T,Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982036604,A,A,"Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response."
982036604,A,G,"Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response."
982036604,G,G,"Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response."
982037753,A,A,Patients with the AA genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982037753,A,G,Patients with the AG genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982037753,G,G,Patients with the GG genotype and hypercholesterolemia may have a reduced response to treatment with less reduction in total cholesterol when treated with simvastatin compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982045124,A,A,Patients with AA genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045124,A,G,Patients with AG genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045124,G,G,Patients with GG genotypes may have increased the time to achieve a first INR within the therapeutic range and longer time to have over-anticoagulation (INR >4) risk when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1043858685,A,A,Patients with the AA genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.
1043858685,A,G,Patients with the AG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.
1043858685,G,G,Patients with the GG genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the AG or AA genotype. The study did not discuss the direction of the association but it might be an increased risk. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.
1043858840,C,C,Patients with the CC genotype may require increased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.
1043858840,C,T,Patients with the CT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.
1043858840,T,T,Patients with the TT genotype may require decreased warfarin dose requirement in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's dose of warfarin.
1183697531,C,C,Patients with the CC genotype and metastatic colorectal cancer may have increased rapid response to treatment containing irinotecan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
1183697531,C,T,Patients with the CT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
1183697531,T,T,Patients with the TT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.
1183697570,A,A,Women with the AA genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1183697570,A,G,Women with the AG genotype and breast cancer may have an increased chance of disease recurrence when treated with tamoxifen as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1183697570,G,G,Women with the GG genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1183698841,C,C,Patients with the CC genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.
1183698841,C,T,Patients with the CT genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.
1183698841,T,T,Patients with the TT genotype and cancer may have a poorer response to treatment with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to progression.
982038273,A,A,Patients with the AA genotype may be less likely to respond to venlafaxine as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
982038273,G,A,Patients with the GA genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
982038273,G,G,Patients with the GG genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.
1043858632,G,G,"Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to citalopram treatment as compared to patients with the GT or TT genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment."
1043858632,G,T,"Patients with the GT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment."
1043858632,T,T,"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment."
1183697623,C,C,"Patients with the CC genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab."
1183697623,C,T,"Patients with the CT genotype and macular degeneration may have greater decreases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the TT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab."
1183697623,T,T,"Patients with the TT genotype and macular degeneration may have greater increases in central subfield macular thickness (CSMT) when treated with ranibizumab, as compared to patients with the CC or CT genotype. However, no associations have been seen when considering changes in visual acuity. Other genetic and clinical factors may also influence response to ranibizumab."
1451398299,C,C,Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with risperidone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.
1451398299,C,T,Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.
1451398299,T,T,Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.
1451403428,C,C,Patients with the rs1079596 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403428,C,T,Patients with the rs1079596 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403428,T,T,Patients with the rs1079596 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1183697575,G,G,"The current evidence base suggests that there is no significant association between the rs1801131 GG genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1183697575,G,T,"The current evidence base suggests that there is no significant association between the rs1801131 GT genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1183697575,T,T,"The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1043858882,A,A,Patients with the AA genotype may have decreased risk of bone fractures when treated with Calcium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to calcium.
1043858882,A,G,Patients with the AG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.
1043858882,G,G,Patients with the GG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.
1043859365,A,A,Patients with the AA genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043859365,A,G,Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043859365,G,G,Patients with the GG genotype and Depressive Disorder may have a decreased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.
1043873003,C,C,Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043873003,C,T,Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043873003,T,T,Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043880165,A,A,"Patients with the AA genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment."
1043880165,A,G,"Patients with the AG genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment."
1043880165,G,G,"Patients with the GG genotype may have increased response to venlafaxine in people with Depressive Disorder but a decreased response to venlafaxine in people with Anxiety Disorders as compared to patients with the AA genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment."
1043880649,A,A,"Patients with the AA genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough."
1043880649,A,T,"Patients with the AT genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough."
1043880649,T,T,Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
1127445681,A,A,Patients with the AA genotype may have a dereased metabolism of zidovudine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.
1127445681,G,A,Patients with the GA genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.
1127445681,G,G,Patients with the GG genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.
1131245975,C,C,"Patients with the CC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have a decreased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism."
1131245975,T,C,"Patients with the TC genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism."
1131245975,T,T,"Patients with the TT genotype and HIV who are treated with indinavir, lamivudine or zidovudine may have an increased median zidovudine-triphosphate concentration at a marginally significance after gender adjustment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism."
1183491298,C,C,"Patients with the CC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have higher biochemical response, optimal cytoreduction, and sensitivity to the treatment as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel."
1183491298,T,C,"Patients with the TC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel."
1183491298,T,T,"Patients with the TT genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel."
1183491385,A,A,"Patients with the AA genotype were not studied, however patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment."
1183491385,A,G,Patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183491385,G,G,Patients with the GG genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in triglycerides) as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.
1183533882,C,C,Patients with the CC genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183533882,C,G,Patients with the CG genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183533882,G,G,Patients with the GG genotype who are treated with pravastatin may have a better response (higher decreases in total cholesterol) as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183533972,A,A,"Women with the AA genotype and hypertension may have smaller decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the GG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol."
1183533972,A,G,Women with the AG genotype and hypertension may have smaller decreases in systolic blood pressure when treated with atenolol as compared to women with the GG genotype. The same result was seen for women and men combined; no significant results were seen in men. Other genetic and clinical factors may also influence systolic blood pressure response to atenolol.
1183533972,G,G,"Women with the GG genotype and hypertension may have greater decreases in systolic or diastolic blood pressure when treated with atenolol as compared to women with the AA or AG genotype. No significant results were seen in men. When considering systolic blood pressure only, significant results were seen for men and women combined. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol."
1183589777,G,G,"Healthy males with the GG genotype may have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
1183589777,G,T,"Healthy males with the GT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
1183589777,T,T,"Healthy males with the TT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the GG genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
1183614687,A,A,Patients with the AA genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence general side-effect burden.
1183614687,A,C,"Patients with the AC genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype, or a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden."
1183614687,C,C,Patients with the CC genotype and major depressive disorder may have a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.
1183614701,A,A,"Patients with the AA genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
1183614701,A,G,"Patients with the AG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
1183614701,G,G,"Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
1183615383,A,A,Patients with the AA genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the AG genotype. Other genetic and clinical factors may also influence time to progression.
1183615383,A,G,Patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression.
1183615383,G,G,"No patients with the GG genotype were present in this study. However, patients with the AG genotype and gastrointestinal stromal tumors may have prolonged time to progression when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence time to progression."
1183630271,G,G,Patients with the GG genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1183630271,G,T,Patients with the GT genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1183630271,T,T,Patients with the TT genotype and NSCLC who are treated with cisplatin may have an reduced risk of severe ototoxicity as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.
1183631545,A,A,"Patients with the AA genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631545,A,G,"Patients with the AG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631545,G,G,"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183632160,A,A,Patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632160,A,G,Patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632160,G,G,Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183634192,A,A,"Patients with the AA genotype and HIV may have decreased plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence plasma concentrations of efavirenz."
1183634192,A,C,"Patients with the AC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence plasma concentrations of efavirenz."
1183634192,C,C,Patients with the CC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.
1183679775,A,A,"Patients with the AA genotype may have decreased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype CC or AC. Other genetic and clinical factors may also influence a patient's response to antipsychotics."
1183679775,A,C,"Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics."
1183679775,C,C,"Patients with the CC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics."
1183679799,C,C,Patients with the CC genotype may have decreased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1183679799,C,T,Patients with the CT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1183679799,T,T,Patients with the TT genotype may have increased risk of sorafenib-induced grade 2 diarrhea when treated with sorafenib in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to sorafenib.
1451398380,A,A,"Patients with the rs489693 AA genotype may be at an increased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride."
1451398380,A,C,"Patients with the rs489693 AC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride."
1451398380,C,C,"Patients with the rs489693 CC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride."
1451403440,C,C,Patients with the rs1125394 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403440,C,T,Patients with the rs1125394 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403440,T,T,Patients with the rs1125394 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1183631507,A,A,Patients with the AA genotype and Hypertension may have decreased response to diuretics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to diuretics.
1183631507,A,G,Patients with the AG genotype and Hypertension may have increased response to diuretics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to diuretics.
1183631507,G,G,Patients with the GG genotype and Hypertension may have increased response to diuretics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to diuretics.
1183679808,C,C,Patients with the CC genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679808,C,T,Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679808,T,T,Patients with the TT genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183684132,C,C,"Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684132,C,T,"Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1183684132,T,T,"Patients with the TT genotype may have an increased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin."
1451398387,C,C,Patients with the rs17782313 CC genotype may be at an increased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.
1451398387,C,T,Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.
1451398387,T,T,Patients with the rs17782313 TT genotype may be at a decreased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.
1451398394,A,A,Patients with the rs489693 AA genotype may have an increased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.
1451398394,A,C,Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.
1451398394,C,C,Patients with the rs489693 CC genotype may have a decreased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.
1183682148,C,C,"Patients with the rs7668258 CC genotype and epilepsy may have increased clearance of lamotrigine as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance."
1183682148,C,T,"Patients with the rs7668258 CT genotype may have decreased clearance of lamotrigine as compared to patients with the CC genotype but increased clearance as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance."
1183682148,T,T,"Patients with the rs7668258 TT genotype may have decreased clearance of lamotrigine as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance."
1043859063,C,C,Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1043859063,C,T,Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1043859063,T,T,Patients with the TT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183491044,G,G,Patients with the GG genotype and Adrenocortical Carcinoma who are treated with mitotane may have lower mitotane plasma concentrations as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.
1183491044,T,G,Patients with the TG genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.
1183491044,T,T,Patients with the TT genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.
1183594148,A,A,"Patients with the AA genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels."
1183594148,A,T,"Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels."
1183594148,T,T,"Patients with the TT genotype and hypertension may have increased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence fasting glucose levels."
1183603970,C,C,Patients with the CC genotype and mental disorders may have decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.
1183603970,C,T,"Patients with the CT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype, or decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain."
1183603970,T,T,Patients with the TT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.
1183614807,A,A,Women with the AA genotype and hypertension may have a better blood pressure response when treated with atenolol as compared to those with the AC or CC genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.
1183614807,A,C,Women with the AC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to women with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.
1183614807,C,C,Women with the CC genotype and hypertension may have a poorer blood pressure response when treated with atenolol as compared to patients with the AA genotype. No significant results were seen when considering men only. Other genetic and clinical factors may also influence blood pressure response.
1183615268,A,A,"Patients with the AA genotype and colon cancer may have an increased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of neutropenia."
1183615268,A,G,"Patients with the AG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia."
1183615268,G,G,"Patients with the GG genotype and colon cancer may have a decreased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia."
1183615317,A,A,Patients with the AA genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.
1183615317,A,G,Patients with the AG genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.
1183615317,G,G,Patients with the GG genotype and colorectal cancer may have decreased metabolism of irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.
1183693527,G,G,Female patients with the GG genotype may have decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1183693527,G,T,Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1183693527,T,T,Female patients with the TT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1183697628,C,C,Pregnant women with the CC genotype may have decreased clearance of nifedipine as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of nifedipine.
1183697628,C,T,Pregnant women with the CT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.
1183697628,T,T,Pregnant women with the TT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.
1183697633,A,A,"Patients with the AA genotype and asthma may have a poorer response when treated with methacholine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methacholine."
1183697633,A,G,"Patients with the AG genotype and asthma may have a better response when treated with methacholine as compared to patients with the AA genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine."
1183697633,G,G,"Patients with the GG genotype and asthma may have a better response when treated with methacholine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methacholine."
1183698813,A,A,"Patients with the AA (i.e. UGT1A1 *6/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol."
1183698813,A,G,"Patients with the AG (i.e. UGT1A1 *1/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype, or increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol."
1183698813,G,G,"Patients with the GG (i.e. UGT1A1 *1/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol."
1451403437,A,A,Patients with the rs2654754 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403437,A,G,Patients with the rs2654754 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403437,G,G,Patients with the rs2654754 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1183689558,C,C,"Patients with the CC genotype (normal Factor V) may have a decreased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CT or TT genotype (carriers of Factor V Leiden). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis."
1183689558,C,T,"Patients with the CT genotype (heterozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis."
1183689558,T,T,"Patients with the TT genotype (homozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis."
1183700483,C,C,Patients with the CC genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.
1183700483,C,T,Patients with the CT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.
1183700483,T,T,Patients with the TT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.
1183700493,C,C,Patients with the CC genotype may have decreased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.
1183700493,C,T,Patients with the CT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
1183700493,T,T,Patients with the TT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
1183700857,C,C,Patients with the CC genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1183700857,C,T,Patients with the CT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1183700857,T,T,Patients with the TT genotype and metastatic gastric cancer who are treated with platinum-based chemotherapy may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1451403454,A,A,Patients with the rs9288993 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403454,A,G,Patients with the rs9288993 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403454,G,G,Patients with the rs9288993 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403500,C,C,"Patients with the rs510769 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence."
1451403500,C,T,"Patients with the rs510769 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence."
1451403500,T,T,"Patients with the rs510769 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence."
981238570,C,C,"Pediatric patients with the CC genotype may have decreased, but not absent, risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine."
981238570,C,T,"Pediatric patients with the CT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine."
981238570,T,T,"Pediatric patients with the TT genotype may have an increased risk of moderate anemia when treated with artesunate, primaquine, pyrimethamine and sulfadoxine as compared to pediatric patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk of toxicity to artesunate, primaquine, pyrimethamine and sulfadoxine."
982009415,A,A,Patients with the AA genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AA genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.
982009415,A,G,Patients with the AG genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AG genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.
982009415,G,G,Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.
1451403476,C,C,Patients with the rs7597593 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403476,C,T,Patients with the rs7597593 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403476,T,T,Patients with the rs7597593 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
981239773,G,G,"Patients with the rs8099917 GG genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha/ribavirin."
981239773,G,T,"Patients with the rs8099917 GT genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha/ribavirin."
981239773,T,T,"Patients with the rs8099917 TT genotype and chronic hepatitis C infection may have increased response (higher SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha/ribavirin."
1451403467,A,A,Patients with the rs735668 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403467,A,C,Patients with the rs735668 AC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403467,C,C,Patients with the rs735668 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1450375074,A,A,"Patients with testicular cancer and the AA genotype may have an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide."
1450375074,A,C,"Patients with testicular cancer and the AC genotype may have a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide."
1450375074,C,C,"Patients with testicular cancer and the CC genotype may have a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide."
1450811417,A,A,Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450811417,A,C,Patients with the AC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450811417,C,C,Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1156076089,G,G,"Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes."
1156076089,G,T,"Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes."
1156076089,T,T,"Patients with the TT genotype may have increased exposure to fluvastatin as compared to patients with the GT and GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes."
982031013,A,A,Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031013,G,A,Patients with the GA genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031013,G,G,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031125,A,A,"Patients with the AA genotype were not studied, however they may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin."
982031125,A,G,Patients with the AG genotype and tumors may have decreased metabolism of erythromycin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
982031125,G,G,Patients with the GG genotype and tumors may have increased metabolism of erythromycin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
982032512,C,C,Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032512,C,T,Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032512,T,T,Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032657,A,A,"Patients with the rs558025 AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone dose required for effective treatment."
982032657,A,G,"Patients with the rs558025 AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone dose required for effective treatment."
982032657,G,G,"Patients with the rs558025 GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone dose required for effective treatment."
982034831,A,A,Patients with the AA genotype and colorectal cancer may have a shorter period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982034831,A,G,Patients with the AG genotype and colorectal cancer may have a longer period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982034831,G,G,Patients with the GG genotype and colorectal cancer did not have a statistically significant different period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982045698,C,C,Patient with CC + CT genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045698,C,T,Patient with CT + CC genotypes may have a decreased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045698,T,T,Patient with TT genotypes may have an increased IGF-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with CC + CT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1043858887,C,C,Patients with the CC genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
1043858887,C,T,Patients with the CT genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
1043858887,T,T,Patients with the TT genotype may have increased metabolism of erythromycin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.
1043880077,A,A,Patients with the AA genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1043880077,A,G,Patients with the AG genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1043880077,G,G,Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1043880362,A,A,Patients with the AA genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880362,A,G,Patients with the AG genotype may require decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880362,G,G,Patients with the GG genotype may require increased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880467,A,A,Patients with the AA genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.
1043880467,A,G,"Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment."
1043880467,G,G,Patients with the GG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment.
1043880567,A,A,Patients with the AA genotype may have decreased pitavastatin plasma concentrations as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.
1043880567,A,G,Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.
1043880567,G,G,Patients with the GG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.
1043880654,C,C,"Patients with the CC genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough."
1043880654,C,T,"Patients with the CT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough."
1043880654,T,T,Patients with the TT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.
1043880792,C,C,"Patients with the CC genotype and essential hypertension who are treated with atenolol may have an increased response as compared to patients with the TT or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol."
1043880792,C,T,"Patients with the CT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol."
1043880792,T,T,"Patients with the TT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol."
1043880828,A,A,Patients with the AA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.
1043880828,G,A,Patients with the GA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.
1043880828,G,G,Patients with the GG genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.
1050579065,G,G,Patients with the GG genotype who are treated with pravastatin may be less likely to benefit from treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1050579065,G,T,Patients with the GT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1050579065,T,T,Patients with the TT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1156497684,A,A,Patients with the AA genotype may have an increased metabolism of clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
1156497684,A,T,The AT genotype was not studied.
1156497684,T,T,Patients with the TT genotype may have a decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
1183490994,A,A,Patients with the AA genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
1183490994,A,T,Patients with the AT genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
1183490994,T,T,Patients with the TT genotype and Nephrosclerosis may have a lower baseline mean arterial blood pressure when treated with diuretics as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
1183491746,A,A,Patients with the AA genotype may have a better response (a higher reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491746,A,T,Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491746,T,T,Patients with the TT genotype were not studied. Patients with the AT genotype may have a reduced response (less reduction in LDL and total cholesterol) to pravastatin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492181,C,C,Patients with the CC genotype (non-carriers of APOE E2) who are treated with pravastatin may have a reduced response (a smaller reduction in LDL-cholesterol) as compared to patients with the TT genotype (also known as APOE E2/E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492181,C,T,Patients with the CT genotype (carriers of APOE E2) who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the CC genotype (non-carriers of APOE E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492181,T,T,Patients with the TT genotype (also known as APOE E2/E2) who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
982037307,C,C,"Patients with the CC genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin."
982037307,C,T,"Patients with the CT genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin."
982037307,T,T,"Patients with the TT genotype may be more likely to respond to aspirin as compared to patients with the CC or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin."
1142234402,A,A,Patients with the AA genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1142234402,A,G,Patients with the AG genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype or may have a reduced response (measured by a lower reduction in total cholesterol) as compared to patients with the AA genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1142234402,G,G,Patients with the GG genotype who are treated with simvastatin may have a reduced response to treatment (measured by a lower reduction in total cholesterol) compared to patients with the AA genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1154959505,A,A,"Patients with the AA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) a decreased, but not absent, risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) increased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant."
1154959505,G,A,"Patients with the GA genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant."
1154959505,G,G,"Patients with the GG genotype and Kidney Transplantation who are treated with cyclosporine and mycophenolate mofetil may have 1) an increased risk of biopsy-proven acute rejection (BPAR) at 12 month post-transplant 2) decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant."
1150414901,A,A,Patients with the AA genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1150414901,A,C,Patients with the AC genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1150414901,A,T,Patients with the AT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1150414901,C,C,"Patients with the CC genotype who are treated with simvastatin may have a reduced response (as measured by lower reductions in total cholesterol) as compared to patients with the AC, AA, TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment."
1150414901,T,T,Patients with the TT genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
982032442,G,G,Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032442,G,T,Patients with the GT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032442,T,T,Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982034869,A,A,Patients with the AA genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982034869,A,G,Patients with the AG genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982034869,G,G,Patients with the GG genotype and colorectal cancer may have a decreased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1183618209,A,A,Patients with the AA genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the del/del genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1451403484,C,C,Patients with the rs2023239 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403484,C,T,Patients with the rs2023239 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403484,T,T,Patients with the rs2023239 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
982030369,A,A,Patients with the rs12777823 AA genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage.
982030369,A,G,Patients with the rs12777823 AG genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage.
982030369,G,G,Patients with the rs12777823 GG genotype may require a higher dose of warfarin in African Americans as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dosage.
982037811,A,A,Patients with the AA genotype and Coronary Artery Disease may be less likely to benefit from treatment with pravastatin and have an increased risk of death or cardiovascular disease events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
982037811,A,G,Patients with the AG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
982037811,G,G,Patients with the GG genotype and Coronary Artery Disease may be more likely to benefit from treatment with pravastatin and have a reduced risk of death or cardiovascular disease events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
982040619,A,A,Patients with the AA genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
982040619,A,C,Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
982040619,C,C,"Patients with the CC genotype may have a decreased, but not absent, risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
1043858877,G,G,Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.
1043858877,G,T,Patients with the GT genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.
1043858877,T,T,Patients with the TT genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.
1043858975,A,A,Patients with the AA genotype may have an increased risk for aspirin resistance as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.
1043858975,A,G,"Patients with the AG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance."
1043858975,G,G,"Patients with the GG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance."
1043873013,A,A,Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.
1043873013,A,G,Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.
1043873013,G,G,Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.
1043880039,A,A,Patients with the AA genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1043880039,A,G,Patients with the AG genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1043880039,G,G,Patients with the GG genotype and major Depressive Disorder may have a decreased response to fluvoxamine treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.
1043880426,C,C,Patients with the CC genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1043880426,C,T,Patients with the CT genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1043880426,T,T,Patients with the TT genotype and Hypercholesterolemia may have a reduced response to simvastatin treatment as compared to patients with the the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1157204541,A,A,"Patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have a decreased response as compared to patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine."
1157204541,G,A,"Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine."
1157204541,G,G,"Patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine."
982040676,C,C,"Patients with the CC genotype who are treated with mycophenolate mofetil may have 1) no changes in mycophenolic acid exposure-related parameters and 2) a decreased, but not absent, risk of acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
982040676,T,C,"Patients with the TC genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
982040676,T,T,"Patients with the TT genotype who are treated with mycophenolate mofetil may have 1) changes in mycophenolic acid exposure-related parameters and 2) increased risk of acute allograft rejection within 3 month after transplantation as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
1451403580,C,C,Patients with the rs6928499 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403580,C,G,Patients with the rs6928499 CG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403580,G,G,Patients with the rs6928499 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1043880397,A,A,Patients with the rs4917639 AA genotype may require increased dose of warfarin as compared to patients with the CC or CA genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880397,C,A,Patients with the rs4917639 CA genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880397,C,C,Patients with the rs4917639 CC genotype may require decreased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.
1183491004,A,A,"Patients with the rs1800566 AA genotype who are treated with platinum chemotherapy regimens may have decreased overall survival as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival."
1183491004,A,G,"Patients with the rs1800566 AG genotype who are treated with platinum chemotherapy regimens may have decreased overall survival as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival."
1183491004,G,G,"Patients with the rs1800566 GG genotype who are treated with platinum chemotherapy regimens may have increased overall survival as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival."
1183491364,A,A,"Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have an increased severity of pain lesser reduction in homocysteine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1183491364,A,G,"Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1183491364,G,G,"Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1043859020,C,C,Patients with the CC genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the CT or TT genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.
1043859020,C,T,Patients with the CT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.
1043859020,T,T,Patients with the TT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.
1043859046,C,C,Patients with the CC genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1043859046,C,G,Patients with the CG genotype and diabetes may be less likely to respond to fenofibrate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1043859046,G,G,Patients with the GG genotype and diabetes may be more likely to respond to fenofibrate treatment as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183491055,A,A,Patients with the AA genotype may have higher ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
1183491055,A,G,Patients with the AG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
1183491055,G,G,Patients with the GG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
1183491098,C,C,"Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. This may be influenced by rs3808607 genotype, with an increased response in patients with the rs3808607 TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
1183491098,C,G,"Patients with the CG genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. However, this association was not observed in the majority of studies. This may be influenced by rs3808607 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
1183491098,G,G,Patients with the GG genotype who are treated with atorvastatin may have a decreased response to treatment (measured by lower decreases in LDL-cholesterol) as compared to patients with the CC genotype. This association may be influenced by rs3808607 genotype. Several studies show no association as compared to the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491262,A,A,Patients with the AA genotype who are treated with ondansetron may have increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1183491262,A,C,Patients with the AC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1183491262,C,C,Patients with the CC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.
1183491390,A,A,Patients with the AA genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491390,A,G,"Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment."
1183491390,G,G,Patients with the GG genotype who have Hypercholesterolemia may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491541,G,G,"Patients with the GG genotype were not studied, however patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
1183491541,G,T,Patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491541,T,T,Patients with the TT genotype may have a better response to pravastatin treatment (higher decreases in LDL-cholesterol and total cholesterol) as compared to patients with the GT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183602693,A,A,Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602693,A,G,"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects."
1183602693,G,G,Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183604439,C,C,Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183604439,C,T,"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects."
1183604439,T,T,Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183614711,A,A,Patients with the AA genotype and schizophrenia may have a poorer response when treated with antipsychotics as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1183614711,A,C,Patients with the AC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1183614711,C,C,Patients with the CC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1183614726,A,A,Patients with the AA genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614726,A,G,Patients with the AG genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614726,G,G,Patients with the GG genotype and HIV infection who are treated with efavirenz may have an increased risk of sadness as a side effect as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614860,C,C,Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183614860,C,G,Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183614860,G,G,Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183615140,C,C,"Patients with the CC genotype and colon cancer may have an increased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia."
1183615140,C,T,"Patients with the CT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia."
1183615140,T,T,"Patients with the TT genotype and colon cancer may have a decreased risk of thrombocytopenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of thrombocytopenia."
1183615273,A,A,"Patients with the AA genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time."
1183615273,A,G,"Patients with the AG genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time."
1183615273,G,G,"Patients with the GG genotype and colorectal cancer may have increased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time."
1183622368,A,A,Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622368,A,C,Patients with the AC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622368,C,C,Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622651,C,C,Patients with the CC genotype and major depressive disorder who are treated with escitalopram 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183622651,C,T,Patients with the CT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype or 1) may have increased metabolism of escitalopram at week 2 of treatment 2) may experience more severe side effects as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183622651,T,T,Patients with the TT genotype and major depressive disorder who are treated with escitalopram 1) may have reduced metabolism of escitalopram at week 2 of treatment 2) may experience less severe side effects as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram and severity of drug-induced side effects.
1183629305,C,C,Patients with the CC genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1183629305,C,T,Patients with the CT genotype who are treated with antidepressants may have an increased likelihood of remission as compared to patients with TT genotype and a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1183629305,T,T,Patients with the TT genotype and Depression who are treated with antidepressants may have a decreased likelihood of remission as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
1183629475,A,A,Patients with the AA genotype who are treated with quetiapine may have an increased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.
1183629475,A,G,Patients with the AG genotype who are treated with quetiapine may have a decreased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.
1183629475,G,G,Patients with the GG genotype who are treated with quetiapine may have a decreased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.
1183533961,C,C,"Women with the CC genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CT or TT genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine."
1183533961,C,T,"Women with the CT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine."
1183533961,T,T,"Women with the TT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine."
1183615208,T,T,"Patients with the T/T genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan or irinotecan-based regimens as compared to patients with the del/del genotype. However, a different study of similar size found no association between this genotype and diarrhea. No significant results have been seen when considering neutropenia or tumor response. Other genetic and clinical factors may also influence risk of diarrhea."
1183619225,C,C,Patients with the CC genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.
1183619225,C,T,Patients with the CT genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype or may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.
1183619225,T,T,Patients with the TT genotype and major depressive disorder who are treated with fluoxetine may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.
1451403608,C,C,Patients with the rs6280 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403608,C,T,Patients with the rs6280 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403608,T,T,Patients with the rs6280 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403621,A,A,Patients with the rs1065852 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403621,A,G,Patients with the rs1065852 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403621,G,G,Patients with the rs1065852 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403720,A,A,Patients with the rs1384401 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403720,A,G,Patients with the rs1384401 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403720,G,G,Patients with the rs1384401 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1183533940,A,A,Patients with the AA genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.
1183533940,A,G,Patients with the AG genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.
1183533940,G,G,Patients with the GG genotype and non-small cell lung cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.
1183592332,C,C,"Patients with the CC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
1183592332,C,T,"Patients with the CT genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
1183592332,T,T,"Patients with the TT genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC or CT genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
1183614766,A,A,Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614766,A,G,Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614766,G,G,Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183615400,A,A,Purified DCK proteins with the AA genotype may have reduced clearance of gemcitabine as compared to those proteins with the AG or GG genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
1183615400,A,G,Purified DCK proteins with the AG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
1183615400,G,G,Purified DCK proteins with the GG genotype may have increased clearance of gemcitabine as compared to those proteins with the AA genotype. Other genetic and clinical factors may also affect clearance of gemcitabine.
1183631460,C,C,Patients with the CC genotype and dementia may have increased clearance of memantine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of memantine.
1183631460,C,T,Patients with the CT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.
1183631460,T,T,Patients with the TT genotype and dementia may have decreased clearance of memantine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of memantine.
1183631787,C,C,"Patients with the CC genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram."
1183631787,C,T,"Patients with the CT genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram."
1183631787,T,T,"Patients with the TT genotype may have increased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the CC or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram."
1183632073,A,A,Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have slightly decreased reduction of systolic blood pressure as compared to patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632073,A,G,"Patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure as compared to patients with the AA genotype, and slightly decreased reduction of systolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment."
1183632073,G,G,Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure as compared to patients with the AA or the AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632190,A,A,Patients with the AA genotype may have increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.
1183632190,A,G,Patients with the AG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.
1183632190,G,G,Patients with the GG genotype may have decreased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.
1183679780,A,A,Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679780,A,G,Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679780,G,G,Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679818,A,A,Patients with the AA genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183679818,A,G,Patients with the AG genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183679818,G,G,Patients with the GG genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183679843,A,A,Patients with the AA genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AC or CC. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183679843,A,C,Patients with the AC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183679843,C,C,Patients with the CC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1183679863,C,C,Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679863,C,T,Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183679863,T,T,Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.
1183680415,A,A,"Patients with the AA genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori."
1183680415,A,G,"Patients with the AG genotype who are infected with Helicobacter pylori (H. pylori) may have a lower chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the GG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori."
1183680415,G,G,"Patients with the GG genotype who are infected with Helicobacter pylori (H. pylori) may have an increased chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the AA or AG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori."
1183680516,A,A,Patients with the AA genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183680516,A,G,Patients with the AG genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183680516,G,G,Patients with the GG genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183680555,A,A,Patients with the AA genotype may have decreased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.
1183680555,A,T,Patients with the AT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.
1183680555,T,T,Patients with the TT genotype may have increased reduction in blood pressure when treated with diltiazem in people with Hypertension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to diltiazem.
1183680560,A,A,Patients with the AA genotype may have decreased response to metformin in people with Diabetes Mellitus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1183680560,A,G,Patients with the AG genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1183680560,G,G,Patients with the GG genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1183680565,A,A,"Individuals with the AA genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin."
1183680565,A,G,"Individuals with the AG genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin."
1183680565,G,G,"Individuals with the GG genotype may have decreased renal and secretory clearance of metformin as compared to individuals with the AA genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin."
1183680575,A,A,Patients with the AA genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AG and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183680575,A,G,Patients with the AG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and GG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183680575,G,G,Patients with the GG genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the AA and AG genotypes. Another study found no association with drug toxicity and doxorubicin. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183680665,A,A,Patients with the AA genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.
1183680665,A,G,Patients with the AG genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus.
1183680665,G,G,"Patients with the GG genotype and Kidney Transplantation who are treated with tacrolimus may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to tacrolimus."
1451403600,G,G,Patients with the rs3745274 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403600,G,T,Patients with the rs3745274 GT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403600,T,T,Patients with the rs3745274 TT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1183680511,C,C,Patients with the CC genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183680511,C,G,Patients with the CG genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183680511,G,G,Patients with the GG genotype may have decreased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1183680526,C,C,Patients with the CC genotype may have increased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1183680526,C,T,Patients with the CT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1183680526,T,T,Patients with the TT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1450377339,C,C,Patients who are undergoing liver transplantation and receive a donor liver with the CC genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM.
1450377339,C,T,Patients who are undergoing liver transplantation and receive a donor liver with the CT genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM.
1450377339,T,T,Patients who are undergoing liver transplantation and receive a donor liver with the TT genotype may have a decreased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the CC or CT genotype. Other genetic and clinical factors may also influence risk for NODM.
1450814641,C,C,"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814641,C,T,"Patients with the CT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814641,T,T,"Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814647,C,C,"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814647,C,T,"Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814647,T,T,"Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450822023,A,A,"Patients with the AA genotype may have a decreased severity of heroin dependence as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and severity of heroin dependence. Other genetic or clinical factors may also affect severity of heroin dependence."
1450822023,A,G,"Patients with the AG genotype may have an increased severity of heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and severity of heroin dependence. Other genetic or clinical factors may also affect severity of heroin dependence."
1450822023,G,G,"Patients with the GG genotype may have an increased severity of heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and severity of heroin dependence. Other genetic or clinical factors may also affect severity of heroin dependence."
1451403680,A,A,Patients with the rs324029 AA genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403680,A,G,Patients with the rs324029 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403680,G,G,Patients with the rs324029 GG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403687,C,C,Patients with the rs718656 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403687,C,T,Patients with the rs718656 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403687,T,T,Patients with the rs718656 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
982031106,A,A,"Patients with the AA genotype were not studied, however they may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam."
982031106,A,G,Patients with the AG genotype and tumors may have decreased metabolism of midazolam as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.
982031106,G,G,Patients with the GG genotype and tumors may have increased metabolism of midazolam as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of midazolam.
982031517,A,A,Patients with the AA genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
982031517,A,G,Patients with the AG genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
982031517,G,G,Patients with the GG genotype and depression may be more likely to respond to citalopram or escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
982032329,A,A,Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032329,A,G,Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032329,G,G,Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032477,A,A,Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032477,A,G,Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032477,G,G,Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032672,A,A,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032672,A,G,Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032672,G,G,Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982034400,C,C,"Patients with the CC genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
982034400,C,G,"Patients with the CG genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
982034400,G,G,"Patients with the GG genotype and hypertensive coronary artery disease may have an increased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
982045076,A,A,Patients with AA genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045076,A,G,Patients with AG genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045076,G,G,Patients with GG genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1043858661,G,G,"Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
1043858661,G,T,"Patients with the GT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
1043858661,T,T,Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858680,A,A,Patients with the AA genotype and asthma may have an increased risk for aspirin sensitivity but patients with chronic urticaria may have a decreased risk for aspirin sensitivity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1043858680,A,G,Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1043858680,G,G,Patients with the GG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1043858722,A,A,Patients with the AA genotype may have a decreased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858722,A,C,No information are provided for the AC genotype. But patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858722,C,C,Patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858845,C,C,Patients with the CC genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.
1043858845,C,T,Patients with the CT genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.
1043858845,T,T,Patients with the TT genotype may be associated with a decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.
1043873008,G,G,"Patients with the GG genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine."
1043873008,G,T,"Patients with the GT genotype may have decreased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype TT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine."
1043873008,T,T,"Patients with the TT genotype may have increased response to fluvoxamine, milnacipran and paroxetine in people with major depression as compared to patients with genotype GG or GT. Other clinical or genetic factors may also influence a patient's response to fluvoxamine, milnacipran and paroxetine."
1043873023,C,C,Patients with the CC genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.
1043873023,C,G,Patients with the CG genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.
1043873023,G,G,Patients with the GG genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the CC genotype. Other clinical or genetic factors may also influence a patient's response to hydrochlorothiazide.
1043873028,A,A,Patients with the AA genotype may require decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin.
1043873028,A,G,"Patients with the AG genotype may 1) require decreased dose of phenytoin, 2) have increase metabolism of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin."
1043873028,G,G,"Patients with the GG genotype may 1) require increased dose of phenytoin, 2) have decrease metabolism of phenytoin in people with Epilepsy as compared to patients with genotype AA or AG. Other clinical or genetic factors may also influence a patient's dose of phenytoin."
1043880298,A,A,"Patients with the AA genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AG or GG. Authors caution ""the relevance of these data is uncertain, given the low number of rare alleles"". Other clinical or genetic factors may also influence a patient's response."
1043880298,A,G,"Patients with the AG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution ""the relevance of these data is uncertain, given the low number of rare alleles"". Other clinical or genetic factors may also influence a patient's response."
1043880298,G,G,"Patients with the GG genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the genotype AA. Authors caution ""the relevance of these data is uncertain, given the low number of rare alleles"". Other clinical or genetic factors may also influence a patient's response."
1043880723,C,C,Patients with the CC genotype and Schizophrenia who are treated antipsychotics with may have an increased risk for antipsychotic-induced parkinsonism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism.
1043880723,G,C,"Patients with the GC genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism."
1043880723,G,G,"Patients with the GG genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism."
1043880750,A,A,"Patients with the AA genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain."
1043880750,A,C,"Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain."
1043880750,C,C,"Patients with the CC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have a decreased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the AA or AC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain."
1043880900,A,A,"Patients with the AA genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and increased risk of adverse events in response to treatment as compared to patients with the GG or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment."
1043880900,A,G,"Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment."
1043880900,G,G,"Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of adverse events in response to treatment as compared to patients with the AA or AG genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment."
1183490957,G,G,Patients with the GG genotype may have decreased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183490957,T,G,Patients with the TG genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183490957,T,T,Patients with the TT genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1135389481,A,A,"Patients with the AA genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection."
1135389481,A,T,"Patients with the AT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk for acute allograft rejection within 3 month after transplantation as compared to patients with the TT genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection."
1135389481,T,T,"Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased, but not absent, risk for acute allograft rejection within 3 month after transplantation as compared to patients with the AA genotype. However, only a trend of associations or no associations are reported. Other genetic and clinical factors may also influence a patient's risk for acute allograft rejection."
1451403740,A,A,Patients with the rs4530637 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403740,A,G,Patients with the rs4530637 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451403740,G,G,Patients with the rs4530637 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1183491792,C,C,Patients with the CC genotype and Acute coronary syndrome who are treated with statins may have an increased response to treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183491792,C,G,Patients with the CG genotype and Acute coronary syndrome who are treated with statins may have a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183491792,G,G,Patients with the GG genotype and Acute coronary syndrome who are treated with statins may have a deceased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183491822,C,C,Patients with the CC genotype were not studied. Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491822,C,T,Patients with the CT genotype and stable ischemic heart disease may have an increased response to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491822,T,T,Patients with the TT genotype and stable ischemic heart disease may have a reduced response to simvastatin as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183492023,A,A,"Patients with the AA genotype and cancer may have a decreased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AC or CC genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab."
1183492023,C,A,"Patients with the AC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab."
1183492023,C,C,"Patients with the CC genotype and cancer may have an increased response and survival times when treated with cetuximab or panitumumab as compared to patients with the AA genotype. However, conflicting and negative evidence exists for this association. Other genetic and clinical factors may also influence response and survival times in patients taking cetuximab or panitumumab."
1183549413,C,C,Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183549413,C,G,Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183549413,G,G,Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183605282,A,A,Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183605282,A,C,Patients with the AC genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183605282,C,C,Patients with the CC genotype and asthma may have a higher frequency of asthma exacerbationswhen treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183607013,A,A,Patients with the AA genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183607013,A,C,Patients with the AC genotype an type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183607013,C,C,Patients with the CC genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183607142,C,C,Patients with the CC genotype and type 2 diabetes may have a decreased response when treated with repaglinide as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183607142,C,T,Patients with the CT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183607142,T,T,Patients with the TT genotype and type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
1183614716,G,G,Patients with the GG genotype and HIV infection who are treated with efavirenz may have a reduced risk of abnormal dreams as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614716,G,T,Patients with the GT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614716,T,T,Patients with the TT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.
1183614816,C,C,Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CT or TT genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614816,C,T,Human liver microsomes with the CT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614816,T,T,Human liver microsomes with the TT genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183614825,C,C,Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183614825,C,T,Patients with the CT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183614825,T,T,Patients with the TT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.
1183614830,A,A,Patients with the AA genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.
1183614830,A,G,Patients with the AG genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.
1183614830,G,G,Patients with the GG genotype and schizophrenia may have an increased QTc interval when treated with iloperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval.
1183614835,A,A,Women with the AA genotype and breast cancer may have decreased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614835,A,G,Women with the AG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614835,G,G,Women with the GG genotype and breast cancer may have increased progression-free survival time when treated with capecitabine and docetaxel as compared to women with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183622348,C,C,Patients with the CC genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622348,C,G,Patients with the CG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622348,G,G,Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183629489,A,A,Patients with the AA genotype who are treated with risperidone may have an increased likelihood of cardiovascular adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.
1183629489,A,G,"Patients with the AG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions."
1183629489,G,G,"Patients with the GG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions."
1183614682,C,C,Patients with the CC genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.
1183614682,C,T,"Patients with the CT genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype, or increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects."
1183614682,T,T,Patients with the TT genotype and major depressive disorder may have increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.
1183614886,A,A,Patients with the AA genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1183614886,A,G,"Patients with the AG genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype, or more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine."
1183614886,G,G,Patients with the GG genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1183631422,A,A,Patients with the AA genotype may have decreased clearance of L-tryptophan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response.
1183631422,A,C,"Patients with the AC genotype may have decreased clearance of L-tryptophan as compared to patients with the CC genotype, but an increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response."
1183631422,C,C,Patients with the CC genotype may have increased clearance of L-tryptophan as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response.
1183680521,C,C,Patients with the CC genotype may have increased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.
1183680521,C,T,Patients with the CT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.
1183680521,T,T,Patients with the TT genotype may have decreased reduction in mean blood pressure when treated with Thiazides in people with Essential hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazides.
1183533986,A,A,"Patients with the AA genotype and hypertension may have a decreased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AG or GG genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine."
1183533986,A,G,"Patients with the AG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine."
1183533986,G,G,"Patients with the GG genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 92 mm Hg when treated with amlodipine as compared to patients with the AA genotype. No significant associations were seen when considering a target mean arterial pressure of <= 107 mm Hg, or when considering men or women individually. Other genetic and clinical factors may also influence the likelihood of reaching target mean arterial pressure in patients taking amlodipine."
1183679117,A,A,Patients with the AA genotype may be less likely to experience myopathy when treated with statins as compared to patients with the AG or GG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1183679117,A,G,"Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins."
1183679117,G,G,Patients with the GG genotype may be more likely to experience myopathy when treated with statins as compared to patients with the AA or AG genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.
1183614676,C,C,Patients with the rs17782313 CC genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.
1183614676,C,T,Patients with the rs17782313 CT genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.
1183614676,T,T,Patients with the rs17782313 TT genotype may have decreased but not absent likelihood of weight gain when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence weight gain.
982034197,A,A,"Patients with the rs1799971 AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements."
982034197,A,G,"Patients with the rs1799971 AG genotype may have increased morphine dose requirements as compared to patients with the AA genotype, but decreased morphine dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements."
982034197,G,G,"Patients with the rs1799971 GG genotype may have increased morphine dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements."
982030757,G,G,Patients with genotype GG may have decreased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's chance of response.
982030757,T,G,Patients with genotype TG may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response.
982030757,T,T,Patients with genotype TT may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response.
982030887,C,C,Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030887,C,T,Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030887,T,T,Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030900,C,C,Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030900,C,T,Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030900,T,T,Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982031241,A,A,Patients with the AA genotype and arthritis may have increased response to TNF inhibitors as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.
982031241,A,G,Patients with the AG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.
982031241,G,G,Patients with the GG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.
982032306,C,C,Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032306,C,T,Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032306,T,T,Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982030381,C,C,Patients with the rs1954787 CC genotype and depressive disorders may be more likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
982030381,C,T,Patients with the rs1954787 CT genotype and depressive disorders may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
982030381,T,T,Patients with the rs1954787 TT genotype and depressive disorders may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
982044867,A,A,Patients with colonic neoplasms and the rs9344 AA genotype may have decreased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to fluorouracil.
982044867,A,G,Patients with colonic neoplasms and the rs9344 AG genotype may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluorouracil.
982044867,G,G,Patients with colonic neoplasms and the rs9344 GG genotype may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluorouracil.
982045137,C,C,Patients with CC genotypes may have worse response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045137,C,T,Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045137,T,T,Patients with CT + TT genotypes may have better response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1043858698,A,A,"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
1043858698,A,G,"Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
1043858698,G,G,Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043880066,G,G,Patients with the GG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1043880066,G,T,Patients with the TG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1043880066,T,T,Patients with the TT genotype and Kidney Transplantation may have an increased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.
1043880082,C,C,"Patients with the CC genotype and Kidney Transplantation may have an increased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea."
1043880082,C,G,"Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea."
1043880082,G,G,"Patients with the CG genotype and Kidney Transplantation may have a decreased risk of diarrhoea when treated with mycophenolate mofetil and cyclosporine as compared to patients with the CG or GG genotype. However, no association is reported for treatment with mycophenolate mofetil, sirolimus or tacrolimus. Other genetic and clinical factors may also influence a patient's diarrhoea."
1051394394,G,G,Men with the GG genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1051394394,G,T,Men with the GT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1051394394,T,T,Men with the TT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have higher decreases in triglyceride levels as compared to patients with the GT or GG genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1139265477,A,A,Patients with the AA genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1139265477,A,G,Patients with the AG genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) as compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1139265477,G,G,Patients with the GG genotype who are treated with atorvastatin may have a reduced response to treatment (as measured by a lower reduction in LDL-cholesterol or total cholesterol) as compared to patients with the AG or AA genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1158793019,A,A,Patients with the AA genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1158793019,A,G,Patients with the AG genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the GG genotype and a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1158793019,G,G,Patients with the GG genotype and Coronary Disease may have a decreased response to rosuvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1183491214,C,C,"Patients with the CC genotype may have an decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with an increased metabolic ratio of midazolam as compared to patients with the CT genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam."
1183491214,C,T,"Patients with the TC genotype may have a decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with a decreased metabolic ratio of midazolam as compared to patients with the CC genotype in CYP3A5*1 patients. Other genetic and clinical factors may also influence a patient's metabolism of midazolam."
1183491214,T,T,Patients with the TT genotype may have an increased metabolic ratio of midazolam as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of midazolam.
1183491333,A,A,Patients with the AA genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491333,A,G,Patients with the AG genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491333,G,G,Patients with the GG genotype and Hypercholesterolemia may benefit less from simvastatin treatment due to a lower reduction in DNA damage as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491809,A,A,Patients with the AA genotype were not studied. Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491809,A,G,Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491809,G,G,Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183532521,C,C,"Patients with the CC genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment."
1183532521,C,G,"Patients with the CG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the GG genotype or may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment."
1183532521,G,G,"Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, pravastatin or simvastatin may have a better response (a higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment."
1183617623,C,C,Patients with the CC genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183617623,C,T,Patients with the CT genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype or may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183617623,T,T,Patients with the TT genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.
1183617685,C,C,Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a slower response time but an increased likelihood of experiencing remission as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183617685,C,T,Patients with the CT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1183617685,T,T,Patients with the TT genotype and major depressive disorder who are treated with paroxetine may have a faster response time but a decreased likelihood of experiencing remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1043880170,A,A,Patients with the AA genotype and hypercholesterolemia who are treated with simvastatin may have an increased risk of cardiovascular disease events as compared to patients with the AG or GG genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1043880170,A,G,Patients with the AG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1043880170,G,G,Patients with the GG genotype and hypercholesterolemia who are treated with simvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1043858905,C,C,"Patients with the CC genotype may have increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CT or TT genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives."
1043858905,C,T,"Patients with the CT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives."
1043858905,T,T,"Patients with the TT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives."
982035703,A,A,Patients with the rs2884737 AA genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.
982035703,A,C,Patients with the rs2884737 AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.
982035703,C,C,Patients with the rs2884737 CC genotype may require lower dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.
1183547855,C,C,Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183547855,C,G,Human liver microsomes with the CG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183547855,G,G,Human liver microsomes with the GG genotype may have increased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CC genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.
1183603016,C,C,Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183603016,C,T,"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects."
1183603016,T,T,Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183614476,A,A,Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183614476,A,G,Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183614476,G,G,Patients with the GG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183619292,A,A,"Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619292,A,G,"Patients with the AG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619292,G,G,"Patients with the GG genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619303,A,A,"Patients with the AA genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619303,A,C,"Patients with the AC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype and a decreased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619303,C,C,"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619317,C,C,"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619317,C,T,"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619317,T,T,"Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183632117,C,C,Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the CT or the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632117,C,T,Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the TT genotype and increased reduction of systolic blood pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632117,T,T,Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of systolic blood pressure as compared to patients with the CC or the CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632180,C,C,Patients with the CC genotype may have increased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1183632180,C,T,Patients with the CT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1183632180,T,T,Patients with the TT genotype may have decreased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1183614850,A,A,"Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure."
1183614850,A,G,"Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure."
1183614850,G,G,"Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant results have been seen for systolic blood pressure. Additionally, the same study reported no significant differences in systolic or diastolic blood pressure between genotypes in a different cohort. Other genetic and clinical factors may also influence change in diastolic or systolic blood pressure."
1183632195,A,A,Patients with the rs1045642 AA genotype may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to ondansetron.
1183632195,A,G,Patients with the rs1045642 AG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.
1183632195,G,G,Patients with the rs1045642 GG genotype may have increased likelihood of nausea and vomiting shortly after being treated with treated with ondansetron as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to ondansetron.
981204851,A,A,"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
981204851,A,G,"Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
981204851,G,G,"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the AG and AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation."
981237871,A,A,"Patients with the AA genotype and Neoplasms who are treated with docetaxel may have 1) a decreased, but not absent, risk of leukopenia, 2) an increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel."
981237871,A,G,"Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel."
981237871,G,G,"Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel."
981237930,A,A,"Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result"
981237930,A,G,Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.
981237930,G,G,"Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment."
981238415,A,A,"Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AA genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AA genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
981238415,A,C,"Patients with the AC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) an increased risk for gastrointestinal toxicities 2) a decreased response to folic acid and methotrexate as compared to patients with the CC genotype. However, this association is contradicted in other studies that show the AC genotype may have an increased response to methotrexate as compared to patients with the CC genotype or or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the AC genotype may have decreased event free survival when treated with mercaptopurine and methotrexate as compared to children with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
981238415,C,C,"Patients with the CC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) a decreased, but not absent, risk for gastrointestinal toxicities 2) an increased response to folic acid and methotrexate as compared to patients with the AA and AC genotype. However, this association is contradicted in other studies that show the CC genotype may have decreased response to methotrexate as compared to patients with the AC and AA genotype or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the CC genotype may have increased event free survival when treated with mercaptopurine and methotrexate as compared to children with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
1183615535,A,A,Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.
1183615535,A,G,"Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype, or decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin."
1183615535,G,G,Patients with the GG genotype may have decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.
1183680506,A,A,Patients with the AA genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183680506,A,G,Patients with the AG genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1183680506,G,G,Patients with the GG genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.
1449164857,C,C,"Individuals with the CC genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA."
1449164857,C,T,"Individuals with the CT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA."
1449164857,T,T,"Individuals with the TT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA."
1449713231,A,A,Patients with the AA genotype and multiple sclerosis may have a decreased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.
1449713231,A,G,Patients with the AG genotype and multiple sclerosis may have an increased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.
1449713231,G,G,Patients with the GG genotype and multiple sclerosis may have an increased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.
1449752810,C,C,Patients with the CC genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752810,C,T,Patients with the CT genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752810,T,T,Patients with the TT genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
981204210,A,A,Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.
981204210,A,G,Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of CNS adverse events as compared to patients with the GG genotype. Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of CNS adverse events.
981204210,G,G,Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a decreased response to methotrexate as compared to patients with the AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1183679838,A,A,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity."
1183679838,A,G,"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity."
1183679838,G,G,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity."
981238550,C,C,Patients with the CC genotype and Epilepsy may have increased metabolism of carbamazepine as compared to patients with the the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.
981238550,C,T,"Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine."
981238550,T,T,Patients with the TT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.
1450373520,A,A,"Postoperative patients with the AA genotype may have higher morphine requirements as compared to patients with the AG or GG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements."
1450373520,A,G,"Postoperative patients with the AG genotype may have higher morphine requirements as compared to patients with the GG genotype, but lower morphine requirements as compared to patients with the AA genotype. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements."
1450373520,G,G,"Postoperative patients with the GG genotype may have lower morphine requirements as compared to patients with the AA or AG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Chinese or Indian ethnicity, while the opposite association was seen in patients of Malay ethnicity (see clinical annotation 1450373514). Other genetic and clinical factors may also affect a patient's morphine requirements."
1450373622,A,A,Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373622,A,G,Patients with the AG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373622,G,G,Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1451404212,C,C,Patients with the rs7967354 CC genotype may require decreased doses of rocuronium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence rocuronium dosage requirements.
1451404212,C,T,Patients with the rs7967354 CT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.
1451404212,T,T,Patients with the rs7967354 TT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.
1451404219,C,C,Patients with the rs11045995 CC genotype may require decreased doses of rocuronium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence rocuronium dosage requirements.
1451404219,C,T,Patients with the rs11045995 CT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.
1451404219,T,T,Patients with the rs11045995 TT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.
981239532,A,A,"Patients with the AA genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose."
981239532,A,C,"Patients with the AC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dose."
981239532,C,C,Patients with the CC genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence warfarin dose.
981239556,C,C,"Patients with the CC genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose."
981239556,C,T,"Patients with the CT genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose."
981239556,T,T,Patients with the TT genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose.
981204902,A,A,"Patients with rs16969968 AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence risk of nicotine dependency."
981204902,A,G,"Patients with rs16969968 AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype, but a decreased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence risk of nicotine dependency."
981204902,G,G,"Patients with rs16969968 GG genotype may have a decreased, but not absent, risk for nicotine dependence when exposed to nicotine as compared to patients with the AG or AA genotypes. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1051730. Other genetic and clinical factors may influence risk of nicotine dependency."
655387745,C,C,"Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
655387745,C,T,"Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
655387745,T,T,"Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
981419487,C,C,Patients with the rs118192172 CC genotype may have decreased risk to statin-related myopathy as compared patients with the TT or CT genotype. Other genetic and clinical factors may also influence risk of toxicity to statins.
981419487,C,T,Patients with the rs118192172 CT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to statins.
981419487,T,T,Patients with the rs118192172 TT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to statins.
981419550,A,A,Patients with the AA genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
981419550,A,G,Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
981419550,G,G,Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
981478113,C,C,Patients with the CC genotype may have decreased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
981478113,C,T,Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
981478113,T,T,Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.
1449167328,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167328,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167328,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449168072,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168072,G,T,Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168072,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168079,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168079,C,T,Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168079,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449167453,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167453,C,G,Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167453,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
982029652,A,A,Patients with the AA genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.
982029652,A,C,"Patients with the AC genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype, or a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects."
982029652,C,C,Patients with the CC genotype may have a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.
982030862,A,A,Patients with the AA genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030862,A,G,Patients with the AG genotype and Major Depressive Disorder may be more likely to respond to anti-depressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030862,G,G,Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.
982030971,G,G,Patients with the GG genotype may have more inhibition of platelet aggregation with crangrelor as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
982030971,G,T,"No information is reported for the GT genotype. However, patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor."
982030971,T,T,Patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.
982031308,C,C,Patients with the CC genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982031308,C,T,Patients with the CT genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982031308,T,T,Patients with the TT genotype and Bipolar Disorder may have an increased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982031346,A,A,Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031346,A,G,Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031346,G,G,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031374,C,C,Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031374,T,C,Patients with the TC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031374,T,T,Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031407,C,C,Patients with the CC genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031407,C,T,Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031407,T,T,Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031795,A,A,Patients with the AA genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.
982031795,A,G,Patients with the AG genotype may have an increased risk of anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil.
982031795,G,G,"Patients with the GG genotype may have a decreased, but not absent, risk of anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity with mycophenolate mofetil."
982032228,A,A,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032228,A,C,Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032228,C,C,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032638,A,A,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032638,A,C,Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032638,C,C,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982029578,A,A,Patients with the AA genotype and Macular Degeneration who are treated with ranibizumab may have a lack of early response to treatment compared to patients with the AC or CC genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.
982029578,A,C,Patients with the AC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.
982029578,C,C,Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.
982030916,C,C,"Female patients with the CC genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants."
982030916,C,T,"Female patients with the CT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants."
982030916,T,T,"Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants."
982031034,A,A,"Patients with the AA genotype and treated with clopidogrel may have 1) a stronger aggregation 2) increased risk of non-response as compared to patients with the AC or CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
982031034,A,C,"Patients with the AC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
982031034,C,C,"Patients with the CC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
982035482,G,G,Patients with the GG genotype may require lower dose of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.
982035482,G,T,Patients with the GT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.
982035482,T,T,Patients with the TT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes.
982036238,A,A,Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
982036238,A,G,Patients with the AG genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
982036238,G,G,Patients with the GG genotype may have decreased metabolism of verapamil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
982037378,C,C,"Patients with the CC genotype may be more likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
982037378,C,T,"Patients with the CT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
982037378,T,T,"Patients with the TT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel."
982045674,C,C,Patient with CC genotype may have decreased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045674,C,T,Patient with CT + TT genotypes may have increased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045674,T,T,Patient with CT + TT genotypes may have increased IGF-I response when treated with somatropin recombinant in children with Turner Syndrome as compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1451406523,A,A,"Patients with the rs1799971 AA genotype may have a decreased analgesic response to tramadol as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to tramadol."
1451406523,A,G,"Patients with the rs1799971 AG genotype may have an increased analgesic response to tramadol as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to tramadol."
1451406523,G,G,"Patients with the rs1799971 GG genotype may have an increased analgesic response to tramadol as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to tramadol."
982045082,C,C,Patients with CC genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045082,T,C,Patients with TC genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045082,T,T,Patients with TT genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982032743,A,A,"Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine."
982032743,A,C,"Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine."
982032743,C,C,"Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine."
1043858606,C,C,"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine but less likely to respond to citalopram or antidepressants as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants."
1043858606,C,T,"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants."
1043858606,T,T,"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine or antidepressants but more likely to respond to citalopram as compared to patients with the CC or CT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants."
1043858642,A,A,"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
1043858642,A,G,Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858642,G,G,Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858651,C,C,"Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity."
1043858651,C,T,"Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin hypersensitivity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity."
1043858651,T,T,Patients with the TT genotype and asthma may have an increased risk for aspirin hypersensitivity as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin hypersensitivity.
1043858666,C,C,"Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
1043858666,C,T,"Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
1043858666,T,T,Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858872,A,A,Patients with the AA genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.
1043858872,A,G,Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.
1043858872,G,G,Patients with the GG genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.
1043859119,A,A,Patients with the AA genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1043859119,A,C,Patients with the AC genotype may have a decreased chance of response to citalopram or ecitalopram treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1043859119,C,C,Patients with the CC genotype may have an increased chance of response to citalopram or ecitalopram treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
1043858990,A,A,"Patients with the rs10306114 AA genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to aspirin."
1043858990,A,G,Patients with the rs10306114 AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin.
1043858990,G,G,Patients with the rs10306114 GG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to aspirin.
1183490999,G,G,"Patients with the GG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have a decreased, but not absent, risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation."
1183490999,T,G,Patients with the TG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.
1183490999,T,T,Patients with the TT genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.
1043880357,C,C,Patients with the rs11150606 CC genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880357,C,T,Patients with the rs11150606 CT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880357,T,T,Patients with the rs11150606 TT genotype may require increased dose of warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.
1155598159,G,G,"Patients with the GG genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin."
1155598159,G,T,"Patients with the GT genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin."
1155598159,T,T,"Patients with the TT genotype may have higher plasma concentrations of atorvastatin as compared to patients with the GT or GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin."
982030399,A,A,Patients with the AA genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
982030399,A,T,Patients with the AT genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
982030399,T,T,Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to venlafaxine treatment as compared to those with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.
982045146,A,A,Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045146,A,G,Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
982045146,G,G,Patients with GG genotypes may have worse response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with AA +AG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.
1043859269,A,A,"Patients with the AA genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have a decreased, but not absent, risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
1043859269,A,G,Patients with the AG genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1043859269,G,G,Patients with the GG genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1043872998,C,C,Patients with the CC genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043872998,C,T,Patients with the CT genotype may have decreased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the TT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043872998,T,T,Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotypes. Other clinical or genetic factors may also influence a patient's response to fenofibrate.
1043880214,A,A,Patients with the AA genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1043880229,A,A,Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with lisinopril as compared to patients with the AA genotype treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1043880313,C,C,Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880313,C,T,Patients with CT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880313,T,T,Patients with TT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.
1043880337,G,G,Patients with the GG genotype may require increased dose of warfarin when treated with warfarin as compared to patients with the TT or TG genotype. Other clinical or genetic factors may also influence the dose of warfarin.
1043880337,T,G,Patients with the TG genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.
1043880337,T,T,Patients with the TT genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.
1043880409,C,C,"Patients with the CC genotype who are treated with fluvastatin may have a larger change in apolipoprotein A1 and C3 levels, as compared to patients with the C/del or del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment."
1043880447,A,A,"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough."
1043880447,A,G,"Patients with the AG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough."
1043880447,G,G,"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough."
1043880669,C,C,Patients with the CC genotype may have increased Euphoric and Energetic after amphetamine exposure as compared to patients with the CT or TT genotype.
1043880669,C,T,Patients with the CT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.
1043880669,T,T,Patients with the TT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype.
1043880823,G,G,"Patients with the GG genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
1043880823,G,T,"Patients with the GT genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
1043880823,T,T,"Patients with the TT genotype may have an increased response to atorvastatin as compared to patients with the GG or GT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
1043880872,A,A,Patients with the AA genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1043880872,A,G,Patients with the AG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1043880872,G,G,Patients with the GG genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1043880818,C,C,"Patients with the rs4149056 CC genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin."
1043880818,C,T,"Patients with the rs4149056 CT genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin."
1043880818,T,T,"Patients with the rs4149056 TT genotype may have a decreased risk of myopathy when treated with atorvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin."
1048764135,A,A,"Patients with the AA genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
1048764135,A,G,"Patients with the AG genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
1048764135,G,G,"Patients with the GG genotype who are treated with pravastatin may 1) have lower IL1B serum levels, and 2) be more likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
1124035501,G,G,Patients with the GG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1124035501,G,T,Patients with the GT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1124035501,T,T,Patients with the TT genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion.
1145963221,C,C,Patients with the CC genotype and asthma who are treated with corticosteroids may have increased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1145963221,C,G,Patients with the CG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1145963221,G,G,Patients with the GG genotype and asthma who are treated with corticosteroids may have a decreased change in forced expiratory volume in 1 s (FEV1) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1147261601,A,A,The AA genotype was not studied but female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.
1147261601,A,T,Female patients with the AT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.
1147261601,T,T,Female patients with the TT genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression-free survival as compared to patients with the AT genotype. Other genetic and clinical factors may also influence a patient's likelihood of progression-free survival.
1155650524,A,A,Patients with the AA genotype may have a decreased metabolism of clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
1155650524,A,G,The AG genotype was not studied.
1155650524,G,G,Patients with the GG genotype may have an increased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's clozapine metabolism.
1157877076,C,C,"Patients with the CC genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib."
1157877076,C,T,"Patients with the CT genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib."
1157877076,T,T,Patients with the TT genotype and Carcinoma who are treated with sunitinib may have an increased risk for dose reductions due to toxicity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1183490967,A,A,Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183490967,A,C,Patients with the AC genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183490967,C,C,Patients with the CC genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AC or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183490978,A,A,Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183490978,A,G,Patients with the AG genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183490978,G,G,Patients with the GG genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AG or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.
1183491035,A,A,Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
1183491035,A,G,Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
1183491035,G,G,Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have increased severity of pain as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.
1183491140,C,C,Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491140,C,T,Patients with the CT genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491140,T,T,Patients with the TT genotype who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the CC or CT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1043880192,A,A,"Patients with the AA genotype who are treated with atorvastatin may have a decreased response to treatment and an increased risk of cardiovascular disease events as compared to patients with the GG genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
1043880192,A,G,"Patients with the AG genotype who are treated with atorvastatin may have a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
1043880192,G,G,"Patients with the GG genotype who are treated with atorvastatin may have an increased response to treatment and a decreased risk of cardiovascular disease events as compared to patients with the AA genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
1183491189,C,C,Patients with the CC genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491189,C,T,Patients with the CT genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491189,T,T,Patients with the TT genotype and Hypercholesterolemia may have a reduced response to atorvastatin treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1183491354,A,A,Patients with the AA genotype and Schizophrenia who are treated with haloperidol may have an increased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1183491354,A,G,Patients with the AG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1183491354,G,G,Patients with the GG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1183491617,G,G,Patients with the GG genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491617,G,T,Patients with the GT genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491617,T,T,Patients with the TT genotype may have a better response to simvastatin treatment (higher reductions in LDL cholesterol) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491741,A,A,Patients with the AA genotype may have a better response to simvastatin treatment (a higher reduction in LDL-cholesterol) as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491741,A,T,Patients with the AT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491741,T,T,Patients with the TT genotype may have a reduced response to simvastatin treatment (a lower reduction in LDL-cholesterol) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183491775,A,A,Patients with the AA genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491775,A,G,Patients with the AG genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183491775,G,G,Patients with the GG genotype and Hypertension who are treated with pravastatin may have a decreased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492030,A,A,"Patients with the AA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have a decreased, but not absent, risk for drug-resistance as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance."
1183492030,G,A,"Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance."
1183492030,G,G,"Patients with the GG genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance."
1183492128,C,C,Patients with the CC genotype who are treated with fluvastatin may have a reduced response (a smaller reduction in LDL-cholesterol or change in HDL) as compared to patients with the CT genotype (carriers of E2). Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183492128,C,T,Patients with the CT genotype (carriers of E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.
1183492128,T,T,"Patients with the TT genotype (also known as E2/E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype, although the studies did not have C homozygotes and only reported the effect for the heterozygote. Other genetic and clinical factors may also influence a patient's response to statin treatment."
1183492235,C,C,Patients with the CC genotype and Coronary Disease who are treated with pravastatin may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492235,C,T,Patients with the CT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype or may have a reduced response (lower increases in HDL-cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492235,T,T,Patients with the TT genotype and Coronary Disease who are treated with pravastatin may have a better response (increased HDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183614547,A,A,Patients with the AA genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.
1183614547,A,G,Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.
1183614547,G,G,Patients with the GG genotype may have better pain relief to opioids in cancer patients as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to opioids.
1183614624,C,C,Patients with the CC genotype and epilepsy who are treated with carbamazepine may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1183614624,C,T,Patients with the CT genotype and epilepsy who are treated with carbamazepine may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1183614624,T,T,Patients with the TT genotype and epilepsy who are treated with carbamazepine may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.
1183614578,A,A,Patients with the AA genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1183614578,A,G,Patients with the AG genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1183614578,G,G,Patients with the GG genotype and epilepsy may be more likely to respond to antiepileptic drugs as compared to patients with the AG or AA genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
1183614591,C,C,"Patients with the CC genotype and epilepsy who are treated with carbamazepine or oxcarbazepine may have a decreased likelihood of a good response within as compared to patients with the CT or TT genotypes, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment."
1183614591,C,T,"Patients with the CT genotype and epilepsy who are treated with carbamazepine may have a decreased likelihood of a good response as compared to patients with the TT genotype, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment."
1183614591,T,T,"Patients with the TT genotype and epilepsy who are treated with carbamazepine may have an increased likelihood of a good response as compared to patients with the CC or CT genotypes, although most studies have found no association with response. Several studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment."
1183614776,A,A,Patients with the AA genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1183614776,A,C,Patients with the AC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1183614776,C,C,Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of efavirenz as compared to patients with the AA genotype. Studies conflict as to associations with plasma concentrations. The association with risk of side effects is currently unclear. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1154221922,G,G,Patients with the rs2231142 GG genotype and who are treated with rosuvastatin may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.
1154221922,G,T,Patients with the rs2231142 GT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.
1154221922,T,T,Patients with the rs2231142 TT genotype and who are treated with rosuvastatin may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.
1183615573,A,A,"Patients with the rs699 AA genotype may have a decreased response to irbesartan as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
1183615573,A,G,"Patients with the rs699 AG genotype may have an increased response to irbesartan as compared to patients with the AA genotype, but a decreased response as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
1183615573,G,G,"Patients with the rs699 GG genotype may have an increased response to irbesartan as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
1183618199,C,C,Patients with the rs12208357 CC genotype may have lower plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.
1183618199,C,T,Patients with the rs12208357 CT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.
1183618199,T,T,Patients with the rs12208357 TT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs12208357 and tramadol and does not include evidence about clinical outcomes. Other genetic or clinical factors may influence O-desmethyltramadol concentrations.
982031323,A,A,Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031323,A,G,Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982031323,G,G,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032495,A,A,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032495,A,C,Patients with the AC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032495,C,C,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.
982032734,A,A,Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032734,G,A,Patients with the GA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982032734,G,G,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
982047849,C,C,Patients with the CC genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
982047849,C,T,Patients with the CT genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
982047849,T,T,Patients with the TT genotype and major depressive disorder may have a reduced response when treated with paroxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1043858637,A,A,Patients with the AA genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858637,A,G,Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.
1043858637,G,G,"Patients with the GG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma."
1043858675,A,A,Patients with the AA genotype were not studied but patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858675,A,G,Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858675,G,G,"Patients with the GG genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1043858703,A,A,Patients with the AA genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858703,A,G,Patients with the AG genotype and Myocardial Infarction may have an increased risk for residual platelet reactivity when treated with aspirin as compared to patients with the GG genotype Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858703,G,G,"Patients with the GG genotype and Myocardial Infarction may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin as compared to patients with the AG or AA genotype Other genetic and clinical factors may also influence a patient's response to aspirin."
1183590959,A,A,"Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
1183590959,A,G,"Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
1183590959,G,G,"Patients with the GG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
1183614696,A,A,"Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
1183614696,A,G,"Patients with the AG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype, or more likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
1183614696,G,G,"Patients with the GG genotype and major depressive disorder may be more likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline."
1183614721,G,G,Patients with the GG genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.
1183614721,G,T,"Patients with the GT genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype, or a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline."
1183614721,T,T,Patients with the TT genotype and major depressive disorder may experience a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline.
1183616495,A,A,Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183616495,A,G,Patients with the AG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183616495,G,G,Patients with the GG genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183616511,A,A,Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183616511,A,C,Patients with the AC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183616511,C,C,Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183617565,A,A,Patients with the AA genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.
1183617565,A,T,Patients with the AT genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype or may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.
1183617565,T,T,Patients with the TT genotype and depression who are treated with paroxetine may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.
1043858615,C,C,"Patients with the CC genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment."
1043858615,C,T,"Patients with the CT genotype and Major Depressive Disorder may be more likely to respond to antidepressant treatment as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment."
1043858615,T,T,"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to antidepressant treatment as compared to patients with the CT or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment."
1043858892,A,A,Patients with the AA genotype may require lower dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1043858892,T,A,Patients with the TA genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1043858892,T,T,Patients with the TT genotype may require higher dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1183618859,A,A,"Patients with the AA genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions."
1183618859,A,G,"Patients with the AG genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions."
1183618859,G,G,"Patients with the GG genotype and depression who are treated with paroxetine may have an increased risk of adverse drug reactions as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk of adverse reactions."
1043859029,C,C,Patients with the CC genotype and non-small cell lung cancer may have an increased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum compounds.
1043859029,C,T,Patients with the CT genotype and non-small cell lung cancer may have an increased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum compounds.
1043859029,T,T,Patients with the TT genotype and non-small cell lung cancer may have a decreased response to platinum compounds (cisplatin or carboplatin) as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence response to platinum compounds.
1183545767,C,C,Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183545767,C,G,Patients with the CG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype or a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183545767,G,G,Patients with the GG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183556815,C,C,Patients with the CC genotype may have decreased metabolism of ondansetron as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.
1183556815,C,T,Patients with the CT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.
1183556815,T,T,Patients with the TT genotype may have increased metabolism of ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.
1183563324,C,C,"Healthy males with the CC genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
1183563324,C,T,"Healthy males with the CT genotype may have an increased response when given bumetanide, furosemide and torasemide as compared to healthy males with the TT genotype, or a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
1183563324,T,T,"Healthy males with the TT genotype have have a decreased response when given bumetanide, furosemide and torasemide as compared to healthy males with the CC genotype. Other genetic and clinical factors may also influence response to bumetanide, furosemide and torasemide."
1183620349,A,A,Female patients with the AA genotype (homozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have an increased risk of hemolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183620349,A,G,Female patients with the AG genotype (heterozygous for the G6PD Mediterranean variant) and Type 2 diabetes who are treated with glibenclamide may have a varying degree of G6PD deficient red blood cells and an unknown risk of hemolysis as compared to patients with the GG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183620349,G,G,Female patients with the GG genotype and Type 2 diabetes who are treated with glibenclamide may have a reduced risk of hemolysis as compared to patients with the AA genotype (homozygous for the G6PD Mediterranean variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.
1183622321,C,C,Patients with the CC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622321,C,T,Patients with the CT genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622321,T,T,Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to prasugrel treatment.
1183622557,G,G,Patients with the GG genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.
1183622557,G,T,Patients with the GT genotype and major depressive disorder may have increased metabolism of escitalopram as compared to patients with the TT genotype or may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.
1183622557,T,T,Patients with the TT genotype and major depressive disorder may have reduced metabolism of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of escitalopram.
1183624306,C,C,Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624306,C,T,Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624306,T,T,Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624313,C,C,Patients with the CC genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624313,C,T,Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624313,T,T,Patients with the TT genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624328,A,A,Patients with the AA genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624328,A,G,Patients with the AG genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624328,G,G,Patients with the GG genotype and Anxiety Disorders who are treated with duloxetine may have increased response to duloxetine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.
1183624421,A,A,"Patients with the AA genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation."
1183624421,A,T,"Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation."
1183624421,T,T,"Patients with the TT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation."
1183630276,A,A,"Patients with the AA genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
1183630276,A,C,"Patients with the AC genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy."
1183630276,C,C,Patients with the CC genotype and lung cancer who are treated with carboplatin or cisplatin may have a higher risk of distant disease progression as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
1451406840,C,C,Patients with the rs16952570 CC genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with azathioprine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with azathioprine.
1451406840,C,T,Patients with the rs16952570 CT genotype may be at an increased risk of developing leukopenia or neutropenia when treated with azathioprine as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with azathioprine.
1451406840,T,T,Patients with the rs16952570 TT genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with azathioprine as compared to patients with the CT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with azathioprine.
982036249,A,A,Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
982036249,A,C,Patients with the AC genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
982036249,C,C,Patients with the CC genotype may have decreased metabolism of verapamil as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.
1043858970,A,A,Male patients with the AA genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858970,A,C,Male patients with the AC genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043858970,C,C,Male patients with the CC genotype may have a decreased inhibition of FXIII activation by aspirin as compared to the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1043859274,A,A,Patients with the AA genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.
1043859274,A,G,Patients with the AG genotype may have an increased risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin.
1043859274,G,G,"Patients with the GG genotype may have a decreased, but not absent, risk for residual platelet reactivity when treated with aspirin and clopidogrel as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel and aspirin."
1043872993,A,A,"Patients with the AA genotype and non-small cell lung cancer may have an improved response when treated with platinum compounds as compared to patients with the GG genotype, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer."
1043872993,A,G,"Patients with the AG genotype and non-small cell lung cancer may have improved response when treated with platinum compounds as compared to patients with the GG genotype, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer."
1043872993,G,G,"Patients with the GG genotype and non-small cell lung cancer may have a worse response when treated with platinum compounds as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer."
1043876904,A,A,Patients with the AA genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1043876904,A,C,Patients with the AC genotype and major depression and high anxiety may have a decreased response to fluoxetine treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1043876904,C,C,Patients with the CC genotype and major depression and high anxiety may have an increased response to fluoxetine treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1043880438,A,A,"Patients with AA genotype were not studied. However, patients with the AC genotype and neoplasms may have a decreased plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism."
1043880438,A,C,Patients with the AC genotype and neoplasms may have a decreased plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.
1043880438,C,C,Patients with the CC genotype and neoplasms may have an increased plasma predose concentration as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.
1043880608,A,A,"Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels and another found increased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
1043880608,A,G,"Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
1043880608,G,G,"Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may a larger reduction in LDL as compared to patients with the AA or AG genotype. However, one study found no association with LDL levels and another found decreased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment."
1043880664,C,C,Patients with the CC genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.
1043880664,C,T,Patients with the CT genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.
1043880664,T,T,Patients with the TT genotype may have decreased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the CC or CT genotype.
1043880783,A,A,"Patients with the AA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have a decreased, but not absent, risk for cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events."
1043880783,G,A,Patients with the GA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.
1043880783,G,G,Patients with the GG genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.
1043880851,A,A,"Patients with the AA who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy."
1043880851,A,G,"Patients with the AG who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy."
1043880851,G,G,"Patients with the GG who are treated with bortezomib, melphalan and prednisone may have an earlier onset of bortezomib-induced peripheral neuropathy as compared to patients with the AA or AG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influence a patient's risk for treatment-induced peripheral neuropathy."
1143918642,A,A,Patients with the AA genotype may have a decreased affinity to losartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to losartan.
1143918642,A,G,The AG genotype was not studied in association with affinity to losartan.
1143918642,G,G,Patients with the GG genotype may have an increased affinity to losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to losartan.
1183490962,C,C,Patients with the CC genotype may have an increased sedative response to dexmedetomidine as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183490962,G,C,Patients with the GC genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183490962,G,G,Patients with the GG genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.
1183492244,C,C,Men with the CC genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to men with the CT or TT genotype. Women with the CC genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492244,C,T,Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183492244,T,T,Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.
1183533592,A,A,Patients with the AA genotype may have a larger reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.
1183533592,A,T,Patients with the AT genotype may have a higher reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype or may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.
1183533592,T,T,Patients with the TT genotype may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.
1183533981,A,A,Patients with the AA genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.
1183533981,A,G,Patients with the AG genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.
1183533981,G,G,Patients with the GG genotype and epilepsy may have decreased retention rates when treated with carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.
1183603158,A,A,Patients with the AA genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183603158,A,G,"Patients with the AG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects."
1183603158,G,G,Patients with the GG genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183614509,A,A,Patients with the AA genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.
1183614509,A,G,Patients with the AG genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.
1183614509,G,G,Patients with the GG genotype and left ventricular hypertrophy may have an increased response when treated with atenolol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to atenolol.
1183614752,C,C,Patients with the CC genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
1183614752,C,T,Patients with the CT genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
1183614752,T,T,Patients with the TT genotype and depression may be more likely to respond to antidepressant treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antidepressants.
1183614845,C,C,Patients with the CC genotype and left ventricular hypertrophy may have a smaller percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.
1183614845,C,G,Patients with the CG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.
1183614845,G,G,Patients with the GG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.
1183614891,C,C,"Patients with the CC genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics."
1183614891,C,T,"Patients with the CT genotype and schizophrenia may have a poorer response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antipsychotics."
1183614891,T,T,"Patients with the TT genotype and schizophrenia may have a better response when treated with antipsychotics, including amisulpride, olanzapine, quetiapine and risperidone, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to antipsychotics."
1183615150,G,G,Patients with the GG genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.
1183615150,G,T,Patients with the GT genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.
1183615150,T,T,Patients with the TT genotype and hypertension may have greater decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence change in systolic and diastolic blood pressure.
1183615213,A,A,Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1183615213,A,G,Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1183615213,G,G,Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.
1183615410,A,A,Purified CDA proteins with the AA genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.
1183615410,A,G,Purified CDA proteins with the AG genotype may have decreased catalytic activity when exposed to cytarabine as compared to those proteins with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.
1183615410,G,G,Purified CDA proteins with the GG genotype may have increased catalytic activity when exposed to cytarabine as compared to those proteins with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.
1183615415,C,C,Patients with the CC genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1183615415,C,T,Patients with the CT genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1183615415,T,T,Patients with the TT genotype and rheumatoid arthritis may have a decreased response to treatment with anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
982037557,A,A,"Patients with the AA genotype may have 1) a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the GA or GG genotype and 2) an increased incidence of lymphopenia as compared to patients with the GA genotype. However, the AA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
982037557,G,A,Patients with the GA genotype may have 1) an increased risk for acute rejection after kidney transplantation and 2) decreased incidence of lymphopenia as compared to patients with the AA genotype but the GA genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
982037557,G,G,Patients with the GG genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the AA genotype but the GG genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.
1451406860,C,C,Patients with the rs16952570 CC genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with mercaptopurine.
1451406860,C,T,Patients with the rs16952570 CT genotype may be at an increased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with mercaptopurine.
1451406860,T,T,Patients with the rs16952570 TT genotype may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with the CT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing leukopenia or neutropenia when treated with mercaptopurine.
1183615582,A,A,"Patients with the rs699 AA genotype may have a decreased response to atenolol as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol."
1183615582,A,G,"Patients with the rs699 AG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol."
1183615582,G,G,"Patients with the rs699 GG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol."
982031045,G,G,"Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis."
982031045,T,G,"Male patients with the TG genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis."
982031045,T,T,"Male patients with the TT genotype and Coronary Artery Disease may have an increased risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis."
982031956,A,A,Patients with the AA genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra.
982031956,A,G,Patients with the AG genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra.
982031956,G,G,Patients with the GG genotype and Asthma may be more likely to respond when treated with pitrakinra as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to pitrakinra.
982036595,C,C,"Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response."
982036595,C,T,"Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response."
982036595,T,T,"Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response."
1183564845,A,A,Patients with the AA genotype and heart failure may have an increased response when treated with candesartan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence response to candesartan.
1183564845,A,C,Patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan.
1183564845,C,C,"No patients with the CC genotype were present in the study analysis. However, patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan."
1183614481,C,C,Patients with the CC genotype and left ventricular hypertrophy may have an increased response when treated with irbesartan as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to irbesartan.
1183614481,C,T,Patients with the CT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.
1183614481,T,T,Patients with the TT genotype and left ventricular hypertrophy may have a decreased response when treated with irbesartan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to irbesartan.
1183614486,C,C,"Healthy males with the CC genotype may have a greater increase in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CG or GG genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure."
1183614486,C,G,"Healthy males with the CG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure."
1183614486,G,G,"Healthy males with the GG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure."
1183614706,A,A,Patients with the AA genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183614706,A,T,Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183614706,T,T,Patients with the TT genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183614771,A,A,Patients with the AA genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614771,A,G,Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614771,G,G,Patients with the GG genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1183614840,A,A,Patients with the AA genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.
1183614840,A,G,Patients with the AG genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.
1183614840,G,G,Patients with the GG genotype who underwent kidney transplantation may have decreased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.
1183614881,A,A,Patients with the AA genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183614881,A,G,Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183614881,G,G,Patients with the GG genotype and asthma may have a reduced frequency of asthma exacerbationse when treated with pitrakinra as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to pitrakinra.
1183614970,C,C,Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT or TT genotype (carriers of E2 or E2/E2). Other genetic and clinical factors may also influence response to fenofibrate.
1183614970,C,T,Patients with the CT genotype (carriers of E2) and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183614970,T,T,Patients with the TT genotype (also known as E2/E2) and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1183615145,C,C,"Patients with the CC genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes."
1183615145,C,T,"Patients with the CT genotype and colorectal cancer may have decreased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes."
1183615145,T,T,"Patients with the TT genotype and colorectal cancer may have increased severity of neurotoxicity syndromes when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence severity of neurotoxicity syndromes."
1183615186,C,C,"Patients with the CC genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea."
1183615186,C,T,"Patients with the CT genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. However, a different study of similar size found no association between the CT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea."
1183615186,T,T,"Patients with the TT genotype and cancer may have a decreased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the CC or CT genotype. However, a different study of similar size found no association between the TT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea."
1183543916,C,C,"Patients with the CC genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate."
1183543916,C,T,"Patients with the CT genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate."
1183543916,T,T,"Patients with the TT genotype and hypertriglyceridemia may have a decreased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the CC or CT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate."
1183615288,C,C,Patients with the CC genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.
1183615288,C,T,"Patients with the CT genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype, or may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine."
1183615288,T,T,Patients with the TT genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.
1183615373,C,C,Patients with the CC genotype who underwent kidney transplantation may have a longer post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
1183615373,C,T,Patients with the CT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
1183615373,T,T,Patients with the TT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.
1183619322,C,C,"Patients with the CC genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619322,C,T,"Patients with the CT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype and a decreased likelihood of remission as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1183619322,T,T,"Patients with the TT genotype and depression who are treated with amitriptyline, citalopram, paroxetine or venlafaxine may have an increased likelihood of remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to amitriptyline, citalopram, paroxetine or venlafaxine."
1043858733,A,A,Patients with the AA genotype may have an increased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1043858733,A,G,Patients with the AG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1043858733,G,G,Patients with the GG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.
1043859108,C,C,Patients with the CC genotype and non-small cell lung cancer may have receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.
1043859108,C,T,Patients with the CT genotype and non-small cell lung cancer may receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.
1043859108,T,T,Patients with the TT genotype and non-small cell lung cancer may have a decreased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the CC or CT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.
1043880059,T,T,Patients with the TT genotype with Kidney Transplantation may have a decreased metabolism of mycophenolate mofetil as compared to patients with the DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's metabolism of mycophenolate mofetil.
1183554425,C,C,"Patients with the CC genotype and non-small cell lung cancer show no significant differences in progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. However, patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time."
1183554425,C,T,"Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time."
1183554425,T,T,"Patients with the TT genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence progression-free survival time."
1183602849,G,G,Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183602849,G,T,"Patients with the GT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects."
1183602849,T,T,Patients with the TT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183613866,C,C,Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183613866,C,T,"Patients with the CT genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype, or decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects."
1183613866,T,T,Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.
1183615199,T,T,"Patients with the rs3832043 TT genotype and non-small cell lung cancer may have increased glucuronidation of SN-38 as compared to patients with the T/del or del/del genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A9 into an inactive form (SN-38G). This annotation only covers the pharmacokinetic relationship between rs3832043 and SN-38 and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence SN-38 metabolism."
982030948,C,C,Patients with the CC genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982030948,C,T,Patients with the CT genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982030948,T,T,Patients with the TT genotype and depression may have decreased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
982040598,A,A,"Patients with the AA genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel."
982040598,A,G,"Patients with the AG genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel."
982040598,G,G,"Patients with the GG genotype who are treated with prasugrel may have a lower rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel."
982040717,C,C,"Patients with CC genotype were not studied but patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported for C allele carriers. Other genetic and clinical factors may also influence a patient's response to aspirin."
982040717,C,T,"Patients with the CT genotype who are treated with aspirin may have an increased risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin."
982040717,T,T,"Patients with the TT genotype who are treated with aspirin may have a decreased, but not absent, risk of an aspirin-resistant phenotype as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin."
1183631465,A,A,Patients with the AA genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183631465,A,G,Patients with the AG genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183631465,G,G,Patients with the GG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. A seperate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.
1183631554,C,C,"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631554,C,T,"Patients with the CT genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631554,T,T,"Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631559,C,C,"Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631559,C,G,"Patients with the CG genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183631559,G,G,"Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity."
1183632078,A,A,Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have greater reduction of diastolic blood pressure as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632078,A,C,"Patients with the AC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA genotype, and greater reduction of diastolic blood pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment."
1183632078,C,C,Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have smaller reduction of diastolic blood pressure as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632091,C,C,Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have increased reduction of diastolic blood pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632091,C,T,Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased reduction of diastolic blood pressure as compared to patients with the CC genotype and increased reduction of diastolic blood pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632091,T,T,Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of diastolic blood pressure as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.
1183632150,C,C,Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the TT genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632150,C,T,Patients with the CT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632150,T,T,Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632155,C,C,Patients with the CC genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632155,C,G,Patients with the CG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics..
1183632155,G,G,Patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1183632175,A,A,Patients with the AA genotype may have decreased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1183632175,A,G,Patients with the AG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1183632175,G,G,Patients with the GG genotype may have increased likelihood of sexual adverse events when treated with risperidone in people with Schizophrenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1183632140,A,A,Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.
1183632140,A,G,Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.
1183632140,G,G,Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substance.
1183614735,A,A,"Patients with the AA genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
1183614735,A,C,"Patients with the AC genotype and non-small cell lung cancer may have increased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
1183614735,C,C,"Patients with the CC genotype and non-small cell lung cancer may have decreased overall survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the AA or AC genotype. No significant association between this SNP and overall survival time was seen when considering patients taking gemcitabine only. Other genetic and clinical factors may also influence overall survival time."
1448636930,A,A,Patients with the AA genotype and breast cancer who are treated with everolimus may have a decreased likelihood of leukopenia and an increased likelihood of hyperglycemia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or hyperglycemia in patients with breast cancer who are treated with everolimus.
1448636930,A,G,"Patients with the AG genotype and breast cancer who are treated with everolimus may have an increased likelihood of leukopenia as compared to patients with the AA genotype, and a decreased likelihood of leukopenia as compared to patients with the GG genotype. In addition, the AG genotype may have an increased likelihood of hyperglycemia as compared to patients with the AA genotype, and a decreased likelihood as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of hyperglycemia or leukopenia in patients with breast cancer who are treated with everolimus."
1448636930,G,G,Patients with the GG genotype and breast cancer who are treated with everolimus may have an increased likelihood of leukopenia and a decreased likelihood of hyperglycemia as compared to patients with the AG or AA genotype. Other clinical and genetic factors may also influence likelihood of hyperglycemia or leukopenia in patients with breast cancer who are treated with everolimus.
1451407348,C,C,"Patients with the rs6311 CC genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline."
1451407348,C,T,"Patients with the rs6311 CT genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline."
1451407348,T,T,"Patients with the rs6311 TT genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline."
1451407329,A,A,Patients with the rs6313 AA genotype and major depressive disorder may be more likely to develop sexual dysfunction and less likely to develop heart palpitations and when treated with citalopram as compared to patients with the AG or GG genotype. The current evidence base suggests that there is no association between the genotype and gastrointestinal toxicity. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.
1451407329,A,G,Patients with the rs6313 AG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with citalopram as compared to patients with the AA genotype. The current evidence base suggests that there is no association between the genotype and gastrointestinal toxicity. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.
1451407329,G,G,Patients with the rs6313 GG genotype and major depressive disorder may be less likely to develop sexual dysfunction and more likely to develop heart palpitations when treated with citalopram as compared to patients with the AA genotype. The current evidence base suggests that there is no association between the genotype and gastrointestinal toxicity. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.
1451407321,A,A,"Patients with the rs6313 AA genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sertraline."
1451407321,A,G,"Patients with the rs6313 AG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sertraline."
1451407321,G,G,"Patients with the rs6313 GG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sertraline."
1449003934,A,A,Patients with the AA genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003934,A,G,"Patients with the AG genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AA genotype, but a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations."
1449003934,G,G,Patients with the GG genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003956,A,A,"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AC or CC genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid."
1449003956,A,C,"Patients with the AC genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the AA genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid."
1449003956,C,C,"Patients with the CC genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the AA genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid."
1449003995,C,C,Patients with the CC genotype may have increased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the CT or TT genotypes. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.
1449003995,C,T,"Patients with the CT genotype may have increased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the TT genotype, but decreased binding affinity compared to the CC genotype. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients."
1449003995,T,T,Patients with the TT genotype may have decreased binding affinity of salbutamol to ADRB2 based on computational modeling studies as compared to the CT or CC genotypes. Other genetic or clinical factors may also influence the binding affinity of salbutamol to ADRB2 in patients.
1449165479,A,A,"Patients with the AA genotype and cancer may have decreased survival times when treated with cetuximab as compared to patients with the GG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the AA genotype had increased survival times compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence survival times in patients taking cetuximab."
1449165479,A,G,"Patients with the AG genotype and cancer may have decreased survival times when treated with cetuximab as compared to patients with the GG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the AG genotype had decreased survival times compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival times in patients taking cetuximab."
1449165479,G,G,"Patients with the GG genotype and cancer may have increased survival times when treated with cetuximab as compared to patients with the AA or AG genotype. However, a meta-analysis found no association between this variant and response to cetuximab while a large clinical study found that patients with the GG genotype had decreased survival times compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival times in patients taking cetuximab."
1449157773,A,A,"Patients with the rs118192168 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449157773,A,G,"Patients with the rs118192168 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449157773,G,G,"Patients with the rs118192168 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449752825,A,A,Patients with the AA genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752825,A,G,Patients with the AG genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752825,G,G,Patients with the GG genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1451407962,C,C,Patients with the rs702764 CC genotype may have an increased analgesic response to butorphanol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to butorphanol.
1451407962,C,T,Patients with the rs702764 CT genotype may have a decreased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.
1451407962,T,T,Patients with the rs702764 TT genotype may have a decreased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.
1450810236,C,C,Patients with the CC genotype may be at a decreased risk of developing heroin dependence or opioid dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810236,C,T,Patients with the CT genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810236,T,T,Patients with the TT genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450931416,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931416,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931416,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451407981,A,A,Patients with the rs6269 AA genotype may have a decreased analgesic response to morphine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to morphine.
1451407981,A,G,Patients with the rs6269 AG genotype may have an increased analgesic response to morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to morphine.
1451407981,G,G,Patients with the rs6269 GG genotype may have an increased analgesic response to morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to morphine.
1451408000,A,A,"The current evidence base suggests that there is no significant association between the rs6269 AA genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements."
1451408000,A,G,"The current evidence base suggests that there is no significant association between the rs6269 AG genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements."
1451408000,G,G,"The current evidence base suggests that there is no significant association between the rs6269 GG genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements."
1449716056,A,A,Patients with the AA genotype may require an increased dose of opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's opioids dose requirements.
1449716056,A,G,"Patients with the AG genotype may require an increased dose of opioids as compared to patients with the GG genotype, but a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioids dose requirements."
1449716056,G,G,Patients with the GG genotype may require a decreased dose of opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's opioids dose requirements.
1449716178,A,A,"Patients with the rs9397685 AA genotype may experience an increased severity of nausea and vomiting as a result of taking fentanyl as compared to patients with the AG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the severity of nausea and vomiting as a result of taking fentanyl."
1449716178,A,G,"Patients with the rs9397685 AG genotype may experience a decreased severity of nausea and vomiting as a result of taking fentanyl as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the severity of nausea and vomiting as a result of taking fentanyl."
1449716178,G,G,"There is currently no information concerning the effect of the GG genotype on the severity of nausea and vomiting as a result of taking fentanyl. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the severity of nausea and vomiting as a result of taking fentanyl."
1450810351,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810351,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810351,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810381,A,A,Patients with the AA genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.
1450810381,A,G,Patients with the AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.
1450810381,G,G,Patients with the GG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.
1450811972,A,A,Patients with the AA genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811972,A,G,Patients with the AG genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811972,G,G,Patients with the GG genotype may have decreased subjective responses to alcohol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.
1449191379,C,C,"Patients with the CC genotype (do not have a copy of the CFTR P67L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence response to ivacaftor."
1449191379,C,T,"Patients with the CT genotype (one copy of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence response to ivacaftor."
1449191379,T,T,"Patients with the TT genotype (two copies of the CFTR P67L variant) and cystic fibrosis may respond to ivacaftor treatment.FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including P67L. Other genetic and clinical factors may also influence response to ivacaftor."
1449191385,C,C,"Patients with the CC genotype (do not carry a copy of the CFTR R74W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence response to ivacaftor."
1449191385,C,T,"Patients with the CT genotype (one copy of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence response to ivacaftor."
1449191385,T,T,"Patients with the TT genotype (two copies of the CFTR R74W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R74W. Other genetic and clinical factors may also influence response to ivacaftor."
1449191367,A,A,"Patients with the rs397508328 AA genotype (do not have a copy of the CFTR M1V variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191367,A,G,Patients with the rs397508328 AG genotype (one copy of the CFTR M1V variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191367,G,G,Patients with the rs397508328 GG genotype (two copies of the CFTR M1V variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191401,A,A,"Patients with the AA genotype (two copies of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence response to ivacaftor."
1449191401,A,C,"Patients with the AC genotype (one copy of the CFTR D110E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence response to ivacaftor."
1449191401,C,C,"Patients with the CC genotype (do not have a copy of the CFTR D110E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110E. Other genetic and clinical factors may also influence response to ivacaftor."
1449716207,A,A,Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716207,A,G,Patients with the AG genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716207,G,G,Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449191395,A,A,"Patients with the rs121908751 AA genotype (two copies of the CFTR E92K variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191395,A,G,"Patients with the rs121908751 AG genotype (one copy of the CFTR E92K variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191395,G,G,"Patients with the rs121908751 GG genotype (do not have a copy of the CFTR E92K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449270967,C,C,"Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270967,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270967,T,T,"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449750773,A,A,Patients with the AA genotype and colorectal cancer may have decreased overall survival time when treated with cetuximab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.
1449750773,A,C,Patients with the AC genotype and colorectal cancer may have decreased overall survival time when treated with cetuximab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.
1449750773,C,C,Patients with the CC genotype and colorectal cancer may have increased overall survival time when treated with cetuximab as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence overall survival time.
1449750832,C,C,Patients with the CC genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750832,C,T,Patients with the CT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750832,T,T,Patients with the TT genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750838,G,G,Patients with the GG genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750838,G,T,Patients with the GT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750843,C,C,Patients with the CC genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750843,C,T,Patients with the CT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449750843,T,T,Patients with the TT genotype and major depressive disorder may have a better response to treatment with duloxetine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence duloxetine response.
1449191407,C,C,"Patients with the CC genotype (two copies of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor."
1449191407,C,G,"Patients with the CG genotype (one copy of the CFTR D110H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor."
1449191407,G,G,"Patients with the GG genotype (do not have a copy of the CFTR D110H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor."
1449191413,C,C,"Patients with the CC genotype (do not have a copy of the CFTR R117C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor."
1449191413,C,T,"Patients with the CT genotype (one copy of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor."
1449191413,T,T,"Patients with the TT genotype (two copies of the CFTR R117C variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor."
1449191424,A,A,"Patients with the AA genotype (two copies of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence response to ivacaftor."
1449191424,A,G,"Patients with the AG genotype (one copy of the CFTR E193K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence response to ivacaftor."
1449191424,G,G,"Patients with the GG genotype (do not have a copy of the CFTR E193K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E193K. Other genetic and clinical factors may also influence response to ivacaftor."
1449191430,G,G,"Patients with the GG genotype (two copies of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor."
1449191430,G,T,"Patients with the GT genotype (one copy of the CFTR L206W variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor."
1449191430,T,T,"Patients with the TT genotype (do not have a copy of the CFTR L206W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor."
1449163934,A,A,"Patients with the AA genotype may have increased metabolism of caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking."
1449163934,A,C,"Patients with the AC genotype may have increased metabolism of caffeine as compared to patients with the CC genotype, or decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking."
1449163934,C,C,"Patients with the CC genotype may have decreased metabolism of caffeine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking."
1449169484,C,C,"Patients with the CC genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the TT genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy."
1449169484,C,T,"Patients with the CT genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the CC genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy."
1449169484,T,T,"Patients with the TT genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the CC genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy."
1449169546,G,G,The GG genotype is associated with an increased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.
1449169546,G,T,The GT genotype is associated with increased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the TT genotype and decreased risk as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.
1449169546,T,T,The TT genotype is associated with a decreased risk of hemorrhage in patients who are treated with clopidogrel as compared to patients with the GT or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered clopidogrel.
1449169601,C,C,Subjects with the CC genotype may have decreased exposure to atorvastatin as compared to subjects with the CT genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449169601,C,T,Subjects with the CT genotype may have increased exposure to atorvastatin as compared to subjects with the CC or TT genotypes. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449169601,T,T,Subjects with the TT genotype may have decreased exposure to atorvastatin as compared to subjects with the CT genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449169675,A,A,Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AC or CC genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449169675,A,C,Patients with the AC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449169675,C,C,Patients with the CC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1451408008,C,C,Patients with the rs4633 CC genotype may have a decreased analgesic response to butorphanol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to butorphanol.
1451408008,C,T,Patients with the rs4633 CT genotype may have an increased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.
1451408008,T,T,Patients with the rs4633 TT genotype may have an increased analgesic response to butorphanol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to butorphanol.
1449564720,A,A,Patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype who are treated with methotrexate may have a decreased risk of leukopenia and neutropenia as compared to the CC genotype. Other clinical and genetic factors may also influence risk of leukopenia and neutropenia in patients with precursor cell lymphoblastic leukemia-lymphoma who are treated with mercaptopurine and methotrexate.
1449564720,C,C,Patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype who are treated with methotrexate may have an increased risk of leukopenia and neutropenia as compared to the AA genotype. Other clinical and genetic factors may also influence risk of leukopenia and neutropenia in patients with precursor cell lymphoblastic leukemia-lymphoma who are treated with mercaptopurine and methotrexate.
1449566673,A,A,"Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer."
1449566673,A,C,"Patients with the AC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of thrombocytopenia, and decresed likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer."
1449566673,C,C,"Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer."
1449566679,A,A,Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have a decreased severity of thrombocytopenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.
1449566679,A,G,Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.
1449566679,G,G,Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.
1449566685,A,A,Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased likelihood of drug toxicity and increased likelihood of overall survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1449566685,A,G,Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1449566685,G,G,Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1450044803,C,C,Patients with central nervous system infections and the CC genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.
1450044803,C,T,Patients with central nervous system infections and the CT genotype may have a decreased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.
1450044803,T,T,Patients with central nervous system infections and the TT genotype may have an increased cerebrospinal fluid (CSF) to plasma ratio of ceftriaxone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect CSF to plasma ratios of ceftriaxone.
1450813484,A,A,"Patients with the AA genotype may have more severe nicotine dependence, as measured by mean pack years smoked, as compared to patients with the GG genotype. However, other measures showed no significant difference between genotype groups. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450813484,A,G,"Patients with the AG genotype may have more severe nicotine dependence, as measured by mean pack years smoked, as compared to patients with the GG genotype. However, other measures showed no significant difference between genotype groups. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450813484,G,G,"Patients with the GG genotype may have less severe nicotine dependence, as measured by mean pack years smoked, as compared to patients with the AA or AG genotypes. However, other measures showed no significant difference between genotype groups. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450928835,A,A,Female patients with the AA genotype may be more likely to respond to nicotine replacement therapy (NRT) for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to NRT.
1450928835,A,G,Female patients with the AG genotype may be more likely to respond to nicotine replacement therapy (NRT) for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to NRT.
1450928835,G,G,Female patients with the GG genotype may be less likely to respond to nicotine replacement therapy (NRT) for smoking cessation as compared to female patients with the AA or AG genotypes. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to NRT.
1450929015,A,A,Patients with the AA genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.
1450929015,A,G,Patients with the AG genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.
1450929015,G,G,Patients with the GG genotype may have a decreased analgesic response to opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.
1450929025,A,A,Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's opioid dose requirements.
1450929025,A,G,Patients with the AG genotype may have increased opioid dose requirements as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.
1450929025,G,G,Patients with the GG genotype may have increased opioid dose requirements as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.
1450929816,A,A,"Patients with the rs1045642 AA genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol."
1450929816,A,G,"Patients with the rs1045642 AG genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol."
1450929816,G,G,"Patients with the rs1045642 GG genotype may have a decreased analgesic response to tramadol as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol."
1451408023,A,A,Patients with the rs6269 AA genotype may have an increased analgesic response to butorphanol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to butorphanol.
1451408023,A,G,Patients with the rs6269 AG genotype may have an increased analgesic response to butorphanol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to butorphanol.
1451408023,G,G,Patients with the rs6269 GG genotype may have a decreased analgesic response to butorphanol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to butorphanol.
1450930536,C,C,Patients with hypertension and the CC genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.
1450930536,C,T,Patients with hypertension and the CT genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.
1450930536,T,T,Patients with hypertension and the TT genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.
1449005372,A,A,"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the AC or CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications."
1449005372,A,C,"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications."
1449005372,C,C,"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the CC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of LDL cholesterol concentrations as compared to patients with the AC or AA genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications."
1448821500,G,G,Patients with the GG genotype and HIV may have decreased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence AUC of tenofovir.
1448821500,G,T,Patients with the GT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.
1448821500,T,T,Patients with the TT genotype and HIV may have increased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence AUC of tenofovir.
1449164681,C,C,Patients with the CC genotype and Type 2 diabetes may have a better response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to OADs.
1449164681,C,T,Patients with the CT genotype and Type 2 diabetes may have a poorer response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to OADs.
1449164681,T,T,Patients with the TT genotype and Type 2 diabetes may have a poorer response when treated with oral antidiabetes drugs (OADs) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to OADs.
1449171114,C,C,"Patients with the CC genotype may have decreased concentrations of [S-(E)]-2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (S-EDDP), a metabolite of methadone, following administration of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect concentrations of S-EDDP."
1449171114,C,T,"Patients with the CT genotype may have increased concentrations of [S-(E)]-2-ethylidene-1,5-dimethyl-3,3-diphenyl-pyrrolidine (S-EDDP), a metabolite of methadone, following administration of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect concentrations of S-EDDP."
1449171114,T,T,There is currently no evidence to show the effect of the TT genotype on serum concentrations of S-EDDP.
1449171120,C,C,Patients with the CC genotype may have decreased serum concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.
1449171120,C,T,Patients with the CT genotype may have decreased serum concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.
1449171120,T,T,Patients with the TT genotype may have increased serum concentrations of methadone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.
1449192313,A,A,Patients with the rs121909047 AA genotype (two copies of the CFTR A561E variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.
1449192313,A,C,Patients with the rs121909047 AC genotype (one copy of the CFTR A561E variant) and cystic fibrosis may respond to lumacaftor treatment. Other genetic and clinical factors may also influence response to lumacaftor.
1449192313,C,C,"Patients with the rs121909047 CC genotype (do not have a copy of the CFTR A561E variant) and cystic fibrosis have an unknown response to lumacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to lumacaftor."
1449718300,C,C,"Patients with CC genotype and breast cancer may have a decreased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy."
1449718300,C,G,"Patients with CG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy."
1449718300,G,G,"Patients with GG genotype and breast cancer may have an increased risk of anemia and leukopenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the risk for anemia and leukopenia in patients taking FAC chemotherapy."
1450821128,C,C,"Patients with hypertension and the CC genotype may have a decreased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to spironolactone."
1450821128,C,G,"Patients with hypertension and the CG genotype may have an increased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to spironolactone."
1450821128,G,G,"Patients with hypertension and the GG genotype may have an increased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to spironolactone."
1450928486,C,C,"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the CT or TT genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928486,C,T,"Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928486,T,T,"Patients with schizophrenia and the TT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1451408961,C,C,Patients with the rs2230806 CC genotype may have an increased response to atorvastatin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to atorvastatin.
1451408961,C,T,Patients with the rs2230806 CT genotype may have a decreased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin.
1451408961,T,T,Patients with the rs2230806 TT genotype may have a decreased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin.
1451409020,C,C,Patients with the rs2230806 CC genotype may have an increased response to rosuvastatin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.
1451409020,C,T,Patients with the rs2230806 CT genotype may have a decreased response to rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to rosuvastatin.
1451409020,T,T,Patients with the rs2230806 TT genotype may have a decreased response to rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to rosuvastatin.
1451409026,C,C,Patients with the rs2230806 CC genotype may have an increased response to simvastatin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to simvastatin.
1451409026,C,T,Patients with the rs2230806 CT genotype may have a decreased response to simvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to simvastatin.
1451409026,T,T,Patients with the rs2230806 TT genotype may have a decreased response to simvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to simvastatin.
1448995134,G,G,Patients with the GG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.
1448995134,G,T,Patients with the TG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.
1448995134,T,T,Patients with the TT genotype may have increased plasma concentrations of dolutegravir as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence response to dolutegravir.
1449157530,A,A,Patients with the AA genotype who are administered allopurinol may have an decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1449157530,A,G,Patients with the AG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1449157530,G,G,Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1450820856,A,A,Patients with the AA genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.
1450820856,A,G,Patients with the AG genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.
1450820856,G,G,Patients with the GG genotype may have a decreased incidence of nausea following treatment with prochlorperazine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.
1450820863,C,C,Patients with the CC genotype may have a decreased incidence of nausea following treatment with prochlorperazine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.
1450820863,C,T,Patients with the CT genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.
1450820863,T,T,Patients with the TT genotype may have an increased incidence of nausea following treatment with prochlorperazine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.
1450820963,A,A,"Patients with the AA genotype may have a decreased severity of nicotine dependence, as indicated by a lower Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence."
1450820963,A,G,"Patients with the AG genotype may have an increased severity of nicotine dependence, as indicated by a higher Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence."
1450820963,G,G,"Patients with the GG genotype may have an increased severity of nicotine dependence, as indicated by a higher Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence."
1450821349,A,A,Patients with the AA genotype may have a decreased severity of heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect severity of heroin dependence in a patient.
1450821349,A,G,Patients with the AG genotype may have a decreased severity of heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect severity of heroin dependence in a patient.
1450821349,G,G,Patients with the GG genotype may have an increased severity of heroin dependence as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect severity of heroin dependence in a patient.
1449167289,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167289,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167289,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167300,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167300,C,G,Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167300,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167300,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167300,G,T,Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167300,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167317,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167317,A,T,Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167317,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167339,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167339,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167339,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167350,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167350,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167350,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167361,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167361,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167361,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167409,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167409,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167409,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167420,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167420,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167420,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167431,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167431,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167431,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167442,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167442,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167442,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449168364,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168364,C,G,Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168364,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168371,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168371,G,T,Patients with the GT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168371,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168378,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168378,C,T,Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168378,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168385,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168385,A,G,Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168385,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168392,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168392,A,G,Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168392,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168399,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168399,A,G,Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168399,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168405,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168405,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168405,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168412,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168412,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168412,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168419,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168419,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168419,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168426,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168426,A,C,Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168426,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168433,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168433,G,T,Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168433,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168440,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168440,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168440,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168447,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168447,C,G,Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168447,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1451409133,A,A,Patients with the rs708272 AA genotype may have a decreased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.
1451409133,A,G,Patients with the rs708272 AG genotype may have a decreased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.
1451409133,G,G,Patients with the rs708272 GG genotype may have an increased response to rosuvastatin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.
1451409141,A,A,Patients with the rs5882 AA genotype may have a decreased response to rosuvastatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.
1451409141,A,G,Patients with the rs5882 AG genotype may have an increased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rosuvastatin.
1451409141,G,G,Patients with the rs5882 GG genotype may have an increased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rosuvastatin.
1449004504,C,C,"Patients with nasopharyngeal cancer and the CC genotype may have an increased risk of anemia as compared to the CT and TT genotypes. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy."
1449004504,C,T,"Patients with nasopharyngeal cancer and the CT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy."
1449004504,T,T,"Patients with nasopharyngeal cancer and the TT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy."
1449156029,A,A,Patients with the AA genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.
1449156029,A,T,Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.
1449156029,T,T,Patients with the TT genotype may have 1) a decreased risk of nicotine dependence and 2) a decreased response to smoking cessation therapies as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.
1449156045,C,C,Patients with the CC genotype may have a decreased risk of developing nicotine dependence when smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1449156045,C,G,Patients with the CG genotype may have a decreased risk of developing nicotine dependence when smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1449156045,G,G,Patients with the GG genotype may have an increased risk of developing nicotine dependence when smoking as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence risk of nicotine dependence.
1450377187,C,C,Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377187,C,T,Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377187,T,T,Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450810255,A,A,Patients with the AA genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1450810255,A,C,Patients with the AC genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1450810255,C,C,Patients with the CC genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1450930470,A,A,"Patients with the AA genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
1450930470,A,G,"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
1450930470,G,G,"Patients with the GG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
1450934632,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934632,C,G,Patients with the CG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934632,C,T,"Patients with the CT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934632,G,G,Patients with the GG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934632,G,T,Patients with the GT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934632,T,T,"Patients with the TT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934693,A,A,"Patients with the AA genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934693,A,C,"Patients with the AC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934693,A,T,Patients with the AT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934693,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934693,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934693,T,T,Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934717,A,A,Patients with the AA genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934717,A,C,Patients with the AC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934717,A,T,Patients with the AT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934717,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934717,C,T,"Patients with the CT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934717,T,T,"Patients with the TT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1449155310,G,G,Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have shorter overall survival times when treated with sunitinib as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time.
1449155310,G,T,Patients with the GT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.
1449155310,T,T,Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.
1450807912,A,A,"Patients with the AA genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AG or GG genotypes. However, another study failed to find a significant association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence."
1450807912,A,G,"Patients with the AG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, another study failed to find a significant association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence."
1450807912,G,G,"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, another study failed to find a significant association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence."
1450812417,C,C,Patients with the rs2239050 CC genotype may have a decreased response to nimodipine as compared to patients with the CG genotype. Other genetic and clinical factors may also affect response to nimodipine.
1450812417,C,G,Patients with the rs2239050 CG genotype may have an increased response to nimodipine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to nimodipine.
1450812417,G,G,There is currently no available evidence regarding the association of the rs2239050 GG genotype and response to nimodipine.
1449270961,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270961,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270961,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1450934684,A,A,"Patients with the AA genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934684,A,C,Patients with the AC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934684,A,G,"Patients with the AG genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934684,C,C,Patients with the CC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934684,C,G,Patients with the CG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934684,G,G,"Patients with the GG genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450373854,C,C,Patients with the CC genotype may have an increased analgesic response to morphine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to morphine.
1450373854,C,T,"Patients with the CT genotype may have an increased analgesic response to morphine as compared to patients with the TT genotype, but a decreased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to morphine."
1450373854,T,T,Patients with the TT genotype may have a decreased analgesic response to morphine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to morphine.
1451409760,C,C,"There is currently no available evidence regarding the association between the rs12471326 CC genotype and concentrations of cotinine glucuronide. However, patients with the CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism."
1451409760,C,T,"Patients with the rs12471326 CT genotype may have increased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism."
1451409760,T,T,"Patients with the rs12471326 TT genotype may have decreased concentrations of cotinine glucuronide, a metabolite of nicotine, as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs12471326 and cotinine glucuronide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism."
1449168684,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168684,C,G,Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168684,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449171162,C,C,Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449171162,C,T,It is currently unclear how the CT genotype affects a patient's risk of developing heroin dependence.
1449171162,T,T,Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449271051,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271051,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271051,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1450928430,A,A,"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928430,A,G,"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928430,G,G,"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the AA or AG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928499,C,C,"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CT or TT genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928499,C,T,"Patients with schizophrenia and the CT genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928499,T,T,"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1449171168,A,A,Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449171168,A,C,Patients with the AC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449171168,C,C,Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451409780,G,G,Patients with the rs145014075 GG genotype may have decreased concentrations of nicotine as compared to patients with the GT genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.
1451409780,G,T,Patients with the rs145014075 GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations.
1451409780,T,T,"There is currently no available evidence regarding the association between the rs145014075 TT genotype and nicotine concentrations. However, patients with the GT genotype may have increased concentrations of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145014075 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine concentrations."
1450932674,A,A,"Patients with the rs1799971 AA genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more adverse events as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence."
1450932674,A,G,"Patients with the rs1799971 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report fewer adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence."
1450932674,G,G,"Patients with the rs1799971 GG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report fewer adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence."
1450928528,C,C,"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the CT or TT genotypes. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928528,C,T,"Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928528,T,T,"Patients with schizophrenia and the TT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance in one study following correction for multiple testing, while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450933017,A,A,"Patients with beta-thalassemia and the AA genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450933017,A,G,"Patients with beta-thalassemia and the AG genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450933017,G,G,"Patients with beta-thalassemia and the GG genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1449713738,G,G,Patients with ankylosing spondylitis and the GG genotype may have an increased response to etanercept as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's response to etanercept.
1449713738,G,T,Patients with ankylosing spondylitis and the GT genotype may have a decreased response to etanercept as compared to patients with the GG or TT genotypes. Other genetic and clinical factors may also affect a patient's response to etanercept.
1449713738,T,T,Patients with ankylosing spondylitis and the TT genotype may have an increased response to etanercept as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's response to etanercept.
1449717941,G,G,Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1449717941,G,T,Patients with the GT genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1449717941,T,T,Patients with the TT genotype may have a shorter recovery time from general anesthesia as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1450813869,C,C,Patients with the CC genotype may have decreased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1450813869,C,T,Patients with the CT genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1450813869,T,T,Patients with the TT genotype may have increased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1449732040,A,A,Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.
1449732040,A,G,Patients with the AG genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.
1449732040,G,G,Patients with the GG genotype may have increased exposure to risperidone as compared to patients with the AA or AG genotypes. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.
1450813881,C,C,Patients with the CC genotype may be less likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect response to varenicline.
1450813881,C,T,Patients with the CT genotype may be more likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CC genotype. Other genetic or clinical factors may also affect response to varenicline.
1450813881,T,T,Patients with the TT genotype may be more likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CC genotype. Other genetic or clinical factors may also affect response to varenicline.
1450813994,A,A,Patients with the AA genotype may have a decreased response to modafinil in the treatment of methamphetamine dependence as compared to patients with the GG genotype. This association was only observed in Latino subjects. Other genetic and clinical factors may also affect a patient's response to modafinil.
1450813994,A,G,Patients with the AG genotype may have a decreased response to modafinil in the treatment of methamphetamine dependence as compared to patients with the GG genotype. This association was only observed in Latino subjects. Other genetic and clinical factors may also affect a patient's response to modafinil.
1450813994,G,G,Patients with the GG genotype may have an increased response to modafinil in the treatment of methamphetamine dependence as compared to patients with the AA or AG genotypes. This association was only observed in Latino subjects. Other genetic and clinical factors may also affect a patient's response to modafinil.
1449565066,C,C,"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have shorter overall survival as compared to patients with the CT and TT genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine."
1449565066,C,T,"Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine."
1449565066,T,T,"Patients with the TT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine."
1448820584,C,C,"Patients undergoing liver transplantation with the CC genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus."
1448820584,C,T,"Patients undergoing liver transplantation with the CT genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus."
1448820584,T,T,"Patients undergoing liver transplantation with the TT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus."
1448820590,C,C,"Patients undergoing liver transplantation whose donor livers have the CC genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus."
1448820590,C,T,"Patients undergoing liver transplantation whose donor livers have the CT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus."
1448820590,T,T,"Patients undergoing liver transplantation whose donor livers have the TT genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus."
1449157883,A,A,Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotype. They also may have a shorter time between waking in the morning and the first cigarette as compared to the AG or GG genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.
1449157883,A,G,Patients with the AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. They also may have a longer time between waking in the morning and the first cigarette as compared to the AA genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.
1449157883,G,G,Patients with the GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. They also may have a longer time between waking in the morning and the first cigarette as compared to the AA genotype. Other genetic and clinical factors may also influence nicotine metabolism and smoking habits.
1449296290,A,A,Patients with the AA genotype may be more likely to experience insomnia as a result of consuming caffeine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.
1449296290,A,C,Patients with the AC genotype may be less likely to experience insomnia as a result of consuming caffeine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.
1449296290,C,C,Patients with the CC genotype may be less likely to experience insomnia as a result of consuming caffeine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.
1449296320,C,C,Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to metformin.
1449296320,C,T,Patients with the CT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to metformin.
1449296320,T,T,Patients with the TT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to metformin.
1449296326,C,C,Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
1449296326,C,T,Patients with the CT genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
1449296326,T,T,Patients with the TT genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to metformin.
1449296332,C,C,Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to metformin.
1449296332,C,G,Patients with the CG genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to metformin.
1449296332,G,G,Patients with the GG genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to metformin.
1449565060,G,G,"Patients with the GG genotype and non-small cell lung cancer may have shorter progression-free survival, and decreased severity of thrombocytopenia, as compared to patients with the GT and TT genotypes. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine."
1449565060,G,T,"Patients with the GT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine."
1449565060,T,T,"Patients with the TT genotype and non-small cell lung cancer may have longer progression-free survival, and increased severity of thrombocytopenia, as compared to patients with the GG genotype. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine."
1449565184,A,A,The AA genotype is associated with decreased concentrations of UGT1A1 and decreased glucoronidation of oxazepam as compared to the AG and GG genotypes. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.
1449565184,A,G,"The AG genotype is associated with decreased concentrations of UGT1A1 and decreased glucoronidation of oxazepam as compared to the GG genotypes, and increased concentrations of UGT1A1 and increased glucoronidation of oxazepam. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam."
1449565184,G,G,The GG genotype is associated with increased concentrations of UGT1A1 and increased glucoronidation of oxazepam as compared to the AA and AG genotypes. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.
1450824479,C,C,Patients with the CC genotype may have increased levels of alcohol consumption as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.
1450824479,C,T,Patients with the CT genotype may have increased levels of alcohol consumption as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.
1450824479,T,T,Patients with the TT genotype may have decreased levels of alcohol consumption as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.
1449563861,A,A,Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1449563861,A,G,Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1449563861,G,G,"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with desflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449004841,C,C,"Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 CC genotype may have a decreased response to methotrexate as compared to patients with the CT and TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate."
1449004841,C,T,"Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 CT genotype may have an increased response to methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate."
1449004841,T,T,"Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 TT genotype may have an increased response to methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate."
1449165169,A,A,"The current evidence base suggests that there is no significant association between the rs2273697 AA genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1449165169,A,G,"The current evidence base suggests that there is no significant association between the rs2273697 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1449165169,G,G,"The current evidence base suggests that there is no significant association between the rs2273697 GG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1449165158,A,A,"The current evidence base suggests that there is no significant association between the rs1128503 AA genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1449165158,A,G,"The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1449165158,G,G,"The current evidence base suggests that there is no significant association between the rs1128503 GG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1450810228,C,C,Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810228,C,T,Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810228,T,T,Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810283,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810283,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810283,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810289,A,A,Patients with the AA genotype may be at an increased risk of developing cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1450810289,A,G,Patients with the AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1450810289,G,G,Patients with the GG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1450810369,A,A,Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810369,A,G,Patients with the AG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810369,G,G,Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810393,C,C,Patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.
1450810393,C,T,Patients with the CT genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.
1450810393,T,T,Patients with the TT genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.
1450934647,A,A,"Patients with the AA genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934647,A,C,"Patients with the AC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934647,A,T,Patients with the AT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934647,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934647,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934647,T,T,Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1449715596,A,A,Patients with the AA genotype may have an increased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715596,A,C,Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715596,C,C,Patients with the CC genotype may have a decreased response to fentanyl as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449715626,A,A,"Patients with the rs1799971 AA genotype may experience an increased severity of respiratory depression when treated with alfentanil as compared to patients with the GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of respiratory depression when treated with alfentanil."
1449715626,A,G,"Patients with the rs1799971 AG genotype may experience an increased severity of respiratory depression when treated with alfentanil as compared to patients with the GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of respiratory depression when treated with alfentanil."
1449715626,G,G,"Patients with the rs1799971 GG genotype may experience a decreased severity of respiratory depression when treated with alfentanil as compared to patients with the AA or AG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of respiratory depression when treated with alfentanil."
1451410280,C,C,Patients with the rs2024627 CC genotype and cancer may have a decreased likelihood of progression-free survival when treated with everolimus as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.
1451410280,C,T,Patients with the rs2024627 CT genotype and cancer may have an increased likelihood of progression-free survival when treated with everolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.
1451410280,T,T,Patients with the rs2024627 TT genotype and cancer may have an increased likelihood of progression-free survival when treated with everolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.
1450373489,C,C,"Patients with the CC genotype may have a decreased response to methadone in the treatment of heroin dependence as compared to patients with the CT or TT genotypes. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence."
1450373489,C,T,"Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence."
1450373489,T,T,"Patients with the TT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence."
1449003976,A,A,"Patients with the AA genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid."
1449003976,A,G,"Patients with the AG genotype who are taking isoniazid may have decreased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid."
1449003976,G,G,"Patients with the GG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid."
1449161127,A,A,Patients with the AA genotype may have an increased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.
1449161127,A,G,Patients with the AG genotype may have a decreased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.
1449161127,G,G,Patients with the GG genotype may have a decreased risk of experiencing a hypersensitivity reaction as a result of treatment with NSAIDs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patients risk of experiencing NSAID hypersensitivity.
1449161156,G,G,"Patients with the GG genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or GT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics."
1449161156,G,T,Patients with the GT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1449161156,T,T,Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1449161162,C,C,"Patients with the CC genotype may have a decreased, but not absent, risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence response to antipyretic analgesics."
1449161162,C,T,Patients with the CT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1449161162,T,T,Patients with the TT genotype may have an increased risk for antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antipyretic analgesics.
1450374101,A,A,Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374101,A,C,Patients with the AC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374101,C,C,Patients with the CC genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450375059,C,C,"Patients with testicular cancer and the CC genotype may have a decreased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375059,C,T,"Patients with testicular cancer and the CT genotype may have a decreased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375059,T,T,"Patients with testicular cancer and the TT genotype may have an increased risk of developing anemia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of anemia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375734,A,A,Patients with the AA genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375734,A,G,Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375734,G,G,Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450931447,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931447,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931447,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931822,A,A,"Patients with the rs1799971 AA genotype may be less likely to experience somnolence following fentanyl administration as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of fentanyl-induced somnolence."
1450931822,A,G,"Patients with the rs1799971 AG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of fentanyl-induced somnolence."
1450931822,G,G,"Patients with the rs1799971 GG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of fentanyl-induced somnolence."
1450932389,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450932389,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450932389,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450932703,C,C,Patients with the CC genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.
1450932703,C,T,Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.
1450932703,T,T,Patients with the TT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience adverse events as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.
1450932995,C,C,"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450932995,C,T,"Patients with beta-thalassemia and the CT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450932995,T,T,"Patients with beta-thalassemia and the TT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450375710,C,C,Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375710,C,T,Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375710,T,T,Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450813988,C,C,Patients with the CC genotype may be more likely to respond to treatment for methamphetamine dependence as compared to patients with the CT or TT genotypes. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.
1450813988,C,T,Patients with the CT genotype may be less likely to respond to treatment for methamphetamine dependence as compared to patients with the CC genotype. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.
1450813988,T,T,Patients with the TT genotype may be less likely to respond to treatment for methamphetamine dependence as compared to patients with the CC genotype. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.
1450929031,C,C,Patients with the CC genotype may have an increased analgesic response to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to opioids.
1450929031,C,T,Patients with the CT genotype may have an increased analgesic response to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to opioids.
1450929031,T,T,Patients with the TT genotype may have a decreased analgesic response to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to opioids.
1450934049,A,A,Patients with the AA genotype may be less likely to require a dose reduction of imatinib due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.
1450934049,A,C,Patients with the AC genotype may be less likely to require a dose reduction of imatinib due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.
1450934049,C,C,Patients with the CC genotype may be more likely to require a dose reduction of imatinib due to toxicity as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.
1451412140,C,C,"Patients with the rs3219489 CC genotype and oral squamous cell carcinoma may have an increased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy."
1451412140,C,G,"Patients with the rs3219489 CG genotype and oral squamous cell carcinoma may have a decreased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy."
1451412140,G,G,"Patients with the rs3219489 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy."
1449566697,A,A,Patients with the AA genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence overall survival in patients who are treated with platinum compounds.
1449566697,A,C,Patients with the AC genotype and non-small cell lung cancer may have decreased likelihood of overall survival in as compared to patients with the AA genotype. Other clinical and genetic factors may also influence overall survival in patients who are treated with platinum compounds.
1449566697,C,C,Patients with the CC genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.
1449753229,A,A,Patients with the AA genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1449753229,A,G,Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1450042856,A,A,Patients with the AA genotype may have decreased exposure to atazanavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.
1450042856,A,C,Patients with the AC genotype may have decreased exposure to atazanavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.
1450042856,C,C,Patients with the CC genotype may have increased exposure to atazanavir as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.
1450934175,A,A,Patients with the AA genotype may have a decreased response to flecainide as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to flecainide.
1450934175,A,T,Patients with the AT genotype may have an increased response to flecainide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.
1450934175,T,T,Patients with the TT genotype may have an increased response to flecainide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.
1450934494,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934494,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934494,T,T,Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934533,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934533,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934533,T,T,Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1449718271,A,A,"Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy."
1449718271,A,G,"Patients with AG genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy."
1449718271,G,G,"Patients with GG genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy."
1449718277,A,A,"Patients with AA genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy."
1449718277,A,G,"Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy."
1449718277,G,G,"Patients with GG genotype and breast cancer may have an increased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy."
1449718283,C,C,"Patients with CC genotype and breast cancer may have a decreased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy."
1449718283,C,T,"Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy."
1449718283,T,T,"Patients with TT genotype and breast cancer may have an increased risk of nausea and neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy."
1449718289,A,A,"Patients with AA genotype and breast cancer may have an increased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy."
1449718289,A,G,"Patients with AG genotype and breast cancer may have an increased risk of nausea as compared to the GG genotype, and a decreased risk of vomiting as compared to the AA genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy."
1449718289,G,G,"Patients with GG genotype and breast cancer may have a decreased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy."
1449718311,A,A,"Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy."
1449718311,A,C,"Patients with AC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy."
1449718311,C,C,"Patients with CC genotype and breast cancer may have a decreased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy."
1449718317,A,A,"Patients with AA genotype and breast cancer may have a decreased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy."
1449718317,A,G,"Patients with AG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy."
1449718317,G,G,"Patients with GG genotype and breast cancer may have an increased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy."
1449718323,C,C,"Patients with CC genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy."
1449718323,C,T,"Patients with CT genotype and breast cancer may have a decreased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy."
1449718323,T,T,"Patients with TT genotype and breast cancer may have an increased risk of vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also affect the risk for vomiting in patients taking FAC chemotherapy."
1449718331,C,C,"Patients with the CC genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy."
1449718331,C,T,"Patients with the CT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy."
1449718331,T,T,"Patients with the TT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy."
1449718337,A,A,"Patients with the AA genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy."
1449718337,A,G,"Patients with the AG genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy."
1449718337,G,G,"Patients with the GG genotype and breast cancer may have a decreased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy."
1449718343,A,A,"Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy."
1449718343,A,G,"Patients with the AG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy."
1449718343,G,G,"Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy."
1450374095,A,A,Patients with the AA genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374095,A,G,Patients with the AG genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374095,G,G,Patients with the GG genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374917,A,A,Patients with the AA genotype and attention deficit disorder with hyperactivity may have an increased risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1450374917,A,C,Patients with the AC genotype and attention deficit disorder with hyperactivity may have an increased risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1450374917,C,C,"Patients with the CC genotype and attention deficit disorder with hyperactivity may have a decreased, but not absent, risk for side effects (presence or absence of the 17 symptoms listed on the Side Effects Rating Scale developed by Barkley) when treated with methylphenidate as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate."
1450375041,A,A,"Patients with testicular cancer and the AA genotype may have a decreased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide."
1450375041,A,G,"Patients with testicular cancer and the AG genotype may have a decreased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide."
1450375041,G,G,"Patients with testicular cancer and the GG genotype may have an increased risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of infection or nausea as a result of treatment with bleomycin, cisplatin and etoposide."
1450375080,A,A,"Patients with testicular cancer and the AA genotype may have an increased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375080,A,G,"Patients with testicular cancer and the AG genotype may have a decreased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375080,G,G,"Patients with testicular cancer and the GG genotype may have a decreased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375746,A,A,Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450375746,A,G,Patients with the AG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450375746,G,G,Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450376139,A,A,Patients with the AA genotype may require a decreased dose of morphine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450376139,A,G,Patients with the AG genotype may require a decreased dose of morphine as compared to patients with the GG genotype but an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1450376139,G,G,Patients with the GG genotype may require an increased dose of morphine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.
1451411080,A,A,"Patients with the rs1051792 AA genotype and rheumatoid arthritis may have a decreased response to TNF inhibitors as compared to patients with the AG genotype, but an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to TNF inhibitors."
1451411080,A,G,Patients with the rs1051792 AG genotype and rheumatoid arthritis may have an increased response to TNF inhibitors as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also influence response to TNF inhibitors.
1451411080,G,G,Patients with the rs1051792 GG genotype and rheumatoid arthritis may have a decreased response to TNF inhibitors as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to TNF inhibitors.
1451412069,A,A,"Patients with the rs1799782 AA genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy."
1451412069,A,G,"Patients with the rs1799782 AG genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy."
1451412069,G,G,"Patients with the rs1799782 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy."
1450934209,A,A,Patients with the AA genotype may have an increased response to flecainide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.
1450934209,A,G,Patients with the AG genotype may have an increased response to flecainide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to flecainide.
1450934209,G,G,Patients with the GG genotype may have a decreased response to flecainide as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to flecainide.
1450934539,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934539,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934539,T,T,Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934641,A,A,"Patients with the AA genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934641,A,G,Patients with the AG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934641,G,G,Patients with the GG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1451412100,G,G,"Patients with the rs1760944 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy."
1451412100,G,T,"Patients with the rs1760944 GT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy."
1451412100,T,T,"Patients with the rs1760944 TT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy."
1451411220,A,A,Patients with the rs2253201 AA genotype may be at a decreased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.
1451411220,A,G,Patients with the rs2253201 AG genotype may be at an increased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.
1451411220,G,G,Patients with the rs2253201 GG genotype may be at an increased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.
1449576610,A,A,Patients with the AA genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of experiencing rhabdomyolysis as compared to the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.
1449576610,A,G,Patients with the AG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of experiencing rhabdomyolysis as compared to the GG genotypes and a decreased likelihood as compared to the AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.
1449576610,G,G,Patients with the GG genotype and cardiovascular diseases who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of experiencing rhabdomyolysis as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients taking statins.
1449576616,G,G,Patients with cardiovascular disease and the GG genotype who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the GT or TT genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.
1449576616,G,T,Patients with cardiovascular disease and the GT genotype who are taking statins (hmg CoA reductase inhibitors) may have an increased likelihood of rhabdomyolysis as compared to patients with the TT genotype and a decreased likelihood as compared to the GG genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.
1449576616,T,T,Patients with cardiovascular disease and the TT genotype who are taking statins (hmg CoA reductase inhibitors) may have a decreased likelihood of rhabdomyolysis as compared to patients with the GT or GG genotype. Other clinical and genetic factors may also influence likelihood of rhabdomyolysis in patients with cardiovascular disease who are taking statins.
1449717935,A,A,Patients with the AA genotype may have a longer recovery time from general anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1449717935,A,G,Patients with the AG genotype may have a longer recovery time from general anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1449717935,G,G,Patients with the GG genotype may have a shorter recovery time from general anesthesia as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.
1451413082,G,G,Patients with the rs10494366 GG genotype and type 2 diabetes may have a decreased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.
1451413082,G,T,Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.
1451413082,T,T,Patients with the rs10494366 TT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.
1449747595,C,C,"Patients with the rs193922768 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449747595,C,T,"Patients with the rs193922768 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449747595,T,T,"Patients with the rs193922768 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449747617,C,C,"Patients with the rs193922762 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449747617,C,T,"Patients with the rs193922762 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449747617,T,T,"Patients with the rs193922762 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449747643,C,C,"Patients with the rs193922748 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449747643,C,T,"Patients with the rs193922748 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449747643,T,T,"Patients with the rs193922748 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451411286,C,C,Patients with the rs3781727 CC genotype may have decreased exposure to voriconazole as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.
1451411286,C,T,Patients with the rs3781727 CT genotype may have decreased exposure to voriconazole as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.
1451411286,T,T,Patients with the rs3781727 TT genotype may have increased exposure to voriconazole as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.
1450373514,A,A,"Postoperative patients with the AA genotype may have lower morphine requirements as compared to patients with the AG or GG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements."
1450373514,A,G,"Postoperative patients with the AG genotype may have lower morphine requirements as compared to patients with the GG genotype, but higher morphine requirements as compared to patients with the AA genotype. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements."
1450373514,G,G,"Postoperative patients with the GG genotype may have higher morphine requirements as compared to patients with the AA or AG genotypes. However, there was an interaction between this variant and ethnicity and this association was only seen in patients of Malay ethnicity, while the opposite association was seen in patients of Chinese or Indian ethnicity (see clinical annotation 1450373520). Other genetic and clinical factors may also affect a patient's morphine requirements."
1450373583,C,C,Patients with the CC genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373583,C,T,Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373583,T,T,Patients with the TT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373745,A,A,Patients with pancreatic cancer and the AA genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373745,A,G,Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373745,G,G,Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1449170621,C,C,"Patients with the CC genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have shorter of progression-free survival as compared to patients with the CT genotype but only in a sub-group of patients with ""standard risk cytogenetic profiles"". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma."
1449170621,C,T,"Patients with the CT genotype and multiple myeloma who are treated with lenalidomide and dexamethasone may have longer of progression-free survival as compared to patients with the CC genotype but only in a sub-group of patients with ""standard risk cytogenetic profiles"". The genotype was not significantly associated with hematologic toxicities or overall survival. Other clinical and genetic factors may also influence progression-free survival in patients multiple myeloma."
1449171921,A,A,Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for nausea and/or vomiting when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea and/or vomiting.
1449171921,A,C,Patients with the AC genotype who are undergoing kidney transplantation may have an increased risk for nausea and/or vomiting when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea and/or vomiting.
1449171921,C,C,Patients with the CC genotype who are undergoing kidney transplantation may have a decreased risk for nausea and/or vomiting when treated with tacrolimus as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for nausea and/or vomiting.
1449171933,C,C,"Patients with the CC genotype who are undergoing kidney transplantation may have decreased concentrations of tacrolimus, and require an increased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose."
1449171933,C,T,"Patients with the CT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose."
1449171933,T,T,"Patients with the TT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose."
1451413140,G,G,Patients with the rs10494366 GG genotype and type 2 diabetes may have a decreased risk of hypoglycemia when treated with glipizide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.
1451413140,G,T,Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glipizide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.
1451413140,T,T,Patients with the rs10494366 TT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glipizide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.
1449269612,G,G,Patients atrial fibrillation and the GG genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.
1449269612,G,T,Patients atrial fibrillation and the GT genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.
1449269612,T,T,Patients with atrial fibrillation and the TT genotype may have decreased clearance and increased concentrations of apixaban as compared to patients with the GG and GT genotypes. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.
1449269830,C,C,"Patients with atrial fibrillation and the CC genotype may have increased concentrations of apixaban as compared to patients with the TT genotype, although this is contraindicated by another study which found that the CC genotype was associated with increased clearance of apixaban as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation."
1449269830,C,T,"Patients with atrial fibrillation and the CT genotype may have increased concentrations of apixaban as compared to genotype TT, although this is contraindicated by another study which found that the CT and TT genotypes were associated with increased clearance of apixaban as compared to the CC genotype. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation."
1449269830,T,T,Patients with atrial fibrillation and the TT genotype may have decreased concentrations of apixaban as compared to patients with the CC and CT genotype and may be associated with increased clearance of apixaban as compared to the CC genotype. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.
1449269938,C,C,Patients with thromboembolism and the CC genotype may have an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.
1449269938,C,T,Patients with thromboembolism and the CT genotype may have an increased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the TT genotypes and decreased risk as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.
1449269938,T,T,Patients with thromboembolism and the TT genotype may have a decreased risk of hemorrhage when treated with acenocoumarol or warfarin as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with venous thromboembolism.
1449269960,C,C,Patients with the CC genotype may have decreased concentrations of Vitamin K as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence concentrations of Vitamin K.
1449269960,C,T,Patients with the CT genotype may have increased concentrations of Vitamin K as compared to patients with the CC. Other clinical and genetic factors may also influence concentrations of Vitamin K.
1449269960,T,T,Patients with the TT genotype may have increased concentrations of Vitamin K as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of Vitamin K.
1451413120,G,G,Patients with the rs10494366 GG genotype and type 2 diabetes may have a decreased risk of hypoglycemia when treated with glimepiride as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.
1451413120,G,T,Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glimepiride as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.
1451413120,T,T,Patients with the rs10494366 TT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glimepiride as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.
1451411555,C,C,Patients with the rs17004921 CC genotype and rheumatoid arthritis may have a decreased response to methotrextrate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to methotrexate.
1451411555,C,T,Patients with the rs17004921 CT genotype and rheumatoid arthritis may have an increased response to methotrextrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451411555,T,T,Patients with the rs17004921 TT genotype and rheumatoid arthritis may have an increased response to methotrextrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.
1449155302,C,C,Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have shorter progression-free survival time when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.
1449155302,C,T,Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have shorter progression-free survival time when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib response.
1449155302,T,T,Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have longer progression-free survival time when treated with sunitinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence sunitinib response.
1449271045,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271045,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271045,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271349,C,C,"Female patients with the CC genotype may have decreased levels of cocaine, ethanol or nicotine use, which may lead to a decreased risk of developing substance dependence, as compared to female patients with the TT genotype. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence."
1449271349,C,T,"Female patients with the CT genotype may have decreased levels of cocaine, ethanol or nicotine use, which may lead to a decreased risk of developing substance dependence, as compared to female patients with the TT genotype. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence."
1449271349,T,T,"Female patients with the TT genotype may have increased levels of cocaine, ethanol or nicotine use, which may lead to an increased risk of developing substance dependence, as compared to female patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's levels of drug use and risk of developing substance dependence."
1449748187,A,A,"Patients with the AA genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin."
1449748187,A,G,"Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin."
1449748187,G,G,"Patients with the GG genotype may have a decreased lipid-lowering response to simvastatin as compared to patients with the AA or AG genotypes. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin."
1450811273,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450811273,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450811273,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450812235,C,C,Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812235,C,T,Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812235,T,T,Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812748,C,C,"Patients with the CC genotype may show an improved performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CT or TT genotypes, who may not show a difference in performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine."
1450812748,C,T,"Patients with the CT genotype may show no change in performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CC genotype, who may show an improved performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine."
1450812748,T,T,"Patients with the TT genotype may show no change in performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CC genotype, who may show an improved performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine."
1449188526,A,A,Patients with the AA genotype may require a lower dose of acenocoumarol as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.
1449188526,A,G,Patients with the AG genotype may require a lower dose of acenocoumarol as compared to patients with the GG genotype and a higher dose as compared to the AA genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.
1449188526,G,G,Patients with the GG genotype may require a higher dose of acenocoumarol as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.
1449188545,C,C,Patients with the CC genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.
1449188545,C,T,Patients with the CT genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the TT genotypes and increased likelihood as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.
1449188545,T,T,Patients with the TT genotype may have an increased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.
1449188673,A,A,"Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188673,A,G,"Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188673,G,G,"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188701,C,C,"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188701,C,T,"Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188701,T,T,"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188707,C,C,"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188707,C,T,"Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188707,T,T,"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188713,C,C,"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188713,C,T,"Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188713,T,T,"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188719,G,G,"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188719,G,T,"Patients with the GT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188719,T,T,"Patients with the TT genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188725,A,A,"Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188725,A,G,"Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188725,G,G,"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188731,A,A,"Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188731,A,G,"Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188731,G,G,"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188743,A,A,"Patients with the AA genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188743,A,G,"Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188743,G,G,"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
655385392,A,A,"Patients with the rs9934438 AA genotype may require a lower dose of warfarin as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements."
655385392,A,G,"Patients with the rs9934438 AG genotype may require a lower dose of warfarin as compared to patients with the GG genotype, and a higher dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence warfarin dose requirements."
655385392,G,G,"Patients with the rs9934438 GG genotype may require higher dose of warfarin as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements."
655385462,A,A,"Patients with the rs1045642 AA genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased risk of drug toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
655385462,A,G,"Patients with the rs1045642 AG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as copmared to patients with the AA genotype but a decreased risk as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
655385462,G,G,"Patients with the rs1045642 GG genotype and rheumatoid arthritis who are treated with methotrexate may have an increased risk of drug toxicity as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
655385379,A,A,"Patients with the AA genotype and Hypercholesterolemia may have a decreased, but not absent, risk of statin-related myalgia as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia."
655385379,A,G,"Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia."
655385379,G,G,Patients with the GG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.
655385388,A,A,"Patients with the AA genotype may have a decreased, but not absent, risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction."
655385388,A,C,Patients with the AC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.
655385388,C,C,Patients with the CC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.
655385404,C,C,Patients with the CC genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.
655385404,C,T,Patients with the CT genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.
655385404,T,T,Patients with the TT genotype may have less effective lowering of systolic blood pressure with atenolol as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's likelihood of response.
655385418,A,A,Patients with the AA genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
655385418,A,G,Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
655385418,G,G,Patients with the GG genotype may have a decreased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.
655385426,C,C,"Patients with the CC genotype may have decreased but not non-existent, risk for statin-related myalgia as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins."
655385426,C,T,"Patients with the CT genotype may have increased risk for statin-related myalgia as compared to patients with the CC genotypes, or may have a decreased risk for statin-related myalgia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins."
655385426,T,T,Patients with the TT genotype may have increased risk for statin-related myalgia as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to statins.
655385466,A,A,Patients with the AA genotype and childhood acute lymphoblastic leukemia (ALL) may have reduced exposure to methotrexate and higher likelihood of minimal residual disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
655385466,A,G,Patients with the AG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
655385466,G,G,Patients with the GG genotype and childhood acute lymphoblastic leukemia (ALL) may have increased exposure to methotrexate and lower likelihood of minimal residual disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
655385471,C,C,Pediatric patients with the CC genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.
655385471,C,T,Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.
655385471,T,T,Pediatric patients with the TT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have lower methotrexate polyglutamate accumulation as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.
655385475,A,A,Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
655385475,A,G,Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype or may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
655385475,G,G,Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a higher drug toxicity score as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.
655385479,A,A,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have less improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.
655385479,A,G,Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.
655385479,G,G,Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have better improvement in disease symptoms at 3 months but not at 6 months of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate therapy.
655385483,A,A,"Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects."
655385483,A,G,Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
655385483,G,G,Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
655385491,A,A,"Patients with the AA genotype may have decreased, but not absent risk, for weight gain when treated with clozapine or olanzepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects."
655385491,A,G,Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
655385491,G,G,Patients with the GG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.
655385579,C,C,Patients with the CC genotype who are treated with antihypertensive drugs may have an increased risk for resistance as compared to patients with the CT or TT genotype.
655385579,C,T,"Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance."
655385579,T,T,"Patients with the TT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance."
655385604,A,A,Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
655385604,A,C,Patients with the AC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
655385604,C,C,Patients with the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
655385613,A,A,Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have an increased risk for more side effects as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.
655385613,A,G,"Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment."
655385613,G,G,"Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment."
655385701,A,A,"Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity."
655385701,A,G,"Patients with the GA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity."
655385701,G,G,"Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity."
655385705,G,G,Patients with the GG genotype with major depressive disorder may experience a greater response when treated with desipramine or fluoxetine compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to antidepressants.
655385705,G,T,Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.
655385705,T,T,Patients with the TT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.
655385749,C,C,The expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells.
655385749,C,G,"While the expression of a construct caring the C variant is associated with decreased clearance of midazolam in transfected cells, it is not clear what the influence of one G allele with the C allele is."
655385749,G,G,The expression of a construct caring the G variant is not associated with decreased clearance of midazolam in transfected cells.
655385763,C,C,"Patients with the CC genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse."
655385763,C,T,"Patients with the CT genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse."
655385763,T,T,"Patients with the TT genotype may have better response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's repsonse."
655385818,A,A,Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
655385818,A,G,There were too few patients with the AG genotype in this one small study for a conclusion to be drawn.
655385818,G,G,Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
655385856,A,A,"Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp."
655385856,A,T,"Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp."
655385856,C,A,"Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp."
655385856,C,C,Patients with the CC genotype may have decreased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.
655385856,C,T,"Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp."
655385856,T,T,"Patients with the TT, AT or AA genotype may have increased response to paclitaxel as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp."
655385969,A,A,"Cancer patients with the AA genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for drug toxicity as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity."
655385969,A,T,Cancer patients with the AT genotype who are treated with doxorubicin or idarubicin may have an increased risk for drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.
655385969,T,T,Cancer patients with the TT genotype who are treated with doxorubicin or idarubicin may have an increased risk for drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug toxicity.
655385973,A,A,Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
655385973,A,T,"Patients with the AT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the TT genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
655385973,T,T,"Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
655385977,A,A,Cancer patients with the AA genotype who are treated with doxorubicin or idarubicin may have an increased risk for cardiotoxicity as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
655385977,A,G,"Cancer patients with the AG genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
655385977,G,G,"Cancer patients with the GG genotype who are treated with doxorubcin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
655385981,G,G,"Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
655385981,G,T,"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
655385981,T,T,Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.
655385985,A,A,"Cancer patients with the AA genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
655385985,A,G,"Cancer patients with the AG genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
655385985,G,G,"Cancer patients with the GG genotype who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA or AG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity."
655385989,C,C,Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of having a child with a craniofacial abnormality.
655385989,C,T,Patients with the CT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
655385989,T,T,Patients with the TT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
655385993,A,A,"Patients with the AA genotype who are exposed to phenytoin during the first trimester of pregnancy may have a decreased, but not absent, risk for having a child with a craniofacial abnormality as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a person's risk for having a child with a craniofacial abnormality after phenytoin exposure."
655385993,A,G,Patients with the AG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385993,G,G,Patients with the GG genotype who are exposed to phenytoin during the first trimester of pregnancy may have an increased risk for having a child with a craniofacial abnormality as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385997,A,A,Patients with the AA genotype may have increased risk of toxicity with etoposide compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385997,A,G,Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385997,G,G,Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385814,A,A,"Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment."
655385814,A,G,"Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment."
655385814,G,G,"Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs may be less likely to be resistant to treatment as compared to patients with the AG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment."
655385422,A,A,"Patients with the AA genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking."
655385422,A,G,"Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking."
655385422,G,G,"Patients with the GG genotype who are treated with bupropion may be more likely to quit smoking as compared to patients with the AA or AG genotypes, however contradictory findings about abstinence exist. Other genetic and clinical factors may also influence a patient's chance for quitting smoking."
655385495,A,A,Patients with the AA genotype and schizophrenia may have increased prolactin when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rsiperidone related hyperprolactinemia.
655385495,A,G,Patients with the AG genotype and schizophrenia may have increased prolactin when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rsiperidone related hyperprolactinemia.
655385495,G,G,Patients with the GG genotype and schizophrenia may have decreased prolactin when treated with risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence rsiperidone related hyperprolactinemia.
655385674,C,C,Patients with two X-chromosomes and the CC genotype who are treated with clozapine may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.
655385674,C,G,Patients with two X-chromosomes and the CG genotype who are treated with clozapine may have an increased risk of developing metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.
655385674,G,G,"Patients with two X-chromosomes and the GG genotype who are treated with clozapine may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele."
655385400,C,C,"Patients with the rs2108622 CC genotype may have decreased warfarin dosage requirements as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements."
655385400,C,T,"Patients with the rs2108622 CT genotype may have increased warfarin dosage requirements as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements."
655385400,T,T,"Patients with the rs2108622 TT genotype may have increased warfarin dosage requirements as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dosage requirements."
655385384,C,C,Patients with the rs5443 CC genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a smaller reduction in risk of myocardial infarction compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence response to antihypertensive drugs.
655385384,C,T,Patients with the rs5443 CT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.
655385384,T,T,Patients with the rs5443 TT genotype and hypercholesterolemia who are treated with antihypertensive drugs and exposed to statins may have a greater reduction in risk of myocardial infarction compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antihypertensive drugs.
655386421,C,C,Patients with the rs1051266 CC genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.
655386421,C,T,Patients with the rs1051266 CT genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the TT genotype but a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate toxicity.
655386421,T,T,Patients with the rs1051266 TT genotype and rheumatoid arthritis may have decreased likelihood of toxicity when treated with methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.
655386436,G,G,"Patients with the rs1801131 GG genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment."
655386436,G,T,"Patients with the rs1801131 GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype or may have an increased risk of drug toxicity and adverse events as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment."
655386436,T,T,"Patients with the rs1801131 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment."
655386002,A,A,Patients with the AA genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655386002,A,G,Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655386002,G,G,Patients with the GG genotype may have increased risk of toxicity with etoposide compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655386028,A,A,Healthy individuals with the AA genotype who are treated with fexofenadine may have lower plasma drug levels as compared to healthy individuals with the AG or GG genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
655386028,A,G,Healthy individuals with the AG genotype who are treated with fexofenadine may have higher plasma drug levels as compared to healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
655386028,G,G,Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
655386070,A,A,"In patients with the AA genotype, the levels of clearance and exposure to doxorubicin may be similar to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin."
655386070,A,G,Patients with the AG genotype 1) may have decreased clearance of doxorubicin 2) increased exposure to doxorubicin compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.
655386070,G,G,Patients with the GG genotype 1) may have increased clearance of doxorubicin 2) decreased exposure to doxorubicin compared to patients with the AG genotype. Other genetic and clinical factors may also influence clearance and exposure to doxorubicin.
655386079,A,A,Patients with the AA genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity.
655386079,A,G,"Patients with the AG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk of cardiotoxicity as compared to patients with the GG genotype or may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity."
655386079,G,G,"Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk of cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of cardiotoxicity."
655386083,C,C,Patients with the CC genotype may have increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CT or TT. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.
655386083,C,T,Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.
655386083,T,T,Patients with the TT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.
655386088,C,C,Patients with the CC genotype may have 1) increased clearance of doxorubicin 2) decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.
655386088,C,T,Patients with the CT genotype may have 1) decreased clearance of doxorubicin 2) increased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with CC genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.
655386088,T,T,Patients with the TT genotype 1) may have similar levels of clearance of doxorubicin 2) may have similar exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence doxorubicin clearance and exposure.
655386093,A,A,Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386093,A,G,Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386093,G,G,Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386099,C,C,Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386099,C,T,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386099,T,T,Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386104,A,A,Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386104,A,G,Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386104,G,G,Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386109,C,C,Patients with the CC genotype may have a decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386109,C,T,Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386109,T,T,Patients with the TT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386114,A,A,Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386114,A,G,Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386114,G,G,Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386120,C,C,Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386120,C,T,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386120,T,T,Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386126,C,C,Patients with the CC genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386126,C,T,Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386126,T,T,Patients with the TT genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386131,C,C,Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386131,C,T,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386131,T,T,Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.
655386136,C,C,Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence treatment response.
655386136,C,T,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386136,T,T,Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386141,A,A,Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386141,A,G,Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386141,G,G,Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386146,A,A,Patients with the AA genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386146,A,G,Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386146,G,G,Patients with the GG genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386151,C,C,Patients with the CC genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386151,C,T,Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386151,T,T,Patients with the TT genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.
655386156,C,C,Patients with the CC genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386156,C,G,Patients with the CG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386156,G,G,Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386161,C,C,Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386161,C,T,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386161,T,T,Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.
655386166,C,C,Patients with the CC genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386166,C,T,Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.
655386166,T,T,Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.
655386171,A,A,Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386171,A,G,Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386171,G,G,Patients with the GG genotype may have a 1) decreased chance of response to treatment with docetaxel and thalidomide 2) decreased but not absent risk of toxicity as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386176,A,A,Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386176,A,G,Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386176,G,G,Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386181,C,C,Patients with the CC genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386181,C,G,Patients with the CG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386181,G,G,Patients with the GG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.
655386186,A,A,Patients with the AA genotype may have decreased but not absent risk of toxicity with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.
655386186,A,G,Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386186,G,G,Patients with the GG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.
655386191,A,A,Patients with the AA genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386191,A,G,Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.
655386191,G,G,Patients with the GG genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence treatment response.
655386212,C,C,"Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CC genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone."
655386212,C,T,"Patients with the CT genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CT genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone."
655386212,T,T,"Patients with the TT genotype and post-operative pain may be more likely to require rescue analgesic administration as compared to patients with the CT or CC genotype. Additionally, patients with the TT genotype who are addicted to heroin may require an increased dose of methadone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone."
655386585,C,C,"Patients with the rs1142345 CC genotype and cancer who are treated with cisplatin may have an increased risk for ototoxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386585,C,T,"Patients with the rs1142345 CT genotype and cancer who are treated with cisplatin may have an increased risk for ototoxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386585,T,T,"Patients with the rs1142345 TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to patients with the TC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386310,A,A,Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386310,A,C,Patients with the CA genotype may have increased clearance of docetaxel compared to patients with the AA genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386310,C,C,Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386315,C,C,Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386315,C,T,Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386315,T,T,Patients with the TT genotype may have decreased clearance of docetaxel compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386320,A,A,Patients with the AA genotype may have increased clearance of docetaxel compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386320,A,G,Patients with the AG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386320,G,G,Patients with the GG genotype may have decreased clearance of docetaxel compared to patients with the AA genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386324,C,C,Patients with the CC genotype may have decreased clearance of docetaxel compared to patients with TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386324,C,T,"Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance."
655386324,T,T,Patients with the TT genotype may have increased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.
655386447,A,A,Patients with the AA genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
655386447,A,C,Patients with the AC genotype and major depressive disorder who are treated with paroxetine may have an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
655386447,C,C,Patients with the CC genotype and major depressive disorder who are treated with paroxetine may have a decreased response as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
655386550,A,A,Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
655386550,A,G,Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
655386550,G,G,Has average risk for metabolic syndrome when treated with antipsychotics. Patients with the GG genotype treated with antipsychotics may have decreased risk for metabolic syndrome as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking antipsychotics based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
655386589,C,C,Children with the CC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
655386589,C,T,Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.
655386589,T,T,"Children with the TT genotype and cancer who are treated with cisplatin may have a lower, but not absent, risk for hearing loss as compared to children with the TC or CC genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386593,A,A,"Children with the AA genotype and cancer may have a lower, but not absent, risk for hearing loss with cisplatin treatment compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386593,A,T,"Children with the AT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386593,T,T,"Children with the TT genotype and cancer may have an increased risk for hearing loss with cisplatin treatment compared to children with the AA genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386597,C,C,"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386597,C,T,"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386597,T,T,"Children with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386601,C,C,"Children with the CC genotype and cancer who are treated with cisplatin may have an lower, but not absent, risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386601,C,T,"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386601,T,T,"Children with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment."
655386616,G,G,Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence survival.
655386616,G,T,Patients with the GT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence survival.
655386616,T,T,Patients with the TT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence survival.
655386665,A,A,Patients with the AA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.
655386665,A,C,Patients with the CA genotype and ovarian cancer who are treated with platinum compounds may have decreased survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.
655386665,C,C,Patients with the CC genotype and ovarian cancer who are treated with platinum compounds may have increased survival as compared to patients with the CA or AA genotype. Other genetic and clinical factors may also influence a patient's survival with platinum compounds.
655386801,A,A,Patients with the AA genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.
655386801,A,G,Patients with the AG genotype may have increased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.
655386801,G,G,Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.
655386830,A,A,Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.
655386830,A,G,"Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia."
655386830,G,G,Patients with the GG genotype and cancer who are treated with gemcitabine 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.
655386852,A,A,Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs2227631. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386852,A,G,Patients with the AG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386852,G,G,Patients with the GG genotype and genotype GG or AG at rs2227631 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386856,A,A,Patients with the AA genotype and major depressive disorder may be more likely to respond to citalopram and fluoxetine as compared to patients with the AG and GG genotype who also have genotype GG or AG at rs1799889. Patients with the AA genotype may still be at risk for non-response to antidepressants based on their genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386856,A,G,Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386856,G,G,Patients with the GG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.
655386869,C,C,Patients with the rs1544410 CC genotype who are treated with alendronate may have greater improvement in bone mineral density as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to alendronate.
655386869,C,T,Patients with the rs1544410 CT genotype who are treated with alendronate have an undocumented response compared to that of patients with the CC or the TT genotype.
655386869,T,T,Patients with the rs1544410 TT genotype who are treated with alendronate may have less improvement in bone mineral density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to alendronate.
655386873,A,A,Patients with the AA genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clodronate.
655386873,A,G,"Patients with the AG genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with genotype GG, or may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate."
655386873,G,G,Patients with the GG genotype may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.
655386888,A,A,"Patients with the AA genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates."
655386888,A,G,"Patients with the AG genotype and Paget's disease of bone who are treated with bisphosphonates may have a decreased, but not absent, risk of resistance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates."
655386888,G,G,Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.
655386244,A,A,"Patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment."
655386244,A,G,"While patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype, it is not clear what the association is between the AG genotype and risk of neravirapine hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment."
655386244,G,G,Patients with the rs1045642 GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.
655386612,G,G,"Patients with the GG genotype may have an increased risk for ototoxicity with cisplatin treatment as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin."
655386612,G,T,"Patients with the GT genotype may have an increased risk for ototoxicity with cisplatin treatment as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin."
655386612,T,T,"Patients with the TT genotype may have a decreased, but not non-existent, risk for ototoxicity with cisplatin treatment as compared to patients with the GG or GT genotypes. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin."
655386639,A,A,Patients with the AA genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
655386639,A,G,Patients with the AG genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
655386639,G,G,Patients with the GG genotype may have a decreased but not absent risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.
655386661,A,A,Patients with the AA genotype may have decreased risk for nephrotoxicity with cisplatin regimens as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.
655386661,A,C,Patients with the AC genotype may have increased risk for nephrotoxicity with cisplatin regimens as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.
655386661,C,C,Patients with the CC genotype may have increased risk for nephrotoxicity with cisplatin regimens as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence response to platinum-based regimens.
655386657,C,C,"Patients with cancer and the rs25487 CC genotype may have increased response when treated with platinum-based therapies as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens."
655386657,C,T,"Patients with cancer and the rs25487 CT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens."
655386657,T,T,"Patients with cancer and the rs25487 TT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens."
655387949,C,C,"Pediatric patients with the rs4149056 CC genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate."
655387949,C,T,"Pediatric patients with the rs4149056 CT genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate."
655387949,T,T,"Pediatric patients with the rs4149056 TT genotype and cancers may have increased clearance of methotrexate as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate."
655386969,C,C,"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
655386969,C,T,"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
655386969,T,T,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655386981,C,C,"Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
655386981,C,T,"Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate."
655386981,T,T,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.
655387942,C,C,"The current evidence base suggests that there is no significant association between the rs11045879 CC genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
655387942,C,T,"The current evidence base suggests that there is no significant association between the rs11045879 CT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
655387942,T,T,"The current evidence base suggests that there is no significant association between the rs11045879 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
655386990,A,A,"Patients with the AA genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have a decreased, but not absent, risk for oral mucositis as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis."
655386990,A,G,Patients with the AG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.
655386990,G,G,Patients with the GG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.
655386995,C,C,Premenopausal patients with the CC genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.
655386995,C,T,Premenopausal patients with the CT genotype and breast cancer who are treated with cyclophosphamide may have a longer period of time before chemotherapy-induced ovarian failure compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.
655386995,T,T,Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.
655386999,C,C,"Recipients of HLA-identical hematopoietic stem cell transplantation with the CC genotype and leukemia may have a decreased, but not absent, risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis."
655386999,C,T,Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.
655386999,T,T,Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.
655387004,G,G,"Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment."
655387004,G,T,"Patients with the GT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment."
655387004,T,T,"Patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have an increased risk of adverse drug reactions, in particular neutropenia/ leukopenia and gastrointestinal toxicity, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with cyclophosphamide treatment."
655387009,G,G,"Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival."
655387009,G,T,"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival."
655387009,T,T,"Patients with the TT genotype 1) may have shorter disease-free survival when treated with cyclophosphamide-based regimens 2) may have longer disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence disease-free survival."
655387014,C,C,Patients with the CC genotype and breast cancer who are not treated with adjuvant cyclophophamide-based regimens may have longer disease-free survival as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence disease-free survival.
655387014,C,T,Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.
655387014,T,T,Patients with the TT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.
655387023,A,A,"Patients with the AA genotype who are treated with cytarabine may have a decreased, but not absent, risk of toxicity as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity."
655387023,A,C,Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
655387023,C,C,Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.
655387027,C,C,Patients with the genotype CC who are treated with cytarabine may have reduced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
655387027,C,T,Patients with the genotype CT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
655387027,T,T,Patients with the genotype TT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
699639332,G,G,"The current evidence base suggests that there is no significant association between the rs1801131 GG genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
699639332,G,T,"The current evidence base suggests that there is no significant association between the rs1801131 GT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
699639332,T,T,"The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
655387221,C,C,"Patients with the CC genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response."
655387221,C,T,"Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response."
655387221,T,T,"Patients with the TT genotype may have smaller reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating poorer response to risperidone in Children with Autism, than TT homozygotes compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response."
655387229,A,A,"Patients with the AA genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response."
655387229,A,G,"Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response."
655387229,G,G,"Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patient's response."
655387237,C,C,Patients with the CC genotype may have poorer response to risperidone in children with autism as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
655387237,C,T,"Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
655387237,T,T,"Patients with the TT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
655387257,A,A,"Patients with autism spectrum disorder (ASD), or mood disorders and the AA genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone."
655387257,A,G,"Patients with autism spectrum disorder (ASD), or mood disorders and the AG genotype may have a decreased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the GG genotype; patients with the AG genotype may have an increased likelihood of weight gain as compared to patients with the AA genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone."
655387257,G,G,"Patients with autism spectrum disorder (ASD), or mood disorders and the GG genotype may have an increased likelihood of weight gain when taking antipsychotics, including risperidone as compared to patients with the AG or AA genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain when taking antipsychotics, including risperidone."
655387672,C,C,Patients with the CC genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655387672,C,T,Patients with the CT genotype may have increased risk of Hyperprolactinemia when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655387672,T,T,"Patients with the TT genotype may have decreased but not absent, risk of Hyperprolactinemia when treated with risperidone as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
655387688,A,A,Female patients with the AA genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.
655387688,A,G,Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.
655387688,G,G,"Female patients with the GG genotype and schizophrenia treated with nemonapride may have a decreased, but not absent, prolactin response to nemonapride compared to female patients with the AG and AA genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride."
655387767,C,C,"Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
655387767,C,T,"Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
655387767,T,T,"Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration."
655387821,A,A,Patients with the AA genotype and rheumatoid arthritis who are treated with methotrexate may be less likely to have improvement in disease activity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387821,A,G,Patients with the AG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387821,G,G,Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387825,C,C,Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to respond to methotrexate as compared to patients with the TC and TT genotype. Patients with the CC genotype may still be at risk for non-response to methotrexate based on their genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387825,C,T,Patients with the TC genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387825,T,T,Patients with the TT genotype and rheumatoid arthritis may be less likely to respond to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655387835,A,A,Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.
655387835,A,G,Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.
655387835,G,G,Patients with the GG genotype who undergo elective surgery with nitrous oxide anesthesia may have lower plasma total homocysteine concentrations as compared to patients with the GA of AA genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.
655387839,G,G,Patients with the GG genotype may have higher homocysteine levels after nitrous oxide anesthesia as compared to patients with the TG and TT genotype.Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.
655387839,G,T,Patients with the TG genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.
655387839,T,T,Patients with the TT genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.
655387876,A,A,Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655387876,A,G,Patients with the AG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655387876,G,G,Patients with the GG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655388022,A,A,Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.
655388022,A,G,Pediatric patients with the AG genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.
655388022,G,G,Pediatric patients with the GG genotype who are treated with prednisone and tacrolimus may have an increased risk of remaining on steroids 1 year after heart transplantation compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.
699639328,C,C,Patients with the CC genotype may have increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
699639328,C,G,Patients with the CG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
699639328,G,G,Patients with the GG genotype may have decreased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
699639336,G,G,"Patients with the GG genotype who are treated with methotrexate may have a decreased likelihood of methotrexate response as compared to patients with the GT and TT genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment."
699639336,G,T,"Patients with the GT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GG genotype, but decreased response as compared to patients with the TT genotype. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment."
699639336,T,T,"Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GT and GG genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment."
699639343,A,A,Patients with the AA genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment.
699639343,A,G,Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.
699639343,G,G,"Patients with the GG genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment."
699639347,C,C,"Patients with the CC genotype and hypertension who are treated with ACE inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors."
699639347,C,T,Patients with the genotype have not been studied.
699639347,T,T,Patients with the TT genotype and hypertension who are treated with ACE inhibitors may have an increased risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with ACE inhibitors.
699639351,C,C,Patients with the CC genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.
699639351,C,T,Patients with the CT genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. (please note that patients with this genotype were not studied directly). Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.
699639351,T,T,"Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors."
699642190,C,C,Patients with the CC genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
699642190,C,T,Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
699642190,T,T,Patients with the TT genotype who are treated with antidepressants may have less improvement in symptoms as compared to patients with the CT and CC genotype.
769143802,A,A,"Patients with the AA genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
769143802,A,G,"Patients with the AG genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
769143802,G,G,"Patients with the GG genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response."
769171387,A,A,Patients with the AA genotype and cancer who are treated with fluorouracil may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.
769171387,A,G,"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil."
769171387,G,G,"Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to flourouracil."
769171582,A,A,Patients with the AA genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.
769171582,A,G,Patients with the AG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.
769171582,G,G,Patients with the GG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have more improvement in symptoms as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.
655387245,A,A,Female patients with the AA genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.
655387245,A,G,Female patients with the AG genotype may have worse symptoms and a poorer response to risperidone as compared to patients with the GG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.
655387245,G,G,Female patients with the GG genotype may have better response to risperidone as compared to patients with the AA or AG genotype in autistic children. Other genetic and clinical factors may also influence a patient's response.
655387938,A,A,"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate and 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity."
655387938,A,G,Patients with the AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate and 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.
655387938,G,G,Patients with the GG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate and 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.
655386985,C,C,"Patients with the rs2236624 CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for an adverse event as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event."
655386985,C,T,"Patients with the rs2236624 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype or may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event."
655386985,T,T,"Patients with the rs2236624 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event."
655386961,C,C,"Patients with the rs2298383 CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate."
655386961,C,T,"Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate."
655386961,T,T,"Patients with the rs2298383 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate."
655386945,A,A,Patients with the AA genotype and asthma who are treated with short-acting beta2-antagonists may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.
655386945,A,T,"Patients with the AT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype, or may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists."
655386945,T,T,Patients with the TT genotype and asthma who are treated with short-acting beta2-antagonists may have a poorer response (decreased acute bronchodilation) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.
655387798,A,A,Subjects with the AA genotype may have decreased clearance or glucuronidation of oxazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the metabolism of oxazepam.
655387798,A,C,"Subjects with the AC genotype may have decreased clearance or glucuronidation of oxazepam as compared to subjects with the CC genotype, or increased clearance or glucuronidation as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of oxazepam."
655387798,C,C,Subjects with the CC genotype may have increased clearance or glucuronidation of oxazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of oxazepam.
637879869,A,A,Patients with the AA genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.
637879869,A,G,Patients with the AG genotype who are treated with methotrexate: 1) may have higher accumulation of active methotrexate metabolites 2) may have an increased risk for thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.
637879869,G,G,Patients with the GG genotype who are treated with methotrexate: 1) may have reduced accumulation of active methotrexate metabolites 2) may have a decreased risk for thrombocytopenia as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence methotrexate clearance and toxicity.
637879631,C,C,Patients with the CC genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.
637879631,C,T,Patients with the CT genotype and Major Depressive Disorder who are treated with fluoxetine may be less likely to respond compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response.
637879631,T,T,Patients with the TT genotype and Major Depressive Disorder who are treated with fluoxetine may be more likely to respond compared to patients with genotype CC or CT . Other genetic and clinical factors may also influence a patient's response.
613976848,C,C,Patients with the CC genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.
613976848,C,T,Patients with the CT genotype who are treated with carbamazepine may have an increased risk of Stevens-Johnson syndrome as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.
613976848,T,T,"Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment."
613977037,A,A,Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
613977037,A,G,Patients with the AG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
613977037,G,G,Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.
613977064,A,A,Patients with the AA genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
613977064,A,G,Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
613977064,G,G,"Patients with the GG genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence."
613979021,C,C,Patients with the CC genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.
613979021,C,G,Patients with the CG genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the GG genotype and a better response as compared to patients with the CC genotype. Patients with the CG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
613979021,G,G,Patients with the GG genotype and heart failure may have a better response to carvedilol treatment as compared to patients with the CC or CG genotype. Patients with the GG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.
613979403,C,C,Patients with the CC genotype and cluster headache who are treated with triptans may be less likely to have reduced pain or attack frequency as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.
613979403,C,T,Patients with the CT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sumatriptan.
613979403,T,T,"Patients with the TT genotype and cluster headache who are treated with triptans may be more likely to have reduced pain or attack frequency as compared to patients with the CC genotype. However, patients with this genotype were not studied directly. Other genetic and clinical factors may also influence a patient's response to sumatriptan."
618376538,A,A,"Patients with the AA genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence."
618376538,A,G,Patients with the AG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
618376538,G,G,Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
619523389,A,A,Patients with the AA genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
619523389,A,G,Patients with the AG genotype may have increased risk for Torsades de Point when treated with amiodarone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
619523389,G,G,Patients with the GG genotype may have decreased risk for Torsades de Point when treated with amiodarone as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking amiodarone based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
619523400,A,A,"Patients with the AA genotype with cancer who are treated with gemcitabine 1) may be more likely to experience neutropenia and 2) may have decreased progression-free survival (PFS) as compared to patients with the AG or GG genotype. However, evidence is very contradictory for this association: one study found a decreased risk for hematological toxicity in those with the AA genotype, one study found increased PFS in those with the AA genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine."
619523400,A,G,"Patients with the AG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, one study found no association with PFS for this variant. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine."
619523400,G,G,"Patients with the GG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, evidence is very contradictory for this association: one study found an increased risk for hematological toxicity in those with the GG genotype, one study found decreased PFS in those with the GG genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine."
619523414,A,A,"Patients with the AA genotype and depression who are treated with antidepressants 1) may be less likely to experience adverse effects 2) may be less likely to experience remission as compared to patients with the AG or GG genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects."
619523414,A,G,"Patients with the AG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects."
619523414,G,G,"Patients with the GG genotype and depression who are treated with antidepressants 1) may be more likely to experience adverse effects 2) may be more likely to experience remission as compared to patients with the AA genotype. However, not all studies found a significant association. Other genetic and clinical factors may also influence a patient's chance for remission and risk of side effects."
619523422,A,A,"Patients with the AA genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission."
619523422,A,C,"Patients with the AC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be more likely to experience remission as compared to patients with the CC genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission."
619523422,C,C,"Patients with the CC genotype and depression who are treated with amitryptiline, citalopram, paraxetine, or venlafaxine may be less likely to experience remission as compared to patients with the AC or AA genotype. However, another study did not find an association. Other genetic and clinical factors may also influence a patient's chance for remission."
637879590,C,C,Patients with the CC genotype may have decreased risk of side effects with amodiaquine as compared to patients with the CT or TT genotype. Patients with the CC genotype may still be at risk for adverse events when taking amodiaquine based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
637879590,C,T,Patients with the CT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
637879590,T,T,Patients with the TT genotype may have increased risk of side effects with amodiaquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
637879595,C,C,Patients with the CC genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
637879595,C,T,Patients with the CT genotype may have increased risk of side effects to amodiaquine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
637879595,T,T,Patients with the TT genotype may have decreased but not non-existent risk of side effects to amodiaquine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.
637879637,A,A,Patients with the AA genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AA genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.
637879637,A,C,Patients with the AC genotype may experience a greater response to azathiopurine treatment for SLE as compared to patients with the CC genotype. Patients with the AC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.
637879637,C,C,Patients with the CC genotype may experience less response to azathiopurine treatment for SLE as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's likelihood of response.
637879864,A,A,"Patients with the AA genotype who are treated with methotrexate may have a decreased, but not absent, risk of adverse events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment."
637879864,A,G,Patients with the AG genotype who are treated with methotrexate may have an increased risk of gastrointestinal adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
637879864,G,G,Patients with the GG genotype who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.
637879932,C,C,Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.
637879932,C,T,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.
637879932,T,T,Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.
637879937,C,C,Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.
637879937,C,T,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
637879937,T,T,Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.
637879942,C,C,Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.
637879942,C,T,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to a patient with genotype TT.
637879942,T,T,Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to a patient with genotype CC or CT .
637879947,C,C,Rheumatoid Arthritis patients with the genotype CC may be more likely to respond to TNF inhibitors compared with patients with genotypes TT or CT . Other genetic and clinical factors may also influence a patient's response.
637879947,C,T,Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC . Other genetic and clinical factors may also influence a patient's response.
637879947,T,T,Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.
637879952,A,A,Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879952,A,G,Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879952,G,G,Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.
637879957,A,A,Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.
637879957,A,C,Rheumatoid Arthritis patients with the AC genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.
637879957,C,C,Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AC. Other genetic and clinical factors may also influence a patient's response.
637879962,A,A,Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879962,A,G,Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879962,G,G,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.
637879967,A,A,Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879967,A,G,Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879967,G,G,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.
637879785,A,A,Patients with the AA genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.
637879785,A,G,Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.
637879785,G,G,Patients with the GG genotype may require a higher dose of warfarin than patients with the AA or AG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.
637879972,G,G,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with the genotypes GT or TT. Other genetic and clinical factors may also influence a patient's response.
637879972,G,T,Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879972,T,T,Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879977,C,C,Rheumatoid Arthritis patients with the genotype CC may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.
637879977,C,T,Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype TT . Other genetic and clinical factors may also influence a patient's response.
637879977,T,T,Rheumatoid Arthritis patients with the genotype TT may be more likely to respond to TNF inhibitors compared with patients with genotypes CC or CT . Other genetic and clinical factors may also influence a patient's response.
637879982,G,G,Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors as compared with patients with GT or TT genotypes . Other genetic and clinical factors may also influence a patient's response.
637879982,G,T,Rheumatoid Arthritis patients with genotype GT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879982,T,T,Rheumatoid Arthritis patients with genotype TT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879987,C,C,Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.
637879987,C,T,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.
637879987,T,T,Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CC or CT. Other genetic and clinical factors may also influence a patient's response.
637879992,A,A,Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879992,A,G,Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879992,G,G,Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.
637879997,A,A,Rheumatoid Arthritis patients with genotype AA may be less likely to respond to TNF inhibitors compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879997,A,G,Rheumatoid Arthritis patients with genotype AG may be less likely to respond to TNF inhibitors compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637879997,G,G,Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.
613976757,A,A,"Patients with the AA genotype may require a decreased dose of carbamazepine as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine."
613976757,A,G,"Patients with the AG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine."
613976757,G,G,"Patients with the GG genotype may require an increased dose of carbamazepine as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence dose of carbamazepine."
613978937,C,C,Patients with the CC genotype who are treated with phenytoin may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of phenytoin.
613978937,C,T,Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.
613978937,T,T,Patients with the TT genotype who are treated with phenytoin may require the highest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.
613979643,A,A,"Patients with the rs730012 AA genotype who are treated with aspirin may have a decreased, but not absent, risk of urticaria as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for urticaria."
613979643,A,C,Patients with the rs730012 AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria.
613979643,C,C,Patients with the rs730012 CC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria.
619523395,G,G,Patients with the GG genotype may have a decreased chance of response to bisphosphonate treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's chance of response.
619523395,G,T,Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.
619523395,T,T,"Patients with the TT genotype may have an increased chance of response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's chance of response."
637879879,A,A,"Patients with the AA genotype who are treated with warfarin may require a lower maintenance dose as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose."
637879879,A,G,"Patients with the AG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose."
637879879,G,G,"Patients with the GG genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's warfarin dose."
637880014,A,C,Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
637880014,C,C,"Patients with the CC genotype may have decreased but not non-existent risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CA, CT, AA or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens."
637880014,C,T,Patients with the CT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
655384011,C,C,"Patients with the rs4149056 CC genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin."
655384011,C,T,"Patients with the rs4149056 CT genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin."
655384011,T,T,"Patients with the rs4149056 TT genotype may have a lower risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin."
637880217,A,A,"Patients with the AA genotype and cancer who are treated with oxaliplatin or platinum compounds may have an increased risk of toxicities as compared to patients with the AG or GG genotype. However, conflicting data exist. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment."
637880217,A,G,"Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk of toxicities as compared to patients with the AA genotype. However, conflicting data exist. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment."
637880217,G,G,"Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk of toxicities as compared to patients with the AA genotype. However, conflicting data exist. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment."
637880425,A,A,"Patients with the rs7997012 AA genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram."
637880425,A,G,"Patients with the rs7997012 AG genotype and depression who are treated with citalopram may be more likely to have improvement in symptoms as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram."
637880425,G,G,"Patients with the rs7997012 GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram."
637880226,A,A,"Patients with the AA genotype may have increased risk for progression and decreased survival with platinum-based treatments with cancer as compared to patients with the GG genotype, but some studies found increased survival or no association with survival. Other genetic and clinical factors may also influence a patient's response."
637880226,A,G,Patients with the AG genotype may have an average risk for progression with platinum-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
637880226,G,G,Patients with the GG genotype may have decreased risk for progression with platinum-based treatments as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
637880243,G,G,Patients with the GG genotype may be less sensitive to treatment with erlotinib compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence drug sensitivity.
637880243,G,T,Patients with the GT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.
637880243,T,T,Patients with the TT genotype may be more sensitive to treatment with erlotinib compared to patients with the GG genotype. Other genetic and clinical factors may also influence drug sensitivity.
637880250,G,G,Cancer patients with genotype GG may be more likely to respond to topoisomerase I inhibitors compared to patients with genotypes GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.
637880250,G,T,Cancer patients with genotype GT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.
637880250,T,T,Cancer patients with genotype TT may be less likely to respond to topoisomerase I inhibitors compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.
637880258,G,G,Patients with the genotype GG who are treated with geldanamycin may be more likely to respond as compared to patients with genotype GT or TT (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.
637880258,G,T,Patients with the genotype GT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.
637880258,T,T,Patients with the genotype TT who are treated with geldanamycin may be less likely to respond as compared to patients with genotype GG (based solely on in vitro work). Other genetic and clinical factors may also influence a patient's response.
637880263,G,G,Cancer cells with the GG genotype may be more sensitive to Alkylating agents than are cells with genotype GT or TT. Other genetic and clinical factors may also influence tumor response to Alkylating agents.
637880263,G,T,Cancer cells with the GT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.
637880263,T,T,Cancer cells with the TT genotype may be less sensitive to Alkylating agents than cells with genotype GG. Other genetic and clinical factors may also influence tumor response to Alkylating agents.
637880267,G,G,Patients with the GG genotype who are treated with gefitinib may be less likely to respond compared to a patient with one or more T alleles. Other genetic and clinical factors may also influence a patient's response.
637880267,G,T,Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637880267,T,T,Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.
637880078,C,C,"Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events."
637880078,C,T,"Patients with the CT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events."
637880078,T,T,"Patients with the TT genotype treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events."
637880471,C,C,Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.
637880471,C,T,Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
637880471,T,T,Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
637880534,C,C,Cells with the CC genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.
637880534,C,T,Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype TT.
637880534,T,T,Cells with the TT genotype have normal ability to efflux fluorescently labelled paclitaxel.
637880563,C,C,Cells with the CC genotype have normal ability to efflux fluorescently labelled paclitaxel.
637880563,C,T,Cells with the CT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
637880563,T,T,Cells with the TT genotype have a slight decrease in ability to efflux fluorescently labelled paclitaxel compared to cells with genotype CC.
652472012,A,A,"Patients with the AA genotype who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril."
652472012,A,G,Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.
652472012,G,G,Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.
652509715,A,A,Patients with the AA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.
652509715,A,T,Patients with the TA genotype and coronary artery disease who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril.
652509715,T,T,"Patients with the TT genotype and coronary artery disease who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the TA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when treated with perindopril."
652519736,C,C,Patients with the CC genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
652519736,C,T,Patients with the CT genotype may have higher risk for cardiac events when treated with perindopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
652519736,T,T,Patients with the TT genotype may have reduced risk for cardiac events when treated with perindopril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response.
652595205,C,C,Patients with the CC genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652595205,C,T,Patients with the CT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the CT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652595205,T,T,Patients with the TT genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the CC genotype. Patients with the TT genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652882846,A,A,Patients with the AA genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.
652882846,A,G,"Patients with the AG genotype and breast cancer who are treated with doxorubicin: 1) may have decreased metabolism of doxorubicin 2) may have greater tumor reduction 3) may have increased severity of neutropenia as compared to patients with the GG genotype, or 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity."
652882846,G,G,Patients with the GG genotype and breast cancer who are treated with doxorubicin: 1) may have increased metabolism of doxorubicin 2) may have less tumor reduction 3) may have decreased severity of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to doxorubicin treatment and risk of toxicity.
655384474,A,A,Patients with the AA genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
655384474,A,T,"Patients with the AT genotype and cancer who are treated with taxanes and platinum therapy may have a decreased, but not absent, risk for gastrointestinal toxicity as compared to patients with the CA and AA genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxanes and platinum therapy."
655384474,T,T,Patients with the TT genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.
655384485,A,A,"Patients with the AA genotype may have increased survival when treated with cetuximab as compared to patients with the AG or GG genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab."
655384485,A,G,"Patients with the AG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab."
655384485,G,G,"Patients with the GG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab."
655384510,A,A,"Patients with the AA genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AA genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants."
655384510,A,G,"Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants."
655384510,G,G,Patients with the GG genotype may have increased likelihood of remission on anti-depressants as compared to patients with the AA or AG genotype. Male patients with the GG genotype and depression who are treated with citalopram may have an increased risk of suicidal ideation as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.
655384529,C,C,Patients with the CC genotype and Schizophrenia may have a decreased response to clozapine compared to patients with a CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
655384529,C,T,Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
655384529,T,T,Patients with the TT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
655384539,A,A,Patients with the AA genotype may have an increased risk of resistance to cyclosporine compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.
655384539,A,C,Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.
655384539,C,C,Patients with the CC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.
655384546,A,A,"Patients with the AA genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Patients with the AA genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine."
655384546,A,G,"Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine."
655384546,G,G,"Patients with the GG genotype and myasthenia gravis or organ transplantation may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Patients with the GG genotype may also have a decreased risk of infection as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine."
637880221,A,A,Patients with the rs1695 AA genotype and cancer when treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with platinum-based drugs.
637880221,A,G,Patients with the rs1695 AG genotype and cancer when treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with platinum-based drugs.
637880221,G,G,"Patients with the rs1695 GG genotype and cancer when treated with platinum-based drugs may have a decreased, but not absent, risk of toxicity as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with platinum-based drugs."
652779372,A,A,Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652779372,A,G,Patients with the AG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
652779372,G,G,Patients with the GG genotype may have increased risk of cardiac damage after anthracycline exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
655384534,A,A,Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.
655384534,A,G,Patients with the AG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype or may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.
655384534,G,G,Patients with the GG genotype and breast cancer who are treated with cyclophosphamide may have a decreased survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.
655384738,A,A,"The current evidence base suggests that there is no significant association between the rs17708472 AA genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements."
655384738,A,G,"The current evidence base suggests that there is no significant association between the rs17708472 AG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements."
655384738,G,G,"The current evidence base suggests that there is no significant association between the rs17708472 GG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements."
655384563,A,A,"Patients with the AA genotype and depression who are treated with antidepressants may be less likely to have improvement in symptoms as compared to patients with the AC or CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
655384563,A,C,"Patients with the AC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
655384563,C,C,"Patients with the CC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
655384568,C,C,"Patients with the CC genotype may 1) have decreased response to antidepressants 2) have decreased, but not absent, risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CT or TT genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
655384568,C,T,"Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
655384568,T,T,"Patients with the TT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants."
655384578,C,C,"Patients with the CC genotype may have increased clearance of docetaxel and an increased risk of infusion-related reaction as compared to patients with the TT genotype. These patients may experience an increased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel."
655384578,C,T,"Patients with the CT genotype may have increased clearance of docetaxel as compared to patients with the TT genotype or decreased clearance of docetaxel compared to patients with the CC genotype. Patients with the CT genotype may have an increased risk of an infusion-related reaction as compared to patients with the TT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel."
655384578,T,T,"Patients with the TT genotype may have decreased clearance of docetaxel and a decreased risk of an infusion-related reaction as compared to patients with the CC or CT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel."
655384582,A,A,Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's response to fluvastatin.
655384582,A,C,Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin.
655384582,C,C,Patients with the CC genotype who are treated with fluvastatin may have a lesser reduction in LDL-C as compared to patients with the AC and AA genotype.
655384592,C,C,Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.
655384592,C,G,Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.
655384592,G,G,Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.
655384602,C,C,Patients with the CC genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.
655384602,C,T,Patients with the CT genotype may have decreased chance of response to risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients chance of response to risperidone.
655384602,T,T,Patients with the TT genotype may have increased chance of response to risperidone as compared to patients with CC or CT genotypes. Other genetic and clinical factors may also influence a patients chance of response to risperidone.
655384607,C,C,Patients with the CC genotype and schizophrenia: 1) may have increased treatment response with perphanzine and olanzapine treatment 2) may have decreased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.
655384607,C,T,Patients with the CT genotype and schizophrenia may have increased treatment response with olanzapine as compared to perphenazine. Other genetic and clinical factors may also influence response to antipsychotics.
655384607,T,T,Patients with the TT genotype and schizophrenia may have increased treatment response with quetiapine and ziprasidone treatment. Other genetic and clinical factors may also influence response to antipsychotics.
655384794,C,C,"The current evidence base suggests that there is no significant association between the rs1799722 CC genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough."
655384794,C,T,"The current evidence base suggests that there is no significant association between the rs1799722 CT genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough."
655384794,T,T,"The current evidence base suggests that there is no significant association between the rs1799722 TT genotype and ACE inhibitor-induced cough. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for cough."
655384616,G,G,Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
655384616,G,T,Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
655384616,T,T,Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.
655384635,A,A,Patients with the AA genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.
655384635,A,G,Patients with the AG genotype may have increased risk of adverse effects when treated with propofol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propofol.
655384635,G,G,Patients with the GG genotype may have decreased but not non-existent risk of adverse effects when treated with propofol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to propofol.
655384645,C,C,Patients with the CC genotype may experience increased repaglinide exposure and improved response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.
655384645,C,T,Patients with the CT genotype may have decreased exposure of repaglinide and decreased response to repaglinide as compared to patients with the CC genotype and increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.
655384645,T,T,Patients with the TT genotype may have decreased exposure of repaglinide and decreased response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.
655384670,C,C,Patients with the CC genotype may have decreased but not non-existent risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655384670,C,T,Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655384670,T,T,Patients with the TT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655384679,C,C,Patients with the CC genotype may have better pain relief response to rofecoxib as compared to patients with GG or CG genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.
655384679,C,G,Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.
655384679,G,G,Patients with the GG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.
655384694,A,A,Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patient's with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
655384694,A,G,Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
655384694,G,G,Patients with the GG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
655384703,C,C,Patients with the CC genotype and at high-risk for type II diabetes who are treated with troglitazone may have increased beta cell function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.
655384703,C,T,Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to troglitazone.
655384703,T,T,Patients with the TT genotype and at high risk for type II diabetes who are treated with troglitazone may have decreased beta cell function as compared to patients with the CT and CC genotype.
655384724,C,C,Patients with the CC genotype may require an increased dose of acenocoumarol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
655384724,C,T,Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
655384724,T,T,Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
655384767,A,A,Patients with Hypertension and the AA genotype 1) may have an increased chance of positive treatment response to amlodipine as compared to patients with the AG or GG genotype 2) may have lower chance of positive treatment response to chlorthalidone as compared to patients with the AG or GG genotype 3) may have an increased chance of positive treatment response to amlodipine compared to treatment with chlorthalidone. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.
655384767,A,G,Patients with Hypertension and the AG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.
655384767,G,G,Patients with Hypertension and the GG genotype 1) may have a decreased chance of positive treatment response to amlodipine as compared to patients with the AA genotype 2) may have an increased chance of positive treatment response to chlorthalidone as compared to patients with the AA genotype 3) may have an increased chance of positive treatment response to chlorthalidone compared to treatment with amlodipine. Other genetic and clinical factors may also influence response to amlodipine and chlorthalidone.
655384772,C,C,Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.
655384772,C,G,Patients with the CG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
655384772,G,G,Patients with the GG genotype may have a increased likelihood of response to antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
655384781,C,C,Patients with the CC genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.
655384781,C,G,Patients with the CG genotype and acute coronary artery syndrome who are treated with beta blockers may have an increased chance of rehospitalization as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization.
655384781,G,G,"Patients with the GG genotype and acute coronary artery syndrome who are treated with beta blockers may have a decreased, but not absent, chance of rehospitalization as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk for rehospitalization."
655384804,A,A,Patients with the AA genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.
655384804,A,G,Patients with the AG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype or may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.
655384804,G,G,Patients with the GG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.
655384809,A,A,"Patients with the AA genotype and the GG genotype at rs2289669 who have diabetes may have a better response to metformin, as measured by a larger reduction in HbA1c levels, as compared to patients with the CC genotype and the GG genotype at rs2289669. This association is not significant when compared to patients with the CC genotype and the AG or AA genotype at rs2289699. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment."
655384809,A,C,"Patients with the AC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype. Although contradictory information exists for this association, and may be dependent on the absence of an A allele at rs2289669. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment."
655384809,C,C,"Patients with the CC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype and the GG genotype at rs2289669. This association is no longer significant in patients with the CC genotype and the AG or AA genotype at rs2289669. Other genetic and clinical factors may also influence a patient's response to metformin treatment."
655384813,C,C,"Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment."
655384813,C,G,Patients with the CG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.
655384813,G,G,Patients with the GG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype but the results were not statistically significant. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.
655384817,G,G,"Patients with the GG genotype and type 2 diabetes who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment."
655384817,G,T,No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.
655384817,T,T,Patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.
655384821,A,A,Patients with the AA genotype may have higher plasma concentrations of repaglinide in people with no health problems compared to GG genotype. Other genetic and clinical factors may also influence a patient's response.
655384821,A,G,"While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype."
655384821,G,G,Patients with the GG genotype may have reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake in people with no health problems compared to AA genotype. Other genetic and clinical factors may also influence a patient's response.
655384587,A,A,"Patients with the AA genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
655384587,A,T,"Patients with the AT genotype may have decreased clearance of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
655384587,T,T,"Patients with the TT genotype may have increased clearance of paclitaxel as compared to patients with the AA or AT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
655384597,C,C,Patients with the CC genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.
655384597,C,T,Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.
655384597,T,T,Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.
655384611,A,A,Patients with the AA genotype who are treated with pravastatin may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with pravastatin.
655384611,A,T,Patients with the AT genotype who are treated with pravastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with pravastatin.
655384611,T,T,Patients with the TT genotype who are treated with pravastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with pravastatin.
655384626,A,A,Patients carrying the AA genotype may have decreased pravastatin plasma AUC compared with patients carrying the GG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.
655384626,A,G,Patients carrying the AG genotype may have decreased pravastatin plasma AUC compared with patients carrying the GG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.
655384626,G,G,Patients carrying the GG genotype may have increased pravastatin plasma AUC compared to patients carrying the AA or AG genotype. This annotation only covers the pharmacokinetic relationship between rs4149015 and pravastatin and does not include evidence about clinical outcomes.
655384674,A,A,Lymphoma patients with the AA genotype who are treated with rituximab may be less likely to have tumor shrinkage as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.
655384674,A,C,Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.
655384674,C,C,Lymphoma patients with the CC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.
655384799,A,A,Patients with the rs1800629 AA genotype may have decreased response to etanercept as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence response to etanercept.
655384799,A,G,Patients with the rs1800629 AG genotype may have increased response to etanercept as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to etanercept.
655384799,G,G,Patients with the rs1800629 GG genotype may have increased response to etanercept as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to etanercept.
655384621,A,A,Patients with the rs20455 AA genotype may be less likely to benefit from pravastatin treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to pravastatin treatment.
655384621,A,G,Patients with the rs20455 AG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment.
655384621,G,G,Patients with the rs20455 GG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment.
655384966,C,C,"Patients with two X-chromosomes, the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele."
655384966,C,G,"Patients with two X-chromosomes, the CG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele."
655384966,G,G,"Patients with two X-chromosomes, the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele."
655385028,C,C,Patients with the rs8050894 CC genotype may require a higher dose of warfarin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.
655385028,C,G,Patients with the rs8050894 CG genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.
655385028,G,G,Patients with the rs8050894 GG genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.
655384975,G,G,"Patients with the GG genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine."
655384975,G,T,"Patients with the GT genotype and schizophrenia may be less likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine."
655384975,T,T,"Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine."
655385012,C,C,Patients with the rs9923231 CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.
655385012,C,T,Patients with the rs9923231 CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype or an increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.
655385012,T,T,Patients with the rs9923231 TT genotype may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.
655384834,C,C,"Patients with the CC genotype may have increased clearance of paclitaxel as compared to patients with the CT or TT genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
655384834,C,T,"Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
655384834,T,T,"Patients with the TT genotype may have decreased metabolism of paclitaxel as compared to patients with the CC genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
655384838,C,C,"Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
655384838,C,T,"Patients with the CT genotype may have decreased metabolism of paclitaxel as compared to patients with the TT genotype, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
655384838,T,T,"Patients with the TT genotype may have increased metabolism of paclitaxel as compared to patients with the CT or CC genotypes, however this has not been shown in vivo. Other genetic and clinical factors may also influence clearance of paclitaxel."
655384842,C,C,"Patients with the CC genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity."
655384842,C,T,"Patients with the CT genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype or may be at increased risk of neurotoxicity when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity."
655384842,T,T,Patients with the TT genotype may be at increased risk of neurotoxicity when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.
655384846,A,A,Patients with the AA genotype and depression who are treated with nortriptyline may have a higher likelihood to develop postural hypotension as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.
655384846,A,G,"Patients with the AG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment."
655384846,G,G,"Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment."
655384850,A,A,Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.
655384850,A,G,Patients with the AG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.
655384850,G,G,Patients with the GG genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have increased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence lansoprazole clearance.
655384854,C,C,Patients with the CC genotype and HIV infection may have decreased metabolism of indinavir compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence indinavir metabolism.
655384854,C,T,Patients with the CT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.
655384854,T,T,Patients with the TT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.
655384862,C,C,"Patients with the CC genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have a better response to treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response."
655384862,C,T,"Patients with the CT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
655384862,T,T,"Patients with the TT genotype and Major Depressive Disorder who are treated with fluvoxamine, paroxetine, or milnacipran may have decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response."
655384866,C,C,Patients with the CC genotype and Schizophrenia may have a reduced response to haloperidol as compared to patients with the CT genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.
655384866,C,T,Patients with the CT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the the CC genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.
655384866,T,T,"Patients with the TT genotype and Schizophrenia may have a better response to haloperidol as compared to patients with the the CC genotype. Please note, while the CT genotype was associated with suggestively better response to haloperidol in unrelated schizophrenic inpatients, no results were shown for the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol."
655384878,G,G,Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response.
655384878,G,T,"Patients with the GT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
655384878,T,T,"Patients with the TT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
655384882,A,A,Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655384882,A,G,Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655384882,G,G,"Patients with the GG genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
655384886,C,C,"Patients with the CC genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response."
655384886,C,T,Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
655384886,T,T,Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
655384890,C,C,Patients with the CC genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.
655384890,C,T,"Patients with the CT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with either the CC or the TT genotype. It is unclear at this time why the heterozygous genotype would confer a different phenotype than either homozygous genotype."
655384890,T,T,Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.
655384894,C,C,"Patients with the CC genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk."
655384894,C,G,"While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk."
655384894,G,G,Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
655384898,G,G,Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.
655384898,G,T,"While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype, it was not shown conclusively if heterzygous (GT) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk."
655384898,T,T,"Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk."
655384902,A,A,"Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment."
655384902,A,C,"Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment."
655384902,C,C,Patients with the CC genotype and rheumatoid arthritis who are treated with leflunomide may have an increased risk of toxicity as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.
655384906,A,A,Patients with the AA genotype who are treated with leflunomide may be less likely to respond compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.
655384906,A,C,It is not clear how patients with the AC genotype who are treated with leflunomide respond as compared to patients with the AA or the CC genotype.
655384906,C,C,Patients with the CC genotype who are treated with leflunomide may be more likely to respond compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
655384914,C,C,Children with the CC genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.
655384914,C,T,Children with the CT genotype may have a decreased response to measles vaccination as compared to patients with the CC and TT genotype. Other genetic and clinical factors may also influence response to measles vaccination.
655384914,T,T,Children with the TT genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.
655384918,G,G,"Patients with the GG genotype who are methamphetamine abusers may have a decreased, but not absent, risk for spontaneous relapse of psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse."
655384918,G,T,Patients with this genotype were not studied.
655384918,T,T,Patients with the TT genotype who are methamphetamine abusers may have an increased risk for spontaneous relapse of psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.
655384922,C,C,Patients with this genotype were not studied.
655384922,C,T,Patients with the CT genotype who are exposed to methamphetamine may have an increased risk for psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.
655384922,T,T,"Patients with the TT genotype who are exposed to methamphetamine may have a decreased, but not absent, risk for psychosis as compared to patients with the TC genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure."
655384926,A,A,"Patients with the AA genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note that in the study reporting this association there were no subjects with the AA genotype, but the A allele was found to be associated with increased risk. Please note the associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis."
655384926,A,T,"Patients with the AT genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note this associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis."
655384926,T,T,"Patients with the TT genotype may have a decreased risk for methamphetamine psychosis compared to patients with the AT genotype. Please note this association did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis."
655384930,A,A,"Patients with the AA genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
655384930,A,G,"Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
655384930,G,G,"Patients with the GG genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
655384934,A,A,"Patients with the AA genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment."
655384934,A,G,Patients with the AG genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
655384934,G,G,Patients with the GG genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
655384938,A,A,Patients with the AA genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.
655384938,A,C,"Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment."
655384938,C,C,"Patients with the CC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. However, this difference was not statistically significant. This may be related to the relatively low frequency of CC homozygotes (11%) in the study. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment."
655384942,C,C,"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine."
655384942,C,T,Patients with the CT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.
655384942,T,T,Patients with the TT genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.
655384946,A,A,Patients with the AA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
655384946,A,G,Patients with the GA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
655384946,G,G,"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment."
655384950,A,A,Patients with the AA genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.
655384950,A,G,Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.
655384950,G,G,Patients with the GG genotype and Alzheimer disease may have decreased but not non-existent risk for treatment-resistance to olanzapine or risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.
655384954,C,C,"Patients with two X-chromosomes, the CC genotype and schizophrenia, treated with risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype GG. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele."
655384954,C,G,"Patients with two X-chromosomes, the CG genotype and schizophrenia, treated with risperidone, may have a decreased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele."
655384954,G,G,"Patients with two X-chromosomes, the GG genotype and schizophrenia, treated with risperidone, may have an increased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele."
655384958,A,A,"Patients with the AA genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment."
655384958,A,G,"Patients with the AG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment."
655384958,G,G,Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.
655384962,C,C,Patients with the CC genotype and schizophrenia who are treated with olanzapine may have greater positive symptom improvement and positive symptom remission as compared to patients with the TT and CT genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
655384962,C,T,Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
655384962,T,T,Patients with the TT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
655384979,G,G,"Patients with the GG genotype is associated with better response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response."
655384979,G,T,"Patients with the GT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
655384979,T,T,"Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response."
655384983,C,C,"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment."
655384983,C,G,"Patients with the CG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of extreme weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment."
655384983,G,G,Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of extreme weight gain as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of extreme weight gain with olanzapine treatment.
655384987,A,A,Patients with the AA genotype who are treated with nifedipine may have larger changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.
655384987,A,G,Patients with the GA genotype who are treated with nifedepine may have larger changes in systolic and diastolic blood pressures compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.
655384987,G,G,Patients with the GG genotype who are treated with nifediping may have smaller changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.
655384991,A,A,Patients with the AA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.
655384991,A,G,Patients with the GA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.
655384991,G,G,Patients with the GG genotype who are treated with nifedipine may have larger mean changes in systolic and diastolic blood pressure as compared to patients with the GA and AA genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.
655385041,A,A,Patients with the AA genotype may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.
655385041,A,G,"Patients with the AG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype, or may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics."
655385041,G,G,Patients with the GG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.
655385054,A,A,"Patients with the AA genotype and schizophrenia may have an increased response to risperidone as compared to patients with the GG genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone."
655385054,A,G,"Patients with the AG genotype and schizophrenia may have an increased response to risperidone as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone."
655385054,G,G,"Patients with the GG genotype and schizophrenia may have a decreased response to risperidone as compared to patients with the AA genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone."
655385016,C,C,Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype.
655385016,C,T,Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.
655385016,T,T,Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.
655385033,A,A,Patients with the AA genotype may have decreased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
655385033,A,G,Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.
655385033,G,G,Cardiotox was not not found in GG group in this small study. The GG genotype (Val form) is more sensitive to trastuzamab in vitro. There was no link between tumor response or survival and HER2 genotype in clinical study.
655385037,C,C,Patients with the CC genotype may have decreased response to pramipexole in Chinese patients with Parkinson's disease compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
655385037,C,T,Patients with the CT genotype may have lower response rate to pramipexole in Chinese patients with Parkinson's disease than TT allele carriers. Other genetic and clinical factors may also influence a patient's response.
655385037,T,T,Patients with the TT genotype may have better therapeutic efficacy (response rate = 60%)of pramipexole in Chinese patients with Parkinson's disease compared to patiens carrying the C allele (response rate =13%). Other genetic and clinical factors may also influence a patient's response.
655385045,C,C,Genotype CC is associated with higher CYP3A4 acitvity induced by rifampin compared to genotype CT or TT in liver samples.
655385045,C,T,"Genotype CT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects."
655385045,T,T,"Genotype TT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects."
655385050,C,C,Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385050,C,T,Patients with the CT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype or may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385050,T,T,Patients with the TT genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385062,C,C,"Patients with the CC genotype and schizophrenia may have a decreased response to risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone."
655385062,C,T,"Patients with the CT genotype and schizophrenia may have a decreased response to risperidone compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone."
655385062,T,T,"Patients with the TT genotype and schizophrenia may have an increased response to risperidone as compared to patients with the CC or CT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone."
655385067,C,C,"Patients with the CC genotype and schizophrenia may have a decrease response to risperidone as compared to patients with the CT or TT genotype. Please note this association did not reach statistical significance in one study, while another study failed to find an association. Other genetic and clinical factors may also influence a patient's response to risperidone."
655385067,C,T,"Patients with the CT genotype and schizophrenia may have an increased response to risperidone as compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone."
655385067,T,T,"Patients with the TT genotype and schizophrenia may have a decreased response to risperidone as compared to patients with the CT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone."
655385072,A,A,Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385072,A,G,Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385072,G,G,Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385077,A,A,Patients with the AA genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385077,A,G,Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385077,G,G,Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
655385082,C,C,Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's triglyceride levels.
655385082,C,T,Patients with the TC genotype and HIV who are treated with ritonavir may have higher triglyceride (increased risk of Hypertriglyceridemia) levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385082,T,T,Patients with the TT genotype and HIV who are treated with ritonavir may have higher triglyceride levels (increased risk of Hypertriglyceridemia) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
655385087,C,C,Patients with the CC genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
655385087,C,T,Patients with the CT genotype and HIV who are treated with ritonavir may have decreased severity of triglyceride elevation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
655385087,T,T,Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
655385092,C,C,Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.
655385092,C,G,"Patients with the CG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation."
655385092,G,G,"Patients with the GG genotype and HIV who are treated with ritonavir may have a decreased, but not absent, risk of triglyceride elevation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of triglyceride elevation."
655385097,C,C,"Patients with the CC genotype and type 2 diabetes who are treated with rosiglitazone may have the smallest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone."
655385097,C,G,"Patients with the CG genotype and type 2 diabetes who are treated with rosiglitazone may have a decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone."
655385097,G,G,"Patients with the GG genotype and type 2 diabetes who are treated with rosiglitazone may have the largest decrease in fasting plasma glucose, 2-hour postprandial glucose, and HbA1c as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to rosiglitazone."
655385110,A,A,"Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response."
655385110,A,G,"Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response."
655385110,G,G,"Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compare to patients with the AA genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response."
1451414840,A,A,Patients with the rs1045642 AA genotype and acute respiratory diseases and suspected influenza infection may have decreased risk of side effects when treated with oseltamivir as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.
1451414840,A,G,Patients with the AG genotype and acute respiratory diseases and suspected influenza infection may have increased risk of side effects when treated with oseltamivir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.
1451414840,G,G,Patients with the GG genotype and acute respiratory diseases and suspected influenza infection may have increased risk of side effects when treated with oseltamivir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.
655384971,C,C,"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with antipsychotics may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
655384971,C,T,"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
655384971,T,T,"Patients with two X-chromosomes, the TT genotype and psychiatric disorders or schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
655385004,G,G,Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.
655385004,G,T,Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.
655385004,T,T,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.
655385102,A,A,"Patients with the rs1042713 AA genotype and asthma may have a decreased response to salmeterol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a response to salmeterol."
655385102,A,G,"Patients with the rs1042713 AG genotype and asthma may have an increased response to salmeterol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a response to salmeterol."
655385102,G,G,"Patients with the rs1042713 GG genotype and asthma may have an increased response to salmeterol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to salmeterol."
655385144,A,A,"People with the rs2273697 AA genotype may have increased clearance of talinolol as compared to people with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol."
655385144,A,G,"People with the rs2273697 AG genotype may have increased clearance of talinolol as compared to people with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol."
655385144,G,G,"People with the rs2273697 GG genotype may have decreased clearance of talinolol as compared to people with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol."
655385164,C,C,Patients with the rs1138272 CC genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1138272 and thiotepa and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thiotepa clearance.
655385164,C,T,Patients with the rs1138272 CT genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1138272 and thiotepa and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thiotepa clearance.
655385164,T,T,Patients with the rs1138272 TT genotype may have increased clearance of thiotepa as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1138272 and thiotepa and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence thiotepa clearance.
655385134,G,G,Patients with the GG genotype and type II diabetes who are treated with sulfonylureas may be more likely to achieve a HbA1c level of <7% as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response.
655385134,G,T,Patients with the GT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655385134,T,T,Patients with the TT genotype and type II diabetes who are treated with sulfonylureas may be less likely to achieve a target HbA1c level of <7% as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655385139,C,C,Patients with the CC genotype are less likely to respond to repaglinide than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.
655385139,C,T,Patients with the CT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.
655385139,T,T,Patients with the TT genotype are more likely to respond to repaglinide than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.
655385159,C,C,"Patients with the rs1751034 CC genotype carriers may have decreased concentrations of tenofovir as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations."
655385159,C,T,"Patients with the rs1751034 CT genotype carriers may have decreased concentrations of tenofovir as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations."
655385159,T,T,"Patients with the rs1751034 TT genotype carriers may have increased concentrations of tenofovir as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tenofovir concentations."
655385149,C,C,Patients with the CC genotype may have higher tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the TT or CT genotype. Other genetic and clinical factors may influence the response to tamoxifen.
655385149,C,T,Patients with the CT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.
655385149,T,T,Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.
655385154,A,A,The AA genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and tamoxifen-induced decrease in triglycerides and increase in high density lipoprotein in premenopausal women compared to GG genotype carriers
655385154,A,G,The AG genotype carriers had smaller tamoxifen-induced decrease in total cholesterol in postmenopausal woman and intermediate tamoxifen-induced increase in triglycerides and decrease in high density lipoprotein in premenopausal women compared to GG genotype carriers.
655385154,G,G,The GG genotype carriers had larger tamoxifen-induced decrease in total cholesterol in postmenopausal woman compared to GA/AA genotypes (P=0.03; GG vs GA/AA) and tamoxifen-induced increase in triglycerides (P=0.002; gene-dose effect) and decrease in high density lipoprotein (P=0.004; gene-dose effect) in premenopausal women.
655385307,A,A,"Patients with the rs1801133 AA genotype and Arthritis who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
655385307,A,G,"Patients with the rs1801133 AG genotype and Arthritis who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or may have a decreased risk of adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
655385307,G,G,"Patients with the rs1801133 GG genotype and Arthritis who are treated with methotrexate may have a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
655385168,C,C,"Patients with the CC genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant. (The frequency for CC allele is very low, homozygous minor allele carriers were pooled together with the heterozygous samples and compared with the homozygous major allele (T) carrier.)"
655385168,C,T,Patients with the CT genotype may respond better to antidepressant treatments as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.
655385168,T,T,Patients with the TT genotype may be less likely to respond to antidepressant treatments as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant.
655385178,C,C,"Patients with the CC genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
655385178,C,T,"Patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
655385178,T,T,"Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast."
655385195,A,A,No AA genotype carrier was found in the study. But patients with the AG genotype and Asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
655385195,A,G,Patients with the AG genotype and asthma treated with montelukast may have significantly reduced plasma concentration of montelukast and poorer response to montelukast compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
655385195,G,G,Patients with the GG genotype and Asthma treated with montelukast may have higher plasma concentration of montelukast and better response to montelukast compared to patients with the GA genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.
655385210,C,C,Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar.
655385210,C,T,"No conclusive results were found for patients with the CT genotype. But patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar."
655385210,T,T,"Patients with the TT genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for edema when treated with muraglitazar."
655385257,A,A,"Patients with the AA genotype were not studied, and so conclusions cannot be made in regard to response to methotrexate. However, patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
655385257,A,G,Patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385257,G,G,Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385262,A,A,"Patients with the AA genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity."
655385262,A,G,"Patients with the AG genotype and psoriasis who are treated with methotrexate: 1) may be less likely to have a reduction in psoriasis area or disease severity 2) may have a reduced, but not absent, risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity."
655385262,G,G,Patients with the GG genotype and psoriasis who are treated with methotrexate: 1) may be more likely to have a reduction in psoriasis area or disease severity 2) may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.
655385267,C,C,Patients with the CC genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385267,C,T,Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the TT genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385267,T,T,Patients with the TT genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT or CC genotype. There is no association with response to rheumatoid arthritis. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385272,A,A,"Patients with the AA genotype were not studied. However, patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate."
655385272,A,G,Patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385272,G,G,Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area or severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385277,A,A,Patients with the AA genotype and psoriasis who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate.
655385277,A,G,"Patients with the AG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate."
655385277,G,G,"Patients with the GG genotype and psoriasis who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity to methotrexate."
655385286,C,C,Patients with the CC genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385286,C,T,Patients with the CT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385286,T,T,Patients with the TT genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
655385299,C,C,"Patients with the CC genotype and rheumatoid arthritis who are treated with methotrexate may have a poorer response to the drug and a decreased risk for toxicity as compared to those with the CG or GG genotype. However, conflicting evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence methotrexate response and toxicity."
655385299,C,G,"Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may have a poorer response to the drug and a decreased risk for toxicity as compared to those with the GG genotype, and an increased risk for toxicity as compared to the CC genotype. However, conflicting evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence methotrexate response and toxicity."
655385299,G,G,"Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may have a better response to the drug and an increased risk for toxicity as compared to those with the CC or CG genotype. However, conflicting evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence methotrexate response and toxicity."
655385328,A,A,"Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of end-of-induction minimal residual disease (MRD)."
655385328,A,G,Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
655385328,G,G,Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
655385333,A,A,"Patients with the AA genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have a decreased, but not absent, risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for MRD."
655385333,A,G,Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
655385333,G,G,Patients with the GG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.
655385338,A,A,Patients with the AA genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.
655385352,C,C,"Patients with CC genotype may have lower plasma concentrations of metoprolol and have smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype."
655385352,C,T,"Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype."
655385352,T,T,"Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype."
655385115,A,A,"Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compared to patients with the GG or AG genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response."
655385115,A,G,"Patients with the AG genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the AA genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response."
655385115,G,G,"Patients with the GG genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the AA genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response."
655385361,A,A,The AA genotype was found less often in smokers as compared to the GG genotype. In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
655385361,A,G,The AG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.13). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
655385361,G,G,The GG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.28). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.
655385369,A,A,Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype. Other genetic and clinical factors may also influence a patient's response.
655385369,A,G,Patients with the AG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
655385369,G,G,Patients with the GG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.
655385120,A,A,"Patients with the AA genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the TT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response."
655385120,A,T,"Patients with the AT genotype may have decreased response to salbutamol in people with Asthma as compared to patients with the TT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response."
655385120,T,T,"Patients with the TT genotype may have increased response to salbutamol in people with Asthma as compared to patients with the AA or AT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response."
655385223,C,C,Patients with the CC genotype may have an increased risk for acute rejection after kidney transplantation as compared to patients with the CT or TT genotypes but the CC genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation.
655385223,C,T,"Patients with the CT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the CT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation."
655385223,T,T,"Patients with the TT genotype may have a decreased, but not absent, risk for acute rejection after kidney transplantation as compared to patients with the CC genotype but the TT genotype influence is controversy discussed among different studies. Other genetic and clinical factors may also influence a patient's risk for acute rejection after transplantation."
655385125,C,C,Patients with the CC genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
655385125,C,T,Patients with the CT genotype and erectile dysfunction who are treated with sildenafil may be less likely to have positive erectile response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
655385125,T,T,Patients with the TT genotype and erectile dysfunction who are treated with sildenafil may be more likely to have positive erectile response as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.
655385205,A,A,"Patients with the rs4680 AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect morphine dose requirements."
655385205,A,G,"Patients with the rs4680 AG genotype may have increased morphine dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect morphine dose requirements."
655385205,G,G,"Patients with the rs4680 GG genotype may have increased morphine dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect morphine dose requirements."
655385241,A,A,Patients with the AA genotype who are treated with naloxone may have lower cortisol response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence the response to naloxone.
655385241,A,G,Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.
655385241,G,G,Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.
1449575633,C,C,The CC genotype is associated with decreased catalytic activity of DPYD as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575633,C,T,The CT genotype is associated with decreased catalytic activity of DPYD as compared to the CC and increased catalytic activity as compared to the TT genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575633,T,T,The TT genotype is associated with increased catalytic activity of DPYD as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575668,C,C,"The CC genotype is associated with decreased expression of DPYD, but increased catalytic activity as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD."
1449575668,C,T,"The CT genotype is associated with decreased expression of DPYD, but increased catalytic activity as compared to the TT genotype and increased expression, but decreased catalytic activity as compared to the CC genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD."
1449575668,T,T,"The TT genotype is associated with increased expression of DPYD, but decreased catalytic activity as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of and protein expression of DPYD."
1449575690,A,A,The AA genotype is associated with decreased catalytic activity and increased expression of DPYD protein as compared to the AG or GG genotypes. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.
1449575690,A,G,The AG genotype is associated with decreased catalytic activity and increased expression of DPYD protein as compared to the GG genotypes and increased catalytic activity and decreased expression as compared to the AA genotype. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.
1449575690,G,G,The GG genotype is associated with increased catalytic activity and decreased expression of DPYD protein as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence catalytic activity and expression of DPYD.
1449575696,A,A,The AA genotype is associated with decreased expression of DPYD as compared to the AT or TT genotypes. Other clinical and genetic factors may also influence DPYD protein expression.
1449575696,A,T,The AT genotype is associated with increased expression of DPYD as compared to the TT genotypes and decreased expression as compared to the AA genotype. Other clinical and genetic factors may also influence DPYD protein expression.
1449575696,T,T,The TT genotype is associated with increased expression of DPYD as compared to the AT or AA genotypes. Other clinical and genetic factors may also influence DPYD protein expression.
1449575656,A,A,The A allele of rs59086055 is assigned as no function by CPIC. The AA genotype may have decreased catalytic activity of DPYD as compared to the GG genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575656,A,G,The A allele of rs59086055 is assigned as no function by CPIC.The AG genotype may have decreased catalytic activity of DPYD as compared to the GG genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575656,G,G,The A allele of rs59086055 is assigned as no function by CPIC. The GG genotype may have increased catalytic activity of DPYD as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575662,C,C,"Both variants of rs148994843 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1449575662,C,T,"Both variants of rs148994843 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1449575662,T,T,"Both variants of rs148994843 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1449748511,A,A,Patients with the AA genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1449748511,A,G,Patients with the AG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1449748511,G,G,Patients with the GG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.
1450371713,A,A,Patients with rheumatoid arthritis and the AA genotype may have an increased response to rituximab as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to rituximab.
1450371713,A,G,Patients with rheumatoid arthritis and the AG genotype may have a decreased response to rituximab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to rituximab.
1450371713,G,G,Patients with rheumatoid arthritis and the GG genotype may have a decreased response to rituximab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to rituximab.
1450373100,G,G,Patients with the GG genotype may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.
1450373100,G,T,Patients with the GT genotype may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.
1450373100,T,T,Patients with the TT genotype may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.
1450373628,A,A,Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373628,A,G,Patients with the AG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373628,G,G,Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373634,C,C,Patients with the CC genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373634,C,T,Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373634,T,T,Patients with the TT genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450375692,C,C,"Patients with the CC genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375692,C,G,"Patients with the CG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375692,C,T,"Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375692,G,G,"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the CT, GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375692,G,T,"Patients with the GT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375692,T,T,"Patients with the TT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol."
981237695,A,A,Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.
981237695,A,T,Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.
981237695,T,T,Patients with the TT genotype and HIV who are treated with tenofovir may have an increased risk of renal proximal tubulopathy as compared to patients with the AT and AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with tenofovir treatment.
981238459,A,A,Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the CA and CC genotype. Other genetic and clinical factors may also influence metabolism of losartan.
981238459,A,C,Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.
981238459,C,C,Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.
981237922,A,A,Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.
981237922,A,G,Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.
981237922,G,G,Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.
981237950,A,A,"Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment."
981237950,A,G,"Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment."
981237950,G,G,"Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to cisplatin and cyclophosphamide treatment."
981204890,A,A,"Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency."
981204890,A,G,"Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency."
981204890,G,G,"Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency."
981344897,C,C,Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
981344897,C,T,Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
981344897,T,T,Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
981352141,C,C,"Patients with the CC genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have a decreased, but not absent, risk of hemolysis and severe/unsafe hemoglobin decreases as compared to patients with the CT or TT genotypes. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone."
981352141,C,T,"Patients with the CT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of hemolysis and severe/unsafe hemoglobin decreases as compared to patients with the CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone."
981352141,T,T,"Patients with the TT genotype with Malaria who are treated with artesunate, chlorproguanil and dapsone may have an increased risk of hemolysis and severe/unsafe hemoglobin decreases as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to artesunate, chlorproguanil and dapsone."
827830327,A,A,Patients with the AA genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
827830327,A,C,Patients with the AC genotype may experience less response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's chance of response.
827830327,C,C,Patients with the CC genotype may experience a greater response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the AA or AC genotype. Patients with the CC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.
827831021,C,C,Patients with the CC genotype and Myeloid Leukemia who are treated with cytarabine may have an increased survival time and a decreased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
827831021,C,T,Patients with the CT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
827831021,T,T,Patients with the TT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.
827831123,G,G,Patients with the GG genotype and cancer who are treated with erlotinib may have increased severity of Diarrhea compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.
827831123,G,T,Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.
827831123,T,T,Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.
827831417,A,A,"Patients with the AA genotype may have worse response when treated with platinum compounds in people with Non-Small-Cell Lung Carcinoma or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds."
827831417,A,C,"Patients with the AC genotype may have worse response when treated with platinum compounds in people with Non-Small-Cell Lung Carcinoma or Ovarian Neoplasms as compared to patients with CC genotype. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds."
827831417,C,C,"Patients with the CC genotype may have better response when treated with platinum compounds in people with Non-Small-Cell Lung Carcinoma or Ovarian Neoplasms as compared to patients with AA and AC genotypes. However, contradictory findings (better and poorer responses or no association) have been reported. Other genetic and clinical factors may also influence a patient's response to Platinum compounds."
827831435,A,A,"Patients with the AA genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations."
827831435,A,C,"Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations."
827831435,C,C,"Patients with the CC genotype may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations."
827831435,C,T,"Patients with the CT genotype may have higher blood trough concentrations of cyclosporine compared to patients with the AC and CC genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations."
827832280,C,C,"Patients with the CC genotype may have an increased response to metoprolol as compared to patients with the CG or GG genotype. However, some studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol."
827832280,C,G,"Patients with the CG genotype may have a decreased response to metoprolol as compared to patients with the CC genotype. However, some studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol."
827832280,G,G,"Patients with the GG genotype may have a decreased response to metoprolol as compared to patients with the CC genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol."
1451415425,C,C,Patients with the rs7668258 CC genotype and epilepsy may require decreased doses of lamotrigine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence lamotrigine dosage requirements.
1451415425,C,T,Patients with the rs7668258 CT genotype and epilepsy may require increased doses of lamotrigine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence lamotrigine dosage requirements.
1451415425,T,T,Patients with the rs7668258 TT genotype and epilepsy may require increased doses of lamotrigine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence lamotrigine dosage requirements.
827847788,A,A,Patients with the AA genotype may have decreased response when treated with oxaliplatin regimens as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to oxaliplatin.
827847788,A,G,Patients with the AG genotype may have increased response when treated with oxaliplatin regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to oxaliplatin.
827847788,G,G,Patients with the GG genotype may have increased response when treated with oxaliplatin regimens as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence response to oxaliplatin.
827847738,A,A,Patients with the AA genotype may have decreased event free survival when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
827847738,A,T,Patients with the AT genotype may have decreased event free survival when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
827847738,T,T,Patients with the TT genotype may have increased event free survival when treated with methotrexate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
827847744,G,G,"Patients with the rs9679162 GG genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy."
827847744,G,T,"Patients with the rs9679162 GT genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy."
827847744,T,T,"Patients with the rs9679162 TT genotype and Liver Neoplasms may increased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy."
827847751,C,C,Patients with the CC genotype may have increased risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.
827847751,C,T,"Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects."
827847751,T,T,"Patients with the TT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects."
827847768,C,C,Patients with the CC genotype may have a decreased response to cisplatin and irinotecan as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.
827847768,C,G,Patients with the CG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment.
827847768,G,G,"Patients with the GG genotype may have an increased response to cisplatin and irinotecan as compared to patients with the CC genotype, although the GG genotype was not observed in the supporting study. Other genetic and clinical factors may also influence a patient's response to cisplatin and irinotecan treatment."
827848563,A,A,Patients with the AA genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.
827848563,A,G,Patients with the AG genotype may have an increased risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.
827848563,G,G,Patients with the GG genotype may have decreased but not non-existent risk of acute coronary syndrome when exposed to NSAIDs as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patients risk of adverse events when taking NSAIDs.
827848725,A,A,Patients with the AA genotype may have decreased but not absent risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse events.
827848725,A,G,Patients with the AG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
827848725,G,G,Patients with the GG genotype may have increased risk for kidney tubular dysfunction when exposed to tenofovir as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.
827849079,C,C,Patients with the CC genotype may have a decreased but not absent risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.
827849079,C,T,Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.
827849079,T,T,Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.
827849095,A,A,Patients with the AA genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.
827849095,A,T,Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.
827849095,T,T,Patients with the TT genotype may have decreased but not absent risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk for drug induced liver injury.
827848555,A,A,"Patients with the AA genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
827848555,A,G,"Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
827848555,G,G,"Patients with the GG genotype may have an increased risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA or AG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
981201399,A,A,"Patients with the AA genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events."
981201399,A,G,"Patients with the AG genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events."
981201399,G,G,"Patients with the GG genotype may have decreased but not absent risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events."
827849109,A,A,Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.
827849109,A,G,Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.
827849109,G,G,Patients with the GG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.
978639596,C,C,"Individuals with the CC genotype were not studied, however individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide and blood glucose levels."
978639596,C,T,"Individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide."
978639596,T,T,"Individuals with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of repaglinide compared to patients with the CT genotype (CYP2C8*3/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide."
981188353,A,A,Patients with the AA genotype may require a decreased dose of valproic acid compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients dose requirements.
981188353,A,G,Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.
981188353,G,G,Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.
981188379,A,A,Patients with the AA genotype who are treated with gemcitabine may have an increased risk of toxicity when compared to patients with the CC genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.
981188379,A,C,Patients with the AC genotype who are treated with gemcitabine may have a decreased risk of toxicity when compared to patients with the AA genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.
981188379,C,C,Patients with the CC genotype who are treated with gemcitabine may have a decreased risk of toxicity when compared to patients with the AA genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.
981201333,A,A,"Patients with the AA genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity."
981201333,A,G,"Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity."
981201333,G,G,"Patients with the GG genotype may have an increased risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the AA or AG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity."
981201817,C,C,"Patients with the CC genotype may have decreased plasma drug concentration when treated with efavirenz as compared to patients with the CT or TT genotypes. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked."
981201817,C,T,"Patients with the CT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked."
981201817,T,T,"Patients with the TT genotype may have increased plasma drug concentration when treated with efavirenz as compared to patients with the CC genotype. Other studies have not found an association. Other genetic and clinical factors may also influence a patient's drug metabolism, in particular CYP2A6*9 (rs8192726) should be cross checked."
981201864,A,A,"Patients with the AA genotype may have increased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the GG or AG genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel."
981201864,A,G,"Patients with the AG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel."
981201864,G,G,"Patients with the GG genotype may have decreased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the AA genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel."
981201895,A,A,"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics."
981201895,A,G,"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics."
981201895,G,G,"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics."
981201937,C,C,"Genotype CC may be associated with decreased dose of warfarin as compared to genotype TT, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin."
981201937,C,T,"Genotype CT may be associated with decreased dose of warfarin as compared to genotype TT, and increased dose as compared to genotype CC, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin."
981201937,T,T,"Genotype TT may be associated with increased dose of warfarin as compared to genotype CC, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin."
981202068,C,C,"Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
981202068,C,T,"Patients with the CT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
981202068,T,T,"Patients with the TT genotype who are treated with clopidogrel 1) may have lower levels of active metabolite, resulting in decreased platelet inhibition and decreased response 2) may have an increased risk for stent thrombosis, target vessel revascularization, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CC genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel."
981202261,C,C,Patients with the CC genotype and Epilepsy who are treated with antiepileptics may have a decreased risk of drug resistance as compared to patients with the CT or TT genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
981202261,C,T,Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
981202261,T,T,Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
827848548,G,G,"Patients with the rs9561778 GG genotype may have a decreased but not absent risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for ADRs."
827848548,G,T,"Patients with the rs9561778 GT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs."
827848548,T,T,"Patients with the rs9561778 TT genotype may have an increased risk of ADR when treated with CAF (cyclophosphamide, doxorubicin and fluorouracil) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for ADRs."
978608464,A,A,"Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
978608464,A,G,"Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
978608464,G,G,"Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
827923032,G,G,Patients with the rs3745274 GG genotype and HIV infection may have decreased plasma concentrations and increased clearance of efavirenz as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.
827923032,G,T,Patients with the rs3745274 GT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.
827923032,T,T,Patients with the rs3745274 TT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.
827923042,G,G,"Patients with the rs3745274 GG genotype may have a decreased, but not absent risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of efavirenz toxicity."
827923042,G,T,"Patients with the rs3745274 GT genotype may have an increased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of efavirenz toxicity."
827923042,T,T,"Patients with the rs3745274 TT genotype may have an increased risk for efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the risk of efavirenz toxicity."
981201535,C,C,"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981201535,C,T,"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981201535,T,T,"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981201981,A,A,"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981201981,A,G,"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981201981,G,G,"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981202294,G,G,"Patients with the rs3745274 GG genotype and HIV infection may have increased clearance of and decreased exposure to nevirapine as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes."
981202294,G,T,"Patients with the rs3745274 GT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes."
981202294,T,T,"Patients with the rs3745274 TT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes."
981202609,C,C,Patients with the rs4673993 CC genotype and Rheumatoid Arthritis may have increased response when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate response.
981202609,C,T,Patients with the rs4673993 CT genotype and Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate response.
981202609,T,T,Patients with the rs4673993 TT genotype and Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate response.
981202714,G,G,"Patients with the rs4961 GG genotype may have decreased response to hydrochlorothiazide treatment as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide."
981202714,G,T,"Patients with the rs4961 GT genotype may have increased response to hydrochlorothiazide treatment as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide."
981202714,T,T,"Patients with the rs4961 TT genotype may have increased response to hydrochlorothiazide treatment as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to hydrochlorothiazide."
981204695,A,A,"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to naltrexone."
981204695,A,G,"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to naltrexone."
981204695,G,G,"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to naltrexone."
981237907,A,A,"Patients with the AA genotype and chronic hepatitis C may not require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin."
981237907,A,C,"Patients with the AC genotype and chronic hepatitis C may not require a dose reduction or ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin."
981237907,C,C,"Patients with the CC genotype and chronic hepatitis C may require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin."
1451416140,A,A,Patients with the rs745364489 AA genotype may have an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of apnea following administration of succinylcholine.
1451416140,A,G,Patients with the rs745364489 AG genotype may have a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of apnea following administration of succinylcholine.
1451416140,G,G,Patients with the rs745364489 GG genotype may have a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of apnea following administration of succinylcholine.
981238370,A,A,"Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate."
981238370,A,G,"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate."
981238370,G,G,"Pediatric patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate."
1451416408,C,C,Patients with the rs6311 CC genotype may be at an increased risk of experiencing side effects when treated with antidepressants as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.
1451416408,C,T,Patients with the rs6311 CT genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.
1451416408,T,T,Patients with the rs6311 TT genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.
981237900,A,A,Patients with the AA genotype with diabetes mellitus or polycystic ovarian syndrome who are treated with metformin may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.
981237900,A,C,"Patients with the AC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin."
981237900,C,C,"Patients with the CC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin."
1451416400,C,C,"The current evidence base suggests that there is no significant association between the rs6311 CC genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
1451416400,C,T,"The current evidence base suggests that there is no significant association between the rs6311 CT genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
1451416400,T,T,"The current evidence base suggests that there is no significant association between the rs6311 TT genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
1451416422,A,A,Patients with the rs6313 AA genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.
1451416422,A,G,Patients with the rs6313 AG genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.
1451416422,G,G,Patients with the rs6313 GG genotype may be at an increased risk of experiencing side effects when treated with antidepressants as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.
1451416434,A,A,"Patients with the rs7997012 AA genotype may have a decreased response to antidepressants as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
1451416434,A,G,"Patients with the rs7997012 AG genotype may have and increased response to antidepressants as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
1451416434,G,G,"Patients with the rs7997012 GG genotype may have an increased response to antidepressants as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
981238025,C,C,Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.
981238025,C,T,Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.
981238025,T,T,Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin.
981240029,C,C,Patients with CC genotype and Type 2 diabetes may have a poorer response (smaller decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.
981240029,C,T,"Patients with CT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC, or a poorer response (smaller decrease in HbA1c) as compared to patients with genotype TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas."
981240029,T,T,Patients with TT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.
1451416946,A,A,Patients with pancreatic cancer and the rs2072671 AA genotype may have a decreased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.
1451416946,A,C,Patients with pancreatic cancer and the rs2072671 AC genotype may have a decreased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.
1451416946,C,C,Patients with pancreatic cancer and the rs2072671 CC genotype may have an increased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.
1451417123,A,A,Patients with glioma and the rs1128503 AA genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.
1451417123,A,G,Patients with glioma and the rs1128503 AG genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.
1451417123,G,G,Patients with glioma and the rs1128503 GG genotype may have increased concentrations of temozolomide as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.
981239544,A,A,Patients with the AA genotype are unlikely to be resistant to warfarin and may require a decreased dose of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose.
981239544,A,G,"Patients with the AG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose."
981239544,G,G,"Patients with the GG genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence warfarin dose."
981202598,A,A,"Patients with the rs4444903 AA genotype may have a poorer response to cetuximab as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment."
981202598,A,G,"Patients with the rs4444903 AG genotype may have a poorer response to cetuximab as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment."
981202598,G,G,"Patients with the rs4444903 GG genotype may have a better response to cetuximab as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment."
981202618,A,A,"Patients with the AA genotype who are treated with nicotine replacement therapy may have an increased likelihood of smoking cessation and decreased risk of relapse as compared to patients with the GG genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy."
981202618,A,G,"Patients with the AG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy."
981202618,G,G,"Patients with the GG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy."
981220481,A,A,Patients with AA genotype may have an increased risk of drug toxicity when treated with platinum drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.
981220481,A,G,Patients with AG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.
981220481,G,G,Patients with GG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.
981202393,A,A,Patients with the rs1801394 AA genotype may be at a decreased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.
981202393,A,G,Patients with the rs1801394 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.
981202393,G,G,Patients with the rs1801394 GG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.
981345293,C,C,"Patients with the rs4149056 CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes."
981345293,C,T,"Patients with the rs4149056 CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes."
981345293,T,T,"Patients with the rs4149056 TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes."
1451264120,A,A,Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264120,A,G,Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264120,G,G,"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia"
1451274140,C,C,The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CC genotype may have decreased DPYD activity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1451274140,C,T,The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1451274140,T,T,The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the TT genotype may have increased DPYD activity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1451286040,C,C,"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286040,C,T,"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286040,T,T,"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286320,C,C,"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286320,C,T,"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286320,T,T,"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286326,C,C,"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286326,C,T,"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286326,T,T,"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451287240,A,A,"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451287240,A,G,"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451287240,G,G,"Both variants of rs1801265 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451287360,C,C,"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451287360,C,T,"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451287360,T,T,"Both variants of rs2297595 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451287440,A,A,"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451287440,A,G,"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451287440,G,G,"Both variants of rs17376848 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AG or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451290840,C,C,Patients with the rs116855232 CC genotype may have increased dose of mercaptopurine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence mercaptopurine dose.
1451290840,C,T,Patients with the rs116855232 CT genotype may have decreased dose of mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mercaptopurine dose.
1451290840,T,T,Patients with the rs116855232 TT genotype may have decreased dose of mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mercaptopurine dose.
1451288269,C,C,"The T allele of rs56038477 is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451288269,C,T,"The T allele of rs56038477 is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451288269,T,T,"The T allele of rs56038477 is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451289700,C,C,The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also affect DPYD activity.
1451289700,C,G,The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also affect DPYD activity.
1451289700,G,G,The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the CC or CG genotype. Other genetic and clinical factors may also affect DPYD activity.
981202790,G,G,"Patients with the GG genotype and Hypertension who are treated with diuretics may have an increased likelihood of Myocardial Infarction as compared to patients with the GT or TT genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics."
981202790,G,T,"Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics."
981202790,T,T,"Patients with the TT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics."
981204258,A,A,"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel."
981204258,A,G,"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel."
981204258,G,G,"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and risk of drug toxicity when treated with paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with paclitaxel."
981203854,C,C,Patients with the CC genotype and recipients of kidney transplant who are treated with tacrolimus may have an increased risk of developing hyperlipidemia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.
981203854,C,T,"Patients with the CT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia."
981203854,T,T,"Patients with the TT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia."
981204026,C,C,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
981204026,C,T,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being ineffective as compared to patients with the CC genotype or may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
981204026,T,T,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have increased likelihood of treatment being ineffective as compared to patients with the CC genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
981204116,A,A,"Patients with AA genotype may have higher success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with AC or CC genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus."
981204116,A,C,"Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus."
981204116,C,C,"Patients with CC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus."
981204433,A,A,"Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine."
981204433,A,G,"Patients with the AG genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine."
981204433,G,G,"Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine."
981204444,A,A,"Genotype AA may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported."
981204444,A,G,"Genotype AG may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported."
981204444,G,G,"Genotype GG may be associated with increased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes AA + AG. However, contradictory finding has been reported."
981204466,A,A,"Patients with AA genotype may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine."
981204466,A,G,"Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine."
981204466,G,G,"Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine."
981237713,A,A,Patients with the AA genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.
981237713,A,G,Patients with the AG genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.
981237713,G,G,Patients with the GG genotype and cancer may have an increased risk for drug toxicity and an increased response to treatment with cisplatin or carboplatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemotherapy.
981238041,A,A,"Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy."
981238041,A,C,"Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy."
981238041,C,C,"Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy."
981203697,C,C,Patients with the CC genotype and Epilepsy who are treated with antiepileptics may be less likely to be resistant to treatment as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
981203697,C,T,Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
981203697,T,T,Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.
981203886,C,C,"Patients with the CC genotype and HIV infection who are treated with nevirapine may have increased clearance of the drug as compared to patients with the CT and TT genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine."
981203886,C,T,"Patients with the CT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine."
981203886,T,T,"Patients with the TT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine."
981203954,C,C,Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
981203954,C,T,Patients with the CT genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
981203954,T,T,Patients with the TT genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of the drug as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
981204345,A,A,"Patient with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine."
981204345,A,G,"Patient with genotype AG may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine."
981204345,G,G,"Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine."
981204912,A,A,"Cancer patients with the AA genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AG or GG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs."
981204912,A,G,"Cancer patients with the AG genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the GG genotype, or a decreased risk of drug toxicities as compared to patients with the AA genotype. This has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs."
981204912,G,G,"Cancer patients with the GG genotype may have a decreased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AA or AG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs."
981238288,A,A,Patients with the AA genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.
981238288,A,C,Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.
981238288,C,C,Patients with the CC genotype may have increased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the AA genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz
981202806,G,G,Patients with the GG genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be more likely to respond to diuretic treatment as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
981202806,G,T,Patients with the GT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
981202806,T,T,Patients with the TT genotype and Liver Cirrhosis who are treated with furosemide and spironolactone may be less likely to respond to diuretic treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.
981204044,C,C,"Patients with the rs9923231 CC genotype may require an increased dose of acenocoumarol as compared to patients with the TT and CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements."
981204044,C,T,"Patients with the rs9923231 CT genotype may require a decreased dose of acenocoumarol as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements."
981204044,T,T,"Patients with the rs9923231 TT genotype may require a decreased dose as of acenocoumarol compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements."
981475450,C,C,Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to erlotinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect response to erlotinib.
981475450,C,T,Patients with the somatic rs121434569 CT genotype (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib compared to patients with CC genotype. Other genetic and clinical factors may also affect response to erlotinib.
981475450,T,T,"Patients with the somatic rs121434569 TT genotype, (i.e. carrying two copies of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to erlotinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to erlotinib."
1451286020,C,C,"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286020,C,T,"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451286020,T,T,"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981203618,A,A,"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981203618,A,T,"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981203618,T,T,"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981345382,C,C,"Patients with the rs4149056 CC genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy."
981345382,C,T,"Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy."
981345382,T,T,"Patients with the rs4149056 TT genotype may have a decreased risk of developing myopathy when treated with statins as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy."
981420042,G,G,"Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GG genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating EGFR mutation, for example the TT genotype at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib."
981420042,G,T,"Patients with advanced non-small-cell lung cancer and an activating somatic EGFR mutation, for example the GT genotype at rs121434568 (also known as L858R), may have an increased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who do not have an activating EGFR mutation, for example the TT genotype at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib."
981420042,T,T,"Patients with advanced non-small-cell lung cancer and who do not carry an activating somatic EGFR mutation, for example the TT genotype at rs121434568 (also known as L858R), may have a decreased response to gefitinib, as measured by response rate and progression-free survival time, as compared to patients who have an activating EGFR mutation, for example the GG or GT genotypes at rs121434568. Many of the studies listed here combine patients with different activating somatic EGFR mutations, such as L858R and exon 19 deletions, together for analysis. Other genetic and clinical factors may also affect response to gefitinib."
981203518,C,C,Individuals with the CC genotype may be less likely to experience anxiety when exposed to caffeine as compared to individuals with the TT genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.
981203518,C,T,Individuals with the CT genotype may be less likely to experience anxiety when exposed to caffeine as compared to individuals with the TT genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.
981203518,T,T,Individuals with the TT genotype may be more likely to experience anxiety when exposed to caffeine as compared to individuals with the CT or CC genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.
981203532,A,A,Patients with the AA genotype who are treated with cytarabine may have lower levels of toxicity as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.
981203532,A,G,Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.
981203532,G,G,Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.
981203578,C,C,Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.
981203578,C,T,Patients with the CT genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.
981203578,T,T,Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a better response to treatment as compared to patients with the CC or CT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.
981203641,G,G,Patients with the GG genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.
981203641,G,T,Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.
981203641,T,T,Patients with the TT genotype and Epilepsy who are treated with valproic acid may require a lower dose as compared to patients with the GG and GT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.
981203709,C,C,Patients with the CC genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
981203709,C,T,Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
981203709,T,T,Patients with the TT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.
981204080,C,C,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
981204080,C,T,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
981204080,T,T,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
981204090,A,A,"Patients with the AA genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies."
981204090,A,G,"Patients with the AG genotype and Cancer who are treated with anthracyclines and related substances may have a decreased, but not absent, risk of developing Cardiomyopathies as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies."
981204090,G,G,Patients with the GG genotype and Cancer who are treated with anthracyclines and related substances may have an increased risk of developing Cardiomyopathies as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced Cardiomyopathies.
981204107,C,C,"Patients with the CC genotype may have increased risk of Coronary Disease when treated with aspirin as compared to patients with the GG or CG genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin."
981204107,C,G,"Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin."
981204107,G,G,"Patients with the GG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin."
981204286,A,A,"Patients with genotype AA may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine."
981204286,A,G,"Patients with genotype AG may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine."
981204286,G,G,"Patients with genotype GG may have decreased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine."
981204306,A,A,"Patients with epilepsy and the AA genotype may have decreased likelihood of drug resistance when treated with phenytoin as compared to patients with the AG or GG genotypes. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin."
981204306,A,G,"Patients with epilepsy and the AG genotype may have increased likelihood of drug resistance when treated with phenytoin as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin."
981204306,G,G,"Patients with epilepsy and the GG genotype may have increased likelihood of drug resistance when treated with phenytoin as compared to patients with the AA genotype. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin."
981204317,A,A,"Patients with genotype AA may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin."
981204317,A,G,"Patients with genotype AG may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin."
981204317,G,G,"Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin."
981204361,A,A,"People with AA genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel."
981204361,A,G,"People with AG genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel."
981204361,G,G,"People with GG genotype may have decreased, but not absent, risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel."
981204455,A,A,"Genotype AA may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin."
981204455,A,G,"Genotype AG may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin."
981204455,G,G,"Genotype GG may be associated with increased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype AG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin."
981203918,C,C,Patients with the CC genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
981203918,C,T,Patients with the CT genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype or may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
981203918,T,T,Patients with the TT genotype and HIV infection who are treated with efavirenz may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.
981204137,A,A,"Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics."
981204137,A,C,"Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics."
981204137,C,C,"Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics."
981204403,A,A,Patients with the AA genotype may have a decreased risk of lymph node metastases and increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.
981204403,A,G,Patients with the AG genotype may have a decreased risk of lymph node metastases and an increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.
981204403,G,G,Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.
981204414,A,A,Patients with AA genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.
981204414,A,G,Patients with AG genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.
981204414,G,G,Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.
981204975,A,A,"Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine."
981204975,A,G,"Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine."
981204975,G,G,"Patients with the GG genotype may have decreased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype AA or AG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine."
981204372,A,A,Patients with AA genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.
981204372,A,G,Patients with AG genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.
981204372,G,G,Patients with GG genotype may have increased metabolism and decreased serum concentration of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.
981204272,A,A,"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel."
981204272,A,G,"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel."
981204272,G,G,"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to paclitaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paclitaxel."
981203545,A,A,"Patients with the rs6275 AA genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
981203545,A,G,"Patients with the rs6275 AG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype or may require an increased dose of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
981203545,G,G,"Patients with the rs6275 GG genotype and Heroin Dependence may require an increased dose of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
981345350,C,C,Patients with the rs4149056 CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.
981345350,C,T,Patients with the rs4149056 CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.
981345350,T,T,Patients with the rs4149056 TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.
1451244800,C,C,Patients with the CC genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.
1451244800,C,T,Patients with the CT genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.
1451244800,T,T,Patients with the TT genotype may have decreased exposure to atorvastatin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.
1451254525,C,C,Patients with the rs71647871 CC genotype who are treated with clopidogrel may have increased platelet aggregation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to clopidogrel.
1451254525,C,T,Patients with the rs71647871 CT genotype who are treated with clopidogrel may have decreased platelet aggregation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clopidogrel.
1451254525,T,T,Patients with the rs71647871 TT genotype who are treated with clopidogrel may have decreased platelet aggregation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clopidogrel.
1451261620,A,A,Patients with two X-chromosomes and the rs3788853 AA genotype may have increased likelihood of angioedema when treated with ace inhibitors as compared to patients with the CC genotype. This gene is on the X chromosome therefore some individuals may have only one allele. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.
1451261620,A,C,Patients with two X-chromosomes and the rs3788853 AC genotype may have decreased likelihood of angioedema when treated with ace inhibitors as compared to patients with the A or AA genotype. This gene is on the X chromosome therefore some individuals may have only one allele. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.
1451261620,C,C,Patients with two X-chromosomes and the rs3788853 CC genotype may have decreased likelihood of angioedema when treated with ace inhibitors as compared to patients with the AA genotype. This gene is on the X chromosome therefore some individuals may have only one allele. Other genetic and clinical factors may also influence ace inhibitor associated angioedema.
1451263877,C,C,"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with enflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451263877,C,T,Patients with the rs1800559 CT genotype may have increased risk for Malignant Hyperthermia when treated with enflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263877,T,T,Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with enflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263966,C,C,"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451263966,C,T,Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263966,T,T,Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263973,C,C,Patients with the rs1800559 CC genotype may have a decreased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263973,C,T,Patients with the rs1800559 CT genotype may have increased risk for malignant yperthermia when treated with sevoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263973,T,T,Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263980,C,C,"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with halothane as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451263980,C,T,Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263980,T,T,Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263986,C,C,"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with isoflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451263986,C,T,Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451263986,T,T,Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264020,C,C,"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451264020,C,T,Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264020,T,T,Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264060,A,A,Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with enflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264060,A,G,Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with enflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264060,G,G,"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with enflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451264081,A,A,Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264081,A,G,Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with halothane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264081,G,G,"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with halothane as compared to patients with the AA or AG genotype. OOther genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451264087,A,A,Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264087,A,G,Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with isoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264087,G,G,"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with isoflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451264128,A,A,Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264128,A,G,Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264128,G,G,"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451264140,A,A,Patients with the rs772226819 AA genotype may have increased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264140,A,G,Patients with the rs772226819 AG genotype may have increased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451264140,G,G,"Patients with the rs772226819 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451274200,A,A,The A allele of rs78060119 is assigned no function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1451274200,A,C,The A allele of rs78060119 is assigned no function by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1451274200,C,C,The A allele of rs78060119 is assigned no function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1451274045,A,A,"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype may have decreased activity of DPYD as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1451274045,A,T,"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AT genotype may have decreased activity of DPYD as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1451274045,T,T,"The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype may have increased activity of DPYD as compared to patients with the AT or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1451274090,A,A,"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451274090,A,T,"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the AT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451274090,T,T,"The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451274984,C,C,"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the TT or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451274984,C,T,"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451274984,T,T,"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451275020,C,C,"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CC genotype may have increased activity of DPYD as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1451275020,C,T,"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype may have decreased activity of DPYD as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1451275020,T,T,"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype may have decreased activity of DPYD as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1451276160,A,A,"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AA genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk of drug toxicity as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451276160,A,C,"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451276160,C,C,"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451275220,A,A,"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AA genotype may have increased DPYD activity as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1451275220,A,C,"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1451275220,C,C,"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the CC genotype may have decreased DPYD activity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1451274165,C,C,"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451274165,C,G,"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1451274165,G,G,"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CG or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981419540,A,A,"Patients with the AA genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin."
981419540,A,G,"Patients with the AG genotype may have increased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk to statin."
981419540,G,G,"Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin."
981238323,A,A,"Patients with the rs1695 AA genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide."
981238323,A,G,"Patients with the rs1695 AG genotype and Neoplasms may have increased response to cyclophosphamide as compared to patients with GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide."
981238323,G,G,"Patients with the rs1695 GG genotype and Neoplasms may have decreased response to cyclophosphamide as compared to patients with AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cyclophosphamide."
1451592476,C,C,Patients with postoperative pain and the rs7858836 CC genotype may have increased fentanyl dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.
1451592476,C,T,Patients with postoperative pain and the rs7858836 CT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.
1451592476,T,T,Patients with postoperative pain and the rs7858836 TT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.
1451592484,C,C,Patients with postoperative pain and the rs958804 CC genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.
1451592484,C,T,Patients with postoperative pain and the rs958804 CT genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.
1451592484,T,T,Patients with postoperative pain and the rs958804 TT genotype may have increased fentanyl dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.
981238397,A,A,Patients with acute lymphoblastic leukemia (ALL) and the rs1695 AA genotype may be less likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with mercaptopurine and methotrexate.
981238397,A,G,Patients with acute lymphoblastic leukemia (ALL) and the rs1695 AG genotype may be less likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with mercaptopurine and methotrexate.
981238397,G,G,Patients with acute lymphoblastic leukemia (ALL) and the rs1695 GG genotype may be more likely to experience drug toxicity when treated with mercaptopurine and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence likelihood of drug toxicity when treated with mercaptopurine and methotrexate.
1451599320,A,A,"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with carbamazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with carbamazepine."
1451599320,A,G,"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with carbamazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with carbamazepine."
1451599320,G,G,"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with carbamazepine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with carbamazepine."
1449004210,C,C,Patients with acute coronary syndrome and the CC genotype may have decreased response to clopidogrel as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.
1449004210,C,T,Patients with acute coronary syndrome and the CT genotype may have increased response to clopidogrel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.
1449004210,T,T,Patients with acute coronary syndrome and the TT genotype may have increased response to clopidogrel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to clopidogrel in patients with acute coronary syndrome.
1449004220,A,A,Pediatric patients with epilepsy and the AA genotype who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.
1449004220,A,G,Pediatric patients with epilepsy and the AG genotype who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotypes and increased concentrations as compared to the AA genotype. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.
1449004220,G,G,Pediatric patients with epilepsy and the GG genotype who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the pharmacokinetics of valproic acid.
1449004239,A,A,Patients with nasopharyngeal cancer and the AA genotype who are treated with platinum compounds and radiotherapy may have an increased risk of dermatitis as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449004239,A,C,Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449004239,C,C,Patients with nasopharyngeal cancer and the CC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449004245,C,C,Patients with the CC genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have an increased risk of dermatitis as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449004245,C,T,Patients with the CT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449004245,T,T,Patients with the TT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.
1449004487,A,A,"Patients with nasopharyngeal cancer and the AA genotype who are treated with platinum compounds and radiotherapy may have an increased risk of myelosuppression and neutropenia as compared to the AC and CC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy."
1449004487,A,C,"Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have an increased risk of myelosuppression and neutropenia as compared to the CC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy."
1449004487,C,C,"Patients with nasopharyngeal cancer and the CC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of myelosuppression and neutropenia as compared to the AA and AC genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Neutropenia or Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy."
1449004522,A,A,"Patients with nasopharyngeal cancer and the AA genotype may have an increased risk of Anemia and Neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype GG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds."
1449004522,A,G,"Patients with nasopharyngeal cancer and the AG genotype may have an increased risk of anemia and neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype GG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds."
1449004522,G,G,"Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of anemia and neutropenia when treated with Platinum compounds and radiotherapy as compared to genotype AA and AG. There was no association with risk of dermatitis, leukopenia, mucositis, myelosuppression and thrombocytopenia. Other clinical and genetic factors may also influence risk of anemia and neutropenia in patients with nasopharyngeal cancer who are treated with radiotherapy and platinum compounds."
1449004528,A,A,"Patients with nasopharyngeal cancer and the AA genotype may have an increased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AG and GG genotypes. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy."
1449004528,A,G,"Patients with nasopharyngeal cancer and the AG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy."
1449004528,G,G,"Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy."
1449004567,A,A,Patients with epilepsy and the AA genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.
1449004567,A,G,Patients with epilepsy and the AG genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the GG genotypes but improved response as compared to the AA genotype. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.
1449004567,G,G,Patients with epilepsy and the GG genotype may have increased concentrations of oxcarbazepine and improved response as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.
1449140063,C,C,"Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype, and an increased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer."
1449140063,C,T,"Patients with the CT genotype and bladder cancer may have increased metabolism of temsirolimus as compared to patients with the TT genotype. Patients with the CT genotype who are administered temsirolimus may also have a decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CC genotypes and a increased likelihood as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer."
1449140063,T,T,"Patients with the TT genotype and bladder cancer may have decreased metabolism of temsirolimus as compared to patients with the CC or CT genotypes, and an decreased likelihood of adverse events including bone marrow, gastro-intestinal and other toxicities as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of temsirolimus as well as likelihood of adverse events in patients with bladder cancer."
1449140273,G,G,"Patients with the GG genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer."
1449140273,G,T,"Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer."
1449140273,T,T,"Patients with the TT genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the GT or GG genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer."
1449144292,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144292,A,G,"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144292,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144298,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144298,A,G,"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144298,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144304,C,C,Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144304,C,T,"Patients with the CT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the TT genotype, but a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144304,T,T,Patients with the TT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449004229,C,C,"Patients with epilepsy and the CC genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the CT or TT genotypes, although this is contradicted in four studies. Other clinical and genetic factors may also influence the response of epileptic patients to anti-epileptic drugs."
1449004229,C,T,"Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs."
1449004229,T,T,"Patients with epilepsy and the TT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have a worse response as compared to patients with the CT or CC genotypes, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs."
1449144310,C,C,Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144310,C,T,"Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144310,T,T,Patients with the TT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144316,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144316,A,G,"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144316,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449005066,C,T,Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A/*1B) may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A/*1A). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.
1449005066,T,T,Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A/*1A) may have a greater likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A/*1B). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.
1451599327,A,A,Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with lamotrigine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with lamotrigine.
1451599327,A,G,Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with lamotrigine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with lamotrigine.
1451599327,G,G,Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with lamotrigine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of drug resistance when treated with lamotrigine.
1449144322,C,C,Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144322,C,G,"Patients with the CG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144322,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144328,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144328,A,G,"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144328,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144334,C,C,Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144334,C,T,"Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response when compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144334,T,T,Patients with the TT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144340,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144340,A,G,"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144340,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144346,C,C,Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144346,C,T,"Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144346,T,T,Patients with the TT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144352,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144352,A,G,"Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144352,G,G,Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449564190,A,A,Patients with the AA genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564190,A,C,Patients with the AC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564190,C,C,Patients with the CC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564196,A,A,Patients with the AA genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564196,A,G,Patients with the AG genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564196,G,G,Patients with the GG genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564202,A,A,Patients with the AA genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564202,A,C,Patients with the AC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564202,C,C,Patients with the CC genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1451599340,A,A,"Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with oxcarbazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with oxcarbazepine."
1451599340,A,G,"Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with oxcarbazepine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with oxcarbazepine."
1451599340,G,G,"Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with oxcarbazepine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug resistance when treated with oxcarbazepine."
1449564208,C,C,Patients with the CC genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564208,C,T,Patients with the CT genotype may have an increased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1449564208,T,T,Patients with the TT genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.
1450112801,G,G,Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112801,G,T,Patients with osteosarcoma and the GT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1450112801,T,T,Patients with osteosarcoma and the TT genotype may have increased clearance of methotrexate as compared to patients with the GG genotype. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.
1451599347,A,A,Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with phenytoin.
1451599347,A,G,Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with phenytoin.
1451599347,G,G,Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with phenytoin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of drug resistance when treated with phenytoin.
1451599354,A,A,Patients with epilepsy and the rs2304016 AA genotype may have an increased risk of experiencing drug resistance when treated with topiramate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with topiramate.
1451599354,A,G,Patients with epilepsy and the rs2304016 AG genotype may have an increased risk of experiencing drug resistance when treated with topiramate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug resistance when treated with topiramate.
1451599354,G,G,Patients with epilepsy and the rs2304016 GG genotype may have a decreased risk of experiencing drug resistance when treated with topiramate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of drug resistance when treated with topiramate.
1450932687,A,A,"Patients with the rs4680 AA genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more adverse events as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence."
1450932687,A,G,"Patients with the rs4680 AG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report fewer adverse events as compared to patients with the AA or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence."
1450932687,G,G,"Patients with the rs4680 GG genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may report more adverse events as compared to patients with the AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence."
1449163928,A,A,"Patients with the AA genotype may have decreased metabolism of caffeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking."
1449163928,A,G,"Patients with the AG genotype may have decreased metabolism of caffeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking."
1449163928,G,G,"Patients with the GG genotype may have increased metabolism of caffeine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking."
1449162866,A,A,Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1449162866,A,G,"Patients with the AG genotype may have an increased exposure to tramadol as compared to patients with the GG genotype, but a decreased exposure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol."
1449162866,G,G,Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1449162899,A,A,"Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the CC genotype. However, another study found no association between this variant and exposure to tramadol. Other genetic and clinical factors may also influence a patient's exposure to tramadol."
1449162899,A,C,There is currently no evidence to show whether the AC genotype affects a patient's exposure to tramadol.
1449162899,C,C,"Patients with the CC genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. However, another study found no association between this variant and exposure to tramadol. Other genetic and clinical factors may also influence a patient's exposure to tramadol."
1449162912,A,A,Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1449162912,A,G,There is currently no evidence to show whether the AG genotype affects a patient's exposure to tramadol.
1449162912,G,G,Patients with the GG genotype may have a decreased exposure to tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's exposure to tramadol.
1449163252,C,C,High-risk pediatric patients with acute lymphoblastic leukemia who have the CC genotype may have an increased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449163252,C,T,High-risk pediatric patients with acute lymphoblastic leukemia who have the CT genotype may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449163252,T,T,High-risk pediatric patients with acute lymphoblastic leukemia who have the TT genotype may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449163306,A,A,Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449163306,A,C,Pediatric patients with the AC genotype and acute lymphoblastic leukemia may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449163306,C,C,Pediatric patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.
1449164609,A,A,"Patients with the AA genotype were not analyzed in this study, but patients with the AT genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of complete remission."
1449164609,A,T,Patients with the AT genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1449164609,T,T,Patients with the TT genotype and acute myeloid leukemia may be less likely to have complete remission when treated with idarubicin as compared to patients with the AT genotype. Other genetic and clinical factors may also influence likelihood of complete remission.
1449164746,A,A,Patients with the AA genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449164746,A,G,Patients with the AG genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449164746,G,G,Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449164752,C,C,Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1449164752,C,G,Patients with the CG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1449164752,G,G,Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1449164863,A,A,"Individuals with the AA genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically mean arterial pressure, as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA."
1449164863,A,G,"Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA."
1449164863,G,G,"Individuals with the GG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA."
1449164869,A,A,"Individuals with the AA genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA."
1449164869,A,G,"Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA."
1449164869,G,G,"Individuals with the GG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence an individual's response to MDMA."
1449165034,G,G,Patients with the GG genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate toxicity.
1449165034,G,T,"Patients with the GT genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype, or a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate toxicity."
1449165034,T,T,Patients with the TT genotype and rheumatoid arthritis who are taking methotrexate may have a decreased risk for adverse events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate toxicity.
1449188737,C,C,"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188737,C,T,"Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188737,T,T,"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449271360,C,C,Patients with the CC genotype and sickle-cell anemia may have decreased levels of glucuronidation of morphine as compared to patients with the TT genotype and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.
1449271360,C,T,Patients with the CT genotype and sickle-cell anemia may have decreased levels of glucuronidation of morphine as compared to patients with the TT genotype and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.
1449271360,T,T,Patients with the TT genotype and sickle-cell anemia may have increased levels of glucuronidation of morphine as compared to patients with the CC or CT genotypes and sickle cell anemia. Other genetic and clinical factors may also affect morphine glucuronidation in patients with sickle cell anemia.
1449169595,A,A,Subjects with the AA genotype may have a decreased exposure to atorvastatin as compared to individuals with the AC genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449169595,A,C,Subjects with the AC genotype may have an increased exposure to atorvastatin as compared to individuals with the AA or CC genotypes. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449169595,C,C,Subjects with the CC genotype may have a decreased exposure to atorvastatin as compared to individuals with the AC genotype. Other clinical and genetic factors may also influence exposure to atorvastatin.
1449169668,A,A,Patients with the AA genotype may be more likely have a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AG or GG genotypes who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449169668,A,G,Patients with the AG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449169668,G,G,Patients with the GG genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.
1449170150,A,A,"Patients with the AA genotype who are treated with allopurinol may have a decreased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AG or GG genotypes. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol."
1449170150,A,G,"Patients with the AG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol."
1449170150,G,G,"Patients with the GG genotype who are treated with allopurinol may have an increased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA genotype. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol."
1449752771,C,C,Patients with the CC genotype and colorectal cancer may have decreased survival times when treated with oxaliplatin-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.
1449752771,C,G,Patients with the CG genotype and colorectal cancer may have decreased survival times when treated with oxaliplatin-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.
1449752771,G,G,Patients with the GG genotype and colorectal cancer may have increased survival times when treated with oxaliplatin-based treatments as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.
1450813825,C,C,Patients with the CC genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.
1450813825,C,T,Patients with the CT genotype may be more likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.
1450813825,T,T,Patients with the TT genotype may be more likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.
1450814653,C,C,"Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814653,C,T,"Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814653,T,T,"Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450928460,A,A,"Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928460,A,G,"Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928460,G,G,"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928473,C,C,"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928473,C,G,"Patients with schizophrenia and the CG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928473,G,G,"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the CC or CG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928522,C,C,"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the TT genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928522,C,T,"Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the TT genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928522,T,T,"Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC or CT genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450822470,C,C,Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450822470,C,G,Patients with the CG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450822470,G,G,Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450822778,A,A,"Patients with the AA genotype may be at a decreased risk of suffering from cardiac arrest or respiratory arrest following overdose of antidepressants, antipsychotics, benzodiazepines, opioids or sympathomimetics as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of cardiac arrest or respiratory arrest following overdose."
1450822778,A,G,"Patients with the AG genotype may be at an increased risk of suffering from cardiac arrest or respiratory arrest following overdose of antidepressants, antipsychotics, benzodiazepines, opioids or sympathomimetics as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of cardiac arrest or respiratory arrest following overdose."
1450822778,G,G,"Patients with the GG genotype may be at an increased risk of suffering from cardiac arrest or respiratory arrest following overdose of antidepressants, antipsychotics, benzodiazepines, opioids or sympathomimetics as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of cardiac arrest or respiratory arrest following overdose."
1450822829,C,C,Patients with the CC genotype may be more likely to successfully quit smoking for at least one year as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking.
1450822829,C,T,Patients with the CT genotype may be less likely to successfully quit smoking for at least one year as compared to patients with the CC genotype. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking.
1450822829,T,T,Patients with the TT genotype may be less likely to successfully quit smoking for at least one year as compared to patients with the CC genotype. Other genetic or clinical factors may also affect the likelihood of a patient successfully quitting smoking.
1450823316,A,A,Patients with the AA genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.
1450823316,A,G,Patients with the AG genotype may be less likely to adhere to nicotine replacement therapy (NRT) and may consume less NRT at 7 days post quit attempt as compared to patients with the GG genotype but more likely to adhere to NRT and may consume more NRT at 7 days post quit attempt as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.
1450823316,G,G,Patients with the GG genotype may be more likely to adhere to nicotine replacement therapy (NRT) and may consume more NRT at 7 days post quit attempt as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's adherence to or consumption of NRT.
1450823707,C,C,"Patients with schizophrenia, schizoaffective disorders or other psychotic disorders, and the CC genotype may have an increased response to treatment with either aripiprazole or risperidone as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to aripiprazole or risperidone."
1450823707,C,T,"Patients with schizophrenia, schizoaffective disorders or other psychotic disorders, and the CT genotype may have a decreased response to treatment with either aripiprazole or risperidone as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to aripiprazole or risperidone."
1450823707,T,T,"Patients with schizophrenia, schizoaffective disorders or other psychotic disorders, and the TT genotype may have a decreased response to treatment with either aripiprazole or risperidone as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to aripiprazole or risperidone."
1450928608,A,A,"Patients with the AA genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the AC or CC genotypes. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs."
1450928608,A,C,"Patients with the AC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs."
1450928608,C,C,"Patients with the CC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs."
1450812333,A,A,"Male patients with the AA genotype may have an increased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the GG genotype. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine."
1450812333,A,G,"Male patients with the AG genotype may have an increased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the GG genotype. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine."
1450812333,G,G,"Male patients with the GG genotype may have a decreased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the AA or AG genotypes. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine."
1448636924,A,A,Patients with the AA genotype and breast cancer who are treated with everolimus may have decreased likelihood of drug discontinuation as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of discontinuation in patients with breast cancer who are treated with everolimus.
1448636924,A,G,"Patients with the AG genotype and breast cancer who are treated with everolimus may have decreased likelihood of of drug discontinuation as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of drug discontinuation in patients with breast cancer who are treated with everolimus."
1448636924,G,G,Patients with the GG genotype and breast cancer who are treated with everolimus may have increased likelihood of drug discontinuation as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence drug discontinuation in patients with breast cancer who are treated with everolimus.
1450812912,A,A,Alcohol-dependent patients with the AA genotype may have decreased stress-induced alcohol cravings as compared to patients with the TT genotype. Other genetic and clinical factors may also affect stress-induced alcohol craving in alcohol-dependent patients.
1450812912,A,T,Alcohol-dependent patients with the AT genotype may have decreased stress-induced alcohol cravings as compared to patients with the TT genotype. Other genetic and clinical factors may also affect stress-induced alcohol craving in alcohol-dependent patients.
1450812912,T,T,Alcohol-dependent patients with the TT genotype may have increased stress-induced alcohol cravings as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect stress-induced alcohol craving in alcohol-dependent patients.
1450820979,C,C,"Patients with the CC genotype may have an increased severity of nicotine withdrawal, as indicated by a higher Minnesota Nicotine Withdrawal Scale score, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms."
1450820979,C,T,"Patients with the CT genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms."
1450820979,T,T,"Patients with the TT genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms."
1449565072,C,C,"Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer."
1449565072,C,T,"Patients with the CT genotype and non-small cell lung cancer who are treated with gemcitabine may have decreased severity of thrombocytopenia as compared to patients with the CC genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer."
1449748502,A,A,"Patients with the AA genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome."
1449748502,A,C,"Patients with the AC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome."
1449748502,A,T,"Patients with the AT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome."
1449748502,C,C,"Patients with the CC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome."
1449748502,C,T,"Patients with the CT genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome."
1449748502,T,T,"Patients with the TT genotype and nephrotic syndrome may have an increased response when treated with tacrolimus as compared to patients with the CC, CT or AC genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome."
1450810266,A,A,Patients with the AA genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810266,A,C,Patients with the AC genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence or opioid dependence.
1450810266,C,C,Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450822281,A,A,"Patients with the AA genotype may have decreased cravings for nicotine, both in general and following consumption of alcohol, as compared to patients with the AG genotype. However, another study found no association between this variant and nicotine craving. Other genetic or clinical factors may also affect nicotine cravings."
1450822281,A,G,"Patients with the AG genotype may have increased cravings for nicotine, both in general and following consumption of alcohol, as compared to patients with the AA genotype. However, another study found no association between this variant and nicotine craving. Other genetic or clinical factors may also affect nicotine cravings."
1450822281,G,G,There is currently no available evidence on the relationship between the GG genotype and nicotine craving.
1450823109,C,C,Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823109,C,T,Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823109,T,T,Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823322,A,A,Patients with the AA genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.
1450823322,A,G,Patients with the AG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.
1450823322,G,G,Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence.
1450814529,A,A,Patients with the AA genotype may have increased alcohol consumption as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's consumption of alcohol.
1450814529,A,G,Patients with the AG genotype may have increased alcohol consumption as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's consumption of alcohol.
1450814529,G,G,Patients with the GG genotype may have decreased alcohol consumption as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's consumption of alcohol.
1450814671,C,C,There is currently no available evidence regarding the association of the CC genotype with response to bupropion.
1450814671,C,T,"Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814671,T,T,"Patients with the TT genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to bupropion."
1450814929,C,C,Patients with Type II diabetes and the CC genotype may have an increased response to pioglitazone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to pioglitazone.
1450814929,C,T,Patients with Type II diabetes and the CT genotype may have a decreased response to pioglitazone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to pioglitazone.
1450814929,T,T,Patients with Type II diabetes and the TT genotype may have a decreased response to pioglitazone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to pioglitazone.
1450931522,C,C,Patients with the CC genotype may have a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931522,C,G,Patients with the CG genotype may have a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931522,G,G,Patients with the GG genotype may have an increased risk of developing alcoholism as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450936205,C,C,Patients with the CC genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936205,C,T,Patients with the CT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936205,T,T,Patients with the TT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1449269473,C,C,Patients with the CC genotype may have an increased response to oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to oxycodone.
1449269473,C,T,Patients with the CT genotype may have an increased response to oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to oxycodone.
1449269473,T,T,Patients with the TT genotype may have a decreased response to oxycodone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to oxycodone.
1449269910,C,C,"Patients with the rs9923231 CC genotype may have a decreased risk of bleeding when treated with warfarin as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding."
1449269910,C,T,"Patients with the rs9923231 CT genotype may have an increased risk of bleeding when treated with warfarin as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding."
1449269910,T,T,"Patients with the rs9923231 TT genotype may have an increased risk of bleeding when treated with warfarin as compared to the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding."
1145231686,A,A,"Patients with the rs2032582 AA genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment."
1145231686,A,C,"Patients with the rs2032582 AC genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment."
1145231686,A,T,"Patients with the rs2032582 AT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment."
1145231686,C,C,"Patients with the rs2032582 CC genotype who are treated with pravastatin may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment."
1145231686,C,T,"Patients with the rs2032582 CT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment."
1145231686,T,T,"Patients with the rs2032582 TT genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the AC, CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment."
1451605911,A,A,"Patients with schizophrenia and the rs11872992 AA genotype may have a decreased, but not absent, risk for weight gain when treated with olanzapine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk for weight gain when treated with olanzapine."
1451605911,A,G,"Patients with schizophrenia and the rs11872992 AG genotype may have an increased risk for weight gain when treated with olanzapine as compared to patients with the AA genotype and a decreased, but not absent, risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for weight gain when treated with olanzapine."
1451605911,G,G,Patients with schizophrenia and the rs11872992 GG genotype may have an increased risk for weight gain when treated with olanzapine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk for weight gain when treated with olanzapine.
1451605946,A,A,Patients with schizophrenia and the rs2268639 AA genotype who are treated with olanzapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.
1451605946,A,T,Patients with schizophrenia and the rs2268639 AT genotype who are treated with olanzapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.
1451605946,T,T,Patients with schizophrenia and the rs2268639 TT genotype who are treated with olanzapine may have greater weight gain as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.
1450377214,A,A,Patients with the AA genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377214,A,G,Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377214,G,G,Patients with the GG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1451606000,A,A,Patients with thrombosis and the rs1800566 AA genotype may have a decreased response to warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to warfarin.
1451606000,A,G,Patients with thrombosis and the rs1800566 AG genotype may have a decreased response to warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to warfarin.
1451606000,G,G,Patients with thrombosis and the rs1800566 GG genotype may have an increased response to warfarin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to warfarin.
1449271027,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271027,C,G,"Patients with breast cancer and the CG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271027,G,G,"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271033,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271033,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271033,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271057,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271057,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271057,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271063,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271063,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271063,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271069,G,G,"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271069,G,T,"Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271069,T,T,"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449165230,C,C,"Patients with the CC genotype who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotypes, however the opposite is reported in one study, and no association was reported in two studies. Other clinical and genetic factors may also influence bioavailability of metformin."
1449165230,C,T,"Patients with the CT genotype and who are treated with metformin may have increased bioavailability of metformin as compared to patients with the TT genotype, however the opposite is reported in one study, and no association was reported in two studies. Other clinical and genetic factors may also influence bioavailability of metformin."
1449165230,T,T,"Patients with the TT genotype who are treated with metformin may have decreased bioavailability of metformin as compared to patients with the CC or CT genotypes, however the opposite is reported in one study, and no association was reported in two studies . Other clinical and genetic factors may also influence bioavailability of metformin."
1449165794,A,A,"Patients who are undergoing liver transplantation and receive a liver from a DONOR with the AA genotype may have decreased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations."
1449165794,A,G,"Patients who are undergoing liver transplantation and receive a liver from a DONOR with the AG genotype may have increased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations."
1449165794,G,G,"Patients who are undergoing liver transplantation and receive a liver from a DONOR with the GG genotype may have increased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations."
1448636814,C,C,Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of progression-free survival and increased likelihood of pneumonitis as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.
1448636814,C,T,Patients with the CT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.
1448636814,T,T,Patients with the TT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.
1448636842,A,A,Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.
1448636842,A,C,"Patients with the AC genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the CC genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus."
1448636842,C,C,Patients with the CC genotype and breast cancer who are treated with everolimus may have decreased likelihood of Lymphopenia as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.
1448636848,A,A,Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Mucositis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.
1448636848,A,G,"Patients with the AG genotype and breast cancer who are treated with everolimus may have increased likelihood of mucositis as compared to patients with the GG genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus."
1448636848,G,G,Patients with the GG genotype and breast cancer who are treated with everolimus may have decreased likelihood of Mucositis as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.
1450822790,A,A,"Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence."
1450822790,A,G,"Patients with the AG genotype may have an increased risk of developing opioid dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence."
1450822790,G,G,"Patients with the GG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. However, another study did not find an association between this variant and opioid dependence. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence."
1450932989,G,G,"Patients with beta-thalassemia and the GG genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450932989,G,T,"Patients with beta-thalassemia and the GT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450932989,T,T,"Patients with beta-thalassemia and the TT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1451608148,C,C,Patients with breast cancer and the rs1937840 CC genotype may have increased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.
1451608148,C,G,Patients with breast cancer and the rs1937840 CG genotype may have increased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.
1451608148,G,G,Patients with breast cancer and the rs1937840 GG genotype may have decreased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.
1449189236,G,G,Patients with the GG genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449189236,G,T,Patients with the GT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449189236,T,T,Patients with the TT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a lower increase in blood glucose than patients with the GG or GT genotypes. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1450374881,A,A,Patients with the AA genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have higher adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1450374881,A,C,Patients with the AC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1450374881,C,C,Patients with the CC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.
1450375024,A,A,"Patients with testicular cancer and the AA genotype may be at an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide."
1450375024,A,G,"Patients with testicular cancer and the AG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide."
1450375024,G,G,"Patients with testicular cancer and the GG genotype may be at a decreased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide."
1450375035,C,C,"There is currently no available evidence on the effect of the CC genotype on a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375035,C,T,"Patients with testicular cancer and the CT genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375035,T,T,"Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide."
1449556772,C,C,Patients with the rs4149056 CC genotype may have increased serum concentrations of simvastatin acid as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.
1449556772,C,T,"Patients with the rs4149056 CT genotype may have increased serum concentrations of simvastatin acid as compared to patients with the TT genotype, but decreased concentrations as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid."
1449556772,T,T,Patients with the rs4149056 TT genotype may have decreased serum concentrations of simvastatin acid as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.
1449188679,G,G,"Patients with the GG genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188679,G,T,"Patients with the GT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188679,T,T,"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449557359,C,C,Patients with metastatic colorectal cancer and the rs11574077 CC genotype may have decreased metabolism of irinotecan as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs11574077 and irinotecan and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of irinotecan.
1449557359,C,T,Patients with metastatic colorectal cancer and the rs11574077 CT genotype may have decreased metabolism of irinotecan as compared to patients with the TT genotype but increased metabolism as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs11574077 and irinotecan and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of irinotecan.
1449557359,T,T,Patients with metastatic colorectal cancer and the rs11574077 TT genotype may have increased metabolism of irinotecan as compared to patients with the CT or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs11574077 and irinotecan and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of irinotecan.
1449166824,C,C,Individuals with the CC genotype may have a decreased response to caffeine or chlorocresol as compared to individuals with the CT or TT genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.
1449166824,C,T,Individuals with the CT genotype may have an increased response to caffeine or chlorocresol as compared to individuals with the CC genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.
1449166824,T,T,Individuals with the TT genotype may have an increased response to caffeine or chlorocresol as compared to individuals with the CC genotypes. Other clinical and genetic factors may also influence response to caffeine or chlorocresol.
1449270865,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270865,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270865,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449564951,C,C,"Patients with diabetes mellitus and the CC genotype who are taking sulfonylureas may have worse response as compared to patients with the CT or TT genotypes, although no association with response is also reported, and one found that the heterozygous genotype had an improved response as compared to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus."
1449564951,C,T,"Patients with diabetes mellitus and the CT genotype who are taking sulfonylureas may have improved response as compared to patients with the CC genotype, although no association with response is also reported, and one found that this genotype had an improved response as compared to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus."
1449564951,T,T,"Patients with diabetes mellitus and the TT genotype who are taking sulfonylureas may have improved response as compared to patients with the CC genotype, although no association with response is also reported, and one found that the heterozygous genotype had an improved response as compared to to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus."
1449270871,C,C,"Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270871,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270871,T,T,"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270877,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270877,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270877,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270889,C,C,"Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270889,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270889,T,T,"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270895,C,C,"Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270895,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270895,T,T,"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270901,A,A,"Patients with breast cancer and the AA genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270901,A,G,"Patients with breast cancer and the AG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but an increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270901,G,G,"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270907,G,G,"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270907,G,T,"Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270907,T,T,"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270925,G,G,"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270925,G,T,"Patients with breast cancer and the GT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270925,T,T,"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270931,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270931,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270931,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270937,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270937,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270937,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270943,C,C,"Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270943,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270943,T,T,"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270949,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270949,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270949,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270955,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270955,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270955,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270973,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270973,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270973,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270979,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270979,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270979,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449564957,A,A,"Patients with the AA genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus."
1449564957,A,C,"Patients with the AC genotype and diabetes mellitus may have a worse response to sulfonylureas as compared to the AA and CC genotypes. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus."
1449564957,C,C,"Patients with the CC genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus."
1449564963,C,C,"Patients with the CC genotype and and Alzheimer Disease may have an improved response to donepezil (slower cognitive decline) as compared to patients with the CT and TT genotypes, although this is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease."
1449564963,C,T,"Patients with the CT genotype and and Alzheimer Disease may have an improved response to donepezil (slower cognitive decline) as compared to patients with the TT genotypes, and worse response as compared to CC genotype. This is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease."
1449564963,T,T,"Patients with the TT genotype and and Alzheimer Disease may have a worse response to donepezil (faster cognitive decline) as compared to patients with the CT and CC genotypes, although this is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease."
1450928454,A,A,"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928454,A,C,"Patients with schizophrenia and the AC genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928454,C,C,"Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the AA or AC genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1449003717,C,C,There is currently no available evidence regarding the effect of the CC genotype on oseltamivir concentrations in patients.
1449003717,C,T,Patients with the CT genotype may have increased concentrations of oseltamivir compared to patients with the TT genotype. Other genetic and clinical factors may also influence oseltamivir concentrations in patients.
1449003717,T,T,Patients with the TT genotype may have decreased concentrations of oseltamivir compared to patients with the CT genotype. Other genetic and clinical factors may also influence oseltamivir concentrations in patients.
1449003723,G,G,Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003723,G,T,Patients with the GT genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the TT genotype or an increased risk of coronary artery disease compared to patients with the GG. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003723,T,T,Patients with the TT genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GT and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003729,A,A,Patients with the AA genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003729,A,G,Patients with the AG genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GG genotype or a decreased risk of coronary artery disease compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003729,G,G,Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003741,A,A,Patients with the AA genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003741,A,G,Patients with the AG genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GG genotype or a decreased risk of coronary artery disease compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1449003741,G,G,Patients with the GG genotype may have decreased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.
1451553602,G,G,"The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
1451553602,G,T,"The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
1451553602,T,T,"The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
1450928505,C,C,"Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CG or GG genotypes. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928505,C,G,"Patients with schizophrenia and the CG genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928505,G,G,"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone."
1451615421,A,A,"The current evidence base suggests that there is no significant association between the rs3740065 AA genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
1451615421,A,G,"The current evidence base suggests that there is no significant association between the rs3740065 AG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
1451615421,G,G,"The current evidence base suggests that there is no significant association between the rs3740065 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3740065 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure."
1450928534,A,A,"Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, the association lost significance following correction for multiple testing while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928534,A,G,"Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, the association lost significance following correction for multiple testing while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450928534,G,G,"Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the AA or AG genotypes. However, the association lost significance following correction for multiple testing while another study failed to find an association. Other genetic or clinical factors may also affect a patient's response to risperidone."
1450373610,A,A,Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373610,A,G,Patients with the AG genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373610,G,G,Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.
1450373616,A,A,Patients with the AA genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.
1450373616,A,G,Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.
1450373616,G,G,Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival times when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.
1450377181,C,C,Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377181,C,T,Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377181,T,T,Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377193,C,C,Patients with the CC genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377193,C,T,Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377193,T,T,Patients with the TT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1449752982,C,C,"CC genotype may be associated with a decreased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the TT or CT genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir."
1449752982,C,T,"CT genotype may be associated with an increased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the CC genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir."
1449752982,T,T,"TT genotype may be associated with an increased affinity for the nucleoside phosphonate analogs cidofovir, adefovir, and tenofovir as compared with the CC genotype. Other genetic and clinical factors may affect the transport of adefovir dipivoxil, cidofovir or tenofovir."
1449753021,C,C,"Genotype CC may be associated with increased uptake of adefovir dipivoxil as compared to genotype TT or CT. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir."
1449753021,C,T,"Genotype CT may be associated with decreased uptake of adefovir dipivoxil as compared to genotype CC. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir."
1449753021,T,T,"Genotype TT may be associated with decreased uptake of adefovir dipivoxil as compared to genotype CC. However, this has not been demonstrated clinically and other genetic and clinical factors may affect the renal clearance of adefovir."
1450823344,A,A,Patients with the AA genotype may have increased nicotine consumption as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's nicotine consumption.
1450823344,A,G,Patients with the AG genotype may have decreased nicotine consumption as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption.
1450823344,G,G,Patients with the GG genotype may have decreased nicotine consumption as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption.
1450931422,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931422,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931422,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931428,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931428,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931428,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931440,C,C,Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931440,C,T,Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931440,T,T,Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC or CT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931815,A,A,Patients with the AA genotype may be less likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AC genotype. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1450931815,A,C,Patients with the AC genotype may be more likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AA or CC genotypes. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1450931815,C,C,Patients with the CC genotype may be less likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AC genotype. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1450931828,A,A,"Patients with the rs4680 AA genotype may be less likely to experience somnolence following fentanyl administration as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of experiencing fentanyl-induced somnolence."
1450931828,A,G,"Patients with the rs4680 AG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of experiencing fentanyl-induced somnolence."
1450931828,G,G,"Patients with the rs4680 GG genotype may be more likely to experience somnolence following fentanyl administration as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect the likelihood of experiencing fentanyl-induced somnolence."
1450823773,A,A,"Patients with the AA genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AG or GG genotypes. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence."
1450823773,A,G,"Patients with the AG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence."
1450823773,G,G,"Patients with the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and nicotine dependence. Other genetic or clinical factors may also affect a patient's risk of developing nicotine dependence."
1450823785,A,A,"Patients with the AA genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence."
1450823785,A,G,"Patients with the AG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence."
1450823785,G,G,"Patients with the GG genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the AA genotype. However, this association was not significant and other studies have not found an association between this variant and cocaine dependence. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence."
1449157600,A,A,Patients with the AA genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1449157600,A,G,Patients with the AG genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1449157600,G,G,Patients with the GG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.
1450377220,A,A,Patients with the AA genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377220,A,G,Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450377220,G,G,Patients with the GG genotype who are receiving concomitant phenytoin and isoniazid may be at a decreased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.
1450826907,A,A,"Patients with the rs1799971 AA genotype may have an increased analgesic response to alfentanil as compared to patients with the AG or GG genotypes. Note that one study reported a non-significant association. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a patient's response to alfentanil."
1450826907,A,G,"Patients with the rs1799971 AG genotype may have a decreased analgesic response to alfentanil as compared to patients with the AA genotype. Note that one study reported a non-significant association. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a patient's response to alfentanil."
1450826907,G,G,"Patients with the rs1799971 GG genotype may have a decreased analgesic response to alfentanil as compared to patients with the AA genotype. Note that one study reported a non-significant association. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a patient's response to alfentanil."
1450826913,A,A,"Patients with the rs1799971 AA genotype may have decreased plasma concentrations of alfentanil as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and alfentanil and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect plasma concentrations of alfentanil."
1450826913,A,G,"Patients with the rs1799971 AG genotype may have increased plasma concentrations of alfentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and alfentanil and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect plasma concentrations of alfentanil."
1450826913,G,G,"Patients with the rs1799971 GG genotype may have increased plasma concentrations of alfentanil as compared to patients with the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and alfentanil and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect plasma concentrations of alfentanil."
1450826993,A,A,"Patients with the rs1799971 AA genotype may have an increased response to opioids as compared to patients with the AG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to opioids."
1450826993,A,G,"Patients with the rs1799971 AG genotype may have a decreased response to opioids as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to opioids."
1450826993,G,G,"There is currently no available evidence regarding the association between the rs1799971 GG genotype and response to opioids. However, patients with the AG genotype may have a decreased response to opioids as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to opioids."
1450933062,A,A,"Patients with the AA genotype may have a decreased response to anti-TNF drugs, as measured by a decrease in quality of life scores, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs."
1450933062,A,G,"Patients with the AG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs."
1450933062,G,G,"Patients with the GG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs."
1450933116,A,A,Patients with ADHD and the AA genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AT genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.
1450933116,A,T,Patients with ADHD and the AT genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.
1450933116,T,T,There is currently no available evidence regarding the association of the TT genotype and a patient's risk of developing nicotine dependence.
1451615920,C,C,Patients with the rs2736308 CC genotype may have an increased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.
1451615920,C,T,Patients with the rs2736308 CT genotype may have an increased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.
1451615920,T,T,Patients with the rs2736308 TT genotype may have a decreased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.
1449140229,A,A,Patients with the AA genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.
1449140229,A,G,Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.
1449140229,G,G,Patients with the GG genotype and bladder cancer may have decreased exposure to sirolimus and temsirolimus as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.
1449645366,C,C,Patients with the CC genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645366,C,T,Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645366,T,T,Patients with the TT genotype may have an increased rate of sulfation of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645372,C,C,Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645372,C,T,Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645372,T,T,Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645378,C,C,"Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645378,C,T,"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645378,T,T,"Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645386,C,C,Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645386,C,T,Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645386,T,T,Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645392,C,C,Patients with the CC genotype may have an increased rate of sulfation of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645392,C,T,Patients with the CT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645392,T,T,Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1450813534,C,C,"Patients with the CC genotype may have less severe nicotine dependence as compared to patients with the CG genotype, as measured by mean number of cigarettes smoked per day. However, analysis of other measurements did not find a significant association. Other genetic and clinical factors may also affect the severity of nicotine dependence."
1450813534,C,G,"Patients with the CG genotype may have more severe nicotine dependence as compared to patients with the CC genotype, as measured by mean number of cigarettes smoked per day. However, analysis of other measurements did not find a significant association. Other genetic and clinical factors may also affect the severity of nicotine dependence."
1450813534,G,G,There is currently no available evidence regarding the association between the GG genotype and severity of nicotine dependence.
1450813554,A,A,"Patients with the AA genotype may have more severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence."
1450813554,A,C,"Patients with the AC genotype may have more severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence."
1450813554,C,C,"Patients with the CC genotype may have less severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the AA or AC genotypes. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence."
1451447387,A,A,Patients with the rs12422149 AA genotype may have decreased LDL lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvasatin.
1451447387,A,G,Patients with the rs12422149 AG genotype may have decreased LDL lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvasatin.
1451447387,G,G,Patients with the rs12422149 GG genotype may have increased LDL lowering effect as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvasatin.
1449168058,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168058,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168058,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168065,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168065,A,T,Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168065,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168321,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168321,A,T,Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168321,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168628,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168628,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168628,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168635,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168635,A,C,Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168635,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168642,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168642,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168642,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449169490,G,G,Patients with the GG genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.
1449169490,G,T,Patients with the GT genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.
1449169490,T,T,Patients with the TT genotype and epilepsy who are treated with valproic acid may have decreased concentrations of valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence concentrations of valproic acid in patients with epilepsy.
1449271393,A,A,"Patients with breast cancer and the AA genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271393,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with AA genotype, but a decreased risk compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271393,G,G,"Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1451447440,C,C,Patients with irritable bowel disorders and the rs2413739 CC genotype may have an increased response to azathioprine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to azathioprine.
1451447440,C,T,Patients with irritable bowel disorders and the rs2413739 CT genotype may have a decreased response to azathioprine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to azathioprine.
1451447440,T,T,Patients with irritable bowel disorders and the rs2413739 TT genotype may have a decreased response to azathioprine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to azathioprine.
1449004548,C,C,"Patients with epilepsy and the CC genotype may have a worse response to oxcarbazepine as compared to patients with the CT or TT genotypes. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy."
1449004548,C,T,"Patients with epilepsy and the CT genotype may have a worse response to oxcarbazepine as compared to patients with the TT genotype and an improved response as compared to patients with the CC genotype. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy."
1449004548,T,T,"Patients with epilepsy and the TT genotype may have improved response to oxcarbazepine as compared to patients with the CC and CT genotypes. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy."
1449752787,C,C,Patients with the CC genotype and colorectal cancer may have increased survival times when treated with irinotecan-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.
1449752787,C,G,Patients with the CG genotype and colorectal cancer may have increased survival times when treated with irinotecan-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.
1449752787,G,G,Patients with the GG genotype and colorectal cancer may have decreased survival times when treated with irinotecan-based treatments as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.
1449747881,A,A,Patients with the AA genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449747881,A,G,Patients with the AG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449747881,G,G,Patients with the GG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1450810387,A,A,Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.
1450810387,A,G,Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.
1450810387,G,G,Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.
1449168086,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168086,C,T,Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168086,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168670,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168670,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168670,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168677,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168677,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168677,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1450810247,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810247,A,C,Patients with the AC genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810247,C,C,Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810295,A,A,Patients with the AA genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810295,A,G,Patients with the AG genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810295,G,G,Patients with the GG genotype may be at a decreased risk of developing heroin dependence or opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810345,C,C,Patients with the rs1381376 CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810345,C,T,Patients with the rs1381376 CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450810345,T,T,Patients with the rs1381376 TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1449169795,C,C,Men with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a greater decrease in triglycerides as compared to men with either the CT or TT genotypes. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.
1449169795,C,T,Men with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atorvastatin.
1449169795,T,T,Men with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have a lower decrease in triglycerides as compared to men with the CC genotype. Other clinical and genetic factors may also influence the efficacy of atorvastatin in lowering triglyceride levels in men with hypercholesterolemia who are taking atrovastatin.
1449170133,A,A,"Patients with the AA genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol."
1449170133,A,G,"Patients with the AG genotype and who are treated with allopurinol may have an increased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the GG genotype. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol."
1449170133,G,G,"Patients with the GG genotype and who are treated with allopurinol may have a decreased risk of developing DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AA or AG genotypes. Please note: the AA and AG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol."
1449189242,A,A,Patients with the AA genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449189242,A,T,Patients with the AT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a greater increase in blood glucose than patients with the TT genotype. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449189242,T,T,Patients with the TT genotype and hypertension who are administered hydrochlorothiazide or chlorothiazide may have a lower increase in blood glucose than patients with the AA or AT genotypes. Other clinical and genetic factors may also influence elevations in blood glucose in patients administered chlorothiazide or hydrochlorothiazide.
1449752561,C,C,Patients with cancer and the CC genotype may have a decreased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1449752561,C,T,Patients with cancer and the CT genotype may have an increased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1449752561,T,T,Patients with cancer and the TT genotype may have an increased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1449752602,C,C,Patients with lung cancer and the CC genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1449752602,C,T,Patients with lung cancer and the CT genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1449752602,T,T,Patients with lung cancer and the TT genotype may have a decreased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1450376443,A,A,"Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the AT or TT genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate."
1450376443,A,T,"Pediatric patients with the AT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate."
1450376443,T,T,"Pediatric patients with the TT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate."
1451621726,A,A,"Patients with the rs1128503 AA genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate."
1451621726,A,G,"Patients with the rs1128503 AG genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate."
1451621726,G,G,"Patients with the rs1128503 GG genotype may be at a decreased risk of experiencing side effects when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate."
1450376745,A,A,"The current evidence base suggests that there is no significant association between the rs4680 AA genotype and response to methylphenidate. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to methylphenidate."
1450376745,A,G,"The current evidence base suggests that there is no significant association between the rs4680 AG genotype and response to methylphenidate. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to methylphenidate."
1450376745,G,G,"The current evidence base suggests that there is no significant association between the rs4680 GG genotype and response to methylphenidate. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to methylphenidate."
1449157951,C,C,Patients with the CC genotype and beta-thalassemia may have increased metabolism of deferasirox as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157951,C,T,Patients with the CT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157951,T,T,Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157957,C,C,Patients with the CC genotype and beta-thalassemia may have increased metabolism of deferasirox as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157957,C,T,Patients with the CT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157957,T,T,Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157963,C,C,Patients with the CC genotype and beta-thalassemia may have increased metabolism of deferasirox as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157963,C,T,Patients with the CT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449157963,T,T,Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.
1449170460,A,A,Patients with the AA genotype and cancer who are treated with granisetron or palonosetron may have a lower response and increased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AC or CC genotypes. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.
1449170460,A,C,Patients with the AC genotype and cancer who are treated with granisetron or palonosetron may have a better response and decreased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AA genotype. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.
1449170460,C,C,Patients with the CC genotype and cancer who are treated with granisetron or palonosetron may have a better response and decreased vomiting during the first 24 hours post-cisplatin administration as compared to patients with the AA genotype. Other clinical and genetic factors may also influence incidence of vomiting in patients with cancer who are administered granisetron or palonosetron.
1449270486,A,A,Patients with the AA genotype may have reduced alcohol consumption as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.
1449270486,A,G,"Patients with the AG genotype may have reduced alcohol consumption as compared to patients with the GG genotype, but an increased level of alcohol consumption compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's level of alcohol consumption."
1449270486,G,G,Patients with the GG genotype may have increased alcohol consumption as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.
1449270883,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270883,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270883,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1452044040,C,C,"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
1452044040,C,T,"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
1452044040,T,T,"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
1449140263,C,C,Patients with hypertension and the CC genotype who are administered thiazides may have a decreased likelihood of hyponatremia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.
1449140263,C,T,Patients with hypertension and the CT genotype who are administered thiazides may have a decreased likelihood of hyponatremia as compared to patients with the TT genotypes and an increased likelihood as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.
1449140263,T,T,Patients with hypertension and the TT genotype who are administered thiazides may have an increased likelihood of hyponatremia as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence likelihood of hyponatremia in patients with hypertension who are administered thiazides.
1449140279,A,A,"Patients with the AA genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer."
1449140279,A,G,"Patients with the AG genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the GG genotypes and a worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer."
1449140279,G,G,"Patients with the GG genotype and stomach cancer may have a worse response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer."
1449752818,A,A,Patients with the AA genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752818,A,G,Patients with the AG genotype and who carry the HLA-B*13:01 allele may be at an increased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1449752818,G,G,Patients with the GG genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.
1451621742,A,A,"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1451621742,A,G,"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1451621742,G,G,"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1452050105,A,A,"The current evidence base suggests that there is no association between the rs7997012 AA genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
1452050105,A,G,"The current evidence base suggests that there is no association between the rs7997012 AG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
1452050105,G,G,"The current evidence base suggests that there is no association between the rs7997012 GG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
1449310234,C,C,"Patients with the rs193922764 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449310234,C,T,"Patients with the rs193922764 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449310234,T,T,"Patients with the rs193922764 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449310249,A,A,"Patients with the rs193922832 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449310249,A,G,"Patients with the rs193922832 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449310249,G,G,"Patients with the rs193922832 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449310265,G,G,"Patients with the rs193922843 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449310265,G,T,"Patients with the rs193922843 GT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449310265,T,T,"Patients with the rs193922843 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1452044020,A,A,"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
1452044020,A,G,"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
1452044020,G,G,"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to escitalopram. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to escitalopram."
1452044060,C,C,The current evidence base suggests that there is no association between the rs6311 CC genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.
1452044060,C,T,The current evidence base suggests that there is no association between the rs6311 CT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.
1452044060,T,T,The current evidence base suggests that there is no association between the rs6311 TT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.
1452044066,A,A,The current evidence base suggests that there is no association between the rs6313 AA genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.
1452044066,A,G,The current evidence base suggests that there is no association between the rs6313 AG genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.
1452044066,G,G,The current evidence base suggests that there is no association between the rs6313 GG genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.
1452050405,C,C,The current evidence base suggests that there is no association between the rs6311 CC genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.
1452050405,C,T,The current evidence base suggests that there is no association between the rs6311 CT genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.
1452050405,T,T,The current evidence base suggests that there is no association between the rs6311 TT genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.
1452043985,C,C,"The current evidence base suggests that there is no association between the rs6311 CC genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
1452043985,C,T,"The current evidence base suggests that there is no association between the rs6311 CT genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
1452043985,T,T,"The current evidence base suggests that there is no association between the rs6311 TT genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
1452043960,A,A,"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
1452043960,A,G,"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
1452043960,G,G,"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to paroxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine."
1452050600,A,A,The current evidence base suggests that there is no association between the rs7997012 AA genotype and response to paroxetine. Other genetic and clinical factors may also influence response to paroxetine.
1452050600,A,G,The current evidence base suggests that there is no association between the rs7997012 AG genotype and response to paroxetine. Other genetic and clinical factors may also influence response to paroxetine.
1452050600,G,G,The current evidence base suggests that there is no association between the rs7997012 GG genotype and response to paroxetine. Other genetic and clinical factors may also influence response to paroxetine.
827863843,A,A,Patients with the AA genotype may have better response to inhaled glucocorticoids in asthma patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response to glucocorticoids.
827863843,A,G,Patients with the AG genotype may have intermediate increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with heterozygous AG genotype has an intermediate GLCC1 expression value.
827863843,G,G,Patients with the GG genotype may have increased risk of poor response to inhaled glucocorticoids in asthma patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to glucocorticoids. The G allele is associated with decrease in the expression of GLCCI1 gene and cells with homozygous GG genotype has the lowest GLCC1 expression value compared to AA or AG.
827864159,C,C,"In male patients with the rs1024323 CC genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment."
827864159,C,T,"In male patients with the rs1024323 CT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a reduced response to metoprolol compared to those with rs1024323 genotype TT, or better response compared to those with rs1024323 genotype CC, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CC and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment."
827864159,T,T,"In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment."
827864179,A,A,Patients with the AA genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.
827864179,A,T,Patients with the AT genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.
827864179,T,T,Patients with the TT genotype may have minimal 7-hydroxylation of coumarin compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of coumarin.
827864301,C,C,"Patients with the CC genotype: 1) may have increased blood pressure, 2) increased risk for hypertension and 3) slower control of blood pressure when treated with verapamil as compared to patients with the TT or CT genotypes. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
827864301,C,T,"Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
827864301,T,T,"Patients with the CT genotype: 1) may have decreased blood pressure, 2) decreased risk for hypertension and 3) faster control of blood pressure when treated with verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's blood pressure and response to antihypertensives."
1450930548,G,G,Patients with hypertension and the GG genotype may have a decreased systolic blood pressure response to hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.
1450930548,G,T,Patients with hypertension and the GT genotype may have a decreased systolic blood pressure response to hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.
1450930548,T,T,Patients with hypertension and the TT genotype may have an increased systolic blood pressure response to hydrochlorothiazide as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.
1450930554,A,A,Patients with hypertension and the AA genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.
1450930554,A,G,Patients with hypertension and the AG genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.
1450930554,G,G,Patients with hypertension and the GG genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.
1450930560,A,A,Patients with hypertension and the AA genotype may require an increased dose of atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect atenolol dose.
1450930560,A,G,Patients with hypertension and the AG genotype may require an increased dose of atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect atenolol dose.
1450930560,G,G,Patients with hypertension and the GG genotype may require a decreased dose of atenolol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect atenolol dose.
1450930827,C,C,"Patients with the CC genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450930827,C,T,"Patients with the CT genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450930827,T,T,"Patients with the TT genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450936741,C,C,Patients with the CC genotype may have an increased blood alcohol concentration (BAC) as compared to patients with the CT genotype. Note that this association was not consistently observed over all timepoints studied. Other genetic and clinical factors may also affect BAC.
1450936741,C,T,Patients with the CT genotype may have a decreased blood alcohol concentration (BAC) as compared to patients with the CC genotype. Note that this association was not consistently observed over all timepoints studied. Other genetic and clinical factors may also affect BAC.
1450936741,T,T,There is currently no available evidence regarding an association between the TT genotype and blood alcohol concentration (BAC). Other genetic and clinical factors may also affect BAC.
1450929786,A,A,"Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl."
1450929786,A,G,"Patients with the AG genotype may have an increased response to fentanyl as compared to patients with the AA genotype. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl."
1450929786,G,G,"Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the AA genotype. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl."
827864250,C,C,Patients with the CC genotype may have decreased response to corticosteroids compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
827864250,C,T,Patients with the CT genotype may have increased response to corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
827864250,T,T,Patients with the TT genotype may have increased response to corticosteroids compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
827862764,C,C,"Patients with the rs12979860 CC genotype and hepatitis C infection may have increased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin."
827862764,C,T,"Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin."
827862764,T,T,"Patients with the rs12979860 TT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a response to peginterferon alpha and ribavirin."
1452043460,A,A,The current evidence base suggests that there is no association between the rs6313 AA genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.
1452043460,A,G,The current evidence base suggests that there is no association between the rs6313 AG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.
1452043460,G,G,The current evidence base suggests that there is no association between the rs6313 GG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.
1452050620,A,A,The current evidence base suggests that there is no association between the rs7997012 AA genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.
1452050620,A,G,The current evidence base suggests that there is no association between the rs7997012 AG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.
1452050620,G,G,The current evidence base suggests that there is no association between the rs7997012 GG genotype and response to sertraline. Other genetic and clinical factors may also influence response to sertraline.
1452050380,C,C,"Patients with the CC genotype who are treated with paroxetine may have increased risk of nausea or sexual dysfunctions as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine."
1452050380,C,T,"Patients with the CT genotype who are treated with paroxetine may have decreased, but not absent, risk of nausea or sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine."
1452050380,T,T,"Patients with the TT genotype who are treated with paroxetine may have decreased, but not absent, risk of nausea or sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to paroxetine."
1452050260,C,C,"Patients with the CC genotype may have an increased response to fluvoxamine as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
1452050260,C,T,"Patients with the CT genotype may have a decreased response to fluvoxamine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
1452050260,T,T,"Patients with the TT genotype may have a decreased response to fluvoxamine as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
1451634907,A,A,"Patients with rheumatoid arthritis and the rs1805087 AA genotype may have an increased response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine."
1451634907,A,G,"Patients with rheumatoid arthritis and the rs1805087 AG genotype may have an increased response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine."
1451634907,G,G,"Patients with rheumatoid arthritis and the rs1805087 GG genotype may have a decreased response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to combination therapy of folic acid, hydroxychloroquine, methotrexate and sulfasalazine."
1451634914,A,A,Patients with rheumatoid arthritis and the rs1805087 AA genotype may have a decreased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451634914,A,G,Patients with rheumatoid arthritis and the rs1805087 AG genotype may have a decreased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451634914,G,G,Patients with rheumatoid arthritis and the rs1805087 GG genotype may have an increased response to methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to methotrexate.
1451634940,A,A,Patients with rheumatoid arthritis and the rs1805087 AA genotype may be at a decreased risk of toxicity when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.
1451634940,A,G,Patients with rheumatoid arthritis and the rs1805087 AG genotype may be at a decreased risk of toxicity when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.
1451634940,G,G,Patients with rheumatoid arthritis and the rs1805087 GG genotype may be at an increased risk of toxicity when treated with methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.
1452050120,A,A,"Patients with the rs7997012 AA genotype may have decreased clinical benefit to fluoxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine."
1452050120,A,G,"Patients with the rs7997012 AG genotype may have decreased clinical benefit to fluoxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine."
1452050120,G,G,"Patients with the rs7997012 GG genotype may have increased clinical benefit to fluoxetine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine."
1452050340,C,C,"Patients with the CC genotype who are treated with fluoxetine may have increased risk of sexual dysfunctions as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine."
1452050340,C,T,"Patients with the CT genotype who are treated with fluoxetine may have decreased, but not absent, risk of sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine."
1452050340,T,T,"Patients with the TT genotype who are treated with fluoxetine may have decreased, but not absent, risk of sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to fluoxetine."
1452043240,C,C,The current evidence base suggests that there is no association between the rs6311 CC genotype and response to fluoxetine. Other genetic and clinical factors may also influence response to fluoxetine.
1452043240,C,T,The current evidence base suggests that there is no association between the rs6311 CT genotype and response to fluoxetine. Other genetic and clinical factors may also influence response to fluoxetine.
1452043240,T,T,The current evidence base suggests that there is no association between the rs6311 TT genotype and response to fluoxetine. Other genetic and clinical factors may also influence response to fluoxetine.
1452043220,A,A,"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to fluoxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine."
1452043220,A,G,"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to fluoxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine."
1452043220,G,G,"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to fluoxetine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluoxetine."
1449310001,C,C,"Patients with the CC genotype and hypertension may have a worse response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension."
1449310001,C,G,"Patients with the CG genotype and hypertension may have an improved response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension."
1449310013,A,A,Patients with cancer and the AA genotype who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.
1449310013,A,G,Patients with cancer and the AG genotype who are treated with gemcitabine may have a increased risk of leukopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.
1449310013,G,G,Patients with cancer and the GG genotype who are treated with gemcitabine may have a increased risk of leukopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.
1449716392,A,A,"Patients with the AA genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl."
1449716392,A,C,"Patients with the AC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl."
1449716392,A,T,"Patients with the AT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl."
1449716392,C,C,"Patients with the CC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl."
1449716392,C,T,"Patients with the CT genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl."
1449716392,T,T,"Patients with the TT genotype may have a decreased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AC, CC or CT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl."
1449716764,A,A,"Patients with the AA genotype may have a decreased response to fentanyl and may therefore require an increased dose as compared to patients with the AG or GG genotypes. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements."
1449716764,A,G,"Patients with the AG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements."
1449716764,G,G,"Patients with the GG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements."
1449748823,C,C,Patients with the CC genotype who are undergoing kidney transplantation may have a decreased risk for allograft loss when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for allograft loss.
1449748823,C,T,Patients with the CT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.
1449748823,T,T,Patients with the TT genotype who are undergoing kidney transplantation may have an increased risk for allograft loss when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for allograft loss.
1449309975,A,A,"Patients with inflammatory bowel disease and the AA genotype who are treated with azathioprine may have decreased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine."
1449309975,A,C,"Patients with inflammatory bowel disease and the AC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the CC genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine."
1449309975,C,C,"Patients with inflammatory bowel diseases and the CC genotype who are treated with azathioprine may have an increased likelihood of adverse events as compared to patients with the AA genotype, however no association is found in some studies. Other clinical and genetic factors may also influence likelihood of adverse events in response to azathioprine."
1452043786,C,C,The current evidence base suggests that there is no association between the rs6311 CC genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.
1452043786,C,T,The current evidence base suggests that there is no association between the rs6311 CT genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.
1452043786,T,T,The current evidence base suggests that there is no association between the rs6311 TT genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.
1452043780,A,A,The current evidence base suggests that there is no association between the rs6313 AA genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.
1452043780,A,G,The current evidence base suggests that there is no association between the rs6313 AG genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.
1452043780,G,G,The current evidence base suggests that there is no association between the rs6313 GG genotype and response to venlafaxine. Other genetic and clinical factors may also influence response to venlafaxine.
1451635027,A,A,Patients with acute lymphoblastic leukemia (ALL) and the rs9344 AA genotype may have a decreased response to methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to methotrexate.
1451635027,A,G,Patients with acute lymphoblastic leukemia (ALL) and the rs9344 AG genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451635027,G,G,Patients with acute lymphoblastic leukemia (ALL) and the rs9344 GG genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451635034,A,A,"Patients with osteosarcoma and the rs9344 AA genotype may have a decreased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate."
1451635034,A,G,"Patients with osteosarcoma and the rs9344 AG genotype may have an increased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate."
1451635034,G,G,"Patients with osteosarcoma and the rs9344 GG genotype may have an increased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate."
1450375716,C,C,Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375716,C,T,Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375716,T,T,Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375722,C,C,Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375722,C,T,Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375722,T,T,Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375728,C,C,Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375728,C,T,Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450375728,T,T,Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.
1450822476,A,A,Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450822476,A,C,Patients with the AC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450822476,C,C,Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823115,C,C,Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823115,C,T,Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823115,T,T,Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823333,A,A,Patients with the AA genotype may have increased alcohol consumption as compared to patients with the AG genotype. Other genetic or clinical factors may also affect a patient's alcohol consumption.
1450823333,A,G,Patients with the AG genotype may have decreased alcohol consumption as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's alcohol consumption.
1450823333,G,G,There is currently no available evidence regarding the effect of the GG genotype on alcohol consumption.
1450823350,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.
1450823350,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.
1450823350,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.
1450823626,A,A,"Patients with the AA genotype may be at an increased risk of developing drug dependence as compared to patients with the AC or CC genotypes. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence."
1450823626,A,C,"Patients with the AC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence."
1450823626,C,C,"Patients with the CC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence."
1450823791,A,A,"Patients with the AA genotype may be at an increased risk of developing cannabis dependence as compared to patients with the AG or GG genotypes. However, this association was not significant. Other genetic or clinical factors may also affect a patient's risk of developing cannabis dependence."
1450823791,A,G,"Patients with the AG genotype may be at a decreased risk of developing cannabis dependence as compared to patients with the AA genotype. However, this association was not significant. Other genetic or clinical factors may also affect a patient's risk of developing cannabis dependence."
1450823791,G,G,"Patients with the GG genotype may be at a decreased risk of developing cannabis dependence as compared to patients with the AA genotype. However, this association was not significant. Other genetic or clinical factors may also affect a patient's risk of developing cannabis dependence."
1449004876,A,A,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a worse response to methotrexate as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.
1449004876,A,G,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.
1449004876,G,G,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the GG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.
1449005017,A,A,"Pregnant patients infected with malaria and the AA genotype, may have elevated concentrations of lumefantrine as compared to patients with the A/del or del/del genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant women infected with malaria."
1449005031,C,C,Pregnant patients infected with malaria and the CC genotype may have lower concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.
1449005031,C,T,Pregnant patients infected with malaria and the CT genotype may have lower concentrations of lumefantrine as compared to patients with the TT genotype and elevated concentrations as compared to patients with the CC genotype. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.
1449005031,T,T,Pregnant patients infected with malaria and the TT genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or CC genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.
1449005382,A,A,"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications."
1449005382,A,G,"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AG genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of fasting glucose concentrations as compared to patients with the AA genotype. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications."
1449005382,G,G,"Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the GG genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of fasting glucose concentrations as compared to patients with the AA genotype. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications."
1449005393,A,A,"Pediatric patients undergoing surgery with the AA genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil."
1449005393,A,G,"Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil."
1449005393,G,G,"Pediatric patients undergoing surgery with the GG genotype may have a decreased likelihood of adverse events, as well as an improved response to sevoflurane and remifentanil as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil."
1449004807,C,C,Patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have increased concentrations of methotrexate as compared to patients with the CT and TT genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.
1449004807,C,T,Patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.
1449004807,T,T,Patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have decreased concentrations of methotrexate as compared to patients with the CC genotypes. There is no association with risk of mucositis or response to methotrexate. Other clinical and genetic factors may also influence concentrations of methotrexate in patients with precursor cell lymphoblastic leukemia-lymphoma.
1449575639,C,C,The CC genotype may be associated with decreased catalytic activity of DPYD as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575639,C,T,The CT genotype may be associated with decreased catalytic activity of DPYD as compared to the TT genotypes and increased catalytic activity as compared to the CC genotype. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575639,T,T,The TT genotype may be associated with increased catalytic activity of DPYD as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1183702975,G,G,"Patients with the rs3745274 GG genotype may have increased methadone dose requirements as compared to patients with the GT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone."
1183702975,G,T,"Patients with the rs3745274 GT genotype may have increased methadone dose requirements as compared to patients with the TT genotype but decreased dose requirements as compared to the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone."
1183702975,T,T,"Patients with the rs3745274 TT genotype may have decreased methadone dose requirements as compared to patients with the GG or GT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone."
1183702959,C,C,Patients with the CC genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183702959,C,T,Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183702959,T,T,Patients with the TT genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183702964,C,C,Patients with the CC genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183702964,C,T,Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183702964,T,T,Patients with the TT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183704353,A,A,Patients with the AA genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.
1183704353,A,G,Patients with the AG genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.
1183704353,G,G,Patients with the GG genotype may have decreased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to methotrexate.
1183704339,C,C,Patients with the CC genotype may have decreased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183704339,C,T,Patients with the CT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183704339,T,T,Patients with the TT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183703010,A,A,"Patients with the AA genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole."
1183703010,A,G,"Patients with the AG genotype may have decreased glucuronidation of anastrozole as compared to patients with the GG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole."
1183703010,G,G,"Patients with the GG genotype may have increased glucuronidation of anastrozole as compared to patients with the AA or AG genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole."
1183704233,C,C,Patients with the CC genotype may have decreased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to gemcitabine.
1183704233,C,T,Patients with the CT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.
1183704233,T,T,Patients with the TT genotype may have increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to gemcitabine.
1183704404,A,A,"Patients with the AA genotype may have increased response to etanercept in people with Arthritis, Rheumatoid as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept."
1183704404,A,G,"Patients with the AG genotype may have increased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept."
1183704404,G,G,"Patients with the GG genotype may have decreased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to etanercept."
1184169936,A,A,Patients with the AA genotype and rheumatoid arthritis who are with infliximab may have an increased response based on European League Against Rheumatism (EULAR) criteria and show more improvement using the Disease Activity Score 28 as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.
1184169936,G,A,Patients with the GA genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.
1184169936,G,G,Patients with the GG genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.
1183704302,A,A,"Patients with the AA genotype may have decreased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds."
1183704302,A,G,"Patients with the AG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds."
1183704302,G,G,"Patients with the GG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds."
1183960795,A,A,"Patients with the AA genotype (two copies of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence response to ivacaftor."
1183960795,A,G,"Patients with the AG genotype (one copy of the CFTR G1244E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence response to ivacaftor."
1183960795,G,G,"Patients with the GG genotype (do not have a copy of the CFTR G1244E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1244E. Other genetic and clinical factors may also influence response to ivacaftor."
1183682436,C,C,Patients with the CC genotype may have similar response to treatment with flecainide as to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.
1183682436,C,T,Patients with the CT genotype may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.
1183682436,T,T,Patients with the TT genotype may respond better to treatment with flecainide than to treatment with mexiletine. Other genetic and clinical factors may also influence a patient's response to treatment.
1183704272,A,A,Patients with the AA genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.
1183704272,A,G,Patients with the AG genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.
1183704272,G,G,Patients with the GG genotype may have decreased AUC and increased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the clearance of docetaxel.
1183704316,A,A,Patients with the AA genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.
1183704316,A,C,Patients with the AC genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.
1183704316,C,C,Patients with the CC genotype may have increased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sildenafil.
1451635167,A,A,"The current evidence base suggests that there is no significant association between the rs1801394 AA genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1451635167,A,G,"The current evidence base suggests that there is no significant association between the rs1801394 AG genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1451635167,G,G,"The current evidence base suggests that there is no significant association between the rs1801394 GG genotype and risk of methotrexate-induced toxicity in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate."
1184348731,C,C,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348731,C,T,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348731,T,T,"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 2-4 anemia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy."
1184472737,C,C,Patients with cancer and the CC genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.
1184472737,C,T,Patients with cancer and the CT genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.
1184472737,T,T,Patients with cancer and the TT genotype may have a decreased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.
1184472746,A,A,Patients with cancer and the AA genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.
1184472746,A,G,"Patients with cancer and the AG genotype may experience increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the GG genotype, or decreased as compared to the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain."
1184472746,G,G,Patients with cancer and the GG genotype may experience decreased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to the patients with the AA genotype. Other genetic and clinical factors may influence risk of musculoskeletal pain.
1183702981,A,A,"Patients with the rs2279343 AA genotype may have increased methadone dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
1183702981,A,G,"Patients with the rs2279343 AG genotype may have increased methadone dose requirements as compared to patients with the GG genotype but decreased dose requirements as compared to the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
1183702981,G,G,"Patients with the rs2279343 GG genotype may have decreased methadone dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
1184661207,C,C,Patients with the CC genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.
1184661207,C,T,Patients with the CT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype or a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.
1184661207,T,T,Patients with the TT genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dose.
1183705788,C,C,"Patients with the rs118192170 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705788,C,T,"Patients with the rs118192170 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705788,T,T,"Patients with the rs118192170 TT genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183960800,A,A,"Patients with the AA genotype (two copies of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence response to ivacaftor."
1183960800,A,G,"Patients with the AG genotype (one copy of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence response to ivacaftor."
1183960800,G,G,"Patients with the GG genotype (do not have a copy of the CFTR S1251N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence response to ivacaftor."
1183960766,A,A,"Patients with the rs121908757 AA genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor."
1183960766,A,C,"Patients with the rs121908757 AC genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor."
1183960766,C,C,"Patients with the rs121908757 CC genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor."
1183960775,G,G,"Patients with the rs121909005 GG genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor."
1183960775,G,T,"Patients with the rs121909005 GT genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor."
1183960775,T,T,"Patients with the rs121909005 TT genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence response to ivacaftor."
1183960785,C,C,"Patients with the rs121909041 CC genotype (two copies of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor."
1183960785,C,T,"Patients with the rs121909041 CT genotype (one copy of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor."
1183960785,T,T,"Patients with the rs121909041 TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence response to ivacaftor."
1184136380,G,G,"Patients with the rs368234815 GG genotype and chronic hepatitis C infection may have decreased response (including sustained virological response (svr)) to pegIFN-alpha/ribavirin as compared to people with with TT/TT genotype. However, conflicting evidence has been reported. Please note: this SNP has been found to be in high LD with rs12979860 and rs8099917, both of which are also associated with response to pegIFN-alpha/ribavirin. Other genetic and clinical factors may also influence the response to pegIFN-alpha/ribavirin-based therapy."
1183704321,A,A,Patients with the AA genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.
1183704321,A,C,Patients with the AC genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.
1183704321,C,C,Patients with the CC genotype may have lower increase in systolic blood pressure and decreased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to sunitinib.
1183704372,G,G,Patients with the GG genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.
1183704372,G,T,Patients with the GT genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.
1183704372,T,T,Patients with the TT genotype may have increased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to losartan.
1184233161,C,C,Patients with the CC genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1184233161,C,T,Patients with the CT genotype and hypertension may have a lower reduction in diastolic blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1184233161,T,T,Patients with the TT genotype and hypertension may have a greater reduction in diastolic blood pressure when treated with enalapril as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1184348713,C,C,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1184348713,C,T,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be less likely to have a complete response to treatment as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1184348713,T,T,Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1184348718,C,C,Patients with the CC genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1184348718,C,T,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1184348718,T,T,Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.
1184514202,A,A,Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514202,A,C,"Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity."
1184514202,C,C,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1183888959,G,G,"Patients with the rs8099917 GG genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy."
1183888959,G,T,"Patients with the rs8099917 GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy."
1183888959,T,T,"Patients with the rs8099917 TT genotype may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy."
1183960805,A,A,"Patients with the rs80282562 AA genotype (two copies of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor."
1183960805,A,G,"Patients with the rs80282562 AG genotype (one copy of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor."
1183960805,G,G,"Patients with the rs80282562 GG genotype (do not have a copy of the CFTR G178R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor."
1184348872,A,A,Patients with schizophrenia and the rs2268639 AA genotype who are treated with clozapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.
1184348872,A,T,Patients with schizophrenia and the rs2268639 AT genotype who are treated with clozapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.
1184348872,T,T,Patients with schizophrenia and the rs2268639 TT genotype who are treated with clozapine may have greater weight gain as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.
1183704297,C,C,Patients with the CC genotype may have increased dose of simvastatin and atorvastatin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the dose of simvastatin.
1183704297,C,T,Patients with the CT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.
1183704297,T,T,Patients with the TT genotype may have decreased dose of simvastatin and atorvastatin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of simvastatin.
1184348774,C,C,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348774,C,T,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348774,T,T,"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy."
1184348859,C,C,Patients with the CC genotype and Schizophrenia who are treated with clozapine or olanzapine may have greater weight gain as compared to patients with the CT or TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.
1184348859,C,T,Patients with the CT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype or may have greater weight gain as compared to patients with the TT genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.
1184348859,T,T,Patients with the TT genotype and Schizophrenia who are treated with clozapine or olanzapine may have less weight gain as compared to patients with the CC genotype. Weight gain may be higher in patients who also have a T allele at SNP rs2268639. Other genetic and clinical factors may also influence a patient's likelihood of weight gain and extent when treated with antipsychotics.
1184512128,A,A,Children with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1184512128,A,C,"Children with the AC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a worse treatment response as compared to patients with the CC genotype, or may have a better treatment response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment."
1184512128,C,C,Children with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with combination chemotherapy may have a better treatment response as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1183704277,A,A,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines."
1183704277,A,G,"Patients with the AG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines."
1183704277,G,G,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines."
1183704367,G,G,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1183704367,G,T,"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1183704367,T,T,"Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1183960318,A,A,"Patients with the rs121908755 AA genotype (two copies of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence response to ivacaftor."
1183960318,A,G,"Patients with the rs121908755 AG genotype (one copy of the CFTR S549N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence response to ivacaftor."
1183960318,G,G,"Patients with the rs121908755 GG genotype (do not have a copy of the CFTR S549N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S549N. Other genetic and clinical factors may also influence response to ivacaftor."
1183703005,C,C,"Patients with the CC genotype may have increased glucuronidation of anastrozole as compared to patients with the CT or TT genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole."
1183703005,C,T,"Patients with the CT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole."
1183703005,T,T,"Patients with the TT genotype may have decreased glucuronidation of anastrozole as compared to patients with the CC genotype, as determined by in vitro assays. Glucuronidation allows for the elimination of xenobiotics like anastrozole. Other genetic and clinical factors may also influence glucuronidation of anastrozole."
1183704399,A,A,Patients with the AA genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.
1183704399,A,T,Patients with the AT genotype may have decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.
1183704399,T,T,Patients with the TT genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.
1183704419,A,A,Patients with the AA genotype may have increased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.
1183704419,G,A,Patients with the GA genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.
1183704419,G,G,Patients with the GG genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to irinotecan.
1184348703,C,C,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348703,C,T,"Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy."
1184348703,T,T,"Patients with the TT genotype were not studied. Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy."
1184348708,C,C,Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348708,C,T,Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348708,T,T,"Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 1-4 nephrotoxicity as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy."
1183704267,A,A,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1183704267,A,G,"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1183704267,G,G,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1183888969,C,C,"Patients with the rs12979860 CC genotype and hepatitis C infection may have higher response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy."
1183888969,C,T,"Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy."
1183888969,T,T,"Patients with the rs12979860 TT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy."
1184134160,A,A,"Patients with the AA genotype and solid tumors, may have increased response to gemcitabine compared to the CC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
1184134160,A,C,"Patients with the AC genotype and solid tumors, may have increased response to gemcitabine compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
1184134160,C,C,"Patients with the CC genotype and solid tumors, may have decreased response to gemcitabine compared to the AA and AC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
1184134170,C,C,Patients with CC genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.
1184134170,C,T,"Patients with CT genotype and pancreatic cancer who are treated with gemcitabine may have an decreased risk of neutropenia compared to patients with the TT genotype, and increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine."
1184134170,T,T,Patients with TT genotype and pancreatic cancer who are treated with gemcitabine may have an increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.
1184514449,A,A,Patients with the AA genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514449,A,T,Patients with the AT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514449,T,T,Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514458,A,A,Patients with the AA genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514458,A,G,Patients with the AG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514458,G,G,Patients with the GG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514464,C,C,Patients with the CC genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514464,C,T,Patients with the CT genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514464,T,T,Patients with the TT genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514469,A,A,Patients with the AA genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514469,A,G,Patients with the AG genotype may have an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype and a decreased risk of Heroin Dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514469,G,G,Patients with the GG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514474,C,C,Patients with the CC genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514474,C,T,Patients with the CT genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514474,T,T,Patients with the TT genotype may have an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.
1184514253,A,A,Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514253,A,C,"Patients with the AC genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity."
1184514253,C,C,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514260,C,C,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514260,C,G,"Patients with the CG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity."
1184514260,G,G,Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184473080,C,C,"The current evidence base suggests that there is no significant association between the rs717620 CC genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance."
1184473080,C,T,"The current evidence base suggests that there is no significant association between the rs717620 CT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance."
1184473080,T,T,"The current evidence base suggests that there is no significant association between the rs717620 TT genotype and clearance of methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs717620 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance."
1184473109,C,C,"Patients with the rs717620 CC genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate."
1184473109,C,T,"Patients with the rs717620 CT genotype who are administered methotrexate may have a decreased risk of drug toxicity as compared to patients with TT genotypes, and an increased risk of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate."
1184473109,T,T,"Patients with the rs717620 TT genotype who are administered methotrexate may have an increased risk of drug toxicity as compared to patients with the CT or CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate."
1184472550,A,A,"Patients with the AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG, or GG genotype. Other genetic and clinical factors may also influence serum creatine kinase levels."
1184472550,A,G,Patients with the AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.
1184472550,G,G,Patients with the GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.
1183960780,A,A,"Patients with the rs121909013 AA genotype (two copies of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence response to ivacaftor."
1183960780,A,G,"Patients with the rs121909013 AG genotype (one copy of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence response to ivacaftor."
1183960780,G,G,"Patients with the rs121909013 GG genotype (do not have a copy of the CFTR G551S variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence response to ivacaftor."
1184472555,A,A,Patients with the rs1128503 AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels.
1184472555,A,G,Patients with the rs1128503 AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.
1184472555,G,G,Patients with the rs1128503 GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.
1451635460,C,C,Patients with cocaine dependence and the rs678849 CC genotype may have an increased response to disulfiram as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to disulfiram.
1451635460,C,T,Patients with cocaine dependence and the rs678849 CT genotype may have a decreased response to disulfiram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to disulfiram.
1451635460,T,T,Patients with cocaine dependence and the rs678849 TT genotype may have a decreased response to disulfiram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to disulfiram.
1183702969,A,A,Patients with the AA genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183702969,A,G,Patients with the AG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183702969,G,G,Patients with the GG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.
1183848120,C,C,Patients with the CC genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have an increased response to eculizumab as compared with patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.
1183848120,C,T,Patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.
1183848120,T,T,Patients with the TT genotype were not part of the study. But patients with the CT genotype and paroxysmal nocturnal hemoglobinuria who are treated with eculizumab may have a decreased response to eculizumab as compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to eculizumab.
1183703760,A,A,Patients with genotype AA may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.
1183703760,A,G,Patients with genotype AG may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.
1183703760,G,G,Patients with genotype GG may have decreased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.
1183704248,C,C,"Patients with the CC genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan."
1183704248,C,T,"Patients with the CT genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan."
1183704248,T,T,"Patients with the TT genotype may have decreased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the toxicity to irinotecan."
1183863775,A,A,Patients with the AA genotype may have a significantly higher odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863775,A,G,Patients with the AG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863775,G,G,Patients with the GG genotype may have a lower odds of Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863780,C,C,Patients with the CC genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863780,C,T,Patients with the CT genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863780,T,T,Patients with the TT genotype may have a higher odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1184472751,C,C,"Patients with cancer and the CC genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine."
1184472751,C,T,"Patients with cancer and the CT genotype may have increased metabolism of gemcitabine as compared to patients with the TT genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine."
1184472751,T,T,"Patients with cancer and the TT genotype may have decreased metabolism of gemcitabine as compared to patients with the CC genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine."
1184472841,C,C,Patients with the CC genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.
1184472841,C,T,"Patients with the CT genotype may have decreased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the TT genotypes, and increased steady-state levels as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements."
1184472841,T,T,Patients with the TT genotype may have increased steady-state levels of vitamin E when taking vitamin E supplements as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence steady-state levels of vitamin E in patients taking vitamin E supplements.
1184472890,C,C,Patients with acute myeloid leukemia and the CC genotype may have a decreased response to cytarabine and idarubicin as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1184472890,C,T,"Patients with acute myeloid leukemia and the CT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin."
1184472890,T,T,Patients with acute myeloid leukemia and the TT genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1183704243,A,A,Patients with the AA genotype may have increased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AG or GG. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.
1183704243,A,G,Patients with the AG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.
1183704243,G,G,Patients with the GG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.
1183848125,A,A,Patients with the AA genotype and Coronary Disease who are treated with clopidogrel may have a decreased on-treatment platelet activity as compared to patients with the CC or CA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.
1183848125,C,A,Patients with the CA genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.
1183848125,C,C,Patients with the CC genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.
1183960790,A,A,"Patients with the rs193922525 AA genotype (two copies of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor."
1183960790,A,G,"Patients with the rs193922525 AG genotype (one copy of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor."
1183960790,G,G,"Patients with the rs193922525 GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence response to ivacaftor."
1184513736,A,A,Patients with the AA genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1184513736,A,G,Patients with the AG genotype who are treated with escitalopram may have a decreased chance of response and may require an increase in dose during treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1184513736,G,G,Patients with the GG genotype who are treated with escitalopram may have an increased chance of response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.
1183704287,A,A,Patients with the AA genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
1183704287,A,G,Patients with the AG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
1183704287,G,G,Patients with the GG genotype may have decreased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cyclophosphamide and doxorubicin.
1184472708,C,C,Patients with breast cancer and the CC genotype may have an increased response to gemcitabine and paclitaxel as compared to the patients with the CG and GG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.
1184472708,C,G,"Patients with breast cancer and the CG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC genotypes, and an increased response as compared to patients with the GG genotype when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel."
1184472708,G,G,Patients with breast cancer and the GG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC and CG genotypes when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.
1184513893,A,A,Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513893,A,G,Patients with the AG genotype have an decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513893,G,G,Patients with the GG genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the A genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513880,C,C,Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513880,C,T,Patients with the CT genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513880,T,T,Patients with the TT genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513863,C,C,Patients with the CC genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513863,C,T,Patients with the CT genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and a decreased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513863,T,T,Patients with the TT genotype have a decreased risk of post anesthesia apnea as compared to patients with the CC genotype when treated with succinylcholine. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1452138940,G,G,"Patients with the rs2231142 GG genotype may have a decreased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the TT or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin."
1452138940,G,T,"Patients with the rs2231142 GT genotype may have an increased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin."
1452138940,T,T,"Patients with the rs2231142 TT genotype may have an increased risk of drug-induced toxicity when treated with atorvastatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing drug-induced toxicity when treated with atorvastatin."
1183863785,C,C,Patients with the CC genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863785,C,T,Patients with the CT genotype may have a lower odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863785,T,T,Patients with the TT genotype may have a higher odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.
1183863989,C,C,Patients with the CC genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.
1183863989,C,T,"Patients with the CT genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype and may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity."
1183863989,T,T,"Patients with the TT genotype who are treated with capecitabine may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity."
1184472900,C,C,Patients with acute myeloid leukemia and the CC genotype may have an decreased response to cytarabine and idarubicin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1184472900,C,G,"Patients with acute myeloid leukemia and the CG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype, and a decreased response compared to patients with the GG genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin."
1184472900,G,G,Patients with acute myeloid leukemia and the GG genotype may have an increased response to cytarabine and idarubicin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response in patients administered cytarabine and idarubicin.
1184514240,C,C,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514240,C,T,"Patients with the CT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity."
1184514240,T,T,Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1450821418,A,A,"Patients with the AA genotype may have decreased alcohol consumption as compared to patients with the AG or GG genotype. Other studies have not found an association between this variant and alcohol consumption, while some studies have found the opposite association. Other genetic or clinical factors may also affect a person's alcohol consumption."
1450821418,A,G,"Patients with the AG genotype may have increased alcohol consumption as compared to patients with the AA genotype. Other studies have not found an association between this variant and alcohol consumption, while some studies have found the opposite association. Other genetic or clinical factors may also affect a person's alcohol consumption."
1450821418,G,G,"Patients with the GG genotype may have increased alcohol consumption as compared to patients with the AA genotype. Other studies have not found an association between this variant and alcohol consumption, while some studies have found the opposite association. Other genetic or clinical factors may also affect a person's alcohol consumption."
1184514209,G,G,Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514209,G,T,"Patients with the GT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity."
1184514209,T,T,Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514217,C,C,Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514217,C,T,"Patients with the CT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity."
1184514217,T,T,Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514248,A,A,Patients with the AA genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514248,A,G,"Patients with the AG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype, or may have a reduced risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity."
1184514248,G,G,Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.
1184514050,C,C,"Patients with the rs116855232 CC genotype and inflammatory bowel diseases who are treated with azathioprine may have a reduced, but not absent risk of myelosuppression as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects."
1184514050,C,T,Patients with the rs116855232 CT genotype and inflammatory bowel diseases who are treated with azathioprine may have an increased risk of myelosuppression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.
1184514050,T,T,Patients with the rs116855232 TT genotype and inflammatory bowel diseases who are treated with azathioprine may have an increased risk of myelosuppression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of azathioprine related side effects.
1451636580,C,C,Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CC genotype may be at a decreased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.
1451636580,C,T,Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.
1451636580,T,T,Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 TT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.
1183704330,A,A,"Patients with the AA genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs."
1183704330,A,G,"Patients with the AG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to NSAIDs."
1183704330,G,G,"Patients with the GG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to NSAIDs."
1184472764,C,C,Patients with the CC genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.
1184472764,C,T,Patients with the CT genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.
1184472764,T,T,Patients with the TT genotype may have decreased clearance of gemcitabine as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.
1184513898,A,A,Patients with the AA genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513898,A,C,Patients with the AC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the AA genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1184513898,C,C,Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the T genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.
1451637000,A,A,Patients with the rs115346678 AA genotype may be at an increased risk of adverse events when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with aspirin.
1451637000,A,G,Patients with the rs115346678 AG genotype may be at an increased risk of adverse events when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with aspirin.
1451637000,G,G,Patients with the rs115346678 GG genotype may be at a decreased risk of adverse events when treated with aspirin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with aspirin.
1183704262,C,C,Patients with the CC genotype may have decreased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.
1183704262,C,T,Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.
1183704262,T,T,Patients with the TT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.
1184233711,A,A,"Patients with the AA genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the AG or GG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics."
1184233711,A,G,"Patients with the AG genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the GG genotype and may have reduced clearance of efavirenz as compared to patients with the AA genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics."
1184233711,G,G,"Patients with the GG genotype and HIV infection who are treated with efavirenz may have reduced clearance of efavirenz as compared to patients with the AG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics."
1184133889,C,C,"Patients with CC genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug."
1184133889,C,T,"Patients with the CT genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug."
1184133889,T,T,"Patients with the TT genotype, and HIV infection, have decreased exposure to efavirenz compared to patients with the CC, or CT genotypes. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug."
1184134274,A,A,Patients with the AA genotype may have increased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence response to morphine.
1184134274,A,G,Patients with the AG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.
1184134274,G,G,Patients with the GG genotype may have decreased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence response to morphine.
1184348745,C,C,"Patients the CC genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy."
1184348745,C,G,"Patients the CG genotype and early stage ovarian cancer may have increased progression-free survival and overall survival, whereas patients with the CC genotype and late stage ovarian cancer may have decreased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy."
1184348745,G,G,"Patients the GG genotype and early stage ovarian cancer may have decreased progression-free survival and overall survival, whereas patients with the GG genotype and late stage ovarian cancer may have increased progression-free survival and overall survival, when treated with platinum-based chemotherapy as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy."
1184472721,A,A,"Patients with cancer and the AA genotype may have increased response to gemcitabine as compared to patients with the AG and GG genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine."
1184472721,A,G,"Patients with cancer and the AG genotype may have increased response to gemcitabine as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine."
1184472721,G,G,"Patients with cancer and the GG genotype may have decreased response to gemcitabine as compared to patients with the AG and AA genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine."
1184472796,C,C,Patients with the CC genotype may have increased formation of gemcitabine triphosphate as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.
1184472796,C,T,Patients with the CT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.
1184472796,T,T,Patients with the TT genotype may have decreased formation of gemcitabine triphosphate as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also affect formation of gemcitabine triphosphate in patients administered gemcitabine.
1184348736,A,A,Patients with the AA genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a similar risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184348736,A,G,"Patients with the AG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy."
1184348736,G,G,Patients with the GG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 3-4 neutropenia as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.
1184661194,C,C,"Patients with the rs2108622 CC genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose."
1184661194,C,T,"Patients with the rs2108622 CT genotype who are treated with acenocoumarol may require a lower dose as compared to patients with the TT genotype or may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose."
1184661194,T,T,"Patients with the rs2108622 TT genotype who are treated with acenocoumarol may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence required acenocoumarol dose."
1450826763,A,A,"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and nicotine consumption, as measured by the number of cigarettes smoked per day. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence nicotine consumption."
1450826763,A,G,"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and nicotine consumption, as measured by the number of cigarettes smoked per day. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence nicotine consumption."
1450826763,G,G,"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and nicotine consumption, as measured by the number of cigarettes smoked per day. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence nicotine consumption."
1450826857,A,A,"Patients with the rs1799971 AA genotype may be more likely to experience adverse events following administration of morphine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect likelihood of experiencing adverse events when treated with morphine."
1450826857,A,G,"Patients with the rs1799971 AG genotype may be less likely to experience adverse events following administration of morphine as compared to patients with the AA genotype but more likely to experience adverse events as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect likelihood of experiencing adverse events when treated with morphine."
1450826857,G,G,"Patients with the rs1799971 GG genotype may be less likely to experience adverse events following administration of morphine as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect likelihood of experiencing adverse events when treated with morphine."
1183705764,A,A,"Patients with the rs121918592 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705764,A,G,"Patients with the rs121918592 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705764,C,C,"Patients with the rs121918592 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705764,C,G,"Patients with the rs121918592 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705764,G,G,"Patients with the rs121918592 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype CC, CG, AA or AG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705773,A,A,"Patients with the rs118192162 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype AC or CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705773,A,C,"Patients with the rs118192162 AC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705773,C,C,"Patients with the rs118192162 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705817,C,C,"Patients with the rs28933397 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705817,C,T,"Patients with the rs28933397 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705817,T,T,"Patients with the rs28933397 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705822,C,C,"Patients with the rs121918595 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705822,C,T,"Patients with the rs121918595 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705822,T,T,"Patients with the rs121918595 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705827,A,A,"Patients with the rs121918594 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705827,A,G,"Patients with the rs121918594 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705827,G,G,"Patients with the rs121918594 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183704257,A,A,Patients with the AA genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or AT. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.
1183704257,A,T,Patients with the AT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.
1183704257,T,T,Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype AA. Other genetic and clinical factors may also influence the risk of toxicity to Bisphosphonates.
1183704282,A,A,"Patients with the AA genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel."
1183704282,A,G,"Patients with the AG genotype may have decreased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel."
1183704282,G,G,"Patients with the GG genotype may have increased overall survival due to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to carboplatin, cisplatin, docetaxel, erlotinib, gefitinib or paclitaxel."
1183704292,A,A,"Patients with the AA genotype may have increased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan."
1183704292,A,G,"Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan."
1183704292,G,G,"Patients with the GG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan."
1183704390,A,A,Patients with the AA genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.
1183704390,A,G,Patients with the AG genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.
1183704390,G,G,Patients with the GG genotype may have decreased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to bupropion or nicotine.
1183705010,C,C,"Patients with the rs2279345 CC genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz."
1183705010,C,T,"Patients with the rs2279345 CT genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz."
1183705010,T,T,"Patients with the rs2279345 TT genotype and HIV may have decreased metabolism of efavirenz resulting in higher efavirenz plasma levels as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz."
1450826788,C,C,Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.
1450826788,C,T,Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.
1450826788,T,T,Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.
1450931434,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931434,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931434,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931453,C,C,Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931453,C,T,Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931453,T,T,Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931583,C,C,"Patients with major depressive disorder and the CC genotype may be more likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects."
1450931583,C,T,"Patients with major depressive disorder and the CT genotype may be less likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects."
1450931583,T,T,"Patients with major depressive disorder and the TT genotype may be less likely to experience nausea, vomiting, or sexual dysfunction when treated with citalopram as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced side effects."
1450929804,A,A,"Patients with the AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements."
1450929804,A,G,"Patients with the AG genotype may have decreased morphine dose requirements as compared to patients with the GG genotype, but increased dose requirements as compared to patients with the AA genotype. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements."
1450929804,G,G,"Patients with the GG genotype may have increased morphine dose requirements as compared to patients with the AA or AG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements."
1183863836,C,C,"Patients infected with the human immunodeficiency virus (HIV) and the CC genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation."
1183863836,C,T,"Patients infected with the human immunodeficiency virus (HIV) and the CT genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation."
1183863836,T,T,"Patients infected with the human immunodeficiency virus (HIV) and the TT genotype who are treated with atazanavir may have an increased risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation."
1450823887,A,A,"Patients with the rs1799971 AA genotype may be less likely to engage in smoking behaviors as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic or clinical factors may also affect smoking behaviors."
1450823887,A,G,"Patients with the rs1799971 AG genotype may be more likely to engage in smoking behaviors as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic or clinical factors may also affect smoking behaviors."
1450823887,G,G,"Patients with the rs1799971 GG genotype may be more likely to engage in smoking behaviors as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic or clinical factors may also affect smoking behaviors."
1450822836,C,C,Patients with the CC genotype may have an increased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy.
1450822836,C,T,Patients with the CT genotype may have a decreased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy.
1450822836,T,T,Patients with the TT genotype may have a decreased response to nicotine replacement therapy (NRT) and be abstinent from smoking 6 months after therapy as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to nicotine replacement therapy.
1450823583,A,A,"Patients with the AA genotype may have increased nicotine consumption and a decreased neural response to nicotine, as measured by MRI, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption and response to nicotine."
1450823583,A,G,"Patients with the AG genotype may have increased nicotine consumption and a decreased neural response to nicotine, as measured by MRI, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's nicotine consumption and response to nicotine."
1450823583,G,G,"Patients with the GG genotype may have decreased nicotine consumption and an increased neural response to nicotine, as measured by MRI, as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's nicotine consumption and response to nicotine."
1450934702,C,C,Patients with the CC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934702,C,G,Patients with the CG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934702,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934702,G,G,"Patients with the GG genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934702,G,T,Patients with the GT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934702,T,T,Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934767,C,C,Patients with the CC genotype who receive thiopurine treatment for autoimmune disease may be at a decreased risk of developing thiopurine-related cytopenia as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.
1450934767,C,T,Patients with the CT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.
1450934767,T,T,Patients with the TT genotype who receive thiopurine treatment for autoimmune disease may be at an increased risk of developing thiopurine-related cytopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thiopurine-related cytopenia.
1183704238,A,A,Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1183704238,A,G,Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1183704238,G,G,Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1449157419,A,A,Patients with alcoholism and the AA genotype may have a shorter survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients with alcoholism.
1449157419,A,G,Patients with alcoholism and the AG genotype may have a shorter survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients with alcoholism.
1449157419,G,G,Patients with alcoholism and the GG genotype may have a longer survival time as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence survival time in patients with alcoholism.
1449157547,A,A,"Patients with the AA genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol."
1449157547,A,C,"Patients with the AC genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the CC genotype. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol."
1449157547,C,C,"Patients with the CC genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA or AC genotypes. Please note: the AA and AC genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of SCARs in patients administered allopurinol."
1451637008,G,G,Patients with the rs34545984 GG genotype may be at a decreased risk of experiencing adverse events when treated with cephalexin as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with cephalexin.
1451637008,G,T,Patients with the rs34545984 GT genotype may be at an increased risk of experiencing adverse events when treated with cephalexin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with cephalexin.
1451637008,T,T,Patients with the rs34545984 TT genotype may be at an increased risk of experiencing adverse events when treated with cephalexin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with cephalexin.
1451475700,A,A,"Patients with osteosarcoma and the rs2236225 AA genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate."
1451475700,A,G,"Patients with osteosarcoma and the rs2236225 AG genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate."
1451475700,G,G,"Patients with osteosarcoma and the rs2236225 GG genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate."
1183703019,C,C,"Patients (mainly pediatric patients) with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to methylphenidate treatment as compared to patients with the CG or GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate."
1183703019,C,G,"Patients (mainly pediatric patients) with the CG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate."
1183703019,G,G,"Patients (mainly pediatric patients) with the GG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate."
1183705698,C,C,"Patients with the rs118192172 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705698,C,T,"Patients with the rs118192172 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705698,T,T,"Patients with the rs118192172 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705759,C,C,"Patients with the rs118192161 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705759,C,T,"Patients with the rs118192161 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia. T"
1183705759,T,T,"Patients with the rs118192161 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705807,C,C,"Patients with the rs118192177 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the TT, CT, CG, or GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705807,C,G,"Patients with the rs118192177 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705807,C,T,"Patients with the rs118192177 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705807,G,G,"Patients with the rs118192177 GG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705807,T,T,"Patients with the rs118192177 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705812,A,A,"Patients with the rs121918593 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705812,A,G,"Patients with the rs121918593 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705812,G,G,"Patients with the rs121918593 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451475720,C,C,"Patients with osteosarcoma and the rs717620 CC genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate."
1451475720,C,T,"Patients with osteosarcoma and the rs717620 CT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate."
1451475720,T,T,"Patients with osteosarcoma and the rs717620 TT genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate."
1451637100,C,C,Patients with the rs9620007 CC genotype may be at an increased risk of experiencing adverse events when treated with codeine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.
1451637100,C,G,Patients with the rs9620007 CG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.
1451637100,G,G,Patients with the rs9620007 GG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.
1450936169,C,C,Patients with the CC genotype may have decreased levels of acetaminophen sulfation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936169,C,T,Patients with the CT genotype may have increased levels of acetaminophen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936169,T,T,Patients with the TT genotype may have increased levels of acetaminophen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936177,A,A,Patients with the AA genotype may have decreased sulfation of tapentadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936177,A,G,Patients with the AG genotype may have increased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936177,G,G,Patients with the GG genotype may have increased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936189,A,A,Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936189,A,G,Patients with the AG genotype may have increased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936189,G,G,Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936217,C,C,Patients with the CC genotype may have increased sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936217,C,T,Patients with the CT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936217,T,T,Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936272,A,A,Patients with the AA genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936272,A,T,Patients with the AT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936272,T,T,Patients with the TT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936302,A,A,Patients with the AA genotype may have decreased sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936302,A,G,Patients with the AG genotype may have decreased sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936302,G,G,Patients with the GG genotype may have increased sulfation of tapentadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936308,G,G,Patients with the GG genotype may have decreased sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936308,G,T,Patients with the GT genotype may have decreased sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936308,T,T,Patients with the TT genotype may have increased sulfation of tapentadol as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.
1451637140,C,C,Patients with the rs62436463 CC genotype may be at an increased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.
1451637140,C,T,Patients with the rs62436463 CT genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.
1451637140,T,T,Patients with the rs62436463 TT genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.
1183705783,A,A,"Patients with the rs118192167 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705783,A,G,"Patients with the rs118192167 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705783,G,G,"Patients with the rs118192167 GG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183704358,A,A,"Patients with the AA genotype may have increased risk for neutropenia and an increased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AG and GG genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil."
1183704358,A,G,"Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil."
1183704358,G,G,"Patients with the GG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil."
1184233486,A,A,Patients with the AA genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233486,A,G,Patients with the AG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233486,G,G,Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233504,C,C,Patients with the CC genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233504,C,T,Patients with the CT genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233504,T,T,Patients with the TT genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233517,C,C,Patients with the CC genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233517,C,G,Patients with the CG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233517,G,G,Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1451637147,C,C,Patients with the rs62436463 CC genotype may be at an increased risk of experiencing adverse events when treated with oxycodone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.
1451637147,C,T,Patients with the rs62436463 CT genotype may be at a decreased risk of experiencing adverse events when treated with oxycodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.
1451637147,T,T,Patients with the rs62436463 TT genotype may be at a decreased risk of experiencing adverse events when treated with oxycodone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone.
1184233524,A,A,Patients with the AA genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233524,A,G,Patients with the AG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1184233524,G,G,Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.
1451475800,A,A,"Patients with osteosarcoma and the rs1695 AA genotype may have an increased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate."
1451475800,A,G,"Patients with osteosarcoma and the rs1695 AG genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate."
1451475800,G,G,"Patients with osteosarcoma and the rs1695 GG genotype may have a decreased response to treatment with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin, doxorubicin and methotrexate."
1183703748,A,A,"Patients with the rs61742245 AA genotype may require an increased dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin."
1183703748,A,C,"Patients with the rs61742245 AC genotype may require an increased dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin."
1183703748,C,C,"Patients with the rs61742245 CC genotype may have require a decreased dose of warfarin as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the dose of warfarin."
1449162249,C,C,Patients with the CC genotype who are treated with ketorolac and undergo oral surgery may have a slower analgesic onset as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.
1449162249,C,T,Patients with the CT genotype who are treated with ketorolac and undergo oral surgery may have a faster analgesic onset as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.
1449162249,T,T,Patients with the TT genotype who are treated with ketorolac and undergo oral surgery may have a faster analgesic onset as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.
1449164763,C,C,Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1449164763,C,T,Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1449164763,T,T,Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.
1449164769,C,C,Patients with the CC genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449164769,C,T,Patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for periorbital edema.
1449164769,T,T,"The TT genotype was not analyzed, but patients with the CT genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for periorbital edema."
1449192406,C,C,"Patients with the rs121909011 CC genotype (do not have a copy of the CFTR R334W variant) and cystic fibrosis have an unknown response to treatment with ivacaftor/lumacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor/lumacaftor."
1449192406,C,T,Patients with the rs121909011 CT genotype (one copy of the CFTR R334W variant) and cystic fibrosis may respond to treatment with ivacaftor/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor/lumacaftor.
1449192406,T,T,Patients with the rs121909011 TT genotype (two copies of the CFTR R334W variant) and cystic fibrosis may respond to treatment with ivacaftor/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor/lumacaftor.
1449182358,A,A,Patients with the AA genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the AC or CC genotypes. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.
1449182358,A,C,"Patients with the AC genotype and cancer-related pain may require a reduced dose escalation of morphine as compared to patients with the CC genotype, but an increased escalation as compared to patients with the AA genotype. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine."
1449182358,C,C,Patients with the CC genotype and cancer-related pain may require a increased dose escalation of morphine as compared to patients with the AA or AC genotypes. It should be noted that the same study found no association between this variant and a patient's initial morphine dose requirements. Other genetic and clinical factors may also affect a patient's dose escalation of morphine.
1449191373,A,A,"Patients with the rs397508256 AA genotype (two copies of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence response to ivacaftor."
1449191373,A,G,"Patients with the rs397508256 AG genotype (one copy of the CFTR E56K variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence response to ivacaftor."
1449191373,G,G,"Patients with the rs397508256 GG genotype (do not have a copy of the CFTR E56K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including E56K. Other genetic and clinical factors may also influence response to ivacaftor."
1451463900,C,C,Patients with the rs4948496 CC genotype and lymphoblastic leukemia-lymphoma may be at an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developed methotrexate-induced leukopenia.
1451463900,C,T,Patients with the rs4948496 CT genotype and lymphoblastic leukemia-lymphoma may be at an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developed methotrexate-induced leukopenia.
1451463900,T,T,Patients with the rs4948496 TT genotype and lymphoblastic leukemia-lymphoma may be at a decreased risk of developing leukopenia when treated with methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developed methotrexate-induced leukopenia.
1451637160,C,C,Patients with the rs62436463 CC genotype may be at an increased risk of experiencing adverse events when treated with tramadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.
1451637160,C,T,Patients with the rs62436463 CT genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.
1451637160,T,T,Patients with the rs62436463 TT genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.
1451637200,A,A,Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.
1451637200,A,G,Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.
1451637200,G,G,Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.
1451476060,A,A,"Patients with osteosarcoma and the rs9344 AA genotype may have a decreased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate."
1451476060,A,G,"Patients with osteosarcoma and the rs9344 AG genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate."
1451476060,G,G,"Patients with osteosarcoma and the rs9344 GG genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate."
1183705778,A,A,"Patients with the rs118192163 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705778,A,G,"Patients with the rs118192163 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705778,G,G,"Patients with the rs118192163 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183702417,C,C,"Patients with the CC genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy."
1183702417,C,T,"Patients with the CT genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy."
1183702417,T,T,"Patients with the TT genotype may have increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy."
1183704409,C,C,Patients with the CC genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183704409,C,T,Patients with the CT genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183704409,T,T,Patients with the TT genotype may have increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes CC + CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.
1183705797,C,C,"Patients with the rs118192175 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705797,C,T,"Patients with the rs118192175 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705797,T,T,"Patients with the rs118192175 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705802,A,A,"Patients with the rs118192176 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705802,A,G,"Patients with the rs118192176 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1183705802,G,G,"Patients with the rs118192176 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451464245,G,G,"The current evidence base suggests that there is no significant association between the rs1801131 GG genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements."
1451464245,G,T,"The current evidence base suggests that there is no significant association between the rs1801131 GT genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements."
1451464245,T,T,"The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements."
1183703000,C,C,Patients with the CC genotype and prostate cancer may have shorter progression-free survival time when treated with cyclophosphamide as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence length of progression-free survival.
1183703000,C,G,Patients with the CG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.
1183703000,G,G,Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.
1183703784,C,C,"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity."
1183703784,C,T,"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity."
1183703784,T,T,"The C allele of rs115232898 is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk for drug toxicity as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of drug toxicity."
1451637155,G,G,Patients with the rs113100019 GG genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.
1451637155,G,T,Patients with the rs113100019 GT genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.
1451637155,T,T,Patients with the rs113100019 TT genotype may be at a decreased risk of experiencing adverse events when treated with meperidine as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.
1444668236,A,A,"In healthy volunteers as well as patients with diabetes mellitus the AA genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668236,A,G,"In healthy volunteers as well as patients with diabetes mellitus the AG genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the GG genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668236,G,G,"In healthy volunteers as well as patients with diabetes mellitus the GG genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444673084,C,C,Patients with the CC genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to imatinib treatment.
1444673084,C,G,Patients with the CG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.
1444673084,G,G,Patients with the GG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.
1444673142,A,A,Patients with the AA genotype and paroxysmal nocturnal hemoglobinuria may have a better response to treatment with eculizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to eculizumab.
1444673142,A,G,Patients with the AG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.
1444673142,G,G,Patients with the GG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.
1444673156,A,A,Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444673156,A,C,Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444673156,C,C,Patients with the CC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444700509,G,G,"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700509,G,T,"Patients with the GT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype. Patients with the GT genotype are not studied for sensitivity to imatinib, but based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700509,T,T,"Patients with the TT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype based on the finding of the GT genotype being associated with decreased metabolism as compared to the GG genotype. Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700522,C,C,"Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700522,C,T,"Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700522,T,T,"Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700796,A,A,Patients with the AA genotype and HIV who are treated with nevirapine may have decreased clearance of nevirapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1444700796,A,G,Patients with the AG genotype and HIV who are treated with nevirapine may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1444700796,G,G,Patients with the GG genotype and HIV who are treated with nevirapine may have increased clearance of nevirapine as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1444700881,A,A,Patients with the AA genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.
1444700881,A,G,Patients with the AG genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.
1444700881,G,G,Patients with the GG genotype and open-angle glaucoma who are treated with timolol may have a decreased risk for bradycardia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.
1444703131,C,C,Patients with the CC genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.
1444703131,C,T,Patients with the CT genotype and Schizophrenia who are treated with olanzapine or risperidone may have decreased time until response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.
1444703131,T,T,Patients with the TT genotype and Schizophrenia who are treated with olanzapine or risperidone may have increased time until response as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine or risperidone.
1444703146,A,A,Patients with the AA genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1444703146,A,G,Patients with the AG genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1444703146,G,G,Patients with the GG genotype who are treated with aspirin may have a decreased risk of aspirin-intolerant chronic urticaria as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.
1444703154,C,C,"Patients with the CC genotype and Hepatitis C who are treated with interferons and ribavirin may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin."
1444703154,C,T,"Patients with the CT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype or may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin."
1444703154,T,T,Patients with the TT genotype and Hepatitis C who are treated with interferons and ribavirin may have increased risk for non-response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.
1445401118,A,A,Patients with the AA genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401118,A,C,Patients with the AC genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401118,C,C,Patients with the CC genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401125,A,A,Patients with the AA genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401125,A,G,Patients with the AG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401125,G,G,Patients with the GG genotype and rectal cancer may have a poorer response to capecitabine-based chemoradiotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.
1445401897,C,C,"Patients with the CC genotype (CYP3A4 *1/*1) and epilepsy may have increased concentrations of carbamazepine as compared to patients with the CT (*1/*1G) or TT (*1G/*1G) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine."
1445401897,C,T,"Patients with the CT (CYP3A4 *1/*1G) genotype and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine."
1445401897,T,T,"Patients with the TT genotype (CYP3A4 *1G/*1G) and epilepsy may have decreased concentrations of carbamazepine as compared to patients with the CC (*1/*1) genotype. However, studies conflict. Other genetic and clinical factors may also influence concentrations of carbamazepine."
1444673149,A,A,Patients with the AA genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444673149,A,G,Patients with the AG genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444673149,G,G,Patients with the GG genotype and psoriasis may have a higher psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444703571,A,A,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1444703571,A,C,Patients with the AC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype or may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1444703571,C,C,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1451476200,A,A,"Patients with the rs2236225 AA genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate."
1451476200,A,G,"Patients with the rs2236225 AG genotype may have an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate."
1451476200,G,G,"Patients with the rs2236225 GG genotype may have a decreased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing anemia when treated with methotrexate."
1451493592,A,A,"There is currently no available evidence regarding the association between the rs4762 AA genotype and response to irbesartan. However, patients with the rs4762 AG genotype may have an increased response to irbesartan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
1451493592,A,G,"Patients with the rs4762 AG genotype may have an increased response to irbesartan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
1451493592,G,G,"Patients with the rs4762 GG genotype may have a decreased response to irbesartan as compared to patients with the AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
1445401317,G,G,Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for respiratory depression when treated with opioids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of respiratory depression.
1445401317,G,T,Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.
1445401317,T,T,Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.
1445737062,G,G,"Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens."
1445737062,G,T,"Patients with the GT genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens."
1445737062,T,T,"Patients with the TT genotype and breast cancer, stomach cancer, or other cancer may have a improved response (decreased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS NOT GIVEN AS AN ADJUVANT as compared to patients with the GG and GT genotypes. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens."
1446898857,C,C,"Patients with schizophrenia, or autism spectrum disorder (ASD) and the CC genotype, may have a decreased likelihood of weight gain as compared to patients with the CT and TT genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients with ASD or schizophrenia who are taking risperidone, clozapine, or olanzapine."
1446898857,C,T,"Patients with schizophrenia, or autism spectrum disorder (ASD) and the CT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine."
1446898857,T,T,"Patients with schizophrenia, or autism spectrum disorder (ASD) and the TT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine."
1446899151,C,C,"Patients with the CC genotype may require a decreased dose of warfarin as compared to patients with the CT and TT genotypes, however, no association was found in the majority of studies, and in one study, the CC genotype was associated with an increased dose of warfarin. Other clinical and genetic factors may also influence dose of warfarin."
1446899151,C,T,"Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the CT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin."
1446899151,T,T,"Patients with the TT genotype may require an increased dose of warfarin as compared to patients with the CC genotype, however, no association was found in the majority of studies, and in one study, the TT genotype was associated with a decreased dose of warfarin as compared to the CC genotype. Other clinical and genetic factors may also influence dose of warfarin."
1185000205,C,C,Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CT (*1/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.
1185000205,C,T,Patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.
1185000205,T,T,"No individuals with the TT genotype (CYP3A5 *1/*1) were available for analysis. However, patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus."
1444673025,A,A,Patients with the AA genotype and heart conditions may have a poorer response to treatment with beta-blockers or antihypertensives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.
1444673025,A,T,Patients with the AT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.
1444673025,T,T,Patients with the TT genotype and heart conditions may have a better response to treatment with beta-blockers or antihypertensives as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to beta-blockers or antihypertensives.
1444673072,C,C,Patients with the CC genotype and rheumatoid or psoriatic arthritis may have a better response when treated with anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.
1444673072,C,G,Patients with the CG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.
1444673072,G,G,Patients with the GG genotype and rheumatoid or psoriatic arthritis may have a poorer response when treated with anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapies.
1444700822,A,A,Patients with the AA genotype may have increased response to hmg coa reductase inhibitors as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444700822,A,G,Patients with the AG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444700822,G,G,Patients with the GG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444700830,A,A,"Patients with the AA genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1444700830,A,G,"Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1444700830,G,G,Patients with the GG genotype and asthma may have an increased risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703178,C,C,Patients with the CC genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444703178,C,G,Patients with the CG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype or may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444703178,G,G,Patients with the GG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444703187,A,A,Patients with the AA genotype who are treated with timolol may have increased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to timolol.
1444703187,A,G,Patients with the AG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.
1444703187,G,G,Patients with the GG genotype who are treated with timolol may have decreased systolic (SAP) and diastolic (DAP) arterial pressure responses as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to timolol.
1444703195,C,C,Patients with the CC genotype and Coronary Artery Disease may have decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1444703195,C,G,Patients with the CG genotype and Coronary Artery Disease may have increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype or may have decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1444703195,G,G,Patients with the GG genotype and Coronary Artery Disease may have increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.
1444703840,C,C,"Patients with the CC genotype were not studied. However, patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib."
1444703840,C,T,Patients with the CT genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444703840,T,T,Patients with the TT genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444703848,A,A,"Patients with the AA genotype were not studied. However, patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib."
1444703848,A,C,Patients with the AC genotype and Renal Cell Carcinoma who are treated with sunitinib may have reduced progression-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444703848,C,C,Patients with the CC genotype and Renal Cell Carcinoma who are treated with sunitinib may have increased progression-free survival as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.
1444704055,C,C,Patients with the CC genotype and rs2501873 TT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1444704055,C,T,Patients with the CT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype or may require decreased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1444704055,T,T,Patients with the TT genotype and rs2501873 TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's warfarin dose.
1444704067,C,C,Patients with the CC genotype may have decreased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1444704067,C,T,Patients with the CT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1444704067,T,T,Patients with the TT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1444704074,C,C,Patients with the CC genotype may have increased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1444704074,C,T,Patients with the CT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1444704074,T,T,Patients with the TT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.
1444704134,A,A,Patients with the AA genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1444704134,A,G,"Patients with the AG genotype and Hypertension may have increased risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype or may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide."
1444704134,G,G,"Patients with the GG genotype and Hypertension may have decreased, but not absent, risk of diabetes when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide."
1444704141,C,C,"Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
1444704141,C,T,"Patients with the CT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype or may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
1444704141,T,T,Patients with the TT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444930850,C,C,"Patients with CC genotype may have increased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CT or TT. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy."
1444930850,C,T,"Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy."
1444930850,T,T,"Patients with TT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy."
1445401179,A,A,Patients with the AA genotype and prostate cancer may have shorter progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1445401179,A,G,Patients with the AG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1445401179,G,G,Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1445401310,C,C,"Cancer patients with the CC genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. However, one study failed to find an association. Other genetic and clinical factors may also influence risk for ototoxicity."
1445401310,C,T,"Cancer patients with the CT genotype may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the TT genotype. However, one study failed to find an association. Other genetic and clinical factors may also influence risk for ototoxicity."
1445401310,T,T,"Cancer patients with the TT genotype may have an increased risk of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotype. However, one study failed to find an association. Other genetic and clinical factors may also influence risk for ototoxicity."
1445117525,C,C,"Patients with the rs193922876 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445117525,C,T,"Patients with the rs193922876 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445117525,T,T,"Patients with the rs193922876 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445401008,C,C,"Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with desflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445401008,C,T,Patients with the rs1800559 CT genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1445401008,T,T,Patients with the rs1800559 TT genotype may have increased risk for malignant hyperthermia when treated with desflurane as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451637183,A,A,Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.
1451637183,A,G,Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.
1451637183,G,G,Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with codeine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.
1184986744,A,A,Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.
1184986744,A,G,Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype and an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.
1184986744,G,G,Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.
1184986770,C,C,Patients with the CC genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the CT genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1184986770,C,T,Patients with the CT genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1184986770,T,T,The TT genotype was not evaluated for its influence on risk of opioid dependence upon exposure to opioids.Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids.
1445722592,C,C,"Patients with the CC genotype and cancer, including cancer of the stomach, may have an increased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer."
1445722592,C,T,"Patients with the CT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer."
1445722592,T,T,"Patients with the TT genotype and cancer, including cancer of the stomach, may have a decreased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer."
1450371701,A,A,Patients with rheumatoid arthritis and the AA genotype may have an increased response to tocilizumab as compared to patients with the AC or CC genotypes. Note that an increased response was only seen with one metric at one timepoint from the three analyzed in the study. Other genetic or clinical factors may also affect a patient's response to tocilizumab.
1450371701,A,C,Patients with rheumatoid arthritis and the AC genotype may have a decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to tocilizumab.
1450371701,C,C,Patients with rheumatoid arthritis and the CC genotype may have a decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to tocilizumab.
1450375740,C,C,Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450375740,C,T,Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450375740,T,T,Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s
1450375758,A,A,"Patients with the AA genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375758,A,G,"Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375758,G,G,"Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA or AG genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375752,C,C,"Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375752,C,T,"Patients with the CT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1450375752,T,T,"Patients with the TT genotype may have a decreased response to allopurinol as compared to patients with the CC genotype. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol."
1451637220,A,A,Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.
1451637220,A,G,Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.
1451637220,G,G,Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with codeine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.
1444667234,A,A,Patients with metastasized cancer and the AA genotype may have worse response to capecitabine or fluorouracil as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667234,A,T,Patients with metastasized cancer and the AT genotype may have worse response to capecitabine or fluorouracil as compared to patients with the TT genotype and improved response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667234,T,T,Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667256,A,A,Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667256,A,G,Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667256,G,G,Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667263,A,A,Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667263,A,G,Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444667263,G,G,Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the association with this SNP did not remain significant after Bonferroni correction.
1444700354,A,A,Patients with the AA genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.
1444700354,A,G,Patients with the AG genotype may have increased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.
1444700354,G,G,Patients with the GG genotype may have decreased isoproterenol-mediated desensitization in the vasculature when exposed to isoproterenol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to isoproterenol.
1444700362,C,C,Patients with the CC genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700362,C,T,Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700362,T,T,Patients with the TT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700371,C,C,Patients with the CC genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700371,C,T,Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700371,T,T,Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700382,C,C,Patients with the CC genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700382,C,T,Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700382,T,T,Patients with the TT genotype and Schizophrenia who are treated with clozapine may have a decreased response to clozapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1444700597,C,C,Patients with the CC genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nausea.
1444700597,C,T,Patients with the CT genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype or may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.
1444700597,T,T,Patients with the TT genotype who are treated with gemcitabine and platinum compounds may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.
1444700605,A,A,Patients with the AA genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.
1444700605,A,G,Patients with the AG genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype or may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.
1444700605,G,G,Patients with the GG genotype with colorectal neoplasms who are treated with celecoxib may have a decreased risk of adenoma recurrence as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.
1444700838,C,C,Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700838,T,C,Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700838,T,T,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700845,C,C,Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700845,C,T,Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700845,T,T,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700853,C,C,Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700853,C,T,Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700853,T,T,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444701017,C,C,Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.
1444701017,C,T,Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.
1444701017,T,T,Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.
1444701024,C,C,Patients with the CC genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.
1444701024,C,T,Patients with the CT genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.
1444701024,T,T,Patients with the TT genotype may have decreased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the response to sildenafil.
1444705158,C,C,"Patients with the CC genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain."
1444705158,C,T,"Patients with the CT genotype and Hypertension may have decreased, but not absent, risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain."
1444705158,T,T,"Patients with the TT genotype and Hypertension may have increased risk of Myocardial Infarction when treated with Ace Inhibitors as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to Ace Inhibitors, Plain."
1444705166,A,A,Patients with the AA genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705166,A,G,Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705166,G,G,Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1445400945,G,G,Patients with the GG genotype and coronary heart disease may have a better response to treatment with salvianolate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to salvianolate.
1445400945,G,T,Patients with the GT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.
1445400945,T,T,Patients with the TT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.
1445401205,A,A,"Patients with the AA genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib."
1445401205,A,G,"Patients with the AG genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib."
1445401205,G,G,"Patients with the GG genotype and chronic myeloid leukemia may have a better response to imatinib treatment as compared to patients with the AA or AG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib."
1445401247,A,A,Patients with the AA genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401247,A,G,Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401247,G,G,Patients with the GG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445402144,C,C,"Patients with the CC genotype and acute lymphoblastic leukemia may have a lower risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of relapse."
1445402144,C,T,"Patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse."
1445402144,T,T,"No patients with the TT genotype were studied, but patients with the CT genotype and acute lymphoblastic leukemia may have a greater risk of relapse when treated with doxorubicin, methotrexate, prednisolone and vincristine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of relapse."
1445402163,A,A,"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
1445402163,A,G,"Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
1445402163,G,G,"Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
1445402175,A,A,"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AT or TT genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
1445402175,A,T,"Patients with the AT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
1445402175,T,T,"Patients with the TT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
1445402182,A,A,"Patients with the AA genotype who are undergoing kidney transplantation may have lower concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
1445402182,A,G,"Patients with the AG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
1445402182,G,G,"Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus."
1445585748,C,C,"Patients with the CC genotype may require a decreased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or TT genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement."
1445585748,C,T,"Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement."
1445585748,T,T,"Patients with the TT genotype may require an increased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement."
1451476309,A,A,Patients with osteosarcoma and the rs17222723 AA genotype may have a decreased risk of developing leukopenia when treated with methotrexate as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.
1451476309,A,T,Patients with osteosarcoma and the rs17222723 AT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.
1451476309,T,T,Patients with osteosarcoma and the rs17222723 TT genotype may have an increased risk of developing leukopenia when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with methotrexate.
1451637280,A,A,Patients with the rs739296 AA genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.
1451637280,A,G,Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.
1451637280,G,G,Patients with the rs739296 GG genotype may be at an increased risk of experiencing adverse events when treated with tramadol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.
1184987460,A,A,"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987460,A,G,"Patients with the AG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987460,G,G,"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1444608441,C,C,Patients with the CC genotype and autism spectrum disorders may have a better tolerance for methylphenidate treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.
1444608441,C,T,Patients with the CT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.
1444608441,T,T,Patients with the TT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.
1444700740,C,C,"Patients with the CC genotype and major depression who are treated with citalopram may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation."
1444700740,C,T,"Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype or may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation."
1444700740,T,T,Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.
1444700748,C,C,Patients with the CC genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1444700748,C,T,"Patients with the CT genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia."
1444700748,T,T,"Patients with the TT genotype and neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia."
1444703339,C,C,Patients with the CC genotype and asthma who are treated with aspirin may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703339,C,G,Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype or may have increased risk of aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703339,G,G,Patients with the GG genotype and asthma who are treated with aspirin may have decreased risk of aspirin-intolerant asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703346,C,C,Patients with the CC genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1444703346,C,T,Patients with the CT genotype and acute coronary syndrome may have increased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CC or TT genotype and and a decreased response to aspirin and clopidogrel in patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1444703346,T,T,Patients with the TT genotype and acute coronary syndrome may have decreased platelet aggregation with epinephrine when treated with aspirin and clopidogrel as compared to patients with the CT genotype and and an increased response to aspirin and clopidogrel in patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel.
1444703380,A,A,"Patients with the AA genotype who are treated with warfarin may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin."
1444703380,A,G,"Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin."
1444703380,G,G,"Patients with the GG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin."
1444703393,A,A,Female patients with the AA genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444703393,A,G,Female patients with the AG genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444703393,G,G,Female patients with the GG genotype and major depression may have increased response to paroxetine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444703784,C,C,Patients with the CC genotype who are treated with metformin may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703784,C,T,Patients with the CT genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin as compared to patients with the CC genotype or may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703784,T,T,Patients with the TT genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703791,A,A,Patients with the AA genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703791,A,G,Patients with the AG genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin as compared to patients with the GG genotype or may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703791,G,G,Patients with the GG genotype who are treated with metformin may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444703869,A,A,Patients with the AA genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1444703869,A,G,Patients with the AG genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1444703869,G,G,Patients with the GG genotype and Coronary Disease who are treated with simvastatin may have less LDL-C reduction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin
1444703884,A,A,Patients with the AA genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444703884,A,G,Patients with the AG genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype or may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444703884,G,G,Patients with the GG genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444703250,A,A,"Patients with the AA genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
1444703250,A,G,"Patients with the AG genotype and Epilepsy who are treated with carbamazepine may have decreased concentration-to-dose ratios as compared to patients with the GG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
1444703250,G,G,"Patients with the GG genotype and Epilepsy who are treated with carbamazepine may have increased concentration-to-dose ratios as compared to patients with the AA or AG genotype, although this is contradicted in one study which found no association. There is no association with response to carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine."
1444703578,C,C,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1444703578,C,T,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype or may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1444703578,T,T,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1451476360,A,A,Patients with osteosarcoma and the rs11615 AA genotype may have a decreased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.
1451476360,A,G,"There is currently no available evidence regarding the association between the rs11615 AG genotype and risk of developing mucositis when treated with cisplatin and doxorubicin. However, patients with osteosarcoma and the rs11615 AA genotype may have a decreased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin."
1451476360,G,G,Patients with osteosarcoma and the rs11615 GG genotype may have an increased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.
1444703619,A,A,"Patients with the rs3740065 AA genotype who are treated with methotrexate may have a decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate."
1444703619,A,G,Patients with the rs3740065 AG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.
1444703619,G,G,Patients with the rs3740065 GG genotype and leukemia who are treated with methotrexate may have an increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate.
1296666989,A,A,Patients with the AA genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.
1296666989,A,G,Patients with the AG genotype may have increased response to simvastatin (higher LDL lowering effect) as compared to patients withe the GG genotype. Other genetic or clinical factors may also influence the response to simvastatin.
1296666989,G,G,Patients with the GG genotype may have decreased response to simvastatin (higher LDL lowering effect) as compared to patients withe the AA or AG genotype. Other genetic or clinical factors may also influence the response to simvastatin.
1445400792,A,A,"Patients with the AA genotype may have an increased response to bisphosphonate treatment, or may have an increase in bone density when treated with atorvastatin, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response."
1445400792,A,G,"Patients with the AG genotype may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response."
1445400792,G,G,"Patients with the GG genotype may have a decreased response to bisphosphonate treatment, or may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response."
1445400917,C,C,Patients with the CC genotype who are alcohol-dependent may have a poorer response to treatment with naltrexone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to naltrexone.
1445400917,C,T,Patients with the CT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.
1445400917,T,T,Patients with the TT genotype who are alcohol-dependent may have a better response to treatment with naltrexone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to naltrexone.
1445594343,C,C,Patients with the CC genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594343,C,T,Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594343,T,T,Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594352,A,A,Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594352,A,G,Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594352,G,G,Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594359,A,A,Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594359,A,G,Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594359,G,G,Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1446902898,A,A,Patients with the AA genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.
1446902898,A,C,Patients with the AC genotype may have increased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to atenolol.
1446902898,C,C,Patients with the CC genotype may have decreased response to atenolol pr bisoprolol in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to atenolol.
1446902905,A,A,Patients with the AA genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1446902905,A,C,Patients with the AC genotype may have decreased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1446902905,C,C,Patients with the CC genotype may have increased response to hydrochlorothiazide in hypertensive patients as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1446902912,A,A,Patients with the AA genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.
1446902912,A,G,Patients with the AG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to atenolol.
1446902912,G,G,Patients with the GG genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to atenolol.
1446902920,G,G,Patients with the GG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.
1446902920,G,T,Patients with the GT genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.
1446902920,T,T,Patients with the TT genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to atenolol.
1446902927,C,C,Patients with the CC genotype may have decreased risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence the response to verapamil.
1446902927,T,C,Patients with the TC genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.
1446902927,T,T,Patients with the TT genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.
1446905759,G,G,Patients with the GG genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.
1446905759,G,T,Patients with the GT genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.
1446905759,T,T,Patients with the TT genotype may have increased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the bone response to atorvastatin.
1446906439,A,A,Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to capecitabine.
1446906439,A,C,Patients with genotype AC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.
1446906439,C,C,Patients with genotype CC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.
1446906446,C,C,Patients with genotype CC may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.
1446906446,C,T,Patients with genotype CT may have decreased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype TT. Other genetic and clinical factors may also influence the toxicity to efavirenz.
1446906446,T,T,Patients with genotype TT may have increased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the toxicity to efavirenz.
1451493693,A,A,"Patients with the rs5186 AA genotype may have a decreased response to irbesartan as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
1451493693,A,C,"Patients with the rs5186 AC genotype may have an increased response to irbesartan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
1451493693,C,C,"Patients with the rs5186 CC genotype may have an increased response to irbesartan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan."
1445400910,C,C,"Patients with the rs193922747 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400910,C,T,"Patients with the rs193922747 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400910,T,T,"Patients with the rs193922747 TT genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype CT and CC. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1446905691,A,A,"Patients with the rs1127354 AA genotype and chronic hepatitis C may have a decreased risk of anemia when compared to patients with the CC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin."
1446905691,A,C,"Patients with the rs1127354 AC genotype and chronic hepatitis C may have a decreased risk of anemia when compared to patients with the CC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin."
1446905691,C,C,"Patients with the rs1127354 CC genotype and chronic hepatitis C may have an increased risk of anemia as compared to patients with the AA or AC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin."
1446905703,A,A,"Patients with the rs7270101 AA genotype and chronic hepatitis C may have an increased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AC and CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia."
1446905703,A,C,"Patients with the rs7270101 AC genotype and chronic hepatitis C may have a decreased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia."
1446905703,C,C,"Patients with the rs7270101 CC genotype and chronic hepatitis C may have a decreased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia."
1445400880,A,A,Patients with the AA genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.
1445400880,A,G,Patients with the AG genotype and multiple myeloma may have a decreased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.
1445400880,G,G,Patients with the GG genotype and multiple myeloma may have an increased risk of gastrointestinal toxicity when treated with melphalan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence melphalan-induced toxicity.
1445401156,G,G,"Patients with the GG genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab."
1445401156,G,T,"Patients with the GT genotype and colorectal cancer may have a poorer response when treated with FOLFIRI and bevacizumab as compared to patients with the TT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab."
1445401156,T,T,"Patients with the TT genotype and colorectal cancer may have a better response when treated with FOLFIRI and bevacizumab as compared to patients with the GG or GT genotype. However, this result only applied to tumors occurring in the right colon. Other genetic and clinical factors may also influence response to FOLFIRI and bevacizumab."
1445401168,A,A,"The current evidence base suggests there that is no significant association between the rs6313 AA genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
1445401168,A,G,"The current evidence base suggests there that is no significant association between the rs6313 AG genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
1445401168,G,G,"The current evidence base suggests there that is no significant association between the rs6313 GG genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants."
1445402111,A,A,Patients with the AA genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1445402111,A,G,Patients with the AG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1445402111,G,G,Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to clozapine.
1445400887,A,A,"Patients with the rs112563513 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400887,A,G,"Patients with the rs112563513 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400887,G,G,"Patients with the rs112563513 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1444694385,C,C,Patients with the CC genotype who undergo kidney transplant may have a decreased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk for PTDM.
1444694385,C,T,Patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM.
1444694385,T,T,"No patients with the TT genotype were present in the population. However, patients with the CT genotype who undergo kidney transplant may have an increased risk for new-onset posttransplant diabetes mellitus (PTDM) when treated with tacrolimus compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for PTDM."
1444694562,G,G,"Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
1444694562,G,T,"Patients undergoing liver transplantation who receive a donor liver with the GT genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
1444694562,T,T,"Patients undergoing liver transplantation who receive a donor liver with the TT genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the GG or GT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
1444694574,A,A,"Patients undergoing liver transplantation who receive a donor liver with the AA genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
1444694574,A,G,"Patients undergoing liver transplantation who receive a donor liver with the AG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
1444694574,G,G,"Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
1445400873,G,G,Patients with acute myeloid leukemia and the GG genotype may have increased survival time when treated with daunorubicin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to daunorubicin.
1445400873,G,T,Patients with acute myeloid leukemia and the GT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.
1445400873,T,T,Patients with acute myeloid leukemia and the TT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.
1449753224,A,G,Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1449753224,G,G,Patients with the GG genotype and autism may have a decreased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.
1450375053,G,G,"Patients with testicular cancer and the GG genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375053,G,T,"Patients with testicular cancer and the GT genotype may have an increased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375053,T,T,"Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of alopecia as a result of treatment with bleomycin, cisplatin and etoposide."
1445400894,A,A,"Patients with the rs28933396 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400894,A,G,"Patients with the rs28933396 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400894,G,G,"Patients with the rs28933396 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AG and AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1449747575,A,A,Patient harbors the rs144336148 AA genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs144336148 G>A variant as a variant of uncertain significance (VUS) using ACMG/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1449747575,A,G,Patient harbors the rs144336148 AG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs144336148 G>A variant as a variant of uncertain significance (VUS) using ACMG/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1449747575,G,G,Patient harbors the rs144336148 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs144336148 G>A variant as a variant of uncertain significance (VUS) using ACMG/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1451476500,G,G,"The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate."
1451476500,G,T,"The current evidence base suggests that there is no significant association between the rs2231142 GT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate."
1451476500,T,T,"The current evidence base suggests that there is no significant association between the rs2231142 TT genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate."
1451637320,A,A,Patients with the rs185462714 AA genotype may be at a decreased risk of experiencing adverse events when treated with meperidine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.
1451637320,A,C,Patients with the rs185462714 AC genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.
1451637320,C,C,Patients with the rs185462714 CC genotype may be at an increased risk of experiencing adverse events when treated with meperidine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with meperidine.
1445400156,C,C,"Patients with the rs193922803 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400156,C,T,"Patients with the rs193922803 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400156,T,T,"Patients with the rs193922803 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1444679942,A,A,Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1444679942,A,C,"Patients with the AC genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the CC genotype, or a better response as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine."
1444679942,C,C,Patients with the CC genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1444680131,A,A,"Patients with the AA genotype and Parkinson's disease may have an increased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa."
1444680131,A,G,"Patients with the AG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa."
1444680131,G,G,"Patients with the GG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa."
1444680138,A,A,"Patients with the AA genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin."
1444680138,A,G,"Patients with the AG genotype and atrial fibrillation may require a higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin."
1444680138,G,G,"Patients with the GG genotype and atrial fibrillation may require a lower dose of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin."
1444703768,C,C,Patients with the CC genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1444703768,C,T,Patients with the CT genotype and major depression who are treated with nortriptyline may have less improvement in neurovegetative symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1444703768,T,T,Patients with the TT genotype and major depression who are treated with nortriptyline may have more improvement in neurovegetative symptoms as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.
1444703777,A,A,Patients with the AA genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have increased risk of anemia as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin.
1444703777,A,C,"Patients with the AC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin."
1444703777,C,C,"Patients with the CC genotype and Hepatitis C who are treated with peginterferon alfa-2a and ribavirin may have decreased, but not absent, risk of anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to peginterferon alfa-2a and ribavirin."
1444704025,A,A,Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect nicotine metabolism.
1444704025,A,G,Patients with the AG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect nicotine metabolism.
1444704025,G,G,Patients with the GG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect nicotine metabolism.
1444704032,A,A,"Patients with the AA genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
1444704032,A,C,"Patients with the AC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype or may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
1444704032,C,C,Patients with the CC genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk for cardiovascular toxicity and symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444704040,C,C,Patients with the CC genotype who are treated with fexofenadine may have increased area under the plasma concentration-time curve as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.
1444704040,C,T,Patients with the CT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.
1444704040,T,T,Patients with the TT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.
1444704048,C,C,Patients with the CC genotype and major depression may have increased response to paroxetine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444704048,C,T,Patients with the CT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444704048,T,T,Patients with the TT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1446766000,A,A,Patients with the AA genotype and postoperative pain may require an increased dose when treated with fentanyl as compared to patients with the AG+GG genotype. Other genetic and clinical factors may also influence the required dose of fentanyl.
1446766000,A,G,Patients with the AG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.
1446766000,G,G,Patients with the GG genotype and postoperative pain may require a decreased dose when treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence required dose of fentanyl.
1446899476,C,C,Patients with the rs71647871 CC genotype may have increased metabolism of enalapril as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.
1446899476,C,T,Patients with the rs71647871 CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril.
1446899476,T,T,"There is currently no available evidence regarding the association between the rs71647871 TT genotype and metabolism of enalapril. However, patients with the CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and enalapril and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of enalapril."
1444673170,A,A,Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444673170,A,C,Current literature evidence finds no significant effect of the AC genotype on progression-free survival time in patients taking docetaxel.
1444673170,C,C,Patients with the CC genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444680101,A,A,Patients with the AA genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1444680101,A,G,Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1444680101,G,G,Patients with the GG genotype who are opioid-dependent may have a better response to treatment with buprenorphine as compared to patients with the AA or AG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.
1451648366,A,A,Patients with opioid dependence and the rs62368105 AA genotype may have a decreased response to buprenorphine therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1451648366,A,G,Patients with opioid dependence and the rs62368105 AG genotype may have a decreased response to buprenorphine therapy as compared to patients GG genotype but an increased response as compared to the AA genotype. Other genetic and clinical factors may also influence response to buprenorphine.
1451648366,G,G,Patients with opioid dependence and the rs62368105 GG genotype may have an increased response to buprenorphine therapy as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1451648374,C,C,Patients with opioid dependence and the rs6973474 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1451648374,C,T,Patients with opioid dependence and the rs6973474 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.
1451648374,T,T,Patients with opioid dependence and the rs6973474 TT genotype may have an increased response to buprenorphine therapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1445400172,C,C,"Patients with the rs118192124 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the TT or CT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400172,C,T,"Patients with the rs118192124 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400172,T,T,"Patients with the rs118192124 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451476520,A,A,Patients with osteosarcoma and the rs4673 AA genotype may be at a decreased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.
1451476520,A,G,Patients with osteosarcoma and the rs4673 AG genotype may be at a decreased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.
1451476520,G,G,Patients with osteosarcoma and the rs4673 GG genotype may be at an increased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.
1451637387,A,A,Patients with the rs76103438 AA genotype may be at an increased risk of experiencing adverse events when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with simvastatin.
1451637387,A,T,Patients with the rs76103438 AT genotype may be at an increased risk of experiencing adverse events when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with simvastatin.
1451637387,T,T,Patients with the rs76103438 TT genotype may be at a decreased risk of experiencing adverse events when treated with simvastatin as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with simvastatin.
1451648382,C,C,Patients with opioid dependence and the rs13169373 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1451648382,C,T,Patients with opioid dependence and the rs13169373 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.
1451648382,T,T,Patients with opioid dependence and the rs13169373 TT genotype may have an increased response to buprenorphine therapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1451648420,C,C,Patients with opioid dependence and the rs7205113 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1451648420,C,T,Patients with opioid dependence and the rs7205113 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.
1451648420,T,T,Patients with opioid dependence and the rs7205113 TT genotype may have an increased response to buprenorphine therapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1451678080,A,A,"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone."
1451678080,A,G,"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone."
1451678080,G,G,"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone."
1446896644,C,C,Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to olanzapine.
1446896644,C,T,Patients with the CT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.
1446896644,T,T,Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.
1446897502,G,G,Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897502,G,T,Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotypes and an increased response as compared to patients with a GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897502,T,T,Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GG and GT genotypes genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897509,A,A,Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.
1446897509,A,G,Patients with asthma and the AG genotype may have a decreased response to montelukast as compared to patients with the AA genotype and an increased response to GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.
1446897509,G,G,Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with Asthma.
1446897520,A,A,Patients with asthma and the AA genotype may have an increased response to montelukast as compared to patients with the GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897520,G,G,Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the AA genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897526,G,G,Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897526,G,T,Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897526,T,T,Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GT and GG genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.
1446897533,C,C,"Patients with breast cancer and the CC genotype may have an increased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CG and GG. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases who are taking anastrozole or letrozole."
1446897533,C,G,"Patients with breast cancer and the CG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to CC genotypes. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole."
1446897533,G,G,"Patients with breast cancer and the GG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to genotypes CC. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole."
1446897540,C,C,"Patients with breast cancer and the CC genotype may have an increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CG and GG genotypes."
1446897540,C,G,"Patients with breast cancer and the genotype CG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype."
1446897540,G,G,"Patients with breast cancer and the genotype GG may have a decreased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CC genotype."
1446897675,A,A,"Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have a decreased risk of neutropenia, leukopenia, and diarrhea as compared to patients with the AG and GG genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib."
1446897675,A,G,"Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia as compared to patients with the AA genotypes and a decreased risk of diarrhea as compared to patients with the GG genotype, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib."
1446897675,G,G,"Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia, and diarrhea as compared to patients with the AA genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib."
1446897710,A,A,"Patients with renal cell carcinoma and the AA genotype may have a decreased overall survival, or ""clinical benefit"" defined as defined as either partial response or stable disease, as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma."
1446897710,A,C,Patients with renal cell carcinoma and the AC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.
1446897710,A,T,Patients with renal cell carcinoma and the AT genotype may have a decreased overall survival as compared to the AC or CC genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.
1446897710,C,C,Patients with renal cell carcinoma and the CC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.
1183632200,A,A,"Patients with the rs2032582 AA genotype may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AC, AT, CC, CT or TT genotypes. Other genetic and clinical factors may also influence response to ondansetron."
1183632200,A,C,Patients with the rs2032582 AC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.
1183632200,A,T,Patients with the rs2032582 AT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.
1183632200,C,C,"Patients with the rs2032582 CC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA, AC, AT, CT or TT genotypes. Other genetic and clinical factors may also influence a patient's response to ondansetron."
1183632200,C,T,Patients with the rs2032582 CT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.
1183632200,T,T,Patients with the rs2032582 TT genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.
1451476540,A,A,"Patients with osteosarcoma and the rs1695 AA genotype may be at a decreased risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate."
1451476540,A,G,"Patients with osteosarcoma and the rs1695 AG genotype may be at an increased risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate."
1451476540,G,G,"Patients with osteosarcoma and the rs1695 GG genotype may be at an increased risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cardiotoxicity when treated with cisplatin, doxorubicin and methotrexate."
1451648440,A,A,Patients with opioid dependence and the rs756770 AA genotype may have an increased response to buprenorphine therapy as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1451648440,A,C,Patients with opioid dependence and the rs756770 AC genotype may have an increased response to buprenorphine therapy as compared to patients with the CC genotype but a decreased response as compared to the AA genotype. Other genetic and clinical factors may also influence response to buprenorphine.
1451648440,C,C,Patients with opioid dependence and the rs756770 CC genotype may have a decreased response to buprenorphine therapy as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence response to buprenorphine.
1446899616,C,C,"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype who is also CYP3A4 low or intermediate expressers may have decreased metabolism of cyclosporine resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype, regardless of CYP3A4 expresser status. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement."
1446899616,C,T,"Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype who is also a CYP3A4 low or intermediate expresser. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement."
1446899616,T,T,"Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement."
1446899680,A,A,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a decreased risk of hypersensitivity to asparaginase as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899680,A,T,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AA genotype and a decreased risk as compared to patients with the TT genotype. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899680,T,T,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AT and AA genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899688,A,A,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a decreased risk of hypersensitivity to asparaginase as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899688,A,T,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AA genotype and a decreased risk as compared to patients with the TT genotype. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899688,T,T,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AT and AA genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.
1446899949,C,C,"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899949,C,T,"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899949,T,T,"Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1451476581,G,G,"Patients with osteosarcoma and the rs13181 GG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate."
1451476581,G,T,"Patients with osteosarcoma and the rs13181 GT genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate."
1451476581,T,T,"Patients with osteosarcoma and the rs13181 TT genotype may be at a decreased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate."
1451504280,C,C,Patients with the rs774072493 CC genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the del/del genotype. Other genetics and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1444704928,A,A,Patients with the AA genotype may have increased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1444704928,A,G,Patients with the AG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1444704928,G,G,Patients with the GG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1444607408,A,A,"Patients with the AA genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response."
1444607408,A,G,"Patients with the AG genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response."
1444607408,G,G,"Patients with the GG genotype and chronic myeloid leukemia may have an increased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the AA or AG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response."
1444607420,A,A,"Patients with the AA genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder."
1444607420,A,G,"Patients with the AG genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder."
1444607420,G,G,"Patients with the GG genotype and major depressive disorder may be more likely to enter remission when treated with antidepressants, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder."
1444607666,C,C,Patients with the CC genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1444607666,T,C,Patients with the TC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1444607666,T,T,Patients with the TT genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1444608238,C,C,"Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have an increased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine."
1444608238,C,T,"Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine."
1444608238,T,T,"Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine."
1444666622,G,G,Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1444666622,G,T,Patients with the GT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1444666622,T,T,Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1444666629,C,C,Patients with the CC genotype and non-small-cell lung cancer may have 1) a decreased risk for pneumonitis and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1444666629,C,T,Patients with the CT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype and 2) an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1444666629,T,T,Patients with the TT genotype and non-small-cell lung cancer may have 1) an increased risk for pneumonitis and 2) a decreased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis.
1444668457,A,A,Patients with the AA genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668457,A,T,Patients with the AT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the TT genotypes and an increased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668457,T,T,Patients with the TT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668468,A,A,Patients with the AA genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668468,A,G,Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444668468,G,G,Patients with the GG genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.
1444686836,A,A,"Patients with the AA genotype who have undergone kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes."
1444686836,A,G,"Patients with the AG genotype who have undergone kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes."
1444686836,G,G,"Patients with the GG genotype who have undergone kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the pharmacokinetics of tacrolimus. This annotation only covers the pharmacokinetic relationship between rs1800871 and tacrolimus and does not include evidence about clinical outcomes."
1444673108,C,C,"Patients with the CC genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
1444673108,C,T,"Patients with the CT genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. This may be due to decreased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the C allele as compared to those with the T allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
1444673108,T,T,"Patients with the TT genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the CC genotype. This may be due to increased enzymatic activity toward SN-38, the active metabolite of irinotecan, found in cells with the T allele as compared to those with the C allele. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
1444673115,A,A,"Patients with the AA genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
1444673115,A,G,"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
1444673115,G,G,"Patients with the GG genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan."
1444686816,G,G,"Patients undergoing liver transplantation who receive a donor liver with the GG genotype may have increased metabolism of tacrolimus, as compared to patients with the GT or TT genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus."
1444686816,G,T,"Patients undergoing liver transplantation who receive a donor liver with the GT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus."
1444686816,T,T,"Patients undergoing liver transplantation who receive a donor liver with the TT genotype may have decreased metabolism of tacrolimus, as compared to patients with the GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence metabolism of tacrolimus."
1444686824,G,G,Patients with the GG genotype and rheumatoid arthritis may have a lower likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to sulfasalazine.
1444686824,G,T,Patients with the GT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.
1444686824,T,T,Patients with the TT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.
1444700688,A,A,"Patients with the AA genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexual dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine."
1444700688,A,C,"Patients with the AC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexual dysfunction as compared to patients with the CC genotype or may have a decreased, but not absent, risk of sexual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine."
1444700688,C,C,"Patients with the CC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have a decreased, but not absent, risk of sexual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect patients' response to fluvoxamine, milnacipran or paroxetine."
1444704921,C,C,Patients with the CC genotype may have increased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype TT or CT. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.
1444704921,C,T,Patients with the CT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.
1444704921,T,T,Patients with the TT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.
1444704936,A,A,Patients with the AA genotype may have decreased response to candesartan in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to candesartan.
1444704936,A,G,Patients with the AG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.
1444704936,G,G,Patients with the GG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.
1444704943,C,C,Patients with the CC genotype may have decreased imatinib clearance when treated with imatinib as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the clearance of imatinib.
1444704943,C,T,Patients with the CT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the clearance of imatinib.
1444704943,T,T,Patients with the TT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the clearance of imatinib.
1444843382,A,A,"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT or AT. Other genetic and clinical factors may also influence the response to methotrexate."
1444843382,A,T,"Patients with the AT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
1444843382,T,T,"Patients with the TT genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
1444843389,A,A,"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate."
1444843389,A,G,"Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
1444843389,G,G,"Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
1444843402,A,A,"Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate."
1444843402,A,G,"Patients with the AG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
1444843402,G,G,"Patients with the GG genotype may have decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. Other genetic and clinical factors may also influence the response to methotrexate."
1447673027,A,A,Patients with the AA genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.
1447673027,A,G,Patients with the AG genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.
1447673027,G,G,Patients with the GG genotype may have increased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype AG or AA. Other genetic and clinical factors may also influence the response to warfarin.
1447681808,A,A,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and elevated concentrations of hdl cholsterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole."
1447681808,A,G,"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased hdl cholsterol as compared to women with GG genotypes and increased levels of triglycerides and decreased levels of hdl cholsterol as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole."
1447681808,G,G,"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole may have increased plasma concentrations of triglycerides and decreased hdl cholsterol concentrations as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole."
1444686803,G,G,Patients with the GG genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a poorer response rate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.
1444686803,G,T,Patients with the GT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.
1444686803,T,T,Patients with the TT genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a better response rate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.
1444668444,A,A,Patients with the rs10455872 AA genotype may have an improved response to statins as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence response to statins.
1444668444,A,G,Patients with the rs10455872 AG genotype may have an improved response to statins as compared to patients with the GG genotypes and a decreased response to statins as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to statins.
1444668444,G,G,Patients with the rs10455872 GG genotype may have a decreased response to statins as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence response to statins.
1447673659,A,A,Patient harbors the rs111888148 AA genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs111888148 G>A variant as a variant of uncertain significance (VUS) using ACMG/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1447673659,A,G,Patient harbors the rs111888148 AG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs111888148 G>A variant as a variant of uncertain significance (VUS) using ACMG/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1447673659,G,G,Patient harbors the rs111888148 GG genotype. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel has classified the rs111888148 G>A variant as a variant of uncertain significance (VUS) using ACMG/AMP criteria [PMID:33767344]. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.
1444930642,C,C,Patients with Hepatitis C and the rs12979860 CC genotype may have an increased response to ledipasvir and sofosbuvir as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1444930642,C,T,Patients with Hepatitis C and the rs12979860 CT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1444930642,T,T,Patients with Hepatitis C and the rs12979860 TT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1451678101,A,A,"The current evidence base suggests that there is no significant association between the rs4680 AA genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone."
1451678101,A,G,"The current evidence base suggests that there is no significant association between the rs4680 AG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone."
1451678101,G,G,"The current evidence base suggests that there is no significant association between the rs4680 GG genotype and risk of adverse events when treated with oxycodone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with oxycodone."
1447672998,C,C,"Patients with the rs9923231 CC genotype may require longer time to therapeutic INR when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin."
1447672998,C,T,"Patients with the rs9923231 CT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin."
1447672998,T,T,"Patients with the rs9923231 TT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin."
1447673015,C,C,"Patients with the rs9923231 CC genotype may spent more time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin."
1447673015,C,T,"Patients with the rs9923231 CT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin."
1447673015,T,T,"Patients with the rs9923231 TT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin."
1447673669,A,A,"Patients with the rs193922809 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673669,A,G,"Patients with the rs193922809 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673669,G,G,"Patients with the rs193922809 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451476547,A,A,Patients with osteosarcoma and the rs1695 AA genotype may be at a decreased risk of developing leukopenia when treated with doxorubicin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with doxorubicin.
1451476547,A,G,Patients with osteosarcoma and the rs1695 AG genotype may be at an increased risk of developing leukopenia when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with doxorubicin.
1451476547,G,G,Patients with osteosarcoma and the rs1695 GG genotype may be at an increased risk of developing leukopenia when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing leukopenia when treated with doxorubicin.
1451465324,C,C,Patients with the rs4149056 CC genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.
1451465324,C,T,TPatients with the rs4149056 CT genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.
1451465324,T,T,Patients with the rs4149056 TT genotype may have a decreased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.
1451718264,A,A,Patients with the rs13210472 AA genotype may be at a decreased risk of developing cancer when taking statins as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence risk of developing cancer when taking statins.
1451718264,A,C,Patients with the rs13210472 AC genotype may be at an increased risk of developing cancer when taking statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cancer when taking statins.
1451718264,C,C,Patients with the rs13210472 CC genotype may be at an increased risk of developing cancer when taking statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing cancer when taking statins.
1444607730,C,C,"Patients with the CC genotype and schizophrenia may experience a greater weight gain when treated with clozapine or olanzapine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine."
1444607730,C,T,"Patients with the CT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine."
1444607730,T,T,"Patients with the TT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine."
1444667334,C,C,"Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667334,C,T,"Patients with metastasized cancer and the CT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CC genotype and improved response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667334,T,T,"Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667346,A,A,"Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667346,A,G,"Patients with metastasized cancer and the AG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AA genotype and improved response as compared to people with the GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667346,G,G,"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444700474,C,C,Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1444700474,C,T,Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1444700474,T,T,Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1444700488,A,A,Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1444700488,A,C,Patients with the AC genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1444700488,C,C,Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.
1444700495,C,C,"Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700495,C,G,"Patients with the CG genotype are not studied. But based on in-vitro experiments the C allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700495,G,G,"Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700502,A,A,"Patients with AA genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700502,A,G,"Patients with the AG genotype are not studied. But based on in-vitro experiments the G allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the A allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444700502,G,G,"Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib."
1444703936,A,A,"Patients with the AA genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin."
1444703936,A,G,"Patients with the AG genotype and Leukemia who are treated with cytarabine and idarubicin may have decreased, but not absent, risk for induction failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin."
1444703936,G,G,Patients with the GG genotype and Leukemia who are treated with cytarabine and idarubicin may have increased risk for induction failure as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.
1444703951,G,G,"Patients with the GG genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril."
1444703951,G,T,"Patients with the GT genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril."
1444703951,T,T,Patients with the TT genotype and Hypertension who are treated with enalapril may have increased risk for Cough as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.
1444703976,C,C,"Patients with the CC genotype were not studied. However, patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide."
1444703976,C,T,Patients with the CT genotype who are treated with topiramate or zonisamide may have increased serum bicarbonate levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444703976,T,T,Patients with the TT genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.
1444704795,C,C,"Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1444704795,C,T,"Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype or may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1444704795,T,T,Patients with the TT genotype may have increased risk for asthma as compared to patients with the CC gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444704810,C,C,Patients with the CC genotype may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.
1444704810,C,T,Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype or may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.
1444704810,T,T,Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.
1444706854,C,C,Patients with the CC genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706854,C,T,Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706854,T,T,Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706861,A,A,Patients with the AA genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706861,A,G,Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype.or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706861,G,G,Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706876,C,C,Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706876,C,G,Female patients with the CG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706876,G,G,Female patients with the GG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706883,A,A,Patients with the AA genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706883,A,G,Patients with the AG genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the GG genotype or may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706883,G,G,Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706890,C,C,"Patients with the CC genotype and Schizophrenia may have increased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone."
1444706890,C,T,"Patients with the CT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone."
1444706890,T,T,"Patients with the TT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone."
1445400939,G,G,Patients with the GG genotype and schizophrenia or schizoaffective disorder may have greater weight gain when treated with clozapine or olanzapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.
1445400939,G,T,Patients with the GT genotype and schizophrenia or schizoaffective disorder may have less weight gain when treated with clozapine or olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.
1445401413,A,A,"Patients with the AA genotype and metastatic colorectal cancer may have increased concentrations of bilirubin, possibly indicating reduced UGT1A1 activity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations."
1445401413,A,G,"Patients with the AG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations."
1445401413,G,G,"Patients with the GG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations."
1445401420,A,A,"Patients with the AA genotype and metastatic colorectal cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia."
1445401420,A,G,"Patients with the AG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia."
1445401420,G,G,"Patients with the GG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia."
1445401439,A,A,Patients with the AA genotype and epilepsy may have decreased dose-adjusted trough concentrations of phenytoin as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.
1445401439,A,T,Patients with the AT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.
1445401439,T,T,Patients with the TT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.
1447678614,G,G,Patients with the GG genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1447678614,G,T,Patients with the GT genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1447678614,T,T,Patients with the TT genotype and schizophrenia may lower weight gain when treated with antipsychotics as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1445400924,A,A,"Patients with the rs63749869 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400924,A,G,"Patients with the rs63749869 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400924,G,G,"Patients with the rs63749869 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1451476564,A,A,"Patients with osteosarcoma and the rs1801133 AA genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate."
1451476564,A,G,"Patients with osteosarcoma and the rs1801133 AG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate."
1451476564,G,G,"Patients with osteosarcoma and the rs1801133 GG genotype may be at a decreased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate."
1451504300,A,A,Patients with the rs568724445 AA genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1451504300,A,C,"There is currently no available evidence regarding the association between the rs568724445 AC genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the AA genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine."
1451504300,C,C,Patients with the rs568724445 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1444704784,C,C,"Patients with the CC genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil."
1444704784,C,T,"Patients with the CT genotype and hypertension and coronory artery disease may have decreased, but not absent, risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil."
1444704784,T,T,Patients with the TT genotype and hypertension and coronory artery disease may have increased risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.
1444703739,A,A,"The current evidence base suggests that there is no association between the rs6313 AA genotype and response to fluvoxamine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluvoxamine."
1444703739,A,G,"The current evidence base suggests that there is no association between the rs6313 AG genotype and response to fluvoxamine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluvoxamine."
1444703739,G,G,"The current evidence base suggests that there is no association between the rs6313 GG genotype and response to fluvoxamine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluvoxamine."
1446904283,C,C,Patients with chronic hepatitis C genotype 1 and the CC genotype who also carry the CT or TT genotype at rs12979860 may have a decreased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.
1446904283,C,T,Patients with chronic hepatitis C genotype 1 and the CT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.
1446904283,T,T,Patients with chronic hepatitis C genotype 1 and the TT genotype who also carry the CT or TT genotype at rs12979860 may have an increased response to peg interferon alpha-2a or peg interferon alpha-2b as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to peginterfon in patients with chronic hepatitis C.
1446904972,C,C,"Pediatric patients with major thalassemia and the CC genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the CT or TT genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
1446904972,C,T,"Pediatric patients with major thalassemia and the CT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
1446904972,T,T,"Pediatric patients with major thalassemia and the TT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the CC genotype. Please note, the evidence comes solely from a single case study report of a 3 year old female patient with major thalassemia of genotype CT, therefore there is no information for patients with the CC or TT genotypes. Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
1446905018,A,A,"Pediatric patients with major thalassemia and the AA genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
1446905018,A,G,"Pediatric patients with major thalassemia and the AG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the GG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
1446905018,G,G,"Pediatric patients with major thalassemia and the GG genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the AA or AG genotype. Please note, the evidence comes solely from a single case study report of a single individual, a 3 year old female patient with major thalassemia of genotype AG, therefore there is no information for patients with the GG or AA genotypes.Other clinical and genetic factors may also influence risk of adverse reactions in patients with major thalassemia who are administered deferasirox."
1446906399,A,A,"Patients with genotype AA may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar."
1446906399,A,G,"Patients with genotype AG may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar."
1446906399,G,G,"Patients with genotype GG may have decreased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to Farglitazar."
1446906412,A,A,Patients with genotype AA may have decreased response to calcium channel blockers in people with Hypertension as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to calcium channel blockers.
1446906412,A,G,Patients with genotype AG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.
1446906412,G,G,Patients with genotype GG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.
1446906421,C,C,Patients with genotype CC may have decreased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to methadone.
1446906421,C,T,Patients with genotype CT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.
1446906421,T,T,Patients with genotype TT may have increased severity of opioid withdrawal symptoms and side effects when treated with methadone in people with Heroin Dependence as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to methadone.
1446907957,C,C,Patients with lupus and the CC genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.
1446907957,C,T,Patients with lupus and the CT genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the TT genotypes and increased metabolism of cyclophosphamide and increased concentrations of cyclophosphide metabolite as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.
1446907957,T,T,Patients with lupus and the TT genotype may have increased metabolism of cyclophosphamide resulting in increased concentrations of cyclophosphamide metabolites as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.
1446908002,C,C,"Patients with the CC genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus."
1446908002,C,T,"Patients with the CT genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the TT genotypes and increased metabolism and increased risk of toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus."
1446908002,T,T,"Patients with the TT genotype may have increased metabolism of cyclophosphamide, resulting in increased concentrations of active cyclophosphamide metabolites, and increased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus."
1447680035,A,A,Patients with colorectal cancer and the AA genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1447680035,A,G,Patients with colorectal cancer and the AG genotype may have a better response to capecitabine or fluorouracil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1447680035,G,G,Patients with colorectal cancer and the GG genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1447680045,C,C,Patients with colorectal cancer and the CC genotype may have a worse response to capecitabine or fluorouracil as compared to patients with the CT genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1447680045,C,T,Patients with colorectal cancer and the CT genotype may have a better response to capecitabine or fluorouracil as compared to patients with the CC genotype. There were no patients with the TT genotype. Other clinical and genetic factors may also influence response to capecitabine or fluorouracil in patients with colorectal cancer.
1447680068,A,A,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
1447680068,A,C,"Post-menopausal women with the AC genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the CC genotype and increased plasma concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
1447680068,C,C,"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AA or AC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
1447681831,C,C,"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence plasma triglyceride or cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole."
1447681831,C,T,"Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to women with TT genotypes and increased triglycerides and decreased hdl cholsterol as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride and hdl cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole."
1447681831,T,T,"Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole may have increased plasma concentrations of triglycerides and decreased hdl cholsterol as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole."
1447682293,A,A,"Post-menopausal women with breast cancer and the AA genotype may have increased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
1447682293,A,C,"Post-menopausal women with breast cancer and the AC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AA genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
1447682293,C,C,"Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or AA genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
1446905231,C,C,"Patients with HIV and the CC genotype may have lower plasma concentrations of efavirenz as compared to patients with the CT or TT genotypes. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes."
1446905231,C,T,"Patients with HIV and the CT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CC genotype and lower plasma concentrations as compared to patients with the TT genotype. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes."
1446905231,T,T,"Patients with HIV and the TT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CT or CC genotypes. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes."
1451743169,C,C,Patients with acute coronary syndrome and the rs17064642 CC genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451743169,C,T,Patients with acute coronary syndrome and the rs17064642 CT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451743169,T,T,Patients with acute coronary syndrome and the rs17064642 TT genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451504307,A,A,Patients with the rs764841347 AA genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1451504307,A,C,Patients with the rs764841347 AC genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1451504307,C,C,"There is currently no available evidence regarding the association between the rs764841347 CC genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs764841347 AC genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine."
1444666110,G,G,Patients with the GG genotype may decreased likelihood of toxicity when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib toxicity.
1444666110,G,T,Patients with the GT genotype may decreased likelihood of toxicity when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib toxicity.
1444666110,T,T,Patients with the TT genotype may increased likelihood of toxicity when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sunitinib toxicity.
1444666589,A,A,Patients with the AA genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666589,A,G,"Patients with the AG genotype and non-small-cell lung cancer may have a decreased response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype, and an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy."
1444666589,G,G,Patients with the GG genotype and non-small-cell lung cancer may have an increased response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666601,C,C,Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666601,C,T,Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666601,T,T,Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666608,C,C,Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666608,C,T,Patients with the CT genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666608,T,T,Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666667,A,A,Patients with the AA genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666667,A,G,Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666667,G,G,Patients with the GG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444673184,G,G,Patients with the GG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444700625,A,A,Patients with the AA genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
1444700625,G,A,Patients with the GA genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
1444700625,G,G,Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to nicotine.
1444700639,A,A,Patients with the AA genotype and asthma may have increased risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also effect patients' response to aspirin.
1444700639,A,G,"Patients with the AG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin."
1444700639,G,G,"Patients with the GG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin."
1444700647,C,C,Patients with the CC genotype and HIV may have an increased creatinine clearance when treated with tenofovir as compared to patients with the CT genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.
1444700647,C,T,Patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance.
1444700647,T,T,"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV may have a decreased creatinine clearance when treated with tenofovir as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' creatinine clearance."
1444704081,G,G,Patients with the GG genotype and depression may have decreased response to citalopram as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444704081,G,T,Patients with the GT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444704081,T,T,Patients with the TT genotype and depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1445402209,A,A,Patients with the AA genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.
1445402209,A,C,Patients with the AC genotype and multiple sclerosis may have a better response to treatment with interferon beta 1a/1b as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.
1445402209,C,C,Patients with the CC genotype and multiple sclerosis may have a poorer response to treatment with interferon beta 1a/1b as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to interferon beta treatment.
1446897159,A,A,Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897159,A,G,Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897159,G,G,Patients with the GG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1451504376,C,C,Patients with the rs201820739 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1451504376,C,T,Patients with the rs201820739 CT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1451504376,T,T,"There is currently no available evidence regarding the association between the rs201820739 TT genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs201820739 CT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine."
1446906343,C,C,Patients with the CC genotype may have increased heart rate when treated with Beta Blocking Agents as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.
1446906343,C,T,Patients with the CT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.
1446906343,T,T,Patients with the TT genotype may have decreased heart rate when treated with Beta Blocking Agents as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to Beta Blocking Agents.
1446906350,C,C,"Patients with the CC genotype may have poorer response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation."
1446906350,C,T,"Patients with the CT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation."
1446906350,T,T,"Patients with the TT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation."
1444607641,C,C,"Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for nausea or vomiting and be more likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy."
1444607641,C,G,No significant findings available.
1444607641,G,G,"Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for nausea or vomiting and be less likely to be responders to treatment when receiving with platinum-based chemotherapy, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nausea or vomiting and likelihood of being a responder when receiving platinum-based chemotherapy."
1444666543,C,C,Patients with the CC genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666543,C,T,Patients with the CT genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666543,T,T,Patients with the TT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444607648,C,C,Patients with the CC genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1444607648,C,G,Patients with the CG genotype who are treated with nevirapine may have an increased alanine aminotransferase levels as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1444607648,G,G,Patients with the GG genotype who are treated with nevirapine may have a decreased alanine aminotransferase levels as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's alanine aminotransferase levels.
1444608053,A,A,Patients with the AA genotype and soft tissue sarcoma may have a longer progression-free survival time when treated with doxorubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444608053,A,G,Patients with the AG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444608053,G,G,Patients with the GG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444666550,A,A,"No patients with the AA genotype were available for analysis. However, patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox."
1444666550,A,G,Patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666550,G,G,Patients with the GG genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444667461,A,A,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667461,A,G,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667461,G,G,Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444700815,A,A,Patients with the AA genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease or abnormal liver-function tests as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.
1444700815,A,G,Patients with the AG genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease or abnormal liver-function tests as compared to patients with GG genotype or may have decreased risk for toxic liver disease or abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.
1444700815,G,G,"Patients with the GG genotype who are treated with drugs for treatment of tuberculosis may have decreased, but not absent, risk for toxic liver disease or abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease."
1444706209,A,A,Patients with the AA genotype may have decreased response to atorvastatin as compared to patients with the CC or AC genotypes. Other genetic and clinical factors may influence also a patient's atorvastatin response.
1444706209,A,C,Patients with the AC genotype may have increased response to atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's atorvastatin response.
1444706209,C,C,Patients with the CC genotype may have increased response to atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's atorvastatin response.
1444607611,A,A,"Patients with the AA genotype and depression may have a decreased response and remission rate when treated with escitalopram as compared to patients with the AG and GG genotype. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response."
1444607611,A,G,"Patients with the AG genotype and depression may have an increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response."
1444607611,G,G,"Patients with the GG genotype and depression may have an increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response."
1444706830,C,C,Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706830,C,G,Patients with the CG genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706830,G,G,Patients with the GG genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444930908,C,C,"Patients with genotype CC may have increased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CT or TT genotypes. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy."
1444930908,C,T,"Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy."
1444930908,T,T,"Patients with genotype TT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy."
1445401260,A,A,Patients with the AA genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401260,A,G,Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401260,G,G,Patients with the GG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.
1445401267,C,C,Children with the CC genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.
1445401267,C,T,Children with the CT genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.
1445401267,T,T,Children with the TT genotype who are undergoing a tonsillectomy and are treated with morphine may have a decreased chance of a prolonged hospital stay due to respiratory depression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence respiratory depression.
1446906328,G,G,Patients with the GG genotype may have decreased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1446906328,G,T,Patients with the GT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1446906328,T,T,Patients with the TT genotype may have increased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype GG. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1446906335,A,A,Patients with the AA genotype may have decreased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to citalopram.
1446906335,A,G,Patients with the AG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.
1446906335,G,G,Patients with the GG genotype may have increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to citalopram.
1446906363,A,A,Patients with the genotype AA may have increased response to aripiprazole in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aripiprazole.
1446906363,A,G,Patients with the genotype AG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Though this association was found not statistically significant. Other genetic and clinical factors may also influence the response to aripiprazole.
1446906363,G,G,Patients with the genotype GG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to aripiprazole.
1446906370,C,C,Patients with genotype CC may have decreased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CT. Other genetic and clinical factors may also influence the metabolism of efavirenz.
1446906370,C,T,Patients with genotype CT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.
1446906370,T,T,Patients with genotype TT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.
1446906391,C,C,Patients with genotype CC may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.
1446906391,C,T,Patients with genotype CT may have decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to gemcitabine.
1446906391,T,T,Patients with genotype TT may have increased response to gemcitabine in people with Pancreatic Neoplasms as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to gemcitabine.
1447813539,A,A,Individuals with the AA genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or GG genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.
1447813539,A,G,Individuals with the AG genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the GG genotype and an increased risk as compared to those with the AA genotype. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.
1447813539,G,G,Individuals with the GG genotype and HIV may have a increased risk of developing Kidney disease when treated with tenofovir as compared to those with the AG or AA genotypes. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.
1447813708,C,C,Individuals with the CC genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the CT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813708,C,T,Individuals with the CT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813708,T,T,Individuals with the TT genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813720,G,G,Individuals with the GG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813720,G,T,Individuals with the GT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813720,T,T,Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the GT or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813855,A,A,"Women with the AA genotype were not studied. However, women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss."
1447813855,A,C,Women with the AC genotype and breast neoplasms may have a decreased risk of bone density loss when exposed to letrozole as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone density loss.
1447813855,C,C,Women with the CC genotype and breast neoplasms may have an increased risk of bone density loss when exposed to letrozole as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk of bone density loss.
1447813873,C,C,"Women with the CC genotype and breast neoplasms may have less bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane."
1447813873,C,T,Women with the CT genotype and breast neoplasms may have less bone mineral loss when taking letrozole as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole.
1447813873,T,T,"Women with the TT genotype and breast neoplasms may have greater bone mineral loss when taking letrozole, with or without exemestane, as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to letrozole, with and without exemestane."
1447813969,A,A,"Patients with genotype AA and colorectal neoplasms may have an increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the GG genotype. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy."
1447813969,A,G,"Patients with genotype AG and colorectal neoplasms may have an increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the GG genotype. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy."
1447813969,G,G,"Patients with genotype GG and colorectal neoplasms may have a decreased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the AA or AG genotypes. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy."
1447814178,C,C,"Patients with the CC genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1447814178,C,G,"Patients with the CG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1447814178,G,G,"Patients with the GG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1447814397,C,C,Patients with the CC genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.
1447814397,C,T,Patients with the CT genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.
1447814397,T,T,Patients with the TT genotype and Breast Neoplasms may be at increased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.
1447814403,C,C,Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.
1447814403,C,T,Patients with the CT genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.
1447814403,T,T,Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's circulating concentrations of efavirenz.
1447814424,A,A,"Patients with the AA genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine."
1447814424,A,G,"Patients with the AG genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine."
1447814424,G,G,"Patients with the GG genotype and Alzheimer Disease may have increased response to donepezil, galantamine, or rivastigmine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine."
1447814450,C,C,"Patients with CC genotype and Colonic Neoplasms may have decreased response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil."
1447814450,C,T,"Patients with CT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil."
1447814450,T,T,"Patients with TT genotype and Colonic Neoplasms may have improved response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil."
1451504360,C,C,Patients with the rs1560022535 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1451504360,C,G,Patients with the rs1560022535 CG genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1451504360,G,G,"There is currently no available evidence regarding the association between the rs1560022535 GG genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs1560022535 CG genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine."
1451504368,A,A,Patients with the rs531738678 AA genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1451504368,A,T,Patients with the rs531738678 AT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.
1451504368,T,T,"There is currently no available evidence regarding the association between the rs531738678 TT genotype and risk of experiencing apnea following administration of succinylcholine. However, patients with the rs531738678 AT genotype may be at an increased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine."
1447943620,C,C,Patients with the CC genotype and hypertension may have decreased response to hydrochlorothiazide compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to hydrochlorothiazide.
1447943626,C,C,Patients with the CC genotype and hypertension may have decreased response to metoprolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to metoprolol.
1444686850,C,C,"Patients with the CC genotype and chronic myeloid leukemia may have increased clearance of imatinib, as well as increased event-free survival time, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time."
1444686850,C,G,"Patients with the CG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time."
1444686850,G,G,"Patients with the GG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time."
1444686857,A,A,"In human liver microsomes, the AA genotype was associated with increased glucuronidation of SN-38, as compared to the AC or CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
1444686857,A,C,"In human liver microsomes, the AC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
1444686857,C,C,"In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the AA genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
1444686868,A,A,"Patients with the AA genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib."
1444686868,A,G,"Patients with the AG genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the GG genotypes. Conversely, patients with the AG genotype may have decreased steady state levels of KDR, and an increased response to pazopanib as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism and response to pazopanib."
1444686868,G,G,"Patients with the GG genotype and Kidney Neoplasms may have decreased steady state levels of KDR, possibly leading to decreased metabolism of and increased response to pazopanib as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib."
1444686880,C,C,"In human liver microsomes, the CC genotype was associated with decreased glucuronidation of SN-38, as compared to the CT or TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
1444686880,C,T,"In human liver microsomes, the CT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
1444686880,T,T,"In human liver microsomes, the TT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38."
1444687039,A,A,"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444687039,A,C,"Patients with the AC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444687039,C,C,"Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1447813701,C,C,Individuals with the CC genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the CT or TT genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813701,C,T,Individuals with the CT genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the TT genotype and an improved response as compared to individuals with the CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813701,T,T,Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the CT or CC genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447814153,C,C,"Patients with the CC genotype may have more favorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib."
1447814153,C,T,"Patients with the CT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib."
1447814153,T,T,"Patients with the TT genotype may have unfavorable progression-free survival and overall survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib."
1447814165,A,A,"Patients with the AA genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
1447814165,A,G,"Patients with the AG genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
1447814165,G,G,"Patients with the GG genotype may have more favorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to sorafenib."
1447814185,A,A,"Patients with the AA genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1447814185,A,G,"Patients with the AG genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1447814185,G,G,"Patients with the GG genotype may have decreased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1447814385,A,A,Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.
1447814385,A,G,"Patients with the AG genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the GG genotype, but increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo."
1447814385,G,G,Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.
1447943597,A,A,Patients with genotype AA and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AA genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.
1447943597,A,G,Patients with genotype AG and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.
1447943597,G,G,Patients with genotype GG and depressive disorder may have increased response to venlafaxine compared to patients with genotype AA or AG. Patients with GG genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.
1447943608,A,A,Patients with the AA genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.
1447943608,A,G,Patients with the AG genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.
1447943608,G,G,Patients with the GG genotype and depressive disorder may have increased response to serotonin reuptake inhibitors compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.
1447943614,C,C,Patients with the CC genotype and hypertension may have decreased response to atenolol compared to patients with genotype del/del. Other genetic and clinical factors may influence the patient's response to atenolol.
1447943700,A,A,Patients with genotype AA and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.
1447943700,A,G,Patients with genotype AG and narcolepsy may have increased response to modafinil compared to patients with genotypes AA or GG. Other clinical and genetic factors may affect a patient's response to modafinil.
1447943700,G,G,Patients with genotype GG and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.
1447943721,A,A,Patients with genotype AA and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.
1447943721,A,C,Patients with genotype AC and schizophrenia may have increased response to olanzapine compared to patients with CC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.
1447943721,C,C,Patients with genotype CC and schizophrenia may have decreased response to olanzapine compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to olanzapine.
1447943760,A,A,Patients with AA genotype and schizophrenia may have decreased response to antipsychotics compared to patients with the AG and GG genotype. Other clinical and genetic factors may affect response to antipsychotics.
1447943760,A,G,Patients with AG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.
1447943760,G,G,Patients with GG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.
1447943772,C,C,Patients with genotype CC and hypertension have decreased response to atenolol compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect patient response to atenolol.
1447943772,C,T,Patients with genotype CT and hypertension have increased response to atenolol compared to patients with the TT genotype. Other clinical and genetic factors may affect patient response to atenolol.
1447943772,T,T,Patients with genotype TT and hypertension have increased response to atenolol compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect patient response to atenolol.
1447944813,A,A,Patients with the AA genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1447944813,A,G,Patients with the AG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1447944813,G,G,Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1444686843,A,A,"Patients with the rs4646437 AA genotype may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus."
1444686843,A,G,"Patients with the rs4646437 AG genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA genotype, or decreased concentrations as compared to the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus."
1444686843,G,G,"Patients with the rs4646437 GG genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus."
1447749024,A,A,"The current evidence base suggests that there is no significant association between the rs1800566 AA genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements."
1447749024,A,G,"The current evidence base suggests that there is no significant association between the rs1800566 AG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements."
1447749024,G,G,"The current evidence base suggests that there is no significant association between the rs1800566 GG genotype and warfarin dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose requirements."
1449157278,C,C,"Patients with the rs678849 CC genotype may have a decreased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine."
1449157278,C,T,"Patients with the rs678849 CT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine."
1449157278,T,T,"Patients with the rs678849 TT genotype may have an increased response to buprenorphine when being treated for opioid dependence, as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to buprenorphine."
1445594491,A,A,Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594491,A,T,Patients with the AT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with TT genotypes and a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594491,T,T,Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT or AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594498,A,A,Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594498,A,T,Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594498,T,T,Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594505,A,A,Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594505,A,T,Patients with the AT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594505,T,T,Patients with the TT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1446897166,A,A,Patients with the AA genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897166,A,G,Patients with the AG genotype and schizophrenia may have higher weight gain when treated with antipsychotics as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897166,G,G,Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897184,A,A,Patients with the AA genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897184,A,G,Patients with the AG genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897184,G,G,Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446899372,G,G,Patients with the GG genotype may have improved clearance and metabolism of sulfasalazine as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.
1446899372,G,T,Patients with the GT genotype may have improved clearance of sulfasalazine as compared to patients with the TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.
1446899372,T,T,Patients with the TT genotype may have decreased clearance and metabolism of sulfasalazine as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.
1447673759,C,C,"Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673759,C,G,"Patients with the rs118192178 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673759,C,T,"Patients with the rs118192178 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673759,G,G,"Patients with the rs118192178 GG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673759,T,T,"Patients with the rs118192178 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673778,A,A,"Patients with the rs193922818 AA genotype may develop malignant hyperthermia (MH) when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673778,A,G,"Patients with the rs193922818 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673778,G,G,"Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673787,C,C,"Patients with the rs193922878 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CG or GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673787,C,G,"Patients with the rs193922878 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447673787,G,G,"Patients with the rs193922878 GG genotype may develop malignant hyperthermia (MH) when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447675871,G,G,"Patients with the rs193922753 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GT and TT. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447675871,G,T,"Patients with the rs193922753 GT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447675871,T,T,"Patients with the rs193922753 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447676001,C,C,"Patients with the rs118192116 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with CG or GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447676001,C,G,"Patients with the rs118192116 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447676001,G,G,"Patients with the rs118192116 GG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447676077,C,C,"Patients with the rs193922807 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447676077,C,G,"Patients with the rs193922807 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447676077,G,G,"Patients with the rs193922807 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CG or CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1444666290,A,A,Patients with the AA genotype and asthma may have a better response to treatment with tiotropium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to tiotropium.
1444666290,A,G,Patients with the AG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium.
1444666290,G,G,Patients with the GG genotype and asthma may have a poorer response to treatment with tiotropium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tiotropium.
1444667758,G,G,Patients with the GG genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.
1444667758,G,T,Patients with the GT genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.
1444667758,T,T,Patients with the TT genotype and kidney or lung transplantation may experience increased metabolism of tacrolimus resulting in decreased exposure as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence metabolism of tacrolimus.
1444686760,C,C,Patients with the CC (CYP2C9 *1/*1) genotype undergoing hemopoietic stem cell transplant may have increased metabolism of busulfan as compared to patients with the CT (*1/*2) or TT (*2/*2) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.
1444686760,C,T,Patients with the CT (CYP2C9 *1/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.
1444686760,T,T,Patients with the TT (CYP2C9 *2/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.
1444686789,G,G,"Patients with the GG genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a greater risk for side effects as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib."
1444686789,G,T,"Patients with the GT genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) a decreased risk of developing cytogenetic resistance to imatinib as compared to patients with the GG or TT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib."
1444686789,T,T,"Patients with the TT genotype and chronic myeloid leukemia may have a 1) a poorer response to treatment with imatinib as compared to patients with the GG or GT genotype, 2) an increased risk of developing cytogenetic resistance to imatinib as compared to patients with the GT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib."
1444706869,A,A,Female patients with the AA genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706869,A,C,Female patients with the AC genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1444706869,C,C,Female patients with the CC genotype may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1447676781,G,G,Patients with genotype GG may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-naïve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.
1447676781,G,T,Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-naïve patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.
1447676781,T,T,Patients with genotype TT may have increased response to simeprevir plus peginterferon and ribavirin therapy in treatment-naïve patients and relapsers as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.
1447681869,C,C,"Post-menopausal women with breast cancer and the CC genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT and TT genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer."
1447681869,C,T,"Post-menopausal women with breast cancer and the CT genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the TT genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer."
1447681869,T,T,"Post-menopausal women with breast cancer and the TT genotype who are taking letrozole, with or without a statin, may have increased plasma concentrations of triglycerides as compared to women with the CT and CC genotypes. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer."
1447681876,C,C,"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the CT or TT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
1447681876,C,T,"Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with TT genotypes and increased levels as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
1447681876,T,T,"Post-menopausal women with the TT genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of triglycerides as compared to women with the CC or CT genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
1447681883,A,A,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
1447681883,A,G,"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the GG genotype and decreased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
1447681883,G,G,"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin."
1451649020,A,A,Patients with alcoholism and the rs671 AA genotype may have a decreased response to naltrexone as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to naltrexone.
1451649020,A,G,Patients with alcoholism and the rs671 AG genotype may have an increased response to naltrexone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to naltrexone.
1451649020,G,G,Patients with alcoholism and the rs671 GG genotype may have an increased response to naltrexone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to naltrexone.
1447945800,C,C,"Patients with the CC genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
1447945800,C,G,"Patients with the CG genotype and breast cancer may have a decreased chance of experiencing sensory neuropathy as compared to patients with the GG genotype, or an increased chance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
1447945800,G,G,"Patients with the GG genotype and breast cancer may have an increased chance of experiencing sensory neuropathy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for sensory neuropathy. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
1447945850,C,C,"Patients with the CC genotype and non-Hodgkin lymphoma may have a lower risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens."
1447945850,C,T,"Patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens."
1447945850,T,T,"No patients with the TT genotype were studied, but patients with the CT genotype and non-Hodgkin lymphoma may have a greater risk of diarrhea and vomiting when treated with R-CHOP type regimens, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea and vomiting when treated with R-CHOP type regimens."
1447945887,A,A,"Patients with the AA genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab."
1447945887,A,C,"Patients with the AC genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab."
1447945887,C,C,"Patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with infliximab as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab."
1447945958,C,C,Patients with the CC genotype who are treated with antihypertensives may have a lower risk for resistant hypertension as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.
1447945958,C,T,Patients with the CT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.
1447945958,T,T,Patients with the TT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.
1447945967,A,A,"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AG or GG genotype. However, a different study found that the AA genotype was associated with poorer response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment."
1447945967,A,G,"Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the AG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment."
1447945967,G,G,"Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the GG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment."
1447945978,A,A,"Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory."
1447945978,A,T,"Patients with the AT genotype and schizophrenia who are treated with antipsychotics may have a decreased, but not absent, risk for worsening of working memory as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory."
1447945978,T,T,Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have an increased risk for worsening of working memory as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.
1447945985,A,A,Patients with the AA genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945985,A,G,Patients with the AG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945985,G,G,Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945992,C,C,Patients with the CC genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945992,C,T,Patients with the CT genotype and schizophrenia who are treated with antipsychotics may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945992,T,T,Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have a better response to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.
1447945999,C,C,Patients with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a smaller drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447945999,C,T,Patients with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447945999,T,T,Patients with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447946011,G,G,"Patients with the GG genotype and age-related macular degeneration who are treated with bevacizumab may have poorer improvement in visual acuity as compared to patients with the GT or TT genotype. However, another study finds that those with the GG genotype have better improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment."
1447946011,G,T,Patients with the GT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.
1447946011,T,T,"Patients with the TT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. However, another study finds that those with the TT genotype have poorer improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment."
1447946088,C,C,Patients with the CC genotype may be at decreased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism.
1447946088,C,T,"Patients with the CT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype, or decreased risk as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for alcoholism."
1447946088,T,T,Patients with the TT genotype may be at increased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for alcoholism.
1447946098,C,C,"Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine."
1447946098,C,T,"Patients with the CT genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype, or at increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine."
1447946098,T,T,"Patients with the TT genotype may be at increased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine."
1447946107,C,C,"Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine."
1447946107,C,T,"Patients with the CT genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype, or at increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine."
1447946107,T,T,"Patients with the TT genotype may be at increased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine."
1449192991,A,A,"Patients with the AA genotype may be at an increased risk of developing both alcohol and drug dependence as compared to patients with the GG genotype. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence."
1449192991,A,G,"Patients with the AG genotype may be at an increased risk of developing both alcohol and drug dependence as compared to patients with the GG genotype. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence."
1449192991,G,G,"Patients with the GG genotype may be at a decreased risk of developing both alcohol and drug dependence as compared to patients with the AA or AG genotypes. However, this association was not seen in patients diagnosed with alcohol abuse, alcohol dependence or drug dependence alone. Other genetic and clinical factors may also affect a patient's risk of developing alcohol and drug dependence."
1444667668,C,C,Patients with the rs3753380 CC genotype and open angle glaucoma may have an increased response to latanoprost compared to patients with genotypes CT or TT. Other genetic and clinical factors may affect response to latanoprost.
1444667668,C,T,Patients with the rs3753380 CT genotype and open angle glaucoma may have a decreased response to latanoprost compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost.
1444667668,T,T,"Patients with the rs3753380 TT genotype and open angle glaucoma, may have a decreased response to latanoprost compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost."
1451648980,C,C,Patients with alcoholism and the rs698 CC genotype may have an increased response to naltrexone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to naltrexone.
1451648980,C,T,Patients with alcoholism and the rs698 CT genotype may have an increased response to naltrexone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to naltrexone.
1451648980,T,T,Patients with alcoholism and the rs698 TT genotype may have a decreased response to naltrexone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to naltrexone.
1451726525,A,A,"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel."
1451726525,A,G,"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel."
1451726525,G,G,"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to docetaxel. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to docetaxel."
1444667680,A,A,"Patients with the AA genotype and open angle glaucoma, may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AC or CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. A single study reported its association with response to latanoprost by comparing the haplotype of rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."
1444667680,A,C,"Patients with the AC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotype AA and a decreased response compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."
1444667680,C,C,"Patients with the CC genotype and open angle glaucoma, may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) compared to patients with genotypes AA or AC. Other genetic and clinical factors may affect response to latanoprost. *Please note: this SNP was not analyzed alone. Only a single study reported its association with response to latanoprost by comparing the haplotypes rs3753380 C and rs3766355 C versus rs3753380 T and rs3766355 A."
1444667704,A,A,Patients with the AA genotype and open-angle glaucoma may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed.
1444667704,A,G,Patients with the AG genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost.
1444667704,G,G,Patients with the GG genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed.
1444667733,A,A,Patients with the AA genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.
1444667733,A,C,Patients with the AC genotype and open-angle glaucoma may have a decreased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.
1444667733,C,C,Patients with the CC genotype and open-angle glaucoma may have an increased response to latanoprost (as determined by a reduction in intraocular pressure) as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype AA were not analyzed.
1444686893,C,C,Patients with the CC genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.
1444686893,C,T,"Patients with the CT genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype, or more likely to respond as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors."
1444686893,T,T,Patients with the TT genotype and Alzheimer's disease may be more likely to respond to treatment with cholinesterase inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.
1445400992,A,A,Patients with the AA genotype and breast cancer may have a better response when treated with docetaxel and epirubicin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.
1445400992,A,G,Patients with the AG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.
1445400992,G,G,Patients with the GG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.
1445401001,C,C,"Patients with the CC genotype and breast cancer may have a poorer response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
1445401001,C,G,"Patients with the CG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
1445401001,G,G,"Patients with the GG genotype and breast cancer may have a better response when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to treatment with cyclophosphamide, epirubicin and fluorouracil. (Note: with a C/G variant, particularly in a gene on the minus chromosomal strand, and frequencies close to 50% there can be a difficulty in interpreting the evidence for association.)"
1447681902,A,A,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
1447681902,A,G,"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the GG genotypes and increased concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
1447681902,G,G,"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole, alone or with a statin, may have increased plasma concentrations of triglycerides as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin."
1447682300,C,C,"Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CG or GG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
1447682300,C,G,"Post-menopausal women with breast cancer and the CG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC genotypes and decreased concentrations as compared to women with the GG genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
1447682300,G,G,"Post-menopausal women with breast cancer and the GG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC or CG genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer."
1447943640,A,A,Patients with the AA genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.
1447943640,A,G,Patients with the AG genotype and Alzheimer's disease may have increased response to donepezil compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.
1447943640,G,G,Patients with the GG genotype and Alzheimer's disease may have decreased response to donepezil compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.
1447943653,A,A,Patients with the AA genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the AG or GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.
1447943653,A,G,Patients with the AG genotype and Alzheimer's disease may have increased response to rivastigmine compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.
1447943653,G,G,Patients with the GG genotype and Alzheimer's disease may have decreased response to rivastigmine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.
1447943673,C,C,Patients with the CC genotype and heart failure may have decreased response to hydralazine and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.
1447943673,C,T,Patients with the CT genotype and heart failure may have decreased response to hydralazine and isosorbide dinitrate compared with patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.
1447943673,T,T,Patients with the TT genotype and heart failure may have increased response to hydralazine and isosorbide dinitrate compared with patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydralazine treatment and isosorbide dinitrate.
1447943685,C,C,Patients with CC genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan.
1447943685,C,T,Patients with CT genotype and essential hypertension may have increased response to telmisartan compared to patients with genotype TT. Other genetic and clinical factors may influence a patient's response to telmisartan.
1447943685,T,T,Patients with TT genotype and essential hypertension may have decreased response to telmisartan compared to patients with genotype CC and CT. Other genetic and clinical factors may influence a patient's response to telmisartan.
1447943693,C,C,People with CC genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.
1447943693,C,T,People with CT genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.
1447943693,T,T,People with TT genotype may have increased clearance of quetiapine compared with people with genotypes CC or CT. Other genetic and clinical factors may affect a person's clearance of quetiapine.
1447943713,A,A,People with genotype AA may have decreased exposure to silibinin compared to people with genotypes AG or GG. Other clinical and genetic factors may affect a person's exposure to silibinin.
1447943713,A,G,People with genotype AG may have decreased exposure to silibinin compared to people with genotypes GG. Other clinical and genetic factors may affect a person's exposure to silibinin.
1447943713,G,G,People with genotype GG may have increased exposure to silibinin compared to people with genotypes AA or AG. Other clinical and genetic factors may affect a person's exposure to silibinin.
1447943753,A,A,Patients with AA genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.
1447943753,A,G,Patients with AG genotype and narcolepsy may have increased response to modafinil compared to patients with AA or GG genotype. Other clinical and genetic factors may affect response to modafinil.
1447943753,G,G,Patients with GG genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.
1447944755,C,C,"Patients with the CC genotype and schizophrenia may have an increased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride."
1447944755,C,T,"Patients with the CT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride."
1447944755,T,T,"Patients with the TT genotype and schizophrenia may have a decreased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to amisulpride."
1447944806,C,C,Patients with the CC genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1447944806,C,G,Patients with the CG genotype and asthma may have an increased response when treated with inhaled corticosteroids as compared to patients with the GG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1447944806,G,G,Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.
1447944819,C,C,Patients with the CC genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.
1447944819,C,T,Patients with the CT genotype and depressive disorder may have decreased response to fluvoxamine compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's response to fluvoxamine.
1447944819,T,T,Patients with the TT genotype and depressive disorder may have an increased response to fluvoxamine compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect a patient's response to fluvoxamine.
1447944855,C,C,Patients with the CC genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.
1447944855,C,G,Patients with the CG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the GG genotype. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.
1447944855,G,G,Patients with the GG genotype and schizophrenia may have decreased response to antipsychotics compared to patients with the CC or CG genotypes. Other clinical and genetic factors may affect a patient's response to antipsychotic drugs.
1447943739,A,A,"Patients with AA genotype and HIV may have decreased concentrations of efavirenz in plasma compared to patients with AG or GG genotypes. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations."
1447943739,A,G,"Patients with AG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations."
1447943739,G,G,"Patients with GG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations."
1444686796,C,C,"Patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics."
1444686796,C,T,"Patients with the CT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics."
1444686796,T,T,"Patients with the TT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics."
1444704267,C,C,Patients with the CC genotype and Colorectal Neoplasms who are treated with capecitabine may have decreased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.
1444704267,C,T,Patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.
1444704267,T,T,"Patients with the TT genotype were not studied. However, patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine."
1444704373,A,A,Patients with the AA genotype may have increased resistance to etoposide as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444704373,A,G,Patients with the AG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444704373,G,G,Patients with the GG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444704385,A,A,"Patients with the AA genotype and Hypertension may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide."
1444704385,A,T,"Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype or may have decreased, but not absent, risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide."
1444704385,T,T,Patients with the TT genotype and Hypertension may have increased risk for Diabetes Mellitus when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.
1444704392,A,A,Patients with the AA genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.
1444704392,A,G,Patients with the AG genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.
1444704392,G,G,Patients with the GG genotype and Alcoholism may have decreased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.
1444704400,A,A,Patients with the AA genotype and Parkinson Disease may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.
1444704400,A,G,Patients with the AG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype or may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.
1444704400,G,G,Patients with the GG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.
1447944882,A,A,Patients with genotype AA and schizophrenia may have decreased response to antipsychotics compared to patients with AC or CC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.
1447944882,A,C,Patients with genotype AC and schizophrenia may have increased response to antipsychotics compared to patients with AA genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.
1447944882,C,C,Patients with genotype CC and schizophrenia may have increased response to antipsychotics compared to patients with AA or AC genotype. Other clinical and genetic factors may affect a patient's response to antipsychotics.
1444704366,C,C,"Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab."
1444704366,C,T,"Patients with the CT genotype and Rheumatoid Arthritis may have decreased response to tocilizumab as compared to patients with the TT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab."
1444704366,T,T,"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to tocilizumab as compared to patients with the CC or CT genotype. However, a different study found no association with response. Other genetic and clinical factors may also influence a patient's response tocilizumab."
1451648958,A,A,Patients with alcoholism and the rs2066702 AA genotype may have a decreased response to naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to naltrexone.
1451648958,A,G,Patients with alcoholism and the rs2066702 AG genotype may have a decreased response to naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to naltrexone.
1451648958,G,G,Patients with alcoholism and the rs2066702 GG genotype may have an increased response to naltrexone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to naltrexone.
1185000052,C,C,Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation may have an increased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence risk for renal dysfunction.
1185000052,C,T,Patients with the CT genotype (CYP3A5 *1/*3) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence risk for renal dysfunction.
1185000052,T,T,Patients with the TT genotype (CYP3A5 *1/*1) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence risk for renal dysfunction.
1444667661,A,A,Patients with the AA genotype and diabetes mellitus may have an increased response when treated with metformin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to metformin.
1444667661,A,G,Patients with the AG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA genotypes and an increased response to metformin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to metformin.
1444667661,G,G,Patients with the GG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to metformin.
1444686907,A,A,"Patients with the AA genotype who are undergoing kidney transplantation may have lower dose-adjusted trough concentrations of cyclosporine, and have a greater likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine."
1444686907,A,G,"Patients with the AG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine."
1444686907,G,G,"Patients with the GG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine."
1444686914,C,C,Patients with the CC genotype who are undergoing kidney transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.
1444686914,C,T,Patients with the CT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.
1444686914,T,T,Patients with the TT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.
1444686921,A,A,"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686921,A,G,"Patients with the AG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686921,G,G,"Patients with the GG genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686927,C,C,Patients with the CC genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686927,C,T,Patients with the CT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686927,T,T,Patients with the TT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1445401274,A,A,"Patients with the AA genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations."
1445401274,A,G,"Patients with the AG genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations."
1445401274,G,G,"Patients with the GG genotype may have higher levels of morphine as compared to patients with the AA or AG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations."
1444700589,A,A,Patients with the AA genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.
1444700589,A,G,Patients with the AG genotype and breast neoplasms may have an increased frequency of relapse when treated with tamoxifen as compared to patients with the GG genotype or may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.
1444700589,G,G,Patients with the GG genotype and breast neoplasms may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.
1445401281,A,A,Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for mucositis when treated with methotrexate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of mucositis.
1445401281,A,G,Patients with the AG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.
1445401281,G,G,Patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.
1448573506,G,G,"Patients with the GG genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine."
1448573506,G,T,"Patients with the GT genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine."
1448573506,T,T,"Patients with the TT genotype may have increased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the GG genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine."
1448602689,A,A,Patients with the AA genotype and hypertension may be at decreased risk of developing hyperglycemia when taking atenolol compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.
1448602689,A,G,Patients with the AG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA genotype. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.
1448602689,G,G,Patients with the GG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.
1448602859,G,G,Patients with the GG genotype may have increased risk of overall early-onset capecitabine-related toxicity in cancer patients as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602865,A,A,Patients with the AA genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602865,A,G,Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602865,G,G,Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602877,A,A,Patients with the AA genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602877,A,G,Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602877,G,G,Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602883,C,C,Patients with the CC genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602883,C,T,Patients with the CT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602883,T,T,Patients with the TT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602871,G,G,Patients with the rs2244613 GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602871,G,T,Patients with the rs2244613 GT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1448602871,T,T,Patients with the rs2244613 TT genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.
1444687046,A,A,"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444687046,A,T,"Patients with the AT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444687046,T,T,"Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1445401142,A,A,Patients with the AA genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.
1445401142,A,G,Patients with the AG genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.
1445401142,G,G,Patients with the GG genotype may have decreased blood pressure when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.
1445401149,A,A,Patients with the AA genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.
1445401149,A,G,Patients with the AG genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.
1445401149,G,G,Patients with the GG genotype may have reduced fasting glucose levels when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.
1445585156,A,A,"Patients with the AA genotype may decreased clearance of daptomycin, resulting in increased concentrations of the drug, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of daptomycin."
1445585156,A,G,"Patients with the AG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin."
1445585156,G,G,"Patients with the GG genotype may increased clearance of daptomycin, resulting in decreased concentrations of the drug, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of daptomycin."
1451678087,A,A,"The current evidence base suggests that there is no significant association between the rs4680 AA genotype and risk of adverse events when treated with morphine. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine."
1451678087,A,G,"The current evidence base suggests that there is no significant association between the rs4680 AG genotype and risk of adverse events when treated with morphine. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine."
1451678087,G,G,"The current evidence base suggests that there is no significant association between the rs4680 GG genotype and risk of adverse events when treated with morphine. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine."
1451649200,A,A,Patients with the rs3829125 AA genotype may have decreased metabolism of naltrexone as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs3829125 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.
1451649200,A,C,"Patients with the rs3829125 AC genotype may have decreased metabolism of naltrexone as compared to patients with the CC genotype, but increased metabolism as compared to the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3829125 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism."
1451649200,C,C,Patients with the rs3829125 CC genotype may have increased metabolism of naltrexone as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs3829125 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.
1451649186,C,C,Patients with the rs17134592 CC genotype may have increased metabolism of naltrexone as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs17134592 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.
1451649186,C,T,"Patients with the rs17134592 CT genotype may have increased metabolism of naltrexone as compared to patients with the TT genotype, but decreased metabolism as compared to the CC genotype. This annotation only covers the pharmacokinetic relationship between rs17134592 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism."
1451649186,T,T,Patients with the rs17134592 TT genotype may have decreased metabolism of naltrexone as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs17134592 and naltrexone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence naltrexone metabolism.
1451679740,C,C,Patients with heroin dependence and the rs55944529 CC genotype may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs55944529 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concentrations.
1451679740,C,T,Patients with heroin dependence and the rs55944529 CT genotype may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs55944529 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concentrations.
1451679740,T,T,Patients with heroin dependence and the rs55944529 TT genotype may have increased plasma concentrations of methadone as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs55944529 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concentrations.
1451504901,A,A,"Patients with the rs1801133 AA genotype may have increased concentrations of methotrexate as compared to the AG or GG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1451504901,A,G,"Patients with the rs1801133 AG genotype may have increased concentrations of methotrexate as compared to the GG genotype but decreased concentrations as compared to the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1451504901,G,G,"Patients with the rs1801133 GG genotype may have decreased concentrations of methotrexate as compared to the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1444668597,A,A,Patients with genotype AA may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.
1444668597,A,T,Patients with genotype AT may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.
1444668597,T,T,Patients with genotype TT may have higher likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.
1444694373,C,C,"Patients with the CC genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT."
1444694373,C,T,"Patients with the CT genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT."
1444694373,T,T,"Patients with the TT genotype who undergo kidney transplantation may have an increased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the CC genotype. However, no association with diabetes mellitus was seen in other studies in kidney and liver transplant patients. Other genetic and clinical factors may also influence development of NODAT."
1446897191,C,C,Patients with the CC genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897191,C,T,Patients with the CT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446897191,T,T,Patients with the TT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.
1446903007,C,C,Patients with the CC genotype may require an increased dose of codeine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of codeine.
1446903007,C,T,No information is available for the CT genotype.
1446903007,T,T,Patients with the TT genotype may require a decreased dose of codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of codeine.
1451720996,A,A,"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 AA genotype may be less likely to require glucarpidase treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451720996,A,G,"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 AG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451720996,G,G,"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs7317112 GG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1448601910,C,C,Patients with the CC genotype and major depressive disorder may have an increased response to venlafaxine compared to patients with the CT and TT genotypes. Other clinical and genetic factors affect response to venlafaxine.
1448601910,C,T,Patients with the CT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.
1448601910,T,T,Patients with the TT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.
1448602210,C,C,Children with the CC genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.
1448602210,C,T,Children with the CT genotype and major depressive disorder may respond worse to fluoxetine therapy compared to patients with the CC and TT genotypes. Other clinical and genetic factors may affect response to fluoxetine.
1448602210,T,T,Children with the TT genotype and major depressive disorder may respond better to fluoxetine therapy compared to patients with the CT genotype. Other clinical and genetic factors may affect response to fluoxetine.
1451649500,C,C,Patients with the rs997917 CC genotype may be at a decreased risk of developing cocaine dependence when exposed to cocaine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing cocaine dependence.
1451649500,C,T,Patients with the rs997917 CT genotype may be at an increased risk of developing cocaine dependence when exposed to cocaine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing cocaine dependence.
1451649500,T,T,Patients with the rs997917 TT genotype may be at an increased risk of developing cocaine dependence when exposed to cocaine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing cocaine dependence.
1451649540,C,C,Patients with the rs997917 CC genotype may be at a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451649540,C,T,Patients with the rs997917 CT genotype may be at an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451649540,T,T,Patients with the rs997917 TT genotype may be at an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1448603309,A,A,"Patients with the rs324420 AA genotype may be at an increased risk of experiencing adverse events when treated with morphine as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine."
1448603309,A,C,"Patients with the rs324420 AC genotype may be at an increased risk of experiencing adverse events when treated with morphine as compared to patients with the CC genotype but a decreased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine."
1448603309,C,C,"Patients with the rs324420 CC genotype may be at a decreased risk of experiencing adverse events when treated with morphine as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine."
1451679780,C,C,Patients with heroin dependence and the rs55944529 CC genotype may have decreased methadone dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose requirements.
1451679780,C,T,Patients with heroin dependence and the rs55944529 CT genotype may have decreased methadone dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose requirements.
1451679780,T,T,Patients with heroin dependence and the rs55944529 TT genotype may have increased methadone dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methadone dose requirements.
1451721004,A,A,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs9345389 AA genotype may be less likely to require glucarpidase treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451721004,A,G,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs9345389 AG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451721004,G,G,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs9345389 GG genotype may be more likely to require glucarpidase treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451721021,A,A,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs3824662 AA genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451721021,A,C,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs3824662 AC genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451721021,C,C,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs3824662 CC genotype may be less likely to require glucarpidase treatment as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451737460,A,A,Patients with acute coronary syndrome and the rs11640115 AA genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737460,A,G,Patients with acute coronary syndrome and the rs11640115 AG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737460,G,G,Patients with acute coronary syndrome and the rs11640115 GG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1444668402,C,C,Patients with the CC genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
1444668402,C,T,Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
1444668402,T,T,Patients with the TT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.
1444700896,C,C,Patients with the CC genotype may have decreased metabolism of quetiapine as compared to CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.
1444700896,C,T,Patients with the CT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.
1444700896,T,T,Patients with the TT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.
1451721013,C,C,"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451721013,C,T,"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451721013,T,T,"Patients receiving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs4149056 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1446897696,A,A,"Patients with renal cell carcinoma and the AA genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib."
1446897696,A,C,"Patients with renal cell carcinoma and the AC genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib."
1446897696,A,T,"Patients with renal cell carcinoma and the AT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib."
1446897696,C,C,"Patients with renal cell carcinoma and the CC genotypes may have an INCREASED risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the AA, AC, AT, CT, or TT genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib."
1446897696,C,T,"Patients with renal cell carcinoma and the CT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib."
1446897696,T,T,"Patients with renal cell carcinoma and the TT genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib."
1451638961,A,A,Patients with the rs1128503 AA genotype may have increased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.
1451638961,A,G,Patients with the rs1128503 AG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.
1451638961,G,G,Patients with the rs1128503 GG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.
1451720980,C,C,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10908521 CC genotype may be less likely to require glucarpidase treatment as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451720980,C,T,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10908521 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451720980,T,T,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10908521 TT genotype may be more likely to require glucarpidase treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451748166,C,C,Patients with the rs2952768 CC genotype may have increased fentanyl dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.
1451748166,C,T,Patients with the rs2952768 CT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.
1451748166,T,T,Patients with the rs2952768 TT genotype may have decreased fentanyl dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fentanyl dose requirements.
1184987404,C,C,Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987404,C,G,Patients with the CG genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987404,G,G,Patients with the GG genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CG or GG genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184988860,A,A,Patients with the AA genotype and alcoholism may have an increased response to acamprosate as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.
1184988860,A,T,Patients with the AT genotype and alcoholism may have an increased response to acamprosate as compared to patients with the TT genotype and a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.
1184988860,T,T,Patients with the TT genotype and alcoholism may have a decreased response to acamprosate as compared to patients with the AA or AT genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.
1184998947,A,A,Patients with the AA genotype who are treated with morphine may have higher levels of morphine-3-glucuronide formation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1184998947,A,G,Patients with the AG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1184998947,G,G,Patients with the GG genotype who are treated with morphine may have lower levels of morphine-3-glucuronide formation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1184998975,C,C,Patients with the CC genotype may have increased metabolism of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1184998975,C,T,"Patients with the CT genotype may have decreased metabolism of morphine as compared to patients with the CC genotype, but increased metabolism of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine."
1184998975,T,T,Patients with the TT genotype may have decreased metabolism of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism of morphine.
1451720988,C,C,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs1353327 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451720988,C,T,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs1353327 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451720988,T,T,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs1353327 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451737500,C,C,Patients with acute coronary syndrome and the rs4736529 CC genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737500,C,G,Patients with acute coronary syndrome and the rs4736529 CG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737500,G,G,Patients with acute coronary syndrome and the rs4736529 GG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1296598910,A,A,Patients with the AA genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.
1296598910,A,G,Patients with the AG genotype who are treated with phenprocoumon may require a higher dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.
1296598910,G,G,Patients with the AG genotype who are treated with phenprocoumon may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of phenprocoumon.
1451721028,C,C,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 CC genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451721028,C,T,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 CT genotype may be more likely to require glucarpidase treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1451721028,T,T,"Patients recieving methotrexate to treat acute lymphoblastic leukemia (ALL), and the rs10821936 TT genotype may be less likely to require glucarpidase treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence likelihood of requiring glucarpidase treatment."
1444666308,A,A,"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate."
1444666308,A,C,"Patients with the AC genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate."
1444666308,C,C,"Patients with the CC genotype and who are heavy drinkers or have an alcohol-use disorder may have lower concentrations of topiramate, and a better response to treatment with the drug, as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate."
1444673163,C,C,"Patients with the CC genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations."
1444673163,C,T,"Patients with the CT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have increased trough concentrations of cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations."
1444673163,T,T,"Patients with the TT genotype undergoing kidney transplantation who are CYP3A5 nonexpressers (CYP3A5 *1/*3 or *3/*3) and who do not carry the CYP3A4*22 (rs35599367 A) allele may have decreased trough concentrations of cyclosporine as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3 and CYP3A4*22, may also influence cyclosporine concentrations."
1444686935,C,C,"Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686935,C,T,"Patients with the CT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686935,T,T,"Patients with the TT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686942,A,A,Patients with the AA genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686942,A,T,Patients with the AT genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686942,T,T,Patients with the TT genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686958,C,C,"Patients with the CC genotype and Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686958,C,T,"Patients with the CT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686958,T,T,"Patients with the TT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444694504,A,A,Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.
1444694504,A,C,"Patients with the AC genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation."
1444694504,C,C,Patients with the CC genotype who are undergoing kidney transplantation may have an increased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.
1444694544,C,C,"No patients with the CC genotype were present in the population. However, patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
1444694544,C,T,"Patients undergoing liver transplantation who receive a donor liver with the CT genotype may require an increased dose of tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
1444694544,T,T,"Patients undergoing liver transplantation who receive a donor liver with the TT genotype may require a decreased dose of tacrolimus as compared to patients who receive a donor liver with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus."
1444703639,A,A,Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703639,A,T,Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703639,T,T,Patients with the TT genotype may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703668,C,C,Patients with the CC genotype may have increased risk for neutropenia when treated with gemcitabine as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1444703668,C,T,Patients with the CT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1444703668,T,T,Patients with the TT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1445616165,C,C,Patients with the CC genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445616165,C,T,Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotypes and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445616165,T,T,Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619121,G,G,Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619121,G,T,Patients with the GT genotype and essential hypertension may have a decreased response as compared to patients with the TT genotype and an increased response as compared to patients with the GG genotype when treated with hydrochlorothiazide. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619121,T,T,Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the GT and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619585,A,A,Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619585,A,G,Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445619585,G,G,Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1448573300,A,A,Patients with the AA genotype may have decreased dose of warfarin in African American patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the dose of warfarin.
1448573300,A,G,Patients with the AG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
1448573300,G,G,Patients with the GG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
1444694511,A,A,"Patients with the AA genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
1444694511,A,C,"Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
1444694511,C,C,"Patients with the CC genotype who are undergoing organ transplantation may have increased metabolism and dose requirements of tacrolimus, as compared to patients with the AA, AC, CT or TT genotypes. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
1444694511,C,T,"Patients with the CT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
1444694511,T,T,"Patients with the TT genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus."
1444703649,C,C,Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703649,C,T,Patients with the CC genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703649,T,T,Patients with the TT genotype may have increased response to methotrexate as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444666386,C,C,Patients with the rs28399499 CC genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.
1444666386,C,T,Patients with the rs28399499 CT genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.
1444666386,T,T,Patients with the rs28399499 TT genotype and HIV may have a decreased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.
1296599132,A,A,"Patients with the rs1045642 AA genotype and cancer who are treated with methotrexate may have increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities."
1296599132,A,G,"Patients with the rs1045642 AG genotype and cancer who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or a decreased risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities."
1296599132,G,G,"Patients with the rs1045642 GG genotype and cancer who are treated with methotrexate may have a reduced, but not absent, risk of toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities."
1448573615,A,A,Patients with the AA genotype and ulcerative colitis may have a decreased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus response.
1448573615,A,G,Patients with the AG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.
1448573615,G,G,Patients with the GG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.
1448601692,A,A,Patients with the AA genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.
1448601692,A,G,Patients with the AG genotype and coronary disease may have increased response to clopidogrel treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect clopidogrel response.
1448601692,G,G,Patients with the GG genotype and coronary disease may have decreased response to clopidogrel treatment compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect clopidogrel response.
1448603297,C,C,Children with the CC genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603297,C,T,Children with the CT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603297,T,T,Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603303,A,A,Children with the AA genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603303,A,G,Children with the AG genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603303,G,G,Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of PONV.
1448604316,C,C,"Patients with the CC genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome."
1448604316,C,T,"Patients with the CT genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the TT genotype, and decreased fasting triglyceride levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome."
1448604316,T,T,"Patients with the TT genotype and schizophrenia may have decreased fasting triglyceride levels, that may reduce susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome."
1448594289,A,A,"Patients with the AA genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance."
1448594289,A,G,"Patients with the AG genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance."
1448594289,G,G,"Patients with the GG genotype who undergo anesthesia with propofol may have increased clearance of the drug as compared to patients with the AA or AG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance."
1451737520,A,A,Patients with acute coronary syndrome and the rs74569896 AA genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737520,A,G,Patients with acute coronary syndrome and the rs74569896 AG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737520,G,G,Patients with acute coronary syndrome and the rs74569896 GG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1184986481,A,A,"Patients with the AA genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) all as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine."
1184986481,A,G,"Patients with the AG genotype and organ transplantation administered cyclosporine may have a 1) decreased metabolism of cyclosporine 2) decreased clearance of cyclosporine and 3) an increased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the GG genotype. Patients with the AG genotype and organ transplantation administered cyclosporine may have 1) increased metabolism 2) increased clearance and 3) decreased risk of adverse events as compared to patients with the GG genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine."
1184986481,G,G,"Patients with the GG genotype and organ transplantation administered cyclosporine may have a 1) increased metabolism of cyclosporine 2) increased clearance of cyclosporine and 3) a decreased risk in adverse events (e.g. graft rejection or kidney function) as compared to patients with the AA genotype, although this is contradicted in some studies. Other clinical and genetic factors may also affect metabolism and incidence of adverse events in organ transplant patients administered cyclosporine."
1184986491,A,A,Patients with the AA genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.
1184986491,A,G,Patients with the AG genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype and decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.
1184986491,G,G,Patients with the GG genotype and organ transplantation administered tacrolimus may have decreased metabolism of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.
1444607348,C,C,"In lymphoblastoid cell lines, the CC genotype was associated with increased sensitivity to tamoxifen, as compared to the CT or TT genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
1444607348,C,T,"In lymphoblastoid cell lines, the CT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
1444607348,T,T,"In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
1444607366,C,C,"In lymphoblastoid cell lines, the CC genotype was associated with increased sensitivity to tamoxifen, as compared to the CT or TT genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
1444607366,C,T,"In lymphoblastoid cell lines, the CT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
1444607366,T,T,"In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen."
1444607373,C,C,Women with the CC genotype and breast cancer may have increased lumbar bone loss when treated with tamoxifen as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.
1444607373,C,T,Women with the CT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.
1444607373,T,T,Women with the TT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.
1444607634,A,A,Patients with the AA genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444607634,A,G,Patients with the AG genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype and increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444607634,G,G,Patients with the GG genotype who are treated with metformin may have a increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.
1444607674,C,C,Patients with the CC genotype who are treated with fluoxetine may have an increased response as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444607674,C,G,Patients with the CG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444607674,G,G,Patients with the GG genotype who are treated with fluoxetine may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444607851,A,A,Patients with the AA genotype and age-related macular degeneration may have a poorer response when treated with bevacizumab as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1444607851,A,T,Patients with the AT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1444607851,T,T,Patients with the TT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1444607863,C,C,Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of leukopenia as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1444607863,C,T,Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1444607863,T,T,Patients with the TT genotype were not studied but patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.
1444672766,A,A,"Patients with the AA genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the AG or GG genotypes or those who are not taking oral contraceptives. Current evidence suggests that patients with the AA or AG mutations who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AA genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives."
1444672766,A,G,"Patients with the AG genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the GG genotype or those who are not taking oral contraceptives and a decreased risk of DVT as compared to patients with the AA genotype. Current evidence suggests that patients with the AA or AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives."
1444672766,G,G,"Patients with the GG genotype who are taking oral contraceptives (OCs) may have a decreased risk for deep vein thrombosis (DVT), as compared to patients with the AA or AG genotypes or those who are not taking oral contraceptives. Current evidence suggests that patients with the AA or AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AA or AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AA or AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives."
1444672774,C,C,Patients with the CC genotype may have a poorer response to treatment with clonidine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to clonidine.
1444672774,C,T,Patients with the CT genotype may have a better response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.
1444672774,T,T,Patients with the TT genotype may have a betterr response to treatment with clonidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clonidine.
1451649631,A,A,Patients with the rs12678747 AA genotype may be at a decreased risk of developing peptic ulcers when treated with aspirin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also influence risk of developing peptic ulcers when treated with aspirin.
1451649631,A,T,Patients with the rs12678747 AT genotype may be at an increased risk of developing peptic ulcers when treated with aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing peptic ulcers when treated with aspirin.
1451649631,T,T,Patients with the rs12678747 TT genotype may be at an increased risk of developing peptic ulcers when treated with aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing peptic ulcers when treated with aspirin.
1451737560,A,A,Patients with acute coronary syndrome and the rs75750968 AA genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737560,A,T,Patients with acute coronary syndrome and the rs75750968 AT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737560,T,T,Patients with acute coronary syndrome and the rs75750968 TT genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1184986321,C,C,Patients with the CC genotype and cancer may have an improved response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.
1184986321,C,T,Patients with the CT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype and an improved response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.
1184986321,T,T,Patients with the TT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.
1184986585,A,A,Patients with the AA genotype and lung cancer may have an improved response to platinum compounds as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.
1184986585,A,G,Patients with the AG genotype and lung cancer may have a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.
1184986585,G,G,Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.
1184986763,A,A,Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1184986763,A,G,Patients with the AG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1184986763,G,G,Patients with the GG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype but an increased risk as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1184987048,A,A,Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987048,A,G,Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987048,G,G,Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1444700423,A,A,"Patients with the AA genotype may have decreased risk of cisplatin-induced ototoxicity as compared to patients with AC or CC genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin."
1444700423,A,C,"Patients with the AC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin."
1444700423,C,C,"Patients with the CC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin."
1444700445,C,C,Patients with the CC genotype may have increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.
1444700445,C,G,Patients with the CG genotype may have increased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.
1444700445,G,G,Patients with the GG genotype may have decreased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.
1444700767,A,A,"Patients with the AA genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AG genotype. However, a different study found an increased response to tocilizumab for patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab."
1444700767,A,G,"Patients with the AG genotype and rheumatoid arthritis who are treated with tocilizumab may have increased response to tocilizumab as compared to patients with the AA genotype. However, a different study found a decreased response to tocilizumab for patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab."
1444700767,G,G,Patients with the GG genotype and rheumatoid arthritis who are treated with tocilizumab may have decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.
1444700888,G,G,Patients with the GG genotype who are treated with methotrexate may have decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444700888,G,T,Patients with the GT genotype who are treated with methotrexate may have decreased risk for toxicity and decreased plasma level as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444700888,T,T,Patients with the TT genotype who are treated with methotrexate may have increased risk for toxicity and increased plasma level as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703107,A,A,"Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
1444703107,A,G,"Patients with the AG genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity."
1444703107,G,G,Patients with the GG genotype who are treated with gemcitabine may have an increased risk for toxicity as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.
1444706112,C,C,"Patients who are undergoing liver transplant and receive a liver with the CC genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus."
1444706112,C,G,"Patients who are undergoing liver transplant and receive a liver with the CG genotype, or patients undergoing a lung transplant, may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus."
1444706112,G,G,"Patients who are undergoing liver transplant and receive a liver with the GG genotype, or patients undergoing a lung transplant, may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence concentration of tacrolimus."
1444706787,A,A,Patients with the AA genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444706787,A,G,Patients with the AG genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype or may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444706787,G,G,Patients with the GG genotype and major depression may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444706794,C,C,Patients with the CC genotype and major depression may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444706794,C,T,Patients with the CT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype or may have decreased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444706794,T,T,Patients with the TT genotype and major depression may have increased likelihood of treatment-emergent suicidality when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444706810,C,C,Patients with the CC genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706810,C,T,Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706810,T,T,Patients with the TT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706818,C,C,Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706818,C,T,Patients with the CT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype or may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444706818,T,T,Patients with the TT genotype and Obsessive-Compulsive Disorder may have decreased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444703100,C,C,Patients with the CC genotype and Rheumatoid Arthritis may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703100,C,T,Patients with the CT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype or may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703100,T,T,Patients with the TT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444709147,A,A,Patients with the AA genotype and Bipolar disorder may have increased response to lithium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1444709147,A,G,Patients with the AG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1444709147,G,G,Patients with the GG genotype and Bipolar disorder may have decreased response to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.
1451737600,C,C,Patients with acute coronary syndrome and the rs140410716 CC genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737600,C,T,Patients with acute coronary syndrome and the rs140410716 CT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737600,T,T,Patients with acute coronary syndrome and the rs140410716 TT genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1184986174,C,C,"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1184986174,C,G,"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have an increased risk of drug toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1184986174,G,G,"The C allele of rs75017182 when measured on plus chromosomal strand is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the GG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CG or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1185000238,C,C,"Patients with the CC genotype (CYP3A5 *3/*3) and ulcerative colitis may have an increased chance of achieving remission when treated with tacrolimus as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis."
1185000238,C,T,"Patients with the CT genotype (CYP3A5 *1/*3) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis."
1185000238,T,T,"Patients with the TT genotype (CYP3A5 *1/*1) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis."
1444607295,C,C,Individuals with the CC genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607295,C,T,Individuals with the CT genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607295,T,T,Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to those with the CC or CT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607302,G,G,Individuals with the GG genotype may have a decreased risk of cocaine dependence as compared to individuals with the GT or TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607302,G,T,Individuals with the GT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607302,T,T,Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.
1444607737,C,C,Patients with the CC genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.
1444607737,C,T,Patients with the CT genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.
1444607737,T,T,Patients with the TT genotype may have a higher maximal rate (Vmax) of ethanol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.
1444607751,A,A,"Patients with the AA genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy."
1444607751,A,G,"Patients with the AG genotype and non-small-cell lung cancer may be more likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy."
1444607751,G,G,"Patients with the GG genotype and non-small-cell lung cancer may be less likely to respond to treatment with platinum-based chemotherapy, as compared to patients with the AA or AG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to treatment with platinum-based chemotherapy."
1444607979,A,A,Patients with the AA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have an increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.
1444607979,C,A,Patients with the CA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype and increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.
1444607979,C,C,Patients with the CC genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have a decreased overall survival probability as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's survival probability.
1444608491,A,A,"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444608491,A,G,"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444608491,G,G,"Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444665939,A,A,"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444665939,A,G,"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444665939,G,G,"Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444667912,A,A,Patients with genotype AA and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.
1444667912,A,G,Patients with genotype AG and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.
1444667912,G,G,Patients with genotype GG and epilepsy may have an increased risk of drug toxicity when taking valproic acid as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.
1444686969,A,A,"Patients with the AA genotype and inflammatory bowel disease or psoriasis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686969,A,C,"Patients with the AC genotype and inflammatory bowel disease or psoriasis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686969,C,C,"Patients with the CC genotype and inflammatory bowel disease or psoriasis, may have a better response to anti-TNF therapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686976,C,C,Patients with the CC genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686976,C,T,Patients with the CT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686976,T,T,Patients with the TT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686983,A,A,Patients with the AA genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686983,A,G,Patients with the AG genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686983,G,G,Patients with the GG genotype and ulcerative colitis may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444686990,A,A,"Patients with the AA genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686990,A,G,"Patients with the AG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686990,G,G,"Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686997,C,C,"Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686997,C,G,"Patients with the CG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444686997,G,G,"Patients with the GG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444687004,C,C,"Patients with the CC genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444687004,C,T,"Patients with the CT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444687004,T,T,"Patients with the TT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy."
1444687025,A,A,Patients with the AA genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687025,A,G,Patients with the AG genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687025,G,G,Patients with the GG genotype and inflammatory bowel diseases may have a poorer response to anti-TNF therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687032,C,C,Patients with the CC genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687032,C,T,Patients with the CT genotype and inflammatory bowel disease may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444687032,T,T,Patients with the TT genotype and inflammatory bowel disease may have a better response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.
1444700760,G,G,Patients with the GG genotype and major depression who are treated with citalopram or escitalopram may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444700760,G,T,Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444700760,T,T,Patients with the TT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.
1444700999,C,C,Patients with the CC genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.
1444700999,C,T,Patients with the CT genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.
1444700999,T,T,Patients with the TT genotype may have decreased response to enalapril in people with Hypertension as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the efficacy of enalapril.
1444701007,C,C,"Patients with the CC genotype may have decreased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril."
1444701007,C,T,"Patients with the CT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril."
1444701007,T,T,"Patients with the TT genotype may have increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to enalapril, imidapril and lisinopril."
1444704818,A,A,Patients with the AA genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to codeine.
1444704818,A,G,Patients with the AG genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype or may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.
1444704818,G,G,Patients with the GG genotype may have decreased likelihood of CNS depression in breast-feeding infants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to codeine.
1444705191,A,A,Patients with the AA genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705191,A,T,"Patients with the AT genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype or may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram."
1444705191,T,T,"Patients with the TT genotype and major depression may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram."
1444705198,C,C,Patients with the CC genotype and major depression may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.
1444705198,C,G,Patients with the CG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype or may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.
1444705198,G,G,Patients with the GG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.
1444705206,C,C,Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705206,C,G,Patients with the CG genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705206,G,G,Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705222,C,C,Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705222,C,T,Patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705222,T,T,"Patients with the TT genotype were not studied. However, patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram."
1444705229,A,A,Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705229,A,C,Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype or may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705229,C,C,Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444706124,A,A,Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1444706124,A,G,Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1444706124,G,G,Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1444705214,C,C,The current evidence base suggests that there is no association between the rs25531 CC genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.
1444705214,C,T,The current evidence base suggests that there is no association between the rs25531 CT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.
1444705214,T,T,The current evidence base suggests that there is no association between the rs25531 TT genotype and response to citalopram. Other genetic and clinical factors may also influence response to citalopram.
1445556297,C,C,"Patients with the CC genotype who are smokers may have a lower chance of smoking cessation when treated with bupropion as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation."
1445556297,C,T,"Patients with the CT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation."
1445556297,T,T,"Patients with the TT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation."
1184999957,C,C,"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype and are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection."
1184999957,C,T,Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
1184999957,T,T,Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.
1444672826,A,A,"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole."
1444672826,A,G,"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole."
1444672826,G,G,"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole."
1444704833,A,A,"Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements."
1444704833,A,G,"Patients with the AG genotype may have decreased opioid dose requirements as compared to patients with the GG genotype, but increased opioid dose requirements as compared to patients with the AA genotype. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements."
1444704833,G,G,"Patients with the GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements."
1444706154,A,A,Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1444706154,A,G,Pediatric patients with ALL and the AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1444706154,G,G,Pediatric patients with ALL and the GG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.
1184749280,A,A,Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1184749280,A,G,"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity."
1184749280,G,G,"Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity."
1184764189,C,C,Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764189,C,T,"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1184764189,T,T,"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1184986454,A,A,"Female patients with the AA genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine."
1184986454,A,C,"Female patients with the AC genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype and a decreased risk of Stevens-Johnson syndrome as compared to patients with the AA genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine."
1184986454,C,C,"Female patients with the CC genotype and acquired immunodeficiency syndrome (AIDS) may have a decreased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the AA genotype, although the evidence is contradictory. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine."
1184986756,A,A,The AA genotype was only present in one individual and could not be evaluated for its influence on risk of opioid dependence upon exposure to opioids. Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids.
1184986756,A,G,Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1184986756,G,G,Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.
1444666705,G,G,Patients with the GG genotype and acute lymphoblastic leukemia may have an increased risk of granulocytopenia when treated with methotrexate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.
1444666705,G,T,Patients with the GT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.
1444666705,T,T,Patients with the TT genotype and acute lymphoblastic leukemia may have a decreased risk of granulocytopenia when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of agranulocytosis.
1444666731,C,C,Patients with the CC genotype and major depressive disorder may have a poorer response to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to antidepressants.
1444666731,C,T,Patients with the CT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
1444666731,T,T,Patients with the TT genotype and major depressive disorder may have a better response to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to antidepressants.
1444666738,A,A,Patients with the AA genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram.
1444666738,A,G,"Patients with the AG genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram."
1444666738,G,G,Patients with the GG genotype and depression may have a poorer response when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram.
1444667578,A,A,Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667578,A,C,Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the CC genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667578,C,C,Patients with asthma and the CC genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1184997925,C,C,Patients with the CC genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1184997925,C,T,Patients with the CT genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1184997925,T,T,Patients with the TT genotype and rs3212198 T allele who are treated with warfarin may require a higher dose as compared to patients with the CT or CC genotype in combination with any allele of rs3212198. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1444666717,C,C,"Patients with the rs4948496 CC genotype and acute lymphoblastic leukemia may have increased concentrations of methotrexate as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4948496 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methotrexate."
1444666717,C,T,"Patients with the rs4948496 CT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4948496 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methotrexate."
1444666717,T,T,"Patients with the rs4948496 TT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4948496 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence concentrations of methotrexate."
1184749160,G,G,Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1184749160,G,T,"Patients with the GT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 3-4 neurotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity."
1184749160,T,T,"Patients with the TT genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 3-4 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity."
1444704914,A,A,Patients with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444704914,A,G,Patients with the AG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1444704914,G,G,Patients with the GG genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have increased metabolism of etoposide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.
1451640205,A,A,Patients with alcoholism and the rs12749274 AA genotype may have a decreased response to naltrexone as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to naltrexone.
1451640205,A,G,Patients with alcoholism and the rs12749274 AG genotype may have a decreased response to naltrexone as compared to patients with the GG genotype but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to naltrexone.
1451640205,G,G,Patients with alcoholism and the rs12749274 GG genotype may have an increased response to naltrexone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to naltrexone.
1184747857,A,A,Patients with the AA genotype and hypercholesterolemia who are treated with atorvastatin may have better LDL-C responses and are more likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
1184747857,A,G,Patients with the AG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
1184747857,G,G,Patients with the GG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.
1184986985,A,A,Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184986985,A,G,Patients with genotype AG and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotype and an increased risk of hypercholesteremia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184986985,G,G,Patients with genotype GG and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184986992,C,C,Patients with the CC genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184986992,C,G,Patients with the CG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CC genotype and an increased risk of hypercholesteremia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184986992,G,G,Patients with the GG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987008,C,C,Patients with genotype CC and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with genotype CT and TT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987008,C,T,Patients with genotype CT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987008,T,T,Patients with genotype TT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC and CT. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987030,C,C,Patients with the CC genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987030,C,T,Patients with the CT genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT genotype. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987030,T,T,Patients with the TT genotype and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.
1184987041,A,A,Patients with the AA genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987041,A,G,Patients with the AG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987041,G,G,Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1185000225,C,C,Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for infections when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.
1185000225,C,T,Patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.
1185000225,T,T,Patients with the TT genotype (CYP3A5 *1/*1) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.
1444608377,C,C,"Patients with the CC genotype and depression may not respond as well to treatment with escitalopram, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to escitalopram."
1444608377,C,T,"Patients with the CT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram."
1444608377,T,T,"Patients with the TT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram."
1444665984,G,G,"Patients with the GG genotype and colorectal cancer may have a shorter overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment."
1444665984,G,T,"Patients with the GT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment."
1444665984,T,T,"Patients with the TT genotype and colorectal cancer may have a longer overall survival time and progression-free survival time when receiving anti-EGFR plus irinotecan treatment, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time on anti-EGFR plus irinotecan treatment."
1444667902,G,G,Patients with the GG genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.
1444667902,G,T,Patients with the GT genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.
1444667902,T,T,Patients with the TT genotype and diabetes mellitus may have a decreased response to pioglitazone as compared to patients with the GT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.
1444703473,C,C,Male patients with the CC genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.
1444703473,C,T,Male patients with the CT genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.
1444703473,T,T,Male patients with the TT genotype may have increased clearance of vardenafil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.
1444703502,A,A,Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703502,A,T,Patients with the AT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703502,T,T,"Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1444703509,C,C,"Patients with the CC genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1444703509,C,T,Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703509,T,T,Patients with the TT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703985,A,A,Patients with the AA genotype and major depression may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444703985,A,G,Patients with the AG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype or may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444703985,G,G,Patients with the GG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444704005,A,A,Patients with the AA genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444704005,A,G,Patients with the AG genotype and major depression who are treated with fluoxetine may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444704005,G,G,Patients with the GG genotype and major depression who are treated with fluoxetine may have increased response as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444704012,C,C,"Patients with the CC genotype and hypertension and coronary artery disease who are treated with verapamil may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
1444704012,C,T,"Patients with the CT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype or may have decreased, but not absent, risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
1444704012,T,T,"Patients with the TT genotype and hypertension and coronary artery disease who are treated with verapamil may have increased risk for the primary outcome, defined as first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
1444704419,A,A,"Patients with the genotype AA may have better response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AG or GG, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin."
1444704419,A,G,"Patients with genotype AG may have decreased response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin."
1444704419,G,G,"Patients with genotype GG may have decreased response to metformin in people with diabetes mellitus or polycystic ovarian syndrome as compared to patients with genotype AA, though other evidence contradicts this association depending on the measure of response. Other genetic and clinical factors may also influence the response to metformin."
1444705243,A,A,Patients with the AA genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705243,A,G,Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705243,G,G,Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1445556405,A,A,Patients with the AA genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1445556405,A,C,"Patients with the AC genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype, or a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity."
1445556405,C,C,Patients with the CC genotype who are treated with valproic acid may have a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1444704426,A,A,"Patients with genotype AA may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or AC, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1444704426,A,C,"Patients with genotype AC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1444704426,C,C,"Patients with genotype CC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1185003565,A,A,Patients with the AA genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.
1185003565,A,C,Patients with the AC genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.
1185003565,C,C,Patients with the CC genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the response to trastuzumab.
1451683665,C,C,Patients with prostate cancer and the rs523349 CC genotype may have an increased response to abiraterone as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence response to abiraterone.
1451683665,C,G,Patients with prostate cancer and the rs523349 CG genotype may have a decreased response to abiraterone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to abiraterone.
1451683665,G,G,Patients with prostate cancer and the rs523349 GG genotype may have a decreased response to abiraterone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to abiraterone.
1184986201,A,A,Patients with the AA genotype and cancer may have an increased risk of drug toxicity and may require dose modification when administered capecitabine and/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.
1184986201,A,G,Patients with the AG genotype and cancer may have an increased risk of drug toxicity and may require dose modification when administered capecitabine and/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.
1184986201,G,G,Patients with the GG genotype and cancer may have a decreased risk of drug toxicity and may not require dose modification when administered capecitabine and/or fluorouracil as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer.
1184986298,A,A,Patients with the AA genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.
1184986298,A,C,Patients with the AC genotype and cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype and an increased risk of diarrhea as compared to the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.
1184986298,C,C,Patients with the CC genotype and cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of diarrhea in people with cancer.
1184986567,C,C,Organ transplant patients with the CC genotype who are administered tacrolimus may have increased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and TT genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.
1184986567,C,T,Organ transplant patients with the CT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CC genotype. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.
1184986567,T,T,Organ transplant patients with the TT genotype who are administered tacrolimus may have decreased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and CC genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.
1184986578,G,G,Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.
1184986578,G,T,Patients with the GT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.
1184986578,T,T,Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.
1184986654,C,C,Patients with the CC genotype may have a decreased metabolism of repaglinide as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
1184986654,C,T,The CT genotype did not differ significantly in metabolism of repaglinide as compared to patients with the CC or TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
1184986654,T,T,Patients with the TT genotype may have an metabolism of repaglinide as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
1185000097,A,A,Patients with the AA genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1185000097,A,G,Patients with the AG genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.
1185000097,G,G,"Patients with the GG genotype and epilepsy who are treated with carbamazepine may have a reduced, but not absent, risk of neurological adverse drug reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions."
1444706911,A,A,"Patients with the AA genotype and Schizophrenia may have increased clearance of olanzapine as compared to patients with the AG or GG genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine."
1444706911,A,G,"Patients with the AG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine."
1444706911,G,G,"Patients with the GG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine."
1184986386,A,A,Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence the dose of warfarin.
1184986386,A,G,Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the dose of warfarin.
1184986386,G,G,Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence the dose of warfarin.
1451640212,A,A,Patients with alcoholism and the rs77583603 AA genotype may have an increased response to acamprosate treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to acamprosate.
1451640212,A,G,Patients with alcoholism and the rs77583603 AG genotype may have an increased response to acamprosate treatment as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to acamprosate.
1451640212,G,G,Patients with alcoholism and the rs77583603 GG genotype may have a decreased response to acamprosate treatment as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to acamprosate.
1444607768,C,C,"Patients with the CC genotype who are treated with fluvoxamine may have an increased risk of gastrointestinal side effects as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
1444607768,C,T,"Patients with the CT genotype who are treated with fluvoxamine may have an increased risk of gastrointestinal side effects as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
1444607768,T,T,"Patients with the TT genotype who are treated with fluvoxamine may have a decreased, but not absent, risk of gastrointestinal side effects as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine."
1444607697,C,C,Patients with the CC genotype who are treated with docetaxel may have an increased clearance and decreased risk of leukopenia as compared to patients with the GG genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.
1444607697,C,G,Patients with the CG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.
1444607697,G,G,Patients with the GG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.
1444607704,G,G,"Patients with the GG genotype and beta-thalassemia may have a better response, but also an increased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone."
1444607704,G,T,"Patients with the GT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone."
1444607704,T,T,"Patients with the TT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone."
1444607716,A,A,Patients with the AA genotype who are treated with ritonavir may have a decreased intracellular/plasma trough concentration as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.
1444607716,A,C,Patients with the AC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.
1444607716,C,C,Patients with the CC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.
1444607723,A,A,"Patients with the rs1799971 AA genotype who are receiving hydrocodone may have a decreased risk for experiencing side effects as compared to patients with the AG or GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone."
1444607723,A,G,"Patients with the rs1799971 AG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone."
1444607723,G,G,"Patients with the rs1799971 GG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone."
1444607775,G,G,"Patients with the GG genotype and non-small-cell lung cancer may be at increased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed."
1444607775,G,T,"Patients with the GT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed."
1444607775,T,T,"Patients with the TT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed."
1444607782,C,C,Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.
1444607782,C,T,Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype and may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.
1444607782,T,T,Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.
1444607960,G,G,"Patients with the GG genotype and systemic lupus erythematosus may be more likely to respond to treatment with rituximab, as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to treatment with rituximab."
1444607960,G,T,"Patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab."
1444607960,T,T,"No patients with the TT genotype were present in the study. However, patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab."
1444607966,A,A,Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
1444607966,A,C,Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk of leukopenia as compared to patients with the CC genotype and decreased risk of leukopenia as compared to patients with the AA. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
1444607966,C,C,Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have a decreased risk of leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of leukopenia.
1444665946,A,A,"Patients with the AA genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444665946,A,G,"Patients with the AG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment as compared to patients with the AA genotype, but a longer overall survival time as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444665946,G,G,"Patients with the GG genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444665964,A,A,"Patients with the AA genotype and colorectal cancer may have a poorer response to anti-EGFR plus irinotecan treatment, as well as a shorter overall survival time and progression-free survival time, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444665964,A,C,"Patients with the AC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444665964,C,C,"Patients with the CC genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as well as a longer overall survival time and progression-free survival time, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment."
1444666756,A,A,Patients with the AA genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone.
1444666756,A,G,Patients with the AG genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone
1444666756,G,G,Patients with the GG genotype and type 2 diabetes may have a poorer response when treated with rosiglitazone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to rosiglitazone
1444666763,A,A,"Patients with the AA genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the GG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival."
1444666763,A,G,"Patients with the AG genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the GG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival."
1444666763,G,G,"Patients with the GG genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the AA or AG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival."
1444666770,A,A,Patients with the AA genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1444666770,A,G,Patients with the AG genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1444666770,G,G,Patients with the GG genotype and lung cancer may have a decreased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1444666777,A,A,Patients with the AA genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.
1444666777,A,G,"Patients with the AG genotype and lung cancer may have a decreased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed."
1444666777,G,G,Patients with the GG genotype and lung cancer may have an increased risk of experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity in patients receiving pemetrexed.
1444666789,C,C,Patients with the CC genotype and lung cancer may have a better response to treatment with pemetrexed as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to pemetrexed.
1444666789,C,T,Patients with the CT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.
1444666789,T,T,Patients with the TT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.
1444666796,A,A,Patients with the AA genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.
1444666796,A,G,"Patients with the AG genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the GG genotype, and a longer overall survival time as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time."
1444666796,G,G,Patients with the GG genotype and lung cancer may have longer overall and progression-free survival times when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time.
1444666803,G,G,Patients with the GG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
1444666803,G,T,Patients with the GT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
1444666803,T,T,Patients with the TT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence overall survival time.
1444666818,C,C,Patients with the CC genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
1444666818,C,T,Patients with the CT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.
1444666818,T,T,Patients with the TT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival time.
1444703086,A,A,"Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine."
1444703086,A,C,"Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine.."
1444703086,C,C,"Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine."
1444703230,A,A,Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444703230,A,C,Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype or may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1444703230,C,C,Patients with the CC genotype and Depressive Disorder may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.
1445624605,C,C,Patients with the CC genotype may have a decreased response to metformin as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to metformin.
1445624605,C,G,Patients with the CG genotype may have a decreased response to metformin as compared to patients with the GG genotype and an increased response to metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to metformin.
1445624605,G,G,Patients with the GG genotype may have a decreased response to metformin as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to metformin.
1184986623,G,G,"Patients with the rs2011425 GG genotype may have decreased serum concentrations of lamotrigine when treated with lamotrigine as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2011425 and lamotrigine and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of lamotrigine."
1184986623,G,T,"Patients with the rs2011425 GT genotype may have decreased serum concentrations of lamotrigine when treated with lamotrigine as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2011425 and lamotrigine and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of lamotrigine."
1184986623,T,T,"Patients with the rs2011425 TT genotype may have increased serum concentrations of lamotrigine when treated with lamotrigine as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2011425 and lamotrigine and does not include evidence about clinical outcomes. Other clinical and genetic factors may also influence metabolism of lamotrigine."
1184986643,A,A,Patients with the AA genotype may have increased metabolism of repaglinide as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of repaglinide.
1184986643,A,G,The AG genotype did not differ significantly in metabolism of repaglinide as compared to patients with the GG or AA genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.
1184986643,G,G,Patients with the GG genotype may have decreased metabolism of repaglinide as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of repaglinide.
1184988834,C,C,Patients with asthma and the CC genotype may have an increased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CG and GG genotypes. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.
1184988834,C,G,Patients with asthma and the CG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.
1184988834,G,G,Patients with asthma and the GG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.
1445594176,C,C,Pediatric patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
1445594176,C,T,"Pediatric patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the TT genotypes. However, they may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma."
1445594176,T,T,Pediatric patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.
1445594556,A,A,Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594556,A,G,Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445594556,G,G,Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445601678,C,C,Patients with the CC genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445601678,C,G,Patients with the CG genotype and essential hypertension may have a decreased response when treated with hypertension as compared to patients with the GG genotype and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1445601678,G,G,Patients with the GG genotype and and essential hypertension may have an increased response when treated with hypertension as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.
1449003811,C,C,Patients with the CC genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the C/del or del/del genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003817,C,C,Patients with the CC genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003817,C,T,Patients with the CT genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the TT genotype or an increased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003817,T,T,Patients with the TT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003823,A,A,There is currently no available evidence regarding the effect of the AA genotype on the risk of alcoholism in patients.
1449003823,A,G,Patients with the AG genotype may have an increased risk of alcoholism compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for alcoholism in patients.
1449003823,G,G,Patients with the GG genotype may have a decreased risk of alcoholism compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for alcoholism in patients.
1449003829,A,A,Patients with the AA genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.
1449003829,A,G,Patients with the AG genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.
1449003829,G,G,Patients with the GG genotype who are taking clopidogrel may have decreased resistance to clopidogrel as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.
1449003839,A,A,Patients with the AA genotype who are taking methadone may have an increased response as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence response to methadone treatment.
1449003839,A,G,Patients with the AG and GG genotypes who are taking methadone may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone treatment.
1449003839,G,G,Patients with the AG and GG genotypes who are taking methadone may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone treatment.
1449003845,A,A,Patients with the AA and AC genotypes who are taking methadone may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone treatment.
1449003845,A,C,Patients with the AA and AC genotypes who are taking methadone may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone treatment.
1449003845,C,C,Patients with the CC genotype who are taking methadone may have an increased response as compared to patients with the AA and AC genotypes. Other genetic and clinical factors may also influence response to methadone treatment.
1449003869,G,G,Patients with the GG genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003869,G,T,Patients with the GT genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the TT genotype or a decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003869,T,T,Patients with the TT genotype may have a decreased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the GT or GG genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.
1444703243,C,C,"Patients with the CC genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid."
1444703243,C,T,"Patients with the CT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype or may have decreased risk for non-response as compared to patients with the TT genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid."
1444703243,T,T,"Patients with the TT genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for non-response as compared to patients with the CC genotype. However, contradictory findings for no association of the variation with response exist. Other genetic and clinical factors may also influence a patient's response to carbamazepine, phenytoin or valproic acid."
1444703401,C,C,"Patients with the rs924607 CC genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine."
1444703401,C,T,"Patients with the rs924607 CT genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine."
1444703401,T,T,"Patients with the rs924607 TT genotype may have increased risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine."
1444666342,A,A,Patients with the AA genotype and prostate cancer may have increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of docetaxel.
1444666342,A,G,Patients with the AG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.
1444666342,G,G,Patients with the GG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.
1444666376,C,C,Patients with the CC genotype and hypertension may have a better response to treatment with benazepril or imidapril as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.
1444666376,C,T,Patients with the CT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.
1444666376,T,T,Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.
1444666557,A,A,"Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox."
1444666557,A,C,Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666557,C,C,Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666564,A,A,Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666564,A,C,Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666564,C,C,Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666571,C,C,Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666571,C,T,Patients with the CT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.
1444666571,T,T,"Patients with the TT genotype and beta-thalassemia may have decreased concentrations of deferasirox, possibly to levels below therapeutic efficacy, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox."
1444667537,A,A,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667537,A,G,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667537,G,G,Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667549,A,A,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667549,A,C,Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667549,C,C,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667566,C,C,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667566,C,T,Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667566,T,T,Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444702822,A,A,Patients with genotype AA may have decreased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to phenobarbital.
1444702822,A,G,Patients with genotype AG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital.
1444702822,G,G,Patients with genotype GG may have increased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to phenobarbital.
1444703408,C,C,Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703408,C,T,Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703408,T,T,Patients with the TT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703422,C,C,"Patients with the CC genotype and Hypertension who are treated with hydrochlorothiazide may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus."
1444703422,C,T,"Patients with the CT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype or may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus."
1444703422,T,T,Patients with the TT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.
1444703521,G,G,Patients with the GG genotype who are treated with aspirin may have increased risk for Peptic Ulcer Hemorrhage as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703521,G,T,"Patients with the GT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1444703521,T,T,"Patients with the TT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1444703529,C,C,"Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
1444703529,C,T,"Patients with the CT genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
1444703529,T,T,"Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
1444703537,C,C,"Patients with the CC genotype were not studied. However, patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol."
1444703537,C,T,Patients with the CT genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1444703537,T,T,Patients with the TT genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1444703544,A,A,Patients with the AA genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.
1444703544,A,G,"Patients with the AG genotype and Colorectal Neoplasms may have increased risk for Adenoma when treated with celecoxib as compared to patients with the GG genotype or may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
1444703544,G,G,"Patients with the GG genotype and Colorectal Neoplasms may have decreased, but not absent, risk for Adenoma when treated with celecoxib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib."
1444703552,A,A,"Patients with the AA genotype and kidney transplantation may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
1444703552,A,G,"Patients with the AG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype or may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil."
1444703552,G,G,Patients with the GG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.
1444703560,C,C,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1444703560,C,T,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype or may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1444703560,T,T,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748865,C,C,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748865,C,T,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748865,T,T,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748874,A,A,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748874,A,G,Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748874,G,G,Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748879,A,A,Patients with the AA genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748879,A,G,Patients with the AG genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748879,G,G,Patients with the GG genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748884,C,C,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to discontinue treatment due to toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748884,C,T,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748884,T,T,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to discontinue treatment due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of methotrexate-induced toxicity.
1184748889,C,C,Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748889,C,T,Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1184748889,T,T,Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may be less likely to respond to treatment as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.
1444608396,C,C,"Patients with the CC genotype and gastric cancer may have a poorer response when treated with fluorouracil, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fluorouracil."
1444608396,C,T,"Patients with the CT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil."
1444608396,T,T,"Patients with the TT genotype and gastric cancer may have a better response when treated with fluorouracil, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fluorouracil."
1444667175,C,C,Patients with the CC genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.
1444667175,C,T,Patients with the CT genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.
1444667175,T,T,Patients with the TT genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.
1444667499,C,C,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667499,C,G,Patients with asthma and the CG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667499,G,G,Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667512,A,A,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667512,A,C,Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667512,C,C,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444700536,C,C,Patients with the CC genotype and hypertension may have more blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.
1444700536,C,G,Patients with the CG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.
1444700536,G,G,Patients with the GG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.
1446896596,A,A,Patients with the AA genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.
1446896596,A,G,Patients with the AG genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.
1446896596,G,G,Patients with the GG genotype may have decreased concentrations of erlotinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.
1444700391,A,A,Patients with the AA genotype and tobacco use disorder may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700391,A,G,Patients with the AG genotype and tobacco use disorder may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444700391,G,G,Patients with the GG genotype and tobacco use disorder may have a decreased risk for nicotine dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444608384,A,A,"Patients with the rs396991 AA genotype may have a decreased response to rituximab, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to rituximab."
1444608384,A,C,"Patients with the rs396991 AC genotype may have a decreased response to rituximab, as compared to patients with the CC genotype but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab."
1444608384,C,C,"Patients with the rs396991 CC genotype may have an increased response to rituximab, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence response to rituximab."
1444700667,A,A,"Patients with the AA genotype and anxiety disorder who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram."
1444700667,A,C,Patients with the AC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.
1444700667,C,C,Patients with the CC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.
1444700675,C,C,"Patients with the CC genotype who are treated with escitalopram may have decreased, but not absent, risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram."
1444700675,C,T,"Patients with the CT genotype who are treated with escitalopram may have increased risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram."
1444700675,T,T,"Patients with the TT genotype who are treated with escitalopram may have increased risk of adverse cognitive effects and sexual dysfunctions as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also effect patients' response to escitalopram."
1184764194,A,A,Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764194,A,C,"Patients with genotype AC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1184764194,C,C,"Patients with genotype CC may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1184764199,A,A,"Patients with genotype AA may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1184764199,A,G,"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1184764199,G,G,Patients with genotype GG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764204,C,C,Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764204,C,T,"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1184764204,T,T,"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1444700660,A,A,"Patients with the AA genotype who are treated with gemcitabine may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia."
1444700660,A,C,"Patients with the AC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia."
1444700660,C,C,Patients with the CC genotype who are treated with gemcitabine may have an increased risk for neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for neutropenia.
1444703063,A,A,Patients with the AA genotype were not studied. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1444703063,A,G,Patients with the AG genotype and depression who are treated with venlafaxine may have an increased risk for agitation and dysphoria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.
1444703063,G,G,"Patients with the GG genotype and depression who are treated with venlafaxine may have a decreased, but not absent, risk for agitation and dysphoria as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects."
1444703115,A,A,Patients with the AA genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1444703115,A,G,Patients with the AG genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1444703115,G,G,Patients with the GG genotype who are treated with rosuvastatin may have increased LDL-C reduction as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.
1444703207,C,C,Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1444703207,C,T,Patients with the CT genotype may require an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1444703207,T,T,Patients with the TT genotype may require a decreased dose of warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1444703215,A,A,"Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
1444703215,A,C,"Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine."
1444703215,C,C,Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.
1444704321,G,G,"Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GT or TT genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors."
1444704321,G,T,"Patients with the GT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors."
1444704321,T,T,"Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors (including infliximab and rituximab) as compared to patients with the GG genotype. However, a study only investigating the response to rituximab found no association for G vs T allele. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors."
1444704328,C,C,Patients with the CC genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704328,C,T,Patients with the CT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704328,T,T,Patients with the TT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704335,A,A,Patients with the AA genotype and Rheumatoid Arthritis may have decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704335,A,G,Patients with the AG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704335,G,G,Patients with the GG genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.
1444704763,A,A,Patients with the AA genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response citalopram.
1444704763,A,G,"Patients with the AG genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype or may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram."
1444704763,G,G,"Patients with the GG genotype and major depression may have decreased, but not absent, risk for suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response citalopram."
1444704775,C,C,Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704775,C,T,Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype or may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704775,T,T,Patients with the TT genotype may have with decreased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704861,C,C,"Patients with the CC genotype may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol."
1444704861,C,G,"Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype or may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol."
1444704861,G,G,"Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol."
1444704869,C,C,Male patients with the CC genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704869,C,T,Male patients with the CT genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype or may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704869,T,T,Male patients with the TT genotype may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.
1444704881,A,A,"Patients with the AA genotype and Kidney Transplantation may have decreased, but not absent, risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone."
1444704881,A,G,Patients with the AG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.
1444704881,G,G,Patients with the GG genotype and Kidney Transplantation may have increased risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.
1450826374,A,A,Subjects with the AA genotype may have decreased clearance of lorazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the metabolism of lorazepam.
1450826374,A,C,"Subjects with the AC genotype may have decreased clearance of lorazepam as compared to subjects with the CC genotype, or increased clearance as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of lorazepam."
1450826374,C,C,Subjects with the CC genotype may have increased clearance of lorazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the metabolism of lorazepam.
1444703223,A,A,Patients with the AA genotype and Rheumatoid Arthritis may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703223,A,G,Patients with the AG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype or may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703223,G,G,Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1446899836,C,C,"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899836,C,T,"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899836,T,T,"Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1444607318,A,A,"Patients with the AA genotype may have increased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the GG genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone."
1444607318,A,G,No information available.
1444607318,G,G,"Patients with the GG genotype may have decreased levels of the active metabolite of risperidone, 9-hydroxy-risperidone, as compared to those with the AA genotype. This variant does not appear to affect levels of risperidone. Other genetic and clinical factors may also influence levels of 9-hydroxy-risperidone."
1444607325,C,C,No patients with the CC genotype available for analysis.
1444607325,C,T,Patients with the CT genotype and age-related macular degeneration may require a greater number of bevacizumab injections as compared to those with the TT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.
1444607325,T,T,Patients with the TT genotype and age-related macular degeneration may require a fewer number of bevacizumab injections as compared to those with the CT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.
1444607459,A,A,Individuals with the AA genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
1444607459,A,G,Individuals with the AG genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
1444607459,G,G,Individuals with the GG genotype may have decreased area under the curve (AUC) of olanzapine as compared to individuals with the AA or AG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.
1444607796,C,C,"Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to atomoxetine."
1444607796,C,T,Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine as compared to patients with the TT genotype or a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.
1444607796,T,T,"Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a poorer response to treatment with atomoxetine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine."
1444607803,A,A,Patients with the AA genotype and Psychotic Disorders who are treated with olanzapine may have increased social and clinical needs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.
1444607803,A,G,Patients with the AG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.
1444607803,G,G,Patients with the GG genotype and Psychotic Disorders who are treated with olanzapine may have decreased social and clinical needs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.
1444607827,C,C,"Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin."
1444607827,C,T,"Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin."
1444607827,T,T,"Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence patient's response to metformin."
1444608027,C,C,Patients with the CC genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.
1444608027,C,T,Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.
1444608027,T,T,Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to citalopram.
1444608182,C,C,"Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608182,C,T,"Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608182,T,T,"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608189,C,C,"Patients with the CC genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608189,C,T,"Patients with the CT genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or a decreased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608189,T,T,"Patients with the TT genotype and cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608201,C,C,"Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608201,C,T,"Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608201,T,T,"Patients with the TT genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608224,A,A,"Patients with the AA genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608224,A,G,"Patients with the AG genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype, or a decreased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608224,G,G,"Patients with the GG genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608231,A,A,"Individuals with the AA genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine."
1444608231,A,G,"Individuals with the AG genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine."
1444608231,G,G,"Individuals with the GG genotype who are addicted to methamphetamine may be more likely to experience psychosis when taking methamphetamine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine."
1444608284,A,A,"Patients with the AA genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
1444608284,A,G,"Patients with the AG genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
1444608284,G,G,"Patients with the GG genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
1444608291,C,C,"Patients with the CC genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
1444608291,C,T,"Patients with the CT genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
1444608291,T,T,"Patients with the TT genotype and asthma may have a poorer response to treatment with fluticasone propionate or montelukast, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast."
1444667222,A,A,Patients with metastasized cancer and the AA genotype may have improved response to capecitabine or fluorouracil as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.
1444667222,A,G,Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.
1444667222,G,G,Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.
1444667432,A,A,Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667432,A,G,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667432,G,G,Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667585,C,C,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667585,C,T,Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667585,T,T,Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667592,A,A,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667592,A,G,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444667592,G,G,Patients with asthma and the GG genotype may have a increased risk of aspirin induced asthma as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.
1444702771,C,C,Patients with the CC genotype who are opioid-dependent may have a better response when treated with methadone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to methadone.
1444702771,C,T,Patients with the CT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.
1444702771,T,T,Patients with the TT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.
1444843493,A,A,Patients with genotype AA may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
1444843493,A,C,Patients with genotype AC may have lower rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
1444843493,C,C,Patients with genotype CC may have higher rate of sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.
1446899176,A,A,Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.
1446899176,A,G,Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical and genetic factors may also influence dose of warfarin.
1446899176,G,G,Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AA and GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.
1446899708,A,A,Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1446899708,A,C,Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1446899708,C,C,Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.
1446899722,A,A,"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899722,A,T,"Patients with the AT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899722,T,T,"Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AT and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899729,A,A,"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and GG genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899729,A,G,"Patients with the AG genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the GG genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899729,G,G,"Patients with the GG genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899736,C,C,"Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899736,C,T,"Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899736,T,T,"Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899843,C,C,"Women with ovarian cancer and the CC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899843,C,T,"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899843,T,T,"Women with ovarian cancer and the TT genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899860,C,C,"Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CT or TT genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899860,C,T,"Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899860,T,T,"Women with ovarian cancer and the TT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899866,C,C,"Women with ovarian cancer and the CC genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes."
1446899866,C,T,"Women with ovarian cancer and the CT genotype may have an improved response, such as longer survival times, when treated with carboplatin and taxanes as compared to women with the TT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes."
1446899866,T,T,"Women with ovarian cancer and the TT genotype may have a worse response, such as shorter survival times, when treated with carboplatin and taxanes as compared to women with the CC or CT genotype. Other clinical and genetic factors may also influence survival time in women with ovarian cancer who are administered carboplatin and taxanes."
1446899883,A,A,"Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899883,A,G,"Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899883,G,G,"Women with ovarian cancer and the GG genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AG genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899890,A,A,"Women with ovarian cancer and the AA genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899890,A,C,"Women with ovarian cancer and the AC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899890,C,C,"Women with ovarian cancer and the CC genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA or AC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899905,A,A,"Women with ovarian cancer and the AA genotype may have an increased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899905,A,G,"Women with ovarian cancer and the AG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446899905,G,G,"Women with ovarian cancer and the GG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes."
1446903240,A,A,Patients with the AA genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.
1446903240,A,G,"Patients with the AG genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype, or a decreased risk as compare to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib."
1446903240,G,G,Patients with the GG genotype and cancer may have a decreased risk for hypertension when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.
1446903310,C,C,Patients with the CC genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.
1446903310,C,T,Patients with the CT genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.
1446903310,T,T,Patients with the TT genotype and colon cancer may have a shorter time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to fluorouracil.
1185000522,A,A,"Patients with the AA genotype and HIV may have decreased concentrations of atazanavir as compared to patients with the GG genotypes, and may require dose alteration, although this is contradicted in most studies. There is no evidence that the AA genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV."
1185000522,A,G,"Patients with the AG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the AG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV."
1185000522,G,G,"Patients with the GG genotype and HIV may have increased concentrations of atazanavir as compared to patients with the AA genotypes, although this is contradicted in most studies. There is no evidence that the GG genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV."
1444607789,A,A,Patients with the AA genotype and Mental Disorders who are treated with paroxetine may have an increased risk of nausea as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444607789,A,C,Patients with the AC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444607789,C,C,Patients with the CC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.
1444608040,C,C,Patients with the CC genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.
1444608040,C,T,"Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype, or a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram."
1444608040,T,T,Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.
1446899715,A,A,"Patients with the AA genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899715,A,C,"Patients with the AC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC genotype and less likely than patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899715,C,C,"Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446898992,A,A,"Patients with the rs489693 AA genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain."
1446898992,A,C,"Patients with the rs489693 AC genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain."
1446898992,C,C,"Patients with the rs489693 CC genotype may have decreased but not absent likelihood of weight gain when treated with antipsychotics as compared to patients with the AA or AC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain."
1451760600,C,C,"Patients with the rs6311 CC genotype may have a decreased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs."
1451760600,C,T,"Patients with the rs6311 CT genotype may have an increased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CC or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs."
1451760600,T,T,"Patients with the rs6311 TT genotype may have a decreased risk of experiencing adverse events when treated with selective serotonin reuptake inhibitors (SSRIs) as compared to patients with the CT genotype but an increased risk as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing adverse events when treated with SSRIs."
1184987378,C,C,Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987378,C,T,Patients with the CT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987378,T,T,Patients with the TT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987397,C,C,Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987397,C,T,Patients with the CT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CC genotype and a decreased risk of bone fractures as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987397,T,T,Patients with the TT genotype and ER and/or PR positive breast cancer may have an increased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.
1184987471,C,C,"Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987471,C,T,"Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987471,T,T,"Patients with the TT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987488,C,C,"Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987488,C,T,"Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987488,T,T,"Patients with the TT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987503,A,A,"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987503,A,G,"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987503,G,G,"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1185002351,A,A,Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002351,A,G,Patients with the AG genotype may require increased dose of acenocoumarol as compared to patients with the GG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002351,G,G,Patients with the GG genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002357,A,A,Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002357,A,C,Patients with the AC genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002357,C,C,Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002363,C,C,Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the TT or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002363,C,T,Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002363,T,T,Patients with the TT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002369,C,C,Patients with the CC genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002369,C,T,Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1185002369,T,T,Patients with the TT genotype may require decreased dose of acenocoumarol as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.
1184764228,C,C,Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764228,C,T,"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1184764228,T,T,"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1185000534,C,C,"Patients with the CC genotype and HIV may have increased exposure to atazanavir as compared to patients with the CT and TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV."
1185000534,C,T,"Patients with the CT genotype and HIV may have increased exposure to atazanavir as compared to patients with the TT genotype, although this is contradicted in some studies. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV."
1185000534,T,T,"Patients with the TT genotype and HIV may have decreased exposure to atazanavir as compared to patients with the CT and TT genotypes, although this is contradicted in some studies. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV."
1184764213,A,A,Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.
1184764213,A,G,"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1184764213,G,G,"Patients with genotype GG may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions."
1444666674,A,A,Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666674,A,G,Patients with the AG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666674,G,G,Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666681,G,G,Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666681,G,T,Patients with the GT genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666681,T,T,Patients with the TT genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666688,C,C,Patients with the CC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666688,C,G,Patients with the CG genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666688,G,G,Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666695,A,A,Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666695,A,C,Patients with the AC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666695,C,C,Patients with the CC genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.
1444666886,A,A,Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666886,A,G,Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444666886,G,G,Patients with the GG genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1444694602,A,A,"Patients with the AA genotype and ulcerative colitis may have a better chance at achieving remission when treated with tacrolimus as compared to patients with the AG or GG genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission."
1444694602,A,G,"Patients with the AG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission."
1444694602,G,G,"Patients with the GG genotype and ulcerative colitis may have a poorer chance at achieving remission when treated with tacrolimus as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission."
1444694616,A,A,Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.
1444694616,A,G,Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk of hypokalemia when treated with tacrolimus as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.
1444694616,G,G,Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.
1444703076,A,A,Patients with the AA genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.
1444703076,A,G,Patients with the AG genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.
1444703076,G,G,Patients with the GG genotype who are treated with etravirine may have an increased etravirine clearance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.
1444704105,A,A,Patients with the AA genotype and Kidney Transplantation may have decreased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.
1444704105,A,C,Patients with the AC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.
1444704105,C,C,Patients with the CC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.
1444704118,C,C,Patients with the CC genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444704118,C,G,Patients with the CG genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype or may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444704118,G,G,Patients with the GG genotype who are treated with hmg coa reductase inhibitors may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.
1444933020,G,G,Patients under general anaesthesia with genotypes GG may need increased dose of propofol as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence the dose of propofol.
1444933020,G,T,Patients under general anaesthesia with genotypes GT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol.
1444933020,T,T,Patients under general anaesthesia with genotypes TT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol.
1445400703,A,A,Patients with the AA genotype may have a better response to the pertussis vaccine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1445400703,A,G,Patients with the AG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1445400703,G,G,Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1445402201,C,C,Patients with the CC genotype and psychotic illnesses may be at a lower risk for haloperidol-induced toxicities as compared to patients with the CT genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.
1445402201,C,T,Patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.
1445402201,T,T,"No patients with the TT genotype were present, but patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities."
1444694609,A,A,"Patients with the AA genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection."
1444694609,A,G,"Patients with the AG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have an increased risk of experiencing transplant rejection as compared to patients with the AA or GG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection."
1444694609,G,G,"Patients with the GG genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection."
1444704097,A,A,Patients with the AA genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1444704097,A,G,Patients with the AG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1444704097,G,G,Patients with the GG genotype may have increased reduction in total cholesterol or LDL cholesterol levels when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.
1185235008,A,A,Patients with the AA genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. Evidence is conflicting as to this association.
1185235008,A,G,Patients with the AG genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype or may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1185235008,G,G,Patients with the GG genotype and HIV who are treated with efavirenz may have increased efavirenz plasma concentrations as compared to patients with the AA genotype. Evidence is conflicting as to this association. Other genetic and clinical factors may also influence a patient's metabolism of efavirenz.
1444608132,C,C,"Patients with the CC genotype and choroidal neovascularization may have a poorer response to anti-VEGF treatment, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment."
1444608132,C,G,"Patients with the CG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment."
1444608132,G,G,"Patients with the GG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment."
1444608175,A,A,"Patients with the AA genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608175,A,G,"Patients with the AG genotype and colorectal cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the GG genotype, or a decreased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444608175,G,G,"Patients with the GG genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine."
1444666855,A,A,Patients with the AA genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.
1444666855,A,G,Patients with the AG genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.
1444666855,G,G,Patients with the GG genotype and schizophrenia may have a shorter QTc interval when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.
1444667305,G,G,"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667305,G,T,"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667305,T,T,"Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667322,G,G,"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667322,G,T,"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667322,T,T,"Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444702664,A,A,"Patients with the AA genotype may have increased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to anti-TNF treatments."
1444702664,A,G,"Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments."
1444702664,G,G,"Patients with the GG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments."
1445401406,A,A,"Patients with the AA genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities."
1445401406,A,G,"Patients with the AG genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities."
1445401406,G,G,"Patients with the GG genotype and renal cell carcinoma may have an increased risk for adverse effects when treated with sunitinib as compared to patients with the AA or AG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities."
1445402226,C,C,"Patients with the CC genotype and cancer may have longer survival times when treated with cisplatin as compared to patients with the CT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time."
1445402226,C,T,"Patients with the CT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time."
1445402226,T,T,"Patients with the TT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time."
1446897342,C,C,Patients with the CC genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.
1446897342,C,T,Patients with the CT genotype and post-operative pain may require a decreased dose of fentanyl as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.
1446897342,T,T,Patients with the TT genotype and post-operative pain may require an increased dose of fentanyl as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence dose of fentanyl in people with post-operative pain.
1446897485,A,C,"Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer."
1446897485,C,C,"Patients with colorectal cancer and the CC genotype may have an improved response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the AC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer."
1446899695,A,A,Patients with the AA genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AC and CC genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.
1446899695,A,G,Patients with the AG genotype may have a greater likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the CC genotype and a lower likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.
1446899695,C,C,Patients with the CC genotype may have a lower likelihood of experiencing an increase in serum creatine kinase when exposed to vancomycin as compared with patients with the AA genotypes. Other clinical and genetic factors may also affect serum creatine kinase in patients taking vancomycin.
1446903540,C,C,"In pediatric patients with asthma and the CC genotype may have an increased response to beta-adrenergic inhalants as compared to patients with the CT and TT genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma."
1446903540,C,T,"In pediatric patients with asthma and the CT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CC genotypes and an increased response to beta-adrenergic inhalants as compared to patients with the TT genotype. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma."
1446903540,T,T,"In pediatric patients with asthma and the TT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CT and CC genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma."
1446903556,C,C,"Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke with the TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
1446903556,C,T,"Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke with the TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
1446903556,T,T,"Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke with the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
1446903563,A,A,"Individuals who smoke and have the AA genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the AG or GG genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
1446903563,A,G,"Individuals who smoke and have the AG genotype may have decreased rates of nicotine clearance, and as a consequence may smoke less when compared to individuals who smoke and have the GG genotypes, and increased rates of metabolism as compared to patients with the AA genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
1446903563,G,G,"Individuals who smoke and have the GG genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the AG or AA genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
1446903570,C,C,"Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the CT or TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
1446903570,C,T,"Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke and have the TT genotypes, and decreased rates of metabolism as compared to patients with the CC genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
1446903570,T,T,"Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers."
1446903577,A,A,Patients with diabetes mellitus and the AA genotype may have a decreased response to metformin as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.
1446903577,A,C,Patients with diabetes mellitus and the AC genotype may have a decreased response to metformin as compared to patients with the CC genotypes and an increased response as compared to patients with the AA genotype. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.
1446903577,C,C,Patients with diabetes mellitus and the CC genotype may have an increased response to metformin as compared to patients with the AA and AC genotypes. Other clinical and genetic factors may also have an influence on response to metformin in patients with diabetes mellitus.
1446904604,C,C,"Patients with ovarian cancer and the CC genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. In a single study, the authors compared outcomes between genotypes between treatments. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes."
1446904604,C,G,"Patients with ovarian cancer and the CG genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes."
1446904604,G,G,"Patients with ovarian cancer and the GG genotype may have a decreased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the CC or CG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes."
1446908543,A,A,Patients with the AA genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.
1446908543,A,G,Patients with the AG genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.
1446908543,G,G,Patients with the GG genotype and Tobacco Use Disorder who are treated with varenicline may have a decreased response to varenicline as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.
1446908568,A,A,Patients with the AA genotype and pain who are receiving Opium alkaloids and derivatives may have an increased severity of Substance-Related Disorders as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.
1446908568,A,G,Patients with the AG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.
1446908568,G,G,Patients with the GG genotype and pain who are receiving Opium alkaloids and derivatives may have a decreased severity of Substance-Related Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Substance-Related Disorders.
1445401915,A,A,"Patients with the AA genotype and epilepsy may need a decreased dose carbamazepine as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence dose requirements and concentrations of carbamazepine."
1445401915,A,G,"Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine and may need an increased dose as compared to patients with the AA or GG genotypes. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine."
1445401915,G,G,"Patients with the GG genotype and epilepsy may have decreased metabolism of carbamazepine and may need a decreased dose as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence concentrations of carbamazepine."
1446904693,G,G,Patients with major thalassemia and the GG genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of adverse reactions.
1446904693,G,T,Patients with major thalassemia and the GT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of adverse reactions.
1446904693,T,T,Patients with major thalassemia and the TT genotype may have a decreased risk of adverse reactions when administered deferasirox as compared to patients with the GT or GG genotype. Other clinical and genetic factors may also influence risk of adverse reactions.
1446903527,A,A,"Patients with brain tumors, osteosarcoma, and other cancers and the AA genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence risk of ototoxicity in patients exposed to cisplatin."
1446903527,A,G,"Patients with brain tumors, osteosarcoma, and other cancers and the AG genotype may have an increased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the GG genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence risk of ototoxicity in pediatric patients exposed to cisplatin."
1446903527,G,G,"Patients with brain tumors, osteosarcoma, and other cancers and the GG genotype may have a decreased risk of ototoxicity when treated with regimens containing cisplatin as compared to patients with the AA or AG genotypes. However, one study failed to find an association. Other clinical and genetic factors may also influence risk of ototoxicityin patients exposed to cisplatin."
1184749208,A,A,Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.
1184749208,A,G,Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.
1184749208,G,G,Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased likelihood of event-free survival as compared to patients with the AA genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.
1184987055,A,A,Patients with genotype AA and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987055,A,C,Patients with genotype AC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987055,C,C,Patients with genotype CC and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987062,A,A,Patients with genotype AA and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987062,A,G,Patients with genotype AG and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the GG genotype and an greater reduction in HDL-C as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987062,G,G,Patients with genotype GG and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.
1184987556,A,A,"Patients with the AA genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987556,A,G,"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987556,G,G,"Patients with the GG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987573,A,A,"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987573,A,G,"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184987573,G,G,"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics."
1184989651,A,A,"Patients with the AA genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have a reduced, but not absent, risk of pancreatitis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis."
1184989651,A,C,Patients with the AC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.
1184989651,C,C,Patients with the CC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.
1446897495,C,C,"Patients with colorectal or breast cancer and the CC genotype may have an improved response to bevacizumab-based treatment regimens as compared to patients with the TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer."
1446897495,C,T,"Patients with colorectal or breast cancer and the CT genotype may have an improved response to bevacizumab-based treatment regimens as compared to patients with the TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer."
1446897495,T,T,"Patients with colorectal or breast cancer and the TT genotype may have a worse response to bevacizumab-based treatment regimens as compared to patients with the CC and CT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer."
1446908580,C,C,"Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea."
1446908580,C,T,"Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea."
1446908580,T,T,"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea."
1446908587,A,A,"Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
1446908587,A,G,"Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
1446908587,G,G,"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
1446908594,C,C,"Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
1446908594,C,T,"Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
1446908594,T,T,"Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for Neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia."
1446908603,C,C,Patients with the CC genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.
1446908603,C,T,Patients with the CT genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.
1446908603,T,T,No information were reported regarding patients with the TT genotype.
1446908615,C,C,"Patients with the CC genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CC genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease."
1446908615,C,T,"Patients with the CT genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease."
1446908615,T,T,No information were reported regarding patients with the TT genotype.
1446908622,A,A,"Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea."
1446908622,A,G,"Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea."
1446908622,G,G,"Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea."
1446908672,A,A,"Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria."
1446908672,A,G,"Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria."
1446908672,G,G,"Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria."
1446908679,C,C,"Patients with the CC genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema."
1446908679,C,T,"Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema."
1446908679,T,T,"Patients with the TT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria and Angioedema as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema."
1446908686,A,A,"Patients with the AA genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of Angioedema as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema."
1446908686,A,G,"Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema."
1446908686,G,G,"Patients with the GG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of Angioedema as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for Angioedema."
1451506746,C,C,Patients with the rs139945292 CC genotype may have decreased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.
1451506746,C,T,Patients with the rs139945292 CT genotype may have increased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.
1451506746,T,T,Patients with the rs139945292 TT genotype may have increased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.
1444668292,C,C,"In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668292,C,T,"Patients with the CT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the CC genotype and a lower secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668292,T,T,"Patients with the TT genotype and diabetes mellitus may have a higher secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668298,A,A,"In healthy volunteers the AA genotype may be associated with increased secretory clearance of metformin and in patients with diabetes mellitus may result in decreased efficacy (increased HbA1c levels), as compared to patients with the AG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668298,A,G,"In healthy volunteers the AG genotype may be associated with decreased secretory clearance of metformin and in patients with diabetes mellitus may result in an increase in efficacy (decreased HbA1c levels) as compared to patients with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668298,G,G,"In healthy volunteers the GG genotype may be associated with decreased secretory clearance of metformin, and in patients with diabetes mellitus may result in an increase efficacy (decreased HbA1c levels) as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668306,C,C,"In healthy volunteers as well as patients with diabetes mellitus the CC genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, which is indicative of decreased metformin efficacy, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668306,C,T,"In healthy volunteers as well as patients with diabetes mellitus the CT genotype may be associated with an increased secretory clearance of metformin, leading to reduced exposure and a corresponding increase in HbA1c levels, indicative of a decreased metformin efficacy, as compared to patients with the TT genotype and a decreased secretory clearance of metformin and a corresponding decrease in HbA1c levels as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444668306,T,T,"In healthy volunteers as well as patients with diabetes mellitus the TT genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus."
1444673002,C,C,Patients with the CC genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype. Other genetic and clinical factors may also influence response to loop diuretics.
1444673002,C,G,"Patients with the CG genotype may have a better response to treatment with loop diuretics as compared to those with the GG genotype, or a poorer response to treatment as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics."
1444673002,G,G,Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.
1444673123,A,A,Patients with the AA genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.
1444673123,A,G,Patients with the AG genotype and schizophrenia may have an increased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.
1444673123,G,G,Patients with the GG genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.
1184987911,A,A,Patients with the AA genotype may have a decreased metabolism of itopride as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of itopride.
1184987911,A,G,The AG genotype has not been evaluated.
1184987911,G,G,Patients with the GG genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.
1184987918,A,A,Patients with the AA genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.
1184987918,A,G,The AG genotype has not been evaluated.
1184987918,G,G,Patients with the GG genotype may have a decreased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.
1444667292,C,C,"Patients with metastasized cancer and the CC genotype may have improved response to capecitabine or fluorouracil as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667292,C,T,"Patients with metastasized cancer and the CT genotype may have improved response to capecitabine or fluorouracil as compared to people with the TT genotype and worse response as compared to people with the CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444667292,T,T,"Patients with metastasized cancer and the TT genotype may have worse response to capecitabine or fluorouracil as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."
1444673130,C,C,Patients with the CC genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.
1444673130,C,T,Patients with the CT genotype and HIV may have an increased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for virological failure.
1444673130,T,T,Patients with the TT genotype and HIV may have a decreased risk for virological failure when treated with highly active antiretroviral therapy (HAART) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for virological failure.
1444673197,A,A,Patients with the AA genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444673197,A,G,Patients with the AG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444673197,G,G,Patients with the GG genotype and breast cancer may have a shorter progression-free survival time when treated with docetaxel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1444673209,A,A,"Patients with the AA genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel."
1444673209,A,G,"Patients with the AG genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel."
1444673209,G,G,"Patients with the GG genotype and breast cancer may have a poorer response to docetaxel treatment as compared to patients with the AA or AG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel."
1444680145,C,C,"Patients with the CC genotype (CYP2C19 *1/*1) undergoing transplantation may have decreased metabolism of busulfan as compared to patients with the CT (*1/*17) or TT (*17/*17) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan."
1444680145,C,T,"Patients with the CT (CYP2C19 *1/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan."
1444680145,T,T,"Patients with the TT (CYP2C19 *17/*17) genotype undergoing transplantation may have increased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. However, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence metabolism of busulfan."
1444700452,A,A,Patients with the AA genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700452,A,G,Patients with the AG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700452,G,G,Patients with the GG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700466,C,C,Patients with the CC genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700466,C,G,Patients with the CG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700466,G,G,Patients with the GG genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444700550,C,C,Patients with the CC genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.
1444700550,C,T,Patients with the CT genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.
1444700550,T,T,Patients with the TT genotype who are treated with phenprocoumon may require a decreased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.
1444700558,C,C,Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence phenprocoumon dose.
1444700558,C,T,Patients with the CT genotype may require a lower dose of phenprocoumon as compared to patients with the CC genotype and may require an increased dose of phenprocoumon as compared to patients with the TT. Other genetic and clinical factors may also influence phenprocoumon dose.
1444700558,T,T,Patients with the TT genotype may require the lowest dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.
1444700566,C,C,Patients with the CC genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444700566,C,T,Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444700566,T,T,Patients with the TT genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444700574,C,C,Patients with the CC genotype may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444700574,C,T,Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444700574,T,T,Patients with the TT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.
1444700581,A,A,Patients with the AA genotype and solid tumors may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.
1444700581,G,A,Patients with the AG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype or may have an increased clearance of XK469 as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.
1444700581,G,G,Patients with the GG genotype and solid tumors may have a decreased clearance of XK469 as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' clearance of XK469.
1444700903,A,A,"Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs."
1444700903,A,T,"Patients with the AT genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs."
1444700903,T,T,"Patients with the TT genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) as compared to patients with genotype AA or AT. Other genetic or clinical factors may also influence the risk of toxicity to NSAIDs."
1444700916,C,C,Patients with the CC genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.
1444700916,C,T,Patients with the CT genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.
1444700916,T,T,Patients with the TT genotype may have increased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.
1444700950,G,G,Patients with the GG genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700950,G,T,Patients with the GT genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700950,T,T,Patients with the TT genotype may have decreased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700958,A,A,Patients with the AA genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.
1444700958,A,G,Patients with the AG genotype may have increased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.
1444700958,G,G,Patients with the GG genotype may have decreased risk of sensory peripheral neuropathy when treated with paclitaxel in women with breast cancer as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence the risk of toxicity to paclitaxel.
1444700970,A,A,Patients with the AA genotype may have increased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype TT or AT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700970,A,T,Patients with the AT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700970,T,T,Patients with the TT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.
1444700983,G,G,"Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients."
1444700983,G,T,"Patients with the GT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG. Other genetic or clinical factors may also influence the outcome of heart failure patients."
1444700983,T,T,"Patients with the TT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients."
1444700991,A,A,"Patients with the AA genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs."
1444700991,A,G,"Patients with the AG genotype may have increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs."
1444700991,G,G,"Patients with the GG genotype may have decreased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the risk of toxicity to antituberculosis drugs."
1444672993,A,A,"Patients with the AA genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus."
1444672993,A,G,"Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus."
1444672993,G,G,"Patients with the GG genotype who are undergoing organ transplantation may have decreased concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus."
1451506740,C,C,Patients with the rs139945292 CC genotype may have increased blood pressure reduction after treatment with beta blocking agents as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.
1451506740,C,T,Patients with the rs139945292 CT genotype may have decreased blood pressure reduction after treatment with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.
1451506740,T,T,Patients with the rs139945292 TT genotype may have decreased blood pressure reduction after treatment with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.
1444668477,C,C,Individuals with the CC genotype may have a decreased response to insulin supplemented with zinc acetate as compared to individuals with the CT and TT genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.
1444668477,C,T,Individuals with the CT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.
1444668477,T,T,Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.
1444673032,C,C,"Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
1444673032,C,T,"Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
1444673032,T,T,"Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
1444673039,C,C,"Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
1444673039,C,T,"Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
1444673039,T,T,"Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions."
1444673046,C,C,"Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone."
1444673046,C,T,"Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone."
1444673046,T,T,"Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone."
1444673053,C,C,Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444673053,C,T,Patients with the CT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444673053,T,T,Patients with the TT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444673060,A,A,Patients with the AA genotype and rheumatoid arthritis may have a poorer response when treated with rituximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to rituximab.
1444673060,A,G,Patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.
1444673060,G,G,"No patients with the GG genotype were present in the population. However, patients with the AG genotype and rheumatoid arthritis may have a better response when treated with rituximab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab."
1444700775,A,A,"Patients with the AA genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
1444700775,A,G,"Patients with the AG genotype and hypertension who are treated with verapamil may have decreased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the GG genotype or may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
1444700775,G,G,"Patients with the GG genotype and hypertension who are treated with verapamil may have increased risk for primary outcome as defined by first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to verapamil."
1185003571,A,A,Patients with the AA genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence the response to trastuzumab.
1185003571,A,G,Patients with the AG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.
1185003571,G,G,Patients with the GG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.
1184749271,A,A,"Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity."
1184749271,A,G,"Patients with the AG genotype and acute lymphoblastic leukemia who are treated with vincristine may have a reduced, but not absent, risk of grade 1-2 neurotoxicity as compared to patients with the GG genotype or may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity."
1184749271,G,G,Patients with the GG genotype and acute lymphoblastic leukemia who are treated with vincristine may have an increased risk of grade 1-2 neurotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced neurotoxicity.
1185002307,A,A,Patients with the AA genotype may require increased dose of warfarin as compared to patients with the GG or AG genotype. Other clinical or genetic factors may also influence warfarin dose
1185002307,A,G,Patients with the AG genotype may require increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose
1185002307,G,G,Patients with the GG genotype may require decreased dose of warfarin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence warfarin dose
1444700860,A,A,"Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin."
1444700860,A,G,"Patients with the AG genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype or may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin."
1444700860,G,G,"Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin."
1444702764,C,C,Patients with the CC genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.
1444702764,C,T,Patients with the CT genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.
1444702764,T,T,Patients with the TT genotype and ankylosing spondylitis may have a better response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors.
1444876859,C,C,Patients with the CC genotype may have increased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.
1444876859,C,T,Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.
1444876859,T,T,Patients with the TT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.
1445401325,C,C,Patients with the CC genotype and Crohn's disease may have a poorer response to treatment with adalimumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to adalimumab.
1445401325,C,T,Patients with the CT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.
1445401325,T,T,Patients with the TT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.
1445401377,A,A,"Women with the AA genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine."
1445401377,A,G,"Women with the AG genotype who are undergoing cesarean delivery may require an increased dose of phenylephrine as compared to women with the GG genotype, or a lower dose as compared to women with the AA genotype. Other genetic and clinical factors may also influence dose of phenylephrine."
1445401377,G,G,"Women with the GG genotype who are undergoing cesarean delivery may require a lower dose of phenylephrine as compared to women with the AA genotype. However, the opposite was reported patients receiving elective neurosurgery. Other genetic and clinical factors may also influence dose of phenylephrine."
1445401389,A,A,Patients with the AA genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain.
1445401389,A,G,Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain.
1445401389,G,G,Patients with the GG genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain.
1445401399,A,A,Patients with the AA genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain.
1445401399,A,G,Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.
1445401399,G,G,Patients with the GG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.
1445401824,C,C,Patients with the CC genotype and breast cancer may have a decreased risk for anemia when treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for anemia.
1445401824,C,G,Patients with the CG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.
1445401824,G,G,Patients with the GG genotype and breast cancer may have an increased risk for anemia when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.
1444702725,C,C,"Patients with the CC genotype and macular degeneration may have a poorer improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CT or TT genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab."
1444702725,C,T,"Patients with the CT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab."
1444702725,T,T,"Patients with the TT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab."
1445401817,C,C,"Patients with the CC genotype and breast cancer may have a decreased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for anemia."
1445401817,C,T,"Patients with the CT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia."
1445401817,T,T,"Patients with the TT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia."
1445401831,G,G,"Patients with the GG genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia."
1445401831,G,T,"Patients with the GT genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia."
1445401831,T,T,"Patients with the TT genotype and breast cancer may have an increased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for neutropenia."
1445400186,A,A,"Patients with the rs1801086 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400186,A,G,"Patients with the rs1801086 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400186,C,C,"Patients with the rs1801086 CC genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400186,C,G,"Patients with the rs1801086 CG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype GG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400186,G,G,"Patients with the rs1801086 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with genotype AA, AG, CC, CG. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445401186,A,A,Patients with the AA genotype may have decreased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.
1445401186,A,G,Patients with the AG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.
1445401186,G,G,Patients with the GG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.
1445401193,A,A,Patients with the AA genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.
1445401193,A,G,Patients with the AG genotype and osteoporosis or osteopenia may have a poorer response when treated with alendronate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to alendronate.
1445401193,G,G,Patients with the GG genotype and osteoporosis or osteopenia may have a better response when treated with alendronate as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to alendronate.
1446900938,C,C,"Patients with acute lymphoblastic leukemia and the CC genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience decreased rates of event-free survival, and overall survival rates as compared to patients with the TT genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia."
1446900938,C,T,"Patients with acute lymphoblastic leukemia and the CT genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience increased rates of event-free survival, and overall survival rates as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia."
1446900938,T,T,"Patients with acute lymphoblastic leukemia and the TT genotype may have an increased risk of leukopenia, as compared to patients with the CC and CT genotypes, but may also experience increased rates of event-free survival, as well as overall survival as compared to patients with the CC genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia."
1446901291,A,A,Patients with renal cell carcinoma and the AA genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.
1446901291,A,T,Patients with renal cell carcinoma and the AT genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.
1446901291,T,T,Patients with renal cell carcinoma and the TT genotype may have an increased likelihood of hypertension when taking sunitinib as compared to patients with the AA and AT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.
1446901311,C,C,Patients with renal cell carcinoma and the CC genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.
1446901311,C,T,Patients with renal cell carcinoma and the CT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.
1446901311,T,T,Patients with renal cell carcinoma and the TT genotype may have a decreased severity of drug-induced toxicity when administered sunitinib as compared to patients with the CC or CT genotypes. Other clinical and genetic factors may also influence severity of drug-induced toxicity in patients with renal cell carcinoma who are administered sunitinib.
1185000213,C,C,"Patients with the CC genotype (CYP3A5 *3/*3) undergoing kidney transplantation may have decreased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. However, the majority of studies show no association between the CC genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus."
1185000213,C,T,"Patients with the CT genotype (CYP3A5 *1/*3) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, the majority of studies show no association between the CT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus."
1185000213,T,T,"Patients with the TT genotype (CYP3A5 *1/*1) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, the majority of studies show no association between the TT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus."
1445400222,G,G,"Patients with the rs193922772 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400222,G,T,"Patients with the rs193922772 GT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400222,T,T,"Patients with the rs193922772 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400232,A,A,"Patients with the rs193922802 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400232,A,G,"Patients with the rs193922802 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400232,G,G,"Patients with the rs193922802 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400247,C,C,"Patients with the rs193922816 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400247,C,T,"Patients with the rs193922816 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400247,T,T,"Patients with the rs193922816 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1446846513,A,A,"Patients with the rs2229774 AA genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with rs2229774 GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1446846513,A,G,"Patients with the rs2229774 AG genotype may have increased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with rs2229774 GG. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1446846513,G,G,"Patients with the rs2229774 GG genotype may have decreased risk of anthracycline-induced cardiotoxicity in childhood cancer as compared to patients with rs2229774 AG or AA. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1185000260,C,C,"Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation who are treated with tacrolimus may have a decreased, but not absent, risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity."
1185000260,C,T,Patients with the CT genotype (CYP3A5 *1/*3) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.
1185000260,T,T,Patients with the TT genotype (CYP3A5 *1/*1) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.
1185000350,C,C,Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1185000350,C,T,Patients with the CT genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the TT genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1185000350,T,T,Patients with the TT genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1185000362,C,C,Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1185000362,C,G,Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in people with HIV who are taking atazanavir and ritonavir.
1185000362,G,G,Patients with the GG genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1185000369,C,C,Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1185000369,C,G,Patients with the CG genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the GG genotype and an increased risk of nephrolithiasis as compared to people with the CC genotype. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1185000369,G,G,Patients with the GG genotype and HIV may have an increased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and CC genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.
1444673379,G,G,Patients with the GG genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673379,G,T,Patients with the GT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673379,T,T,Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673386,C,C,Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673386,C,T,Patients with the CT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673386,T,T,Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673412,A,A,Patients with the AA genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673412,A,C,Patients with the AC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.
1444673412,C,C,Patients with the CC genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to imatinib.
1444700808,A,A,Patients with the AA genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.
1444700808,A,C,Patients with the AC genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype or may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.
1444700808,C,C,Patients with the CC genotype who are treated gemcitabine and platinum compounds may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.
1444700867,C,C,"Patients with the CC genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia."
1444700867,C,T,"Patients with the CT genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia."
1444700867,T,T,Patients with the TT genotype and Hepatitis C may have an increased risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
1444700874,C,C,Patients with the CC genotype may have a decreased response to levodopa in people with cocaine-related disorders as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
1444700874,C,T,Patients with the CT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
1444700874,T,T,Patients with the TT genotype may have an increased response to levodopa in people with cocaine-related disorders as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.
1444702778,C,C,Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702778,C,G,Patients with the CG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702778,G,G,Patients with the GG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702784,C,C,Patients with the CC genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702784,C,T,Patients with the CT genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702784,T,T,Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702792,A,A,Patients with the AA genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702792,A,G,Patients with the AG genotype and schizophrenia may have a better response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.
1444702792,G,G,Patients with the GG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to risperidone.
1444703171,C,C,"Patients with the CC genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab."
1444703171,C,G,"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab."
1444703171,G,G,"Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab."
1444703258,C,C,Patients with the CC genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444703258,C,T,Patients with the CT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have early decrease in the percentage of HAMD scores as compared to patients with the TT genotype or may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444703258,T,T,Patients with the TT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.
1444703430,C,C,Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703430,C,T,Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703430,T,T,"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir."
1444703438,C,C,Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703438,C,T,Patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.
1444703438,T,T,"Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir."
1444703446,A,A,"Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol."
1444703446,A,G,Patients with the AG genotype and Schizophrenia may have decreased response to haloperidol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1444703446,G,G,Patients with the GG genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.
1444703453,A,A,"Patients with the AA genotype were not studied. However, patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
1444703453,A,G,"Patients with the AG genotype and Schizophrenia may have increased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
1444703453,G,G,"Patients with the GG genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone."
1444703487,A,A,Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703487,A,T,Patients with the AA genotype and asthma who are treated with aspirin may have increased risk for aspirin-intolerant asthma as compared to patients with the TT genotype or may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703487,T,T,Patients with the TT genotype and asthma who are treated with aspirin may have decreased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703495,C,C,Patients with the CC genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703495,C,T,Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.
1444703495,T,T,"Patients with the TT genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for aspirin intolerance as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin."
1444704089,C,C,"Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones."
1444704089,C,T,"Patients with the CT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype or may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones."
1444704089,T,T,"Patients with the TT genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have increased risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones."
1444705174,A,A,Patients with the AA genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705174,A,G,Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype or may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1444705174,G,G,Patients with the GG genotype and major depression may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.
1445401804,A,A,Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.
1445401804,A,G,Patients with the AG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.
1445401804,G,G,Patients with the GG genotype and breast cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.
1445401838,A,A,Patients with the AA genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.
1445401838,A,C,Patients with the AC genotype and breast cancer may have an decreased risk for mucositis when treated with docetaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for mucositis.
1445401838,C,C,Patients with the CC genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for mucositis.
1445401847,A,A,Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.
1445401847,A,C,Patients with the AC genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for neuropathy.
1445401847,C,C,Patients with the CC genotype and breast cancer may have an decreased risk for neuropathy when treated with paclitaxel as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for neuropathy.
1445401853,A,A,Patients with the AA genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.
1445401853,A,G,Patients with the AG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.
1445401853,G,G,Patients with the GG genotype and breast cancer may have a decreased risk for mucositis when treated with docetaxel as compared to patients with the AA genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.
1445401880,C,C,"Patients with the CC genotype (CYP3A5 *3/*3) and epilepsy may have decreased clearance and increased concentrations of carbamazepine, and require lower doses of the drug, as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. Other genetic and clinical factors may also influence dose or concentrations of carbamazepine."
1445401880,C,T,"Patients with the CT genotype (CYP3A5 *1/*3) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine."
1445401880,T,T,"Patients with the TT genotype (CYP3A5 *1/*1) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine."
1445401952,C,C,Patients with the CC genotype (POR *1/*1) and familial hypercholesterolemia may have a greater decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CT (*1/*28) or TT (*28/*28) genotype. Other genetic and clinical factors may also influence response to atorvastatin.
1445401952,C,T,Patients with the CT genotype (POR *1/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (*1/*1). Other genetic and clinical factors may also influence response to atorvastatin.
1445401952,T,T,Patients with the TT genotype (POR *28/*28) and familial hypercholesterolemia may have a lower decrease in total cholesterol and low-density lipoprotein cholesterol when treated with atorvastatin as compared to patients with the CC genotype (POR *1/*1). Other genetic and clinical factors may also influence response to atorvastatin.
1445402033,A,A,"Patients with the AA genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine."
1445402033,A,G,"Patients with the AG genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine."
1445402033,G,G,"Patients with the GG genotype and acute myeloid leukemia may have a poorer response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the AA or AG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine."
1445402085,C,C,Patients with the CC genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1445402085,C,G,Patients with the CG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.
1445402085,G,G,Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to clozapine.
1446898009,C,C,Women with the CC genotype and obesity and polycystic ovarian syndrome (PCOS) may have an increased response to liraglutide as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898009,C,T,Women with the CT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898009,T,T,Women with the TT genotype and obesity and polycystic ovarian syndrome (PCOS) may have a decreased response to liraglutide as compared to the CC genotypes. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898016,A,A,Women with obesity and polycystic ovarian syndrome (PCOS) and the AA genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898016,A,G,Women with obesity and polycystic ovarian syndrome (PCOS) and the AG genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1446898016,G,G,Women with obesity and polycystic ovarian syndrome (PCOS) and the GG genotype may have a decreased response to liraglutide as compared to women with the AA and AG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.
1444703480,A,A,Patients with the AA genotype and Rheumatoid Arthritis may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703480,A,G,Patients with the AG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype or may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1444703480,G,G,Patients with the GG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.
1446897666,A,A,Patients with the AA genotype may have increased likelihood of myelosuppression when treated with sunitinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence sunitinib related myelosuppression.
1446897666,A,G,Patients with the AG genotype may have decreased likelihood of myelosuppression when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sunitinib related myelosuppression.
1446897666,G,G,Patients with the GG genotype may have decreased likelihood of myelosuppression when treated with sunitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sunitinib related myelosuppression.
1445400206,A,A,"Patients with the rs118192122 AA genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400206,A,G,"Patients with the rs118192122 AG genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1445400206,G,G,"Patients with the rs118192122 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1444703273,A,A,Patients with the rs3742106 AA genotype may have decreased plasma concentrations of tenofovir in people with HIV as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.
1444703273,A,C,Patients with the rs3742106 AC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.
1444703273,C,C,Patients with the rs3742106 CC genotype may have increased plasma concentrations of tenofovir in people with HIV as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs3742106 and tenofovir and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenofovir plasma concentrations.
1451761240,A,A,"Patients with HIV and the rs9349256 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate."
1451761240,A,G,"Patients with HIV and the rs9349256 AG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate."
1451761240,G,G,"Patients with HIV and the rs9349256 GG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate."
1445401303,A,A,Patients with the rs10737062 AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure response to losartan.
1445401303,A,G,Patients with the rs10737062 AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to losartan.
1445401303,G,G,Patients with the rs10737062 GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to losartan.
1445401296,A,A,Patients with the rs10752271 AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.
1445401296,A,G,Patients with the rs10752271 AG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
1445401296,G,G,Patients with the rs10752271 GG genotype and hypertension may have a greater decrease in blood pressure when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure.
1451761248,A,A,Patients with HIV and the rs3742106 AA genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.
1451761248,A,C,Patients with HIV and the rs3742106 AC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.
1451761248,C,C,Patients with HIV and the rs3742106 CC genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of nephrotoxicity when treated with tenofovir disoproxil fumarate.
1447990846,A,A,Individuals with the AA genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.
1447990846,A,T,Individuals with the AT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.
1447990846,T,T,Individuals with the TT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were less likely to develop colorectal cancer as compared to patients with the AA or TT genotypes. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.
1448100067,C,C,Patients with the CC genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.
1448100067,C,G,Patients with the CG genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.
1448100067,G,G,Patients with the GG genotype and renal cell carcinoma may have an increased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.
1448100194,G,G,Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GT and TT genotypes. Other factors may affect response to antidepressants.
1448100194,G,T,Patients with the GT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100194,T,T,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG and GT genotypes. Other factors may affect response to antidepressants.
1448602108,A,A,People who smoke and have the AA genotype may have increased clearance and decreased exposure to cotinine compared to people with the AC and CC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.
1448602108,A,C,People who smoke and have the AC genotype may have increased clearance and decreased exposure to cotinine compared to people with the CC genotype. Other clinical and genetic factors may affect metabolism and exposure of cotinine.
1448602108,C,C,People who smoke and have the CC genotype may have decreased clearance and increased exposure to cotinine compared to people with the AA and AC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.
1448613237,A,A,Patients with the AA genotype and kidney transplantation may have increased exposure (Concentration/Dose) to tacrolimus compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
1448613237,A,G,Patients with the AG genotype and kidney transplantation may have increased exposure (Concentration/Dose) to tacrolimus compared to patients with the GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
1448613237,G,G,Patients with the GG genotype and kidney transplantation may have decreased exposure (Concentration/Dose) to tacrolimus compared to patients with the AG and AA genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.
1448613363,C,C,Patients with the CC genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448613363,C,T,Patients with the CT genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448613363,T,T,Patients with the TT genotype may have low on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
1451678112,C,C,Patients with the rs4149056 CC genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.
1451678112,C,T,Patients with the rs4149056 CT genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.
1451678112,T,T,Patients with the rs4149056 TT genotype may have decreased concentration of lovastatin acid as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.
1451678210,C,C,Patients with the rs4149056 CC genotype may have increased concentrations of pitavastatin when treated with pitavastatin as compared to patients with TT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.
1451678210,C,T,Patients with the rs4149056 CT genotype may have increased concentrations of pitavastatin when treated with pitavastatin as compared to patients with TT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.
1451678210,T,T,Patients with the rs4149056 TT genotype may have decreased concentrations of pitavastatin when treated with pitavastatin as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.
1448427005,A,A,Patients with the AA genotype and non-small cell lung cancer may have an increased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.
1448427005,A,G,Patients with the AG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.
1448427005,G,G,Patients with the GG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.
1448634522,A,A,Patients with the AA and stable coronary artery disease who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AT or TT genotypes. Other clinical and genetic factors may also influence risk hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.
1448634522,A,T,Patients with the AT genotype and stable coronary artery disease who are treated with clopidogrel may have increased risk of hemorrhage as compared to patients with the AA genotype and decreased risk as compared to the TT genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.
1448634522,T,T,Patients with the TT genotype and stable coronary artery disease who are treated with clopidogrel may have Increased risk of of hemorrhage as compared to patients with the AT or AA genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with stable coronary artery disease who are treated with clopidogrel.
1448258741,C,C,Patients with the CC genotype may have decreased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to sorafenib.
1448258741,C,T,Patients with the CT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1448258741,T,T,Patients with the TT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1448423682,A,A,"No patients with the AA genotype were available for analysis, but patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions."
1448423682,A,G,Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423682,G,G,Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423689,A,A,Patients with the AA genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423689,A,G,Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423689,G,G,Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423696,A,A,Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423696,A,G,Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423696,G,G,Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423703,A,A,Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423703,A,G,Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448423703,G,G,Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.
1448428937,C,C,Patients with the CC genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428937,C,T,Patients with the CT genotype and gout may require a lower dose of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428937,T,T,Patients with the TT genotype and gout may require a higher dose of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428944,A,A,Patients with the AA genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428944,A,G,Patients with the AG genotype and gout may be more likely to require a 300 mg/day dose of allopurinol or febuxostat compared to patients with the GG genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448428944,G,G,Patients with the GG genotype and gout may be more likely to require a dose equivalent other than 300 mg/day of allopurinol or febuxostat compared to patients with the AA genotype. Other clinical and genetic factors may affect dose of allopurinol and febuxostat.
1448522754,A,A,Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522754,A,G,Patients with the AG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522754,G,G,Patients with the GG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522760,A,A,Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522760,A,G,Patients with the AG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522760,G,G,Patients with the GG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448526098,C,C,Patients with the CC genotype and rheumatoid arthritis may have a better response when treated with tocilizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence tocilizumab response.
1448526098,C,T,Patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.
1448526098,T,T,Patients with the TT genotype and rheumatoid arthritis may have a poorer response when treated with tocilizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tocilizumab response.
1448530595,G,G,Patients with the GG genotype and kidney transplantation may have decreased risk of acute renal toxicity when taking tacrolimus compared to patients with the GT or TT genotypes. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.
1448530595,G,T,Patients with the GT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.
1448530595,T,T,Patients with the TT genotype and kidney transplantation may have increased risk of acute renal toxicity when taking tacrolimus compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicity in response to tacrolimus therapy.
1448600720,C,C,Children with the CC genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the CT or TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.
1448600720,C,T,Children with the CT genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.
1448600720,T,T,Children with the TT genotype and gating mutations in cystic fibrosis may have decreased response to ivacaftor compared to children with the CC or CT genotypes. Other clinical and genetic factors may affect response to ivacaftor.
1448427833,A,A,"Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron."
1448427833,A,G,"Patients with the AG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron."
1448427833,G,G,"Patients with the GG genotype and cancer may have a lesser likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron."
1448532002,C,C,Patients with the CC genotype may have decreased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to clozapine.
1448532002,C,T,Patients with the CT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.
1448532002,T,T,Patients with the TT genotype may have increased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to clozapine.
1448532196,A,A,People with the AA genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.
1448532196,A,G,People with the AG genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.
1448532196,G,G,People with the GG genotype may have decreased exposure to rivaroxaban compared to people with the AA and AG genotypes when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.
1448532202,A,A,People with the AA genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.
1448532202,A,C,People with the AC genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.
1448532202,C,C,"People with the CC genotype may have decreased exposure to dabigatran compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran."
1448532202,C,T,People with the CT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.
1448532202,T,T,People with the TT genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.
1448532211,A,A,"People with the AA genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
1448532211,A,C,"People with the AC genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
1448532211,C,C,"People with the CC genotype may have decreased exposure to rivaroxaban compared to patients with a variant at this position, including genotypes AA, AC, CT, and TT, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
1448532211,C,T,"People with the CT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
1448532211,T,T,"People with the TT genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban."
1449565416,G,G,Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565416,G,T,Patients with the GT genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565416,T,T,Patients with the TT genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565422,A,A,Patients with the AA genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565422,A,G,Patients with the AG genotype may have an increased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the GG genotype. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449565422,G,G,Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to the AA or AG genotypes. This observation has only been seen in combination with rs544027339 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.
1449575674,T,T,The TT genotype is associated with increased catalytic activity of DPYD as compared to the del/del or del/T genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.
1449575645,G,G,"Both variants of rs56005131 are assigned normal function by CPIC. Patients with the GG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the GT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1449575645,G,T,"Both variants of rs56005131 are assigned normal function by CPIC. Patients with the GT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the GG or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1449575645,T,T,"Both variants of rs56005131 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the GG or GT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1448525458,G,G,Patients with the GG genotype and Parkinson's Disease may have an increased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.
1448615589,A,A,Patients with the AA genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and GG genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.
1448615589,A,G,"Patients with the AG genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the GG genotypes, and a decreased likelihood as compared to patients with the AA genotype. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin."
1448615589,G,G,Patients with the GG genotype who are treated with phenytoin may have an decreased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and AA genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin.
1448617146,A,A,Patients with the AA genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1448617146,A,C,Patients with the AC genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1448617146,A,T,Patients with the AT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1448617146,C,C,"Patients with the CC genotype who are administered atazanavir may have decreased risk of hyperbilirubinemia as compared to patients with the AA, AT, TT, AC, or CT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir."
1448617146,C,T,Patients with the CT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1448617146,T,T,Patients with the TT genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.
1448615575,A,A,"Patients with the AA genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel."
1448615575,A,G,"Patients with the AG genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel."
1448615575,G,G,"Patients with the GG genotype may have an increased response to clopidogrel (increased platelet reactivity) as compared to patients with the AA genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel."
1448525452,C,C,Patients with the rs6280 CC genotype and Parkinson's Disease may have a decreased risk of adverse events when treated with levodopa as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.
1448525452,C,T,Patients with the CT genotype and Parkinson's Disease may have a decreased risk of adverse events when treated with levodopa as compared to patients with the TT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.
1448525452,T,T,Patients with the TT genotype and Parkinson's Disease may have an increased risk for adverse events when treated with levodopa as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.
1448613032,A,A,People with the AA genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448613032,A,G,People with the AG genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448613032,G,G,People with the GG genotype may have decreased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448613038,A,A,People with the AA genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448613038,A,G,People with the AG genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448613038,G,G,People with the GG genotype may have increased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.
1448616855,C,C,Patients with cancer and the CC genotype who are treated with capecitabine may have decreased (but not absent) risk of hyperbilirubinemia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1448616855,C,T,Patients with cancer and the CT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1448616855,T,T,Patients with cancer and the TT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1451510621,A,A,Patients with the rs1045642 AA genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.
1451510621,A,G,Patients with the rs1045642 AG genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.
1451510621,G,G,Patients with the rs1045642 GG genotype may have increased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.
1451510641,C,C,Patients with the rs4148738 CC genotype may have increased risk of bleeding when treated with apixaban as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.
1451510641,C,T,Patients with the rs4148738 CT genotype may have decreased risk of bleeding when treated with apixaban as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.
1451510641,T,T,Patients with the rs4148738 TT genotype may have decreased risk of bleeding when treated with apixaban as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.
1448613011,C,C,Patients with the CC genotype and schizophrenia may have increased response to amisulpride as measured by the PANSS general as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to amisulpride.
1448613011,C,T,Patients with the CT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.
1448613011,T,T,Patients with the TT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.
1448615153,A,A,Postmenopausal women with HR+ breast cancer and the AA genotype may have decreased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615153,A,C,Postmenopausal women with HR+ breast cancer and the AC genotype may have increased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615153,C,C,Postmenopausal women with HR+ breast cancer and the CC genotype may have increased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448634786,A,A,Patients with genotypes AA may have decreased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to beta blocking agents.
1448634786,A,G,Patients with genotypes AG may have increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to beta blocking agents.
1448634786,G,G,Patients with genotypes GG may have increased risk of major adverse cardiac events (mace) when treated with Beta Blocking Agents as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to beta blocking agents.
1450374895,A,A,Patients with the AA genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate.
1450374895,A,G,Patients with the AG genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate.
1450374895,G,G,Patients with the GG genotype and attention deficit hyperactivity disorder (ADHD) who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score may have a decreased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence response to methylphenidate.
1448602934,A,A,"Patients with the AA genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin."
1448602934,A,G,"Patients with the AG genotype may have increased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin."
1448602934,G,G,"Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype AA or AG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin."
1448612776,G,G,Patients with the GG genotype and hypertension may have an increased response to antihypertensives compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect response to antihypertensive therapy.
1448612776,G,T,Patients with the GT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.
1448612776,T,T,Patients with the TT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.
1449166396,A,A,Patients with the AA genotype and gastroesophageal reflux may have increased absorption rate and response to omeprazole compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients.
1449166396,A,G,"Patients with the AG genotype and gastroesophageal reflux who are treated with omeprazole may have Increased absorption of omeprazole, but decreased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients gastroesophageal reflux."
1449166396,G,G,Patients with the GG genotype and Gastroesphageal reflux who are treated with omeprazole may have decreased absorption rate of omeprazole as compared to patients with the AA or AG genotypes and and decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence Response to and absorption rate of omeprazole in patients gastroesphageal reflux.
1448428030,A,A,"Patients with the AA genotype and solid tumors may experience deceased risk of neutropenia compared to patients with the GG genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy."
1448428030,A,G,"Patients with the AG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy."
1448428030,G,G,"Patients with the GG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy."
1451510840,A,A,Patients with rs9958628 AA genotype may have a decreased risk of Pegaspargase Hypersensitivity as compared to patients with the TT or AT genotype. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.
1451510840,A,T,Patients with rs9958628 AT genotype may have an increased risk of Pegaspargase Hypersensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.
1451510840,T,T,Patients with rs9958628 TT genotype may have an increased risk of Pegaspargase Hypersensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of Pegaspargase Hypersensitivity.
1448604251,A,A,"Patients with the rs2032582 AA genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance."
1448604251,A,C,"Patients with the rs2032582 AC genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance."
1448604251,A,T,"Patients with the rs2032582 AT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance."
1448604251,C,C,"Patients with the rs2032582 CC genotype may have decreased clearance of methadone compared to patients with the AA, AC, AT, CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance."
1448604251,C,T,"Patients with the rs2032582 CT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance."
1448604251,T,T,"Patients with the rs2032582 TT genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance."
1448624874,A,A,Patients with the AA genotype may have decreased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to clopidogrel.
1448624874,A,G,Patients with the AG genotype may have increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.
1448624874,G,G,Patients with the GG genotype may have increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.
1448267381,A,A,Patients with the AA genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.
1448267381,A,G,Patients with the AG genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.
1448267381,G,G,Patients with the GG genotype and heart valve replacement may require higher dose of warfarin compared to patients with the AA and AG genotypes. Other clinical and genetic factors affect warfarin dose.
1448267389,A,A,Patients with the AA genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.
1448267389,A,C,Patients with the AC genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.
1448267389,C,C,Patients with the CC genotype and heart valve replacement may require increased dose of warfarin compared to patients with the AA and AC genotypes. Other clinical and genetic factors affect warfarin dose.
1448267397,C,C,Patients with the CC genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.
1448267397,C,T,Patients with the CT genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.
1448267397,T,T,Patients with the TT genotype and heart valve replacement may require higher warfarin dose compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect warfarin dose.
1448617231,A,A,"Patients with the AA genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin."
1448617231,A,G,"Patients with the AG genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin."
1448617231,G,G,"Patients with the GG genotype may have decreased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to aspirin."
1449190330,C,C,"Patients with the CC genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CT or TT genotypes. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence."
1449190330,C,T,"Patients with the CT genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence."
1449190330,T,T,"Patients with the TT genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence."
1449190339,C,C,"Patients with the CC genotype may have a decreased likelihood of developing opioid dependence as compared to patients with the CT or TT genotypes. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence."
1449190339,C,T,"Patients with the CT genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence."
1449190339,T,T,"Patients with the TT genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence."
1448635585,G,G,"Individuals with HIV and the GG genotype may have a decreased risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome) when treated with nevirapine as compared to patients with the GT or TT genotypes, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine."
1448635585,G,T,"Individuals with HIV and the GT genotype may have a decreased risk of SJS/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the TT genotype and an increased risk as compared to patients with the GG genotype, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine."
1448635585,T,T,"Individuals with HIV and the TT genotype may have an increased risk of SJS/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the GT or GG genotypes, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine."
1448632697,C,C,Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.
1448632697,C,G,Patients with the CG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.
1448632697,G,G,Patients with the GG genotype may have increased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.
1447981289,C,C,Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981289,C,G,Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981289,G,G,Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447982825,A,A,"Patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
1447982825,A,G,"No information are available for the AG genotype. However, patients with the AA genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
1447982825,G,G,"Patients with the GG genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
1447983050,C,C,"Patients with the CC genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983050,C,T,"Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983050,T,T,"Patients with the TT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447986967,G,G,Patients with the GG genotype and essential hypertension who are administered atenolol may have a decreased likelihood of developing hyperglycemia as compared to patients with the GT or TT genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.
1447986967,G,T,Patients with the GT genotype and essential hypertension who are administered atenolol may have a increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.
1447986967,T,T,Patients with the TT genotype and essential hypertension who are administered atenolol may have an increased likelihood of developing hyperglycemia as compared to patients with the GG genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.
1447986986,C,C,Patients with the CC genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.
1447986986,C,T,"Patients with the CT genotype may have decreased clearance of sulfinpyrazone as compared to patients with the TT genotype, or increased clearance as compared to those with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone."
1447986986,T,T,Patients with the TT genotype may have increased clearance of sulfinpyrazone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of sulfinpyrazone.
1447952921,C,C,Patients with the CC genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.
1447952921,C,G,Patients with the CG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.
1447952921,G,G,Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's concentrations of efavirenz.
1447953109,A,A,"Women with the AA genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole."
1447953109,A,G,"Women with the AG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole."
1447953109,G,G,"Women with the GG genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole."
1447953130,C,C,Patients with the CC genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.
1447953130,C,T,Patients with the CT genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.
1447953130,T,T,Patients with the TT genotype and essential hypertension may have a decreased likelihood of cough when treated with enalapril as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.
1447953250,A,C,Patients with the AC genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.
1447953250,C,C,Patients with the CC genotype and narcolepsy may have a decreased response to modafinil as compared to patients with the AC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to modafinil.
1447953250,C,T,Patients with the CT genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.
1447960436,C,C,Patients with the CC genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.
1447960436,C,G,"Patients with the CG genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the GG genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence required dose of catecholamines."
1447960436,G,G,Patients with the GG genotype and coronary artery disease may require an increased dose of catecholamines as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.
1447960509,A,A,Patients with the AA genotype and breast cancer may have an increased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1447960509,A,G,No significant association with breast cancer disease recurrence has been seen for patients with the AG genotype as compared to the AA genotype.
1447960509,G,G,Patients with the GG genotype and breast cancer may have a decreased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also influence breast cancer recurrence.
1447960745,C,C,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960745,C,T,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960745,T,T,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960775,C,C,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960775,C,T,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960775,T,T,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447961115,C,C,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961115,C,T,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
1447961115,T,T,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961122,C,C,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961122,C,T,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
1447961122,T,T,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447962603,C,C,Patients with the CC genotype who are also CYP2A6 normal metabolizers may have decreased metabolism of nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of nicotine.
1447962603,C,T,Patients with the CT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.
1447962603,T,T,Patients with the TT genotype who are also CYP2A6 normal metabolizers may have increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine.
1447962649,G,G,Cells with the GG genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962649,G,T,"Cells with the GT genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype, or increased enzymatic activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38."
1447962649,T,T,Cells with the TT genotype may have increased enzymatic activity toward SN-38 as compared to cells with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962843,A,A,Patients with the AA genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.
1447962843,A,G,Patients with the AG genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.
1447962843,G,G,Patients with the GG genotype and hypercholesterolemia may lesser reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence cholesterol levels.
1447964136,C,C,"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CC genotype associated with decreased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity."
1447964136,C,T,"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the CT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity."
1447964136,T,T,"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. In addition, studies show the TT genotype associated with increased risk of hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity."
1447963096,A,A,Patients with the AA genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of busulfan.
1447963096,A,C,"Patients with the AC genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan."
1447963096,C,C,Patients with the CC genotype and acute myeloid leukemia may have increased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan.
1447964236,A,A,"Patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the AG or GG genotypes. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate."
1447964236,A,G,"Patients with the AG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate."
1447964236,G,G,"Patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate."
1447987005,A,A,"Patients with the AA genotype and HIV who do not have the rs3745274 TT genotype may have decreased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
1447987005,A,G,"Patients with the AG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
1447987005,G,G,"Patients with the GG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
1447987030,A,A,"Patients with the AA genotype and HIV may have increased concentrations of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
1447987030,A,G,"Patients with the AG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
1447987030,G,G,"Patients with the GG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
1447987045,C,C,Patients with the CC genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987045,C,T,"Patients with the CT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the TT genotype, or decreased clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine."
1447987045,T,T,Patients with the TT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987052,A,A,Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987052,A,C,"Patients with the AC genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CC genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine."
1447987052,C,C,Patients with the CC genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987059,A,A,Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987059,A,G,"Patients with the AG genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine."
1447987059,G,G,Patients with the GG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987066,A,A,Patients with the AA genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987066,A,G,Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987066,G,G,Patients with the GG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987073,C,C,Patients with the CC genotype may metabolize nicotine more rapidly as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the metabolism of nicotine.
1447987073,C,T,Patients with the CT genotype may metabolize nicotine more rapidly as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the metabolism of nicotine.
1447987073,T,T,Patients with the TT genotype may metabolize nicotine more slowly as compared to patients with the CT CC genotypes. Other clinical and genetic factors may also influence the metabolism of nicotine.
1447987101,C,C,Patients with the CC genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987101,C,T,Patients with the CT genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987101,T,T,Patients with the TT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987113,C,C,Patients with the CC genotype and tobacco use disorder may have a worse response (lack of abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.
1447987113,C,T,Patients with the CT genotype and tobacco use disorder may have a worse response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the TT genotype and an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.
1447987113,T,T,Patients with the TT genotype and tobacco use disorder may have an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.
1448102470,C,C,Patients with the CC genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102470,C,T,Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102470,T,T,Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448427398,G,G,Patients with the GG genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1448427398,G,T,Patients with the GT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1448427398,T,T,Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1448427405,C,C,Patients with the CC genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1448427405,C,T,Patients with the CT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1448427405,T,T,Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1448522766,A,A,Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522766,A,G,Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522766,G,G,Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522772,C,C,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522772,C,T,Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522772,T,T,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522778,C,C,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522778,C,T,Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522778,T,T,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522784,C,C,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522784,C,T,Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522784,T,T,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1450373755,A,A,Patients with pancreatic cancer and the AA genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373755,A,G,Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373755,G,G,Patients with pancreatic cancer and the GG genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA or AG genotypes. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373761,A,A,Patients with pancreatic cancer and the AA genotype may be at an increased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AG or GG genotypes. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373761,A,G,Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA genotype. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1450373761,G,G,Patients with pancreatic cancer and the GG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the AA genotype. Note that this variant is in high LD with rs12148896 (see clinical annotation 1450373755). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.
1447987094,A,A,African American and white patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987094,A,G,African American and white patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447987094,G,G,African American and white patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.
1447963234,A,A,Patients with the rs1076560 AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cocaine-related death.
1447963234,A,C,"Patients with the rs1076560 AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death."
1447963234,C,C,Patients with the v CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence cocaine-related death.
1447986998,A,A,"Patients with the rs1695 AA genotype and various cancers may have a decreased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens."
1447986998,A,G,"Patients with the rs1695 AG genotype and various cancers may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens."
1447986998,G,G,"Patients with the rs1695 GG genotype and various cancer may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens."
1448099568,C,C,"Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
1448099568,C,T,"Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
1448099568,T,T,"Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
1448099745,G,G,"Patients with the GG genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects."
1448102463,A,A,Patients with the AA genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102463,A,G,Patients with the AG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102463,G,G,Patients with the GG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102490,A,A,Patients with the AA genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102490,A,C,"Patients with the AC genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the CC genotype, or an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment."
1448102490,C,C,Patients with the CC genotype and hepatitis C or HIV may have an increased response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448124590,A,C,Patients with the AC genotype and kidney transplant may have increased risk of neutropenia when treated with valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.
1448124590,C,C,Patients with the CC genotype and kidney transplant may have decreased risk of neutropenia when treated with valganciclovir compared to patients with the AC genotype. Other genetic and clinical factors may affect risk of toxicity with valganciclovir treatment.
1448124604,C,C,Patients with the CC genotype and kidney transplantation may have reduced risk of neutropenia when taking valganciclovir compared to patients with the CT genotype. Other genetic and clinical factors may affect response to valganciclovir.
1448124604,C,T,Patients with the CT genotype and kidney transplantation may have increased risk of neutropenia when taking valganciclovir compared to patients with the CC genotype. Other genetic and clinical factors may affect response to valganciclovir.
1448125853,C,C,Patients with the CC genotype and chronic myeloid leukemia have have increased trough concentrations of imatinib compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect concentrations of imatinib.
1448125853,C,T,Patients with the CT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.
1448125853,T,T,Patients with the TT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.
1448265174,A,A,"Patients with the AA genotype may have a decreased, but not absent, risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics."
1448265174,A,T,Patients with the AT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.
1448265174,T,T,Patients with the TT genotype may have an increased risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.
1448602385,A,A,Patients with hypertension and the AA genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.
1448602385,A,G,Patients with hypertension and the AG genotype may have increased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.
1448602385,G,G,Patients with hypertension and the GG genotype may have decreased risk of developing diabetes when taking calcium channel blocker-based treatment or beta-blocker-based treatment compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of developing diabetes while undergoing treatment for hypertension.
1448603291,G,G,Children with the GG genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603291,G,T,Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
1448603291,T,T,Children with the TT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.
1449576307,C,C,"Patients with the CC genotype may have an increased response to treatment with atenolol and hydrochlorothiazide, resulting in a decreased risk of having uncontrolled blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide."
1449576307,C,T,"Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide."
1449576307,T,T,"Patients with the TT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide."
1449576551,C,C,Patients with the CC genotype may have increased plasma concentrations of montelukast as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576551,C,T,Patients with the CT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576551,T,T,Patients with the TT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576566,C,C,Patients with the CC genotype may have increased plasma concentrations of montelukast as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576566,C,T,Patients with the CT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449576566,T,T,Patients with the TT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.
1449715913,A,A,Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715913,A,G,Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715913,G,G,Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715919,A,A,"Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AC, AT, CC, CT or TT genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl."
1449715919,A,C,Patients with the AC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715919,A,T,Patients with the AT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715919,C,C,Patients with the CC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715919,C,T,Patients with the CT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715919,T,T,Patients with the TT genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715928,A,A,Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715928,A,G,Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449715928,G,G,Patients with the GG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.
1449716035,A,A,Patients with the AA genotype may have an increased response to fentanyl as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449716035,A,C,"Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl."
1449716035,C,C,Patients with the CC genotype may have a decreased response to fentanyl as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1449747892,A,A,Patients with the AA genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449747892,A,G,Patients with the AG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449747892,G,G,Patients with the GG genotype undergoing kidney transplantation or liver transplantation (donor or recipient genotype) may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence tacrolimus concentrations.
1449751564,C,C,Patients with the CC genotype (*1/*1) and alcoholism may have an increased response to phenazepam as compared to patients with the TT (*17/*17) genotype. Other genetic and clinical factors may also affect a patient's response to phenazepam.
1449751564,C,T,Patients with the CT genotype (*1/*17) and alcoholism may have an increased response to phenazepam as compared to patients with the TT (*17/*17) genotype. Other genetic and clinical factors may also affect a patient's response to phenazepam.
1449751564,T,T,Patients with the TT genotype (*17/*17) and alcoholism may have a decreased response to phenazepam as compared to patients with the CC (*1/*1) or CT (*1/*17) genotypes. Other genetic and clinical factors may also affect a patient's response to phenazepam.
1450815160,A,A,Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815160,A,G,Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as comapred to patients with the AA genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815160,G,G,Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1451825200,A,A,Patients with the rs1799971 AA genotype may be more likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.
1451825200,A,G,Patients with the rs1799971 AG genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.
1451825200,G,G,Patients with the rs1799971 GG genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.
1451825220,A,A,Patients with the rs4680 AA genotype may be more likely to experience vomiting when treated with oxycodone and naloxone for pain as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect likelihood of experiencing vomiting when treated with oxycodone and naloxone.
1451825220,A,G,Patients with the rs4680 AG genotype may be less likely to experience vomiting when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing vomiting when treated with oxycodone and naloxone.
1451825220,G,G,Patients with the rs4680 GG genotype may be less likely to experience vomiting when treated with oxycodone and naloxone for pain as compared to patients with the AA genotype. Other genetic or clinical factors may also affect likelihood of experiencing vomiting when treated with oxycodone and naloxone.
1451825226,A,A,Patients with the rs4680 AA genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the GG genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.
1451825226,A,G,Patients with the rs4680 AG genotype may be less likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the GG genotype. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.
1451825226,G,G,Patients with the rs4680 GG genotype may be more likely to experience erythema when treated with oxycodone and naloxone for pain as compared to patients with the AG or AA genotypes. Other genetic or clinical factors may also affect likelihood of experiencing erythema when treated with oxycodone and naloxone.
1447954390,C,C,Patients with the rs75039782 CC genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence response to ataluren.
1447954390,C,T,"Patients with the rs75039782 CT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence response to ataluren."
1447954390,T,T,"Patients with the rs75039782 TT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the CC genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence response to ataluren."
1447954397,A,A,"Patients with the rs77010898 AA genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
1447954397,A,G,"Patients with the rs77010898 AG genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
1447954397,G,G,Patients with the rs77010898 GG genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1447949632,C,C,Patients with CC genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1447949632,C,T,Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1447949632,T,T,Patients with TT genotype may have increased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1447954525,A,A,"Patients with the AA genotype may have lower platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the efficacy of clopidogrel."
1447954525,A,G,"Patients with the AG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel."
1447954525,G,G,"Patients with the GG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel."
1447959694,C,C,Patients with the CC genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959694,C,T,"Patients with the CT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype, or an increased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
1447959694,T,T,Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959700,A,A,Patients with the AA genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959700,A,G,"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
1447959700,G,G,Patients with the GG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959717,C,C,Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959717,C,T,"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
1447959717,T,T,Patients with the TT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959724,A,A,Patients with the AA genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959724,A,G,"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype, or a decreased response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
1447959724,G,G,Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447960623,A,A,Patients with the AA genotype may have poorer humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.
1447960623,A,C,Patients with the AC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.
1447960623,C,C,Patients with the CC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.
1447960874,A,A,Patients with the AA genotype and cancer may have increased exposure to tipifarnib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.
1447960874,A,G,Patients with the AG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.
1447960874,G,G,Patients with the GG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.
1447962620,C,C,Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence changes in bone mineral density.
1447962620,C,T,"Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype, or a greater increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density."
1447962620,T,T,Patients with the TT genotype may have a greater increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density.
1447962768,A,A,Patients with the AA genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447962768,A,G,Patients with the AG genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447962768,G,G,Patients with the GG genotype and hypercholesterolemia who have high baseline HDL levels may have a smaller increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447962855,A,A,Patients with the AA genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for myalgia.
1447962855,A,G,"Patients with the AG genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia."
1447962855,G,G,Patients with the GG genotype and hypercholesterolemia may have an increased risk for myalgia when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.
1447962874,A,A,Patients with the AA genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.
1447962874,A,G,Patients with the AG genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.
1447962874,G,G,Patients with the GG genotype and pancreatic cancer or HIV may have increased metabolism and decreased concentrations of nelfinavir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.
1447963219,C,C,Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response.
1447963219,C,G,Patients with the CG genotype and hypertension may have a greater reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response.
1447963219,G,G,Patients with the GG genotype and hypertension may have a smaller reduction in blood pressure when treated with hydrochlorothiazide as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response.
1447963846,C,C,Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.
1447963846,C,G,Patients with the CG genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.
1447963846,G,G,Patients with the GG genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of developing diabetes.
1447963991,A,A,"Male patients with the AA genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics."
1447963991,A,G,"Male patients with the AG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or an increased risk for resistance as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics."
1447963991,G,G,"Male patients with the GG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics."
1447964250,C,C,Patients with the CC genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964250,C,T,Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964250,T,T,Patients with the TT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447987080,A,A,Patients with the AA genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987080,A,G,Patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987080,G,G,"No patients with the GG genotype were available for analysis, but patients with the AG genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine."
1448102306,A,A,Cancer patients with the AA genotype may have a shorter overall and event-free survival time as compared to patients with the AG or GG genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.
1448102306,A,G,Cancer patients with the AG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.
1448102306,G,G,Cancer patients with the GG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.
1448103875,C,C,Patients with the CC genotype and who are addicted to methamphetamines may have an increased risk for methamphetamine-induced psychosis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.
1448103875,C,T,Patients with the CT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.
1448103875,T,T,Patients with the TT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.
1448109754,C,C,"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1448109754,C,T,"Patients with the CT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1448109754,T,T,"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1448257149,C,C,Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also impact the dose of warfarin.
1448257149,C,T,Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin.
1448257149,T,T,Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the dose of warfarin.
1448109591,A,A,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109591,A,C,"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and increased likelihood as compared to patients with the AA genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109591,C,C,"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or AA, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1447964041,C,C,"Patients with the rs1041983 CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for hepatotoxicity."
1447964041,C,T,"Patients with the rs1041983 CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity."
1447964041,T,T,"Patients with the rs1041983 TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity."
1451511220,A,A,Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AA genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.
1451511220,A,G,Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.
1451511220,G,G,Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs3758149 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.
1448101278,C,C,Patients with the CC genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101278,C,G,"Patients with the CG genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype, or a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction."
1448101278,G,G,Patients with the GG genotype may have a decreased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101285,A,A,"Patients with tuberculosis and the AA genotype who are treated with isoniazid and rifampin may have an increased likelihood of drug-induced liver injury as compared to patients with the AG or GG genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury."
1448101285,A,G,"Patients with tuberculosis and the AG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury."
1448101285,G,G,"Patients with tuberculosis and the GG genotype who are treated with isoniazid and rifampin may have an decreased likelihood of drug-induced liver injury as compared to patients with the AA or genotype, although this is contradicted in two studies. Other clinical and genetic factors may also be associated with increased likelihood of drug-induced liver injury."
1448101408,C,C,"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox, as well as an improved response and decreased risk of iron overload as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia."
1448101408,C,T,"Patients with the CT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia."
1448101408,T,T,"Patients with the TT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia."
1448101436,C,C,"Patients with the CC genotype and beta-thalassemia who are treated with deferasirox may have increased concentrations of deferasirox as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia."
1448101436,C,T,"Patients with the CT genotype and beta-thalassemia who are treated with deferasirox may have decreased concentrations of deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia."
1448101436,T,T,"Patients with the TT genotype and beta-thalassemia who are treated with deferasirox may have an worse response to deferasirox as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to and concentrations of deferasirox in patients with beta-thalassemia."
1447962661,G,G,Cells with the GG genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962661,G,T,"Cells with the GT genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the TT genotype, or increased enzymatic activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38."
1447962661,T,T,Cells with the TT genotype may have increased enzymatic activity toward SN-38 as compared to cells with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962737,C,C,"Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the TT genotype, and a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels."
1447962737,C,T,Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962737,T,T,Patients with the TT genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447963042,A,A,Patients with the AA genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1447963042,A,G,Patients with the AG genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1447963042,G,G,Patients with the GG genotype and schizophrenia may have a poorer response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to antipsychotics.
1447979493,C,C,Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447979493,C,G,Patients with the CG genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447979493,G,G,Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to sorafenib.
1447979500,C,C,Patients with the CC genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979500,C,T,Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1447979500,T,T,Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.
1447979507,C,C,Patients with the CC genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979507,C,T,Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979507,T,T,Patients with the TT genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979514,G,G,Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GT or TT. Other genetic and clinical factors may also influence the response to sorafenib.
1447979514,G,T,Patients with the GT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447979514,T,T,Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.
1447980904,A,A,Patients with the AA genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1447980904,A,G,"Patients with the AG genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity."
1447980904,G,G,Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1447980911,G,G,Patients with the GG genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1447980911,G,T,"Patients with the GT genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype, and an increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity."
1447980911,T,T,Patients with the TT genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.
1448100326,C,T,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
1448100326,T,T,Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.
1448100712,A,A,Breast-feeding infants whose mothers have the AA genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.
1448100712,A,G,"Breast-feeding infants whose mothers have the AG genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype, or at decreased risk as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants."
1448100712,G,G,Breast-feeding infants whose mothers have the GG genotype and are taking codeine may be at decreased risk for CNS depression as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.
1448101238,C,C,Patients with the CC genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence neuropathy risk.
1448101238,C,T,"Patients with the CT genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk."
1448101238,T,T,Patients with the TT genotype and HIV may have a decreased risk for neuropathy when treated with stavudine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.
1448101271,A,A,Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101271,A,T,"Patients with the AT genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction."
1448101271,T,T,Patients with the TT genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.
1448102497,A,A,Patients with the AA genotype and hepatitis C or HIV may have an increased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102497,A,T,Patients with the AT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102497,T,T,Patients with the TT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102543,G,G,"Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment."
1448102543,G,T,"Patients with the GT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment."
1448102543,T,T,"Patients with the TT genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment."
1448102666,A,A,Patients with the AA genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.
1448102666,A,C,Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.
1448102666,C,C,Patients with the CC genotype and non-small-cell lung cancer may have an increased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for disease progression.
1448125544,C,C,"Patients with CC genotype may have increased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the response to axitinib and sorafenib."
1448125544,C,T,"Patients with CT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib."
1448125544,T,T,"Patients with TT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib."
1447963662,G,G,"Patients with the GG genotype and lung cancer may have a decreased risk of diarrhea when treated with gefitinib as compared to patients with the GT genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea."
1447963662,G,T,"Patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea."
1447963662,T,T,"No patients with the TT genotype were available for analysis, but patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism, including patients with the GG genotype, and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea."
1447987235,A,A,"Patients with depressive disorder and the AA genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or GG genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder."
1447987235,A,G,"Patients with depressive disorder and the AG genotype may have greater reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the GG genotypes, and smaller reductions in serotonin as compared to patients with the AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder."
1447987235,G,G,"Patients with depressive disorder and the GG genotype may have smaller reductions in serotonin concentrations after taking citalopram or escitalopram as compared to patients with the AG or AA genotypes. However, there is currently no evidence for an association with between the genotypes and response to citalopram or escitalopram. Other clinical and genetic factors may also influence serotonin concentrations in patients with depressive disorder."
1447961108,A,A,Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961108,A,C,"Patients with the AC genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol."
1447961108,C,C,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447963860,C,C,Patients with the CC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447963860,C,T,Patients with the CT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447963860,T,T,Patients with the TT genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447964278,A,A,Patients with the AA genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964278,A,G,Patients with the AG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964278,G,G,Patients with the GG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964324,C,C,Patients with the CC genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.
1447964324,C,G,"Patients with the CG genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma."
1447964324,G,G,Patients with the GG genotype and asthma may have a decreased risk of aspirin intolerance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.
1447983184,C,C,"Patients with the CC genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the TT genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment."
1447983184,C,T,"No information are available for patients with the CT genotype. However, patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment."
1447983184,T,T,"Patients with the TT genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine as compared to patients with the CC genotype based on in-vitro studies. Other genetic and clinical factors may also influence a patient's response to treatment."
1448098793,C,C,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448098793,C,T,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448098793,T,T,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448102432,C,C,Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
1448102432,C,G,"Patients with the CG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype, and a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response."
1448102432,G,G,Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.
1448102477,C,C,Patients with the CC genotype and chronic hepatitis C or HIV may have an increased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102477,C,G,Patients with the CG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102477,G,G,Patients with the GG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448112196,G,G,Patients with the GG genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.
1448112196,G,T,Patients with the GT genotype and breast cancer may have increased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the TT genotype. Other clinical and genetic factors may affect the metabolism of tamoxifen.
1448112196,T,T,Patients with the TT genotype and breast cancer may have decreased concentrations of tamoxifen-n-glucuronide when taking tamoxifen compared to patients with the GG and GT genotypes. Other clinical and genetic factors may affect the metabolism of tamoxifen.
1183679785,A,A,Patients with the AA genotype may have decreased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1183679785,A,G,Patients with the AG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1183679785,G,G,Patients with the GG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.
1447964187,A,A,"Patients with the rs78655421 AA genotype (two copies of the CFTR R117H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117H. Other genetic and clinical factors may also influence response to ivacaftor."
1447964187,A,G,"Patients with the rs78655421 AG genotype (one copy of the CFTR R117H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117H. Other genetic and clinical factors may also influence response to ivacaftor."
1447964187,G,G,"Patients with the rs78655421 GG genotype (do not carry a copy of the CFTR R117H variant) have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117H. Other genetic and clinical factors may also influence response to ivacaftor."
1449296314,A,A,"Patients with the AA genotype may have decreased metabolism of folic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1449296314,A,G,"Patients with the AG genotype may have decreased metabolism of folic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1449296314,G,G,"Patients with the GG genotype may have increased metabolism of folic acid as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by DPWG, as it was determined to be not clinically actionable."
1447946212,A,A,Patients with the AA genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.
1447946212,A,G,Patients with the AG genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.
1447946212,G,G,Patients with the GG genotype may have a lower elevation in systolic blood pressure and a lower incidence of side effects when given regadenoson as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.
1447946219,A,A,"Patients with the AA genotype and osteosarcoma may be at decreased risk for mucositis when receiving methotrexate, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate."
1447946219,A,G,"Patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate."
1447946219,G,G,"No patients with the GG genotype were available for analysis, but patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate."
1447946226,C,C,"Patients with the CC genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate."
1447946226,C,T,"Patients with the CT genotype and osteosarcoma may have reduced severity of mucositis when receiving methotrexate, as compared to patients with the TT genotype, or increased severity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate."
1447946226,T,T,"Patients with the TT genotype and osteosarcoma may have increased severity of mucositis when receiving methotrexate, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence severity of mucositis in patients receiving methotrexate."
1447946233,A,A,"No patients with the AA genotype were available for analysis, but patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate."
1447946233,A,C,"Patients with the AC genotype and osteosarcoma who are receiving methotrexate may have a reduced risk for metastasis, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate."
1447946233,C,C,"Patients with the CC genotype and osteosarcoma who are receiving methotrexate may have an increased risk for metastasis, as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate."
1447960468,A,A,Patients with the AA genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.
1447960468,A,C,Patients with the AC genotype and cancer may have shorter progression-free survival times when treated with gemcitabine as compared to patients with the AA or CC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.
1447960468,C,C,Patients with the CC genotype and cancer may have longer progression-free survival times when treated with gemcitabine as compared to patients with the AC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.
1447960554,A,A,Patients with the AA genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960554,A,G,Patients with the AG genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960554,G,G,Patients with the GG genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960566,C,C,Patients with the CC genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960566,C,T,Patients with the CT genotype and hypertension may reach target blood pressure slower when treated with ramipril as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960566,T,T,Patients with the TT genotype and hypertension may reach target blood pressure faster when treated with ramipril as compared to patients with the CT genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving ramipril.
1447960649,A,A,Patients with the AA genotype and hypertension may have a smaller reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.
1447960649,A,C,Patients with the AC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.
1447960649,C,C,Patients with the CC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.
1447960850,A,A,Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.
1447960850,A,G,"Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AA genotype, and shorter overall survival times as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time."
1447960850,G,G,Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence survival time.
1447961178,A,A,"No patients with the AA genotype are available for analysis, but patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity."
1447961178,A,C,Patients with the AC genotype and colorectal cancer may have a decreased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence drug toxicity.
1447961178,C,C,Patients with the CC genotype and colorectal cancer may have an increased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence drug toxicity.
1447961337,A,A,Patients with the AA genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1447961337,A,G,"Patients with the AC genotype who take methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis."
1447961337,G,G,Patients with the GG genotype who take methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1447962751,C,C,Patients with the CC genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447962751,C,T,"Patients with the CT genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the TT genotype, and a smaller increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence HDL cholesterol levels."
1447962751,T,T,Patients with the TT genotype and hypercholesterolemia may have a smaller increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.
1447963255,C,C,"Pediatric patients with the CC genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse."
1447963255,C,T,"Pediatric patients with the CT genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse."
1447963255,T,T,"Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have a smaller risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of relapse."
1447981070,A,A,Patients with the AA genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1447981070,A,G,"Patients with the AG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype, and a poorer improvement as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab."
1447981070,G,G,Patients with the GG genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.
1447981158,C,C,Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981158,C,G,Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981158,G,G,Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981207,A,A,Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981207,A,T,Patients with the AT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981207,T,T,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981222,C,C,Patients with the CC genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981222,C,T,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981222,T,T,Patients with the TT genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981250,C,C,Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981250,C,T,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981250,T,T,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981259,A,A,Patients with the AA genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981259,A,G,Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981259,G,G,Patients with the GG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1448423795,C,C,Patients with the CC genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.
1448423795,C,G,"Patients with the CG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response."
1448423795,G,G,Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response.
1447981089,A,A,"Patients with the AA genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab."
1447981089,A,G,"Patients with the AG genotype and age-related macular degeneration may have greater improvement in visual acuity when treated with bevacizumab as compared to patients with the AA or GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab."
1447981089,G,G,"Patients with the GG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab."
1451511240,C,C,"Patients with acute lymphoblastic leukemia and the rs1544105 CC genotype may have decreased concentrations of methotrexate as compared to patients with the CT or TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
1451511240,C,T,"Patients with acute lymphoblastic leukemia and the rs1544105 CT genotype may have increased concentrations of methotrexate as compared to patients with the CC genotype but decreased concentrations as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
1451511240,T,T,"Patients with acute lymphoblastic leukemia and the rs1544105 TT genotype may have increased concentrations of methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1544105 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
1448109812,A,A,"Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1448109812,A,G,"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1448109812,G,G,"Patients with the GG genotype may have a dcreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AG or AA genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1447982582,G,G,Patients with the GG genotype and gout may have increased response when treated with allopurinol as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence allopurinol response.
1447982582,G,T,Patients with the GT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.
1447982582,T,T,Patients with the TT genotype and gout may have decreased response when treated with allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence allopurinol response.
1447981268,A,A,Patients with the AA genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981268,A,G,Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981268,G,G,Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447987087,C,C,"No patients with the CC genotype were available for analysis, but patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine."
1447987087,C,T,Patients with the CT genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987087,T,T,Patients with the TT genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.
1447987264,C,C,Patients with the CC genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.
1447987264,C,T,Patients with the CT genotype and prostate cancer who are treated with docetaxel may have a decreased risk of neuropathy as compared to patients with the TT genotypes and an increased risk of neuropathy as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.
1447987264,T,T,Patients with the TT genotype and prostate cancer who are treated with docetaxel may have an increased risk of neuropathy as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of neuropathy in patients with prostate cancer who are administered docetaxel.
1448099430,A,A,"Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia."
1448099430,A,G,"Pediatric patients with acute lymphoblastic leukemia and the AG genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the GG genotypes and an increased risk as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia."
1448099430,G,G,"Pediatric patients with acute lymphoblastic leukemia and the GG genotype may have an increased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia."
1448099454,A,G,Patients with the AG genotype may have decreased clearance of sulfasalazine as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).
1448099454,G,G,Patients with the GG genotype may have increased clearance of sulfasalazine as compared to patients with the AG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).
1448100187,A,A,Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AG and GG genotypes. Other factors may affect response to antidepressants.
1448100187,A,G,Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100187,G,G,Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448103832,A,A,Patients with the AA genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103832,A,G,"Patients with the AG genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism."
1448103832,G,G,Patients with the GG genotype may have an increased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103839,A,A,Patients with the AA genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103839,A,G,"Patients with the AG genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism."
1448103839,G,G,Patients with the GG genotype may have an increased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103846,A,A,Patients with the AA genotype and colorectal cancer may have longer progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448103846,A,G,Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448103846,G,G,Patients with the GG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448103882,A,A,"Patients with the AA genotype who are given amphetamine may have decreased stop reaction time, or reduced impulsivity, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence stop reaction time."
1448103882,A,G,"Patients with the AG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time."
1448103882,G,G,"Patients with the GG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time."
1448103889,A,A,Patients with the AA genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.
1448103889,A,G,"Patients with the AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence."
1448103889,G,G,Patients with the GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.
1448103910,C,C,Patients with the CC genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.
1448103910,C,T,Patients with the CT genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.
1448103910,T,T,Patients with the TT genotype who are addicted to heroin may have decreased withdrawal symptoms when treated with methadone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.
1448103942,A,A,Patients with the AA genotype may have an increased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103942,A,G,"Patients with the AG genotype may have an increased risk for alcoholism as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism."
1448103942,G,G,Patients with the GG genotype may have a decreased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103949,C,C,Patients with the CC genotype may have an increased risk for alcoholism as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103949,C,T,"Patients with the CT genotype may have an increased risk for alcoholism as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism."
1448103949,T,T,Patients with the TT genotype may have a decreased risk for alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism.
1448103956,C,C,Patients with the CC genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1448103956,C,G,"Patients with the CG genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction."
1448103956,G,G,Patients with the GG genotype may have an increased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1448103963,G,G,Patients with the GG genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103963,G,T,Patients with the GT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103963,T,T,Patients with the TT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103973,A,A,Patients with the AA genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103973,A,C,Patients with the AC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103973,C,C,Patients with the CC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448104005,A,A,Patients with the AA genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.
1448104005,A,T,"Patients with the AT genotype and schizophrenia may have an increased response to treatment with clozapine as compared to patients with the TT genotype, or a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine."
1448104005,T,T,Patients with the TT genotype and schizophrenia may have a decreased response to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.
1448104022,C,C,Patients with the CC genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104022,C,T,Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104022,T,T,Patients with the TT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104029,C,C,Patients with the CC genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104029,C,T,Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104029,T,T,Patients with the TT genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.
1448104036,C,C,Patients with the CC genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1448104036,C,T,"Patients with the CT genotype have an increased risk for cocaine addiction as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction."
1448104036,T,T,Patients with the TT genotype have a decreased risk for cocaine addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.
1448112147,C,C,"Patients with the CC genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea."
1448112147,C,T,"Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea."
1448112147,T,T,"Patients with the TT genotype and hormone insensitive breast cancer may experience increased risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the CT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea."
1448256864,A,A,Patients with the AA genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256864,A,G,Patients with the AG genotype and non-small cell lung cancer may have decreased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256864,G,G,Patients with the GG genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256872,G,G,Patients with the GG genotype and non-small cell lung cancer may have decreased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GT and TT genotypes. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.
1448256872,G,T,Patients with the GT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.
1448256872,T,T,Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.
1448256881,A,A,Patients with the AA genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256881,A,G,Patients with the AG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256881,G,G,Patients with the GG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1447963011,A,A,Patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of myelosuppression when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.
1447963011,A,C,Patients with the AC genotype and acute lymphoblastic leukemia may have an increased risk of myelosuppression when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.
1447963011,C,C,Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk of myelosuppression when treated with mercaptopurine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.
1448109578,G,G,"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109578,G,T,"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG and decreased likelihood as compared to patients with the TT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109578,T,T,"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109598,G,G,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109598,G,T,"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109598,T,T,"Patients with the TT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109605,C,C,"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CT or TT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109605,C,T,"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109605,T,T,"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or CT, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109802,G,G,"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1448109802,G,T,"Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1448109802,T,T,"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1451511344,A,A,Patients with acute lymphoblastic leukemia and the rs1051296 AA genotype may have increased concentrations of methotrexate as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.
1451511344,A,C,Patients with acute lymphoblastic leukemia and the rs1051296 AC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.
1451511344,C,C,Patients with acute lymphoblastic leukemia and the rs1051296 CC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.
1447982688,A,A,Patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1447982688,A,G,"No information are available for the AG genotype. However, patients with the AA genotype may have decreased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane."
1447982688,G,G,Patients with the GG genotype may have increased affinity of the AKR1C4 enzyme for exemestane based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1447982723,C,C,Patients with the CC genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine.
1447982723,C,T,Patients with the CT genotype and pulmonary fibrosis may have decreased response to N-acetylcysteine compared to patients with the TT genotype. Other genetic and clinical factors may affect response to N-acetylcysteine.
1447982723,T,T,Patients with the TT genotype and pulmonary fibrosis may have increased response to N-acetylcysteine compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect response to N-acetylcysteine.
1447982732,G,G,Patients with the GG genotype and asthma who are treated with corticosteroids may have an increased response to corticosteroids as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1447982732,G,T,Patients with the GT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1447982732,T,T,Patients with the TT genotype and asthma who are treated with corticosteroids may have a decreased response to corticosteroids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.
1447952936,A,A,Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.
1447952936,A,G,Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.
1447952936,G,G,Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with SSRIs.
1447953072,C,C,"Patients with the CC genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients."
1447953072,C,G,"Patients with the CG genotype and cancer may have an increased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients."
1447953072,G,G,"Patients with the GG genotype and cancer may have a decreased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients."
1447953116,A,A,Patients with the AA genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1447953116,A,G,Patients with the AG genotype and schizophrenia may have a decreased response to olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1447953116,G,G,Patients with the GG genotype and schizophrenia may have an increased response to olanzapine as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.
1447953123,C,C,Patients with the CC genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953123,C,G,Patients with the CG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953123,G,G,Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the CG and CG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953162,A,A,Patients with the AA genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1447953162,A,T,Patients with the AT genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1447953162,T,T,Patients with the TT genotype and schizophrenia may have a decreased response to antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.
1447953171,A,A,Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953171,A,G,Patients with the AG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953171,G,G,Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953178,A,A,Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953178,A,G,Patients with the AG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953178,G,G,Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953192,C,C,Patients with the CC genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.
1447953192,C,G,Patients with the CG genotype and major depressive disorder may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the CC and GG genotypes. Other genetic and clinical factors may also influence a patient's response to SSRIs.
1447953192,G,G,Patients with the GG genotype and major depressive disorder may have decreased response to selective serotonin reuptake inhibitors as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to SSRIs.
1447953212,G,G,Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953212,G,T,Patients with the GT genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953212,T,T,Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.
1447953263,C,C,"Patients with the rs2075572 CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone."
1447953263,C,G,"Patients with the rs2075572 CG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone."
1447953263,G,G,"There is currently no available evidence regarding the association between the rs2075572 GG genotype and severity of sleep disorders when treated with methadone. However, patients with the CG genotype and opioid dependence may have a decreased severity of sleep disorders when treated with methadone as compared to patients with the CC genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone."
1447953270,A,A,"Patients with the rs1799971 AA genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the AG and GG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the severity of sleep disorders when treated with methadone."
1447953270,A,G,"Patients with the rs1799971 AG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the severity of sleep disorders when treated with methadone."
1447953270,G,G,"Patients with the rs1799971 GG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the severity of sleep disorders when treated with methadone."
1447953277,A,A,Patients with the AA genotype and breast cancer may have a decreased risk of bone density loss when treated with exemestane as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.
1447953277,A,G,Patients with the AG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.
1447953277,G,G,Patients with the GG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.
1447953311,A,A,Patients with the AA genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447953311,A,G,Patients with the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447953311,G,G,Patients with the GG genotype may have an increased response to risperidone as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447953328,A,A,"Patients with the AA genotype and multiple myeloma may have an increased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with GG and AG genotypes. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide."
1447953328,A,G,"Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide."
1447953328,G,G,"Patients with the GG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AA genotypes. However, they may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide."
1447953340,A,A,"Patients with the AA genotype and multiple myeloma may have an increased response to thalidomide as compared to patients with the AC and CC genotypes. However, they may also be at increased risk for neutropenia when treated with lenalidomide compared to patients with genotypes AC and CC. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide."
1447953340,A,C,"Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide."
1447953340,C,C,"Patients with the CC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide."
1447953347,C,C,Patients with the CC genotype may have increased response to risperidone as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447953347,C,G,Patients with the CG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447953347,G,G,Patients with the GG genotype may have decreased response to risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.
1447959508,A,A,Patients with the AA genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
1447959508,A,G,Patients with the AG genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
1447959508,G,G,Patients with the GG genotype and acute lymphoblastic leukemia (ALL) may have an increased risk for hepatotoxicity when treated with asparaginase as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.
1447959731,C,C,Patients with the CC genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959731,C,T,"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype, or a decreased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
1447959731,T,T,Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959738,A,A,Patients with the AA genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959738,A,G,"Patients with the AG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the GG genotype, or an increased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
1447959738,G,G,Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447960211,A,A,Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1447960211,A,G,Patients with the AG genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1447960211,G,G,Patients with the GG genotype and non-small-cell lung cancer may have a better response to platinum-based chemotherapy as compared to patients with the AA or AG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.
1447961194,C,C,"Patients with the CC genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
1447961194,C,T,"Patients with the CT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
1447961194,T,T,"Patients with the TT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz."
1447962703,A,A,Patients with the AA genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962703,A,G,Patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962703,G,G,"No patients with the GG genotype were available for analysis, but patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response."
1447963070,C,C,Patients with the CC genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype. Other genetic and clinical factors may also influence body mass index.
1447963070,C,T,"Patients with the CT genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype, or a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index."
1447963070,T,T,Patients with the TT genotype who smoke tobacco may have a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index.
1447964331,G,G,Patients with the GG genotype and stomach cancer may have a poorer survival outcomes when treated with fluorouracil as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence survival outcome.
1447964331,G,T,Patients with the GT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
1447964331,T,T,Patients with the TT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
1447982739,C,C,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982739,C,T,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
1447982739,T,T,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982674,C,C,Patients with the CC genotype may have increased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1447982674,C,T,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane."
1447982674,T,T,Patients with the TT genotype may have decreased affinity of the AKR1C3 enzyme for exemestane based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of exemestane.
1447982754,C,C,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982754,C,T,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
1447982754,T,T,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982761,C,C,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982761,C,T,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
1447982761,T,T,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447983170,A,A,Patients with the AA genotype may have a decreased response to topiramate as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983170,A,C,Patients with the AC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983170,C,C,Patients with the CC genotype may have an increased response to topiramate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983177,A,A,Patients with the AA genotype may have a increased metabolism of mephenytoin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1447983177,A,G,Patients with the AG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1447983177,G,G,Patients with the GG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.
1447986872,A,A,"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986872,A,G,"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype and decreased concentrations of cottoning as compared to patients with the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986872,G,G,"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986902,A,A,"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986902,A,G,"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and decreased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986902,G,G,"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986910,A,A,"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986910,A,G,"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and decreased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986910,G,G,"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986925,A,A,"Individuals with Tobacco Use Disorder and the AA genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986925,A,G,"Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype and decreased concentrations of cottoning as compared to patients with the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447986925,G,G,"Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1448103860,C,C,Patients with the CC genotype who are stopping methadone treatment may have less of an increase in pulse rate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.
1448103860,C,T,Patients with the CT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.
1448103860,T,T,Patients with the TT genotype who are stopping methadone treatment may have more of an increase in pulse rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence increased pulse rate in patients stopping methadone treatment.
1448103928,C,C,Patients with the CC genotype may have an increased risk for flucloxacillin-induced liver injury as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.
1448103928,C,T,Patients with the CT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.
1448103928,T,T,Patients with the TT genotype may have a decreased risk for flucloxacillin-induced liver injury as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of flucloxacillin-induced liver injury.
1448104043,C,C,Female patients with the CC genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1448104043,C,G,"Female patients with the CG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or increased concentrations as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations."
1448104043,G,G,Female patients with the GG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1448104050,A,A,Female patients with the AA genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1448104050,A,G,"Female patients with the AG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or decreased concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations."
1448104050,G,G,Female patients with the GG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations.
1447983144,A,A,Patients with the AA genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.
1447983144,A,C,Patients with the AC genotype and epilepsy who are treated with valproic acid may have decreased bone density as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.
1447983144,C,C,Patients with the CC genotype and epilepsy who are treated with valproic acid may have increased bone density as compared to patients with the AA + AC genotype. Other genetic and clinical factors may also influence a patient's response to treatment and bone density.
1447983151,A,A,Patients with the AA genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1447983151,A,G,Patients with the AG genotype and hypertension who are treated with chlorthalidone may have an increased risk for stroke as compared to patients with A allele who are treated with amlodipine or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.
1447983151,G,G,No information were reported regarding patients with the GG genotype.
1447983163,C,C,Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983163,C,T,Patients with the CT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
1447983163,T,T,Patients with the TT genotype and Macular Degeneration who are treated with ranibizumab may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.
982045465,A,A,Subjects with AA genotypes may have increased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.
982045465,A,G,Subjects with AG genotypes may have increased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.
982045465,G,G,Subjects with GG genotypes may have decreased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with AA genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.
1447946169,A,A,"No patients with the AA genotype were available for analysis, but patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole."
1447946169,A,G,"Patients with the AG genotype who have invasive fungal infections may have increased concentrations of voriconazole, as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole."
1447946169,G,G,"Patients with the GG genotype who have invasive fungal infections may have decreased concentrations of voriconazole, as compared to patients with the AG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole."
1447960484,C,C,Patients with the CC genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.
1447960484,C,T,Patients with the CT genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.
1447960484,T,T,Patients with the TT genotype and hypertension may have a lesser reduction in blood pressure when treated with enalapril as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.
1447960502,A,A,Patients with the AA genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.
1447960502,A,G,Patients with the AG genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.
1447960502,G,G,Patients with the GG genotype and non-small-cell lung cancer may have a decreased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.
1447960582,A,A,Patients with the AA genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.
1447960582,A,C,Patients with the AC genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.
1447960582,C,C,Patients with the CC genotype and rheumatoid arthritis may have an increased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.
1447960656,A,A,Patients with the AA genotype and cirrhosis may have a greater decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.
1447960656,A,C,Patients with the AC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.
1447960656,C,C,Patients with the CC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.
1447960663,A,A,Patients with the AA genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.
1447960663,A,G,Patients with the AG genotype and coronary artery disease may have a poorer response when treated with quinapril as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to quinapril.
1447960663,G,G,Patients with the GG genotype and coronary artery disease may have a better response when treated with quinapril as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to quinapril.
1447960716,C,C,Patients with the CC genotype and HIV may have decreased concentrations of nevirapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.
1447960716,C,T,Patients with the CT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.
1447960716,T,T,Patients with the TT genotype and HIV may have increased concentrations of nevirapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of nevirapine.
1447960731,C,C,Patients with the CC genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960731,C,T,Patients with the CT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960731,T,T,Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447962710,C,C,Patients with the CC genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962710,C,T,Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962710,T,T,Patients with the TT genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.
1447962723,C,C,"Patients with the CC genotype may have a smaller increase in HDL cholesterol when treated with pravastatin as compared to patients with the CT or TT genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response."
1447962723,C,T,"Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response."
1447962723,T,T,"Patients with the TT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response."
1447963247,A,A,Patients with the AA genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to statins.
1447963247,A,G,"Patients with the AG genotype with high cholesterol may have a poorer response when treated with pravastatin or simvastatin as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins."
1447963247,G,G,Patients with the GG genotype with high cholesterol may have a better response when treated with pravastatin or simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statins.
1447979532,A,A,"Hepatic cells with the AA genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
1447979532,A,G,"Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
1447979532,G,G,"Hepatic cells with the GG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
1447979541,A,A,"Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
1447979541,A,G,"Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the GG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
1447979541,G,G,"Hepatic cells with the GG genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
1447979548,A,A,"Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AC or CC genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
1447979548,A,C,"Hepatic cells with the AC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
1447979548,C,C,"Hepatic cells with the CC genotype may have decreased expression of the CYP2A6 gene, resulting in decreased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism."
1447981410,G,G,Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.
1447981410,G,T,Patients with the GT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.
1447981410,T,T,Patients with the TT genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression in pancreatic cancer patients.
1447981430,C,C,Patients with the CC genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.
1447981430,C,G,Patients with the CG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.
1447981430,G,G,Patients with the GG genotype and pancreatic cancer may have a shorter time to progression when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.
1447981440,G,G,Patients with the GG genotype and pancreatic cancer may have a longer time to progression and overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.
1447981440,G,T,Patients with the GT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.
1447981440,T,T,Patients with the TT genotype and pancreatic cancer may have a shorter time to progression and overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence time to progression and overall survival time in patients with pancreatic cancer.
1447981457,C,C,Patients with the CC genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981457,C,T,Patients with the CT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981457,T,T,Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981465,A,A,Patients with the AA genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981465,A,G,Patients with the AG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981465,G,G,Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981474,G,G,Patients with the GG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981474,G,T,Patients with the GT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447981474,T,T,Patients with the TT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.
1447983137,C,C,"Patients with the CC genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke."
1447983137,C,T,"Patients with the CT genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke."
1447983137,T,T,No information were reported regarding patients with the TT genotype.
1447987124,A,A,"Patients with the AA genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy or myalgia as compared with patients with the AG or GG genotypes, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins."
1447987124,A,G,"Patients with the AG genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy and myalgia as compared with patients with the GG genotypes and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins."
1447987124,G,G,"Patients with the GG genotype and cardiovascular disease who are taking a statin may have a decreased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the AG or GG genotypes, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins."
1448123001,A,A,Patients with the AA genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.
1448123001,A,G,Patients with the AG genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.
1448123001,G,G,Patients with the GG genotype may have poorer response to losartan in people with hypertension as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence the response to losartan.
1448124426,A,A,Children with the AA genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.
1448124426,A,G,Children with the AG genotype and acute lymphoblastic leukemia may have reduced risk of neurotoxicity when taking methotrexate compared to children with the GG genotype. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.
1448124426,G,G,Children with the GG genotype and acute lymphoblastic leukemia may have increased risk of neurotoxicity when taking methotrexate compared to children with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicity when taking methotrexate.
1448265017,A,A,Patients with genotype AA may have increased sustained virological response (svr) when treated with peginterferon/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/ribavirin therapy.
1448265017,A,G,Patients with genotype AG may have increased sustained virological response (svr) when treated with peginterferon/ribavirin therapy in people with Hepatitis C as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/ribavirin therapy.
1448265017,G,G,Patients with genotype GG may have decreased sustained virological response (svr) when treated with peginterferon/ribavirin therapy in people with Hepatitis C as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon/ribavirin therapy.
1448266396,A,A,"This study did not contain individuals with the AA genotype, though individuals with the AA genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics."
1448266396,A,G,Patients with the AG genotype and psychiatric disorders may have reduced clearance of risperidone compared to patients with the GG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.
1448266396,G,G,Patients with the GG genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the AG genotype. Other clinical and genetic factors likely affect risperidone pharmacokinetics.
1448266413,C,C,Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect clearance of risperidone.
1448266413,C,T,Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.
1448266413,T,T,Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotype. Other clinical and genetic factors may affect clearance of risperidone.
1448266429,C,C,Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect clearance of risperidone.
1448266429,C,T,Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.
1448266429,T,T,Patients with the TT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.
1447960204,C,C,Patients with the CC genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.
1447960204,C,G,Patients with the CG genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.
1447960204,G,G,Patients with the GG genotype and hypertension may have an increased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.
1447980691,C,C,Patients with the CC genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980691,C,T,"Patients with the CT genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype, or less severe effects and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone."
1447980691,T,T,Patients with the TT genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447983940,A,A,Pediatric patients with epilepsy and the AA genotype may have increased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AC or CC genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.
1447983940,A,C,Pediatric patients with epilepsy and the AC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.
1447983940,C,C,Pediatric patients with epilepsy and the CC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.
1447983949,A,A,"Individuals with Tobacco Use Disorder and the AA genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447983949,A,G,"Individuals with Tobacco Use Disorder and the AG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and increased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1447983949,G,G,"Individuals with Tobacco Use Disorder and the GG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AA and and AG genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder."
1448531661,A,A,Patients with the AA genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AG and GG genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448531661,A,G,Patients with the AG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448531661,G,G,Patients with the GG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448567797,C,C,Patients with the CC genotype who underwent kidney transplantation may have increased trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.
1448567797,C,T,Patients with the CT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.
1448567797,T,T,Patients with the TT genotype who underwent kidney transplantation may have decreased trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus trough concentrations.
1450930440,A,A,Patients with the AA genotype may begin using heroin at a later age as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.
1450930440,A,G,Patients with the AG genotype may begin using heroin at a later age as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's age at first use of heroin.
1450930440,G,G,Patients with the GG genotype may begin using heroin at an earlier age as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's age at first use of heroin.
1450931410,C,C,Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931410,C,T,Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the TT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450931410,T,T,Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC or CT genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1447960257,C,C,"Patients with the CC genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy."
1447960257,C,T,"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy."
1447960257,T,T,"Patients with the TT genotype and age-related macular degeneration may have a poorer response to treatment with photodynamic therapy as compared to patients with the CC or CT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy."
1447963078,A,A,"Patients with the rs578776 AA genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels."
1447963078,A,G,"Patients with the rs578776 AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels."
1447963078,G,G,"Patients with the rs578776 GG genotype may have an increased risk for nicotine dependence as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels."
1451810680,C,C,Patients with rheumatoid arthritis and the rs2292596 CC genotype may have increased response to methotrexate as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451810680,C,G,Patients with rheumatoid arthritis and the rs2292596 CG genotype may have decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451810680,G,G,Patients with rheumatoid arthritis and the rs2292596 GG genotype may have decreased response to methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methotrexate.
1448098376,C,C,Patients with the CC genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.
1448098376,C,T,Patients with the CT genotype and schizophrenia or psychotic disorder may have reduced metabolism of antiepileptics compared to patients with the TT genotype. Other factor may affect metabolism of antiepileptics.
1448098376,T,T,Patients with the TT genotype and schizophrenia or psychotic disorder may have increased metabolism of antiepileptics compared to patients with the CC or CT genotype. Other factor may affect metabolism of antiepileptics.
1448099118,A,A,"No patients with the AA genotype were available for analysis, but patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance."
1448099118,A,C,Patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448099118,C,C,Patients with the CC genotype may have decreased clearance of rifampin as compared to patients with the AC genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448102644,A,A,Patients with the AA genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448102644,A,C,Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448102644,C,C,Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448107270,C,C,Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1448107270,C,T,Patients with retinal disease and the CT genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the TT genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1448107270,T,T,Patients with retinal disease and the TT genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1448107277,C,C,Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1448107277,C,G,Patients with retinal disease and the CG genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the GG genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1448107277,G,G,Patients with retinal disease and the GG genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CG or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.
1448263285,A,A,"Patients undergoing neurosurgery and with the AA genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane."
1448263285,A,C,"Patients undergoing neurosurgery and with the AC genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane."
1448263285,C,C,"Patients undergoing neurosurgery and with the CC genotype may experience lesser severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the AA genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane."
1447963604,A,A,Patients with the AA genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of smoking addiction.
1447963604,A,G,"Patients with the AG genotype who smoke tobacco may have an increased risk of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction."
1447963604,G,G,Patients with the GG genotype who smoke tobacco may have a decreased risk of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of smoking addiction.
1447963644,G,G,Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.
1447963644,G,T,Patients with the GT genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also influence response to clozapine.
1447963644,T,T,Patients with the TT genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to clozapine.
1447963688,A,A,Patients with the AA genotype may be less likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence THC dependency.
1447963688,A,C,Patients with the AC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency.
1447963688,C,C,Patients with the CC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency.
1447963713,A,A,Patients with the AA genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.
1447963713,A,G,"Patients with the AG genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine."
1447963713,G,G,Patients with the GG genotype and schizophrenia may have an increased likelihood of obesity when treated with olanzapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.
1447990902,A,A,Patients with hypertension and the AA genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.
1447990902,A,C,Patients with hypertension and the AC genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and geneticc factors may also influence response to enalapril in patients with hypertension.
1447990902,C,C,Patients with hypertension and the CC genotype may have a worse response to enalapril as compared to patients with the AA or AC genotype. Other clinical and genetic factors may also influence response to enalapril in patients with hypertension.
1448097768,A,A,Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097768,A,G,Patients with non-small cell lung cancer and the AG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097768,G,G,Patients with non-small cell lung cancer and the GG genotype may have a increased response to cisplatin and gemcitabine as compared to the AA genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097775,C,C,Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097775,C,T,Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097775,T,T,Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC and CT genotype. Please note: the difference was only significant when combining the effect of the TT genotype at rs720106 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448098213,A,A,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.
1448098213,A,G,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.
1448098213,G,G,Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.
1448605477,A,A,Patients with the AA genotype who are undergoing organ transplantation may have an increased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for NODAT.
1448605477,A,G,"Patients with the AG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype, or increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for NODAT."
1448605477,G,G,Patients with the GG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for NODAT.
1447963979,A,A,"Patients with the AA genotype and specificially localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics."
1447963979,A,G,"Patients with the AG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics."
1447963979,G,G,"Patients with the GG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics."
1447987204,C,C,Patients with diabetes mellitus and the rs7754840 CC genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and GG genotypes. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors.
1447987204,C,G,Patients with diabetes mellitus and the rs7754840 CG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype but a worse response as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors.
1447987204,G,G,Patients with diabetes mellitus and the rs7754840 GG genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and CC genotypes. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors.
1447980699,A,A,Patients with the AA genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980699,A,G,"Patients with the AG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or less severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone."
1447980699,G,G,Patients with the GG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980706,A,A,Patients with the AA genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.
1447980706,A,G,"Patients with the AG genotype who are heroin dependent may have more severe side effects when treated with methadone as compared to patients with the GG genotype, or less severe side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone."
1447980706,G,G,Patients with the GG genotype who are heroin dependent may have less severe side effects when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.
1447980713,A,A,Patients with the AA genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980713,A,G,"Patients with the AG genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the GG genotype, or more severe side effects and symptoms as compared to those with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone."
1447980713,G,G,Patients with the GG genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.
1447980724,C,C,Patients with the CC genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980724,C,T,"Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the TT genotype, and a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment."
1447980724,T,T,Patients with the TT genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980740,C,C,Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980740,C,G,Patients with the CG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980740,G,G,Patients with the GG genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980753,C,C,Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980753,C,T,Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980753,T,T,Patients with the TT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.
1447980767,A,A,Patients with the AA genotype and growth hormone deficiency who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant may require a decreased dose of recombinant human growth hormone (somatropin) as compared to patients with the CC genotype who are also homozygotes of the full length GHR gene. Other genetic and clinical factors may also influence dose of somatropin.
1447980767,A,C,This genotype was not analyzed in this study.
1447980767,C,C,Patients with the CC genotype and growth hormone deficiency who are also homozygotes of the full length GHR gene may require an increased dose of recombinant human growth hormone (somatropin) as compared to patients with the AA genotype who are also carriers of the growth hormone receptor (GHR) d3 (deletion of exon 3) variant. Other genetic and clinical factors may also influence dose of somatropin.
1447980875,A,A,Pediatric patients with the AA genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.
1447980875,A,G,Pediatric patients with the AG genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.
1447980875,G,G,Pediatric patients with the GG genotype and HIV may have increased clearance of nevirapine as compared to pediatric patients with the AA or AG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.
1447980897,A,A,Patients with the rs77010898 AA genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.
1447980897,A,G,Patients with the rs77010898 AG genotype and cystic fibrosis may receive benefit when treated with ivacaftor and curcumin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.
1447980897,G,G,Patients with the rs77010898 GG genotype and cystic fibrosis may not receive benefit when treated with ivacaftor and curcumin as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.
1447990296,C,C,"In vitro, the CC genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the CG and GG genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen."
1447990296,C,G,"In vitro, the CG genotype is associated with decreased expression of TRAF1, increased expression of MIRLET7I, and increased sensitivity to endoxifen as compared to the GG genotype and increased expression of TRAF1, decreased expression of MIRLET7I and decreased sensitivity to endoxifen as compared to the CC genotype. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen."
1447990296,G,G,"In vitro, the GG genotype is associated with increased expression of TRAF1, decreased expression of MIRLET7I, and decreased sensitivity to endoxifen as compared to the CG and CC genotypes. Other clinical and genetic factors may also influence expression of TRAF1, MIRLET7I, and sensitivity to endoxifen."
1448112052,C,C,Patients with the CC genotype and anxiety disorder or major depression may have increased risk of becoming agitated when taking citalopram compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.
1448112052,C,G,Patients with the CG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.
1448112052,G,G,Patients with the GG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.
1448256890,C,C,Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256890,C,T,Patients with the CT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256890,T,T,Patients with the TT genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum-based compound chemotherapy compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.
1448256898,C,C,Patients with the CC genotype and non-small cell lung cancer may have decreased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.
1448256898,C,G,Patients with the CG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.
1448256898,G,G,Patients with the GG genotype and non-small cell lung cancer may have increased risk of drug toxicities when treated with platinum compound chemotherapies compared to patients with CC genotype. Other clinical and genetic factors may affect risk of toxicities with platinum compound therapies.
1448276370,C,C,Patients with the CC genotype and ANCA-associated vasculitis may have shorter time to failure when treated with rituximab compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to rituximab.
1448276370,C,T,Patients with the CT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.
1448276370,T,T,Patients with the TT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.
1448428918,C,C,Patients with the CC genotype and gout may require a dose of 300 mg/day or higher equivalent of allopurinol or febuxostat compared to patients with the TT genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.
1448428918,C,T,Patients with the CT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.
1448428918,T,T,Patients with the TT genotype and gout may require a dose lower than 300 mg/day equivalent of allopurinol or febuxostat compared to patients with the CC genotype. Other clinical and genetic factors may affect allopurinol and febuxostat dose.
1447963821,C,C,Patients with the CC genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447963821,C,G,Patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447963821,G,G,"No patients with the GG genotype were available for analysis, but patients with the CG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate."
1447963829,G,G,Patients with the GG genotype and hypertriglyceridemia may have a smaller decrease in triglycerides when treated with fenofibrate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447963829,G,T,Patients with the GT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447963829,T,T,Patients with the TT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447964002,C,C,Patients with the CC genotype and schizophrenia may have lower weight gain when treated with olanzapine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence weight gain.
1447964002,C,G,Patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain.
1447964002,G,G,"No patients with the GG genotype were available for analysis, but patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain."
1447964164,A,A,Patients with the AA genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.
1447964164,A,G,"Patients with the AG genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype, or decreased oxidative stress as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs."
1447964164,G,G,Patients with the GG genotype and hypercholesterolemia may have decreased oxidative stress in response to treatment with atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.
1447989777,C,C,Patients with the CC genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity.
1447989777,C,T,Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity.
1447989777,T,T,"No patients with the TT genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence DPYD activity."
1447989796,C,C,"No patients with the CC genotype were available for analysis, but patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil."
1447989796,C,T,Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.
1447989796,T,T,Patients with the TT genotype may have increased DPYD activity when exposed to fluorouracil as compared to patients with the CT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.
1447989803,A,A,Patients with the AA genotype and pancreatic cancer may have an increased chance of survival when treated with fluorouracil as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.
1447989803,A,G,Patients with the AG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.
1447989803,G,G,Patients with the GG genotype and pancreatic cancer may have a decreased chance of survival when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.
1448101213,A,A,"No patients with the AA genotype were available for analysis, but patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking."
1448101213,A,G,Patients with the AG genotype who are smokers may have increased physical responses to smoking as compared to patients with the GG genotype. Other genetic and clinical factors may also influence physical responses to smoking.
1448101213,G,G,Patients with the GG genotype who are smokers may have decreased physical responses to smoking as compared to patients with the AG genotype. Other genetic and clinical factors may also influence physical responses to smoking.
1448258734,A,A,Patients with the AA genotype may have increased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to sorafenib.
1448258734,A,G,Patients with the AG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.
1448258734,G,G,Patients with the GG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.
1448259025,A,A,Patients with the AA genotype may have decreased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype TT.
1448259025,A,T,Patients with the AT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.
1448259025,T,T,Patients with the TT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.
1447989732,A,A,"Both variants of rs72549306 are assigned normal function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to those with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1447989732,A,C,"Both variants of rs72549306 are assigned normal function by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to those with the CC genotype. However, data is limited and evidence for no association exists. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1447989732,C,C,"Both variants of rs72549306 are assigned normal function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to those with the CA or AA genotype. However, data is limited and evidence for no association exists. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1447989739,A,A,"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1447989739,A,C,"The A allele of rs78060119 is assigned no function by CPIC. Patients with the AC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1447989739,C,C,"The A allele of rs78060119 is assigned no function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1447953199,C,C,Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran
1447953199,C,G,Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran
1447953199,G,G,Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran
1447953354,C,C,Patients with the CC genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447953354,C,T,Patients with the CT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447953354,T,T,Patients with the TT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447960352,A,A,"No patients with the AA genotype are available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients."
1447960352,A,G,Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.
1447960352,G,G,Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival time in non-small-cell lung cancer patients.
1447963674,A,A,Patients with the AA genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1447963674,A,G,"Patients with the AG genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction."
1447963674,G,G,Patients with the GG genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1447963798,C,C,Women with the CC genotype and hypertensive nephrosclerosis may have a better response to treatment with metoprolol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to metoprolol.
1447963798,C,T,Women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol.
1447963798,T,T,"No women with the TT genotype were available for analysis, but women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol."
1448262537,C,C,Patients with the CC genotype may have higher on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448262537,C,T,Patients with the CT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448262537,T,T,Patients with the TT genotype may have lower on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1447989784,C,C,"The T allele of this variant is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have a decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1447989784,C,T,"The T allele of this variant is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1447989784,T,T,"The T allele of this variant is a marker for the HapB3 allele and is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1447989671,G,G,The del allele of rs72549303 is assigned no function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the G/del or del/del genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1447989706,A,A,The A allele of rs1801266 is assigned no function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1447989706,A,G,The A allele of rs1801266 is assigned no function by CPIC. Patients with the AG genotype may have decreased DPYD activity as compared to those with the GG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1447989706,G,G,The A allele of rs1801266 is assigned no function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1447989723,A,A,The A allele of rs1801268 is assigned no function by CPIC. Patients with the AA genotype may have decreased DPYD activity as compared to those with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1447989723,A,C,The A allele of rs1801268 is assigned no function by CPIC. Patients with the AC genotype may have decreased DPYD activity as compared to those with the CC genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1447989723,C,C,The A allele of rs1801268 is assigned no function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to those with the AC or AA genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.
1451829900,A,A,Patients with the rs7662029 AA genotype who are treated with sublingual buprenorphine/naloxone may have increased plasma levels of buprenorphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7662029 and buprenorphine / naloxone and does not include evidence about clinical outcomes.
1451829900,A,G,Patients with the rs7662029 AG genotype who are treated with sublingual buprenorphine/naloxone may have increased plasma levels of buprenorphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7662029 and buprenorphine / naloxone and does not include evidence about clinical outcomes.
1451829900,G,G,Patients with the rs7662029 GG genotype who are treated with sublingual buprenorphine/naloxone may have decreased plasma levels of buprenorphine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7662029 and buprenorphine / naloxone and does not include evidence about clinical outcomes.
1451832220,C,C,Patients with the rs7439366 CC genotype who are treated with sublingual buprenorphine/naloxone may have decreased plasma levels of buprenorphine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence plasma levels of buprenorphine. This annotation only covers the pharmacokinetic relationship between rs7439366 and buprenorphine / naloxone and does not include evidence about clinical outcomes.
1451832220,C,T,Patients with the rs7439366 CT genotype who are treated with sublingual buprenorphine/naloxone may have increased plasma levels of buprenorphine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs7439366 and buprenorphine / naloxone and does not include evidence about clinical outcomes.
1447960245,A,A,Patients with the AA genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.
1447960245,A,C,Patients with the AC genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.
1447960245,C,C,Patients with the CC genotype and cancer may have decreased survival time and a decreased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.
1447963227,A,A,Patients with the AA genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.
1447963227,A,C,"Patients with the AC genotype who abused cocaine may have an increased risk of death from cocaine intoxication as compared to patients with the CC genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death."
1447963227,C,C,Patients with the CC genotype who abused cocaine may have a decreased risk of death from cocaine intoxication as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of cocaine-related death.
1447963432,A,A,Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.
1447963432,A,G,Patients with the AG genotype and hypertension may have an increased risk of stroke when treated with ACE inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of stroke.
1447963432,G,G,Patients with the GG genotype and hypertension may have a decreased risk of stroke when treated with ACE inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of stroke.
1447964123,A,A,Patients with the AA genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype. Cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs.
1447964123,A,T,"Patients with the AT genotype and tuberculosis (TB) may have an increased risk for anti-TB drug-induced hepatitis as compared to patients with the TT genotype, or decreased risk as compared to patients with the AA genotype. Patients with the AT genotype may also have decreased clearance of isoniazid as compared to patients with the TT genotype. Additionally, cells with the A allele have been shown to result in decreased transcription of the NAT2 gene as compared to those with the T allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs."
1447964123,T,T,"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for anti-TB drug-induced hepatitis as compared to patients with the AA genotype. Patients with the TT genotype may also have increased clearance of isoniazid as compared to patients with the AT genotype. Additionally, cells with the T allele have been shown to result in increased transcription of the NAT2 gene as compared to those with the A allele. Other genetic and clinical factors may also influence risk of hepatitis in patients taking anti-TB drugs."
1447964264,C,C,Patients with the CC genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964264,C,G,Patients with the CG genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964264,G,G,Patients with the GG genotype and ADHD may show slower improvement of symptoms when treated with methylphenidate as compared to patients with the CC and CG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1448256091,C,C,Patients with the CC genotype may have increased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT.
1448256091,C,T,Patients with the CT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.
1448256091,T,T,Patients with the TT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.
1448266177,C,C,"Patients with genotype CC may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy."
1448266177,C,G,"Patients with genotype CG may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy."
1448266177,G,G,"Patients with genotype GG may have better rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy."
1448423763,G,G,Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence quetiapine response.
1448423763,G,T,"Patients with the GT genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response."
1448423763,T,T,Patients with the TT genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.
1448423788,A,A,Patients with the AA genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.
1448423788,A,G,"Patients with the AG genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response."
1448423788,G,G,Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response.
1448424039,G,G,Patients with the GG genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to furosemide.
1448424039,G,T,"Patients with the GT genotype and decompensated heart failure may have less weight loss when treated with furosemide as compared to patients with the TT genotype, or greater weight loss as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide."
1448424039,T,T,Patients with the TT genotype and decompensated heart failure may have greater weight loss when treated with furosemide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to furosemide.
1448431545,C,C,"Patients with the CC genotype and heart valve replacement may require a lower stable dose of warfarin compared to patients with the CT and TT genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin."
1448431545,C,T,"Patients with the CT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin."
1448431545,T,T,"Patients with the TT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin."
1447953029,C,C,"Patients with the rs193922770 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447953029,C,T,"Patients with the rs193922770 CT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447953029,T,T,"Patients with the rs193922770 TT genotype may develop malignant hyperthermia when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CC genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia."
1447990050,C,C,"Patients with the CC genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, and as compared to patients with the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease."
1447990050,C,T,"Patients with the CT genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease."
1447990050,T,T,"Patients with the TT genotype and Lewy Body disease or Alzheimer's disease may have worse response to rivastigmine as compared to patients with the CC genotype, as well as the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease."
1448097405,C,C,Patients with the CC genotype and breast neoplasms may have reduced disease-free survival when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.
1448097405,C,T,Patients with the CT genotype and breast neoplasms may have increased disease-free survival when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival with tamoxifen treatment.
1448097405,T,T,No patients with the TT genotype were included in analysis of the association between genotype and disease-free survival in response to tamoxifen treatment in patients with breast neoplasms.
1448097600,C,C,"Patients with HIV and the CC genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CT or TT genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097600,C,T,"Patients with HIV and the CT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097600,T,T,"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448099125,A,A,Patients with the AA genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448099125,A,G,Patients with the AG genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448099125,G,G,Patients with the GG genotype may have decreased clearance of rifampin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence rifampin clearance.
1448256689,C,C,Patients with the CC genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
1448256689,C,T,Patients with the CT genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.
1448256689,T,T,Patients with the TT genotype may have decreased response to metformin in people with Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to metformin.
1448266663,C,C,Patients with the CC genotype may have a worse response to statin therapy compared to patients with the TT genotype. Other clinical and genetic factors may affect response to statins.
1448266663,C,T,Patients with the CT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.
1448266663,T,T,Patients with the TT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.
1448266838,A,A,Patients with the AA genotype and epilepsy may have increased concentrations of carbamazepine compared to patients with the AG and GG genotypes when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.
1448266838,A,G,Patients with the AG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.
1448266838,G,G,Patients with the GG genotype and epilepsy may have decreased concentrations of carbamazepine compared to patients with the AA genotype when patients were also taking phenytoin or phenobarbital. Other clinical and genetic factors may affect concentrations of carbamazepine.
1448526040,A,A,"Patients with the rs10485058 AA genotype who are opioid-dependent may have an increased response to treatment with methadone as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response."
1448526040,A,G,"Patients with the rs10485058 AG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response."
1448526040,G,G,"Patients with the rs10485058 GG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response."
1447963063,C,C,Cells with the CC genotype may have decreased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CT genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.
1447963063,C,T,Cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1.
1447963063,T,T,"No cells with the TT genotype were available for analysis, but cells with the CT genotype may have increased expression of both the FKBP5 and NR3C1 genes when exposed to gemcitabine as compared to cells with the CC genotype. Other genetic and clinical factors may also influence expression of FKBP5 and NR3C1."
1447964091,C,C,"Patients with the CC genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug."
1447964091,C,T,"Patients with the CT genotype may be less likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug."
1447964091,T,T,"Patients with the TT genotype may be more likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug."
1447980968,A,A,Patients with the AA genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.
1447980968,A,G,Patients with the AG genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.
1447980968,G,G,Patients with the GG genotype and Type 2 Diabetes may have decreased response to metformin compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affects response to metformin.
1447983057,C,C,"Patients with the CC genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983057,C,T,"Patients with the CT genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983057,T,T,"Patients with the TT genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983064,A,A,"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983064,A,G,"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983064,G,G,"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983818,A,A,Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1447983818,A,G,"Patients with the AG genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics."
1447983818,G,G,Patients with the GG genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1448098947,A,A,Patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.
1448098947,A,G,Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.
1448098947,G,G,Patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.
1448262901,C,C,Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT or CT in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262901,C,T,Patients with the CT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262901,T,T,Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262908,C,C,Patients with the CC genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262908,C,G,Patients with the CG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262908,G,G,Patients with the GG genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1447960179,A,A,Patients with the AA genotype and heart failure may have decreased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447960179,A,G,"Patients with the AG genotype and heart failure may have decreased emergency department (ED) visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the GG genotype, and increased ED visits and hospital utilization as compared to those with the AA genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs."
1447960179,G,G,Patients with the GG genotype and heart failure may have increased emergency department visits and hospital utilization when treated with cardiovascular drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447960218,A,A,"Patients with the AA genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole."
1447960218,A,G,"Patients with the AG genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype, or increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole."
1447960218,G,G,"Patients with the GG genotype may have increased clearance of voriconazole as compared to patients with the AA genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole."
1447960225,A,A,Patients with the AA genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.
1447960225,A,G,Patients with the AG genotype and hypertension may have a greater reduction in systolic blood pressure when treated with nifedipine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.
1447960225,G,G,Patients with the GG genotype and hypertension may have a lesser reduction in systolic blood pressure when treated with nifedipine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure response to nifedipine.
1447960387,A,A,"Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960387,A,G,"Patients with the AG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960387,G,G,"Patients with the GG genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960403,A,A,"Patients with the AA genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960403,A,G,"Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960403,G,G,"Patients with the GG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960599,A,A,Patients with the AA genotype and hypertension may have a greater reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence pulse wave velocity.
1447960599,A,C,Patients with the AC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.
1447960599,C,C,Patients with the CC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.
1447960795,C,C,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960795,C,T,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960795,T,T,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960803,G,G,Patients with the GG genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960803,G,T,Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447960803,T,T,Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.
1447961322,C,C,Patients with the CC genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1447961322,C,T,"Patients with the CT genotype who use methamphetamine may have an increased risk for methamphetamine psychosis as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis."
1447961322,T,T,Patients with the TT genotype who use methamphetamine may have a decreased risk for methamphetamine psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine psychosis.
1448432217,A,A,Patients with the AA genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448432217,A,G,Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1448432217,G,G,Patients with the GG genotype and colorectal cancer may have longer progression-free survival times when treated with bevacizumab-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival time.
1449191564,A,A,Patients with the rs397508139 AA genotype (two copies of the CFTR I336K variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.
1449191564,A,T,Patients with the rs397508139 AT genotype (one copy of the CFTR I336K variant) and cystic fibrosis may respond to ivacaftor treatment. Response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.
1449191564,T,T,"Patients with the rs397508139 TT genotype (do not have a copy of the CFTR I336K variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191574,C,C,"Patients with the rs77409459 CC genotype (do not have a copy of the CFTR T338I variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191574,C,T,Patients with the rs77409459 CT genotype (one copy of the CFTR T338I variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191574,T,T,Patients with the rs77409459 TT genotype (two copies of the CFTR T338I variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191643,A,A,"Patients with the rs121908753 AA genotype (two copies of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence response to ivacaftor."
1449191643,A,G,"Patients with the rs121908753 AG genotype (one copy of the CFTR R352Q variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence response to ivacaftor."
1449191643,G,G,"Patients with the rs121908753 GG genotype (do not have a copy of the CFTR R352Q variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R352Q. Other genetic and clinical factors may also influence response to ivacaftor."
1449191649,A,A,"Patients with the rs74551128 AA genotype (two copies of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence response to ivacaftor."
1449191649,A,C,"Patients with the rs74551128 AC genotype (one copy of the CFTR A455E variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence response to ivacaftor."
1449191649,C,C,"Patients with the rs74551128 CC genotype (do not have a copy of the CFTR A455E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A455E. Other genetic and clinical factors may also influence response to ivacaftor."
1449191664,A,A,"Patients with the rs397508288 AA genotype (do not have a copy of the CFTR D579G variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence response to ivacaftor."
1449191664,A,G,"Patients with the rs397508288 AG genotype (one copy of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence response to ivacaftor."
1449191664,G,G,"Patients with the rs397508288 GG genotype (two copies of the CFTR D579G variant) and cystic fibrosis may respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D579G. Other genetic and clinical factors may also influence response to ivacaftor."
1449191682,C,C,"Patients with the rs397508442 CC genotype (do not have a copy of the CFTR S945L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence response to ivacaftor."
1449191682,C,T,"Patients with the rs397508442 CT genotype (one copy of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence response to ivacaftor."
1449191682,T,T,"Patients with the rs397508442 TT genotype (two copies of the CFTR S945L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including S945L. Other genetic and clinical factors may also influence response to ivacaftor."
1447961371,C,C,Cells with the CC genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype. Other factors may also influence uptake of these drugs.
1447961371,C,T,"Cells with the CT genotype may have increased uptake of catecholamines or metformin as compared to those with the TT genotype, or decreased uptake as compared to those with the CC genotype. Other factors may also influence uptake of these drugs."
1447961371,T,T,Cells with the TT genotype may have decreased uptake of catecholamines or metformin as compared to those with the CC genotype. Other factors may also influence uptake of these drugs.
1447961389,C,C,Smokers with the CC genotype who are treated with nicotine gum or nicotine patches may have a greater likelihood of abstinence as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.
1447961389,C,T,Smokers with the CT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.
1447961389,T,T,Smokers with the TT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.
1447963004,A,A,"Patients with the AA genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin."
1447963004,A,C,"Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin."
1447963004,C,C,"Patients with the CC genotype and cystic fibrosis may have increased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin."
1447963049,C,C,Patients with the CC genotype were not studied. Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447963049,C,G,Patients with the CG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447963049,G,G,Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1447963442,A,A,Patients with the AA genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.
1447963442,A,G,Patients with the AG genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.
1447963442,G,G,Patients with the GG genotype and chronic myeloid leukemia may have a lower rate of major cytogenetic response when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.
1449191708,G,G,"Patients with the rs150212784 GG genotype (two copies of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence response to ivacaftor."
1449191708,G,T,"Patients with the rs150212784 GT genotype (one copy of the CFTR F1052V variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence response to ivacaftor."
1449191708,T,T,"Patients with the rs150212784 TT genotype (do not have a copy of the CFTR F1052V variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1052V. Other genetic and clinical factors may also influence response to ivacaftor."
1449191722,A,A,"Patients with the rs397508513 AA genotype (do not have a copy of the CFTR K1060T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence response to ivacaftor."
1449191722,A,C,"Patients with the rs397508513 AC genotype (one copy of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence response to ivacaftor."
1449191722,C,C,"Patients with the rs397508513 CC genotype (two copies of the CFTR K1060T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including K1060T. Other genetic and clinical factors may also influence response to ivacaftor."
1447963458,C,C,Pediatric patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to corticosteroids.
1447963458,C,G,Pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids.
1447963458,G,G,"No patients with the GG genotype were available for analysis, but pediatric patients with the CG genotype and asthma may have a better response when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids."
1447963681,A,A,Patients with the AA genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1447963681,A,C,"Patients with the AC genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction."
1447963681,C,C,Patients with the CC genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1447964010,A,A,"Patients with the AA genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels."
1447964010,A,G,"Patients with the AG genotype and HIV may have decreased plasma levels of efavirenz as compared to patients with the GG genotype, and increased plasma levels as compared to those with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels."
1447964010,G,G,"Patients with the GG genotype and HIV may have increased plasma levels of efavirenz as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as rs3745274, may also influence efavirenz levels."
1447964025,A,A,Patients with the AA genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hepatotoxicity.
1447964025,A,G,"Patients with the AG genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity."
1447964025,G,G,Patients with the GG genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatotoxicity.
1449191734,A,A,"Patients with the rs121909020 AA genotype (two copies of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence response to ivacaftor."
1449191734,A,G,"Patients with the rs121909020 AG genotype (one copy of the CFTR A1067T variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence response to ivacaftor."
1449191734,G,G,"Patients with the rs121909020 GG genotype (do not have a copy of the CFTR A1067T variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including A1067T. Other genetic and clinical factors may also influence response to ivacaftor."
1447982712,A,A,Patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982712,A,G,"No information are available for the AG genotype. However, patients with the AA genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
1447982712,G,G,Patients with the GG genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1449191670,C,C,"Patients with the rs1800100 CC genotype (do not have a copy of the CFTR R668C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191670,C,T,Patients with the rs1800100 CT genotype (one copy of the CFTR R668C variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191670,T,T,Patients with the rs1800100 TT genotype (two copies of the CFTR R668C variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191676,C,C,Patients with the rs397508435 CC genotype (two copies of the CFTR L927P variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191676,C,T,Patients with the rs397508435 CT genotype (one copy of the CFTR L927P variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191676,T,T,"Patients with the rs397508435 TT genotype (do not have a copy of the CFTR L927P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191698,C,C,Patients with the rs1800111 CC genotype (two copies of the CFTR L997F variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191698,C,G,Patients with the rs1800111 CG genotype (one copy of the CFTR L997F variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191698,G,G,"Patients with the rs1800111 GG genotype (do not have a copy of the CFTR L997F variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191752,A,A,"Patients with the rs186045772 AA genotype (two copies of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence response to ivacaftor."
1449191752,A,T,"Patients with the rs186045772 AT genotype (one copy of the CFTR F1074L variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence response to ivacaftor."
1449191752,T,T,"Patients with the rs186045772 TT genotype (do not have a copy of the CFTR F1074L variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including F1074L. Other genetic and clinical factors may also influence response to ivacaftor."
1449191716,C,C,Patients with the rs397508510 CC genotype (two copies of the CFTR H1054D variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191716,C,G,Patients with the rs397508510 CG genotype (one copy of the CFTR H1054D variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191716,G,G,"Patients with the rs397508510 GG genotype (do not have a copy of the CFTR H1054D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191728,A,A,Patients with the rs121909019 AA genotype (two copies of the CFTR R1066H variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191728,A,G,Patients with the rs121909019 AG genotype (one copy of the CFTR R1066H variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191728,G,G,"Patients with the rs121909019 GG genotype (do not have a copy of the CFTR R1066H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1447990192,C,C,Patient with the CC genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.
1447990192,C,T,Patient with the CT genotype and Alzheimer's Disease may have a decreased response to rivastigmine as compared to patients with the TT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.
1447990192,T,T,Patient with the TT genotype and Alzheimer's Disease may have an increased response to rivastigmine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also have an influence on response to rivastigmine in patients with Alzheimer's disease.
1447990224,A,A,"Patients with the AA genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer."
1447990224,A,C,"Patients with the AC genotype and Non-small-cell-lung cancer may have an increased response to platinum compounds and gemcitabine as compared to patients with the AA and CC genotypes, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer."
1447990224,C,C,"Patients with the CC genotype and Non-small-cell-lung cancer may have a decreased response to platinum compounds and gemcitabine as compared to patients with the AC genotype, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer."
1448101220,A,A,Patients with the AA genotype who are smokers may have decreased physical responses to smoking as compared to patients with the CC genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.
1448101220,A,C,"Patients with the AC genotype who are smokers may have increased physical responses to smoking as compared to patients with the CC genotype, or decreased physical responses as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking."
1448101220,C,C,Patients with the CC genotype who are smokers may have increased physical responses to smoking as compared to patients with the AA genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.
1448101260,C,C,Patients with the CC genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101260,C,G,"Patients with the CG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction."
1448101260,G,G,Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
1448103818,G,G,Patients with the GG genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.
1448103818,G,T,Patients with the GT genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.
1448103818,T,T,Patients with the TT genotype and hypertension may have a decreased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.
1448256718,C,C,"Patients with the CC genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1448256718,C,T,"Patients with the CT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1448256718,T,T,"Patients with the TT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1448256734,A,A,Patients with the AA genotype and heroin-dependence who are treated with methadone maintenance therapy may have decreased plasma concentrations of R-methadone compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect concentrations of R-methadone.
1448256734,A,G,Patients with the AG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.
1448256734,G,G,Patients with the GG genotype and heroin-dependence who are treated with methadone maintenance therapy may have increased plasma concentrations of R-methadone compared to patients with the AA genotype. Other clinical and genetic factors may affect concentrations of R-methadone.
1448422839,A,A,Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422839,A,G,Patients with the AG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422839,G,G,Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422846,A,A,Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422846,A,G,Patients with the AG genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448422846,G,G,Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.
1448109612,A,A,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109612,A,C,"Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA and decreased likelihood as compared to patients with the CC genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1448109612,C,C,"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances."
1447949639,C,C,Patients with CC genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1447949639,C,T,Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1447949639,T,T,Patients with TT genotype may have increased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.
1447963182,A,A,Patients with the AA genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.
1447963182,A,T,Patients with the AT genotype may have decreased clearance of cefotaxime as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.
1447963182,T,T,Patients with the TT genotype may have increased clearance of cefotaxime as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence clearance of cefotaxime.
1447963701,C,C,"No patients with the CC genotype were available for analysis, but patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer."
1447963701,C,T,Patients with the CT genotype and breast cancer may have an increased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.
1447963701,T,T,Patients with the TT genotype and breast cancer may have a decreased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.
1447983217,C,C,Patients with the CC genotype may have decreased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.
1447983217,C,T,Patients with the CT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.
1447983217,T,T,Patients with the TT genotype may have increased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.
1448262915,C,C,Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262915,C,T,Patients with the CT genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262915,T,T,Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC or CT in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448423436,A,A,Patients with the AA genotype and asthma may have a poorer response when treated with zileuton as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to zileuton treatment.
1448423436,A,G,Patients with the AG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.
1448423436,G,G,Patients with the GG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.
1448427972,G,G,Patients with the GG genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.
1448427972,G,T,Patients with the GT genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.
1448427972,T,T,Patients with the TT genotype and depression may have decreased risk of suicidal thoughts when taking antidepressants compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.
1448428108,C,C,"No patients with the CC genotype were available for analysis, but patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms."
1448428108,C,T,Patients with the CT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428108,T,T,Patients with the TT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428117,C,C,Patients with the CC genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428117,C,T,Patients with the CT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428117,T,T,Patients with the TT genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428124,A,A,Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428124,A,G,Patients with the AG genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428124,G,G,Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428151,A,A,Patients with the AA genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428151,A,G,Patients with the AG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448428151,G,G,Patients with the GG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.
1448531639,A,A,Patients with the AA genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AC and CC genotypes when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.
1448531639,A,C,Patients with the AC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.
1448531639,C,C,Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia with irinotecan treatment.
1448531652,A,A,Patients with the AA genotype and colorectal neoplasm may have decreased exposure to SN-38 compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.
1448531652,A,T,Patients with the AT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.
1448531652,T,T,Patients with the TT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.
1448531802,C,C,Patients with the CC genotype and colorectal neoplasms may have increased severity of neutropenia when taking irinotecan compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448531802,C,T,Patients with the CT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1448531802,T,T,Patients with the TT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.
1447960443,C,C,Patients with the rs1801253 CC genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447960443,C,G,Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447960443,G,G,Patients with the rs1801253 GG genotype and heart failure may have decreased emergency department utilization when treated with cardiovascular drugs as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.
1447952004,C,C,Patients with the CC genotype may have decreased response (decreased LDL-C reduction) to rosuvastatin as compared to patients who have genotype TT or CT. Other Genetic and clinical factors may also influence the response to rosuvastatin.
1447952004,C,T,Patients with the CT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.
1447952004,T,T,Patients with the TT genotype may have increased response (increased LDL-C reduction) to rosuvastatin as compared to patients who have genotype CC. Other Genetic and clinical factors may also influence the response to rosuvastatin.
1447959745,C,C,Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959745,C,T,"Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
1447959745,T,T,Patients with the TT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959752,A,A,Patients with the AA genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447959752,A,G,"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment."
1447959752,G,G,Patients with the GG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.
1447962730,C,C,Patients with the CC genotype may have a smaller decrease in total cholesterol when treated with pravastatin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962730,C,G,Patients with the CG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962730,G,G,Patients with the GG genotype may have a greater decrease in total cholesterol when treated with pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1448097455,A,A,Patients with the AA genotype and colonic neoplasms may have decreased area under the curve of irinotecan-based therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the AUC of irinotecan.
1448097455,A,G,Patients with the AG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.
1448097455,G,G,Patients with the GG genotype and colonic neoplasms may have increased area under the curve of irinotecan-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the AUC of irinotecan.
1448098299,A,A,Patients with nasopharyngeal cancer and the AA genotype may have a decreased severity of neutropenia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098299,A,G,Patients with nasopharyngeal cancer and the AG genotype may have a increased severity of neutropenia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448102324,C,C,Patients with the CC genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1448102324,C,G,"Patients with the CG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy."
1448102324,G,G,Patients with the GG genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1448102337,G,G,Patients with the GG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1448102337,G,T,"Patients with the GT genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy."
1448102337,T,T,Patients with the TT genotype and chronic hepatitis C may have a better response to treatment with interferons and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.
1448102346,C,C,Patients with the CC genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.
1448102346,C,T,"Patients with the CT genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes."
1448102346,T,T,Patients with the TT genotype may have an increased risk of drug-induced torsades de pointes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes.
1448102407,C,C,Patients with the CC genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.
1448102407,C,T,Patients with the CT genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.
1448102407,T,T,Patients with the TT genotype and HIV may have decreased cognitive impairment when taking methamphetamines as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.
1448265266,C,C,Patients with the CC genotype and Psoriasis may have decreased response to ustekinumab compared to patients with the CT genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265266,C,T,Patients with the CT genotype and Psoriasis may have increased response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265266,T,T,Patients with the TT genotype and Psoriasis were not found to have different response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265280,G,G,Evidence conflicts as to whether patients with the GG genotype and psoriasis have decreased response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265280,G,T,Patients with the GT genotype and psoriasis do not seem to have different response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448265280,T,T,Evidence conflicts as to whether patients with the TT genotype and psoriasis have increased response to ustekinumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to ustekinumab.
1448104059,A,A,"Pediatric patients with the AA genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate."
1448104059,A,G,"Pediatric patients with the AG genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate."
1448104059,G,G,"Pediatric patients with the GG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA or AG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate."
1448102439,A,A,Patients with the rs11881222 AA genotype and hepatitis C or HIV may have a better response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102439,A,G,Patients with the rs11881222 AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102439,G,G,Patients with the rs11881222 GG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1451834440,A,A,Patients with the rs1045642 AA genotype may have a decreased risk of developing opioid dependence when treated with tramadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451834440,A,G,Patients with the rs1045642 AG genotype may have an increased risk of developing opioid dependence when treated with tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451834440,G,G,Patients with the rs1045642 GG genotype may have an increased risk of developing opioid dependence when treated with tramadol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1448423855,C,C,"Patients with the rs121909011 CC genotype (do not have a copy of the CFTR R334W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1448423855,C,T,Patients with the rs121909011 CT genotype (one copy of the CFTR R334W variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1448423855,T,T,Patients with the rs121909011 TT genotype (two copies of the CFTR R334W variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1448531857,G,T,Patients with the GT genotype may have higher maximal platelet aggregation as compared to patients with the TT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.
1448531857,T,T,Patients with the TT genotype may have lower maximal platelet aggregation as compared to patients with the GT genotype when taking ticagrelor. Other clinical and genetic factors may affect response to ticagrelor.
1448531862,A,A,People with the AA genotype may have increased inhibition of platelet aggregation in response to ticagrelor compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect response to ticagrelor.
1448531862,A,G,People with the AG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.
1448531862,G,G,People with the GG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to people with the AA genotype. Other clinical and genetic factors may affect response to ticagrelor.
1448531868,G,G,People with the GG genotype may have increased inhibition of platelet aggregation when taking ticagrelor compared to people with the GT and TT genotypes. Other clinical and genetic factors may affect response to ticagrelor.
1448531868,G,T,People with the GT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.
1448531868,T,T,People with the TT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.
1448616865,A,A,Patients with cancer and the AA genotype may have a decreased risk of hyperbilirubinemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1448616865,A,G,Patients with cancer and the AG genotype may have an increased risk of hyperbilirubinemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.
1447953291,C,C,Patients with the CC genotype and lupus nephritis may have an increased response to cyclophosphamide as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.
1447953291,C,T,Patients with the CT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.
1447953291,T,T,"Although there is no data on patients with the TT genotype, one might expect patients with the TT genotype and lupus nephritis may have a decreased response to cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide."
1447953304,C,C,"Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran."
1447953304,C,G,"Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran."
1447953304,G,G,"Patients with the GG genotype and depressive disorder may have a decreased response to milnacipran as compared to patients with the CC and CG genotypes. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran."
1447960327,A,A,"Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960327,A,G,"Patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960327,G,G,"No patients with the GG genotype were available for analysis, but patients with the AG genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960335,C,C,Patients with the CC genotype and non-small-cell lung cancer may have a shorter median survival time when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival.
1447960335,C,T,Patients with the CT genotype and non-small-cell lung cancer may have a longer median survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival.
1447960335,T,T,Patients with the TT genotype and non-small-cell lung cancer may have a longer median survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival.
1447960371,C,C,"Patients with the CC genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960371,C,T,"Patients with the CT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960371,T,T,"Patients with the TT genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with taxanes, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960379,A,A,"Patients with the AA genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AT genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960379,A,T,"Patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447960379,T,T,"No patients with the TT genotype were available for analysis, but patients with the AT genotype and non-small-cell lung cancer may have shorter overall survival times when treated with platinum agents in combination with gemcitabine or taxanes, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients."
1447964346,A,A,Patients with the AA genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
1447964346,A,G,Patients with the AG genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.
1447964346,G,G,Patients with the GG genotype and stomach cancer may have better poorer survival outcomes when treated with fluorouracil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival outcome.
1447984146,A,A,Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1447984146,A,C,"Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics."
1447984146,C,C,Patients with the CC genotype and schizophrenia who responded to treatment with antipsychotics may require an increased dose of antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.
1447990143,A,A,"Patients with the AA genotype and essential hypertension may have increased metabolism or clearance of irbesartan as compared to patients with the AC genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension."
1447990143,A,C,"Patients with the AC genotype and essential hypertension may have decreased metabolism or clearance of irbesartan as compared to patients with the AA genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension."
1447990283,C,C,"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CC genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy."
1447990283,C,T,"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy."
1447990283,T,T,"Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have a increased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the CT and CC genotypes. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy."
1448097681,A,A,The AA genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.
1448097681,A,C,The AC genotype may be associated with increased CYP4F2 activity and decreased vitamin e metabolism as compared to the AA genotype and decreased metabolism as compared to the CC genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.
1448097681,C,C,The CC genotype may be associated with decreased CYP4F2 activity and decreased vitamin e metabolism as compared to the AC or AA genotype. This is based solely on an in vitro study in a haploid heterologous cell system. Other clinical and genetic factors may also influence metabolism of vitamin e.
1448097711,A,A,Patients with non-small cell lung cancer and the AA genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097711,A,C,Patients with non-small cell lung cancer and the AC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097711,C,C,Patients with non-small cell lung cancer and the CC genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the AA or AC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.
1448097718,C,C,"Patients with non-small cell lung cancer and the CC genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer."
1448097718,C,T,"Patients with non-small cell lung cancer and the CT genotype may have an improved response to cisplatin and gemcitabine as compared to patients with the TT genotype. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer."
1448097718,T,T,"Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC or CT genotypes. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer."
1448100861,C,C,Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.
1448100861,C,T,"Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity."
1448100861,T,T,Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for GI toxicity when treated with mercaptopurine and methotrexate as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity.
1448100874,A,A,Patients with the AA genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.
1448100874,A,T,"Patients with the AT genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction."
1448100874,T,T,Patients with the TT genotype may have an increased risk of becoming addicted to nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.
1448100887,A,A,Patients with the AA genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1448100887,A,G,"Patients with the AG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate."
1448100887,G,G,Patients with the GG genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.
1448616900,A,A,Patients with the AA genotype and Cancer who are treated with Capecitabine may have an increased risk of Diarrhea as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine
1448616900,A,G,"Patients with the AG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine"
1448616900,G,G,"Patients with the GG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine"
1450932374,G,G,"Patients with cancer and the GG genotype may be at an increased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GT or TT genotypes. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity."
1450932374,G,T,"Patients with cancer and the GT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity."
1450932374,T,T,"Patients with cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity."
1448423861,A,A,"Patients with the rs77932196 AA genotype (two copies of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. Other genetic and clinical factors may also influence response to ivacaftor."
1448423861,A,C,"Patients with the rs77932196 AC genotype (one copy of the CFTR R347H variant and one copy of the CFTR R347P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. R347P is not on this list of approved variants. Other genetic and clinical factors may also influence response to ivacaftor."
1448423861,A,G,"Patients with the rs77932196 AG genotype (one copy of the CFTR R347H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R347H. Other genetic and clinical factors may also influence response to ivacaftor."
1448423861,C,C,Patients with the rs77932196 CC genotype (two copies of the CFTR R347P variant) and cystic fibrosis may not respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1448423861,C,G,"Patients with the rs77932196 CG genotype (one copy of the CFTR R347P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1448423861,G,G,"Patients with the rs77932196 GG genotype (do not have a copy of the CFTR R347H or R347P variants) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1451868500,A,A,Patients with the rs3740563 AA genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to beta blocking agents.
1451868500,A,C,Patients with the rs3740563 AC genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to beta blocking agents.
1451868500,C,C,Patients with the rs3740563 CC genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.
1447953102,A,A,Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.
1447953102,A,G,Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's respond to SSRIs.
1447953102,G,G,Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.
1447960191,C,C,Patients with the CC genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.
1447960191,C,G,Patients with the CG genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.
1447960191,G,G,Patients with the GG genotype may experience slower desensitization to effects of terbutaline as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.
1447961166,C,C,Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with gefitinib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to gefitinib.
1447961166,C,T,Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.
1447961166,T,T,Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib.
1447961329,A,A,Patients with the AA genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961329,A,G,"Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol."
1447961329,G,G,Patients with the GG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447964292,C,C,Patients with the CC genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964292,C,T,Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447964292,T,T,Patients with the TT genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.
1447983071,A,A,"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983071,A,G,"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983071,G,G,"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983078,A,A,"Patients with the AA genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983078,A,G,"Patients with the AG genotype and non-small-cell lung carcinoma may have increased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the GG genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1447983078,G,G,"Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment."
1448100229,C,C,Patients with the CC genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pravastatin response.
1448100229,C,T,"Patients with the CT genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response."
1448100229,T,T,Patients with the TT genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence pravastatin response.
1448102633,C,C,Patients with the CC genotype and non-small-cell lung cancer may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448102633,C,T,No significant results have been seen for patients with the CT genotype.
1448102633,T,T,Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for drug toxicity.
1448125537,A,A,"Patients with the rs2071559 AA genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sorafenib."
1448125537,A,G,"Patients with the rs2071559 AG genotype may have decreased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sorafenib."
1448125537,G,G,"Patients with the rs2071559 GG genotype may have increased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell or hepatocellular carcinoma as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sorafenib."
1448262922,C,C,Patients with the CC genotype may have increased time in therapeutic range when treated with warfarin as compared to patients with genotype GG or CG in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262922,C,G,Patients with the CG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448262922,G,G,Patients with the GG genotype may have decreased time in therapeutic range when treated with warfarin as compared to patients with genotype CC in African-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.
1448525395,A,A,Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448525395,A,G,Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448525395,G,G,Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448615167,A,A,Postmenopausal women with HR+breast cancer and the AA genotype may have an increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the GG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615167,A,G,Postmenopausal women with HR+breast cancer and the AG genotype may have an increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the GG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615167,G,G,Postmenopausal women with HR+breast cancer and the GG genotype may have a decreased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the AA or AG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448109558,C,C,"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1448109558,C,T,"Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1448109558,T,T,"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1448109783,G,G,"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1448109783,G,T,"Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1448109783,T,T,"Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity."
1451666355,C,C,Patients with the rs72549435 CC genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451666355,C,G,Patients with the rs72549435 CG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451666355,G,G,Patients with the rs72549435 GG genotype may have increased metabolism of nicotine as compared to patients with the CC or CG genotypes. This annotation only covers the pharmacokinetic relationship between rs72549435 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451868400,A,A,Patients with the rs10787959 AA genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.
1451868400,A,G,Patients with the rs10787959 AG genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.
1451868400,G,G,Patients with the rs10787959 GG genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.
1447961129,A,A,Patients with the AA genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961129,A,G,"Patients with the AG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol."
1447961129,G,G,Patients with the GG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961136,A,A,Patients with the AA genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961136,A,G,"Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol."
1447961136,G,G,Patients with the GG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961144,C,C,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961144,C,T,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
1447961144,T,T,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1448100630,A,A,Patients with the AA genotype may have a better response to treatment with methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methadone.
1448100630,A,G,"Patients with the AG genotype may have a better response to treatment with methadone as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone."
1448100630,G,G,Patients with the GG genotype may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone.
1447961151,C,C,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961151,C,T,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
1447961151,T,T,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961158,C,C,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447961158,C,T,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol."
1447961158,T,T,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.
1447962744,C,C,Patients with the CC genotype may have a greater decrease in total cholesterol when treated with lovastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962744,C,T,Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1447962744,T,T,"Patients with the TT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC genotype, or a greater decrease as compared to patients with the CT genotype. Other genetic and clinical factors may also influence total cholesterol levels."
1447963611,A,A,"Patients with the AA genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time."
1447963611,A,G,"Patients with the AG genotype and node-positive breast cancer may have shorter disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence disease-free survival time."
1447963611,G,G,"Patients with the GG genotype and node-positive breast cancer may have longer disease-free survival time when treated with cyclophosphamide, fluorouracil and methotrexate (CMF) chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence disease-free survival time."
1447981346,A,A,Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.
1447981346,A,G,"Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity."
1447981346,G,G,Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.
1447987211,A,A,Patients with diabetes mellitus and the AA genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
1447987211,A,G,Patients with diabetes mellitus and the AG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AA genotype and a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
1447987211,G,G,Patients with diabetes mellitus and the GG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and AA genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.
1447987227,A,A,Patients with depressive disorder and the AA genotype may have improved response to citalopram or escitalopram as compared to patients with the AC and CC genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.
1447987227,A,C,Patients with depressive disorder and the AC genotype may have improved response to citalopram or escitalopram as compared to patients with the CC genotypes and worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.
1447987227,C,C,Patients with depressive disorder and the CC genotype may have worse response to citalopram or escitalopram as compared to patients with the AC and AA genotypes. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.
1447990925,A,A,"The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer."
1447990925,A,G,"The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine oxaliplatin AND cetuximab may be associated with decreased progression-free survival as compared to patients with the GG genotypes and increased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer."
1447990925,G,G,"The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with increased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer."
1448097805,T,T,Patients with kidney transplantation and the TT genotype may have increased metabolism of mycophenolic acid as compared to patients with the del/del or del/T or del/del genotypes. Other clinical and genetic factors may also influence metabolism of mycophenolic acid in patients with kidney transplantation.
1448097837,C,C,Patients with the CC genotype may be less likely to develop an addiction to crack cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.
1448097837,C,T,Patients with the CT genotype may be less likely to develop an addiction to crack cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.
1448097837,T,T,Patients with the TT genotype may be more likely to develop an addiction to crack cocaine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.
1448100644,C,C,Female patients with the CC genotype may have less of a decrease in bone mineral density when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.
1448100644,C,T,Female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen.
1448100644,T,T,"No patients with the TT genotype were available for analysis, but female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen."
1448100661,C,C,Patients with the CC genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.
1448100661,C,T,Patients with the CT genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.
1448100661,T,T,Patients with the TT genotype and breast cancer may have longer recurrence-free survival times when treated with tamoxifen as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.
1448100687,C,C,Patients with the CC genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.
1448100687,C,T,Patients with the CT genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.
1448100687,T,T,Patients with the TT genotype who are addicted to smoking may have a better response to treatment with bupropion as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.
1448100695,C,C,Patients with the CC genotype who are addicted to smoking and are trying to quit may have a reduced cravings for nicotine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence nicotine cravings.
1448100695,C,T,Patients with the CT genotype who are addicted to smoking and are trying to quit may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings.
1448100695,T,T,Patients with the TT genotype who are addicted to smoking and are trying to quite may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings.
1448100751,C,C,"Patients with the CC genotype and hypertension may have poorer blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CT or TT genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide."
1448100751,C,T,"Patients with the CT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide."
1448100751,T,T,"Patients with the TT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide."
1448100777,C,C,"Patients with the CC genotype may have increased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam."
1448100777,C,T,"Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the TT genotype, and decreased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam."
1448100777,T,T,"Patients with the TT genotype may have decreased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam."
1448100786,C,C,"Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam."
1448100786,C,T,"Patients with the CT genotype may have decreased clearance of midazolam as compared to patients with the TT genotype, and increased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam."
1448100786,T,T,"Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam."
1448100804,C,C,"Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam."
1448100804,C,T,"Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam."
1448100804,T,T,"Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam."
1451646580,C,C,Patients with heroin dependence and the rs5326 CC genotype may have decreased methadone dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methadone dose requirements.
1451646580,C,T,Patients with heroin dependence and the rs5326 CT genotype may have decreased methadone dose requirements as compared to patients with the TT genotype but increased dose requirements as compared to the CC genotype. Other genetic and clinical factors may also influence methadone dose requirements.
1451646580,T,T,Patients with heroin dependence and the rs5326 TT genotype may have increased methadone dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methadone dose requirements.
1451868520,A,A,Patients with the rs11198893 AA genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.
1451868520,A,G,Patients with the rs11198893 AG genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.
1451868520,G,G,Patients with the rs11198893 GG genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.
1451868540,G,G,Patients with the rs4752292 GG genotype and coronary artery disease may have increased response when treated with beta blocking agents as compared to patients with the TT or GT genotypes. Other genetic and clinical factors may also influence response to beta blocking agents.
1451868540,G,T,Patients with the rs4752292 GT genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.
1451868540,T,T,Patients with the rs4752292 TT genotype and coronary artery disease may have decreased response when treated with beta blocking agents as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to beta blocking agents.
1448265557,A,A,Patients with the AA genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265557,A,G,Patients with the AG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265557,G,G,Patients with the GG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265565,C,C,Patients with the CC genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265565,C,T,Patients with the CT genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265565,T,T,Patients with the TT genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the CC genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265573,A,A,"Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis."
1448265573,A,G,"Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis."
1448265573,G,G,"Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the AA genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis."
1448265581,A,A,Patients with the AA genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265581,A,G,Patients with the AG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265581,G,G,Patients with the GG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265598,A,A,Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265598,A,G,Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265598,G,G,Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448427559,A,A,"Patients with the AA genotype may have increased clozapine plasma concentrations, as well as an increased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity."
1448427559,A,G,"Patients with the AG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity."
1448427559,G,G,"Patients with the GG genotype may have decreased clozapine plasma concentrations, as well as a decreased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity."
1448532190,A,A,"People with the AA genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran."
1448532190,A,G,"People with the AG genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran."
1448532190,G,G,"People with the GG genotype may have decreased exposure to dabigatran compared to patients with the AA and AG genotypes, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran."
1448613357,C,C,Patients with the CC genotype may have lower on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448613357,C,T,Patients with the CT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448613357,T,T,Patients with the TT genotype may have high on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448635176,C,G,"Patients with acute lymphoblastic leukemia (ALL) and the CG genotype may have higher incidence of toxicity and may tolerate lower doses of mercaptopurine as compared to patients with the GG genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of two adolescents, both of whom had the CG genotype."
1448635176,G,G,"Patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have lower incidence of toxicity and may tolerate higher doses of mercaptopurine as compared to patients with the CG genotype. Other clinical and genetic factors may also affect tolerance and dose of mercaptopurine in patients administered mercaptopurine. Please note: this annotation is based on case studies of two adolescents, both of whom were heterozygotes."
1445401427,C,C,"Patients with the CC genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia."
1445401427,C,T,"Patients with the CT genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia."
1445401427,T,T,"Patients with the TT genotype and hepatitis C may have an increased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for anemia."
1447953284,A,A,Patients with the AA genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447953284,A,G,Patients with the AG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447953284,G,G,Patients with the GG genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.
1447962613,C,C,Patients with the CC genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.
1447962613,C,T,"Patients with the CT genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the TT genotype, and a lower increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting glucose levels."
1447962613,T,T,Patients with the TT genotype and hypertension may have a lower increase in fasting glucose when treated with atenolol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting glucose levels.
1447962862,C,C,Patients with the CC genotype may have decreased clearance of pravastatin as compared to patients with the CG genotype. Other genetic and clinical factors may also influence clearance of pravastatin.
1447962862,C,G,Patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin.
1447962862,G,G,"No patients with the GG genotype were available for analysis, but patients with the CG genotype may have increased clearance of pravastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of pravastatin."
1447963853,A,A,Patients with the AA genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447963853,A,C,Patients with the AC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447963853,C,C,Patients with the CC genotype who are taking thiazide diuretics may have a decreased risk of developing diabetes mellitus as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of diabetes.
1447979272,C,C,Female patients with the CC genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to leflunomide.
1447979272,C,T,"Female patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide."
1447979272,T,T,Female patients with the TT genotype and rheumatoid arthritis may have a better response when treated with leflunomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.
1447979279,A,A,Patients with the AA genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1447979279,A,T,"Patients with the AT genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma."
1447979279,T,T,Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1447980677,C,C,Patients with the CC genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose.
1447980677,C,T,"Patients with the CT genotype who are heroin dependent may require a decreased dose of methadone as compared to patients with the TT genotype, or an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose."
1447980677,T,T,Patients with the TT genotype who are heroin dependent may require an increased dose of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose.
1447981282,C,C,Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981282,C,T,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981282,T,T,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981372,C,C,"Patients with the CC genotype and cancer may have increased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine."
1447981372,C,T,"Patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine."
1447981372,T,T,"No patients with the TT genotype were available for analysis, but patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine."
1447981385,A,A,"Patients with the AA genotype and cancer may have increased clearance of gemcitabine, and decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance."
1447981385,A,G,"Patients with the AG genotype and cancer may have increased clearance of gemcitabine as compared to patients with the GG genotype, or decreased clearance as compared to patients with the AA genotype. Patients may also have decreased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to those with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance."
1447981385,G,G,"Patients with the GG genotype and cancer may have decreased clearance of gemcitabine as compared to patients with the AA genotype, and increased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence gemcitabine clearance."
1447990324,C,C,"Patients with the CC genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the CG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and response to metformin in people with Type II diabetes mellitus."
1447990324,C,G,"Patients with the CG genotype and Type II diabetes mellitus may be associated with increased clearance of metformin leading to worse response to metformin as compared to patients with the GG genotypes and decreased clearance leading to improved response to metformin as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus."
1447990324,G,G,"Patients with the GG genotype and Type II diabetes mellitus may have decreased clearance of metformin leading to improved response to metformin as compared to patients with the CG and CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence response to metformin in people with Type II diabetes mellitus."
1448097693,C,C,"Patients with the CC genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment."
1448097693,C,T,"Patients with the CT genotype and cancer may have an increased risk for toxicity when treated with fluoropyrimidines, as well as decreased DPYD activity, as compared to patients with the TT genotype, or a decreased risk and increased activity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment."
1448097693,T,T,"Patients with the TT genotype and cancer may have a decreased risk for toxicity when treated with fluoropyrimidines, as well as increased DPYD activity, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving fluoropyrimidine treatment."
1450821121,A,A,"Patients with hypertension and the AA genotype may have an increased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone."
1450821121,A,G,"Patients with hypertension and the AG genotype may have an increased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone."
1450821121,G,G,"Patients with hypertension and the GG genotype may have a decreased response to amiloride or spironolactone, as measured by changes in aldosterone levels, as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to amiloride or spironolactone."
1447987018,A,A,"Patients with the AA genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
1447987018,A,G,"Patients with the AG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
1447987018,G,G,"Patients with the GG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have decreased metabolism of efavirenz as compared to patients with the AA or AG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz."
1448109565,G,G,"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or TT genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1448109565,G,T,"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1448109565,T,T,"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GT or GG genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines."
1447981275,C,C,Patients with the rs7668258 CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.
1447981275,C,T,Patients with the rs7668258 CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.
1447981275,T,T,Patients with the rs7668258 TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.
1448102294,A,A,Patients with the AA genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.
1448102294,A,G,Patients with the AG genotype and diffuse large B-cell lymphoma may have a longer event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence event-free survival time.
1448102294,G,G,Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.
1448102368,A,A,Patients with the rs671 AA genotype may have an increased risk for heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin dependence.
1448102368,A,G,Patients with the rs671 AG genotype may have an increased risk for heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin dependence.
1448102368,G,G,Patients with the rs671 GG genotype may have a decreased risk for heroin dependence as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for heroin dependence.
1448259308,C,C,"Female, post-menopausal patients with the CC genotype and schizophrenia may have a decreased response to raloxifene compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to raloxifene."
1448259308,C,T,"Female, post-menopausal patients with the CT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene."
1448259308,T,T,"Female, post-menopausal patients with the TT genotype and schizophrenia may have an increased response to raloxifene compared to patients with the CC genotype. Other clinical and genetic factors may affect response to raloxifene."
1448531674,C,C,Patients with the CC genotype and colorectal neoplasms may have decreased exposure to SN-38 compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.
1448531674,C,T,Patients with the CT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.
1448531674,T,T,Patients with the TT genotype and colorectal neoplasms may have increased exposure to SN-38 compared to patients with the CC genotype. Other clinical and genetic factors may affect exposure to SN-38.
1448568152,A,A,Patients with AA genotype may have decreased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1448568152,A,G,Patients with AG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1448568152,G,G,Patients with GG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.
1448109707,A,A,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines."
1448109707,A,C,"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC, or increased likelihood as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic or clinical factors may also influence the toxicity to anthracyclines."
1448109707,C,C,Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA or AC. Other genetic or clinical factors may also influence the toxicity to anthracyclines.
1448263578,A,A,"Patients with the rs628031 AA genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine."
1448263578,A,G,"Patients with the rs628031 AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine."
1448263578,G,G,"Patients with the rs628031 GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AA and AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine."
1448102550,A,A,Patients with the AA genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
1448102550,A,G,Patients with the AG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
1448102550,G,G,Patients with the GG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon alfa-2b and ribavirin treatment.
1447960458,C,C,Patients with the CC genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.
1447960458,C,T,Patients with the CT genotype and schizophrenia may have greater weight gain when treated with risperidone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.
1447960458,T,T,Patients with the TT genotype and schizophrenia may have lower weight gain when treated with risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence weight gain in patients taking risperidone.
1447990940,C,C,"The CC genotype in patients with depressive disorder who are taking citalopram or escitalopram may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CT or TT genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder."
1447990940,C,T,"The CT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CC genotype and lower baseline and smaller decreases in serotonin levels as compared to the TT genotype. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder."
1447990940,T,T,"The TT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with lower baseline serotonin levels and smaller decreases in serotonin levels as compared to the CT or CC genotypes. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder."
1448616678,G,G,Patients with the GG genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.
1448616678,G,T,Patients with the GT genotype and psoriasis may experience a decreased response to methotrexate as compared to patients with the TT genotypes and and an increased response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.
1448616678,T,T,Patients with the TT genotype and psoriasis may experience an increased response to methotrexate as compared to patients with the GT GG genotypes. Other clinical and genetic factors may also influence response to methotrexate in patients with psoriasis.
1449144364,A,A,Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1449144364,A,C,"Patients with the AC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CC genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder."
1449144364,C,C,Patients with the CC genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.
1451666660,G,G,"The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GG genotype may have decreased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes."
1451666660,G,T,"The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GT genotype may have increased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes."
1451666660,T,T,"The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 TT genotype may have increased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes."
1448100955,A,A,Patients with the AA genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.
1448100955,A,G,Patients with the AG genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.
1448100955,G,G,Patients with the GG genotype and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the AA and AG genotypes. Other clinical factors may affect plasma concentrations of dabigatran.
1448101044,C,C,Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype. Other genetic and clinical factors may also influence hypersensitivity to asparaginase.
1448101044,C,T,"Patients with the CT genotype and acute lymphoblastic leukemia may have a decreased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hypersensitivity to asparaginase."
1448101044,T,T,Patients with the TT genotype and acute lymphoblastic leukemia may have an increased risk for drug hypersensitivity when treated with asparaginase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hypersensitivity to asparaginase.
1447960411,C,C,Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.
1447960411,C,T,Patients with the CT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.
1447960411,T,T,Patients with the TT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.
1447960633,A,A,Patients with the AA genotype may have a greater decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence GFR.
1447960633,A,C,Patients with the AC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.
1447960633,C,C,Patients with the CC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.
1447961057,C,C,"Patients with the CC genotype and cancer may have longer overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Patients with the CC genotype may also have decreased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the TT genotype. Other genetic and clinical factors may also influence survival times."
1447961057,C,T,Patients with the CT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.
1447961057,T,T,"Patients with the TT genotype and cancer may have shorter overall survival and progression-free survival times when treated with gemcitabine as compared to patients with the CC genotype. Patients with the TT genotype may also have increased formation clearance of dFdCTP, an active metabolite of gemcitabine, as compared to those with the CC genotype.Other genetic and clinical factors may also influence survival times."
1447962674,A,A,Cells with the AA genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447962674,A,C,"Cells with the AC genotype may have decreased enzymatic activity toward SN-38 as compared to cells with the CC genotype, or increased activity as compared to those with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38."
1447962674,C,C,Cells with the CC genotype may have increased enzymatic activity toward SN-38 as compared to cells with the AA genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.
1447981296,C,C,Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981296,C,T,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981296,T,T,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.
1447981313,A,A,Infants and children with the AA genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.
1447981313,A,G,Infants and children with the AG genotype and brain tumors may have increased absorption and higher concentrations of topotecan compared to patients with the GG genotype. Other genetic and clinical factors may affect pharmacokinetics of topotecan.
1447981313,G,G,Infants and children with the GG genotype and brain tumors may have decreased absorption and lower concentrations of topotecan compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affect pharmacokinetics of topotecan.
1447982768,A,A,Patients with the AA genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have an increased risk for anemia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.
1447982768,A,G,"Patients with the AG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia."
1447982768,G,G,"Patients with the GG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia."
1447990044,C,C,Patients with the CC genotype and hypertension may have a decreased response to irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.
1447990044,C,T,Patients with the CT genotype and hypertension may have an improved response to irbesartan as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.
1448100437,C,C,Patients with the CC genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.
1448100437,C,T,Patients with the CT genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the TT genotypes. Other factors may affect response to adalimumab.
1448100437,T,T,Patients with the TT genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
1448100444,A,A,Patients with the AA genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
1448100444,A,C,Patients with the AC genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
1448100444,C,C,Patients with the CC genotype and Parkinson Disease may have increased response to rasagiline compared to patients with the AA and AC genotypes. Other factors may affect response to rasagiline.
1448100451,A,A,Rheumatoid Arthritis patients with the genotype AA may be more likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.
1448100451,A,G,"Rheumatoid Arthritis patients with the genotype AG may be more likely to respond to TNF inhibitors compared with patients with genotype GG, or less likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response."
1448100451,G,G,Rheumatoid Arthritis patients with the genotype GG may be less likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.
1448100464,A,A,Patients with the AA genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
1448100464,A,C,Patients with the AC genotype and Parkinson Disease may have decreased response to rasagiline compared to patients with the CC genotype. Other factors may affect response to rasagiline.
1448100464,C,C,Patients with the CC genotype and Parkinson Disease may have increased response to rasagiline compared to patients with the AA and AC genotypes. Other factors may affect response to rasagiline.
1448100471,C,C,Patients with the CC genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the CT and TT genotypes. Other factors may affect trough concentrations of telaprevir.
1448100471,C,T,Patients with the CT genotype and Hepatitis C may have decreased trough concentrations of telaprevir compared to patients with the TT genotype. Other factors may affect trough concentrations of telaprevir.
1448100471,T,T,Patients with the TT genotype and Hepatitis C may have increased trough concentrations of telaprevir compared to patients with the CC and CT genotypes. Other factors may affect trough concentrations of telaprevir.
1448100508,A,A,Patients with the AA genotype and Type 2 Diabetes may have decreased response to sitagliptin or vildagliptin compared to patients with the GG genotype. Other factors may affect response to sitagliptin and vildagliptin.
1448100508,G,G,Patients with the GG genotype and Type 2 Diabetes may have increased response to sitagliptin or vildagliptin compared to patients with the AA genotype. Other factors may affect response to sitagliptin and vildagliptin.
1448100514,C,C,Men with the CC genotype and hypertension may have decreased response to bisoprolol compared to men with the CT and TT genotypes. Other factors may affect response to bisoprolol.
1448100514,C,T,Men with the CT genotype and hypertension may have decreased response to bisoprolol compared to men with the TT genotype. Other factors may affect response to bisoprolol.
1448100514,T,T,Men with the TT genotype and hypertension may have increased response to bisoprolol compared to men with the CC and CT genotypes. Other factors may affect response to bisoprolol.
1448100552,C,C,Patients with the CC genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. Other factors may affect concentration of tacrolimus.
1448100552,C,T,"Patients with the CT genotype who have undergone organ transplantation may have decreased concentrations of tacrolimus compared to patients with the TT genotype. However, conflicting evidence exists for this association. Other factors may affect concentration of tacrolimus."
1448100552,T,T,Patients with the TT genotype and lung transplantation may have increased concentrations of tacrolimus compared to patients with the CC or CT genotype. Other factors may affect concentration of tacrolimus.
1448100567,C,C,"Patients with the CC genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation."
1448100567,C,T,"Patients with the CT genotype and organ transplantation may have decreased concentrations of mycophenolic acid compared to patients with CC and TT genotypes. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation."
1448100567,T,T,"Patients with the TT genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation."
1448100942,C,C,Patients with genotype CC and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the CT and TT genotypes. Other factors may affect dabigatran plasma concentrations.
1448100942,C,T,Patients with genotype CT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.
1448100942,T,T,Patients with genotype TT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.
1448101059,A,A,Patients with the AA genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1448101059,A,G,"Patients with the AG genotype may have a decreased risk for aspirin-intolerant asthma as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma."
1448101059,G,G,Patients with the GG genotype may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.
1448101073,C,C,Pediatric patients undergoing heart transplantation who have the CC genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.
1448101073,C,T,"Pediatric patients undergoing heart transplantation who have the CT genotype may have a decreased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance."
1448101073,T,T,Pediatric patients undergoing heart transplantation who have the TT genotype may have an increased likelihood of gastrointestinal intolerance to treatment with mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of gastrointestinal intolerance.
1448101086,A,A,"Patients with the AA genotype and Parkinson disease may require decreased doses of anti-Parkinsonian drugs, and may have a decreased risk of mortality, as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality."
1448101086,A,C,"Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality."
1448101086,C,C,"Patients with the CC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs, and may have an increased risk of mortality, as compared to patients with the AA and AC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality."
1448101102,G,G,Patients with the GG genotype may have a reduced risk for developing prostate cancer when treated with aspirin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.
1448101102,G,T,Patients with the GT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.
1448101102,T,T,Patients with the TT genotype may have an increased risk for developing prostate cancer when treated with aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing prostate cancer in patients taking aspirin.
1448100501,A,A,"Patients with the AA genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AG and GG genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other factors may affect concentration of lamotrigine."
1448100501,A,G,"Patients with the AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotype. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine."
1448100501,G,G,"Patients with the GG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the AA genotypes. However, another study showed no association of patient genotype with lamotrigine concentrations, dose, or efficacy. Other clinical and genetic factors may affect concentration of lamotrigine."
1448101114,A,A,Patients with the AA genotype and hypertriglyceridemia may have greater decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1448101114,A,G,Patients with the AG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1448101114,G,G,Patients with the GG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1448101149,A,A,Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101149,A,G,"Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for addiction as compared to patients with the GG genotype, or decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction."
1448101149,G,G,Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101163,A,A,Patients with the AA genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101163,A,G,Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101163,G,G,Patients with the GG genotype who are in chronic pain and receive opioid medications for treatment may be at increased risk for nicotine addiction as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.
1448101175,C,C,Patients with the CC genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101175,C,T,"Patients with the CT genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction."
1448101175,T,T,Patients with the TT genotype may have an increased risk for smoking addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101202,A,A,Patients with the AA genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.
1448101202,A,G,Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.
1448101202,G,G,Patients with the GG genotype and chronic hepatitis C may be more likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.
1448101252,A,A,Patients with the AA genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction.
1448101252,A,G,"Patients with the AG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction."
1448101252,G,G,Patients with the GG genotype may have an increased likelihood of smoking addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.
1448102446,C,C,Patients with the CC genotype and chronic hepatitis C may have an increased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102446,C,T,Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448102446,T,T,Patients with the TT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.
1448104353,C,C,Patients with the CC genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.
1448104353,C,G,Patients with the CG genotype and colorectal cancer may have a poorer response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CC or GG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.
1448104353,G,G,Patients with the GG genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.
1448266599,A,A,Patients with the AA genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.
1448266599,A,T,Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.
1448266599,T,T,Patients with the TT genotype and rheumatoid arthritis may have worse response to EULAR therapy after 12 weeks of treatment compared to patients with the AA and AT genotype. Other clinical and genetic factors may affect EULAR response.
1448266609,C,C,Patients with the CC genotype and rheumatoid arthritis may have worse response to EULAR therapy compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to EULAR therapy.
1448266609,C,T,Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.
1448266609,T,T,Patients with the TT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.
1448100487,G,G,"Patients with the rs2231142 GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the GT and TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations."
1448100487,G,T,"Patients with the rs2231142 GT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations."
1448100487,T,T,"Patients with the rs2231142 TT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations."
1448100494,C,C,"Patients with the rs3114020 CC genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine."
1448100494,C,T,"Patients with the rs3114020 CT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine."
1448100494,T,T,"Patients with the rs3114020 TT genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the CC and CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs3114020 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect concentrations of lamotrigine."
1448101182,A,A,"Patients with the AA genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation."
1448101182,A,G,"Patients with the AG genotype may have a increased risk for smoking addiction, and a decreased likelihood of smoking cessation, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation."
1448101182,G,G,"Patients with the GG genotype may have a decreased risk for smoking addiction, and have an increased likelihood of smoking cessation, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence smoking addiction and cessation."
1449164133,C,C,"Patients with the CC genotype may require decreased doses of warfarin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164133,C,G,"Patients with the CG genotype may require decreased doses of warfarin as compared to patients with the GG genotype, and increased doses as compared to the CC genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164133,G,G,"Patients with the GG genotype may require increased doses of warfarin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164149,G,G,"Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164149,G,T,"Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype, and increased doses as compared to the GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164149,T,T,"Patients with the TT genotype may require increased doses of warfarin as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164155,A,A,"Patients with the AA genotype may require decreased doses of warfarin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164155,A,G,"Patients with the AG genotype may require decreased doses of warfarin as compared to patients with the GG genotype, and increased doses as compared to the AA genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164155,G,G,"Patients with the GG genotype may require increased doses of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1448525559,G,G,Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.
1448525559,G,T,Pediatric patients with the GT genotype who are undergoing hematopoietic stem cell transplantation may have a decreased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for SOS.
1448525559,T,T,Pediatric patients with the TT genotype who are undergoing hematopoietic stem cell transplantation may have an increased risk for sinusoidal obstruction syndrome (SOS) when treated with busulfan and cyclophosphamide as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for SOS.
1448612662,C,C,Patients with the CC genotype and seizures may have increased response to oxcarbazepine compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.
1448612662,C,T,Patients with the CT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.
1448612662,T,T,Patients with the TT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.
1448612682,C,C,Patients with the CC genotype and multiple myeloma may have increased response to lenalidomide and thalidomide treatment compared to patients with the CG and GG genotypes. Other clinical and genetic factors may affect progression of multiple myeloma.
1448612682,C,G,Patients with the CG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.
1448612682,G,G,Patients with the GG genotype and multiple myeloma may have decreased response to lenalidomide and thalidomide treatment compared to patients with the CC genotype. Other clinical and genetic factors may affect progression of multiple myeloma.
1448613243,A,A,"People with the AA genotype undergoing a kidney transplantation may have increased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AG and GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus."
1448613243,A,G,"People with the AG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus."
1448613243,G,G,"People with the GG genotype undergoing a kidney transplantation may have decreased exposure to tacrolimus, as measured by concentration/distribution, compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to tacrolimus."
1448614963,T,T,Patients with the TT genotype may have decreased clearance of rocuronium as compared to patients with the del/del genotypes. Other clinical and genetic factors may also influence clearance of rocuronium.
1448615614,A,A,Women with premature births and the AA genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.
1448615614,A,G,Women with premature births and the AG genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.
1448615614,G,G,Women with premature births and the GG genotype who are treated with ritodrine may have a increased likelihood of adverse events as compared to women with premature birth and the AA or AG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.
1448617757,C,C,Patients with the CC genotype may have decreased clearance of atazanavir as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence clearance of atazanavir.
1448617757,C,T,Patients with the CT genotype may have decreased clearance of atazanavir as compared to patients with the TT genotype and increased clearance as compared to patients with the CC genotype. Other clinical and genetic factors may also influence clearance of atazanavir.
1448617757,T,T,Patients with the TT genotype may have increased clearance of atazanavir as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence clearance of atazanavir.
1448633935,A,A,Patients with the AA genotype and who are treated with warfarin may require increased dose as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.
1448633935,A,G,Patients with the AG genotype and who are treated with warfarin may require increased dose as compared to patients with the GG genotypes and decreased dose as compared to those with the AA genotype. Other clinical and genetic factors may also influence dose of warfarin.
1448633935,G,G,Patients with the GG genotype and who are treated with warfarin may require decreased dose as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence dose of warfarin.
1448634752,A,A,"Patients with the AA genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the AG and GG genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine."
1448634752,A,G,"Patients with the AG genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the GG genotype, and increased exposure as compared to patients with the AA genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine."
1448634752,G,G,"Patients with the GG genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have increased exposure of mycophenolic acid as compared to patients with the AG and AA genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine."
1449164121,G,G,"Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164121,G,T,"Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164121,T,T,"Patients with the TT genotype may require increased doses of warfarin as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164127,G,G,"Patients with the GG genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164127,G,T,"Patients with the GT genotype may require decreased doses of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1449164127,T,T,"Patients with the TT genotype may require increased doses of warfarin as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes."
1450374089,C,C,Patients with the CC genotype may have an increased response to acetaminophen (paracetamol) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374089,C,T,Patients with the CT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1450374089,T,T,Patients with the TT genotype may have a decreased response to acetaminophen (paracetamol) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to acetaminophen.
1447960238,C,C,"Patients with the CC genotype may have a greater likelihood of being overanticoagulated when treated with phenprocoumon, and may require a decreased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon."
1447960238,C,T,"Patients with the CT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon."
1447960238,T,T,"Patients with the TT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon."
1447960930,G,G,Patients with the GG genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with bupropion as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence smoking cessation.
1447960937,G,G,Patients with the GG genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence smoking cessation.
1447990235,C,T,Individuals with the CT genotype may have decreased metabolism and clearance of irbesartan which may result may in increased exposure as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.
1447990235,T,T,Individuals with the TT genotype may have increased metabolism and clearance of irbesartan which may result may in decreased exposure of irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.
1447990245,C,C,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group."
1447990245,C,G,"Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group."
1447990245,G,G,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CG and CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group."
1448097556,G,G,"Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097556,G,T,"Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097556,T,T,"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs17868323 GG, rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28 genotypes. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097574,G,G,"Patients with HIV and the GG genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GT or TT genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097574,G,T,"Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097574,T,T,"Patients with HIV and the TT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28.Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097587,A,A,"Patients with HIV and the AA genotype may be more likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097587,A,C,"Patients with HIV and the AC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448097587,C,C,"Patients with HIV and the CC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir."
1448100201,C,C,Patients with the CC genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1448100201,C,T,"Patients with the CT genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype, or increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence."
1448100201,T,T,Patients with the TT genotype may be at increased risk for nicotine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1448100313,A,A,"The current evidence base suggests that there is no significant association between the rs28365063 AA genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations."
1448100313,A,G,"The current evidence base suggests that there is no significant association between the rs28365063 AG genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations."
1448100313,G,G,"The current evidence base suggests that there is no significant association between the rs28365063 GG genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations."
1448100208,A,A,Patients with the AA genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1448100208,A,G,"Patients with the AG genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype, or decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence."
1448100208,G,G,Patients with the GG genotype may be at decreased risk for nicotine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.
1448100215,A,A,"Patients with the AA genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
1448100215,A,C,"Patients with the AC genotype and schizophrenia may have a decreased risk for weight gain when treated with antipsychotics as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
1448100215,C,C,"Patients with the CC genotype and schizophrenia may have an increased risk for weight gain when treated with antipsychotics as compared to patients with the AA genotype. However, conflicting evidence exists. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
1448100222,C,C,Patients with the CC genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
1448100222,C,T,Patients with the CT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
1448100222,T,T,Patients with the TT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
1448100242,A,A,Patients with the AA genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence pravastatin response.
1448100242,A,G,"Patients with the AG genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response."
1448100242,G,G,Patients with the GG genotype and vascular diseases may have a better response to pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response.
1448100249,A,A,Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.
1448100249,A,G,Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.
1448100249,G,G,Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk of osteonecrosis when treated with dexamethasone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.
1448100257,C,C,Patients with the CC genotype and chronic hepatitis C may have a decreased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.
1448100257,C,G,Patients with the CG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.
1448100257,G,G,Patients with the GG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.
1448100296,C,C,Patients with the CC genotype may require an increased dose of warfarin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dosage of warfarin.
1448100296,C,T,Patients with the CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of warfarin.
1448100296,T,T,Patients with the TT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of warfarin.
1448100306,C,C,Patients with the CC genotype and inflammatory bowel disease may have a decreased risk for leukopenia when treated with thiopurines as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.
1448100306,C,T,Patients with the CT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.
1448100306,T,T,Patients with the TT genotype and inflammatory bowel disease may have an increased risk for leukopenia when treated with thiopurines as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of leukopenia in patients receiving thiopurines.
1448100334,C,C,Patients with the CC genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.
1448100334,C,T,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
1448100340,A,A,Patients with the AA genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the AG or GG genotypes. Other factors may affect concentrations of ticagrelor.
1448100340,A,G,Patients with the AG genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the GG genotypes. Other factors may affect concentrations of ticagrelor.
1448100340,G,G,Patients with the GG genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the AA or AG genotypes. Other factors may affect concentrations of ticagrelor.
1448100347,C,C,Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.
1448100347,C,T,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
1448100347,T,T,Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.
1448100354,C,C,Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.
1448100354,C,T,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.
1448100354,T,T,Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.
1448100361,A,A,Patients with the AA genotype may have increased TPMT activity toward mercaptopurine as compared to patients with the AT genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100361,A,T,Patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity.
1448100361,T,T,"No patients with the TT genotype were available for analysis, but patients with the AT genotype may have decreased TPMT activity toward mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence TPMT activity."
1451773100,G,G,Patients with the rs10494366 GG genotype may show a greater QT-interval shortening effect when taking digoxin as compared to patients with the GT and TT genotypes. Other genetic and clinical factors may also influence QT-interval shortening when taking digoxin.
1451773100,G,T,Patients with the rs10494366 GT genotype may show a smaller QT-interval shortening effect when taking digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QT-interval shortening when taking digoxin.
1451773100,T,T,Patients with the rs10494366 TT genotype may show a smaller QT-interval shortening effect when taking digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QT-interval shortening when taking digoxin.
1448123834,A,A,"Patients with the AA genotype and schizophrenia may have increased response to clozapine compared to patients with the AG and GG genotypes. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine."
1448123834,A,G,"Patients with the AG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine."
1448123834,G,G,"Patients with the GG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine."
1449146785,A,A,"Patients with non-small cell lung cancer and the AA genotype who are treated with platinum-based chemotherapy may have a decreased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the GG genotype. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy."
1449146785,A,G,"Patients with non-small cell lung cancer and the AG genotype who are treated with platinum-based chemotherapy may have a decreased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the GG genotype. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy."
1449146785,G,G,"Patients with non-small cell lung cancer and the GG genotype who are treated with platinum-based chemotherapy may have an increased risk of hematologic toxicity, leukopenia, and GI toxicity as compared to patients with the AA or AG genotypes. There is no known association with risk of neutropenia, thrombocytopenia, or anemia. Other clinical and genetic factors may also influence risk of hematologic toxicity, leukopenia, and GI toxicity in patients with non-small cell lung cancer who are treated with platinum-based chemotherapy."
1449146832,C,C,Patients with colorectal cancer and the CC genotype may have a decreased response to tipiracil hydrochloride and trifluridine as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449146832,C,T,Patients with colorectal cancer and the CT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449146832,T,T,Patients with colorectal cancer and the TT genotype may have a improved response to tipiracil hydrochloride and trifluridine as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449146840,A,A,Patients with colorectal cancer and the AA genotype may have a worse response to tipiracil hydrochloride and trifluridine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449146840,A,G,Patients with colorectal cancer and the AG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449146840,G,G,Patients with colorectal cancer and the GG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.
1449147022,C,C,"Patients with genotypes CC may have decreased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype TT or CT."
1449147022,C,T,"Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC."
1449147022,T,T,"Patients with genotypes TT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC."
1451702280,C,C,Patients with the rs71647871 CC genotype may have increased metabolism of sacubitril as compared to patients with the CT genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and sacubitril and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence sacubitril metabolism.
1451702280,C,T,Patients with the rs71647871 CT genotype may have decreased metabolism of sacubitril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and sacubitril and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence sacubitril metabolism.
1451702280,T,T,"There is currently no available evidence regarding the association between the rs71647871 TT genotype and sacubitril metabolism. However, patients with the CT genotype may have decreased metabolism of sacubitril as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and sacubitril and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence sacubitril metabolism."
1449147609,C,C,Patients with the rs2740574 CC genotype who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.
1449147609,C,T,Patients with the rs2740574 CT genotype who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.
1449147609,T,T,Patients with the rs2740574 TT genotype who are taking buprenorphine for pain may have an increased analgesic response as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence analgesic response to buprenorphine.
1447990578,A,A,Kidney transplant patients with the AA genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.
1447990578,A,G,Kidney transplant patients with the AG genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.
1447990578,G,G,Kidney transplant patients with the GG genotype may have more rapid clearance rates of mycophenolic acid as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.
1448099059,A,A,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099059,A,G,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099059,G,G,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099065,A,A,Patients with the AA genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1448099065,A,G,"Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to those with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers."
1448099065,G,G,Patients with the GG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1448099080,C,C,Patients with the CC genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1448099080,C,G,"Patients with the CG genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers."
1448099080,G,G,Patients with the GG genotype and hypertension may have a greater decrease in blood pressure when treated with calcium channel blockers as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.
1448099093,A,A,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099093,A,G,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and a decreased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099093,G,G,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099100,A,A,Patients with the AA genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1448099100,A,G,Patients with the AG genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1448099100,G,G,Patients with the GG genotype and schizophrenia may have a smaller increase or decrease in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total cholesterol levels.
1448104372,C,C,Patients with the CC genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.
1448104372,C,T,Patients with the CT genotype may have increased risk of drug-induced liver injury compared to patients with the TT genotype. Other factors may affect liver toxicity when treated with atorvastatin.
1448104372,T,T,Patients with the TT genotype may have decreased risk of drug-induced liver injury compared to patients with the CC genotype. Other factors may affect liver toxicity when treated with atorvastatin.
1448257263,A,A,Patients with the AA genotype may require increased dose of warfarin as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of warfarin.
1448257263,A,G,Patients with the AG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
1448257263,G,G,Patients with the GG genotype may require decreased dose of warfarin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.
1448257270,G,G,Patients with the GG genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.
1448257270,G,T,Patients with the GT genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.
1448257270,T,T,Patients with the TT genotype may require decreased dose of warfarin as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the dose of warfarin.
1448257290,G,G,Patients with the GG genotype may have increased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype TT. Other genetic and clinical factors may influence the response to warfarin.
1448257290,G,T,Patients with the GT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.
1448257290,T,T,Patients with the TT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.
1448259317,C,C,Post menopausal women with the CC genotype and schizophrenia may have increased response to raloxifene compared to patients with the CG genotype. Other genetic and clinical factors may affect response to raloxifene.
1448259317,C,G,Post menopausal women with the CG genotype and schizophrenia may have decreased response to raloxifene compared to patients with the CC genotype. Other genetic and clinical factors may affect response to raloxifene.
1448259317,G,G,No patients with the GG genotype were studied.
1448264186,C,C,"Patients with the CC genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response."
1448264186,C,G,"Patients with the CG genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response."
1448264186,G,G,"Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes CC or CG. Other genetic and clinical factors may also influence peginterferon response."
1448615137,A,A,Postmenopausal women with HR+ breast cancer and the AA genotype may be less likely to experience arthralgia when treated with anastrozole as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615137,A,G,Postmenopausal women with HR+ breast cancer and the AG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615137,G,G,Postmenopausal women with HR+ breast cancer and the GG genotype may be more likely to experience arthralgia when treated with anastrozole as compared to women with the AA genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.
1448615147,A,A,Postmenopausal women with HR+ breast cancer and the AA genotype may have increased plasma concentrations of anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.
1448615147,A,C,Postmenopausal women with HR+ breast cancer and the AC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.
1448615147,C,C,Postmenopausal women with HR+ breast cancer and the CC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.
1448124242,A,A,Patients with the AA genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.
1448124242,A,G,Patients with the AG genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.
1448124242,G,G,Patients with the GG genotype may have decreased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to clopidogrel.
1448124216,C,C,Patients with the CC genotype may have decreased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.
1448124216,C,T,Patients with the CT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1448124216,T,T,Patients with the TT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.
1183532576,C,C,"Patients with the CC genotype (ApoE E4/E4) may have an increased risk of mortality after myocardial infarction as compared to the TT genotype, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment."
1183532576,C,T,"Patients with the CT genotype (ApoE E4 carriers) may have an increased risk of mortality after myocardial infarction as compared to the TT genotype, which may be mitigated by simvastatin treatment. Therefore, these patients may actually benefit more from simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment."
1183532576,T,T,"Patients with the TT genotype may have a decreased risk of mortality after myocardial infarction as compared to the CC or CT genotypes (ApoE E2 carriers), which may be mitigated by simvastatin treatment. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment."
1447982779,C,C,"Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity."
1447982779,C,T,"Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity."
1447982779,T,T,"Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity."
1447982788,C,C,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982788,C,T,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
1447982788,T,T,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982797,G,G,Patients with the GG genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have an increased risk for anemia and thrombocytopenia as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.
1447982797,G,T,"Patients with the GT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia."
1447982797,T,T,"Patients with the TT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia."
1447982804,A,A,Patients with the AA genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982804,A,G,"No information are available for the AG genotype. However, patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
1447982804,G,G,Patients with the GG genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982811,C,C,Patients with the CC genotype may have increased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982811,C,T,"No information are available for the CT genotype. However, patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan."
1447982811,T,T,Patients with the TT genotype may have decreased clearance of bufuralol or dextromethorphan based on in vitro studies compared to the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of bufuralol or dextromethorphan.
1447982818,A,A,"Patients with the AA genotype may have increased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the GG genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
1447982818,A,G,"No information are available for the AG genotype. However, patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
1447982818,G,G,"Patients with the GG genotype may have decreased sensitivity to cladribine, fluorouracil or gemcitabine based on in vitro studies compared to the AA genotype. Other genetic and clinical factors may also influence a patient's sensitivity to cladribine, fluorouracil or gemcitabine."
1447982832,A,A,Patients with the AA genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.
1447982832,A,G,Patients with the AG genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.
1447982832,G,G,Patients with the GG genotype and psoriasis who are treated with fumaric acid esters may have a decreased response as patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's drug response.
1448103935,G,G,Patients with the GG genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448103935,G,T,"Patients with the GT genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide."
1448103935,T,T,Patients with the TT genotype and type 2 diabetes may have a better response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.
1448265605,A,A,Patients with the AA genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265605,A,G,Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448265605,G,G,Patients with the GG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the AA genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.
1448636111,A,A,"Patients with the AA genotype may have increased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV."
1448636111,A,G,"Patients with the AG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV."
1448636111,G,G,"Patients with the GG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV."
1450933001,A,A,"Patients with beta-thalassemia and the AA genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450933001,A,C,"Patients with beta-thalassemia and the AC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450933001,C,C,"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450933052,G,G,"Patients with the GG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs."
1450933052,G,T,"Patients with the GT genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs."
1450933052,T,T,"Patients with the TT genotype may have a decreased response to anti-TNF drugs, as measured by a decrease in quality of life scores, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs."
1450933104,C,C,Patients with ADHD and the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450933104,C,T,Patients with ADHD and the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450933104,T,T,There is currently no available evidence regarding the association of the TT genotype and a patient's risk of developing alcoholism.
1450933110,A,A,Patients with ADHD and the AA genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.
1450933110,A,G,Patients with ADHD and the AG genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.
1450933110,G,G,Patients with ADHD and the GG genotype may be at a decreased risk of developing nicotine dependence as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.
1450934055,C,C,Patients with the CC genotype may be less likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.
1450934055,C,T,Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.
1450934055,T,T,Patients with the TT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosage requirements.
1450934203,A,A,Patients with the AA genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934203,A,G,Patients with the AG genotype may have a decreased response to mexiletine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934203,G,G,Patients with the GG genotype may have an increased response to mexiletine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934656,A,A,"Patients with the AA genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934656,A,C,Patients with the AC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934656,C,C,Patients with the CC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1043880143,A,A,Patients with the rs708272 AA genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to statin treatment.
1043880143,A,G,"Patients with the rs708272 AG genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the GG genotype, or may have less of a reduction in cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to statin treatment."
1043880143,G,G,Patients with the rs708272 GG genotype and Coronary Artery Disease who are treated with statins may have less of a reduction in cardiovascular events as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to statin treatment.
1447946124,A,A,"No patients with the AA genotype were available for analysis, but patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab."
1447946124,A,G,Patients with the AG genotype may have a poorer response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
1447946124,G,G,Patients with the GG genotype may have a better response to treatment with infliximab as compared to patients with the AG genotype. Other genetic and clinical factors may also influence response to infliximab.
1447947019,C,C,"Patients with the CC genotype may have decreased concentrations of tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations."
1447947019,C,T,"Patients with the CT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations."
1447947019,T,T,"Patients with the TT genotype may have increased concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence a patient's tacrolimus concentrations."
1447960269,C,C,"No patients with the CC genotype are available for analysis, but patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients."
1447960269,C,T,Patients with the CT genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.
1447960269,T,T,Patients with the TT genotype and non-small-cell lung cancer may have better overall survival times when treated with platinum agents and gemcitabine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence overall survival in non-small-cell lung cancer patients.
1447960309,A,A,Patients with the AA genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
1447960309,A,G,Patients with the AG genotype and Crohn's disease may a better response to treatment with infliximab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to infliximab.
1447960309,G,G,Patients with the GG genotype and Crohn's disease may a poorer response to treatment with infliximab as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to infliximab.
1447964180,A,A,"No patients with the AA genotype were available for analysis, but women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy."
1447964180,A,G,Women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.
1447964180,G,G,Women with the GG genotype and breast cancer may have lesser aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy.
1447990932,G,T,The GT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with an increased risk of leukopenia when treated with methotrexate as compared to the TT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.
1447990932,T,T,The TT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with a decreased risk of leukopenia when treated with methotrexate as compared to the GT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.
1448100089,A,A,Patients with the AA genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1448100089,A,T,"Patients with the AT genotype may have a decreased likelihood of developing an addiction to methamphetamines as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction."
1448100089,T,T,Patients with the TT genotype may have an increased likelihood of developing an addiction to methamphetamines as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.
1448100103,C,C,Patients with major depressive disorder and the CC genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100103,C,T,Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100103,T,T,Patients with major depressive disorder and the TT genotype may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1448100110,A,A,Patients with the AA genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.
1448100110,A,G,"Patients with the AG genotype who are undergoing kidney transplantation may have an increased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth."
1448100110,G,G,Patients with the GG genotype who are undergoing kidney transplantation may have a decreased risk for gingival overgrowth when treated with cyclosporine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of gingival overgrowth.
1448100117,C,C,Patients with major depressive disorder and the CC genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100117,C,T,Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100117,T,T,Patients with major depressive disorder and the TT genotype may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1448100132,A,A,Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100132,A,G,Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100132,G,G,Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448100139,C,C,Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100139,C,T,Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100139,T,T,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1448100146,A,A,Patients with the AA genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100146,A,G,Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100146,G,G,Patients with the GG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448100158,C,C,Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100158,C,T,Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100158,T,T,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1448100165,C,C,Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100165,C,T,Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100165,T,T,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1448100173,A,A,Patients with the AA genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100173,A,G,Patients with the AG genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100173,G,G,Patients with the GG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448100180,C,C,Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100180,C,T,Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.
1448100180,T,T,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.
1448100521,C,C,Men with the CC genotype and hypertension may have reduced response to losartan compared to men with the CT and TT genotypes. Other factors may affect response to losartan.
1448100521,C,T,Men with the CT genotype and hypertension may have reduced response to losartan compared to men with the TT genotype. Other factors may affect response to losartan.
1448100521,T,T,Men with the TT genotype and hypertension may have increased response to losartan compared to men with the CC and CT genotypes. Other factors may affect response to losartan.
1448258925,C,C,"Patients with the CC genotype may have increased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1448258925,C,T,"Patients with the CT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1448258925,T,T,"Patients with the TT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib."
1447960948,A,A,Patients with the AA genotype and epilepsy may require an increased dose of valproic acid as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of valproic acid.
1447960948,A,C,"Patients with the AC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of valproic acid."
1447960948,C,C,Patients with the CC genotype and epilepsy may require a decreased dose of valproic acid as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence dose of valproic acid.
1447961028,C,C,"Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity."
1447961028,C,T,"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity."
1447961028,T,T,"Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity."
1447961074,C,C,Patients with the CC genotype and pancreatic cancer may have a shorter overall survival times when treated with gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence survival times.
1447961074,C,T,Patients with the CT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.
1447961074,T,T,Patients with the TT genotype and pancreatic cancer may have a longer overall survival times when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival times.
1447961344,A,A,Patients with the AA genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence alcoholism risk.
1447961344,A,C,"Patients with the AC genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype, or more likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk."
1447961344,C,C,Patients with the CC genotype who are African-American may be more likely to become addicted to alcohol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.
1448099908,A,A,Patients with choroidal neovascularization and the AA genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.
1448099908,A,C,Patients with choroidal neovascularization and the AC genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.
1448099908,C,C,Patients with choroidal neovascularization and the CC genotype may have increased response to photodynamic therapy compared to patients with the AA and AC genotypes. Other factors may affect response to photodynamic therapy.
1448532313,C,C,"Patients with genotype CC may have decreased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype TT. Other genetic and clinical factors may also influences response to ledipasvir/sofosbuvir therapy."
1448532313,C,T,"Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir/sofosbuvir therapy."
1448532313,T,T,"Patients with genotype TT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir/sofosbuvir therapy."
1449156809,A,A,Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449156809,A,G,Patients with the AG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449156809,G,G,Patients with the GG genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1449156815,A,A,"Patients with the AA genotype may have a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
1449156815,A,G,"Patients with the AG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
1449156815,G,G,"Patients with the GG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
1447990855,A,A,Women with the AA genotype and breast cancer who are treated with antineoplastic agents may be associated with improved survival as compared to women with the AG and GG genotypes. Other clinical and genetic factors may also influence survival rates in women with breast cancer.
1447990855,A,G,Women with the AG genotype and breast cancer who are treated with antineoplastic agents may be associated improved survival as compared to women with the GG genotypes and worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer.
1447990855,G,G,Women with the GG genotype and breast cancer who are treated with antineoplastic agents may be associated with worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer.
1448098232,A,A,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098232,A,G,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have a decreased severity of anemia as compared to patients with the GG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098232,G,G,Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have a increased severity of anemia as compared to patients with the AA or AG genotype. Other clinical factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098287,C,C,Patients with nasopharyngeal cancer and the CC genotype may have a decreased severity of anemia when treated with docetaxel as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448098287,C,T,Patients with nasopharyngeal cancer and the CT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448098287,T,T,Patients with nasopharyngeal cancer and the TT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448098293,A,A,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098293,A,T,Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098293,T,T,Patients with nasopharyngeal cancer and the TT genotype who are treated with docetaxel may have a increased severity of neutropenia as compared to patients with the AT or AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098304,A,A,Patients with nasopharyngeal cancer and the AA genotype may have more severe anemia when treated with docetaxel as compared to patients with the AG genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098304,A,G,Patients with nasopharyngeal cancer and the AG genotype may have less severe anemia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098315,C,T,Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia who are treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098315,T,T,Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia who are treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098320,C,C,Patients with nasopharyngeal cancer and the CC genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098320,C,T,Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia as compared to patients with the CC or TT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098320,T,T,Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098325,A,A,Patients with nasopharyngeal cancer and the AA genotype may have less severe anemia and neutropenia as compared to patients with the AG genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098325,A,G,Patients with nasopharyngeal cancer and the AG genotype may have more severe anemia and neutropenia as compared to patients with the AA genotype when treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098354,A,A,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098354,A,G,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099112,C,C,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099112,C,T,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the CT genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the TT genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the CC genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099112,T,T,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the TT genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or CC genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099135,A,A,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AA genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099135,A,G,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the AG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the GG genotypes and an increased risk of osteonecrosis as compared to pediatric patients with the AA genotype. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099135,G,G,"Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have an increased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AA or AG genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients."
1448099156,C,T,Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099156,T,T,Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099162,C,T,Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099162,T,T,Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099178,C,T,Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099178,T,T,Patients with nasopharyngeal cancer and the TT genotype may have more severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099320,A,A,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448099320,A,G,Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.
1448276473,C,C,Patients with the CC genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.
1448276473,C,T,Patients with the CT genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.
1448276473,T,T,Patients with the TT genotype may have decreased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to rosiglitazone.
1448099149,A,A,"Patients with the rs2032582 AA genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol."
1448099149,A,C,"Patients with the rs2032582 AC genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol."
1448099149,C,C,"Patients with the rs2032582 CC genotype may be less likely to respond to tramadol treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol."
1447954378,G,G,Patients with the rs113993959 GG genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.
1447954378,G,T,"Patients with the rs113993959 GT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
1447954378,T,T,"Patients with the rs113993959 TT genotype and cystic fibrosis may have improvement in chloride transport when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis."
1183491175,C,C,Patients with the CC genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.
1183491175,C,T,"Patients with the CT genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype, or may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment."
1183491175,T,T,Patients with the TT genotype and Myocardial Infarction who are treated with rosuvastatin may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.
1444843613,A,A,"Patients with the AA genotype may have increased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy."
1444843613,A,G,"Patients with the AG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy."
1444843613,G,G,"Patients with the GG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy."
1448099168,G,T,Patients with nasopharyngeal cancer and the GT genotype may have more severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099168,T,T,Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the GT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448099784,G,G,"Patients with the GG genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy."
1448099784,G,T,"Patients with the GT genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy."
1448099784,T,T,"Patients with the TT genotype and hepatocellular carcinoma may have a poorer response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy."
1448099828,C,C,Patients with chronic lymphocytic leukemia (CLL) and the genotype CC may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.
1448099828,C,T,Patients with chronic lymphocytic leukemia (CLL) and the genotype CT may have decreased response to anti-CLL treatment compared to patients with the TT genotype. Other factor may affect response to anti-CLL treatment.
1448099828,T,T,Patients with chronic lymphocytic leukemia (CLL) and the genotype TT may have increased response to anti-CLL treatment compared to patients with the CC and CT genotypes. Other factor may affect response to anti-CLL treatment.
1448568208,A,A,Patients with the AA genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.
1448568208,A,G,Patients with the AG genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.
1448568208,G,G,Patients with the GG genotype may have increased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to cetuximab.
1448624484,C,C,"Patients with the CC genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased of likelihood of leukopenia or neutropenia as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine)."
1448624484,C,T,"Patients with the CT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the TT genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the CC genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine)."
1448624484,T,T,"Patients with the TT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have decreased of likelihood of leukopenia or neutropenia as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence likelihood of leukopenia or neutropenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine)."
1451673180,A,A,Patients with the rs199515342 AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451673180,A,G,Patients with the rs199515342 AG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451673180,G,G,Patients with the rs199515342 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs199515342 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1448632491,A,A,"Patients with the AA genotype may have decreased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin."
1448632491,A,G,"Patients with the AG genotype may have decreased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin."
1448632491,G,G,"Patients with the GG genotype may have improved overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin."
1451673200,A,A,Patients with the rs571335587 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs571335587 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451673200,A,C,Patients with the rs571335587 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs571335587 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451673200,C,C,Patients with the rs571335587 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotype. This annotation only covers the pharmacokinetic relationship between rs571335587 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1447949088,A,A,Patients with AA genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.
1447949088,A,G,Patients with AG genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.
1447949088,G,G,Patients with GG genotype may have increased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.
1448098975,A,A,Pediatric cancer patients with the AA genotype may have a decreased risk for ototoxicity when treated with cisplatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.
1448098975,A,G,Pediatric cancer patients with the AG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.
1448098975,G,G,Pediatric cancer patients with the GG genotype may have an increased risk for ototoxicity when treated with cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ototoxicity risk in pediatric cancer patients.
1448099022,A,A,Pediatric patients with the AA genotype who are undergoing hematopoietic stem cell transplantation may have increased clearance of busulfan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence busulfan clearance.
1448099022,A,G,Pediatric patients with the AG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance.
1448099022,G,G,Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance.
1448103867,A,A,Patients with the AA genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.
1448103867,A,G,Patients with the AG genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.
1448103867,G,G,Patients with the GG genotype and schizophrenia may have slower improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.
1448126020,A,A,"Patients with genotype AA may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib."
1448126020,A,T,"Patients with genotype AT may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib."
1448126020,T,T,"Patients with genotype TT may have increased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the response to sorafenib."
1448522748,C,C,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522748,C,T,Patients with the CT genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448522748,T,T,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.
1448532363,G,G,Patients with genotype GG may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1448532363,G,T,Patients with genotype GT may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1448532363,T,T,Patients with genotype TT may have increased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes GG or GT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.
1448112486,A,A,Patients with the AA genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect response to tocilizumab.
1448112486,A,G,Patients with the AG genotype and rheumatoid arthritis may have an increased response to tocilizumab compared to patients with the GG genotype. Other clinical and genetic factors may affect response to tocilizumab.
1448112486,G,G,Patients with the GG genotype and rheumatoid arthritis may have a decreased response to tocilizumab compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect response to tocilizumab.
1448112493,C,C,Patients with the CC genotype and rheumatoid arthritis may have increased response to tocilizumab compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect response to tocilizumab.
1448112493,C,T,Patients with the CT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.
1448112493,T,T,Patients with the TT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.
1451674140,A,A,Patients with the rs61605570 AA genotype may have increased metabolism of nicotine as compared to patients with the AT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs61605570 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674140,A,T,Patients with the rs61605570 AT genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs61605570 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674140,T,T,Patients with the rs61605570 TT genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs61605570 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674148,C,C,Patients with the rs768416963 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674148,C,T,Patients with the rs768416963 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674148,T,T,Patients with the rs768416963 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs768416963 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451704120,A,A,"Patients with infections and the rs1799931 AA genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole/trimethoprim."
1451704120,A,G,"Patients with infections and the rs1799931 AG genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole/trimethoprim."
1451704120,G,G,"Patients with infections and the rs1799931 GG genotype may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole/trimethoprim as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole/trimethoprim."
1450932250,A,A,"Patients with the AA genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema."
1450932250,A,G,"Patients with the AG genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema."
1450932250,G,G,"Patients with the GG genotype may be at an increased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema."
1448603625,C,C,"No patients with the CC genotype were available for analysis, but patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations."
1448603625,C,T,"Patients with the CT genotype who are undergoing lung transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the TT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations."
1448603625,T,T,"Patients with the TT genotype who are undergoing lung transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations."
982043234,C,C,Patients with breast cancer and the rs1937840 CC genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.
982043234,C,G,Patients with breast cancer and the rs1937840 CG genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.
982043234,G,G,Patients with breast cancer and the rs1937840 GG genotype may have an increased response to treatment with docetaxel and doxorubicin as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.
982029200,C,C,Patients with the CC genotype may have increased plasma concentrations of repaglinide in healthy volunteers as compared to patients with the TT or CT genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.
982029200,C,T,Patients with the CT genotype may have reduced plasma concentrations of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.
982029200,T,T,Patients with the TT genotype may have reduced plasma concentrations of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype.
982042110,A,A,Colon cancer patients with AA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.
982042110,C,A,Colon cancer patients with CA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.
982042110,C,C,Colon cancer patients with CC genotype may have shorter time to tumor recurrence when treated 5-fluorouracil compared to patients with CA + AA genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.
1043873018,A,A,Patients with the AA genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.
1043873018,A,G,Patients with the AG genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.
1043873018,G,G,Patients with the GG genotype may have increased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with AA or AG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.
1043880392,C,C,Patients with the CC genotype may require decreased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880392,C,T,Patients with the CT genotype may require decreased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.
1043880392,T,T,Patients with the TT genotype may require increased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.
1183618204,A,A,Patients with the AA genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1183618204,A,G,Patients with the AG genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1183618204,G,G,Patients with the GG genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.
1183631792,C,C,"Patients with the CC genotype may have increased response to citalopram or escitalopram in people with depression as compared to patients with the TT or CT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram."
1183631792,C,T,"Patients with the CT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram."
1183631792,T,T,"Patients with the TT genotype may have decreased response to citalopram or escitalopram in people with depression as compared to patients with the CC genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram."
1183693485,C,C,"Patients with the CC genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have an increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CT and CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain."
1183693485,C,T,"Patients with the CT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have increased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for weight gain."
1183693485,T,T,"Patients with the TT genotype and psychotic disorders, including schizophrenia or autism spectrum disorders (ASD) may have a decreased likelihood of weight gain when treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain."
1184512433,A,A,Patients with the AA genotype who are treated with warfarin may require a higher dose as compared to patients with the GA or GG genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1184512433,G,A,Patients with the GA genotype who are treated with warfarin may require a lower dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1184512433,G,G,Patients with the GG genotype who are treated with warfarin may require a lower dose as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.
1445400672,A,G,Patients with the AG genotype may have a better response to the pertussis vaccine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1445400672,G,G,Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.
1446898324,A,A,"Individuals with tobacco use disorder and the AA genotype may have an improved response to bupropion as compared to individuals with the AG and GG genotypes, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder."
1446898324,A,G,"Individuals with tobacco use disorder and the AG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder."
1446898324,G,G,"Individuals with tobacco use disorder and the GG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder."
1446899639,A,A,Women with breast cancer and the AA genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.
1446899639,A,G,Women with breast cancer and the AG genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the GG genotypes and an increased likelihood of survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.
1446899639,G,G,Women with breast cancer and the GG genotype may have an increased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.
1448112600,A,A,"Patients with the AA genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies."
1448112600,A,G,"Patients with the AG genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies."
1448112600,G,G,"Patients with the GG genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AG genotypes. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies."
1448112607,A,A,Patients with the AA genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112607,A,C,Patients with the AC genotype and bladder cancer may have decreased response to cisplatin-based therapy compared to patients with the CC genotype. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112607,C,C,Patients with the CC genotype and bladder cancer may have increased response to cisplatin-based therapy compared to patients with the AA and AC genotypes. Replication studies did not confirm these findings. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112614,C,C,Patients with the CC genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112614,C,T,Patients with the CT genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448112614,T,T,Patients with the TT genotype and bladder cancer may have an increased response to cisplatin-based therapies compared to patients with the CC and CT genotypes. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.
1448567993,C,C,Patients with the CC genotype who underwent kidney transplantation may have increased dose-adjusted trough concentrations of sirolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.
1448567993,C,T,Patients with the CT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.
1448567993,T,T,Patients with the TT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.
1449576983,A,A,Patients with the rs3828743 AA genotype may have worse response and shorter progression-free survival when treated with abiraterone/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence the response to abiraterone/prednisolone.
1449576983,A,G,Patients with the rs3828743 AG genotype may have better response and longer progression-free survival when treated with abiraterone/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to abiraterone/prednisolone.
1449576983,G,G,Patients with the rs3828743 GG genotype may have better response and longer progression-free survival when treated with abiraterone/prednisolone in metastatic castration-resistant prostate cancer patients as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to abiraterone/prednisolone.
1451704127,A,A,"Patients with infections and the rs1799930 AA genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole/trimethoprim."
1451704127,A,G,"Patients with infections and the rs1799930 AG genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole/trimethoprim."
1451704127,G,G,"Patients with infections and the rs1799930 GG genotype may be at a decreased risk of experiencing adverse events when treated with sulfamethoxazole/trimethoprim as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole/trimethoprim."
1448616381,C,C,"Patients with the CC genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CT or TT genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin."
1448616381,C,T,"Patients with the CT genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the TT genotype, and a decreased risk as compared to patients with the CC genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin."
1448616381,T,T,"Patients with the TT genotype and cancer may have a decreased likelihood of ototoxicity when treated with cisplatin as compared to patients with the CC or CT genotypes. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin."
1449140069,A,A,"Patients with the AA genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and increased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer."
1449140069,A,G,"Patients with the AG genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and decreased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer."
1449140069,G,G,Patients with the GG genotype and bladder cancer who are treated with temsirolimus may have increased exposure as compared to patients with the AA or AG genotypes and decreased likelihood of bone marrow and gastrointestinal toxicities or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.
1449140085,A,A,"Patients with the AA genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus and sirolimus."
1449140085,A,C,"Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus."
1449140085,C,C,"Patients with the CC genotype and bladder cancer may have increased metabolism of temsirolimus or sirolimus as compared to patients with the AA or AC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus."
1450815120,A,A,Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815120,A,T,Patients with schizophrenia and the AT genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815120,T,T,Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the AA or AT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450823713,C,C,Patients with the CC genotype may have increased severity of akathisia when treated with arpiprazole as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect severity of aripiprazole-induced akathisia in patients.
1450823713,C,T,Patients with the CT genotype may have decreased severity of akathisia when treated with arpiprazole as compared to patients with the CC genotype. Other genetic or clinical factors may also affect severity of aripiprazole-induced akathisia in patients.
1450823713,T,T,Patients with the TT genotype may have decreased severity of akathisia when treated with arpiprazole as compared to patients with the CC genotype. Other genetic or clinical factors may also affect severity of aripiprazole-induced akathisia in patients.
1446897383,A,A,Post-menopausal women with the AA genotype and breast cancer may have decreased disease free survival when treated with tamoxifen as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.
1446897383,A,C,Post-menopausal women with the AC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen.
1446897383,C,C,Post-menopausal women with the CC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen.
1450931979,C,C,Patients with the CC genotype may have a decreased analgesic response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1450931979,C,T,Patients with the CT genotype may have a decreased analgesic response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.
1450931979,T,T,Patients with the TT genotype may have an increased analgesic response to fentanyl as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.
982030836,A,A,"Patients with the rs10929302 AA genotype may have increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity."
982030836,A,G,"Patients with the rs10929302 AG genotype may have decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity."
982030836,G,G,"Patients with the rs10929302 GG genotype may have decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity."
982030854,C,C,"Patients with the rs9606186 CC genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone."
982030854,C,G,"Patients with the rs9606186 CG genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone."
982030854,G,G,"Patients with the rs9606186 GG genotype and Schizophrenia may be more likely to respond when treated with risperidone as compared to patients with the CG or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone."
1183491446,A,A,"Patients with the rs20455 AA genotype may have decreased response to atorvastatin as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
1183491446,A,G,"Patients with the rs20455 AG genotype may have increased response to atorvastatin treatment as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
1183491446,G,G,"Patients with the rs20455 GG genotype may have increased response to atorvastatin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin."
1447990271,C,C,Patients with the CC genotype may have an increased risk of addiction to heroin when using heroin as compared to patients with the CT or TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.
1447990271,C,T,Patients with the CT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CC genotype and an increased risk of heroin addiction as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.
1447990271,T,T,Patients with the TT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.
1448255939,A,A,"Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
1448255939,A,G,"Patients with genotype AG may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib."
1448255939,G,G,"Patients with genotype GG may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AG or AA. Other genetic and clinical factors may also influence the response to sorafenib."
1447990913,A,A,"The AA genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer."
1447990913,A,G,"The AG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with increased progression-free survival as compared to patients with the GG genotypes and decreased progression-free survival as compared to patients with the AA genotype. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer."
1447990913,G,G,"The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with decreased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer."
1448097822,A,A,Patients with the AA genotype may have a decreased likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AC or CC genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.
1448097822,A,C,Patients with the AC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.
1448097822,C,C,Patients with the CC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.
1448098339,C,C,Patients with nasopharyngeal cancer and the CC genotype may have less severe anemia as compared to patients with the CT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1448098339,C,T,Patients with nasopharyngeal cancer and the CT genotype may have more severe anemia as compared to patients with the CC genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.
1444706164,G,G,Patients with the GG genotype may have decreased response to lovastatin as compared to patients with the TT or TG genotypes. Other genetic and clinical factors may influence also a patient's lovastatin response.
1444706164,T,G,Patients with the TG genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.
1444706164,T,T,Patients with the TT genotype may have increased response to lovastatin as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's lovastatin response.
1444706201,C,C,"Tuberculosis patients with the CC genotype may have increased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotypes. Other genetic and clinical factors may influence also a patient's exposure to rifampicin."
1444706201,T,C,"Tuberculosis patients with the TC genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's exposure to rifampicin."
1444706201,T,T,"Tuberculosis patients with the TT genotype may have decreased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's exposure to rifampicin."
1447813727,A,A,Individuals with the AA genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the AG or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813727,A,G,Individuals with the AG genotype and bipolar disorder may have a worse response to lithium as compared to individuals with the GG genotype but may have and an improved response as compared to individuals with the AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447813727,G,G,Individuals with the GG genotype and bipolar disorder may have an improved response to lithium as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.
1447943591,A,A,"Patients with the AA genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine."
1447943591,A,G,"Patients with the AG genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine."
1447943591,G,G,"Patients with the GG genotype and depressive disorder may have an increased response to agomelatine, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to agomelatine."
1447949305,A,A,Patients who receive a kidney with the AA genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AG or GG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.
1447949305,A,G,"Patients who receive a kidney with the AG genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the GG genotype, and increased eGFR as compared to patients with the AA genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR."
1447949305,G,G,Patients who receive a kidney with the GG genotype may have increased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AA or AG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.
1447952819,G,G,"Women with the GG genotype and rheumatoid arthritis may have an increased response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
1447952819,G,T,"Women with the GT genotype and rheumatoid arthritis may have an increased response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
1447952819,T,T,"Women with the TT genotype and rheumatoid arthritis may have a worse response when treated with adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
1447952825,A,A,Patients with the AA genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1447952825,A,G,Patients with the AG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1447952825,G,G,Patients with the GG genotype and schizophrenia may have a worse response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.
1447952831,A,A,"Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
1447952831,A,G,"Women with the AG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
1447952831,G,G,"Women with the GG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate."
1447964542,A,A,Patients with the AA genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.
1447964542,A,G,"Patients with the AG genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome."
1447964542,G,G,Patients with the GG genotype and colorectal cancer may have an increased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.
1447979295,A,A,"Female patients with the AA genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
1447979295,A,G,"Female patients with the AG genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. In males, this association may be in the opposite direction. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
1447979295,G,G,"Female patients with the GG genotype may have an increased likelihood of weight gain when treated with antipsychotics as compared to patients with the AA genotype. In males, this association was found in the opposite direction, though it was not statistically significant. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics."
1448098344,A,A,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to the GG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel.
1448098344,G,G,Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have more severe anemia as compared to the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel.
1448099574,C,C,"Patients with the CC genotype may have less favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
1448099574,C,T,"Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
1448099574,T,T,"Patients with the TT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia."
1448100125,A,A,Patients with major depressive disorder and the AA genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100125,A,G,Patients with major depressive disorder and the AG genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.
1448100125,G,G,Patients with major depressive disorder and the GG genotype may have increased response to antidepressants compared to patients with the AA and AG genotypes. Other factors may affect response to antidepressants.
1448100235,C,C,Patients with the CC genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.
1448100235,C,T,Patients with the CT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.
1448100235,T,T,Patients with the TT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.
1448100826,C,C,"Women with the CC genotype and breast or ovarian cancer may have a decreased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy."
1448100826,C,T,"Women with the CT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC genotype, and a decreased risk as compared to women with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy."
1448100826,T,T,"Women with the TT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy."
1448104015,A,A,Female patients with the AA genotype and epilepsy may have a poorer response when treated with antiepileptic drugs as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antiepileptics.
1448104015,A,C,Female patients with the AC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.
1448104015,C,C,Female patients with the CC genotype and epilepsy may have a better response when treated with antiepileptic drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antiepileptics.
1448259106,A,A,Patients with the AA genotype and Alzheimer's Disease may not experience increasing creatinine levels when taking captopril compared to patients with the AT and TT genotypes. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.
1448259106,A,T,Patients with the AT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.
1448259106,T,T,Patients with the TT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.
1448276321,A,A,Patients with the AA genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines.
1448276321,A,G,Patients with the AG genotype may have increased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to thiopurines.
1448276321,G,G,Patients with the GG genotype may have decreased risk of thiopurine-induced Leukopenia in people with Irritable Bowel Syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to thiopurines.
1448615319,A,A,Patients with coronary disease and the AA genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.
1448615319,A,G,Patients with coronary disease and the AG genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.
1448615319,G,G,Patients with coronary disease and the GG genotype who are treated with clopidogrel may have a decreased risk of hemorrhage as compared to patients with the AG or GG genotype. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.
1448616890,C,C,"Patients with the CC genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine."
1448616890,C,T,"Patients with the CT genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine."
1448616890,T,T,Patients with the TT genotype and colorectal cancer who are treated with capecitabine may have an increased risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.
1444706245,C,C,Patients with the CC genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.
1444706245,C,T,Patients with the CT genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.
1444706245,T,T,Patients with the TT genotype may be at decreased risk of myopathy when treated with simvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.
1446899702,C,C,"Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899702,C,T,"Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1446899702,T,T,"Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC and CT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors."
1444672986,C,C,Patients with the rs3135506 CC genotype and hypertriglyceridemia may have a decreased response to treatment with fenofibrate as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1444672986,C,G,Patients with the rs3135506 CG genotype and hypertriglyceridemia may have an increased response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1444672986,G,G,Patients with the rs3135506 GG genotype and hypertriglyceridemia may have an increased response to treatment with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.
1447961082,A,C,"Patients with the rs112445441 AC genotype (G13V) and colorectal cancer may have similar response when treated with cetuximab as compared to patients with the CC genotype (reference KRAS with no mutations in codon 13). However, conflicting evidence has been reported. Note, the FDA label for cetuximab does not recommend cetuximab treatment in patients with codon 13 mutations. Other genetic and clinical factors may also influence response to cetuximab."
1447961082,C,C,"Patients with the rs112445441 CC genotype (reference KRAS with no mutations in codon 13) and colorectal cancer may have similar response when treated with cetuximab as compared to patients with the AC or CT genotype (codon 13 mutations). However, conflicting evidence has been reported. Note, the FDA label for cetuximab does not recommend cetuximab treatment in patients with codon 13 mutations. Other genetic and clinical factors may also influence response to cetuximab."
1447961082,C,T,"Patients with the rs112445441 CT genotype (G13D) and colorectal cancer may have similar response when treated with cetuximab as compared to patients with the CC genotype (reference KRAS with no mutations in codon 13). However, conflicting evidence has been reported. Note, the FDA label for cetuximab does not recommend cetuximab treatment in patients with codon 13 mutations. Other genetic and clinical factors may also influence response to cetuximab."
1447990255,C,C,"Patients with the CC genotype may need an increased dose of warfarin as compared to patients with the CG and GG genotypes, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin."
1447990255,C,G,"Patients with the CG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin."
1447990255,G,G,"Patients with the GG genotype may need a decreased dose of warfarin as compared to patients with the CC genotype, however this has been contradicted in some studies. Other clinical and genetic factors may also influence dose of warfarin."
1447990789,A,A,Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 AA genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the AG and GG genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.
1447990789,A,G,Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 AG genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the GG and less sensitive as compared to PBMCs from individuals with the AA genotype. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.
1447990789,G,G,Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 GG genotype may be less sensitive to methotrexate as compared to PBMCs from individuals with the AG and AA genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.
1451674160,C,C,Patients with the rs1302192284 CC genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1302192284 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674160,C,T,Patients with the rs1302192284 CT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1302192284 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674160,T,T,Patients with the rs1302192284 TT genotype may have increased metabolism of nicotine as compared to patients with the CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs1302192284 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674200,A,A,Patients with the rs137904044 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs137904044 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674200,A,C,Patients with the rs137904044 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs137904044 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674200,C,C,Patients with the rs137904044 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs137904044 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674220,A,A,Patients with the rs114558780 AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674220,A,G,Patients with the rs114558780 AG genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674220,G,G,Patients with the rs114558780 GG genotype may have increased metabolism of nicotine as compared to patients with the AA or AG genotypes. This annotation only covers the pharmacokinetic relationship between rs114558780 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1448634065,C,C,The CC genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1448634065,C,T,The CT genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to theTT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1448634065,T,T,The TT genotype may be associated with increased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1448634071,C,C,The CC genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1448634071,C,T,The CT genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to theTT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1448634071,T,T,The TT genotype may be associated with increased likelihood of nephrotoxicity when treated with cisplatin as compared to the CT or TT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.
1448634742,C,C,"Patients with the CC genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the CT and TT genotype, however the evidence is contradictory. In one study, the T allele was associated with increased Cmax in both kidney donors AND kidney recipients, and increased clearance in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine."
1448634742,C,T,"Patients with the CT genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have increased exposure of mycophenolic acid as compared to patients with the CC genotype, and decreased exposure compared to patients with the TT genotype, however the evidence is contradictory. In one study, the T allele was associated with increased Cmax in both kidney donors AND kidney recipients, and increased clearance in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine."
1448634742,T,T,"Patients with the TT genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have increased exposure of mycophenolic acid as compared to patients with the CT and CC genotype, however the evidence is contradictory. In one study, the T allele was associated with increased Cmax in both kidney donors AND kidney recipients, and increased clearance in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine."
1451674180,A,A,Patients with the rs111869995 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs111869995 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674180,A,C,Patients with the rs111869995 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs111869995 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674180,C,C,Patients with the rs111869995 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs111869995 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674240,A,A,Patients with the rs200554095 AA genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674240,A,T,Patients with the rs200554095 AT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674240,T,T,Patients with the rs200554095 TT genotype may have increased metabolism of nicotine as compared to patients with the AA or AT genotypes. This annotation only covers the pharmacokinetic relationship between rs200554095 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674260,C,C,Patients with the rs772964366 CC genotype may have increased metabolism of nicotine as compared to patients with the CG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674260,C,G,Patients with the rs772964366 CG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674260,G,G,Patients with the rs772964366 GG genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs772964366 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
982031723,C,C,Patients with the CC genotype may have increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.
982031723,C,T,Patients with the CT genotype may have increased glucuronidation metabolic ratios of ABT-751 as compared to patients with TT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.
982031723,T,T,Patients with the TT genotype may have decreased glucuronidation metabolic ratios of ABT-751 as compared to patients with CC or CT genotype. Other genetic and clinical factors may also influence clearance of ABT-751.
1183606758,G,G,"Patients with the GG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers."
1183606758,G,T,"Patients with the GT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers."
1183606758,T,T,"Patients with the TT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to calcium channel blockers."
1448616882,C,C,Patients with cancer and the CC genotype who are treated with capecitabine may have an increased risk of asthenia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.
1448616882,C,G,Patients with cancer and the CG genotype who are treated with capecitabine may have an increased risk of asthenia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.
1448616882,G,G,Patients with cancer and the GG genotype who are treated with capecitabine may have a decreased (but not absent) risk of asthenia as compared to patients with the CC and CG genotypes. Other clinical and genetic factors may also influence risk of asthenia in patients with cancer who are treated with capecitabine.
1448616922,C,C,"Patients with the CC genotype and cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of nausea and vomiting as compared to patients with the TT genotype and an increased likelihood of asthenia as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine."
1448616922,C,T,"Patients with the CT genotype and cancer who are treated with Capecitabine may have a decreased, but not absent, risk of of nausea and vomiting as compared to patients with the TT genotype and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine."
1448616922,T,T,Patients with the TT genotype and cancer who are treated with Capecitabine may have an increased risk of of nausea and vomiting as compared to patients with the CC or CT genotypes and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.
1450943780,A,A,Patients with the AA genotype may have better response to beta-blockers as compared to patients with deletion of at least one copy of allele A. This association is statistically significant for cardioselective beta-blockers (eg. metoprolol) but not for carvedilol. Other genetic and clinical factors may also influence the response to beta-blockers.
1444694588,A,A,"Patients with the AA genotype who are undergoing organ transplantation, or who have other diseases, may have decreased clearance and dose requirements of tacrolimus, as compared to patients with the AG or GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus."
1444694588,A,G,"Patients with the AG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance of tacrolimus as compared to patients with the AA genotype, and decreased dose requirements of tacrolimus as compared to patients with the GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus."
1444694588,G,G,"Patients with the GG genotype who are undergoing organ transplantation, or who have other diseases, may have increased clearance and dose requirements of tacrolimus, as compared to patients with the AA or AG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus."
1448640301,C,C,"The current evidence base suggests that there is no association between the rs3918290 CC genotype and response to fluorouracil. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil."
1448640301,C,T,"The current evidence base suggests that there is no association between the rs3918290 CT genotype and response to fluorouracil. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to fluorouracil."
1448640301,T,T,"There is currently no available evidence regarding the association between the rs3918290 TT genotype and response to fluorouracil. However, the current evidence base suggests that there is no association between the CC or CT genotypes and response to fluorouracil. Other genetic and clinical factors may also influence response to fluorouracil."
655385129,A,A,"This intronic variant is associated with differential induction, upon simvastatin exposure, of expression of full-length HMGCR transcript versus alternatively spliced transcript lacking exon 13 (HMGCRv_1). In immortalized lymphocytes, AA homozygotes exhibit 40% greater induction of full-length transcripts and 20% less alternatively spliced HMGCRv_1 transcript relative to AG or GG subjects. These differences may have implications for simvastatin efficacy, since increased induction of the alternatively spliced transcript is correlated with reduced percent response to simvastatin."
655385129,A,G,The AG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype.
655385129,G,G,The GG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype.
655385409,A,A,"Patients with the AA genotype (Ser49/Ser49) may have increased response to metoproplol than those with the AG genotype (Ser49/Gly49) although most benefits appear to be only when in haplotype with Arg389. However other studies also report no association. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253)."
655385409,A,G,"Patients with the AG genotype (Ser49Gly49) may have decreased response to metoproplol than those with the AA genotype (Ser49/Ser49). However other studies also report no association. Other genetic and clinical factors may also influence a patient's likelihood of response, in particular ADRB1 Arg389 (rs1801253)."
655385409,G,G,Patients with the GG genotype (Gly49/Gly49) were not reported in the studies of metoprolol efficacy.
1043872988,A,A,"Patients with the AA genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response."
1043872988,A,G,"Patients with the AG genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response."
1043872988,G,G,"Patients with the GG genotype may have decreased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence a patient's response."
1183605989,C,C,"Patients with the CC genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response."
1183605989,C,T,"Patients with the CT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype, or a poorer blood pressure response compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response."
1183605989,T,T,"Patients with the TT genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response."
1183606395,C,C,"Patients with the CC genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response."
1183606395,C,G,"Patients with the CG genotype and hypertension may have a poorer blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the GG genotype. However, no significant association was seen in a subpopulation of patients taking only lacidipine, nifedipine or nitrendipine. Other genetic and clinical factors may also influence blood pressure response."
1183606395,G,G,"Patients with the GG genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence blood pressure response."
1183700517,C,C,Patients with the CC genotype may have increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.
1183700517,T,C,Patients with the TC genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.
1183700517,T,T,Patients with the TT genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.
1444704963,C,C,People with the CC genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.
1444704963,C,T,People with the CT genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.
1444704963,T,T,People with the TT genotype may have increased Anxiety Disorders when exposed to caffeine as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.
1448125499,C,C,Patients with genotype CC have shorter progression-free survival time when treated with sorafenib as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence the response to sorafenib.
1448125499,C,T,Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.
1448125499,T,T,Patients with genotype TT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.
1449157000,A,A,Patients carrying the AA genotype who are receiving methadone maintenance therapy (MMT) may experience increased insomnia as a side-effect of treatment as compared to patients carrying the GG genotype. Other genetic and clinical factors may also affect development of insomnia during MMT.
1449157000,A,G,Patients carrying the AG genotype who are receiving methadone maintenance therapy (MMT) may experience increased insomnia as a side-effect of treatment as compared to patients carrying the GG genotype. Other genetic and clinical factors may also affect development of insomnia during MMT.
1449157000,G,G,Patients carrying the GG genotype who are receiving methadone maintenance therapy (MMT) may experience decreased insomnia as a side-effect of treatment as compared to patients carrying the AA or AG genotypes. Other genetic and clinical factors may also affect development of insomnia during MMT.
1449157284,C,C,"African-American patients with the CC genotype may have an increased response to methadone when being treated for opioid dependence, as compared to patients with the CT or TT genotypes. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone."
1449157284,C,T,"African-American patients with the CT genotype may have a decreased response to methadone when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone."
1449157284,T,T,"African-American patients with the TT genotype may have a decreased response to methadone when being treated for opioid dependence, as compared to patients with the CC genotype. This association was not seen in European-American patients. Response to methadone treatment was measured by the number of opioid-positive drug screens during treatment. Other genetic and clinical factors may also affect a patient's response to methadone."
1449162591,A,A,Patients with the AA genotype may be at an increased risk of experiencing cognitive dysfunction while being treated with fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.
1449162591,A,G,Patients with the AG genotype may be at a decreased risk of experiencing cognitive dysfunction while being treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.
1449162591,G,G,Patients with the GG genotype may be at a decreased risk of experiencing cognitive dysfunction while being treated with fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of experiencing cognitive dysfunction while being treated with fentanyl.
1449164443,C,C,Patients with the CC genotype may have increased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CT + TT. Other genetic and clinical factors may also influence the response to interferon-alpha.
1449164443,C,T,Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.
1449164443,T,T,Patients with the TT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.
1449167245,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167245,A,C,Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167245,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449192683,A,A,Patients with the rs75527207 AA genotype (two copies of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor/tezacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor/tezacaftor.
1449192683,A,G,Patients with the rs75527207 AG genotype (one copy of the CFTR G551D variant) and cystic fibrosis may respond to ivacaftor/tezacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor/tezacaftor.
1449192683,G,G,"Patients with the rs75527207 GG genotype (do not have a copy of the CFTR G551D variant) and cystic fibrosis have an unknown response to ivacaftor/tezacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor/tezacaftor."
1449269278,C,C,"Patients with the CC genotype who are treated with warfarin may have an increased risk of over-anticoagulation as compared to patients with the TT genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin."
1449269278,C,T,"Patients with the CT genotype who are treated with warfarin may have a decreased risk of over-anticoagulation as compared to patients with the TT genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin."
1449269278,T,T,"Patients with the TT genotype who are treated with warfarin may have a decreased risk of over-anticoagulation as compared to patients with the CT or CC genotype, although not all studies support this. Other clinical factors such as target INR, and dosage (which is also associated with this particular variant) and genetic factors may also influence risk of over-anticoagulation in patients administered warfarin."
1449271075,C,C,"Patients with breast cancer and the CC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271075,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the TT genotype, but a decreased risk compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271075,T,T,"Patients with breast cancer and the TT genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
981201946,C,C,"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981201946,C,T,"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981201946,T,T,"Both variants of rs1801158 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1450810975,C,C,Patients with the CC genotype may experience increased weight gain when treated with rosiglitazone as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment.
1450810975,C,T,"Patients with the CT genotype may experience increased weight gain when treated with rosiglitazone as compared to patients with TT genotype, but decreased weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment."
1450810975,T,T,Patients with the TT genotype may experience decreased weight gain when treated with rosiglitazone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment.
981201962,C,C,"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981201962,C,T,"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CC or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
981201962,T,T,"Both variants of rs1801159 are assigned normal function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1450928601,A,A,Patients with the AA genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.
1450928601,A,G,Patients with the AG genotype may have lower platelet aggregation when treated with antiplatelet drugs as compared to patients with the GG genotype but higher platelet aggregation as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.
1450928601,G,G,Patients with the GG genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.
1445401793,C,C,"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CC genotype may have increased DPYD activity as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1445401793,C,T,"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the CT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1445401793,T,T,"Both variants of rs1801160 are assigned normal function by CPIC. Patients with the TT genotype may have decreased DPYD activity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD."
1450936735,C,C,"Patients with the CC genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde."
1450936735,C,T,"Patients with the CT genotype may have increased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC or TT genotypes. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde."
1450936735,T,T,"Patients with the TT genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde."
827843617,C,C,"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the TT or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
827843617,C,T,"The T allele of rs3918290 is assigned no function by CPIC. Patients with the CT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
827843617,T,T,"The T allele of rs3918290 is assigned no function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk and increased severity of drug toxicity as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1450944540,A,A,"Patients with the AA genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment."
1450944540,A,G,"Patients with the AG genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment."
1450944540,G,G,"Patients with the GG genotype may be at an increased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the AA or AG genotypes. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment."
1450945347,A,A,Patients with the AA genotype may have poorer response to glucocorticoid treatment and lower lung function in glucocortioid-dependent severe asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.
1450945347,A,C,Patients with the AC genotype may have poorer response to glucocorticoid treatment and lower lung function in glucocortioid-dependent severe asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.
1450945347,C,C,Patients with the CC genotype may have better response to glucocorticoid treatment and higher lung function in glucocortioid-dependent severe asthma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.
1451674300,C,C,Patients with the rs140471703 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674300,C,T,Patients with the rs140471703 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674300,T,T,Patients with the rs140471703 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs758479488 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674308,G,G,Patients with the rs145157460 GG genotype may have increased metabolism of nicotine as compared to patients with the GT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674308,G,T,Patients with the rs145157460 GT genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674308,T,T,Patients with the rs145157460 TT genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
637880087,A,A,"Patients with the AA genotype may have reduced but not non-existent risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the CC genotype however studies with other biomarkers showed conflicting results and this geneotype was not reported. Other genetic and clinical factors may also influence a patient's risk for toxicity."
637880087,A,C,"Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the CC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity."
637880087,C,C,"Patients with the CC genotype may have increased risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the AC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity."
1450812229,C,C,"Patients with the rs2236857 CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence."
1450812229,C,T,"Patients with the rs2236857 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence."
1450812229,T,T,"Patients with the rs2236857 TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence."
1450813775,G,G,"Patients with the GG genotype and alcohol dependence may more likely to drink > 36 drinks in 24 hours as compared to patients with the del/del or G/del genotypes. However, this association lost its significance when other measures of alcohol consumption were analyzed. Other genetic and clinical factors may also affect severity of alcohol dependence."
1450815148,A,A,Patients with schizophrenia and the AA genotype may have an increased response to quetiapine as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.
1450815148,A,G,Patients with schizophrenia and the AG genotype may have a decreased response to quetiapine as compared to patients with the AA genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to quetiapine.
1450815148,G,G,Patients with schizophrenia and the GG genotype may have a decreased response to quetiapine as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.
1450820507,C,C,"Patients with postoperative pain and the CC genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements."
1450820507,C,T,"Patients with postoperative pain and the CT genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements."
1450820507,T,T,"Patients with postoperative pain and the TT genotype may have increased fentanyl dose requirements as compared to patients with the CC or CT genotypes. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements."
1450959466,A,A,Patients with the AA genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959466,A,T,Patients with the AT genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959466,T,T,Patients with the TT genotype may have increased metabolism of carbocisteine as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959472,A,A,Patients with the AA genotype may have increased metabolism of phenylalanine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959472,A,G,Patients with the AG genotype may have decreased metabolism of phenylalanine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959472,G,G,Patients with the GG genotype may have decreased metabolism of phenylalanine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1451674315,A,A,Patients with the rs148693084 AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674315,A,G,Patients with the rs148693084 AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674315,G,G,Patients with the rs148693084 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs148693084 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
613978931,C,C,Patients with the rs3812718 CC genotype who are treated with carbamazepine may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.
613978931,C,T,Patients with the rs3812718 CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype but a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.
613978931,T,T,Patients with the rs3812718 TT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence dose of carbamazepine.
1183630664,A,A,"The C allele of this variant is assigned a no function allele by CPIC. Patients with the AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk of drug toxicity as compared to patients with the AC or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1183630664,A,C,"The C allele of this variant is assigned a no function allele by CPIC. Patients with the AC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1183630664,C,C,"The C allele of this variant is assigned a no function allele by CPIC. Patients with the CC genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity."
1448266008,A,A,"Patients with the rs77010898 AA genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor."
1448266008,A,G,"Patients with the rs77010898 AG genotype and cystic fibrosis may respond to ivacaftor treatment, if the outcome considered is the number of exacerbations. Other clinical and genetic factors may affect response to ivacaftor."
1448266008,G,G,"Patients with the rs77010898 GG genotype and cystic fibrosis may not respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other clinical and genetic factors may affect response to ivacaftor."
1448266986,A,A,"Patients with the AA genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity."
1448266986,A,C,"Patients with the AC genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity."
1448266986,C,C,"Patients with the CC genotype and non-small cell lung cancer may have decreased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the AA and AC genotypes. Other clinical and genetic factors may affect risk of toxicity."
1448531101,G,G,Patients with the GG genotype and stenosis may be less likely to suffer from a transient ischemic attack as compared to patients with the GT or TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.
1448531101,G,T,Patients with the GT genotype and stenosis may be less likely to suffer from a transient ischemic attack as compared to patients with the TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.
1448531101,T,T,Patients with the TT genotype and stenosis may be more likely to suffer from a transient ischemic attack as compared to patients with the GG or GT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.
1450963020,C,C,Patients with the CC genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy.
1450963020,C,T,Patients with the CT genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy.
1450963020,T,T,Patients with the TT genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for pneumonitis when treated with platinum-based chemotherapy.
1450963060,C,C,Patients with the CC genotype and non-small-cell lung cancer may have an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy.
1450963060,C,T,Patients with the CT genotype and non-small-cell lung cancer may have an increased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy.
1450963060,T,T,Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for adverse events related to drug toxicities when treated with platinum-based chemotherapy as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's risk of adverse events following treatment with platinum-based chemotherapy.
1451674360,C,C,Patients with the rs1303839356 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674360,C,T,Patients with the rs1303839356 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674360,T,T,Patients with the rs1303839356 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674380,A,A,Patients with the rs778019189 AA genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674380,A,C,Patients with the rs778019189 AC genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674380,C,C,Patients with the rs778019189 CC genotype may have increased metabolism of nicotine as compared to patients with the AA or AC genotypes. This annotation only covers the pharmacokinetic relationship between rs778019189 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
655384666,C,C,"Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment."
655384666,C,T,"Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment."
655384666,T,T,"Patients with the TT genotype who are treated with antiretrovirals for HIV such as ritonavir may have a decreased but not non-existent risk for elevated plasma lipids as compared to patients with the CC or CT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment."
1447521683,C,C,"African-American patients with the CC genotype (especially those who are APOE E3/E3, also having rs429358 TT) may require a longer duration of time to reach a stable warfarin dose as compared to African-American patients with the CT or TT genotype (carriers of E2). Other genetic and clinical factors may also influence the response to warfarin."
1447521683,C,T,"African-American patients with the CT genotype (carriers of E2) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the CC genotype (especially those who are APOE E3/E3, also having rs429358 TT). Other genetic and clinical factors may also influence the response to warfarin."
1447521683,T,T,"African-American patients with the TT genotype (APOE E2/E2) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the CC genotype (especially those who are APOE E3/E3, also having rs429358 TT). Other genetic and clinical factors may also influence the response to warfarin."
1450975180,C,C,"African-American patients with the CC genotype (E4/E4) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the TT genotype (especially those who are APOE E3/E3, also having rs7412 CC). Other genetic and clinical factors may also influence the response to warfarin."
1450975180,C,T,"African-American patients with the CT genotype (carriers of E4) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the TT genotype (especially those who are APOE E3/E3, also having rs7412 CC). Other genetic and clinical factors may also influence the response to warfarin."
1450975180,T,T,"African-American patients with the TT genotype (especially those who are APOE E3/E3, also having rs7412 CC) may require a longer duration of time to reach a stable warfarin dose as compared to African-American patients with the CC or CT genotype (carriers of E4). Other genetic and clinical factors may also influence the response to warfarin."
655384733,C,C,"Patients with the rs7294 CC genotype may require a lower dose of warfarin as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements."
655384733,C,T,"Patients with the rs7294 CT genotype may require a higher dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements."
655384733,T,T,"Patients with the rs7294 TT genotype may require a higher dose as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements."
1183704228,A,A,Patients with the rs9934438 AA genotype may require decreased dose of acenocoumarol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol.
1183704228,A,G,Patients with the rs9934438 AG genotype may require decreased dose of acenocoumarol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol.
1183704228,G,G,Patients with the rs9934438 GG genotype may require increased dose of acenocoumarol as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the dose of acenocoumarol.
655387652,C,C,"Patients with the CC genotype and schizophrenia who are treated with risperidone may be less likely to have improvement in symptoms as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to risperidone."
655387652,C,T,"Patients with the CT genotype and schizophrenia who are treated with risperidone may be less likely to have an improvement in symptoms compared to TT carriers, and more likely to have improvement in symptoms as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to risperidone."
655387652,T,T,"Patients with the TT genotype and schizophrenia who are treated with risperidone may be more likely to have improvement in symptoms as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to risperidone."
1447673005,C,C,"Patients with the rs9923231 CC genotype may have decreased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype TT or CT. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin."
1447673005,C,T,"Patients with the rs9923231 CT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin."
1447673005,T,T,"Patients with the rs9923231 TT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin."
655385024,A,A,Patients with the rs2359612 AA genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.
655385024,A,G,Patients with the rs2359612 AG genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.
655385024,G,G,Patients with the rs2359612 GG genotype may require an increased dose of warfarin as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence dose of warfarin.
655386075,A,A,"Patients with the AA genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens."
655386075,A,G,"Patients with the AG genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens."
655386075,G,G,"Patients with the GG genotype may have decreased response to cytarabine regimens as compared to patients with the AA or AG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens."
1183684172,A,A,"Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the AC, AT, CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment."
1183684172,A,C,"Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment."
1183684172,A,T,"Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment."
1183684172,C,C,"Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment."
1183684172,T,T,"Patients with the TT genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an decreased response as compared to the AC, AT, or AA genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment."
1451674409,C,C,Patients with the rs374515279 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs374515279 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674409,C,T,Patients with the rs374515279 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs374515279 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674409,T,T,Patients with the rs374515279 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs374515279 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674424,C,C,Patients with the rs145308399 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674424,C,T,Patients with the rs145308399 CT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674424,T,T,Patients with the rs145308399 TT genotype may have decreased metabolism of nicotine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs145308399 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674418,A,A,Patients with the rs777098658 AA genotype may have increased metabolism of nicotine as compared to patients with the AG or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs777098658 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674418,A,G,Patients with the rs777098658 AG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs777098658 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1451674418,G,G,Patients with the rs777098658 GG genotype may have decreased metabolism of nicotine as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs777098658 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.
1447959515,A,A,Patients with the AA genotype and Cirrhosis may have a decreased response when treated with propranolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to propranolol.
1447959515,A,G,"Patients with the AG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AA genotype, but decreased response compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to propranolol."
1447959515,G,G,Patients with the GG genotype and Cirrhosis may have an increased response when treated with propranolol as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence response to propranolol.
1451100007,A,A,Patients with the AA genotype and hypertension may be more likely to respond to antihypertensives than patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.
1451100007,A,G,"Patients with the AG genotype and hypertension may be less likely to respond to antihypertensives than patients with the AA genotype, but more likely to respond than patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to antihypertensives."
1451100007,G,G,Patients with the GG genotype and hypertension may be less likely to respond to antihypertensives than patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.
1451100053,A,A,Patients with the AA genotype and hypertension may be less likely to respond to antihypertensives than patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.
1451100053,A,G,"Patients with the AG genotype and hypertension may be more likely to respond to antihypertensives than patients with the AA genotype, but less likely to respond than patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to antihypertensives."
1451100053,G,G,Patients with the GG genotype and hypertension may be more likely to respond to antihypertensives than patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.
1451100080,C,C,Patients with the CC genotype and hypertension may be more likely to respond to antihypertensives than patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.
1451100080,C,T,"Patients with the CT genotype and hypertension may be less likely to respond to antihypertensives than patients with the CC genotype, but more likely to respond than patients with the TT genotype. Other genetic and clincial factors may also affect a patient's response to antihypertensives."
1451100080,T,T,Patients with the TT genotype and hypertension may be less likely to respond to antihypertensives than patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.
1451103240,G,G,Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.
1451103240,G,T,Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.
1451103240,T,T,Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.
1451100100,C,T,Patients with the rs2740574 CT genotype (CYP3A4*1B allele) may have decreased clearance of fentanyl as compared to patients with the rs2740574 TT genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.
1451100100,T,T,Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.
1451103560,C,C,Patients with the CC genotype may have an increased severity of alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of alcohol dependence.
1451103560,C,T,Patients with the CT genotype may have an increased severity of alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of alcohol dependence.
1451103560,T,T,Patients with the TT genotype may have a decreased severity of alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of alcohol dependence.
1449188311,A,A,"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of developing alcoholism when exposed to ethanol. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing alcoholism."
1449188311,A,G,"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of developing alcoholism when exposed to ethanol. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing alcoholism."
1449188311,G,G,"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of developing alcoholism when exposed to ethanol. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing alcoholism."
1450811261,C,C,Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450811261,C,T,Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1450811261,T,T,Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451110071,A,A,Patients with the AA genotype may have an increased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451110071,A,G,Patients with the AG genotype may have a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451110071,G,G,Patients with the GG genotype may have a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451110320,A,A,"Patients with rheumatoid arthritis and the AA genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events."
1451110320,A,G,"Patients with rheumatoid arthritis and the AG genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events."
1451110320,G,G,"Patients with rheumatoid arthritis and the GG genotype may have a decreased risk of experiencing adverse events as compared to patients with the AA or AG genotypes. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events."
1444704359,C,C,"Patients with HIV and the CC genotype may have increased plasma levels of lopinavir as compared to patients with the CT or TT genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes."
1444704359,C,T,"Patients with HIV and the CT genotype may have decreased plasma levels of lopinavir as compared to patients with the CC genotype, but increased plasma levels as compared to patients with the TT genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes."
1444704359,T,T,"Patients with HIV and the TT genotype may have decreased plasma levels of lopinavir as compared to patients with the CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes."
1451116100,C,C,"Patients with HIV infections and the CC genotype may have decreased trough concentrations of amprenavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients."
1451116100,C,T,"Patients with HIV infections and the CT genotype may have decreased trough concentrations of amprenavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients."
1451116100,T,T,"Patients with HIV infections and the TT genotype may have increased trough concentrations of amprenavir as compared to patients with the CC or CT genotypes. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients."
1450812488,A,A,"Patients with the rs1799971 AA genotype may at an increased risk of experiencing opioid-induced adverse effects, including nausea and vomiting, as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of experiencing opioid-induced adverse effects."
1450812488,A,G,"Patients with the rs1799971 AG genotype may at a decreased risk of experiencing opioid-induced adverse effects, as compared to patients with the AA genotype, but at an increased risk of experiencing opioid-induced nausea and vomiting as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of experiencing opioid-induced adverse effects."
1450812488,G,G,"Patients with the rs1799971 GG genotype may at a decreased risk of experiencing adverse effects, including nausea and vomiting, as a result of opioids as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect risk of experiencing opioid-induced adverse effects."
1451117640,G,G,"Patients with hypertension and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451117640,G,T,"Patients with hypertension and the GT genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451117640,T,T,"Patients with hypertension and the TT genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451117646,C,C,"Patients with hypertension and the CC genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451117646,C,T,"Patients with hypertension and the CT genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451117646,T,T,"Patients with hypertension and the TT genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451118241,A,A,"Patients with hypertension and the AA genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118241,A,C,"Patients with hypertension and the AC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118241,C,C,"Patients with hypertension and the CC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118277,C,C,"Patients with hypertension and the CC genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118277,C,G,"Patients with hypertension and the CG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118277,G,G,"Patients with hypertensions and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clincial factors may also affect a patient's response to hydrochlorothiazide."
1451118320,C,C,"Patients with hypertension and the CC genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451118320,C,T,"Patients with hypertension and the CT genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451118320,T,T,"Patients with hypertension and the TT genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451118326,A,A,"Patients with hypertension and the AA genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol."
1451118326,A,C,"Patients with hypertension and the AC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol."
1451118326,C,C,"Patients with hypertension and the CC genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patient with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol."
1451118332,C,C,"Patients with hypertension and the CC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol."
1451118332,C,T,"Patients with hypertension and the CT genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol."
1451118332,T,T,"Patients with hypertension and the TT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol."
1451118338,A,A,"Patients with hypertension and the AA genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118338,A,G,"Patients with hypertension and the AG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118338,G,G,"Patients with hypertension and the GG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118340,C,C,"Patients with hypertension and the CC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118340,C,G,"Patients with hypertension and the CG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118340,G,G,"Patients with hypertension and the GG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451119080,C,C,Pre-menstrual patients with the CC genotype may be less likely to resume menses following chemotherapy for breast cancer as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect return of menses in breast cancer patients.
1451119080,C,G,Pre-menstrual patients with the CG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.
1451119080,G,G,Pre-menstrual patients with the GG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.
1451119086,A,A,Pre-menstrual patients with the AA genotype may be less likely to resume menses following chemotherapy for breast cancer as compared to patients with the AG or GG genotypse. Other genetic and clinical factors may also affect return of menses in breast cancer patients.
1451119086,A,G,Pre-menstrual patients with the AG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.
1451119086,G,G,Pre-menstrual patients with the GG genotype may be more likely to resume menses following chemotherapy for breast cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect return of menses in breast cancer patients.
1451120960,G,G,Patients with the GG genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451120960,G,T,Patients with the GT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451120960,T,T,Patients with the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451120980,G,G,Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451120980,G,T,Patients with the GT genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451120980,T,T,Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451123020,A,A,Patients with the AA genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451123020,A,G,Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451123020,G,G,Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Note that this association was only found in a subset of patients analyzed. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451125512,A,A,Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125512,A,C,Patients with non-small cell lung cancer and the AC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125512,C,C,Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125518,C,C,Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125518,C,G,Patients with non-small cell lung cancer and the CG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125518,G,G,Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125520,C,C,Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125520,C,T,Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125520,T,T,Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125526,C,C,Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125526,C,T,Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125526,T,T,Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125532,C,C,Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125532,C,T,Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125532,T,T,Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125538,C,C,Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125538,C,T,Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125538,T,T,Patients with non-small cell lung cancer and the TT genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125544,A,A,Patients with non-small cell lung cancer and the AA genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125544,A,G,Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125544,G,G,Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
981203689,C,C,"Patients with the CC genotype and HIV infection who are treated with tenofovir may have an increased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction."
981203689,C,T,"Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction."
981203689,T,T,"Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction."
1451125564,A,A,Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125564,A,G,Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125564,G,G,Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125570,A,A,Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125570,A,G,Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125570,G,G,Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125580,A,A,Patients with non-small cell lung cancer and the AA genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125580,A,G,Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125580,G,G,Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125600,C,C,Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125600,C,T,Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125600,T,T,Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125620,C,C,Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125620,C,T,Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125620,T,T,Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125640,A,A,Patients with non-small cell lung cancer and the AA genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125640,A,G,Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125640,G,G,Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125646,A,A,Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125646,A,G,Patients with non-small cell lung cancer and the AG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125646,G,G,Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125660,A,A,Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the del/del genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125666,A,A,Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125666,A,G,Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125666,G,G,Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125672,C,C,Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125672,C,G,Patients with non-small cell lung cancer and the CG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125672,G,G,Patients with non-small cell lung cancer and the GG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125680,C,C,Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125680,C,T,Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125680,T,T,Patients with non-small cell lung cancer and the TT genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125687,C,C,Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125687,C,T,Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125687,T,T,Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125693,A,A,Patients with non-small cell lung cancer and the AA genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125693,A,G,Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125693,G,G,Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451544841,C,C,"The current evidence base suggests that there is no significant association between the rs1801253 CC genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers."
1451544841,C,G,"The current evidence base suggests that there is no significant association between the rs1801253 CG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers."
1451544841,G,G,"The current evidence base suggests that there is no significant association between the rs1801253 GG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers."
1451544880,A,A,"The current evidence base suggests that there is no significant association between the rs1042713 AA genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers."
1451544880,A,G,"The current evidence base suggests that there is no significant association between the rs1042713 AG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers."
1451544880,G,G,"The current evidence base suggests that there is no significant association between the rs1042713 GG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers."
1451544980,A,A,Patients with the rs10799590 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451544980,A,G,Patients with the rs10799590 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451544980,G,G,Patients with the rs10799590 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.
1451547422,C,C,Patients with acute lymphblastic leukemia (ALL) and the rs1544105 CC genotype may have a decreased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451547422,C,T,Patients with acute lymphblastic leukemia (ALL) and the rs1544105 CT genotype may have a decreased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451547422,T,T,Patients with acute lymphblastic leukemia (ALL) and the rs1544105 TT genotype may have an increased response to methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to methotrexate.
1451548374,C,C,"Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 CC genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance"
1451548374,C,T,"Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 CT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance"
1451548374,T,T,"Patients with acute lymphoblastic leukemia (ALL) and the rs4149009 TT genotype may have increased clearance of methotrexate as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149009 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance"
1451952760,A,A,"Patients with the rs4035887 AA genotype may have an increased risk of toxicity when treated with sorafenib as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with sorafenib."
1451952760,A,G,"Patients with the rs4035887 AG genotype may have a decreased risk of toxicity when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with sorafenib."
1451952760,G,G,"Patients with the rs4035887 GG genotype may have a decreased risk of toxicity when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with sorafenib."
1451954480,A,A,"Patients with the rs4864950 AA genotype may have an increased risk of drug toxicity when treated with regorafenib as compared to patients with the AT or TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with regorafenib."
1451954480,A,T,"Patients with the rs4864950 AT genotype may have a decreased risk of drug toxicity when treated with regorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with regorafenib."
1451954480,T,T,"Patients with the rs4864950 TT genotype may have a decreased risk of drug toxicity when treated with regorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with regorafenib."
1451980660,A,A,Patients with the rs1801394 AA genotype who are treated with sevoflurane may have decreased vol% end-tidal sevoflurane concentration as compared to patients with the GG or AG genotypes. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.
1451980660,A,G,Patients with the rs1801394 AG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.
1451980660,G,G,Patients with the rs1801394 GG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.
1451952780,A,A,Patients with the rs4864950 AA genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451952780,A,T,Patients with the rs4864950 AT genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451952780,T,T,Patients with the rs4864950 TT genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451952700,C,C,"Patients with the rs444904 CC genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib."
1451952700,C,T,"Patients with the rs444904 CT genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib."
1451952700,T,T,"Patients with the rs444904 TT genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib."
1451954520,A,A,Patients with the rs10958704 AA genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451954520,A,G,Patients with the rs10958704 AG genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451954520,G,G,Patients with the rs10958704 GG genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1451954540,C,C,Patients with the rs1868089 CC genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1451954540,C,T,Patients with the rs1868089 CT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1451954540,T,T,Patients with the rs1868089 TT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1451954560,C,C,Patients with the rs7557402 CC genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1451954560,C,G,Patients with the rs7557402 CG genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1451954560,G,G,Patients with the rs7557402 GG genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1451954568,A,A,Patients with the rs11125039 AA genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.
1451954568,A,G,Patients with the rs11125039 AG genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.
1451954568,G,G,Patients with the rs11125039 GG genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.
1451954620,C,C,Patients with the rs11651488 CC genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.
1451954620,C,T,Patients with the rs11651488 CT genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.
1451954620,T,T,Patients with the rs11651488 TT genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.
1451954626,C,C,Patients with the rs17682789 CC genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.
1451954626,C,T,Patients with the rs17682789 CT genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.
1451954626,T,T,Patients with the rs17682789 TT genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.
1451954640,A,A,Patients with the rs9927200 AA genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.
1451954640,A,C,Patients with the rs9927200 AC genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.
1451954640,C,C,Patients with the rs9927200 CC genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib.
1451212480,C,C,Patients with opioid dependence and the CC genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.
1451212480,C,T,Patients with opioid dependence and the CT genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of death when using opioids.
1451212480,T,T,Patients with opioid dependence and the TT genotype may be at an increased risk of sudden death when using opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of death when using opioids.
1451212500,A,A,Patients with opioid dependence and the AA genotype may be at a decreased risk of sudden death when using opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect risk of sudden death when using opioids.
1451212500,A,G,Patients with opioid dependence and the AG genotype may be at an increased risk of sudden death when using opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also affect risk of sudden death when using opioids.
1451212500,G,G,Patients with opioid dependence and the GG genotype may be at an increased risk of sudden death when using opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also affect risk of sudden death when using opioids.
1451212540,A,A,Patients with the AA genotype with malaria vivax who are treated with tafenoquine may have increased likelihood of recurrence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence the response to tafenoquine.
1451212540,A,G,"No information about the AG genotype is reported in the study. However, patients with the AA genotype with malaria vivax who are treated with tafenoquine may have increased likelihood of recurrence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence the response to tafenoquine."
1451212540,G,G,Patients with the GG genotype with malaria vivax who are treated with tafenoquine may have decreased likelihood of recurrence as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the response to tafenoquine.
1451954600,A,A,Patients with the rs1346563 AA genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.
1451954600,A,G,Patients with the rs1346563 AG genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.
1451954600,G,G,Patients with the rs1346563 GG genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.
1450823852,A,A,Adolescents with the AA genotype may have increased nicotine cravings as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.
1450823852,A,G,Adolescents with the AG genotype may have increased nicotine cravings as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving.
1450823852,G,G,Adolescents with the GG genotype may have decreased nicotine cravings as compared to adolescents with the AA or AG genotypes. Other genetic or clinical factors may also affect nicotine craving.
1450823858,A,A,"Adolescents with the AA genotype may have a smaller, or absent, increase in nicotine cravings over time when exposed to parental smoke as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving."
1450823858,A,G,"Adolescents with the AG genotype may have a smaller, or absent, increase in nicotine cravings over time when exposed to parental smoke as compared to adolescents with the GG genotype. Other genetic or clinical factors may also affect nicotine craving."
1450823858,G,G,Adolescents with the GG genotype may have a greater increase in nicotine cravings over time when exposed to parental smoke as compared to adolescents with the AA or AG genotypes. Other genetic or clinical factors may also affect nicotine craving.
1451151340,C,C,Patients with the CC genotype may have decreased but not absent risk for toxicity when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1451151340,C,G,Patients with the CG genotype may have decreased but not absent risk for toxicity when treated with antineoplastic agents as compared to patients with the GG genotype although . Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1451151340,G,G,Patients with the GG genotype may have increased risk for toxicity when treated with antineoplastic agents as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.
1451151380,C,C,Patients with the CC genotype may have increased response when treated with platinum drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum drugs.
1451151380,C,G,Patients with the CG genotype may have decreased response when treated with platinum drugs as compared to patients with the CC genotype although evidence is contradictory. Other genetic and clinical factors may also influence a patient's response to platinum drugs.
1451151380,G,G,Patients with the GG genotype may have decreased response when treated with platinum drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum drugs.
1451954607,A,A,Patients with the rs2330951 AA genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.
1451954607,A,C,Patients with the rs2330951 AC genotype may have a decreased risk of hypertension when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.
1451954607,C,C,Patients with the rs2330951 CC genotype may have an increased risk of hypertension when treated with sorafenib as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence risk of hypertension when treated with sorafenib.
1450929222,A,A,"Patients with the rs1045642 AA genotype may have decreased fentanyl dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements."
1450929222,A,G,"Patients with the rs1045642 AG genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype, but increased fentanyl dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements."
1450929222,G,G,"Patients with the rs1054642 GG genotype may have increased fentanyl dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements."
1451243628,C,C,Patients with the CC genotype who are treated with acenocoumarol may have a decreased risk of Hemorrhage as compared to the CT or TT genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.
1451243628,C,T,Patients with the CT genotype who are treated with acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.
1451243628,T,T,Patients with the TT genotype who are treated with acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.
1451244448,A,A,Patients with the AA genotype who are treated with simvastatin may be more likely to respond as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with simvastatin.
1451244448,A,T,Patients with the AT genotype who are treated with simvastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with simvastatin.
1451244448,T,T,Patients with the TT genotype who are treated with simvastatin may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response when treated with simvastatin.
1451237940,C,C,Patients with the rs9923231 CC genotype may require a higher dose when treated with phenprocoumon as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence phenprocoumon dose.
1451237940,C,T,Patients with the rs9923231 CT genotype may require a lower dose when treated with phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.
1451237940,T,T,Patients with the rs9923231 TT genotype may require a lower dose when treated with phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.
1451243676,C,C,"Patients with the CC genotype may have a decreased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the TT or CT genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon."
1451243676,C,T,"Patients with the CT genotype may have an increased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon."
1451243676,T,T,"Patients with the TT genotype may have an increased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon."
1451244040,A,A,Patients with the rs9934438 AA genotype may require a decreased dose of phenprocoumon as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence dose of phenprocoumon.
1451244040,A,G,"Patients with the rs9934438 AG genotype may require a decreased dose of phenprocoumon as compared to patients with the GG genotype, but an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of phenprocoumon."
1451244040,G,G,Patients with the rs9934438 GG genotype may require an increased dose of phenprocoumon as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence dose of phenprocoumon.
1451245360,C,C,"Patients with the rs1051266 CC genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response."
1451245360,C,T,"Patients with the rs1051266 CT genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response."
1451245360,T,T,"Patients with the rs1051266 TT genotype and rheumatoid arthritis may have increased response when treated with methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response."
1451250540,C,C,Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to gefitinib.
1451250540,C,T,"Patients with the somatic rs121434569 CT genotype, (i.e. carrying one copy of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to gefitinib."
1451250540,T,T,Patients with the somatic rs121434569 TT genotype (i.e. carrying two copies of the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have increased likelihood of acquired resistance to gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect response to gefitinib.
1450929125,A,A,Patients who are smokers and who have the AA genotype may have increased cigarette consumption as compared to patients with the GG genotype. Other genetic and clinical factors may also affect cigarette consumption.
1450929125,A,G,Patients who are smokers and who have the AG genotype may have increased cigarette consumption as compared to patients with the GG genotype. Other genetic and clinical factors may also affect cigarette consumption.
1450929125,G,G,Patients who are smokers and who have the GG genotype may have decreased cigarette consumption as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect cigarette consumption.
1450929131,A,A,Patients with the AA genotype may be more likely to smoke when pregnant as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's smoking behaviors.
1450929131,A,G,Patients with the AG genotype may be more likely to smoke when pregnant as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's smoking behaviors.
1450929131,G,G,Patients with the GG genotype may be less likely to smoke when pregnant as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's smoking behaviors.
1451954660,A,A,"Patients with the rs917881 AA genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the AG or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib."
1451954660,A,G,"Patients with the rs917881 AG genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib."
1451954660,G,G,"Patients with the rs917881 GG genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib."
1451954683,A,A,Patients with the rs12948059 AA genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1451954683,A,G,Patients with the rs12948059 AG genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1451954683,G,G,Patients with the rs12948059 GG genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib.
1450811960,A,A,Patients with the AA genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811960,A,G,Patients with the AG genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811960,G,G,Patients with the GG genotype may have decreased subjective responses to alcohol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450930542,C,C,Patients with hypertension and the CC genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.
1450930542,C,T,Patients with hypertension and the CT genotype may have an increased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.
1450930542,T,T,Patients with hypertension and the TT genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.
1449645543,C,C,Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645543,C,T,Patients with the CT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645543,T,T,Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645555,G,G,Patients with the GG genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645555,G,T,Patients with the GT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645555,T,T,Patients with the TT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645561,G,G,Patients with the GG genotype may have an increased rate of sulfation of morphine as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645561,G,T,Patients with the GT genotype may have a decreased rate of sulfation of morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645561,T,T,Patients with the TT genotype may have a decreased rate of sulfation of morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.
1449645567,G,G,Patients with the GG genotype may have an increased rate of sulfation of tapentadol as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645567,G,T,Patients with the GT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645567,T,T,Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645573,G,G,"Patients with the GG genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645573,G,T,"Patients with the GT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645573,T,T,"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449733531,A,A,Patients with the AA genotype and HIV may have a decreased risk of developing sensory neuropathy when taking stavudine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.
1449733531,A,G,Patients with the AG genotype and HIV may have a decreased risk of developing sensory neuropathy when taking stavudine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.
1449733531,G,G,Patients with the GG genotype and HIV may have an increased risk of developing sensory neuropathy when taking stavudine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing sensory neuropathy when taking stavudine.
1450811948,A,A,Patients with the AA genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811948,A,C,Patients with the AC genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811948,C,C,Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450812260,A,A,"Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
1450812260,A,G,"Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
1450812260,G,G,"Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AG genotypes. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
1451952740,C,C,"Patients with the rs12366035 CC genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib."
1451952740,C,T,"Patients with the rs12366035 CT genotype may have a decreased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib."
1451952740,T,T,"Patients with the rs12366035 TT genotype may have an increased risk of dermatologic toxicity when treated with sorafenib as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of dermatologic toxicity when treated with sorafenib."
1451954700,C,C,Patients with the rs315498 CC genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451954700,C,T,Patients with the rs315498 CT genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451954700,T,T,Patients with the rs315498 TT genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451954720,G,G,Patients with the rs9973653 GG genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451954720,G,T,Patients with the rs9973653 GT genotype may have an increased risk of drug toxicity when treated with sorafenib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1451954720,T,T,Patients with the rs9973653 TT genotype may have a decreased risk of drug toxicity when treated with sorafenib as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity when treated with sorafenib.
1449003966,A,A,"Patients with the AA genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients in patients taking isoniazid."
1449003966,A,G,"Patients with the AG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid."
1449003966,G,G,"Patients with the GG genotype who are taking isoniazid may have a decreased risk of drug-induced liver injury as compared to patients with the AG or AA genotypes. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid."
1449167106,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167106,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167106,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167120,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167120,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167120,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167147,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167147,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167147,A,T,Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167147,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167147,G,T,Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167147,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167178,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167178,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167178,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167200,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167200,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167200,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167211,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167211,A,C,Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167211,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167211,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167211,C,G,Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167211,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167228,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167228,A,C,Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167228,A,T,Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167228,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167228,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167228,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167256,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167256,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167256,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167267,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167267,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167267,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167278,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167278,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167278,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449168649,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168649,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168649,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168656,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168656,G,T,Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168656,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168663,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168663,A,T,Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168663,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449715840,A,A,"Patients with the rs540825 AA genotype may have a decreased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl."
1449715840,A,T,"Patients with the rs540825 AT genotype may have a decreased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl."
1449715840,T,T,"Patients with the rs540825 TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl."
1450810399,A,A,Patients with the AA genotype may be at an increased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.
1450810399,A,G,Patients with the AG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.
1450810399,G,G,Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.
1450930833,C,C,"Patients with the CC genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450930833,C,G,"Patients with the CG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence."
1450930833,G,G,"Patients with the GG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence."
1449167469,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167469,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167469,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167480,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167480,G,T,Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167480,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.
1449167495,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167495,C,G,Patients with the CG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167495,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167495,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167495,G,T,Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167495,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167512,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167512,A,G,Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167512,A,T,Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167512,G,G,Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167512,G,T,Patients with the GT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167512,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the G allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167529,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167529,A,C,Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167529,A,T,Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167529,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167529,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167529,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the C allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167546,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167546,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167546,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167557,C,C,Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167557,C,T,Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167557,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167584,A,A,Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167584,A,T,Patients with the AT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449167584,T,T,Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate
1449168093,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168093,G,T,Patients with the GT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168093,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168330,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168330,C,T,Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168330,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168337,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168337,C,G,Patients with the CG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168337,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168343,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168343,A,G,Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168343,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168350,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168350,A,G,Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168350,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168357,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168357,A,T,Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168357,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168454,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168454,C,G,Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168454,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168461,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168461,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168461,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1450812253,C,C,Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812253,C,T,Patients with the CT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812253,T,T,Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1449171009,C,C,Patients with opioid-related disorders and the rs2740574 CC genotype (CYP3A4*1B/*1B) may require an increased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 TT genotype (CYP3A4 *1/*1). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.
1449171009,C,T,Patients with opioid-related disorders and the rs2740574 CT genotype (CYP3A4*1/*1B) may require an increased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 TT genotype (CYP3A4 *1/*1). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.
1449171009,T,T,Patients with opioid-related disorders and the rs2740574 TT genotype (CYP3A4*1/*1) may require a decreased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 CT or CC genotype (CYP3A4*1B). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.
1449168468,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168468,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168468,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168475,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168475,A,G,Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168475,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168482,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168482,A,G,Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168482,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168489,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168489,A,G,Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168489,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168496,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168496,A,T,Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168496,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168503,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168503,A,C,Patients with the AC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168503,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168510,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168510,C,T,Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168510,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168517,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168517,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168517,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168524,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168524,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168524,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168531,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168531,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168531,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168538,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168538,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168538,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168545,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168545,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168545,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168552,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168552,A,C,Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168552,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168559,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168559,A,C,Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168559,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168565,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168565,C,G,Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168565,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168572,C,C,Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168572,C,T,Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168572,T,T,Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168579,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168579,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168579,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168586,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168586,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168586,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168593,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168593,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168593,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168600,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168600,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168600,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168607,A,A,Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168607,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168607,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168614,C,C,Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168614,C,G,Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168614,G,G,Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168691,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168691,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168691,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168698,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168698,G,T,Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168698,T,T,Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168705,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168705,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168705,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168712,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168712,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168712,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168719,A,A,Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168719,A,G,Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1449168719,G,G,Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.
1450808778,A,A,"Patients with the AA genotype may be less likely to quit smoking, regardless of the treatment method, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's ability to quit smoking."
1450808778,A,G,"Patients with the AG genotype may be less likely to quit smoking, regardless of the treatment method, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's ability to quit smoking."
1450808778,G,G,"Patients with the GG genotype may be more likely to quit smoking, regardless of the treatment method, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's ability to quit smoking."
1450814192,A,A,Hispanic patients with the AA genotype may have a greater decrease in viral load following the initiation of HAART as compared to Hispanic patients with the GG genotype. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.
1450814192,A,G,Hispanic patients with the AG genotype may have a greater decrease in viral load following the initiation of HAART as compared to Hispanic patients with the GG genotype. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.
1450814192,G,G,Hispanic patients with the GG genotype may have a smaller decrease in viral load following the initiation of HAART as compared to Hispanic patients with the AA or AG genotypes. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.
1450814424,G,G,Patients with the GG genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the TT genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.
1450814424,G,T,Patients with the GT genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the TT genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.
1450814424,T,T,There is currently no evidence regarding the association between the TT genotype and response to folate supplementation in the context of pharmacotherapy for depression.
1450814430,A,A,Patients with the AA genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the GG genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.
1450814430,A,G,Patients with the AG genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the GG genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.
1450814430,G,G,There is currently no evidence regarding the association between the GG genotype and response to folate supplementation in the context of pharmacotherapy for depression.
1450814563,C,C,Patients with cocaine dependence and the CC genotype may have decreased cocaine cue-reactivity as compared to patients with the CG or GG genotypes. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.
1450814563,C,G,Patients with cocaine dependence and the CG genotype may have increased cocaine cue-reactivity as compared to patients with the CC genotype. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.
1450814563,G,G,Patients with cocaine dependence and the GG genotype may have increased cocaine cue-reactivity as compared to patients with the CC genotype. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.
1450815114,C,C,Patients with schizophrenia and the CC genotype may have an increased response to olanzapine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.
1450815114,C,T,Patients with schizophrenia and the CT genotype may have a decreased response to olanzapine as compared to patients with the CC genotype but an increased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to olanzapine.
1450815114,T,T,Patients with schizophrenia and the TT genotype may have a decreased response to olanzapine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.
1450815136,C,C,Patients with schizophrenia and the CC genotype may have a decreased response to quetiapine as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.
1450815136,C,T,Patients with schizophrenia and the CT genotype may have an increased response to quetiapine as compared to patients with the CC genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to quetiapine.
1450815136,T,T,Patients with schizophrenia and the TT genotype may have an increased response to quetiapine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to quetiapine.
1450928823,A,A,Female patients with the AA genotype may be more likely to respond to varenicline treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to varenicline.
1450928823,A,G,Female patients with the AG genotype may be more likely to respond to varenicline treatment for smoking cessation as compared to female patients with the GG genotype. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to varenicline.
1450928823,G,G,Female patients with the GG genotype may be less likely to respond to varenicline treatment for smoking cessation as compared to female patients with the AA or AG genotypes. Note that this association was not seen in male subjects in the same study. Other genetic and clinical factors may also affect a patient's response to varenicline.
1450929143,A,A,Patients who are smokers and have the AA genotype may have decreased lung function as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's lung function.
1450929143,A,G,Patients who are smokers and have the AG genotype may have decreased lung function as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's lung function.
1450929143,G,G,Patients who are smokers and have the GG genotype may have increased lung function as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's lung function.
1450929810,A,A,"Patients with the AA genotype may have decreased oxycodone dose requirements as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements."
1450929810,A,G,"Patients with the AG genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype, but increased oxycodone dose requirements as compared to patients with the AA genotype. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements."
1450929810,G,G,"Patients with the GG genotype may have increased oxycodone dose requirements as compared to patients with the AA or AG genotypes. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements."
1450934868,C,C,"Patients with the CC genotype may have decreased fentanyl dosage requirements as compared to patients with the CT or TT genotypes. However, another study did not find an association between this variant and fentanyl dosing. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements."
1450934868,C,T,"Patients with the CT genotype may have increased fentanyl dosage requirements as compared to patients with the CC genotype. However, another study did not find an association between this variant and fentanyl dosing. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements."
1450934868,T,T,"Patients with the TT genotype may have increased fentanyl dosage requirements as compared to patients with the CC genotype. However, another study did not find an association between this variant and fentanyl dosing. Other genetic and clinical factors may also affect a patient's fentanyl dosage requirements."
1452003640,A,A,Patients with the rs1801394 AA genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the GG or AG genotypes. Other genetic and clinical factors may also influence mean arterial pressure.
1452003640,A,G,Patients with the rs1801394 AG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003640,G,G,Patients with the rs1801394 GG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1449161121,C,C,Patients with the CC genotype may have a decreased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.
1449161121,C,T,Patients with the CT genotype may have an increased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.
1449161121,T,T,Patients with the TT genotype may have an increased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.
1449715590,C,C,"Patients with the CC genotype may have an increased response to fentanyl as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl."
1449715590,C,T,"Patients with the CT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl."
1449715590,T,T,"Patients with the TT genotype may have a decreased response to fentanyl as compared to patients with the CC or CT genotypes. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl."
1449748202,A,A,"Patients with the AA genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin."
1449748202,A,G,"Patients with the AG genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin."
1449748202,G,G,"Patients with the GG genotype may have a decreased lipid-lowering response to rosuvastatin as compared to patients with the AA or AG genotypes. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin."
1450376319,G,G,Patients with the GG genotype may be at an increased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)
1450376319,G,T,Patients with the GT genotype may be at an increased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the TT genotype but a decreased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)
1450376319,T,T,Patients with the TT genotype may be at a decreased risk of developing maculopapular exanthema (MPE) as a result of phenytoin treatment as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin-induced maculopapular exanthema (MPE)
1450809657,C,C,Patients with the CC genotype may have an increased response to sibutramine in terms of weight loss as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to sibutramine.
1450809657,C,T,Patients with the CT genotype may have a decreased response to sibutramine in terms of weight loss as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to sibutramine.
1450809657,T,T,Patients with the TT genotype may have a decreased response to sibutramine in terms of weight loss as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to sibutramine.
1450810375,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.
1450810375,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.
1450810375,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.
1450811942,C,C,Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811942,C,T,Patients with the CT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811942,T,T,Patients with the TT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450812204,A,A,Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812204,A,G,Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812204,G,G,Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812241,C,C,"Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, one study found no significant main effect of this variant on heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
1450812241,C,T,"Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, one study found no significant main effect of this variant on heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
1450812241,T,T,"Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. However, one study found no significant main effect of this variant on heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence."
1450812247,C,C,Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812247,C,T,Patients with the CT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450812247,T,T,Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450813875,A,A,Patients with the AA genotype may be less likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the GG genotype. Other genetic or clinical factors may also affect response to bupropion.
1450813875,A,G,Patients with the AG genotype may be less likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the GG genotype. Other genetic or clinical factors may also affect response to bupropion.
1450813875,G,G,Patients with the GG genotype may be more likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect response to bupropion.
1450933023,C,C,"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450933023,C,T,"Patients with beta-thalassemia and the CT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450933023,T,T,"Patients with beta-thalassemia and the TT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450806640,C,C,"Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. However, another study did not find an association between this variant and opioid dependence. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
1450806640,C,T,"Patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
1450806640,T,T,"Patients with the TT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, another study did not find an association between this variant and opioid dependence. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
1450806626,A,A,"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of developing opioid dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence."
1450806626,A,G,"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of developing opioid dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence."
1450806626,G,G,"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of developing opioid dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence."
1450935200,C,C,Patients with the rs2740574 CC genotype and who are treated with cyclosporine following kidney transplantation may have decreased blood concentrations of cyclosporine as compared to patients with the rs2740574 CT or TT genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.
1450935200,C,T,Patients with the rs2740574 CT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC genotype. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.
1450935200,T,T,Patients with the rs2740574 TT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.
1450811641,A,A,"The current evidence base suggests that there is no significant association between the rs1128503 AA genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
1450811641,A,G,"The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
1450811641,G,G,"The current evidence base suggests that there is no significant association between the rs1128503 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
1452003696,C,C,Patients with the rs1275988 CC genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence mean arterial pressure.
1452003696,C,T,Patients with the rs1275988 CT genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003696,T,T,Patients with the rs1275988 TT genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003980,C,C,Patients with the rs3813867 CC genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003980,C,G,Patients with the rs3813867 CG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003980,G,G,Patients with the rs3813867 GG genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence mean arterial pressure.
1449188689,A,A,"Patients with the AA genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188689,A,G,"Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188689,G,G,"Patients with the GG genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188695,C,C,"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188695,C,T,"Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188695,T,T,"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188749,C,C,"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188749,C,T,"Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188749,T,T,"Patients with the TT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188755,C,C,"Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188755,C,G,"Patients with the CG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449188755,G,G,"Patients with the GG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy."
1449190104,A,A,Patients with the AA genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.
1449190104,A,G,Patients with the AG genotype and receiving chemotherapy treatment may have increased severity of nausea as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.
1449190104,G,G,Patients with the GG genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.
1449190397,G,G,Patients with the GG genotype may have an increased likelihood of developing either heroin or cocaine dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.
1449190397,G,T,Patients with the GT genotype may have a decreased likelihood of developing either heroin or cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.
1449190397,T,T,Patients with the TT genotype may have a decreased likelihood of developing either heroin or cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the likelihood of developing cocaine or heroin dependence.
1449190422,A,A,"Patients with the AA genotype may have an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, one study failed to find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect risk of developing opioid dependence."
1449190422,A,C,"Patients with the AC genotype may have an increased risk of developing opioid dependence as compared to patients with the CC genotype. However, one study failed to find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect risk of developing opioid dependence."
1449190422,C,C,"Patients with the CC genotype may have a decreased risk of developing opioid dependence as compared to patients with the AA or AC genotypes. However, one study failed to find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect risk of developing opioid dependence."
1449271003,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271003,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271003,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271039,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271039,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271039,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1450808106,A,A,There is currently no available evidence regarding any association between the AA genotype and heroin intake in heroin-dependent patients. Other genetic or clinical factors may also affect heroin intake in heroin-dependent patients.
1450808106,A,G,Patients with heroin dependence and the AG genotype may have an increased daily intake of heroin as compared to heroin-dependent patients with the GG genotype. Other genetic or clinical factors may also affect heroin intake in heroin-dependent patients.
1450808106,G,G,Patients with heroin dependence and the GG genotype may have a decreased daily intake of heroin as compared to heroin-dependent patients with the AG genotype. Other genetic or clinical factors may also affect heroin intake in heroin-dependent patients.
1450813540,C,C,"Patients with the CC genotype may have less severe nicotine dependence as measured by mean pack years smoked as compared to patients with the CT genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect the severity of nicotine dependence."
1450813540,C,T,"Patients with the CT genotype may have more severe nicotine dependence as measured by mean pack years smoked as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect the severity of nicotine dependence."
1450813540,T,T,There is currently no available evidence regarding the association between the TT genotype and severity of nicotine dependence.
1452003680,C,C,Patients with the rs279858 CC genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003680,C,T,Patients with the rs279858 CT genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003680,T,T,Patients with the rs279858 TT genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence mean arterial pressure.
1450934191,A,A,Patients with the AA genotype may have an increased response to mexiletine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934191,A,C,Patients with the AC genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1450934191,C,C,Patients with the CC genotype may have a decreased response to mexiletine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to mexiletine.
1449275238,A,A,"Patients with the AA genotype may have a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. However, other studies have found contradictory evidence or have failed to find a significant association between this variant and heroin dependence. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence."
1449275238,A,G,"Patients with the AG genotype may have a increased risk of developing heroin dependence as compared to patients with the AA genotype. However, other studies have found contradictory evidence or have failed to find a significant association between this variant and heroin dependence. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence."
1449275238,G,G,"Patients with the GG genotype may have a increased risk of developing heroin dependence as compared to patients with the AA genotype. However, other studies have found contradictory evidence or have failed to find a significant association between this variant and heroin dependence. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence."
1452003688,A,A,Patients with the rs2307116 AA genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003688,A,G,Patients with the rs2307116 AG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003688,G,G,Patients with the rs2307116 GG genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence mean arterial pressure.
1450811035,C,C,"Patients with the CC genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide."
1450811035,C,G,"Patients with the CG genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide."
1450811035,C,T,"Patients with the CT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide."
1450811035,G,G,Patients with the GG genotype may experience increased inhibition of KCNH2 by disopyramide as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide.
1450811035,G,T,"Patients with the GT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide."
1450811035,T,T,"Patients with the TT genotype may experience decreased inhibition of KCNH2 by disopyramide as compared to patients with the GG genotype. However, this decrease in inhibition is not considered to be clinically significant. Other genetic and clinical factors may also affect inhibition of KCNH2 by disopyramide."
1450811044,C,C,Patients with the CC genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.
1450811044,C,G,Patients with the CG genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.
1450811044,C,T,Patients with the CT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.
1450811044,G,G,Patients with the GG genotype may experience increased inhibition of KCNH2 by quinidine as compared to patients carrying at least one C or T allele. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.
1450811044,G,T,Patients with the GT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.
1450811044,T,T,Patients with the TT genotype may experience decreased inhibition of KCNH2 by quinidine as compared to patients the GG genotype. Other genetic and clinical factors may also affect inhibition of KCNH2 by quinidine.
1450811267,C,C,"Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. However, the majority of studies have found no association between this variant and the risk of developing alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism."
1450811267,C,T,"Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. However, the majority of studies have found no association between this variant and the risk of developing alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism."
1450811267,T,T,"Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. However, the majority of studies have found no association between this variant and the risk of developing alcoholism. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism."
1450811954,C,C,Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811954,C,T,Patients with the CT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811954,T,T,Patients with the TT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811966,G,G,Patients with the GG genotype may have decreased subjective responses to alcohol as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811966,G,T,Patients with the GT genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811966,T,T,Patients with the TT genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811978,C,C,Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811978,C,G,Patients with the CG genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811978,G,G,Patients with the GG genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811984,C,C,Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811984,C,T,Patients with the CT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450811984,T,T,Patients with the TT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.
1450815104,C,C,Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815104,C,T,Patients with schizophrenia and the CT genotype may have an increased response to risperidone as compared to patients with the CC genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815104,T,T,Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815154,C,C,Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815154,C,T,Patients with schizophrenia and the CT genotype may have an increased response to risperidone as compared to patients with the CC genotype but a decreased response as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815154,T,T,Patients with schizophrenia and the TT genotype may have an increased response to risperidone as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815172,A,A,Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815172,A,C,Patients with schizophrenia and the AC genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815172,C,C,Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450826899,A,A,"Patients with the rs1799971 AA genotype may have reduced alfentanil dose requirements as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a alfentanil dose requirements."
1450826899,A,G,"Patients with the rs1799971 AG genotype may have increased alfentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a alfentanil dose requirements."
1450826899,G,G,"Patients with the rs1799971 GG genotype may have increased alfentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect a alfentanil dose requirements."
1450826919,A,A,"Patients with the rs1799971 AA genotype may have decreased codeine dose requirements as compared to patients with the AG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements."
1450826919,A,G,"Patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements."
1450826919,G,G,"There is currently no available evidence regarding the association between the rs1799971 GG genotype and codeine dose requirements. However, patients with the rs1799971 AG genotype may have increased codeine dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect codeine dose requirements."
1450826949,A,A,"Patients with the rs1799971 AA genotype may have a decreased analgesic response to fentanyl as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to fentanyl."
1450826949,A,G,"Patients with the rs1799971 AG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to fentanyl."
1450826949,G,G,"Patients with the rs1799971 GG genotype may have an increased analgesic response to fentanyl as compared to patients with the AA genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to fentanyl."
1450929037,C,C,Patients with the CC genotype may have decreased opioid dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's opioid dose requirements.
1450929037,C,T,Patients with the CT genotype may have increased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.
1450929037,T,T,Patients with the TT genotype may have increased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's opioid dose requirements.
1450929137,A,A,Patients with the AA genotype may be less likely to remain abstinent from smoking when treated with placebo as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's success at smoking cessation.
1450929137,A,G,Patients with the AG genotype may be less likely to remain abstinent from smoking when treated with placebo as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's success at smoking cessation.
1450929137,G,G,Patients with the GG genotype may be more likely to remain abstinent from smoking when treated with placebo as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's success at smoking cessation.
1450933011,C,C,"Patients with beta-thalassemia and the CC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450933011,C,T,"Patients with beta-thalassemia and the CT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450933011,T,T,"Patients with beta-thalassemia and the TT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to deferasirox."
1450935856,A,A,Patients with the AA genotype may have increased clearance of mephenytoin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935856,A,G,Patients with the AG genotype may have decreased clearance of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect mephenytoin clearance.
1450935856,G,G,Patients with the GG genotype may have decreased clearance of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect mephenytoin clearance.
1450936159,C,C,Patients with the CC genotype may have decreased levels of O-desmethylnaproxen sulfation as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936159,C,T,Patients with the CT genotype may have increased levels of O-desmethylnaproxen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936159,T,T,Patients with the TT genotype may have increased levels of O-desmethylnaproxen sulfation as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936211,C,C,Patients with the CC genotype may have increased sulfation of acetaminophen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect acetaminphen sulfation.
1450936211,C,T,Patients with the CT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminphen sulfation.
1450936211,T,T,Patients with the TT genotype may have decreased sulfation of acetaminophen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect acetaminphen sulfation.
1450936236,A,A,Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936236,A,G,Patients with the AG genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936236,G,G,Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936248,A,A,Patients with the AA genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936248,A,G,Patients with the AG genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936248,G,G,Patients with the GG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936266,A,A,Patients with the AA genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936266,A,C,Patients with the AC genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936266,C,C,Patients with the CC genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936278,A,A,Patients with the AA genotype may have increased sulfation of tapentadol as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936278,A,T,Patients with the AT genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936278,T,T,Patients with the TT genotype may have decreased sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936290,A,A,Patients with the AA genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936290,A,G,Patients with the AG genotype may have decreased sulfation of acetaminophen as compared to patients with the GG genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936290,G,G,Patients with the GG genotype may have increased sulfation of acetaminophen as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936320,G,G,Patients with the GG genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936320,G,T,Patients with the GT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936320,T,T,Patients with the TT genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936577,A,G,Patients with malignant mesothelioma and the AG genotype may be at an increased risk of developing thrombocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.
1450936577,G,G,Patients with malignant mesothelioma and the GG genotype may be at a decreased risk of developing thrombocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.
1450936592,C,C,Patients with malignant mesothelioma and the CC genotype may be at a decreased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.
1450936592,C,G,Patients with malignant mesothelioma and the CG genotype may be at a decreased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.
1450936592,G,G,Patients with malignant mesothelioma and the CGG genotype may be at an increased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.
1450826957,A,A,"Patients with the rs1799971 AA genotype may have an increased analgesic response to morphine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to morphine."
1450826957,A,G,"Patients with the rs1799971 AG genotype may have a decreased analgesic response to morphine as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to morphine."
1450826957,G,G,"Patients with the rs1799971 GG genotype may have a decreased analgesic response to morphine as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect response to morphine."
1450929798,A,A,"The current evidence base suggests that there is no significant association between rs1045642 AA genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
1450929798,A,G,"The current evidence base suggests that there is no significant association between rs1045642 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
1450929798,G,G,"The current evidence base suggests that there is no significant association between rs1045642 GG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements."
1450929792,A,A,"Patients with the rs1045642 AA genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia."
1450929792,A,G,"Patients with the rs1045642 AG genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the GG genotype, but an increased dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia."
1450929792,G,G,"Patients with the rs1045642 GG genotype and who are receiving methadone for analgesia may required an increased dose as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's methadone dose requirements for analgesia."
1450826969,A,A,"Patients with the rs1799971 AA genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect oxycodone dose requirements."
1450826969,A,G,"Patients with the rs1799971 AG genotype may have decreased oxycodone dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect oxycodone dose requirements."
1450826969,G,G,"Patients with the rs1799971 GG genotype may have increased oxycodone dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect oxycodone dose requirements."
1449003759,C,C,Patients with the CC genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003759,C,T,Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the TT genotype or a decreased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003759,T,T,Patients with the TT genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003777,C,C,Patients with the CC genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003777,C,T,Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CC genotype or a decreased risk for venous thrombosis compared to the TT genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003777,T,T,Patients with the TT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003799,C,C,Patients with the CC genotype who are taking oral contraceptives may have a decreased risk of venous thrombosis as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003799,C,T,Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CC genotype or a decreased risk of venous thrombosis compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003799,T,T,Patients with the TT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449003805,G,G,Patients with the GG genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the G/del or del/del genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.
1449270985,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270985,A,C,"Patients with breast cancer and the AC genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270985,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270991,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270991,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270991,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270997,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270997,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449270997,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271009,C,C,"Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271009,C,T,"Patients with breast cancer and the CT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC genotype, but a decreased risk compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271009,T,T,"Patients with breast cancer and the TT genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271015,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271015,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271015,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271021,A,A,"Patients with breast cancer and the AA genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271021,A,G,"Patients with breast cancer and the AG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GG genotype, but a decreased risk compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1449271021,G,G,"Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia."
1450375065,G,G,"Patients with testicular cancer and the GG genotype may have a decreased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375065,G,T,"Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide."
1450375065,T,T,"Patients with testicular cancer and the TT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide."
1450807362,C,C,Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450807362,C,G,Patients with the CG genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450807362,G,G,Patients with the GG genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1450822690,C,C,Patients with the CC genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CT or TT genotypes. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.
1450822690,C,T,Patients with the CT genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the CC genotype. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.
1450822690,T,T,Patients with the TT genotype may be at a decreased risk of developing cocaine dependence as compared to patients with the CC genotype. This association was only seen in African American participants. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.
1450823123,C,C,Patients with the CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823123,C,T,Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823123,T,T,Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823150,A,A,Patients with the AA genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823150,A,G,Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450823150,G,G,Patients with the GG genotype may be at a decreased risk of developing heroin dependence as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.
1450932256,C,C,"Patients with the CC genotype may be at an increased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema."
1450932256,C,T,"Patients with the CT genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema."
1450932256,T,T,"Patients with the TT genotype may be at a decreased risk of developing maculopapular exanthema when treated with ethambutol, isoniazid, pyrazinamide or rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk developing maculopapular exanthema."
1450936183,A,A,Patients with the AA genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936183,A,G,Patients with the AG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936183,G,G,Patients with the GG genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936224,C,C,Patients with the CC genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936224,C,T,Patients with the CT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936224,T,T,Patients with the TT genotype may have decreased sulfation of O-desmethylnaproxen as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.
1450936230,C,C,Patients with the CC genotype may have increased sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936230,C,T,Patients with the CT genotype may have decreased sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936230,T,T,Patients with the TT genotype may have decreased sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation.
1450936254,A,A,Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936254,A,C,Patients with the AC genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936254,C,C,Patients with the CC genotype may have decreased sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1449645356,C,C,Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645356,C,T,Patients with the CT genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645356,T,T,Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645398,C,C,Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645398,C,T,Patients with the CT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645398,T,T,Patients with the TT genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645404,C,C,"Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645404,C,T,"Patients with the CT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645404,T,T,"Patients with the TT genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645414,A,A,Patients with the AA genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645414,A,C,Patients with the AC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645414,C,C,Patients with the CC genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.
1449645420,A,A,Patients with the AA genotype may have an increased rate of sulfation of tapentadol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645420,A,C,Patients with the AC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645420,C,C,Patients with the CC genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.
1449645426,A,A,"Patients with the AA genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645426,A,C,"Patients with the AC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645426,C,C,"Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645549,C,C,"Patients with the CC genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645549,C,T,"Patients with the CT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1449645549,T,T,"Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients."
1450810363,A,A,Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810363,A,G,Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450810363,G,G,Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1450811346,A,A,Female patients with the AA genotype may have an increased relative reinforcing value of nicotine as compared to female patients with the AG or GG genotypes. This association is considered to be the result of a gender x genotype interaction and was not replicated in male patients. Other genetic and clinical factors may also affect a patient's response to nicotine.
1450811346,A,G,Female patients with the AG genotype may have a decreased relative reinforcing value of nicotine as compared to female patients with the AA genotype. This association is considered to be the result of a gender x genotype interaction and was not replicated in male patients. Other genetic and clinical factors may also affect a patient's response to nicotine.
1450811346,G,G,Female patients with the GG genotype may have a decreased relative reinforcing value of nicotine as compared to female patients with the AA genotype. This association is considered to be the result of a gender x genotype interaction and was not replicated in male patients. Other genetic and clinical factors may also affect a patient's response to nicotine.
1450812210,C,C,Patients with the rs510769 CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect risk of developing heroin dependence.
1450812210,C,T,Patients with the rs510769 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.
1450812210,T,T,Patients with the rs510769 TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.
1450812223,C,C,Patients with the rs3766951 CC genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.
1450812223,C,T,Patients with the rs3766951 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.
1450812223,T,T,Patients with the rs3766951 TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect risk of developing heroin dependence.
1450824225,C,C,"Patients with Alzheimer's disease and the CC genotype (also known as ApoE E4/E4) may have an increased response to treatment with statins, as measured by rate of cognitive decline, as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to statin treatment for Alzheimer's disease."
1450824225,C,T,"Patients with Alzheimer's disease and the CT genotype may have a decreased response to treatment with statins, as measured by rate of cognitive decline, as compared to patients with the CC genotype (also known as ApoE E4/E4). Other genetic or clinical factors may also affect a patient's response to statin treatment for Alzheimer's disease."
1450824225,T,T,"Patients with Alzheimer's disease and the TT genotype may have a decreased response to treatment with statins, as measured by rate of cognitive decline, as compared to patients with the CC genotype (also known as ApoE E4/E4). Other genetic or clinical factors may also affect a patient's response to statin treatment for Alzheimer's disease."
1450824473,C,C,Patients with the CC genotype may have a decreased response to ethanol as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to ethanol.
1450824473,C,T,Patients with the CT genotype may have a decreased response to ethanol as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to ethanol.
1450824473,T,T,Patients with the TT genotype may have an increased response to ethanol as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to ethanol.
1450826931,A,A,"Patients with the rs1799971 AA genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect fentanyl dose requirements."
1450826931,A,G,"Patients with the rs1799971 AG genotype may have decreased fentanyl dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect fentanyl dose requirements."
1450826931,G,G,"Patients with the rs1799971 GG genotype may have increased fentanyl dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect fentanyl dose requirements."
1450826975,A,A,"Patients with the rs1799971 AA genotype may have decreased sufentanil dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect sufentanil dose requirements."
1450826975,A,G,"Patients with the rs1799971 AG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect sufentanil dose requirements."
1450826975,G,G,"Patients with the rs1799971 GG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect sufentanil dose requirements."
1449266588,A,A,"Patients with the rs1045642 AA genotype who are receiving methadone maintenance therapy may have increased clearance of methadone, leading to decreased plasma concentration of methadone as compared to patients with the AG and GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes."
1449266588,A,G,"Patients with the rs1045642 AG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes."
1449266588,G,G,"Patients with the rs1045642 GG genotype who are receiving methadone maintenance therapy may have decreased clearance of methadone, leading to increased plasma concentration of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes."
1449266582,C,C,Patients with the CC genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1449266582,C,T,Patients with the CT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1449266582,T,T,Patients with the TT genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1449311670,A,A,Patients with the AA genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.
1449311670,A,G,Patients with the AG genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.
1449311670,G,G,Patients with the GG genotype who are undergoing surgery may have an increased response to propofol and remifentanil administered as anesthesia as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.
1450815098,A,A,Patients with schizophrenia and the AA genotype may have an increased response to olanzapine as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.
1450815098,A,C,Patients with schizophrenia and the AC genotype may have a decreased response to olanzapine as compared to patients with the AA genotype but an increased response as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's response to olanzapine.
1450815098,C,C,Patients with schizophrenia and the CC genotype may have a decreased response to olanzapine as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's response to olanzapine.
1450931960,A,A,Patients with major depressive disorder and the AA genotype may be less likely to respond to sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sertraline.
1450931960,A,G,Patients with major depressive disorder and the AG genotype may be less likely to respond to sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sertraline.
1450931960,G,G,Patients with major depressive disorder and the GG genotype may be more likely to respond to sertraline as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to sertraline.
1450934500,C,C,Patients with the CC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934500,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934500,T,T,Patients with the TT genotype have an unknown response to migalastat as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934662,C,C,Patients with the CC genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934662,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934662,T,T,"Patients with the TT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450936314,G,G,Patients with the GG genotype may have decreased sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936314,G,T,Patients with the GT genotype may have decreased sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936314,T,T,Patients with the TT genotype may have increased sulfation of acetaminophen as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.
1450936557,C,C,Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.
1450936557,C,G,Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.
1450936557,G,G,Patients with malignant mesothelioma and the GG genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.
1450936586,C,C,Patients with malignant mesothelioma and the CC genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.
1450936586,C,G,Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.
1450936586,G,G,Patients with malignant mesothelioma and the GG genotype may be at a decreased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.
1452003988,C,C,Patients with the rs6686529 CC genotype who are treated with sevoflurane may have increased sedation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sedation.
1452003988,C,G,Patients with the rs6686529 CG genotype who are treated with sevoflurane may have increased sedation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sedation.
1452003988,G,G,Patients with the rs6686529 GG genotype who are treated with sevoflurane may have decreased sedation as compared to patients with the CG or CC genotypes. Other genetic and clinical factors may also influence sedation.
1449003875,A,A,Patients with the AA genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003875,A,C,Patients with the AC genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the CC genotype or a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003875,C,C,Patients with the CC genotype may have a decreased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the AC or AA genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.
1449003881,C,C,Patients with the CC genotype may have decreased metabolism of nicotine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence metabolism of nicotine in patients.
1449003881,C,T,"Patients with the CT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype, or increased metabolism compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine in patients."
1449003881,T,T,Patients with the TT genotype may have increased metabolism of nicotine as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence metabolism of nicotine in patients.
1449003926,C,C,Patients with the CC genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449003926,C,T,"Patients with the CT genotype may have an increased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the TT genotype, but a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations."
1449003926,T,T,Patients with the TT genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.
1449191764,G,G,Patients with the rs34911792 GG genotype (two copies of the CFTR S1235R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191764,G,T,Patients with the rs34911792 GT genotype (one copy of the CFTR S1235R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.
1449191764,T,T,"Patients with the rs34911792 TT genotype (do not have a copy of the CFTR S1235R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449191874,C,C,Patients with the CC genotype (two copies of the CFTR G970R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191874,C,G,Patients with the CG genotype (one copy of the CFTR G970R variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence a patient's response to ivacaftor.
1449191874,G,G,"Patients with the GG genotype (do not have a copy of the CFTR G970R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor."
1449192420,A,A,Patients with the rs74551128 AA genotype (two copies of the CFTR A455E variant) and cystic fibrosis may respond to treatment with ivacaftor/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor/lumacaftor.
1449192420,A,C,Patients with the rs74551128 AC genotype (one copy of the CFTR A455E variant) and cystic fibrosis may respond to treatment with ivacaftor/lumacaftor. Other genetic and clinical factors may also influence response to ivacaftor/lumacaftor.
1449192420,C,C,"Patients with the rs74551128 CC genotype (do not have a copy of the CFTR A455E variant) and cystic fibrosis have an unknown response to treatment with ivacaftor/lumacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor/lumacaftor."
1449192431,A,A,"Patients with the rs397508602 AA genotype (two copies of the CFTR G1249R variant) and cystic fibrosis may respond to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449192431,A,G,"Patients with the rs397508602 AG genotype (one copy of the CFTR G1249R variant) and cystic fibrosis may respond to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449192431,G,G,"Patients with the rs397508602 GG genotype (do not have a copy of the CFTR G1249R variant) and cystic fibrosis have an unknown response to treatment with ivacaftor, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor."
1449192570,A,A,"Patients with the rs121909047 AA genotype (two copies of the CFTR A561E variant) and cystic fibrosis may respond to ivacaftor treatment. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ivacaftor."
1449192570,A,C,"Patients with the rs121909047 AC genotype (one copy of the CFTR A561E variant) and cystic fibrosis may respond to ivacaftor treatment. However, another study did not see an effect of ivacaftor on CFTR-A561E activity. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ivacaftor."
1449192570,C,C,"Patients with the rs121909047 CC genotype (do not have a copy of the CFTR A561E variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ivacaftor."
1450809956,C,C,Patients with the CC genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.
1450809956,C,G,Patients with the CG genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.
1450809956,G,G,Patients with the GG genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.
1450812410,C,C,Patients with the CC genotype may have decreased systolic blood pressure following nimodipine administration as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's blood pressure following nimodipine administration.
1450812410,C,T,Patients with the CT genotype may have increased systolic blood pressure following nimodipine administration as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's blood pressure following nimodipine administration.
1450812410,T,T,There is currently no available evidence regarding the association between the TT genotype and response to nimodipine.
1450815130,A,A,Patients with schizophrenia and the AA genotype may have a decreased response to risperidone as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815130,A,G,Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450815130,G,G,Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.
1450826981,A,A,Patients with the rs1799971 AA genotype may have an increased response to combined acetaminophen and tramadol as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.
1450826981,A,G,Patients with the rs1799971 AG genotype may have a decreased response to combined acetaminophen and tramadol as compared to patients with the AA genotype. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.
1450826981,G,G,Patients with the rs1799971 GG genotype may have a decreased response to combined acetaminophen and tramadol as compared to patients with the AA genotype. Other genetic or clinical factors may also affect response to combined acetaminophen and tramadol.
1451985380,C,C,Patients with CC genotype may require an increased dose of fentanyl to manage postoperative pain as compared to patients with the TT genotype. Other genetic and clinical factors may also affect fentanyl dosage requirements.
1451985380,C,T,Patients with CT genotype may require an increased dose of fentanyl to manage postoperative pain as compared to patients with the TT genotype. Other genetic and clinical factors may also affect fentanyl dosage requirements.
1451985380,T,T,Patients with the TT genotype may require a decreased dose of fentanyl to manage postoperative pain as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also affect fentanyl dosage requirements.
1451989360,C,C,"Patients with the CC genotype may have decreased metabolism of tacrolimus as compared to patients with the CT or TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism."
1451989360,C,T,"Patients with the CT genotype may have increased metabolism of tacrolimus as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism."
1451989360,T,T,"Patients with the TT genotype may have increased metabolism of tacrolimus as compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism."
1450826963,A,A,"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and plasma concentrations of morphine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and morphine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements. Other genetic or clinical factors may also affect plasma concentrations of morphine."
1450826963,A,G,"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and plasma concentrations of morphine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and morphine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements. Other genetic or clinical factors may also affect plasma concentrations of morphine."
1450826963,G,G,"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and plasma concentrations of morphine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1799971 and morphine and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect morphine dose requirements. Other genetic or clinical factors may also affect plasma concentrations of morphine."
1451985160,C,C,Patients with the CC genotype may have a decreased risk of developing respiratory depression when treated with sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.
1451985160,C,T,Patients with the CT genotype may have a decreased risk of developing respiratory depression when treated with sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.
1451985160,T,T,Patients with the TT genotype may have an increased risk of developing respiratory depression when treated with sufentanil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.
1451985260,C,C,Patients with the CC genotype may have a decreased analgesic response to sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to sufentanil.
1451985260,C,T,Patients with the CT genotype may have a decreased analgesic response to sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to sufentanil.
1451985260,T,T,Patients with the TT genotype may have an increased analgesic response to sufentanil as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to sufentanil.
1451985292,C,C,Patients with the CC genotype and Hyperlipidemia may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1451985292,C,T,Patients with the CT genotype and Hyperlipidemia may have a better response to atorvastatin treatment (determined by a higher reduction in total cholesterol) as compared to patients with the CC genotype or may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1451985292,T,T,Patients with the TT genotype and Hyperlipidemia may have a better response to atorvastatin treatment (determined by a higher reduction in total cholesterol) as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.
1451985280,C,C,Patients with the CC genotype undergoing organ transplant who received a donor liver with the same genotype may have a decreased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the CT or TT genotype who received a donor liver heterozygous or homozygous for the variant (T) allele. Other genetic and clinical factors may also influence incidence of acute cellular rejection.
1451985280,C,T,Patients with the CT genotype undergoing organ transplant who received a donor liver heterozygous or homozygous for the variant (T) allele may have an increased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the CC genotype who received a donor liver with the same genotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.
1451985280,T,T,Patients with the TT genotype undergoing organ transplant who received a donor liver heterozygous or homozygous for the variant (T) allele may have an increased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the CC genotype who received a donor liver with the same genotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.
1449191758,C,C,"Patients with the rs75541969 CC genotype (two copies of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor."
1449191758,C,G,"Patients with the rs75541969 CG genotype (one copy of the CFTR D1152H variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor."
1449191758,G,G,"Patients with the rs75541969 GG genotype (do not have a copy of the CFTR D1152H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor."
1449191770,G,G,"Patients with the rs11971167 GG genotype (do not have a copy of the CFTR D1270N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence response to ivacaftor."
1449191770,G,T,"Patients with the rs11971167 GT genotype (one copy of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence response to ivacaftor."
1449191770,T,T,"Patients with the rs11971167 TT genotype (two copies of the CFTR D1270N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1270N. Other genetic and clinical factors may also influence response to ivacaftor."
1451989340,C,C,"Patients with the CC genotype may have decreased exposure to fentanyl as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl."
1451989340,C,T,"Patients with the CT genotype may have decreased exposure to fentanyl as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl."
1451989340,T,T,"Patients with the TT genotype may have increased exposure to fentanyl as compared to patients with the CT or CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2242480 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl."
1452003785,C,C,Patients with the rs2031920 CC genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence mean arterial pressure.
1452003785,C,T,Patients with the rs2031920 CT genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452003785,T,T,Patients with the rs2031920 TT genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1449266594,C,C,Patients with the CC genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1449266594,C,T,Patients with the CT genotype who are receiving methadone maintenance therapy may have decreased plasma concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1449266594,T,T,Patients with the TT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.
1450808823,A,A,"Patients with the AA genotype may show a decreased severity of alcoholism as compared to patients with the AG or GG genotypes. However, other studies have not found a significant association between this locus and severity of alcoholism while one found conflicting data. Other genetic and clinical factors may also affect severity of alcoholism."
1450808823,A,G,"Patients with the AG genotype may show an increased severity of alcoholism in measures such as number of drinking days per month and alcohol craving as compared to patients with the AA genotype. However, other studies have not found a significant association between this locus and severity of alcoholism while one found conflicting data. Other genetic and clinical factors may also affect severity of alcoholism."
1450808823,G,G,"Patients with the GG genotype may show an increased severity of alcoholism in measures such as number of drinking days per month and alcohol craving as compared to patients with the AA genotype. However, other studies have not found a significant association between this locus and severity of alcoholism while one found conflicting data. Other genetic and clinical factors may also affect severity of alcoholism."
1450934668,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934668,C,G,Patients with the CG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934668,C,T,"Patients with the CT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934668,G,G,Patients with the GG genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934668,G,T,Patients with the GT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934668,T,T,"Patients with the TT genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934711,C,C,"Patients with the CC genotype have an unknown response to migalastat, as response may depend on the presence of other GLA variants. Other genetic and clinical factors may also affect a patient's response to migalastat."
1450934711,C,T,Patients with the CT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450934711,T,T,Patients with the TT genotype may respond to migalastat for the treatment of Fabry disease. Other genetic and clinical factors may also affect a patient's response to migalastat.
1450935171,A,A,Patients with the AA genotype may be at an increased risk of developing treatment emergent suicidal ideation (TESI) when treated with tianeptine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect suicidal ideation in patients.
1450935171,A,G,Patients with the AG genotype may be at a decreased risk of developing treatment emergent suicidal ideation (TESI) when treated with tianeptine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect suicidal ideation in patients.
1450935171,G,G,Patients with the GG genotype may be at a decreased risk of developing treatment emergent suicidal ideation (TESI) when treated with tianeptine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect suicidal ideation in patients.
1450959380,C,C,Patients with the CC genotype may have increased metabolism of phenylalanine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959380,C,T,Patients with the CT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959380,T,T,Patients with the TT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959386,A,A,Patients with the AA genotype may have increased metabolism of carbocisteine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959386,A,G,Patients with the AG genotype may have decreased metabolism of carbocisteine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959386,G,G,Patients with the GG genotype may have decreased metabolism of carbocisteine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959460,C,C,Patients with the CC genotype may have increased metabolism of carbocisteine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959460,C,T,Patients with the CT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959460,T,T,Patients with the TT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959480,A,A,Patients with the AA genotype may have increased metabolism of carbocisteine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959480,A,G,Patients with the AG genotype may have decreased metabolism of carbocisteine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959480,G,G,Patients with the GG genotype may have decreased metabolism of carbocisteine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959486,C,C,Patients with the CC genotype may have increased metabolism of phenylalanine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959486,C,T,Patients with the CT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959486,T,T,Patients with the TT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959492,C,C,Patients with the CC genotype may have increased metabolism of carbocisteine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959492,C,T,Patients with the CT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959492,T,T,Patients with the TT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959498,C,C,Patients with the CC genotype may have increased metabolism of carbocisteine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959498,C,T,Patients with the CT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959498,T,T,Patients with the TT genotype may have decreased metabolism of carbocisteine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959500,C,C,Patients with the CC genotype may have increased metabolism of phenylalanine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959500,C,T,Patients with the CT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959500,T,T,Patients with the TT genotype may have decreased metabolism of phenylalanine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959506,A,A,Patients with the AA genotype may have decreased metabolism of phenylalanine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959506,A,G,Patients with the AG genotype may have decreased metabolism of phenylalanine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959506,G,G,Patients with the GG genotype may have increased metabolism of phenylalanine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959524,A,A,Patients with the AA genotype may have decreased metabolism of carbocisteine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959524,A,G,Patients with the AG genotype may have decreased metabolism of carbocisteine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959524,G,G,Patients with the GG genotype may have increased metabolism of carbocisteine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959530,C,C,Patients with the CC genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959530,C,T,Patients with the CT genotype may have decreased metabolism of carbocisteine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959530,T,T,Patients with the TT genotype may have increased metabolism of carbocisteine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.
1450959540,C,C,Patients with the CC genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959540,C,T,Patients with the CT genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959540,T,T,Patients with the TT genotype may have increased metabolism of phenylalanine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959560,A,A,Patients with the AA genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959560,A,T,Patients with the AT genotype may have decreased metabolism of phenylalanine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1450959560,T,T,Patients with the TT genotype may have increased metabolism of phenylalanine as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.
1451101225,G,G,Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101225,G,T,Patients with the GT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101225,T,T,Patients with the TT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101231,A,A,Patients with the AA genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101231,A,T,Patients with the AT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101231,T,T,Patients with the TT genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101242,A,A,Patients with the AA genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101242,A,G,Patients with the AG genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101242,G,G,Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101248,C,C,Patients with the CC genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101248,C,G,Patients with the CG genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101248,G,G,Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101280,C,C,Patients with the CC genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101280,C,T,Patients with the CT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101280,T,T,Patients with the TT genotype may have decreased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect tramadol metabolism in a patient.
1451101400,A,A,"Patients with the AA genotype may have increased blood alcohol concentrations (BAC) and decreased concentrations. of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect ethanol metabolism."
1451101400,A,C,"Patients with the AC genotype may have increased blood alcohol concentrations (BAC) and decreased concentrations. of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect ethanol metabolism."
1451101400,C,C,"Patients with the CC genotype may have decreased blood alcohol concentrations (BAC) and increased concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect ethanol metabolism."
1451101406,A,A,"There is currently no available evidence regarding the association between the rs671 AA genotype and blood alcohol concentrations (BAC). However, patients with the rs671 AG genotype may have increased blood alcohol concentrations as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC."
1451101406,A,G,Patients with the rs671 AG genotype may have increased blood alcohol concentrations (BAC) as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.
1451101406,G,G,Patients with the rs671 GG genotype may have decreased blood alcohol concentrations (BAC) as compared to patients with the AG genotype. This annotation only covers the pharmacokinetic relationship between rs671 and ethanol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect BAC.
1451103260,G,G,Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.
1451103260,G,T,Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.
1451103260,T,T,Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.
1451103280,A,A,Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.
1451103280,A,G,Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.
1451103280,G,G,Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.
1451103320,G,G,Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.
1451103320,G,T,Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.
1451103320,T,T,Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.
1451103340,A,A,Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.
1451103340,A,G,Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.
1451103340,G,G,Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.
1451103360,A,A,Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.
1451103360,A,G,Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.
1451103360,G,G,Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.
1451105061,A,A,Patients with the AA genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.
1451105061,A,G,Patients with the AG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.
1451105061,G,G,Patients with the GG genotype and chronic migraine may have an increased response to botulinum toxin A as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.
1451105080,A,A,Patients with the AA genotype and chronic migraine may have an increased response to botulinum toxin A as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.
1451105080,A,G,Patients with the AG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.
1451105080,G,G,Patients with the GG genotype and chronic migraine may have a decreased response to botulinum toxin A as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to botulinum toxin A.
1451105180,C,C,Patients with the CC genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.
1451105180,C,T,Patients with the CT genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.
1451105180,T,T,Patients with the TT genotype may have a decreased AUC of letermovir as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to letermovir.
1451105200,C,C,Patients with the CC genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.
1451105200,C,T,Patients with the CT genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.
1451105200,T,T,Patients with the TT genotype may have a decreased AUC of letermovir as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's exposure to letermovir.
1451105206,A,A,Patients with the AA genotype may have an increased AUC of letermovir as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.
1451105206,A,G,Patients with the AG genotype may have an increased AUC of letermovir as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.
1451105206,G,G,Patients with the GG genotype may have a decreased AUC of letermovir as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's exposure to letermovir.
1451105228,A,A,Patients with the AA genotype may have a decreased risk of developing heroin dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451105228,A,G,Patients with the AG genotype may have an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451105228,G,G,Patients with the GG genotype may have an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.
1451985181,C,C,"Patients with the CC genotype may have increased sufentanil dose requirements as compared to patients with the TT or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect sufentanil dose requirements."
1451985181,C,T,"Patients with the CT genotype may have increased sufentanil dose requirements as compared to patients with the TT genotype and decreased sufentanil dose requirements as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect sufentanil dose requirements."
1451985181,T,T,"Patients with the TT genotype may have decreased sufentanil dose requirements as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect sufentanil dose requirements."
1451985268,C,C,Patients with the CC genotype may have increased plasma concentrations of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs2242480 and sufentanil and does not include evidence about clinical outcomes.
1451985268,C,T,Patients with the CT genotype may have increased plasma concentrations of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs2242480 and sufentanil and does not include evidence about clinical outcomes.
1451985268,T,T,Patients with the TT genotype may have decreased plasma concentrations of sufentanil as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs2242480 and sufentanil and does not include evidence about clinical outcomes.
1452004092,A,A,Patients with the rs2307116 AA genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the GG genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.
1452004092,A,G,Patients with the rs2307116 AG genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the GG genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.
1452004092,G,G,Patients with the rs2307116 GG genotype who are treated with sevoflurane may have decreased vol% end-tidal sevoflurane concentration as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.
1450826987,A,A,"Patients with the rs1799971 AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements."
1450826987,A,G,"Patients with the rs1799971 AG genotype may have increased opioid dose requirements as compared to patients with the AA genotype, but decreased opioid dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements."
1450826987,G,G,"Patients with the rs1799971 GG genotype may have increased opioid dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic or clinical factors may also affect opioid dose requirements."
1451106200,C,C,"Patients with hypertension and the CC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the TT genotype. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol."
1451106200,C,T,"Patients with hypertension and the CT genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the TT genotype. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol."
1451106200,T,T,"Patients with hypertension and the TT genotype may have an increased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the CC or CT genotypes. Other genetic. and clinical factors may also affect a patient's response to atenolol or metoprolol."
1451106206,A,A,"Patients with hypertension and the AA genotype may have an increased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol."
1451106206,A,C,"Patients with hypertension and the AC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AA genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol."
1451106206,C,C,"Patients with hypertension and the CC genotype may have a decreased response to atenolol or metoprolol, as measured by change in diastolic blood pressure, as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol or metoprolol."
1451106265,C,C,Patients with Crohn disease and the CC genotype may have be less likely to develop anti-adalimumab antibodes and therefore may have an increased response to adalimumab therapy as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to adalimumab.
1451106265,C,T,Patients with Crohn disease and the CT genotype may have be more likely to develop anti-adalimumab antibodes and therefore may have a decreased response to adalimumab therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to adalimumab.
1451106265,T,T,Patients with Crohn disease and the TT genotype may have be more likely to develop anti-adalimumab antibodes and therefore may have a decreased response to adalimumab therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to adalimumab.
1451106460,A,A,Patients with the AA genotype may have a decreased risk of developing cocaine dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451106460,A,G,Patients with the AG genotype may have an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451106460,G,G,Patients with the GG genotype may have an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451107342,A,A,"Patients with the AA genotype may have an increased response to atenolol or metoprolol, as measured by a greater decrease in heart rate, as compared to patients with the AG or GG genotypes. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol."
1451107342,A,G,"Patients with the AG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the AA genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol."
1451107342,G,G,"Patients with the GG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the AA genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol."
1451107360,C,C,"Patients with the CC genotype may have an increased response to atenolol or metoprolol, as measured by a greater decrease in heart rate, as compared to patients with the CG or GG genotypes. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol."
1451107360,C,G,"Patients with the CG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol."
1451107360,G,G,"Patients with the GG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol."
1451114072,A,A,Patients with the AA genotype and receiving warfarin following cardiac valve replacement may have a decreased risk of bleeding at therapeutic INR as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.
1451114072,A,G,Patients with the AG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.
1451114072,G,G,Patients with the GG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.
1451114080,A,A,Patients with the AA genotype and receiving warfarin following cardiac valve replacement may have a decreased risk of bleeding at therapeutic INR as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.
1451114080,A,G,Patients with the AG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.
1451114080,G,G,Patients with the GG genotype and receiving warfarin following cardiac valve replacement may have an increased risk of bleeding at therapeutic INR as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of bleeding while on warfarin therapy.
1451116049,C,C,"Patients with HIV infections and the CC genotype may have increased trough concentrations of lopinavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients."
1451116049,C,T,"Patients with HIV infections and the CT genotype may have increased trough concentrations of lopinavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients."
1451116049,T,T,"Patients with HIV infections and the TT genotype may have decreased trough concentrations of lopinavir as compared to patients with the CC or CT genotypes. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients."
1451117560,C,C,"Patients with hypertension and the CC genotype may have a decreased response to metoprolol, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to metoprolol."
1451117560,C,T,"Patients with hypertension and the CT genotype may have an increased response to metoprolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to metoprolol."
1451117560,T,T,"Patients with hypertension and the TT genotype may have an increased response to metoprolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to metoprolol."
1451117580,C,C,"Patients with hypertension and the CC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451117580,C,G,"Patients with hypertension and the CG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451117580,G,G,"Patients with hypertension and the GG genotype may have an increased response to hydrochlorothiazide, as measured by an decrease in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451117590,C,C,"Patients with hypertension and the CC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol."
1451117590,C,T,"Patients with hypertension and the CT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol."
1451117590,T,T,"Patients with hypertension and the TT genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to atenolol."
1451117620,C,C,"Patients with hypertension and the CC genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451117620,C,T,"Patients with hypertension and the CT genotype may have an increased response to candesartan, as measured by. a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451117620,T,T,"Patients with hypertension and the TT genotype may have an increased response to candesartan, as measured by. a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451118364,A,A,"Patients with hypertension and the AA genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118364,A,G,"Patients with hypertension and the AG genotype may have an increased response to hydrochlorothiazide, as measured by a decrease in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118364,G,G,"Patients with hypertension and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide."
1451118370,A,A,"Patients with hypertension and the AA genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451118370,A,G,"Patients with hypertension and the AG genotype may have a decreased response to candesartan, as measured by an increase in systolic blood pressure, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451118370,G,G,"Patients with hypertension and the GG genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to candesartan."
1451118760,A,A,Patients with the AA genotype may have decreased remifentanil requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's remifentanil requirements.
1451118760,A,G,There is currently no evidence of a difference in remifentanil requirements between patients with the AG genotype and patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's remifentanil requirements.
1451118760,G,G,Patients with the GG genotype may have increased remifentanil requirements as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's remifentanil requirements.
1451118766,A,A,Patients with the AA genotype may have show increased anesthesia efficacy of remifentanil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.
1451118766,A,G,There is currently no evidence to suggest a difference in anesthesia efficacy between patients with the AG genotype and patients with the AA or GG genotypes. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.
1451118766,G,G,Patients with the GG genotype may have show decreased anesthesia efficacy of remifentanil as compared to patients with the AA genotype. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.
1451118940,C,C,Patients with the CC genotype may experience decreased severity of opioid overdose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.
1451118940,C,T,Patients with the CT genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.
1451118940,T,T,Patients with the TT genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.
1451118946,C,C,Patients with the CC genotype may experience decreased severity of opioid overdose as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.
1451118946,C,G,Patients with the CG genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.
1451118946,G,G,Patients with the GG genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.
1451118960,A,A,Patients with the AA genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.
1451118960,A,C,Patients with the AC genotype may experience increased severity of opioid overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.
1451118960,C,C,Patients with the CC genotype may experience decreased severity of opioid overdose as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect the severity of opioid overdose in a patient.
1451120280,A,A,Patients with epilepsy and the AA genotype may have an increased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.
1451120280,A,G,There is currently no available evidence regarding the association between the AG genotype and a patient's rick of developing psychosis following phenytoin and phenobarbital treatment.
1451120280,G,G,Patients with epilepsy and the GG genotype may have a decreased risk of developing psychosis following treatment with phenytoin and phenobarbital as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing psychosis following phenytoin and phenobarbital treatment.
1451120359,A,A,Patients with the AA genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.
1451120359,A,C,Patients with the AC genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.
1451120359,C,C,Patients with the CC genotype may be more likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.
1451120421,A,A,Patients with the AA genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.
1451120421,A,G,Patients with the AG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.
1451120421,G,G,Patients with the GG genotype may be more likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.
1451120427,A,A,Patients with the AA genotype may be more likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.
1451120427,A,G,Patients with the AG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.
1451120427,G,G,Patients with the GG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.
1451120561,A,A,"Patients with hypertension and the AA genotype may have an increased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to selective beta blockers."
1451120561,A,G,"Patients with hypertension and the AG genotype may have an increased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to selective beta blockers."
1451120561,G,G,"Patients with hypertension and the GG genotype may have a decreased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to selective beta blockers."
1451120702,A,A,Patients with the AA genotype may gain less weight during treatment with antipsychotics as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.
1451120702,A,G,Patients with the AG genotype may gain more weight during treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.
1451120702,G,G,Patients with the GG genotype may gain more weight during treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.
1451120760,A,A,Patients with the AA genotype may gain more weight during treatment with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.
1451120760,A,G,Patients with the AG genotype may gain more weight during treatment with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.
1451120760,G,G,Patients with the GG genotype may gain less weight during treatment with antipsychotics as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's weight gain during antipsychotic treatment.
1451120986,G,G,Patients with the GG genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.
1451120986,G,T,Patients with the GT genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.
1451120986,T,T,Patients with the TT genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.
1451121780,A,A,Patients with the AA genotype may have decreased subjective positive effects from oxycodone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.
1451121780,A,G,Patients with the AG genotype may have decreased subjective positive effects from oxycodone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.
1451121780,G,G,Patients with the GG genotype may have increased subjective positive effects from oxycodone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.
1451121805,C,C,There is currently no available evidence regarding an association between the CC genotype and subjective responses to oxycodone.
1451121805,C,T,Patients with the CT genotype may have decreased subjective positive effects from oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.
1451121805,T,T,Patients with the TT genotype may have increased subjective positive effects from oxycodone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.
1451123485,A,A,Patients with asthma and the AA genotype may have a decreased response to budesonide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to budesonide.
1451123485,A,G,Patients with asthma and the AG genotype may have an increased response to budesonide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to budesonide.
1451123485,G,G,Patients with asthma and the GG genotype may have an increased response to budesonide as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to budesonide.
1451124260,A,A,Patients with the AA genotype may be at an increased risk of developing alcohol dependence as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451124260,A,G,Patients with the AG genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype but a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451124260,G,G,Patients with the GG genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451124280,C,C,Patients with the CC genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451124280,C,T,"Patients with the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype, but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence."
1451124280,T,T,Patients with the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451124300,C,C,Patients with the CC genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451124300,C,T,"Patients with the CT genotype may be at an increased risk fo developing alcohol dependence as compared to patients wit the TT genotype, but a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also a affect a patient's risk of developing alcohol dependence."
1451124300,T,T,Patients with the TT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1450807831,A,A,"The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and risk of developing substance dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing substance dependence."
1450807831,A,G,"The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and risk of developing substance dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing substance dependence."
1450807831,G,G,"The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and risk of developing substance dependence. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing substance dependence."
1451120724,G,G,Patients with the rs62097526 GG genotype may gain more weight during treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.
1451120724,G,T,Patients with the rs62097526 GT genotype may gain more weight during treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.
1451120724,T,T,Patients with the rs62097526 TT genotype may gain less weight during treatment with antipsychotics as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.
1452004060,A,A,Patients with the rs1806201 AA genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452004060,A,G,Patients with the rs1806201 AG genotype who are treated with sevoflurane may have increased mean arterial pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence mean arterial pressure.
1452004060,G,G,Patients with the rs1806201 GG genotype who are treated with sevoflurane may have decreased mean arterial pressure as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence mean arterial pressure.
1451124486,C,C,Patients with the CC genotype may have an increased analgesic response to morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to morphine.
1451124486,C,T,Patients with the CT genotype may have a decreased analgesic response to morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to morphine.
1451124486,T,T,Patients with the TT genotype may have a decreased analgesic response to morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to morphine.
1451124500,C,C,"Patients with the CC genotype may have increased plasma concentrations of morphine as compared to patients with the CT or TT genotypes. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient."
1451124500,C,T,"Patients with the CT genotype may have decreased plasma concentrations of morphine as compared to patients with the CC genotype. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient."
1451124500,T,T,"Patients with the TT genotype may have decreased plasma concentrations of morphine as compared to patients with the CC genotype. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient."
1451124808,C,C,"Patients with liver cancer and the CC genotype may have increased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy."
1451124808,C,T,"Patients with liver cancer and the CT genotype may have decreased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy."
1451124808,T,T,"Patients with liver cancer and the TT genotype may have increased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy."
1451124852,G,G,Patients with liver cancer and the GG genotype may have increased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy.
1451124852,G,T,Patients with liver cancer and the GT genotype may have decreased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.
1451124852,T,T,Patients with liver cancer and the TT genotype may have decreased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.
1451124880,G,G,"Patients with liver cancer, anti-HCV antibodies and the GG genotype may have an increased overall survival when treated with sorafenib as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to sorafenib."
1451124880,G,T,"Patients with liver cancer, anti-HCV antibodies and the GT genotype may have a decreased overall survival when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sorafenib."
1451124880,T,T,"Patients with liver cancer, anti-HCV antibodies and the TT genotype may have a decreased overall survival when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sorafenib."
1451125500,A,A,Patients with non-small cell lung cancer and the AA genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125500,A,G,Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125500,G,G,Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125506,C,C,Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125506,C,T,Patients with non-small cell lung cancer and the CT genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451125506,T,T,Patients with non-small cell lung cancer and the TT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.
1451126020,C,C,Patients with HIV and the CC genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.
1451126020,C,T,Patients with HIV and the CT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.
1451126020,T,T,Patients with HIV and the TT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.
1451126040,C,C,Patients with HIV and the CC genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.
1451126040,C,T,Patients with HIV and the CT genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.
1451126040,T,T,Patients with HIV and the TT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.
1451126064,A,A,Patients with HIV and the AA genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.
1451126064,A,G,Patients with HIV and the AG genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.
1451126064,G,G,Patients with HIV and the GG genotype may experience a decreased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.
1451126200,C,C,"Patients with glioma and the CC genotype may have increased survival rates when treated with temozolomide as part of radiochemotherapy as compared to patients with the CT genotype. However, this association was not replicated in other cohorts. Other genetic and clinical factors may also affect response to temozolomide."
1451126200,C,T,"Patients with glioma and the CT genotype may have decreased survival rates when treated with temozolomide as part of radiochemotherapy as compared to patients with the CC genotype. However, this association was not replicated in other cohorts. Other genetic and clinical factors may also affect response to temozolomide."
1451126200,T,T,There is currently no available evidence regarding an association between the TT genotype and response to temozolomide as part of radiochemotherapy.
1451126312,A,A,Patients with ALS and the AA genotype may have an increased response to treatment with creatine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to creatine.
1451126312,A,G,Patients with ALS and the AG genotype may have an increased response to treatment with creatine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to creatine.
1451126312,G,G,Patients with ALS and the GG genotype may have a decreased response to treatment with creatine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to creatine.
1449163324,C,C,"Patients with the CC genotype may require decreased dosage of morphine as compared to patients with the TT genotype. However, other studies have found no association between this variant and morphine dose requirements. Other genetic and clinical factors may also influence a patient's morphine dosage requirements."
1449163324,C,T,There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.
1449163324,T,T,"Patients with the TT genotype may require increased dosage of morphine as compared to patients with the CC genotype. However, other studies have found no association between this variant and morphine dose requirements. Other genetic and clinical factors may also influence a patient's morphine dosage requirements."
1452004080,C,C,Patients with the rs3733784 CC genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.
1452004080,C,T,Patients with the rs3733784 CT genotype who are treated with sevoflurane may have increased vol% end-tidal sevoflurane concentration as compared to patients with the TT genotype. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.
1452004080,T,T,Patients with the rs3733784 TT genotype who are treated with sevoflurane may have decreased vol% end-tidal sevoflurane concentration as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence vol% end-tidal sevoflurane concentration.
1451127140,C,C,Patients with the CC genotype may experience an increased severity of sedation during treatment with desloratadine as compared to patients with the CT or TT genotypes. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.
1451127140,C,T,Patients with the CT genotype may experience a decreased severity of sedation during treatment with desloratadine as compared to patients with the CC genotype. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.
1451127140,T,T,Patients with the TT genotype may experience a decreased severity of sedation during treatment with desloratadine as compared to patients with the CC genotype. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.
1452004551,A,A,Patients with the rs1127354 AA genotype and liver transplantation may have increased likelihood of rejection when treated with azathioprine as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence liver transplant rejection.
1452004551,A,C,Patients with the rs1127354 AC genotype and liver transplantation may have decreased likelihood of rejection when treated with azathioprine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence liver transplant rejection.
1452004551,C,C,Patients with the rs1127354 CC genotype and liver transplantation may have decreased likelihood of rejection when treated with azathioprine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence liver transplant rejection.
1451737580,A,A,Patients with acute coronary syndrome and the rs3749187 AA genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737580,A,G,Patients with acute coronary syndrome and the rs3749187 AG genotype may be at an increased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451737580,G,G,Patients with acute coronary syndrome and the rs3749187 GG genotype may be at a decreased risk of experiencing major adverse cardiac events (MACE) when treated with aspirin and clopidogrel as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence risk of MACE when treated with aspirin and clopidogrel.
1451129800,C,C,Patients with bipolar disorder and the CC genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451129800,C,T,Patients with bipolar disorder and the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451129800,T,T,Patients with bipolar disorder and the TT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.
1451129880,C,C,Patients with schizophrenia and the CC genotype may have an increased response to lurasidone as compared to patients with the CG or GG genotypes. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.
1451129880,C,G,Patients with schizophrenia and the CG genotype may have a decreased response to lurasidone as compared to patients with the CC genotype. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.
1451129880,G,G,Patients with schizophrenia and the GG genotype may have a decreased response to lurasidone as compared to patients with the CC genotype. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.
1451130528,A,A,Patients with tuberculosis and the AA genotype may be at an increased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.
1451130528,A,G,Patients with tuberculosis and the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.
1451130528,G,G,Patients with tuberculosis and the GG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing hepatotoxicity.
1451129680,C,C,"Patients with the CC genotype may have increased exposure to efavirenz as compared to patients with the CT or TT genotypes. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz."
1451129680,C,T,"Patients with the CT genotype may have decreased exposure to efavirenz as compared to patients with the CC genotype. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz."
1451129680,T,T,"Patients with the TT genotype may have decreased exposure to efavirenz as compared to patients with the CC genotype. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz."
1451952720,A,A,"Patients with the rs917881 AA genotype may have an increased risk of diarrhea when treated with sorafenib as compared to patients with the GA or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib."
1451952720,A,G,"Patients with the rs917881 AG genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib."
1451952720,G,G,"Patients with the rs917881 GG genotype may have a decreased risk of diarrhea when treated with sorafenib as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of diarrhea when treated with sorafenib."
1451130640,C,C,Patients with multiple sclerosis and the CC genotype may have a decreased response to interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to interferon-beta.
1451130640,C,T,Patients with multiple sclerosis and the CT genotype may have a decreased response to interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to interferon-beta.
1451130640,T,T,Patients with multiple sclerosis and the TT genotype may have an increased response to interferon-beta as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to interferon-beta.
1451131729,A,A,Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.
1451131729,A,C,Patients with non-small cell lung cancer and the AC genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.
1451131729,C,C,Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.
1451131735,C,C,Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131735,C,T,Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131735,T,T,Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131750,A,A,Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131750,A,G,Patients with non-small cell lung cancer and the AG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131750,G,G,Patients with non-small cell lung cancer and the GG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131761,C,C,Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131761,C,T,Patients with non-small cell lung cancer and the CT genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131761,T,T,Patients with non-small cell lung cancer and the TT genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131767,A,A,Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131767,A,G,Patients with non-small cell lung cancer and the AG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131767,G,G,Patients with non-small cell lung cancer and the GG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131781,A,A,Patients with non-small cell lung cancer and the AA genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.
1451131781,A,T,Patients with non-small cell lung cancer and the AT genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.
1451131781,T,T,Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.
1451131787,A,A,Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131787,A,G,Patients with non-small cell lung cancer and the AG genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131787,G,G,Patients with non-small cell lung cancer and the GG genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131820,C,C,Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131820,C,T,Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131820,T,T,Patients with non-small cell lung cancer and the TT genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131840,A,A,Patients with non-small cell lung cancer and the AA genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131840,A,G,Patients with non-small cell lung cancer and the AG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131840,G,G,Patients with non-small cell lung cancer and the GG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131846,C,C,Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.
1451131846,C,G,Patients with non-small cell lung cancer and the CG genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.
1451131846,G,G,Patients with non-small cell lung cancer and the GG genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.
1451131852,C,C,Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131852,C,T,Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131852,T,T,Patients with non-small cell lung cancer and the TT genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131858,C,C,Patients with non-small cell lung cancer and the CC genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131858,C,T,Patients with non-small cell lung cancer and the CT genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131858,T,T,Patients with non-small cell lung cancer and the TT genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.
1451131860,A,A,Patients with non-small cell lung cancer and the AA genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131860,A,G,Patients with non-small cell lung cancer and the AG genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451131860,G,G,Patients with non-small cell lung cancer and the GG genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.
1451134300,C,C,Patients with the CC genotype and treated with long-term opioids may be less likely to develop dizziness as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids.
1451134300,C,T,Patients with the CT genotype and treated with long-term opioids may be more likely to develop dizziness as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids.
1451134300,T,T,Patients with the TT genotype and treated with long-term opioids may be less likely to develop dizziness as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing dizziness when treated with opioids.
1451134540,C,C,Female patients with the CC genotype may be more likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids.
1451134540,C,T,Female patients with the CT genotype may be less likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids.
1451134540,T,T,Female patients with the TT genotype may be less likely to experience a loss of libido when treated with long-term opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of losing libido when treated with opioids.
1451135380,A,A,"Patients with the rs2032582 AA genotype may have increased dose requirements of sufentanil as compared to patients with the AC or CC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil."
1451135380,A,C,"Patients with the rs2032582 AC genotype may have increased dose requirements of sufentanil as compared to patients with the CC genotype but decreased dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil."
1451135380,C,C,"Patients with the rs2032582 CC genotype may have decreased dose requirements of sufentanil as compared to patients with the AA or AC genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil."
1451133765,A,A,Patients with neuropathic pain and the rs1045642 AA genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.
1451133765,A,G,Patients with neuropathic pain and the rs1045642 AG genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.
1451133765,G,G,Patients with neuropathic pain and the rs1045642 GG genotype may have an increased response to combined therapy with morphine and nortriptyline as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect response to morphine and nortriptyline.
1451135197,A,A,"Patients with the rs1323040 AA genotype may have decreased sufentanil dose requirements as compared to patients with the AG or GG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements."
1451135197,A,G,"Patients with the rs1323040 AG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements."
1451135197,G,G,"Patients with the rs1323040 GG genotype may have increased sufentanil dose requirements as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect sufentanil dose requirements."
1451135400,A,A,Patients with the AA genotype may have increased sufentanil dose requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.
1451135400,A,G,Patients with the AG genotype may have increased sufentanil dose requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.
1451135400,G,G,Patients with the GG genotype may have decreased sufentanil dose requirements as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.
1451135574,C,C,African American male patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451135574,C,T,"African American male patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the TT genotype, but a decreased risk as compared to patients with the CC genotype. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence."
1451135574,T,T,African American male patients with the TT genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CC or CT genotypes. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451136460,C,C,Patients with the rs71647871 CC genotype may have increased metabolism of heroin as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs71647871 and heroin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect heroin metabolism.
1451136460,C,T,Patients with the rs71647871 CT genotype may have decreased metabolism of heroin as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and heroin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect heroin metabolism.
1451136460,T,T,Patients with the rs71647871 TT genotype may have decreased metabolism of heroin as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs71647871 and heroin and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect heroin metabolism.
1451137805,A,A,Patients with the AA genotype may be at a decreased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451137805,A,G,Patients with the AG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451137805,G,G,Patients with the GG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451137828,C,C,Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451137828,C,T,Patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451137828,T,T,Patients with the TT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451138160,A,A,Patients with heroin dependence and the AA genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.
1451138160,A,G,Patients with heroin dependence and the AG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.
1451138160,G,G,Patients with heroin dependence and the GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.
1451138166,C,C,Patients with heroin dependence and the CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.
1451138166,C,G,Patients with heroin dependence and the CG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.
1451138166,G,G,Patients with heroin dependence and the GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.
1451138182,C,C,Patients with heroin dependence and the CC genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.
1451138182,C,T,There is currently no studies which have found an association between the CT genotype and methadone dose requirements in patients with heroin dependence receiving methadone maintenance therapy (MMT).
1451138182,T,T,Patients with heroin dependence and the TT genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.
1451138494,G,G,Patients with the GG genotype may require increased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138494,G,T,Patients with the GT genotype may require decreased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138494,T,T,Patients with the TT genotype may require decreased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138544,A,A,Patients with the AA genotype may have increased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.
1451138544,A,G,Patients with the AG genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.
1451138544,G,G,Patients with the GG genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.
1451138560,G,G,Patients with the GG genotype may have increased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.
1451138560,G,T,Patients with the GT genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.
1451138560,T,T,Patients with the TT genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.
1451138860,C,C,Patients with heroin dependence and the CC genotype may have decreased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138860,C,T,Patients with heroin dependence and the CT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138860,T,T,Patients with heroin dependence and the TT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138880,C,C,Patients with heroin dependence and the CC genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138880,C,T,Patients with heroin dependence and the CT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138880,T,T,Patients with heroin dependence and the TT genotype may have decreased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138886,C,C,Patients with heroin dependence and the CC genotype may have decreased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138886,C,T,Patients with heroin dependence and the CT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451138886,T,T,Patients with heroin dependence and the TT genotype may have increased dose requirements of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.
1451139960,G,G,Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to people with the GT or TT genotypes. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.
1451139960,G,T,Patients with the GT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to people with the GG genotype. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.
1451139960,T,T,Patients with the TT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to people with the GG genotype. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.
1451141140,G,G,Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141140,G,T,Patients with the GT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141140,T,T,Patients with the TT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141146,C,C,Patients with the CC genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141146,C,T,Patients with the CT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141146,T,T,Patients with the TT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141152,C,C,Patients with the CC genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141152,C,G,Patients with the CG genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141152,G,G,Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141160,C,C,Patients with the CC genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141160,C,T,Patients with the CT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141160,T,T,Patients with the TT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141166,A,A,The association between the AA genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141166,A,G,The association between the AG genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141166,G,G,The association between the GG genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141180,G,G,Patients with the GG genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141180,G,T,Patients with the GT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451141180,T,T,Patients with the TT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.
1451550960,C,C,Patients with the rs3804100 CC genotype may have decreased morphine dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence morphine dose requirements.
1451550960,C,T,Patients with the rs3804100 CT genotype may have decreased morphine dose requirements as compared to patients with the TT genotype. Other genetic and clinical factors may also influence morphine dose requirements.
1451550960,T,T,Patients with the rs3804100 TT genotype may have increased morphine dose requirements as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence morphine dose requirements.
1451138140,C,C,Patients with heroin dependence and the rs3762555 CC genotype may require decreased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect methadone dose requirements in MMT.
1451138140,C,G,Patients with heroin dependence and the rs3762555 CG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect methadone dose requirements in MMT.
1451138140,G,G,Patients with heroin dependence and the rs3762555 GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect methadone dose requirements in MMT.
1451144760,A,A,There is currently no available evidence regarding an association between the AA genotype and concentrations of alprazolam. Other genetic and clinical factors may also affect concentrations of alprazolam in a patient.
1451144760,A,G,"Patients with alcoholism, anxiety and the AG genotype may have increased concentrations of alprazolam as compared to patients with the GG genotype. This annotation over covers the pharmacokinetic relationship between rs35599367 and alprazolam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect concentrations of alprazolam in a patient."
1451144760,G,G,"Patients with alcoholism, anxiety and the GG genotype may have decreased concentrations of alprazolam as compared to patients with the AG genotype. This annotation over covers the pharmacokinetic relationship between rs35599367 and alprazolam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect concentrations of alprazolam in a patient."
1451145100,C,C,Patients with the CC genotype may be at an increased risk of cocaine dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451145100,C,T,Patients with the CT genotype may be at a decreased risk of cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451145100,T,T,Patients with the TT genotype may be at a decreased risk of cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451145106,A,A,Patients with the AA genotype may be at a decreased risk of cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451145106,A,G,Patients with the AG genotype may be at a decreased risk of cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451145106,G,G,Patients with the GG genotype may be at an increased risk of cocaine dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.
1451146140,A,A,Patients with the AA genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451146140,A,G,Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451146140,G,G,Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451146160,C,C,Patients with the CC genotype may be at a decreased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451146160,C,T,Patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451146160,T,T,Patients with the TT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.
1451146222,C,C,Women with the CC genotype may have an increased analgesic response to dexmedetomidine as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.
1451146222,C,G,Women with the CG genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.
1451146222,G,G,Women with the GG genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.
1451146241,C,C,Women with the CC genotype may have an increased analgesic response to dexmedetomidine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.
1451146241,C,T,Women with the CT genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.
1451146241,T,T,Women with the TT genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.
1451146260,C,C,Women with the CC genotype may have an increased analgesic response to dexmedetomidine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.
1451146260,C,T,Women with the CT genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.
1451146260,T,T,Women with the TT genotype may have a decreased analgesic response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to dexmedetomidine.
1451148025,C,C,Patients with opioid dependence and the CC genotype may have an increased response to methadone maintenance treatment (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to MMT.
1451148025,C,T,Patients with opioid dependence and the CT genotype may have an increased response to methadone maintenance treatment (MMT) as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to MMT.
1451148025,T,T,Patients with opioid dependence and the TT genotype may have a decreased response to methadone maintenance treatment (MMT) as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to MMT.
1451148520,A,A,Patients with chronic pain and the AA genotype may be less likely to develop hyperalgesia when treated with long-term opioids as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing hyperalgesia.
1451148520,A,G,Patients with chronic pain and the AG genotype may be more likely to develop hyperalgesia when treated with long-term opioids as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's likelihood of developing hyperalgesia.
1451148520,G,G,Patients with chronic pain and the GG genotype may be less likely to develop hyperalgesia when treated with long-term opioids as compared to patients with the AG genotype. Other genetic and clinical factors may also affect a patient's likelihood of developing hyperalgesia.
1451966320,A,A,Patients with the rs1045642 AA genotype may have increased clearance of rivaroxaban as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of rivaroxaban. This annotation only covers the pharmacokinetic relationship between rs1045642 and rivaroxaban and does not include evidence about clinical outcomes.
1451966320,A,G,Patients with the rs1045642 AG genotype may have increased clearance of rivaroxaban as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of rivaroxaban. This annotation only covers the pharmacokinetic relationship between rs1045642 and rivaroxaban and does not include evidence about clinical outcomes.
1451966320,G,G,Patients with the rs1045642 GG genotype may have decreased clearance of rivaroxaban as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence clearance of rivaroxaban. This annotation only covers the pharmacokinetic relationship between rs1045642 and rivaroxaban and does not include evidence about clinical outcomes.
1451148780,A,A,"Patients with the AA genotype may have increased metabolism of naproxen as compared to patients with the AT or TT genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes."
1451148780,A,T,"Patients with the AT genotype may have decreased metabolism of naproxen as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes."
1451148780,T,T,"Patients with the TT genotype may have decreased metabolism of naproxen as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes."
1451148820,A,A,Patients with the AA genotype may have increased metabolism of phenytoin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.
1451148820,A,T,Patients with the AT genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.
1451148820,T,T,Patients with the TT genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.
1451148840,A,A,Patients with the AA genotype may have increased metabolism of warfarin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.
1451148840,A,T,Patients with the AT genotype may have decreased metabolism of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.
1451148840,T,T,Patients with the TT genotype may have decreased metabolism of warfarin as compared to patients with the AA genotype. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.
1451149000,A,A,Patients with cancer pain and the AA genotype may have increased morphine dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dose requirements.
1451149000,A,C,Patients with cancer pain and the AC genotype may have increased morphine dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's morphine dose requirements.
1451149000,C,C,Patients with cancer pain and the CC genotype may have decreased morphine dose requirements as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's morphine dose requirements.
1451149980,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149980,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149980,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149986,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149986,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149986,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149992,C,C,Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149992,C,T,Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149992,T,T,Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149998,C,C,Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149998,C,T,Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451149998,T,T,Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150020,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150020,G,T,Patients with the GT genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150020,T,T,Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150040,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150040,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150040,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150046,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150046,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150046,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150060,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150060,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150060,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150080,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150080,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150080,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150086,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150086,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150086,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150092,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150092,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451150092,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151460,C,C,Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151460,C,G,Patients with the CG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151460,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151466,C,C,Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151466,C,T,Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151466,T,T,Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151472,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151472,G,T,Patients with the GT genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151472,T,T,Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151478,C,C,Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151478,C,T,Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151478,T,T,Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151484,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151484,A,C,Patients with the AC genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151484,C,C,Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151490,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151490,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151490,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151496,C,C,Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151496,C,G,Patients with the CG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151496,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151500,C,C,Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151500,C,T,Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151500,T,T,Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151512,C,C,Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151512,C,T,Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151512,T,T,Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151522,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151522,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151522,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151540,A,A,Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151540,A,G,Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151540,G,G,Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151560,A,A,Patients with the AA genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151560,A,G,Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151560,G,G,Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.
1451151857,A,A,"Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the AG or GG genotypes. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone."
1451151857,A,G,"Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone."
1451151857,G,G,"Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone."
1451151920,A,A,"Patients with schizophrenia and the AA genotype may have a decreased response to olanzapine as compared to patients with the AG or GG genotypes. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine."
1451151920,A,G,"Patients with schizophrenia and the AG genotype may have an increased response to olanzapine as compared to patients with the AA genotype. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine."
1451151920,G,G,"Patients with schizophrenia and the GG genotype may have an increased response to olanzapine as compared to patients with the AA genotype. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine."
1451148762,A,A,Patients with the rs780801862 AA genotype may have increased metabolism of flurbiprofen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.
1451148762,A,T,Patients with the rs780801862 AT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.
1451148762,T,T,Patients with the rs780801862 TT genotype may have decreased metabolism of flurbiprofen as compared to patients with the AA genotype. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.
1451207020,A,A,"Patients with the AA genotype may have increased concentrations of morphine as compared to patients with the AG or GG genotypes. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient."
1451207020,A,G,"Patients with the AG genotype may have decreased concentrations of morphine as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient."
1451207020,G,G,"Patients with the GG genotype may have decreased concentrations of morphine as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient."
1451217440,C,C,"Patients with hepatitis B and the CC genotype may have a decreased response to treatment with peginterferon-alpha 2a and/or 2b as compared to patients with the TT genotype. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and/or 2b"
1451217440,C,T,"Patients with hepatitis B and the CT genotype may have a decreased response to treatment with peginterferon-alpha 2a and/or 2b as compared to patients with the TT genotype. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and/or 2b"
1451217440,T,T,"Patients with hepatitis B and the TT genotype may have an increased response to treatment with peginterferon-alpha 2a and/or 2b as compared to patients with the CC or CT genotypes. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and/or 2b"
1451217520,C,C,Patients with the CC genotype may have an increased response to treatment with sofosbuvir and ribavirin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.
1451217520,C,T,Patients with the CT genotype may have a decreased response to treatment with sofosbuvir and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.
1451217520,T,T,Patients with the TT genotype may have a decreased response to treatment with sofosbuvir and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.
1451217560,C,C,Patients with the CC genotype may have an increased response to treatment with interferons and ribavirin as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.
1451217560,C,T,Patients with the CT genotype may have a decreased response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.
1451217560,T,T,Patients with the TT genotype may have a decreased response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.
1451223500,A,A,"Infants with the rs1799971 AA genotype may be more likely to require treatment with methadone for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223500,A,G,"Infants with the rs1799971 AG genotype may be less likely to require treatment with methadone for neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223500,G,G,"Infants with the rs1799971 GG genotype may be less likely to require treatment with methadone for neonatal abstinence syndrome as compared to infants with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223520,A,A,"Infants with the rs1799971 AA genotype may be more likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223520,A,G,"Infants with the rs1799971 AG genotype may be less likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223520,G,G,"Infants with the rs1799971 GG genotype may be less likely to require treatment with morphine for neonatal abstinence syndrome as compared to infants with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223540,A,A,Infants who have been been exposed to methadone in utero and who have the AA genotype may been more likely to require treatment for neonatal abstinence syndrome as compared to infants with the AG or GG genotypes. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.
1451223540,A,G,Infants who have been been exposed to methadone in utero and who have the AG genotype may been less likely to require treatment for neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.
1451223540,G,G,Infants who have been been exposed to methadone in utero and who have the GG genotype may been less likely to require treatment for neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.
1451223580,A,A,"Infants who have been exposed to buprenorphine in utero and are born to women with the AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223580,A,C,"Infants who have been exposed to buprenorphine in utero and are born to women with the AC genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223580,C,C,"Infants who have been exposed to buprenorphine in utero and are born to women with the CC genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA or AC genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223586,A,A,"Infants who have been exposed to methadone in utero and are born to women with the AA genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223586,A,C,"Infants who have been exposed to methadone in utero and are born to women with the AC genotype may be more likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the CC genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223586,C,C,"Infants who have been exposed to methadone in utero and are born to women with the CC genotype may be less likely to require treatment with at least two medications for neonatal abstinence syndrome as compared to infants born to women with the AA or AC genotypes. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome."
1451223592,G,G,Infants who have been exposed to methadone in utero and who have the GG genotype may be more likely to require treatment for neonatal abstinence syndrome as compared to infants with the GT genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.
1451223592,G,T,Infants who have been exposed to methadone in utero and who have the GT genotype may be less likely to require treatment for neonatal abstinence syndrome as compared to infants with the GG genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.
1451223592,T,T,There is currently no available evidence regarding any association between the TT genotype and severity of neonatal abstinence syndrome. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.
1451217540,C,C,"Patients with a HCV genotype I infection and the rs12979860 CC genotype may have an increased response to treatment with interferons as compared to patients with the CT or TT genotypes. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons."
1451217540,C,T,"Patients with a HCV genotype I infection and the rs12979860 CT genotype may have a decreased response to treatment with interferons as compared to patients with the CC genotype. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons."
1451217540,T,T,"Patients with a HCV genotype I infection and the rs12979860 TT genotype may have a decreased response to treatment with interferons as compared to patients with the CC genotype. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons."
1451266120,A,A,"Patients with the rs67376798 AA genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
1451266120,A,T,"Patients with the rs67376798 AT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
1451266120,T,T,"Patients with the rs67376798 TT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AT or AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
1451266065,C,C,"Patients with the rs3918290 CC genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the CT or TT genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
1451266065,C,T,"Patients with the rs3918290 CT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the CC genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
1451266065,T,T,"Patients with the rs3918290 TT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the CC genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy."
1451266020,A,A,"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AA genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable."
1451266020,A,C,"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the AC genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable."
1451266020,C,C,"The C allele of rs55886062 is assigned a no function allele by CPIC. Patients with the CC genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have an increased risk of drug toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable."
1451257700,A,A,Patients with the AA genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate response.
1451257700,A,G,Patients with the AG genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methotrexate response.
1451257700,G,G,Patients with the GG genotype and Rheumatoid Arthritis or Juvenile Rheumatoid Arthritis may have increased response when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methotrexate response.
1451263060,C,C,Patients with the CC genotype may have increased risk of bleeding when treated with warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the side effects to warfarin.
1451263060,C,T,Patients with the CT genotype may have increased risk of bleeding when treated with warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the side effects to warfarin.
1451263060,T,T,Patients with the TT genotype may have decreased risk of bleeding when treated with warfarin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the side effects to warfarin.
1183680656,C,C,"Patients with the CC (POR *1/*1) genotype and Kidney Transplantation who are treated with tacrolimus may have a decreased, but not absent, risk for developing new-onset diabetes after transplantation as compared to patients with the CT and TT (*1/*28 and *28/*28) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus."
1183680656,C,T,"Patients with the CT (POR *1/*28) genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation as compared to patients with the CC (*1/*1) genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus."
1183680656,T,T,"Patients with the TT (POR *28/*28) genotype and Kidney Transplantation who are treated with tacrolimus may have an increased risk for developing new-onset diabetes after transplantation, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to tacrolimus."
1451285000,C,C,Patients with the CC genotype may have increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the response to clodronate.
1451285000,C,T,Patients with the CT genotype may have increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the response to clodronate.
1451285000,T,T,Patients with the TT genotype may have decreased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the response to clodronate.
1451256440,C,C,"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
1451256440,C,T,"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
1451256440,T,T,"Patients with two X-chromosomes, the TT genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
1451256448,C,C,"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with risperidone may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
1451256448,C,T,"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with risperidone may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain, or an association in the opposite direction. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
1451256448,T,T,"Patients with two X-chromosomes, the TT genotype and psychiatric disorders who are treated with risperidone may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
1451256466,C,C,"Patients with two X-chromosomes, the CC genotype and psychiatric disorders who are treated with clozapine may have an increased risk of weight gain as compared to patients with the TT genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
1451256466,C,T,"Patients with two X-chromosomes, the CT genotype and psychiatric disorders who are treated with clozapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
1451256466,T,T,"Patients with two X-chromosomes, the TT genotype and psychiatric disorders who are treated with clozapine may have a decreased, but not absent, risk of weight gain as compared to patients with the CC genotype. However, some studies find no association with weight gain. Other genetic and clinical factors may also influence a patient's risk for weight gain with antipsychotic treatment. This gene is on the X chromosome therefore some individuals may have only one allele."
1451274840,C,C,Patients with the CC genotype may have increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to esomeprazole.
1451274840,C,T,Patients with the CT genotype may have increased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to esomeprazole.
1451274840,T,T,Patients with the TT genotype may have decreased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence response to esomeprazole.
1451282140,A,A,Pre-menopausal women with the AA genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AC and CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.
1451282140,A,C,Pre-menopausal women with the AC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.
1451282140,C,C,Pre-menopausal women with the CC genotype and breast cancer may have decreased disease free survival when treated with tamoxifen as compared to patients with the AA and AC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.
1451551426,A,A,Patients with the rs11615 AA genotype may have an increased response to treatment with cisplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine
1451551426,A,G,Patients with the rs11615 AG genotype may have a decreased response to treatment with cisplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine
1451551426,G,G,Patients with the rs11615 GG genotype may have a decreased response to treatment with cisplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine
1451551460,A,A,"Patients with the rs11615 AA genotype may have an increased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to chemotherapy."
1451551460,A,G,"Patients with the rs11615 AG genotype may have a decreased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to chemotherapy."
1451551460,G,G,"Patients with the rs11615 GG genotype may have a decreased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to chemotherapy."
1451135100,A,A,"Patients with the rs1799971 AA genotype may have an increased analgesic response to oxycodone as compared to patients with the AG or GG genotypes. However, another study failed to find an association. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to oxycodone."
1451135100,A,G,"Patients with the rs1799971 AG genotype may have a decreased analgesic response to oxycodone as compared to patients with the AA genotype. However, another study failed to find an association. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to oxycodone."
1451135100,G,G,"Patients with the rs1799971 GG genotype may have a decreased analgesic response to oxycodone as compared to patients with the AA genotype. However, another study failed to find an association. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect response to oxycodone."
1451289660,A,A,"The A allele of rs59086055 is assigned a no function allele by CPIC. There is currently only available evidence regarding the association between the rs59086055 AG heterozygote and fluorouracil toxicity. However, patients with the rs59086055 AA genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patient with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity."
1451289660,A,G,"The A allele of rs59086055 is assigned a no function allele by CPIC. Patients with AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have increased risk of drug toxicity as compared to patient with the GG genotype. Other genetic and clinical factors may also influence risk of drug toxicity."
1451289660,G,G,"The A allele of rs59086055 is assigned a no function allele by CPIC. Patients with GG genotype and cancer who are treated with fluorouracil and leucovorin may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity."
1451551520,A,A,"The current evidence base suggests that there is no significant association between the rs3212986 AA genotype and response to cisplatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin."
1451551520,A,C,"The current evidence base suggests that there is no significant association between the rs3212986 AC genotype and response to cisplatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin."
1451551520,C,C,"The current evidence base suggests that there is no significant association between the rs3212986 CC genotype and response to cisplatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin."
1451551528,A,A,Patients with the rs2336219 AA genotype may have a decreased response to cisplatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to cisplatin.
1451551528,A,G,Patients with the rs2336219 AG genotype may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to cisplatin.
1451551528,G,G,Patients with the rs2336219 GG genotype may have an increased response to cisplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to cisplatin.
1451551846,C,C,Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 CC genotype may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451551846,C,T,Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 CT genotype may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451551846,T,T,Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 TT genotype may have a decreased response to methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence response to methotrexate.
1451551817,A,A,Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AA genotype may have an increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451551817,A,G,Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 AG genotype may have an increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451551817,G,G,Patients with acute lymphoblastic leukemia (ALL) and the rs3758149 GG genotype may have a decreased response to methotrexate as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to methotrexate.
1451551883,A,A,Patients with acute lymphoblastic leukemia (ALL) and the rs11545076 AA genotype may have a decreased response to methotrexate as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence response to methotrexate.
1451551883,A,C,Patients with acute lymphoblastic leukemia (ALL) and the rs11545076 AC genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451551883,C,C,Patients with acute lymphoblastic leukemia (ALL) and the rs11545076 CC genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.
1451552587,G,G,Patients with the rs3745274 GG genotype may have a decreased exposure to tramadol as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.
1451552587,G,T,Patients with the rs3745274 GT genotype may have a decreased exposure to tramadol as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.
1451552587,T,T,Patients with the rs3745274 TT genotype may have an increased exposure to tramadol as compared to patients with the GG or GT genotypes. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.
1451553595,A,A,"The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1451553595,A,G,"The current evidence base suggests that there is no significant association between the rs1045642 AG genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1451553595,G,G,"The current evidence base suggests that there is no significant association between the rs1045642 GG genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate."
1451553580,A,A,"Patients with the rs1045642 AA genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
1451553580,A,G,"Patients with the rs1045642 AG genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
1451553580,G,G,"Patients with the rs1045642 GG genotype may have decreased concentrations of methotrexate as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations."
1452018880,C,C,Patients with the rs12885713 CC genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cyclosporine.
1452018880,C,T,Patients with the rs12885713 CT genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cyclosporine.
1452018880,T,T,Patients with the rs12885713 TT genotype and psoriasis may have an increased response to cyclosporine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence response to cyclosporine.
1452018886,A,A,Patients with the rs2874116 AA genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cyclosporine.
1452018886,A,G,Patients with the rs2874116 AG genotype and psoriasis may have a decreased response to cyclosporine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cyclosporine.
1452018886,G,G,Patients with the rs2874116 GG genotype and psoriasis may have an increased response to cyclosporine as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence response to cyclosporine.
1451566760,A,A,Patients with the rs1800497 AA genotype may have an increased weight loss response to buproprion and naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight loss response to buproprion and naltrexone.
1451566760,A,G,Patients with the rs1800497 AG genotype may have an increased weight loss response to buproprion and naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight loss response to buproprion and naltrexone.
1451566760,G,G,Patients with the rs1800497 GG genotype may have a decreased weight loss response to buproprion and naltrexone as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence weight loss response to buproprion and naltrexone.
